{"doc_id": 0, "doc": {"person_id": 115968332, "visit_occurrence_id": 144828599, "death_date": null, "visit_concept_name": "Outpatient Visit", "visit_start_datetime": "2019-12-03 10:21:00", "visit_end_datetime": "2019-12-03 23:59:00", "visit_length_in_hours": 13.633333333333333, "integrated_visit_record": "## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-03 10:21:00, ended at 2019-12-03 23:59:00\nThe patient in this visit was 75 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Benign neuroendocrine tumor\n\n### Drug\n- gadoxetate, through Intravenous route, started on 2019-12-03, presumably until 2019-12-03\n\n", "approximate_token_count": 135, "patient_first_visit_date": "2013-01-21 00:00:00", "patient_last_visit_date": "2021-07-01 00:00:00", "end_obs_date": "2020-12-02", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 0, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "recurrent", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "new", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "recurrent", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 67, "cumulated_visit_num": 67, "cumulated_approximate_token_count": 18393, "visit_cumulated": "## Visit\nThis visit record, was from Case Management Visit, started at 2013-01-21 00:00:00, ended at 2013-01-21 00:00:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-01-21 13:35:00, ended at 2013-01-21 17:02:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Endoscopy and biopsy of upper gastrointestinal tract\n- Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s) (includes endoscopic ultrasound examination of the esophagus, stomach, and either the duodenum or a surgicall\n- Ultrasonography of digestive system\n- Morphometric analysis, tumor\n\n### Condition\n- Disorder of pancreas\n- Acquired hypothyroidism\n- Benign carcinoid tumor\n- Essential hypertension\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2013-01-21, presumably until 2013-01-21\n- benzocaine 140 MG/ML / butamben 20 MG/ML / tetracaine 20 MG/ML Mucosal Spray, through Topical route, started on 2013-01-21, presumably until 2013-01-21\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-01-21, presumably until 2013-01-21\n- midazolam 1 MG/ML Injectable Solution, started on 2013-01-21, presumably until 2013-01-21\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-05 08:15:00, ended at 2013-02-05 10:00:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.75\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of pancreas\n\n### Drug\n- atorvastatin 10 MG Oral Tablet, through Oral route, presumably until 2015-01-20. Instructions: take  by mouth Every Day.  \n- 24 HR felodipine 10 MG Extended Release Oral Tablet, through Oral route. Instructions: take 10 mg by mouth daily at noon \n- levothyroxine sodium 0.137 MG Oral Tablet, through Oral route, presumably until 2017-09-03. Instructions: take 112 mcg by mouth every day \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-05 10:01:00, ended at 2013-02-05 10:59:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.4 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 115 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 121 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.1 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.01 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- MCH [Entitic mass] by Automated count: 31.3 (picogram)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.47 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.9 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 28.4 (percent)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 273 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 93.7 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 64.6 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.59 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.6 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.45 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-05 11:00:00, ended at 2013-02-05 23:59:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen; without contrast material, followed by contrast material(s) and further sections\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n\n### Condition\n- Disorder of pancreas\n- Intra-abdominal and pelvic swelling, mass and lump\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-12 08:09:00, ended at 2013-02-12 11:13:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-12 11:14:00, ended at 2013-02-12 13:05:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Neoplasm of digestive tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-17 14:32:00, ended at 2013-03-17 23:59:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.929\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2013-03-18 00:00:00, ended at 2013-03-18 00:00:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Anesthesia for intraperitoneal procedures in upper abdomen including laparoscopy; pancreatectomy, partial or total (eg, Whipple procedure)\n\n### Condition\n- Primary malignant neoplasm of pancreas\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, started on 2013-03-18, presumably until 2013-03-18\n- 1 ML octreotide 0.1 MG/ML Injection, started on 2013-03-18, presumably until 2013-03-18\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2013-03-18, presumably until 2013-03-18\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2013-03-18, presumably until 2013-03-18\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2013-03-18, presumably until 2013-03-18\n- cefoxitin 1000 MG Injection, through Intravenous route, started on 2013-03-18, presumably until 2013-03-18\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-03-18, presumably until 2013-03-18\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-03-18, presumably until 2013-03-18\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-03-18, presumably until 2013-03-18\n- midazolam 1 MG/ML Injectable Solution, started on 2013-03-18, presumably until 2013-03-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2013-03-18 00:00:00, ended at 2013-03-18 00:00:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- water 1000 MG/ML Irrigation Solution, through Topical route, started on 2013-03-18, presumably until 2013-03-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2013-03-18 08:17:00, ended at 2013-03-26 10:15:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- MCH [Entitic mass] by Automated count: 31.3 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 62 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.97 (million per microliter)\n- Globulin [Mass/volume] in Serum: 2.6 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 92.9 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 202 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.2 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 25.7 (second)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Body height: 5' 7.008\" (inch (US))\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 5.8 (gram per deciliter)\n- Prothrombin time (PT): 15.3 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 84 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 207 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.3 (ratio)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.0 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n\n### Procedure\n- Cholecystectomy\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Radiologic examination, abdomen; single anteroposterior view\n- Morphometric analysis, tumor\n- Radical pancreaticoduodenectomy\n- Collection of venous blood by venipuncture\n\n### Condition\n- Low blood pressure\n- Malignant carcinoid tumor\n- Nausea\n- Essential hypertension\n- Primary malignant neoplasm of gastrointestinal tract\n- Chronic cholecystitis\n- Postprocedural state finding\n- Acquired hypothyroidism\n- Hyperlipidemia\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2013-03-25, presumably until 2013-03-25\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2013-03-18, presumably until 2013-03-22\n- 1 ML ketorolac tromethamine 30 MG/ML Injection, started on 2013-03-19, presumably until 2013-03-22\n- 1 ML octreotide 0.05 MG/ML Injection, started on 2013-03-19, presumably until 2013-03-24\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2013-03-26, presumably until 2014-03-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily.\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, through Oral route, started on 2013-03-22, presumably until 2013-09-22, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain.\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2013-03-19, presumably until 2013-03-25\n- 24 HR felodipine 5 MG Extended Release Oral Tablet, through Oral route, started on 2013-03-24, presumably until 2013-03-24\n- sodium chloride 9 MG/ML Injection, started on 2013-03-18, presumably until 2013-03-21\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2013-03-26, presumably until 2014-03-26, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily.\n- levothyroxine sodium 0.1 MG Injection, through Intravenous route, started on 2013-03-19, presumably until 2013-03-26\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2013-03-18, presumably until 2013-03-25\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2013-03-19, presumably until 2013-03-25\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-03-18, presumably until 2013-03-25\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-03-18, presumably until 2013-03-18\n- 72 HR scopolamine 0.0139 MG/HR Transdermal System, through Transdermal route, started on 2013-03-24, presumably until 2013-03-26\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2013-03-18, presumably until 2013-03-25\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2013-03-22, presumably until 2013-03-23\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-02 13:51:00, ended at 2013-04-02 17:44:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.929\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2013-04-02 17:45:00, ended at 2013-04-04 09:48:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.2 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Platelets [#/volume] in Blood by Automated count: 694 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.5 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.1 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 162 (milligram per deciliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 2.9 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 186 (unit per liter)\n- Body height: 5' 7\" (inch (US))\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.2 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.8 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 11 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.09 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 14.2 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 32.3 (second)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.3 (percent)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 91.7 (femtoliter)\n- Prothrombin time (PT): 13.2 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Collection of venous blood by venipuncture\n\n### Condition\n- Acquired hypothyroidism\n- Abdominal pain\n- Essential hypertension\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n- Postprocedural state finding\n- Urinary tract infectious disease\n- Hyperlipidemia\n- Malignant carcinoid tumor\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2013-04-02, presumably until 2013-04-02\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2013-04-02, presumably until 2013-04-04\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, through Oral route, started on 2013-04-02, presumably until 2013-04-02\n- 24 HR felodipine 5 MG Extended Release Oral Tablet, through Oral route, started on 2013-04-02, presumably until 2013-04-03\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2013-04-02, presumably until 2013-04-02\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2013-04-03, presumably until 2013-04-03\n- lactulose 667 MG/ML Oral Solution, through Oral route, started on 2013-04-03, presumably until 2013-04-03\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-04-02, presumably until 2013-04-03\n- levothyroxine sodium 0.137 MG Oral Tablet, through Oral route, started on 2013-04-03, presumably until 2013-04-04\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2013-04-03, presumably until 2014-04-04, with intended 0 refill(s). Instructions: take 1 Tab by mouth Q12H.\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2013-04-02, presumably until 2013-04-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-23 13:11:00, ended at 2013-04-23 16:16:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.929\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abdominal pain\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2013-04-23, presumably until 2014-04-23, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-23 16:17:00, ended at 2013-04-23 23:59:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Leukocytes [#/volume] in Specimen by Automated count: 14.1 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 90.1 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 404 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 132 (millimole per liter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.1 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.0 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 78.2 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 94 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.6 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 162 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.02 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.75 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 59 (milliliter per minute per square meter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.3 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 228 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.4 (percent)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.0 (percent)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.26 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 11.06 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Abdominal pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-23 13:20:00, ended at 2013-07-23 23:59:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-21 10:22:00, ended at 2014-01-21 12:38:00\nThe patient in this visit was 69 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n\n### Condition\n- Malignant poorly differentiated neuroendocrine carcinoma\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-21 12:39:00, ended at 2014-01-21 23:59:00\nThe patient in this visit was 69 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.929\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant carcinoid tumor\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-21 10:11:00, ended at 2014-07-21 12:54:00\nThe patient in this visit was 69 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Diverticular disease of colon\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-21 12:55:00, ended at 2014-07-21 23:59:00\nThe patient in this visit was 69 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.929\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-07-22 00:00:00, ended at 2014-07-22 00:00:00\nThe patient in this visit was 69 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-01-20 09:59:00, ended at 2015-01-20 13:29:00\nThe patient in this visit was 70 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-01-20 13:30:00, ended at 2015-01-20 23:59:00\nThe patient in this visit was 70 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.362\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- ibuprofen 600 MG Oral Tablet, through Oral route, presumably until 2017-09-16, with intended 0 refill(s). Instructions: take 600 mg by mouth every 6 hours as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-02-02 12:02:00, ended at 2016-02-02 23:59:00\nThe patient in this visit was 71 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen; with contrast material(s)\n\n### Condition\n- Benign carcinoid tumor\n- Postoperative state\n- Malignant carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-02-02 14:52:50, ended at 2016-02-02 16:41:03\nThe patient in this visit was 71 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.52\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- temazepam 30 MG Oral Capsule, through Oral route, presumably until 2017-01-31, with intended 0 refill(s). Instructions: take 30 mg by mouth every bedtime as needed for Insomnia\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-02-13 00:00:00, ended at 2016-02-13 00:00:00\nThe patient in this visit was 71 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-31 10:31:00, ended at 2017-01-31 23:59:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Benign neuroendocrine tumor\n- Malignant neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-01-31 12:48:55, ended at 2017-01-31 15:51:30\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.52\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- alprazolam 0.5 MG Oral Tablet, through Oral route, started on 2017-07-12, presumably until 2017-08-20, with intended 0 refill(s). Instructions: take 1 Tab by mouth as directed Take one tablet 1/2 hour before MR, may repeat x1 prn\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-02-03 00:00:00, ended at 2017-02-03 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-01 00:00:00, ended at 2017-08-01 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-01 10:19:00, ended at 2017-08-01 23:59:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Benign neuroendocrine tumor\n- Disease of liver\n\n### Drug\n- gadoxetate, through Intravenous route, started on 2017-08-01, presumably until 2017-08-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-04 00:00:00, ended at 2017-08-04 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-20 00:00:00, ended at 2017-08-20 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- alprazolam 0.5 MG Oral Tablet, through Oral route, started on 2017-08-20, presumably until 2017-10-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth as directed Take one tablet 1/2 hour before MR, may repeat x1 prn\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-29 07:40:00, ended at 2017-08-29 23:59:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-29 07:40:00, ended at 2017-08-29 23:59:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-03 09:15:44, ended at 2017-09-03 10:00:07\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Benign neuroendocrine tumor\n\n### Drug\n- levothyroxine sodium 0.112 MG Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 112 mcg by mouth every morning before breakfast\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, presumably until 2017-09-03, with intended 0 refill(s). Instructions: take 100 mcg by mouth every morning before breakfast\n- omeprazole 20 MG Delayed Release Oral Capsule, through Oral route, presumably until 2017-09-16, with intended 0 refill(s). Instructions: take 20 mg by mouth as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-03 10:20:00, ended at 2017-09-03 23:59:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.65 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 25.1 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 117 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.1 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.9 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 120 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.85 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.8 (thousand per microliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Prothrombin time (PT): 13.4 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.8 (percent)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 230 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 29.9 (picogram)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 90.5 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-04 00:00:00, ended at 2017-09-04 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Anesthesia for intraperitoneal procedures in upper abdomen including laparoscopy; partial hepatectomy or management of liver hemorrhage (excluding liver biopsy)\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n\n### Condition\n- Benign neuroendocrine tumor\n\n### Drug\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2017-09-04, presumably until 2017-09-04\n- cefoxitin 1000 MG Injection, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- lidocaine hydrochloride 40 MG/ML Mucous Membrane Topical Solution, through Submucosal route, started on 2017-09-04, presumably until 2017-09-04\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2017-09-04, presumably until 2017-09-04\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- 250 ML lidocaine hydrochloride 8 MG/ML Injection, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- succinylcholine chloride 20 MG/ML Injectable Solution, started on 2017-09-04, presumably until 2017-09-04\n- midazolam 1 MG/ML Injectable Solution, started on 2017-09-04, presumably until 2017-09-04\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2017-09-04, presumably until 2017-09-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-09-04 11:10:00, ended at 2017-09-09 09:30:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 135 (unit per liter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.9 (milligram per deciliter)\n- Body height: 5' 7\" (inch (US))\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 99 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Prothrombin time (PT): 15.8 (second)\n- Glucose [Mass/volume] in Serum or Plasma: 265 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.80 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 462 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.3 (percent)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 205 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 21 - 50 (per high power field)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.61 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.7 (gram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 101 - 200 (per high power field)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 16.8 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 91.2 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Supplement Abdominal Wall with Autologous Tissue Substitute, Open Approach\n- Excision of Aortic Lymphatic, Open Approach\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Manipulation chest wall, such as cupping, percussing, and vibration to facilitate lung function; initial demonstration and/or evaluation\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Release Peritoneum, Open Approach\n- Morphometric analysis, tumor\n- Excision of Right Lobe Liver, Open Approach\n- Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device\n\n### Condition\n- Malignant neuroendocrine tumor\n- Neuroendocrine tumor\n- Primary diagnosis: Benign neuroendocrine tumor\n- Gastroesophageal reflux disease without esophagitis\n- Hyperlipidemia\n- Peritoneal adhesion\n- Benign neoplasm of peripheral nerves of abdomen\n- Metastatic carcinoid tumor\n- Abnormal findings on diagnostic imaging of lung\n- Essential hypertension\n- Postoperative hypothyroidism\n\n### Drug\n- benzocaine 15 MG / menthol 3.6 MG Oral Lozenge, through Submucosal route, started on 2017-09-08, presumably until 2017-09-08\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2017-09-07, presumably until 2017-09-07\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2017-09-04, presumably until 2017-09-07\n- levothyroxine sodium 0.112 MG Oral Tablet, through Oral route, started on 2017-09-05, presumably until 2017-09-09\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2017-09-04, presumably until 2017-09-04\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2017-09-04, presumably until 2017-09-09\n- cefazolin 1000 MG Injection, started on 2017-09-04, presumably until 2017-09-04\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2017-09-05, presumably until 2017-09-08\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2017-09-04, presumably until 2017-09-08\n- acetaminophen 32 MG/ML Oral Solution, through Oral route, started on 2017-09-06, presumably until 2018-09-09, with intended 1 refill(s). Instructions: take 20.3 mL by mouth every 6 hours\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-09-04, presumably until 2017-09-09\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2017-09-05, presumably until 2017-09-06\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2017-09-09, presumably until 2017-11-21, with intended 1 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2017-09-04, presumably until 2017-09-04\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2017-09-04, presumably until 2017-09-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-09-16 00:00:00, ended at 2017-09-16 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n- Postprocedural fever\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-16 15:42:00, ended at 2017-09-16 16:46:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Disorder of kidney and/or ureter\n- Malignant neuroendocrine tumor\n- Benign neuroendocrine tumor\n- Postprocedural fever\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-16 16:47:00, ended at 2017-09-16 18:29:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.85 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.7 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 457 (unit per liter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- Glucagon [Mass/volume] in Serum or Plasma: 71 (picogram per milliliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 22.35 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 90.3 (percent)\n- Pancreatic polypeptide [Mass/volume] in Serum or Plasma: 62 (picogram per milliliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 93 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.69 (million per microliter)\n- Gastrin [Mass/volume] in Serum or Plasma: 28 (picogram per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 207 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.9 (gram per deciliter)\n- Proinsulin [Moles/volume] in Serum or Plasma: 72 (picomole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 132 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.1 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.10 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.25 (thousand per microliter)\n- Chromogranin A [Moles/volume] in Serum or Plasma: 74 (nanogram per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 24.8 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 4.5 (percent)\n- MCH [Entitic mass] by Automated count: 29.4 (picogram)\n- MCV [Entitic volume] by Automated count: 88.6 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 587 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Enolase.neuron specific [Mass/volume] in Serum or Plasma by Immunoassay: 2.2 (microgram per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.4 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Benign neuroendocrine tumor\n- Postprocedural fever\n- Malignant neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-09-16 18:30:00, ended at 2017-09-20 12:16:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 188 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 346 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.74 (milligram per deciliter)\n- Lactate [Moles/volume] in Blood: 1.6 (millimole per liter)\n- Platelets [#/volume] in Blood by Automated count: 599 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 7.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 17.1 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 89.1 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 131 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.9 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 1.7 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Body height: 5' 7.52\" (inch (US))\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.6 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.8 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 5.7 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Prothrombin time (PT): 15.1 (second)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.23 (million per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n\n### Procedure\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A detailed or comprehensive history; A detailed or comprehensive examination; and Medical decision making that is straightforward or of \n- Image-guided fluid collection drainage by catheter (eg, abscess, hematoma, seroma, lymphocele, cyst); peritoneal or retroperitoneal, percutaneous\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device\n- Drainage of Peritoneal Cavity with Drainage Device, Percutaneous Approach\n\n### Condition\n- Acquired absence of organ\n- Leukocytosis\n- Streptococcal infectious disease\n- Infection due to enterococcus\n- Late effect of complications of procedure\n- Primary diagnosis: Ascites\n- Benign neuroendocrine tumor\n- Hyperlipidemia\n- Hypothyroidism\n- Postprocedural infection\n- Bacterial infectious disease\n- Essential hypertension\n- Abscess of peritoneum\n- Disorder of digestive system\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2017-09-17, presumably until 2017-09-19\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-09-18, presumably until 2017-09-18\n- Lacticaseibacillus rhamnosus GG 15000000000 UNT Oral Capsule, through Oral route, started on 2017-09-20, presumably until 2017-11-21, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-09-16, presumably until 2017-09-18\n- ibuprofen 400 MG Oral Tablet, through Oral route, started on 2017-09-16, presumably until 2017-10-20, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2017-09-16, presumably until 2017-09-19\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2017-09-16, presumably until 2017-09-16\n- amoxicillin 80 MG/ML / clavulanate 11.4 MG/ML Oral Suspension, through Oral route, started on 2017-09-19, presumably until 2017-09-22, with intended 0 refill(s). Instructions: take 10.94 mL by mouth 2 times a day for 2 days\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2017-09-19, presumably until 2017-09-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-09-17 00:00:00, ended at 2017-09-17 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Image-guided fluid collection drainage by catheter (eg, abscess, hematoma, seroma, lymphocele, cyst); peritoneal or retroperitoneal, percutaneous\n\n### Condition\n- Abscess of peritoneum\n- Benign neuroendocrine tumor\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2017-09-17, presumably until 2017-09-17\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2017-09-17, presumably until 2017-09-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-09-26 00:00:00, ended at 2017-09-26 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-09-30 00:00:00, ended at 2017-09-30 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amoxicillin 80 MG/ML / clavulanate 11.4 MG/ML Oral Suspension, started on 2017-10-02, presumably until 2017-10-02, with intended 0 refill(s). Instructions: take 10.94 milliliter twice a day for 2 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-10-02 00:00:00, ended at 2017-10-02 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cystocele\n- Primary diagnosis: Benign neuroendocrine tumor\n- Hydronephrosis\n- Ascites\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-02 16:10:00, ended at 2017-10-02 16:52:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Benign neuroendocrine tumor\n- Hydronephrosis\n- Malignant neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-02 16:53:00, ended at 2017-10-02 23:59:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 2.2 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.93 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.35 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 12.94 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 131 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 5.1 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.1 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.0 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 133 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Chromogranin A [Moles/volume] in Serum or Plasma: 93 (nanogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.3 (percent)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 455 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.55 (million per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.3 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.1 (femtoliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 15.4 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.01 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 84.2 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 243 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.6 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-10-03 00:00:00, ended at 2017-10-03 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2017-10-03, presumably until 2017-10-03\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2017-10-03, presumably until 2017-10-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-03 08:30:00, ended at 2017-10-03 13:38:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 16.0 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 4.9 (percent)\n- MCH [Entitic mass] by Automated count: 29.4 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 87.5 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.13 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.53 (million per microliter)\n- MCV [Entitic volume] by Automated count: 87.6 (femtoliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.79 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 452 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 13.97 (thousand per microliter)\n- Body height: 5' 7\" (inch (US))\n- Hemoglobin [Mass/volume] in Blood: 10.4 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.1 (percent)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Exchange of previously placed abscess or cyst drainage catheter under radiological guidance (separate procedure)\n- Change of percutaneous tube or drainage catheter with contrast monitoring (eg, genitourinary system, abscess), radiological supervision and interpretation\n\n### Condition\n- Hydronephrosis\n- Ascites\n- Benign neuroendocrine tumor\n\n### Drug\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-10-03, presumably until 2017-10-03\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-10-03, presumably until 2017-10-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-10-14 00:00:00, ended at 2017-10-14 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2017-10-14, presumably until 2017-10-14\n- midazolam 1 MG/ML Injectable Solution, started on 2017-10-14, presumably until 2017-10-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-14 13:17:00, ended at 2017-10-14 19:48:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- MCV [Entitic volume] by Automated count: 88.6 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 534 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.10 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.53 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.1 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 73.6 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 11.3 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.83 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.5 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 29.4 (picogram)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.9 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 7.69 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 20.1 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.2 (percent)\n\n### Procedure\n- Change of percutaneous tube or drainage catheter with contrast monitoring (eg, genitourinary system, abscess), radiological supervision and interpretation\n- Change Drainage Device in Liver, External Approach\n- Exchange of previously placed abscess or cyst drainage catheter under radiological guidance (separate procedure)\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Abscess of peritoneum\n- Late effect of complications of procedure\n- Malignant neuroendocrine tumor\n- Postoperative hypothyroidism\n- Exocrine pancreatic insufficiency\n- Neuroendocrine tumor\n- Hyperlipidemia\n- Postprocedural infection\n- Essential hypertension\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-10-14, presumably until 2017-10-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-10-16 00:00:00, ended at 2017-10-16 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Ascites\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-21 11:38:00, ended at 2017-10-21 13:16:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen; with contrast material(s)\n\n### Condition\n- Hydronephrosis\n- Ascites\n- Hydroureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-21 13:17:00, ended at 2017-10-21 15:33:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- Removal of Drainage Device from Peritoneal Cavity, External Approach\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-21 00:00:00, ended at 2017-11-21 00:00:00\nThe patient in this visit was 73 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-21 12:59:42, ended at 2017-11-21 15:06:33\nThe patient in this visit was 73 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.008\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neuroendocrine tumor\n- Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-05-29 10:55:00, ended at 2018-05-29 23:59:00\nThe patient in this visit was 73 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Benign neuroendocrine tumor\n\n### Drug\n- gadoxetate, through Intravenous route, started on 2018-05-29, presumably until 2018-05-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-05-29 12:56:32, ended at 2018-05-29 14:24:53\nThe patient in this visit was 73 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.008\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n- Malignant neuroendocrine tumor\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, presumably until 2018-12-01, with intended 0 refill(s). Instructions: take 50,000 Units by mouth every 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-01 09:58:00, ended at 2018-12-01 23:59:00\nThe patient in this visit was 74 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s), followed by contrast material(s) and further sequences\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Benign neuroendocrine tumor\n- Disease of liver\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2018-12-01, presumably until 2018-12-01\n- gadoxetate, through Intravenous route, started on 2018-12-01, presumably until 2018-12-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-12-01 12:31:08, ended at 2018-12-01 14:51:17\nThe patient in this visit was 74 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.008\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neuroendocrine tumor\n- Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-21 00:00:00, ended at 2018-12-21 00:00:00\nThe patient in this visit was 74 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-01 10:35:00, ended at 2019-06-01 23:59:00\nThe patient in this visit was 74 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s), followed by contrast material(s) and further sequences\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Benign neuroendocrine tumor\n- Malignant neuroendocrine tumor\n\n### Drug\n- gadoxetate, through Intravenous route, started on 2019-06-01, presumably until 2019-06-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-01 12:06:47, ended at 2019-06-01 16:42:17\nThe patient in this visit was 74 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.26\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign neuroendocrine tumor\n- Malignant neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-03 00:00:00, ended at 2019-06-03 00:00:00\nThe patient in this visit was 74 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-03 10:21:00, ended at 2019-12-03 23:59:00\nThe patient in this visit was 75 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Benign neuroendocrine tumor\n\n### Drug\n- gadoxetate, through Intravenous route, started on 2019-12-03, presumably until 2019-12-03\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Malignant tumor of pancreas within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-01-21 00:00:00, ended at 2013-01-21 00:00:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-01-21 13:35:00, ended at 2013-01-21 17:02:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Endoscopy and biopsy of upper gastrointestinal tract\n- Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s) (includes endoscopic ultrasound examination of the esophagus, stomach, and either the duodenum or a surgicall\n- Ultrasonography of digestive system\n- Morphometric analysis, tumor\n\n### Condition\n- Disorder of pancreas\n- Acquired hypothyroidism\n- Benign carcinoid tumor\n- Essential hypertension\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2013-01-21, presumably until 2013-01-21\n- benzocaine 140 MG/ML / butamben 20 MG/ML / tetracaine 20 MG/ML Mucosal Spray, through Topical route, started on 2013-01-21, presumably until 2013-01-21\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-01-21, presumably until 2013-01-21\n- midazolam 1 MG/ML Injectable Solution, started on 2013-01-21, presumably until 2013-01-21\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-05 08:15:00, ended at 2013-02-05 10:00:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.75\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of pancreas\n\n### Drug\n- atorvastatin 10 MG Oral Tablet, through Oral route, presumably until 2015-01-20. Instructions: take  by mouth Every Day.  \n- 24 HR felodipine 10 MG Extended Release Oral Tablet, through Oral route. Instructions: take 10 mg by mouth daily at noon \n- levothyroxine sodium 0.137 MG Oral Tablet, through Oral route, presumably until 2017-09-03. Instructions: take 112 mcg by mouth every day \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-05 10:01:00, ended at 2013-02-05 10:59:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.4 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 115 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 121 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.1 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.01 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- MCH [Entitic mass] by Automated count: 31.3 (picogram)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.47 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.9 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 28.4 (percent)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 273 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 93.7 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 64.6 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.59 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.6 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.45 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-05 11:00:00, ended at 2013-02-05 23:59:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen; without contrast material, followed by contrast material(s) and further sections\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n\n### Condition\n- Disorder of pancreas\n- Intra-abdominal and pelvic swelling, mass and lump\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-12 08:09:00, ended at 2013-02-12 11:13:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-12 11:14:00, ended at 2013-02-12 13:05:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Neoplasm of digestive tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-17 14:32:00, ended at 2013-03-17 23:59:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.929\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2013-03-18 00:00:00, ended at 2013-03-18 00:00:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Anesthesia for intraperitoneal procedures in upper abdomen including laparoscopy; pancreatectomy, partial or total (eg, Whipple procedure)\n\n### Condition\n- Primary malignant neoplasm of pancreas\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, started on 2013-03-18, presumably until 2013-03-18\n- 1 ML octreotide 0.1 MG/ML Injection, started on 2013-03-18, presumably until 2013-03-18\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2013-03-18, presumably until 2013-03-18\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2013-03-18, presumably until 2013-03-18\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2013-03-18, presumably until 2013-03-18\n- cefoxitin 1000 MG Injection, through Intravenous route, started on 2013-03-18, presumably until 2013-03-18\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-03-18, presumably until 2013-03-18\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-03-18, presumably until 2013-03-18\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-03-18, presumably until 2013-03-18\n- midazolam 1 MG/ML Injectable Solution, started on 2013-03-18, presumably until 2013-03-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2013-03-18 00:00:00, ended at 2013-03-18 00:00:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- water 1000 MG/ML Irrigation Solution, through Topical route, started on 2013-03-18, presumably until 2013-03-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2013-03-18 08:17:00, ended at 2013-03-26 10:15:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- MCH [Entitic mass] by Automated count: 31.3 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 62 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.97 (million per microliter)\n- Globulin [Mass/volume] in Serum: 2.6 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 92.9 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 202 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.2 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 25.7 (second)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Body height: 5' 7.008\" (inch (US))\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 5.8 (gram per deciliter)\n- Prothrombin time (PT): 15.3 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 84 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 207 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.3 (ratio)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.0 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n\n### Procedure\n- Cholecystectomy\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Radiologic examination, abdomen; single anteroposterior view\n- Morphometric analysis, tumor\n- Radical pancreaticoduodenectomy\n- Collection of venous blood by venipuncture\n\n### Condition\n- Low blood pressure\n- Malignant carcinoid tumor\n- Nausea\n- Essential hypertension\n- Primary malignant neoplasm of gastrointestinal tract\n- Chronic cholecystitis\n- Postprocedural state finding\n- Acquired hypothyroidism\n- Hyperlipidemia\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2013-03-25, presumably until 2013-03-25\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2013-03-18, presumably until 2013-03-22\n- 1 ML ketorolac tromethamine 30 MG/ML Injection, started on 2013-03-19, presumably until 2013-03-22\n- 1 ML octreotide 0.05 MG/ML Injection, started on 2013-03-19, presumably until 2013-03-24\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2013-03-26, presumably until 2014-03-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily.\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, through Oral route, started on 2013-03-22, presumably until 2013-09-22, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain.\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2013-03-19, presumably until 2013-03-25\n- 24 HR felodipine 5 MG Extended Release Oral Tablet, through Oral route, started on 2013-03-24, presumably until 2013-03-24\n- sodium chloride 9 MG/ML Injection, started on 2013-03-18, presumably until 2013-03-21\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2013-03-26, presumably until 2014-03-26, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily.\n- levothyroxine sodium 0.1 MG Injection, through Intravenous route, started on 2013-03-19, presumably until 2013-03-26\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2013-03-18, presumably until 2013-03-25\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2013-03-19, presumably until 2013-03-25\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-03-18, presumably until 2013-03-25\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-03-18, presumably until 2013-03-18\n- 72 HR scopolamine 0.0139 MG/HR Transdermal System, through Transdermal route, started on 2013-03-24, presumably until 2013-03-26\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2013-03-18, presumably until 2013-03-25\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2013-03-22, presumably until 2013-03-23\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-02 13:51:00, ended at 2013-04-02 17:44:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.929\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2013-04-02 17:45:00, ended at 2013-04-04 09:48:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.2 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Platelets [#/volume] in Blood by Automated count: 694 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.5 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.1 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 162 (milligram per deciliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 2.9 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 186 (unit per liter)\n- Body height: 5' 7\" (inch (US))\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.2 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.8 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 11 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.09 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 14.2 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 32.3 (second)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.3 (percent)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 91.7 (femtoliter)\n- Prothrombin time (PT): 13.2 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Collection of venous blood by venipuncture\n\n### Condition\n- Acquired hypothyroidism\n- Abdominal pain\n- Essential hypertension\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n- Postprocedural state finding\n- Urinary tract infectious disease\n- Hyperlipidemia\n- Malignant carcinoid tumor\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2013-04-02, presumably until 2013-04-02\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2013-04-02, presumably until 2013-04-04\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, through Oral route, started on 2013-04-02, presumably until 2013-04-02\n- 24 HR felodipine 5 MG Extended Release Oral Tablet, through Oral route, started on 2013-04-02, presumably until 2013-04-03\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2013-04-02, presumably until 2013-04-02\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2013-04-03, presumably until 2013-04-03\n- lactulose 667 MG/ML Oral Solution, through Oral route, started on 2013-04-03, presumably until 2013-04-03\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-04-02, presumably until 2013-04-03\n- levothyroxine sodium 0.137 MG Oral Tablet, through Oral route, started on 2013-04-03, presumably until 2013-04-04\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2013-04-03, presumably until 2014-04-04, with intended 0 refill(s). Instructions: take 1 Tab by mouth Q12H.\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2013-04-02, presumably until 2013-04-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-23 13:11:00, ended at 2013-04-23 16:16:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.929\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abdominal pain\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2013-04-23, presumably until 2014-04-23, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-23 16:17:00, ended at 2013-04-23 23:59:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Leukocytes [#/volume] in Specimen by Automated count: 14.1 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 90.1 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 404 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 132 (millimole per liter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.1 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.0 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 78.2 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 94 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.6 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 162 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.02 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.75 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 59 (milliliter per minute per square meter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.3 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 228 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.4 (percent)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.0 (percent)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.26 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 11.06 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Abdominal pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-23 13:20:00, ended at 2013-07-23 23:59:00\nThe patient in this visit was 68 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-21 10:22:00, ended at 2014-01-21 12:38:00\nThe patient in this visit was 69 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n\n### Condition\n- Malignant poorly differentiated neuroendocrine carcinoma\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-21 12:39:00, ended at 2014-01-21 23:59:00\nThe patient in this visit was 69 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.929\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant carcinoid tumor\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-21 10:11:00, ended at 2014-07-21 12:54:00\nThe patient in this visit was 69 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Diverticular disease of colon\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-21 12:55:00, ended at 2014-07-21 23:59:00\nThe patient in this visit was 69 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.929\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-07-22 00:00:00, ended at 2014-07-22 00:00:00\nThe patient in this visit was 69 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-01-20 09:59:00, ended at 2015-01-20 13:29:00\nThe patient in this visit was 70 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-01-20 13:30:00, ended at 2015-01-20 23:59:00\nThe patient in this visit was 70 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.362\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- ibuprofen 600 MG Oral Tablet, through Oral route, presumably until 2017-09-16, with intended 0 refill(s). Instructions: take 600 mg by mouth every 6 hours as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-02-02 12:02:00, ended at 2016-02-02 23:59:00\nThe patient in this visit was 71 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen; with contrast material(s)\n\n### Condition\n- Benign carcinoid tumor\n- Postoperative state\n- Malignant carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-02-02 14:52:50, ended at 2016-02-02 16:41:03\nThe patient in this visit was 71 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.52\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- temazepam 30 MG Oral Capsule, through Oral route, presumably until 2017-01-31, with intended 0 refill(s). Instructions: take 30 mg by mouth every bedtime as needed for Insomnia\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-02-13 00:00:00, ended at 2016-02-13 00:00:00\nThe patient in this visit was 71 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-31 10:31:00, ended at 2017-01-31 23:59:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Benign neuroendocrine tumor\n- Malignant neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-01-31 12:48:55, ended at 2017-01-31 15:51:30\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.52\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- alprazolam 0.5 MG Oral Tablet, through Oral route, started on 2017-07-12, presumably until 2017-08-20, with intended 0 refill(s). Instructions: take 1 Tab by mouth as directed Take one tablet 1/2 hour before MR, may repeat x1 prn\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-02-03 00:00:00, ended at 2017-02-03 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-01 00:00:00, ended at 2017-08-01 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-01 10:19:00, ended at 2017-08-01 23:59:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Benign neuroendocrine tumor\n- Disease of liver\n\n### Drug\n- gadoxetate, through Intravenous route, started on 2017-08-01, presumably until 2017-08-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-04 00:00:00, ended at 2017-08-04 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-20 00:00:00, ended at 2017-08-20 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- alprazolam 0.5 MG Oral Tablet, through Oral route, started on 2017-08-20, presumably until 2017-10-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth as directed Take one tablet 1/2 hour before MR, may repeat x1 prn\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-29 07:40:00, ended at 2017-08-29 23:59:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-29 07:40:00, ended at 2017-08-29 23:59:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-03 09:15:44, ended at 2017-09-03 10:00:07\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Benign neuroendocrine tumor\n\n### Drug\n- levothyroxine sodium 0.112 MG Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 112 mcg by mouth every morning before breakfast\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, presumably until 2017-09-03, with intended 0 refill(s). Instructions: take 100 mcg by mouth every morning before breakfast\n- omeprazole 20 MG Delayed Release Oral Capsule, through Oral route, presumably until 2017-09-16, with intended 0 refill(s). Instructions: take 20 mg by mouth as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-03 10:20:00, ended at 2017-09-03 23:59:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.65 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 25.1 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 117 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.1 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.9 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 120 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.85 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.8 (thousand per microliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Prothrombin time (PT): 13.4 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.8 (percent)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 230 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 29.9 (picogram)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 90.5 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-04 00:00:00, ended at 2017-09-04 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Anesthesia for intraperitoneal procedures in upper abdomen including laparoscopy; partial hepatectomy or management of liver hemorrhage (excluding liver biopsy)\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n\n### Condition\n- Benign neuroendocrine tumor\n\n### Drug\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2017-09-04, presumably until 2017-09-04\n- cefoxitin 1000 MG Injection, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- lidocaine hydrochloride 40 MG/ML Mucous Membrane Topical Solution, through Submucosal route, started on 2017-09-04, presumably until 2017-09-04\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2017-09-04, presumably until 2017-09-04\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- 250 ML lidocaine hydrochloride 8 MG/ML Injection, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- succinylcholine chloride 20 MG/ML Injectable Solution, started on 2017-09-04, presumably until 2017-09-04\n- midazolam 1 MG/ML Injectable Solution, started on 2017-09-04, presumably until 2017-09-04\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2017-09-04, presumably until 2017-09-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-09-04 11:10:00, ended at 2017-09-09 09:30:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 135 (unit per liter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.9 (milligram per deciliter)\n- Body height: 5' 7\" (inch (US))\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 99 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Prothrombin time (PT): 15.8 (second)\n- Glucose [Mass/volume] in Serum or Plasma: 265 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.80 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 462 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.3 (percent)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 205 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 21 - 50 (per high power field)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.61 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.7 (gram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 101 - 200 (per high power field)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 16.8 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 91.2 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Supplement Abdominal Wall with Autologous Tissue Substitute, Open Approach\n- Excision of Aortic Lymphatic, Open Approach\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Manipulation chest wall, such as cupping, percussing, and vibration to facilitate lung function; initial demonstration and/or evaluation\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Release Peritoneum, Open Approach\n- Morphometric analysis, tumor\n- Excision of Right Lobe Liver, Open Approach\n- Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device\n\n### Condition\n- Malignant neuroendocrine tumor\n- Neuroendocrine tumor\n- Primary diagnosis: Benign neuroendocrine tumor\n- Gastroesophageal reflux disease without esophagitis\n- Hyperlipidemia\n- Peritoneal adhesion\n- Benign neoplasm of peripheral nerves of abdomen\n- Metastatic carcinoid tumor\n- Abnormal findings on diagnostic imaging of lung\n- Essential hypertension\n- Postoperative hypothyroidism\n\n### Drug\n- benzocaine 15 MG / menthol 3.6 MG Oral Lozenge, through Submucosal route, started on 2017-09-08, presumably until 2017-09-08\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2017-09-07, presumably until 2017-09-07\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2017-09-04, presumably until 2017-09-07\n- levothyroxine sodium 0.112 MG Oral Tablet, through Oral route, started on 2017-09-05, presumably until 2017-09-09\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2017-09-04, presumably until 2017-09-04\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2017-09-04, presumably until 2017-09-09\n- cefazolin 1000 MG Injection, started on 2017-09-04, presumably until 2017-09-04\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2017-09-05, presumably until 2017-09-08\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2017-09-04, presumably until 2017-09-08\n- acetaminophen 32 MG/ML Oral Solution, through Oral route, started on 2017-09-06, presumably until 2018-09-09, with intended 1 refill(s). Instructions: take 20.3 mL by mouth every 6 hours\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-09-04, presumably until 2017-09-09\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2017-09-05, presumably until 2017-09-06\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-09-04, presumably until 2017-09-04\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2017-09-09, presumably until 2017-11-21, with intended 1 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2017-09-04, presumably until 2017-09-04\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2017-09-04, presumably until 2017-09-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-09-16 00:00:00, ended at 2017-09-16 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n- Postprocedural fever\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-16 15:42:00, ended at 2017-09-16 16:46:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Disorder of kidney and/or ureter\n- Malignant neuroendocrine tumor\n- Benign neuroendocrine tumor\n- Postprocedural fever\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-16 16:47:00, ended at 2017-09-16 18:29:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.85 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.7 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 457 (unit per liter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- Glucagon [Mass/volume] in Serum or Plasma: 71 (picogram per milliliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 22.35 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 90.3 (percent)\n- Pancreatic polypeptide [Mass/volume] in Serum or Plasma: 62 (picogram per milliliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 93 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.69 (million per microliter)\n- Gastrin [Mass/volume] in Serum or Plasma: 28 (picogram per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 207 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.9 (gram per deciliter)\n- Proinsulin [Moles/volume] in Serum or Plasma: 72 (picomole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 132 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.1 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.10 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.25 (thousand per microliter)\n- Chromogranin A [Moles/volume] in Serum or Plasma: 74 (nanogram per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 24.8 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 4.5 (percent)\n- MCH [Entitic mass] by Automated count: 29.4 (picogram)\n- MCV [Entitic volume] by Automated count: 88.6 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 587 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Enolase.neuron specific [Mass/volume] in Serum or Plasma by Immunoassay: 2.2 (microgram per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.4 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Benign neuroendocrine tumor\n- Postprocedural fever\n- Malignant neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2017-09-16 18:30:00, ended at 2017-09-20 12:16:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 188 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 346 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.74 (milligram per deciliter)\n- Lactate [Moles/volume] in Blood: 1.6 (millimole per liter)\n- Platelets [#/volume] in Blood by Automated count: 599 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 7.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 17.1 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 89.1 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 131 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.9 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 1.7 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Body height: 5' 7.52\" (inch (US))\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.6 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.8 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 5.7 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Prothrombin time (PT): 15.1 (second)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.23 (million per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n\n### Procedure\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A detailed or comprehensive history; A detailed or comprehensive examination; and Medical decision making that is straightforward or of \n- Image-guided fluid collection drainage by catheter (eg, abscess, hematoma, seroma, lymphocele, cyst); peritoneal or retroperitoneal, percutaneous\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device\n- Drainage of Peritoneal Cavity with Drainage Device, Percutaneous Approach\n\n### Condition\n- Acquired absence of organ\n- Leukocytosis\n- Streptococcal infectious disease\n- Infection due to enterococcus\n- Late effect of complications of procedure\n- Primary diagnosis: Ascites\n- Benign neuroendocrine tumor\n- Hyperlipidemia\n- Hypothyroidism\n- Postprocedural infection\n- Bacterial infectious disease\n- Essential hypertension\n- Abscess of peritoneum\n- Disorder of digestive system\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2017-09-17, presumably until 2017-09-19\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-09-18, presumably until 2017-09-18\n- Lacticaseibacillus rhamnosus GG 15000000000 UNT Oral Capsule, through Oral route, started on 2017-09-20, presumably until 2017-11-21, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-09-16, presumably until 2017-09-18\n- ibuprofen 400 MG Oral Tablet, through Oral route, started on 2017-09-16, presumably until 2017-10-20, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2017-09-16, presumably until 2017-09-19\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2017-09-16, presumably until 2017-09-16\n- amoxicillin 80 MG/ML / clavulanate 11.4 MG/ML Oral Suspension, through Oral route, started on 2017-09-19, presumably until 2017-09-22, with intended 0 refill(s). Instructions: take 10.94 mL by mouth 2 times a day for 2 days\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2017-09-19, presumably until 2017-09-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-09-17 00:00:00, ended at 2017-09-17 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Image-guided fluid collection drainage by catheter (eg, abscess, hematoma, seroma, lymphocele, cyst); peritoneal or retroperitoneal, percutaneous\n\n### Condition\n- Abscess of peritoneum\n- Benign neuroendocrine tumor\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2017-09-17, presumably until 2017-09-17\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2017-09-17, presumably until 2017-09-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-09-26 00:00:00, ended at 2017-09-26 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-09-30 00:00:00, ended at 2017-09-30 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amoxicillin 80 MG/ML / clavulanate 11.4 MG/ML Oral Suspension, started on 2017-10-02, presumably until 2017-10-02, with intended 0 refill(s). Instructions: take 10.94 milliliter twice a day for 2 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-10-02 00:00:00, ended at 2017-10-02 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cystocele\n- Primary diagnosis: Benign neuroendocrine tumor\n- Hydronephrosis\n- Ascites\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-02 16:10:00, ended at 2017-10-02 16:52:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Benign neuroendocrine tumor\n- Hydronephrosis\n- Malignant neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-02 16:53:00, ended at 2017-10-02 23:59:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 2.2 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.93 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.35 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 12.94 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 131 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 5.1 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.1 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.0 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 133 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Chromogranin A [Moles/volume] in Serum or Plasma: 93 (nanogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.3 (percent)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 455 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.55 (million per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.3 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.1 (femtoliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 15.4 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.01 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 84.2 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 243 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.6 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-10-03 00:00:00, ended at 2017-10-03 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2017-10-03, presumably until 2017-10-03\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2017-10-03, presumably until 2017-10-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-03 08:30:00, ended at 2017-10-03 13:38:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 16.0 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 4.9 (percent)\n- MCH [Entitic mass] by Automated count: 29.4 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 87.5 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.13 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.53 (million per microliter)\n- MCV [Entitic volume] by Automated count: 87.6 (femtoliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.79 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 452 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 13.97 (thousand per microliter)\n- Body height: 5' 7\" (inch (US))\n- Hemoglobin [Mass/volume] in Blood: 10.4 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.1 (percent)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Exchange of previously placed abscess or cyst drainage catheter under radiological guidance (separate procedure)\n- Change of percutaneous tube or drainage catheter with contrast monitoring (eg, genitourinary system, abscess), radiological supervision and interpretation\n\n### Condition\n- Hydronephrosis\n- Ascites\n- Benign neuroendocrine tumor\n\n### Drug\n- 2 ML ondansetron 2 MG/ML Injection, started on 2017-10-03, presumably until 2017-10-03\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-10-03, presumably until 2017-10-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2017-10-14 00:00:00, ended at 2017-10-14 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2017-10-14, presumably until 2017-10-14\n- midazolam 1 MG/ML Injectable Solution, started on 2017-10-14, presumably until 2017-10-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-14 13:17:00, ended at 2017-10-14 19:48:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- MCV [Entitic volume] by Automated count: 88.6 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 534 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.10 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.53 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.1 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 73.6 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 11.3 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.83 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.5 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 29.4 (picogram)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.9 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 7.69 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 20.1 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.2 (percent)\n\n### Procedure\n- Change of percutaneous tube or drainage catheter with contrast monitoring (eg, genitourinary system, abscess), radiological supervision and interpretation\n- Change Drainage Device in Liver, External Approach\n- Exchange of previously placed abscess or cyst drainage catheter under radiological guidance (separate procedure)\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Abscess of peritoneum\n- Late effect of complications of procedure\n- Malignant neuroendocrine tumor\n- Postoperative hypothyroidism\n- Exocrine pancreatic insufficiency\n- Neuroendocrine tumor\n- Hyperlipidemia\n- Postprocedural infection\n- Essential hypertension\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-10-14, presumably until 2017-10-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-10-16 00:00:00, ended at 2017-10-16 00:00:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Ascites\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-21 11:38:00, ended at 2017-10-21 13:16:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen; with contrast material(s)\n\n### Condition\n- Hydronephrosis\n- Ascites\n- Hydroureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-10-21 13:17:00, ended at 2017-10-21 15:33:00\nThe patient in this visit was 72 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- Removal of Drainage Device from Peritoneal Cavity, External Approach\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-21 00:00:00, ended at 2017-11-21 00:00:00\nThe patient in this visit was 73 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-21 12:59:42, ended at 2017-11-21 15:06:33\nThe patient in this visit was 73 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.008\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neuroendocrine tumor\n- Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-05-29 10:55:00, ended at 2018-05-29 23:59:00\nThe patient in this visit was 73 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Benign neuroendocrine tumor\n\n### Drug\n- gadoxetate, through Intravenous route, started on 2018-05-29, presumably until 2018-05-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-05-29 12:56:32, ended at 2018-05-29 14:24:53\nThe patient in this visit was 73 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.008\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n- Malignant neuroendocrine tumor\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, presumably until 2018-12-01, with intended 0 refill(s). Instructions: take 50,000 Units by mouth every 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-01 09:58:00, ended at 2018-12-01 23:59:00\nThe patient in this visit was 74 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s), followed by contrast material(s) and further sequences\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Benign neuroendocrine tumor\n- Disease of liver\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2018-12-01, presumably until 2018-12-01\n- gadoxetate, through Intravenous route, started on 2018-12-01, presumably until 2018-12-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-12-01 12:31:08, ended at 2018-12-01 14:51:17\nThe patient in this visit was 74 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.008\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neuroendocrine tumor\n- Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-21 00:00:00, ended at 2018-12-21 00:00:00\nThe patient in this visit was 74 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-01 10:35:00, ended at 2019-06-01 23:59:00\nThe patient in this visit was 74 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s), followed by contrast material(s) and further sequences\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Benign neuroendocrine tumor\n- Malignant neuroendocrine tumor\n\n### Drug\n- gadoxetate, through Intravenous route, started on 2019-06-01, presumably until 2019-06-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-01 12:06:47, ended at 2019-06-01 16:42:17\nThe patient in this visit was 74 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.26\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign neuroendocrine tumor\n- Malignant neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-03 00:00:00, ended at 2019-06-03 00:00:00\nThe patient in this visit was 74 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neuroendocrine tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-03 10:21:00, ended at 2019-12-03 23:59:00\nThe patient in this visit was 75 years old, unknown race, Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Benign neuroendocrine tumor\n\n### Drug\n- gadoxetate, through Intravenous route, started on 2019-12-03, presumably until 2019-12-03\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Malignant tumor of pancreas within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of pancreatic_cancer means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "1d49a77a25c4d45b8abd666506c2efd284e8e93f2ad719867f2803c1a544f0ce", "prompt_hash": "fc02cfcdc43e146abeb5b2caee3837b861b342e864265a09fe25d1d32c957076", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
{"doc_id": 1, "doc": {"person_id": 115973205, "visit_occurrence_id": 158472964, "death_date": null, "visit_concept_name": "Case Management Visit", "visit_start_datetime": "2020-04-22 00:00:00", "visit_end_datetime": "2020-04-22 00:00:00", "visit_length_in_hours": 0.0, "integrated_visit_record": "## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-22 00:00:00, ended at 2020-04-22 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 94, "patient_first_visit_date": "2011-07-29 14:58:00", "patient_last_visit_date": "2021-08-21 00:00:00", "end_obs_date": "2021-04-22", "hypertension_type": "new", "hypertension_one_year_diagnosis": 0, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "new", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "new", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "recurrent", "type_ii_diabetes_one_year_diagnosis": 1, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "recurrent", "pancreatic_cancer_one_year_diagnosis": 1, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "recurrent", "intestinal_cancer_one_year_diagnosis": 1, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "recurrent", "lung_cancer_one_year_diagnosis": 1, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 181, "cumulated_visit_num": 181, "cumulated_approximate_token_count": 64029, "visit_cumulated": "## Visit\nThis visit record, was from Outpatient Visit, started at 2011-07-29 14:58:00, ended at 2011-07-29 23:59:00\nThe patient in this visit was 34 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' .5\" (inch (US))\n\n### Procedure\n- Consultation and report on referred slides prepared elsewhere\n\n### Condition\n- Benign neoplasm of stomach\n- Carcinoma in situ of colon\n- Primary malignant neoplasm of colon\n- Benign neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2011-08-07 00:00:00, ended at 2011-08-07 00:00:00\nThe patient in this visit was 34 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- polyethylene glycol 3350 236000 MG / potassium chloride 2970 MG / sodium bicarbonate 6740 MG / sodium chloride 5860 MG / sodium sulfate 22740 MG Powder for Oral Solution, through Oral route, started on 2011-08-07, presumably until 2011-08-18, with intended 0 refill(s). Instructions: take 4,000 mL by mouth One Time.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-08-10 10:02:00, ended at 2011-08-10 13:29:00\nThe patient in this visit was 34 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1\" (inch (US))\n\n### Procedure\n- Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique\n- Endoscopic polypectomy of large intestine\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Endoscopic biopsy of large intestine\n- Colonoscopy, flexible; with biopsy, single or multiple\n\n### Condition\n- Benign neoplasm of rectum and anal canal\n- Primary malignant neoplasm of transverse colon\n- Benign neoplasm of colon\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-08-10, presumably until 2011-08-10\n- midazolam 1 MG/ML Injectable Solution, started on 2011-08-10, presumably until 2011-08-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-08-11 07:37:00, ended at 2011-08-18 12:30:00\nThe patient in this visit was 35 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 24.3 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.86 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 28.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.14 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.3 (percent)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 94.5 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.5 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.4 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Body height: 6' 1\" (inch (US))\n- Lymphocytes [#/volume] in Blood by Automated count: 0.84 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.47 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 250 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 159 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 74.1 (femtoliter)\n\n### Procedure\n- Rigid proctosigmoidoscopy\n- Molecular diagnostics; amplification, target, multiplex, first 2 nucleic acid sequences\n- Molecular diagnostics; interpretation and report\n- Molecular diagnostics; isolation or extraction of highly purified nucleic acid, each nucleic acid type (ie, DNA or RNA)\n- Laparoscopic total intra-abdominal colectomy\n- Molecular diagnostics; amplification, target, multiplex, each additional nucleic acid sequence beyond 2 (List separately in addition to code for primary procedure)\n- Other small-to-large intestinal anastomosis\n- Collection of venous blood by venipuncture\n- Molecular diagnostics; separation and identification by high resolution technique (eg, capillary electrophoresis), each nucleic acid preparation\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Benign neoplasm of colon\n- Neoplasm of intrapelvic lymph node\n- Neoplasm of intra-abdominal lymph nodes\n- Primary malignant neoplasm of colon\n- Primary malignant neoplasm of splenic flexure of colon\n- Anemia in neoplastic disease\n- Primary malignant neoplasm of rectosigmoid junction\n\n### Drug\n- psyllium, through Oral route, started on 2011-08-18, presumably until 2012-06-14. Instructions: take 1 Packet by mouth 3 times a day.\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2011-08-11, presumably until 2011-08-16\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2011-08-14, presumably until 2011-08-17\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2011-08-12, presumably until 2011-08-17\n- ispaghula husk, through Oral route, started on 2011-08-18, presumably until 2012-06-14. Instructions: take 1 Packet by mouth 3 times a day.\n- 2 ML ondansetron 2 MG/ML Injection, started on 2011-08-13, presumably until 2011-08-13\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2011-08-11, presumably until 2011-08-14\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-08-11, presumably until 2011-08-11\n- Plantago seed, through Oral route, started on 2011-08-18, presumably until 2012-06-14. Instructions: take 1 Packet by mouth 3 times a day.\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2011-08-13, presumably until 2011-08-14\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2011-08-14, presumably until 2011-08-14\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2011-08-13, presumably until 2012-02-14, with intended 2 refill(s). Instructions: take 1-2 Tabs by mouth every 6 hours as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-08-18 00:00:00, ended at 2011-08-18 00:00:00\nThe patient in this visit was 35 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-09-02 13:55:00, ended at 2011-09-02 23:59:00\nThe patient in this visit was 35 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.25\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign neoplasm of colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-09-14 15:07:00, ended at 2011-09-14 23:59:00\nThe patient in this visit was 35 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.25\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of colon\n- Benign neoplasm of colon\n\n### Drug\n- capecitabine 500 MG Oral Tablet, through Oral route, started on 2011-09-14, presumably until 2012-06-14, with intended 5 refill(s). Instructions: take 4 Tabs by mouth 2 times a day. Take 2 times daily for 2 weeks and then 1 week off.\n- ondansetron 8 MG Oral Tablet, through Oral route, presumably until 2012-06-14, with intended 1 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed. For nausea and vomiting.\n- lorazepam 1 MG Oral Tablet, through Oral route, presumably until 2012-06-14, with intended 2 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed. For nausea and vomiting.\n- prochlorperazine 10 MG Oral Tablet, through Oral route, presumably until 2012-06-14, with intended 2 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed. For nausea and vomiting.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-09-17 00:00:00, ended at 2011-09-17 00:00:00\nThe patient in this visit was 35 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-09-20 08:00:00, ended at 2011-09-20 13:19:00\nThe patient in this visit was 35 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 1 (nanogram per milliliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.22 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 21.7 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.0 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 20.3 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 99 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 100 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.61 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 30.6 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.75 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 51.9 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.3 (percent)\n- MCV [Entitic volume] by Automated count: 66.4 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.1 (percent)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.42 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 30.4 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 224 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.3 (thousand per microliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of colon\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2011-09-20, presumably until 2011-09-20\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2011-09-20, presumably until 2011-09-20\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2011-09-20, presumably until 2011-09-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-09-20 13:20:00, ended at 2011-09-20 23:59:00\nThe patient in this visit was 35 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of colon\n- Disorder of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-10-08 00:00:00, ended at 2011-10-08 00:00:00\nThe patient in this visit was 35 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-10-08 09:45:00, ended at 2011-10-08 11:10:00\nThe patient in this visit was 35 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.228\" (inch (US))\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Chromosome analysis, cytogenetic procedure AND/OR molecular biology method\n- Genetic counseling\n\n### Condition\n- Benign neoplasm of colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-10-12 12:00:00, ended at 2011-10-12 12:18:00\nThe patient in this visit was 35 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 3 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 44.1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.57 (thousand per microliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 2 (nanogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 21.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.11 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 31.2 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 35.9 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.4 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.6 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 16.4 (percent)\n- MCH [Entitic mass] by Automated count: 20.3 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 1.28 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 180 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.58 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 107 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 93 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 65.2 (femtoliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-10-12 12:19:00, ended at 2011-10-12 23:59:00\nThe patient in this visit was 35 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 2\" (inch (US))\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of colon\n- Benign neoplasm of colon\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2011-10-12, presumably until 2011-10-12\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2011-10-12, presumably until 2011-10-12\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2011-10-12, presumably until 2011-10-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-10-20 00:00:00, ended at 2011-10-20 00:00:00\nThe patient in this visit was 35 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-06-01 00:00:00, ended at 2012-06-01 00:00:00\nThe patient in this visit was 35 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-06-14 10:10:00, ended at 2012-06-14 13:39:00\nThe patient in this visit was 35 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 2\" (inch (US))\n\n### Procedure\n- Endoscopic polypectomy of large intestine\n- [Endoscopic] polypectomy of rectum\n- Sigmoidoscopy, flexible; with biopsy, single or multiple\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Benign neoplasm of colon\n- Benign neoplasm of rectum and anal canal\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2012-06-14, presumably until 2012-06-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-03-20 00:00:00, ended at 2013-03-20 00:00:00\nThe patient in this visit was 36 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2013-03-28 00:00:00, ended at 2013-03-28 00:00:00\nThe patient in this visit was 36 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- simethicone 66.7 MG/ML Oral Suspension, through Oral route, started on 2013-03-28, presumably until 2013-03-28\n- water 1000 MG/ML Irrigation Solution, through Topical route, started on 2013-03-28, presumably until 2013-03-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-28 09:47:00, ended at 2013-03-28 13:50:00\nThe patient in this visit was 36 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' .992\" (inch (US))\n\n### Procedure\n- [Endoscopic] polypectomy of rectum\n- Flexible fiberoptic sigmoidoscopy\n- Sigmoidoscopy, flexible; with biopsy, single or multiple\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Primary malignant neoplasm of colon\n- Benign neoplasm of rectum and anal canal\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2013-03-28, presumably until 2013-03-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-11-18 00:00:00, ended at 2014-11-18 00:00:00\nThe patient in this visit was 38 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-03-05 00:00:00, ended at 2016-03-05 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2018-03-29 14:20:00, ended at 2018-03-31 17:26:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- MCH [Entitic mass] by Automated count: 26.0 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.3 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 79.1 (femtoliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 32.6 (second)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.94 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 220 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Chromogranin A [Moles/volume] in Serum or Plasma: 49 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.95 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 58.7 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 98 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Body height: 6' 2\" (inch (US))\n- Hematocrit [Volume Fraction] of Blood by Automated count: 46.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 15.4 (gram per deciliter)\n- Prothrombin time (PT): 13.5 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 30.0 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 8 (nanogram per milliliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Lactate [Moles/volume] in Serum or Plasma: 1.0 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.04 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.00 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 46 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.7 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.8 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of rectosigmoid junction\n- Nausea and vomiting\n- Primary diagnosis: Intestinal obstruction\n- Primary malignant neoplasm of colon\n- Acquired absence of organ\n- Secondary malignant neoplasm of intra-abdominal lymph nodes\n- Primary malignant neoplasm of descending colon\n- Benign neoplasm of colon\n- Secondary malignant neoplasm of left lung\n- Benign neoplasm of transverse colon\n- Primary malignant neoplasm of splenic flexure of colon\n- Secondary malignant neoplasm of intrapelvic lymph nodes\n- Secondary malignant neoplasm of small intestine\n- Disorder of digestive system\n\n### Drug\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2018-03-29, presumably until 2018-03-31\n- barium sulfate, through Oral route, started on 2018-03-30, presumably until 2018-03-30\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2018-03-29, presumably until 2018-03-31\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-04-10 00:00:00, ended at 2018-04-10 00:00:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-04-10 08:42:18, ended at 2018-04-10 10:04:02\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 2.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Intestinal obstruction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-04-10 09:55:46, ended at 2018-04-10 11:10:59\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-10 11:13:00, ended at 2018-04-10 13:53:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 83 (unit per liter)\n- MCV [Entitic volume] by Automated count: 79.0 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.6 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.22 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 119 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 6.46 (million per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.6 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 213 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 51.1 (percent)\n- Hemoglobin [Mass/volume] in Blood: 16.4 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 25.4 (picogram)\n- Prothrombin time (PT): 13.1 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 59 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.0 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 27.8 (second)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 114 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-10 13:54:00, ended at 2018-04-10 18:24:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Intra-abdominal and pelvic swelling, mass and lump\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-04-10 18:25:00, ended at 2018-04-25 15:19:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Base excess in Arterial blood by calculation: 2.7 (millimole per liter)\n- Glucose [Mass/volume] in Blood: 250 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 308 (thousand per microliter)\n- Body height: 6' 2.016\" (inch (US))\n- Erythrocyte distribution width [Ratio] by Automated count: 16.7 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 634 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 80.6 (femtoliter)\n- Bicarbonate [Moles/volume] in Specimen: 26.1 (millimole per liter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.09 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.06 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 6.01 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Oxygen [Partial pressure] in Arterial blood: 155.0 (millimeter mercury column)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.9 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 95 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 15.3 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.1 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 99 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Prothrombin time (PT): 13.8 (second)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Carbon dioxide [Partial pressure] in Arterial blood: 35.8 (millimeter mercury column)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 25.9 (picogram)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 77 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 47.3 (percent)\n\n### Procedure\n- Computed tomography, abdomen and pelvis; without contrast material\n- Excision of Stomach, Via Natural or Artificial Opening Endoscopic, Diagnostic\n- Excision of Pancreas, Open Approach\n- Drainage of Peritoneal Cavity with Drainage Device, Percutaneous Approach\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Physical therapy evaluation: low complexity, requiring these components: A history with no personal factors and/or comorbidities that impact the plan of care; An examination of body system(s) using standardized tests and measures addressing 1-2 elements f\n- Collection of venous blood by venipuncture\n- Radiologic examination, abdomen; 1 view\n- Morphometric analysis, tumor\n- Excision of Aortic Lymphatic, Open Approach\n- Radiologic examination, chest; 2 views\n- Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple\n- Excision of Right Lobe Liver, Open Approach\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Sigmoidoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Excision of Duodenum, Open Approach\n- Radiologic examination, abdomen; 2 views\n- Destruction of Right Lobe Liver, Open Approach\n- Excision of Rectum, Via Natural or Artificial Opening Endoscopic, Diagnostic\n- Image-guided fluid collection drainage by catheter (eg, abscess, hematoma, seroma, lymphocele, cyst); peritoneal or retroperitoneal, percutaneous\n\n### Condition\n- Disorder of digestive system\n- Secondary malignant neoplasm of intra-abdominal lymph nodes\n- Secondary malignant neoplasm of small intestine\n- Adult hypertrophic pyloric stenosis\n- Gastrointestinal complication\n- Steatosis of liver\n- Benign neoplasm of colon\n- Rectal polyp\n- Acquired absence of organ\n- Primary malignant neoplasm of small intestine\n- Abnormal findings on diagnostic imaging of lung\n- Ascites\n- Benign neoplasm of rectum\n- Overlapping malignant neoplasm of pancreas\n- Abdominal distension, gaseous\n- Abscess of peritoneum\n- Late effect of complications of procedure\n- Primary malignant neoplasm of colon\n- Abdominal pain\n- Gastric polyp\n- Intestinal obstruction\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2018-04-10, presumably until 2018-04-13\n- 1 ML octreotide 0.1 MG/ML Injection, started on 2018-04-21, presumably until 2018-04-21\n- 2 ML fentanyl 0.05 MG/ML Injection, through Intravenous route, started on 2018-04-13, presumably until 2018-04-13\n- 2 ML prochlorperazine 5 MG/ML Injection, started on 2018-04-13, presumably until 2018-04-18\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2018-04-17, presumably until 2018-04-20\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-04-11, presumably until 2018-04-25\n- naloxone hydrochloride 0.4 MG/ML Injectable Solution, started on 2018-04-13, presumably until 2018-04-13\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2018-04-14, presumably until 2018-04-24\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-04-13, presumably until 2019-10-25, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 8 hours\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2018-04-16, presumably until 2018-04-16\n- diatrizoate, through Oral route, started on 2018-04-25, presumably until 2018-04-25\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-04-17, presumably until 2018-04-20\n- diatrizoic acid, through Oral route, started on 2018-04-25, presumably until 2018-04-25\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2018-04-14, presumably until 2018-04-21\n- piperacillin 4000 MG / tazobactam 500 MG Injection, through Intravenous route, started on 2018-04-20, presumably until 2018-04-20\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2018-04-20, presumably until 2018-04-24\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2018-04-14, presumably until 2018-04-15\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2018-04-13, presumably until 2018-04-13\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2018-04-13, presumably until 2018-05-08, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 6 hours as needed\n- 1000 ML glucose 50 MG/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2018-04-13, presumably until 2018-04-22\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2018-04-14, presumably until 2018-04-16\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-04-13, presumably until 2018-04-13\n- lidocaine hydrochloride 0.02 MG/MG Topical Gel, through Submucosal route, started on 2018-04-17, presumably until 2018-04-17\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2018-04-13, presumably until 2018-07-18, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 6 hours as needed\n- 50 ML magnesium sulfate 40 MG/ML Injection, through Intravenous route, started on 2018-04-17, presumably until 2018-04-21\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2018-04-23, presumably until 2018-05-02, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 7 days\n- hydromorphone hydrochloride 2 MG/ML Injectable Solution, through Intravenous route, started on 2018-04-13, presumably until 2018-04-13\n- 1 ML promethazine hydrochloride 25 MG/ML Injection, started on 2018-04-18, presumably until 2018-04-18\n- 0.5 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2018-04-13, presumably until 2018-04-13\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2018-04-23, presumably until 2018-04-23\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-04-12 00:00:00, ended at 2018-04-12 00:00:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for combined upper and lower gastrointestinal endoscopic procedures, endoscope introduced both proximal to and distal to the duodenum\n\n### Condition\n- Rectal polyp\n- Gastric polyp\n\n### Drug\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2018-04-12, presumably until 2018-04-12\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2018-04-12, presumably until 2018-04-12\n- 2 ML ondansetron 2 MG/ML Injection, started on 2018-04-12, presumably until 2018-04-12\n- succinylcholine chloride 20 MG/ML Injectable Solution, started on 2018-04-12, presumably until 2018-04-12\n- 2 ML alfentanil 0.5 MG/ML Injection, started on 2018-04-12, presumably until 2018-04-12\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2018-04-12, presumably until 2018-04-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-04-13 00:00:00, ended at 2018-04-13 00:00:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for intraperitoneal procedures in upper abdomen including laparoscopy; partial hepatectomy or management of liver hemorrhage (excluding liver biopsy)\n\n### Condition\n- Primary malignant neoplasm of transverse colon\n\n### Drug\n- 10 ML calcium chloride 100 MG/ML Injection, through Intravenous route, started on 2018-04-13, presumably until 2018-04-13\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2018-04-13, presumably until 2018-04-13\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2018-04-13, presumably until 2018-04-13\n- naloxone hydrochloride 0.4 MG/ML Injectable Solution, started on 2018-04-13, presumably until 2018-04-13\n- cefoxitin 1000 MG Injection, through Intravenous route, started on 2018-04-13, presumably until 2018-04-13\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2018-04-13, presumably until 2018-04-13\n- 10 ML methylene blue 5 MG/ML Injection, through Intravenous route, started on 2018-04-13, presumably until 2018-04-13\n- labetalol hydrochloride 5 MG/ML Injectable Solution, through Intravenous route, started on 2018-04-13, presumably until 2018-04-13\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2018-04-13, presumably until 2018-04-13\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2018-04-13, presumably until 2018-04-13\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2018-04-13, presumably until 2018-04-13\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2018-04-13, presumably until 2018-04-13\n- 2 ML ondansetron 2 MG/ML Injection, started on 2018-04-13, presumably until 2018-04-13\n- ketamine 100 MG/ML Injectable Solution, started on 2018-04-13, presumably until 2018-04-13\n- 250 ML lidocaine hydrochloride 8 MG/ML Injection, through Intravenous route, started on 2018-04-13, presumably until 2018-04-13\n- midazolam 1 MG/ML Injectable Solution, started on 2018-04-13, presumably until 2018-04-13\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2018-04-13, presumably until 2018-04-13\n- 2 ML alfentanil 0.5 MG/ML Injection, started on 2018-04-13, presumably until 2018-04-13\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2018-04-13, presumably until 2018-04-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-04-13 12:38:00, ended at 2018-04-13 12:38:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign neoplasm of colon\n- Primary malignant neoplasm of colon\n- Primary diagnosis: Intestinal obstruction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-04-20 00:00:00, ended at 2018-04-20 00:00:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-04-20, presumably until 2018-04-20\n- midazolam 1 MG/ML Injectable Solution, started on 2018-04-20, presumably until 2018-04-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-05-08 09:47:16, ended at 2018-05-08 11:06:42\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 2.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Epigastric pain\n- Primary malignant neoplasm of colon\n\n### Drug\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2018-05-08, presumably until 2018-07-18, with intended 1 refill(s). Instructions: take 1-2 Tabs by mouth every 6 hours as needed\n- metoclopramide 10 MG Oral Tablet, through Oral route, started on 2018-05-08, presumably until 2018-07-18, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-05-08 11:11:00, ended at 2018-05-08 23:59:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 96 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 53 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 124 (unit per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 31.4 (second)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.1 (percent)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.40 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 155 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 301 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Prothrombin time (PT): 13.6 (second)\n- MCH [Entitic mass] by Automated count: 24.9 (picogram)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.9 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 2 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.93 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.5 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 77.7 (femtoliter)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Epigastric pain\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-05-22 07:06:00, ended at 2018-05-22 23:59:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of duodenum\n- Epigastric pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-05-22 08:21:46, ended at 2018-05-22 12:20:05\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 2.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-05-26 00:00:00, ended at 2018-05-26 00:00:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of transverse colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-06-13 00:00:00, ended at 2018-06-13 00:00:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 20 ML epinephrine 0.005 MG/ML / lidocaine hydrochloride 20 MG/ML Injection, started on 2018-06-13, presumably until 2018-06-13\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-06-13, presumably until 2018-06-13\n- midazolam 1 MG/ML Injectable Solution, started on 2018-06-13, presumably until 2018-06-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-06-13 00:00:00, ended at 2018-06-13 00:00:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Intestinal obstruction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-06-13 14:13:00, ended at 2018-06-13 18:42:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.9 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.26 (million per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.87 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.1 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.72 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 64.7 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- INR in Blood by Coagulation assay: 1.0 (ratio)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 248 (thousand per microliter)\n- Body height: 6' 2\" (inch (US))\n- MCV [Entitic volume] by Automated count: 73.1 (femtoliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 21.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.9 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 31.6 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.1 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.4 (percent)\n- MCH [Entitic mass] by Automated count: 23.1 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 5.11 (thousand per microliter)\n\n### Procedure\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Insertion of Totally Implantable Vascular Access Device into Chest Subcutaneous Tissue and Fascia, Percutaneous Approach\n- Collection of venous blood by venipuncture\n- Fluoroscopic guidance for central venous access device placement, replacement (catheter only or complete), or removal (includes fluoroscopic guidance for vascular access and catheter manipulation, any necessary contrast injections through access site or c\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n- Insertion of tunneled centrally inserted central venous access device, with subcutaneous port; age 5 years or older\n\n### Condition\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-06-20 09:30:00, ended at 2018-06-20 23:59:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 114 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.75 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.06 (thousand per microliter)\n- Prothrombin time (PT): 13.7 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: <10 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.8 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 72.8 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.1 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 105 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.52 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 234 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 54.2 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 33.6 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.47 (million per microliter)\n- MCH [Entitic mass] by Automated count: 23.3 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.69 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 33.6 (second)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 2 (nanogram per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.5 (thousand per microliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of descending colon\n- Intestinal obstruction\n- Primary malignant neoplasm of transverse colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2018-06-20, presumably until 2018-06-20\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2018-06-20, presumably until 2018-06-20\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2018-06-20, presumably until 2018-06-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-06-20 10:19:33, ended at 2018-06-20 11:50:53\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 2.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neoplasm defined only by topography: Colon, NOS\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2018-06-20, presumably until 2018-08-02, with intended 1 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed For nausea and vomiting.\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2018-06-20, presumably until 2018-11-21, with intended 2 refill(s). Instructions: take 0.5 Tabs by mouth every 6 hours as needed For nausea and vomiting.\n- prochlorperazine 10 MG Oral Tablet, through Oral route, started on 2018-06-20, presumably until 2018-11-21, with intended 2 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed For nausea and vomiting.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-06-22 16:56:00, ended at 2018-06-22 23:59:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-06-23 00:00:00, ended at 2018-06-23 00:00:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, through Topical route, started on 2018-06-23, presumably until 2019-06-23, with intended 0 refill(s). Instructions: by Topical route as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-07-04 00:00:00, ended at 2018-07-04 00:00:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-07-04 12:21:00, ended at 2018-07-04 23:59:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.64 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.4 (percent)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 73.0 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.8 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 55.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.5 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 102 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.68 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 30.6 (percent)\n- aPTT in Platelet poor plasma by Coagulation assay: 29.9 (second)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.42 (million per microliter)\n- MCH [Entitic mass] by Automated count: 23.5 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 3.05 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 3 (nanogram per milliliter)\n- MCHC [Mass/volume] by Automated count: 32.2 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 191 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 137 (milligram per deciliter)\n- Prothrombin time (PT): 12.6 (second)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of descending colon\n- Primary malignant neoplasm of transverse colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2018-07-04, presumably until 2018-07-04\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-07-04, presumably until 2018-07-04\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2018-07-04, presumably until 2018-07-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-07-06 16:49:00, ended at 2018-07-06 23:59:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of splenic flexure of colon\n- Primary malignant neoplasm of colon\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-07-18 11:30:00, ended at 2018-07-18 23:59:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 178 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 23.3 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 48.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Prothrombin time (PT): 13.4 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 30.6 (second)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.30 (million per microliter)\n- MCV [Entitic volume] by Automated count: 73.7 (femtoliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 98 (unit per liter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.26 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.1 (percent)\n- MCHC [Mass/volume] by Automated count: 31.6 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 3 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.81 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 124 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.7 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.1 (percent)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.4 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 37.6 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.78 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.53 (thousand per microliter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of descending colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2018-07-18, presumably until 2018-07-18\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-07-18, presumably until 2018-07-18\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2018-07-18, presumably until 2018-07-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-07-20 16:10:00, ended at 2018-07-20 23:59:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-08-01 00:00:00, ended at 2018-08-01 00:00:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- olanzapine 5 MG Oral Tablet, through Oral route, started on 2018-08-01, presumably until 2018-08-21, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime Take 1 tab Q HS x 5 days after each infusion. Don't take with Ativan.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-01 11:12:00, ended at 2018-08-01 23:59:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 3 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.79 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.9 (percent)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.07 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 31.3 (percent)\n- MCH [Entitic mass] by Automated count: 23.9 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.0 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 73.3 (femtoliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 101 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.4 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.79 (thousand per microliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Body height: 6' 1.031\" (inch (US))\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.58 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.52 (million per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 54.3 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.9 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 103 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.2 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.6 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 186 (thousand per microliter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- lorazepam 2 MG/ML Injectable Solution, through Intravenous route, started on 2018-08-01, presumably until 2018-08-01\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2018-08-01, presumably until 2018-08-01\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-08-01, presumably until 2018-08-01\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2018-08-01, presumably until 2018-08-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-08-02 00:00:00, ended at 2018-08-02 00:00:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2018-08-02, presumably until 2019-10-25, with intended 2 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed For nausea and vomiting.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-03 16:30:00, ended at 2018-08-03 23:59:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of splenic flexure of colon\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-14 12:20:00, ended at 2018-08-14 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of colon\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-15 10:53:00, ended at 2018-08-15 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Hemoglobin [Mass/volume] in Blood: 12.6 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.3 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.44 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Body height: 6' .835\" (inch (US))\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 173 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 159 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.6 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.3 (percent)\n- MCV [Entitic volume] by Automated count: 74.4 (femtoliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.80 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 3 (nanogram per milliliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.77 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 24.0 (picogram)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.26 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.0 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Prothrombin time (PT): 13.1 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 8.2 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 27.5 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 88 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 35.1 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 48.4 (percent)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of colon\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2018-08-15, presumably until 2018-08-15\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-08-15, presumably until 2018-08-15\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2018-08-15, presumably until 2018-08-15\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-08-15, presumably until 2018-08-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-08-15 11:19:37, ended at 2018-08-15 14:19:08\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-17 16:52:00, ended at 2018-08-17 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-08-21 00:00:00, ended at 2018-08-21 00:00:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- olanzapine 5 MG Oral Tablet, through Oral route, started on 2018-08-21, presumably until 2019-07-02, with intended 1 refill(s). Instructions: take 1 Tab by mouth every bedtime Take 1 tab Q HS x 5 days after each infusion. Don't take with Ativan.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-29 10:20:00, ended at 2018-08-29 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 3 (nanogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 74.4 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 101 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 37.5 (percent)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.89 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 148 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.68 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.40 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.4 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 167 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 47.5 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.2 (percent)\n- MCH [Entitic mass] by Automated count: 24.8 (picogram)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.6 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.6 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.12 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 144 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.9 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2018-08-29, presumably until 2018-08-29\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-08-29, presumably until 2018-08-29\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2018-08-29, presumably until 2018-08-29\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-08-29, presumably until 2018-08-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-31 16:01:00, ended at 2018-08-31 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-12 08:38:00, ended at 2018-09-12 11:10:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.44 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.5 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 75.9 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.3 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.76 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 29.7 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 55.8 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Prothrombin time (PT): 12.4 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.31 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 110 (unit per liter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 3 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.78 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 162 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 185 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 24.8 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 24.8 (second)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-09-12 09:05:43, ended at 2018-09-12 10:09:59\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' .835\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-12 11:11:00, ended at 2018-09-12 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-09-12, presumably until 2018-09-12\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2018-09-12, presumably until 2018-09-12\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-09-12, presumably until 2018-09-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-14 15:19:00, ended at 2018-09-14 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-26 11:50:00, ended at 2018-09-26 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Body height: 6' 1.504\" (inch (US))\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.78 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.4 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.3 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.79 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.5 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 31.9 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.64 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 53.3 (percent)\n- Platelets [#/volume] in Blood by Automated count: 162 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 146 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.18 (million per microliter)\n- MCH [Entitic mass] by Automated count: 25.2 (picogram)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 142 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 3 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 100 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 76.3 (femtoliter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.1 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.2 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.67 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.5 (millimole per liter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-09-26, presumably until 2018-09-26\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2018-09-26, presumably until 2018-09-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-28 15:57:00, ended at 2018-09-28 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-10-10 11:31:00, ended at 2018-10-10 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 40 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.13 (million per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.73 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.1 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 140 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.8 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 25.5 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 133 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 3 (nanogram per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 36.6 (percent)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.73 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.11 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 96 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.8 (percent)\n- MCV [Entitic volume] by Automated count: 77.5 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.75 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 47.7 (percent)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.0 (percent)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of descending colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2018-10-10, presumably until 2018-10-10\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-10-10, presumably until 2018-10-10\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2018-10-10, presumably until 2018-10-10\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-10-10, presumably until 2018-10-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-10-10 13:00:42, ended at 2018-10-10 15:02:01\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.543\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-10-12 18:43:00, ended at 2018-10-12 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-10-24 09:58:00, ended at 2018-10-24 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of colon\n- Abnormal findings on diagnostic imaging of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-10-24 12:13:13, ended at 2018-10-24 14:07:08\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.543\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-21 08:38:00, ended at 2018-11-21 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Disorder of digestive system\n- Acquired absence of organ\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-21 08:38:00, ended at 2018-11-21 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 179 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- No conditions.\n\n### Drug\n- barium sulfate, through Oral route, started on 2018-11-21, presumably until 2018-11-21\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-02-05 10:12:27, ended at 2019-02-05 11:31:01\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.819\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-02-05 12:54:00, ended at 2019-02-05 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.819\" (inch (US))\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of colon\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n- Primary malignant neoplasm of transverse colon\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2019-02-05, presumably until 2019-02-05\n- 0.5 ML meperidine hydrochloride 50 MG/ML Injection, started on 2019-02-05, presumably until 2019-02-05\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2019-02-05, presumably until 2019-02-05\n- 2 ML ondansetron 2 MG/ML Injection, started on 2019-02-05, presumably until 2019-02-05\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2019-02-05, presumably until 2019-02-05\n- methylprednisolone 125 MG Injection, started on 2019-02-05, presumably until 2019-02-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-02-26 12:37:00, ended at 2019-02-26 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.88 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.57 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.3 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 41.4 (percent)\n- MCV [Entitic volume] by Automated count: 81.7 (femtoliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 2 (nanogram per milliliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.63 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.0 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 108 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.81 (thousand per microliter)\n- Prothrombin time (PT): 13.0 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.5 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.7 (percent)\n- Globulin [Mass/volume] in Serum: 2.7 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 121 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 32.2 (second)\n- MCH [Entitic mass] by Automated count: 26.8 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 186 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.9 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.60 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 44.8 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of descending colon\n- Primary diagnosis: Primary malignant neoplasm of transverse colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2019-02-26, presumably until 2019-02-26\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2019-02-26, presumably until 2019-02-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-02-26 12:59:39, ended at 2019-02-26 17:00:57\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.819\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-15 00:00:00, ended at 2019-03-15 00:00:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of transverse colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-16 07:30:00, ended at 2019-03-16 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 48.6 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Accidental poisoning\n- Primary malignant neoplasm of colon\n- Poisoning by drug AND/OR medicinal substance\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-17 13:00:00, ended at 2019-03-17 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 2 (nanogram per milliliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.1 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 192 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.97 (thousand per microliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Platelets [#/volume] in Blood by Automated count: 169 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 15.8 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 36.1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.79 (million per microliter)\n- MCV [Entitic volume] by Automated count: 80.5 (femtoliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.72 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 46.6 (percent)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 50.7 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.7 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 14 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 112 (unit per liter)\n- Body height: 6' 1.504\" (inch (US))\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.53 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.77 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 27.3 (picogram)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of descending colon\n- Primary diagnosis: Primary malignant neoplasm of transverse colon\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2019-03-17, presumably until 2019-03-17\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2019-03-17, presumably until 2019-03-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-04-09 09:57:00, ended at 2019-04-09 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Globulin [Mass/volume] in Serum: 2.6 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.6 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 189 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.4 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.0 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 35.1 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 92 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.23 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 27.6 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.9 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 128 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.9 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 32.5 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.03 (million per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.88 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 84.5 (femtoliter)\n- Prothrombin time (PT): 13.2 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.64 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 45.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 2 (nanogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.5 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.62 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.09 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of colon\n- Primary malignant neoplasm of descending colon\n- Primary diagnosis: Primary malignant neoplasm of transverse colon\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2019-04-09, presumably until 2019-04-09\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2019-04-09, presumably until 2019-04-09\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2019-04-09, presumably until 2019-04-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-09 10:20:40, ended at 2019-04-09 11:08:08\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.819\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-04-30 09:07:00, ended at 2019-04-30 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2019-04-30, presumably until 2019-04-30\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2019-04-30, presumably until 2019-04-30\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-21 10:55:00, ended at 2019-05-21 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Erythrocytes [#/volume] in Blood by Automated count: 5.46 (million per microliter)\n- MCH [Entitic mass] by Automated count: 27.8 (picogram)\n- MCV [Entitic volume] by Automated count: 84.4 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 50.1 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 2 (nanogram per milliliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.21 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 129 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.60 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 87 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.87 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 15.2 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.1 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 36.2 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 46.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 158 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 2.2 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.06 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.8 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of transverse colon\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2019-05-21, presumably until 2019-05-21\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2019-05-21, presumably until 2019-05-21\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2019-05-21, presumably until 2019-05-21\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-21 11:11:47, ended at 2019-05-21 13:37:08\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.819\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-22 11:26:00, ended at 2019-05-22 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Abnormal findings on diagnostic imaging of lung\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-08 00:00:00, ended at 2019-06-08 00:00:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-11 07:07:00, ended at 2019-06-11 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Platelets [#/volume] in Blood by Automated count: 162 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 2 (nanogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.24 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 27.8 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.58 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.93 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.0 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 91 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 45.3 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.6 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 46.5 (percent)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 15.0 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 86.1 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.7 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.84 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 118 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 39.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.40 (million per microliter)\n- Globulin [Mass/volume] in Serum: 2.5 (gram per deciliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2019-06-11, presumably until 2019-06-11\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2019-06-11, presumably until 2019-06-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-11 07:46:03, ended at 2019-06-11 08:55:05\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.819\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-25 16:25:00, ended at 2019-06-25 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Disease of liver\n- Abnormal findings on diagnostic imaging of lung\n- Primary malignant neoplasm of colon\n- Disorder of pancreas\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-02 09:30:00, ended at 2019-07-02 12:05:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 3 (nanogram per milliliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.6 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.5 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.1 (percent)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 28.6 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.4 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.87 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.60 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 164 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.10 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 44.6 (percent)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 84.5 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.18 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 2.5 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 40.7 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 144 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 81 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 115 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.6 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.39 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-07-02 10:16:37, ended at 2019-07-02 11:16:50\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.268\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-02 12:06:00, ended at 2019-07-02 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of colon\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2019-07-02, presumably until 2019-07-02\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-30 14:00:00, ended at 2019-07-30 16:05:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 2.5 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.5 (percent)\n- MCV [Entitic volume] by Automated count: 84.6 (femtoliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.77 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.7 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.3 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 51.4 (percent)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.14 (million per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 2 (nanogram per milliliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.23 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 148 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 35.1 (percent)\n- MCH [Entitic mass] by Automated count: 28.4 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.53 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 172 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.20 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.22 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.6 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of colon\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-07-30 14:53:10, ended at 2019-07-30 15:46:45\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.268\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-30 16:06:00, ended at 2019-07-30 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2019-07-30, presumably until 2019-07-30\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2019-07-30, presumably until 2019-07-30\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-16 00:00:00, ended at 2019-08-16 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-08-20 13:03:00, ended at 2019-08-20 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.7 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.2 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 84.5 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 45.5 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 4.4 (gram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 135 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 16.3 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 95 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.4 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.43 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 48.6 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.66 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.88 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 197 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.19 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.75 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 39.3 (percent)\n- MCH [Entitic mass] by Automated count: 28.3 (picogram)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 2 (nanogram per milliliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.82 (thousand per microliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2019-08-20, presumably until 2019-08-20\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2019-08-20, presumably until 2019-08-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-10 00:00:00, ended at 2019-09-10 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-09-10 12:00:00, ended at 2019-09-10 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 124 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.2 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 189 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 3 (nanogram per milliliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.1 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.26 (thousand per microliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.80 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.6 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.5 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.64 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 52 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.28 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.9 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 86.2 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.6 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 43.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 41.1 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.37 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2019-09-10, presumably until 2019-09-10\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2019-09-10, presumably until 2019-09-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-09-10 13:29:19, ended at 2019-09-10 15:37:13\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.268\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-25 00:00:00, ended at 2019-09-25 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 51.1 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-09-25 13:38:00, ended at 2019-09-25 14:26:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Disorder of adrenal gland\n- Primary malignant neoplasm of colon\n- Secondary malignant neoplasm of lung\n- Primary malignant neoplasm of descending colon\n- Localized enlarged lymph nodes\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-09-25 14:27:00, ended at 2019-09-25 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Accidental poisoning\n- Poisoning by drug AND/OR medicinal substance\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-01 08:33:00, ended at 2019-10-01 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 12.5 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 30.0 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 203 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 46.8 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.88 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 16.1 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 55.2 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 5 (nanogram per milliliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.6 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 237 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.87 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.16 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 97 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 49 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.42 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 218 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.5 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.26 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 86.3 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 29.7 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-01 08:50:28, ended at 2019-10-01 12:02:55\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.268\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-10-05 00:00:00, ended at 2019-10-05 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-22 11:43:00, ended at 2019-10-22 14:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 74 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 6 (nanogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.15 (million per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.83 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.8 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 87.2 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 44.9 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 228 (unit per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 240 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.90 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.0 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.28 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 29.5 (picogram)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.4 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.1 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.3 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 15.2 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.70 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 57.5 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.49 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 167 (thousand per microliter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-24 14:27:00, ended at 2019-10-24 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.68 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 157 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 49.2 (percent)\n- Hemoglobin [Mass/volume] in Blood: 16.4 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 28.9 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.4 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 278 (unit per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.35 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 86.6 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 8 (nanogram per milliliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.33 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 12.7 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.9 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.7 (percent)\n- Prothrombin time (PT): 12.0 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 53 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.87 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 59.7 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 1.05 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.27 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 137 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of colon\n- Primary malignant neoplasm of descending colon\n- Secondary malignant neoplasm of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-25 08:32:49, ended at 2019-10-25 11:16:33\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.228\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Secondary malignant neoplasm of left lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-10-29 00:00:00, ended at 2019-10-29 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neoplasm of colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-11-09 00:00:00, ended at 2019-11-09 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-11-12 12:00:00, ended at 2019-11-12 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 67 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.75 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 16.5 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.3 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 86.1 (femtoliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 56 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 10 (nanogram per milliliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 28.7 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 12.3 (percent)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 51.1 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.88 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 49.5 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.82 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 34.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 241 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.84 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 322 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 312 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.22 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of colon\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2019-11-12, presumably until 2019-11-12\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2019-11-12, presumably until 2019-11-12\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2019-11-12, presumably until 2019-11-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-11-13 09:00:00, ended at 2019-11-13 10:20:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 97 (milligram per deciliter)\n\n### Procedure\n- Therapeutic radiology simulation-aided field setting; complex\n\n### Condition\n- Secondary malignant neoplasm of left lung\n- Primary malignant neoplasm of rectosigmoid junction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-11-13 10:21:00, ended at 2019-11-13 10:21:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign neoplasm of colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-11-13 10:22:00, ended at 2019-11-13 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of colon\n\n### Drug\n- barium sulfate, through Oral route, started on 2019-11-13, presumably until 2019-11-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-11-13 10:22:00, ended at 2019-11-13 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-11-19 00:00:00, ended at 2019-11-19 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-11-20 00:00:00, ended at 2019-11-20 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- regorafenib 40 MG Oral Tablet, through Oral route, started on 2019-11-20, presumably until 2019-12-10, with intended 3 refill(s). Instructions: take 40 mg by mouth 2 times a day for 3 weeks on and 1 week off.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-11-21 00:00:00, ended at 2019-11-21 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of colon\n\n### Drug\n- regorafenib 40 MG Oral Tablet, through Oral route, started on 2019-11-21, presumably until 2020-01-08, with intended 3 refill(s). Instructions: take 40 mg by mouth 2 times a day for 3 weeks on and 1 week off.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2019-12-03 00:00:00, ended at 2019-12-03 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Abnormal findings on diagnostic imaging of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-10 10:20:00, ended at 2019-12-10 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Secondary malignant neoplasm of left lung\n- Primary malignant neoplasm of descending colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-17 09:20:00, ended at 2019-12-17 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 236 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.1 (percent)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 213 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.2 (picogram)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.06 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 28.7 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Anion gap in Serum or Plasma: 14 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.39 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.68 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 59.4 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 425 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 29 (nanogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.9 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 112 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 85.2 (femtoliter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.26 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 198 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 15.2 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.71 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.5 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.5 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-12-17 09:43:25, ended at 2019-12-17 13:19:34\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' .992\" (inch (US))\n- Hemoglobin A1c/Hemoglobin.total in Blood: 8.6 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-18 00:00:00, ended at 2019-12-18 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2019-12-18, presumably until 2019-12-21, with intended 2 refill(s). Instructions: take 1-2 Tabs (0.5-1 mg total) by mouth every 6 hours as needed For nausea and vomitting\n- capecitabine 500 MG Oral Tablet, started on 2019-12-18, presumably until 2019-12-20, with intended 3 refill(s). Instructions: 4 tabs (2000 mg) in the AM and the evening, for 7 days, then 7 days off\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2019-12-18, presumably until 2019-12-21, with intended 6 refill(s). Instructions: take 1 Tab (8 mg total) by mouth every 8 hours as needed (For nausea and vomitting)\n- prochlorperazine 10 MG Oral Tablet, through Oral route, started on 2019-12-18, presumably until 2019-12-21, with intended 6 refill(s). Instructions: take 1 Tab (10 mg total) by mouth every 6 hours as needed for Nausea/Vomiting\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-20 00:00:00, ended at 2019-12-20 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- capecitabine 500 MG Oral Tablet, started on 2019-12-20, presumably until 2019-12-21, with intended 3 refill(s). Instructions: 4 tabs (2000 mg) in the AM and the evening, for 7 days, then 7 days off\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-21 00:00:00, ended at 2019-12-21 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-25 00:00:00, ended at 2019-12-25 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-25 00:00:00, ended at 2019-12-25 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-26 00:00:00, ended at 2019-12-26 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-26 00:00:00, ended at 2019-12-26 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-26 12:03:00, ended at 2019-12-26 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- C reactive protein [Mass/volume] in Serum or Plasma: 4.8 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 15.3 (gram per deciliter)\n- Lutropin [Units/volume] in Serum or Plasma: 4.2 (milli-international unit per milliliter)\n- MCH [Entitic mass] by Automated count: 27.9 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 53.1 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.12 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.74 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 554 (unit per liter)\n- Anion gap in Serum or Plasma: 15 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.72 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- Testosterone [Mass/volume] in Serum or Plasma: 559 (nanogram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 161 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 96 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.48 (million per microliter)\n- Follitropin [Units/volume] in Serum or Plasma: 7.4 (milli-international unit per milliliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Corticotropin [Mass/volume] in Plasma: 58.8 (picogram per milliliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 46.9 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.6 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 266 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.0 (percent)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 9.0 (percent)\n- MCV [Entitic volume] by Automated count: 85.6 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 296 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.2 (gram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.18 (micro-international unit per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Cortisol [Mass/volume] in Serum or Plasma: 20.3 (microgram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.53 (thousand per microliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.40 (nanogram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.6 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 31.9 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.1 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 348 (milligram per deciliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n- Hyperglycemia\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2019-12-26, presumably until 2019-12-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-28 00:00:00, ended at 2019-12-28 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-02 00:00:00, ended at 2020-01-02 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 84 (unit per liter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter calculated)\n- Glucose [Mass/volume] in Serum or Plasma: 194 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.2 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 143 (unit per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 1.0 (calculated)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 614 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.86 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: NOT APPLICABLE (calculated)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-08 12:14:48, ended at 2020-01-08 14:10:15\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of colon\n\n### Drug\n- regorafenib 40 MG Oral Tablet, started on 2020-01-08, presumably until 2020-01-22, with intended 3 refill(s). Instructions: Take 1 tab in the morning and 2 tabs in the evening for 3 weeks on and 1 week off.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-08 13:45:00, ended at 2020-01-08 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 210 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 96 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.84 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 228 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.72 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 5.52 (micro-international unit per milliliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 2.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 12.8 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 49.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.3 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.2 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.66 (nanogram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 654 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.78 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.23 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.12 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 29.1 (percent)\n- MCV [Entitic volume] by Automated count: 83.9 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 51.2 (percent)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 40 (nanogram per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 16.2 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 27.7 (picogram)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 331 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.2 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.8 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.08 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 272 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Globulin [Mass/volume] in Serum: 4.4 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of colon\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-09 00:00:00, ended at 2020-01-09 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-11 00:00:00, ended at 2020-01-11 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2020-01-13 19:43:00, ended at 2020-01-16 10:16:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Acetaminophen [Presence] in Urine: <5.0 (microgram per milliliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.4 (percent)\n- Platelets [#/volume] in Blood by Automated count: 181 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 997 (unit per liter)\n- Anion gap in Serum or Plasma: 15 (millimole per liter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.60 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.74 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 324 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 60.9 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 235 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.64 (thousand per microliter)\n- Body height: 6' .835\" (inch (US))\n- Glucose [Mass/volume] in Blood: 345 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 83.8 (femtoliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.6 (percent)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 16.3 (gram per deciliter)\n- Prothrombin time (PT): 11.8 (second)\n- aPTT in Platelet poor plasma by Coagulation assay: 31.7 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 8.33 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 339 (milligram per deciliter)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.38 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.1 (percent)\n- MCH [Entitic mass] by Automated count: 28.1 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.80 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 48.3 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n\n### Procedure\n- Hospital discharge day management; more than 30 minutes\n- Dilation of Pancreatic Duct with Intraluminal Device, Via Natural or Artificial Opening Endoscopic\n- Endoscopic retrograde cholangiopancreatography (ERCP); with placement of endoscopic stent into biliary or pancreatic duct, including pre- and post-dilation and guide wire passage, when performed, including sphincterotomy, when performed, each stent\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n- Combined endoscopic catheterization of the biliary and pancreatic ductal systems, radiological supervision and interpretation\n- Dilation of Common Bile Duct with Intraluminal Device, Via Natural or Artificial Opening Endoscopic\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A problem focused interval history; A problem focused examination; Medical decision making that is straightforward or o\n\n### Condition\n- Acquired absence of spleen\n- Disorder of digestive system\n- Hepatic failure\n- Hypoinsulinemia following procedure\n- Jaundice\n- Hypokalemia\n- Secondary malignant neoplasm of right lung\n- Acquired absence of organ\n- Genetic predisposition\n- Secondary malignant neoplasm of left lung\n- Generalized abdominal pain\n- Primary diagnosis: Obstruction of bile duct\n- Pruritic rash\n- Primary malignant neoplasm of colon\n- Secondary malignant neoplasm of intra-abdominal lymph nodes\n\n### Drug\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2020-01-14, presumably until 2020-01-15\n- ondansetron 8 MG Oral Tablet, through Oral route, presumably until 2020-12-13, with intended 0 refill(s). Instructions: take 8 mg by mouth every 8 hours as needed\n- indomethacin 50 MG Rectal Suppository, through Rectal route, started on 2020-01-15, presumably until 2020-01-15\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2020-01-14, presumably until 2020-01-14\n- 3 ML insulin detemir 100 UNT/ML Pen Injector, through Subcutaneous route, presumably until 2020-03-17, with intended 0 refill(s). Instructions: inject 25 Units subcutaneous (under the skin) every bedtime\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2020-01-16, presumably until 2020-01-16\n- insulin glargine 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2020-01-14, presumably until 2020-01-15\n- amylase 120000 UNT / lipase 24000 UNT / protease 76000 UNT Delayed Release Oral Capsule, through Oral route, started on 2020-01-15, presumably until 2020-06-13, with intended 0 refill(s). Instructions: Take 3 caps by mouth 3 times a day with meals.\n- simethicone 80 MG Chewable Tablet, through Oral route, started on 2020-01-14, presumably until 2020-01-16\n- 3 ML insulin aspart, human 100 UNT/ML Pen Injector, through Subcutaneous route, presumably until 2020-03-17, with intended 0 refill(s). Instructions: inject 10 Units subcutaneous (under the skin) 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2020-01-15 00:00:00, ended at 2020-01-15 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for upper gastrointestinal endoscopic procedures, endoscope introduced proximal to duodenum; endoscopic retrograde cholangiopancreatography (ERCP)\n\n### Condition\n- Jaundice\n- Disorder caused by alcohol\n\n### Drug\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2020-01-15, presumably until 2020-01-15\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2020-01-15, presumably until 2020-01-15\n- 2 ML ondansetron 2 MG/ML Injection, started on 2020-01-15, presumably until 2020-01-15\n- midazolam 1 MG/ML Injectable Solution, started on 2020-01-15, presumably until 2020-01-15\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2020-01-15, presumably until 2020-01-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-01-15 00:00:00, ended at 2020-01-15 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Endoscopic retrograde cholangiopancreatography (ERCP); with placement of endoscopic stent into biliary or pancreatic duct, including pre- and post-dilation and guide wire passage, when performed, including sphincterotomy, when performed, each stent\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-16 00:00:00, ended at 2020-01-16 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2020-01-19 16:08:00, ended at 2020-01-22 18:14:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Glucose [Mass/volume] in Blood: 266 (milligram per deciliter)\n- Lactate [Moles/volume] in Blood: 1.2 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.1 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 84.6 (femtoliter)\n- Body height: 6' 1.228\" (inch (US))\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 44.4 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 16.5 (percent)\n- MCH [Entitic mass] by Automated count: 27.8 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 258 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Creatinine [Mass/volume] in Urine: 165.00 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.17 (thousand per microliter)\n- Osmolality of Urine: 883 (milliosmole per kilogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 17.1 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.57 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.0 (percent)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.05 (thousand per microliter)\n- Urate [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.33 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.6 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.9 (percent)\n- Osmolality of Serum or Plasma: 285 (milliosmole per kilogram)\n- Prothrombin time (PT): 13.4 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 1183 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 104 (unit per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.61 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 31.9 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 250 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 276 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.2 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Platelets [#/volume] in Blood by Automated count: 208 (thousand per microliter)\n- Sodium/Creatinine [Molar ratio] in Urine: 67 (millimole per liter)\n\n### Procedure\n- Combined endoscopic catheterization of the biliary and pancreatic ductal systems, radiological supervision and interpretation\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Hospital discharge day management; 30 minutes or less\n- Endoscopic catheterization of the biliary ductal system, radiological supervision and interpretation\n- Endoscopic retrograde cholangiopancreatography (ERCP); with removal and exchange of stent(s), biliary or pancreatic duct, including pre- and post-dilation and guide wire passage, when performed, including sphincterotomy, when performed, each stent exchang\n- Endoscopic cannulation of papilla with direct visualization of pancreatic/common bile duct(s) (List separately in addition to code(s) for primary procedure)\n- Dilation of Common Bile Duct with Intraluminal Device, Via Natural or Artificial Opening Endoscopic\n- Collection of venous blood by venipuncture\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Removal of Intraluminal Device from Hepatobiliary Duct, Via Natural or Artificial Opening Endoscopic\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Abdominal distension, gaseous\n- Benign neoplasm of colon\n- Hypo-osmolality and or hyponatremia\n- Secondary malignant neoplasm of bone\n- Secondary malignant neoplasm of intra-abdominal lymph nodes\n- Type 2 diabetes mellitus without complication\n- Secondary malignant neoplasm of unknown site\n- Acquired absence of organ\n- Primary diagnosis: Primary malignant neoplasm of colon\n- Fever\n- Obstruction of bile duct\n- Disorder of digestive system\n- Jaundice\n- Tachycardia\n- Hypoinsulinemia following procedure\n- Primary malignant neoplasm of descending colon\n- Pruritic rash\n- Cholangitis\n\n### Drug\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2020-01-20, presumably until 2020-01-20\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2020-01-20, presumably until 2020-01-20\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2020-01-19, presumably until 2020-01-27, with intended 0 refill(s). Instructions: take 1 Tab (500 mg total) by mouth 2 times a day for 5 days\n- calcium chloride 0.001 MEQ/ML / glucose 50 MG/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2020-01-19, presumably until 2020-01-20\n- cholestyramine resin 4000 MG Powder for Oral Suspension, through Oral route, started on 2020-01-19, presumably until 2020-01-21\n- metronidazole 500 MG Oral Tablet, through Oral route, started on 2020-01-20, presumably until 2020-01-25, with intended 0 refill(s). Instructions: take 1 Tab (500 mg total) by mouth every 8 hours for 7 doses\n- insulin glargine 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2020-01-19, presumably until 2020-01-21\n- amylase 120000 UNT / lipase 24000 UNT / protease 76000 UNT Delayed Release Oral Capsule, through Oral route, started on 2020-01-20, presumably until 2020-01-21\n- simethicone 80 MG Chewable Tablet, through Oral route, started on 2020-01-20, presumably until 2020-01-21\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2020-01-22 00:00:00, ended at 2020-01-22 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for upper gastrointestinal endoscopic procedures, endoscope introduced proximal to duodenum; endoscopic retrograde cholangiopancreatography (ERCP)\n\n### Condition\n- Obstruction of bile duct\n- Jaundice\n- Disorder caused by alcohol\n\n### Drug\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2020-01-22, presumably until 2020-01-22\n- midazolam 1 MG/ML Injectable Solution, started on 2020-01-22, presumably until 2020-01-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-01-22 00:00:00, ended at 2020-01-22 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Endoscopic cannulation of papilla with direct visualization of pancreatic/common bile duct(s) (List separately in addition to code(s) for primary procedure)\n- Endoscopic retrograde cholangiopancreatography (ERCP); with removal and exchange of stent(s), biliary or pancreatic duct, including pre- and post-dilation and guide wire passage, when performed, including sphincterotomy, when performed, each stent exchang\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-23 00:00:00, ended at 2020-01-23 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 109 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0 (cells per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 5.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 276 (cells per microliter)\n- Globulin [Mass/volume] in Serum: 5.0 (gram per deciliter calculated)\n- Hemoglobin [Mass/volume] in Blood: 14.5 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.0 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: NOT APPLICABLE (calculated)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 103 (unit per liter)\n- Band form neutrophils [#/volume] in Blood: 276 (cells per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 96 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.94 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.16 (million per liter)\n- Monocytes [#/volume] in Blood by Automated count: 828 (cells per microliter)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 9.4 (femtoliter)\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 0.6 (calculated)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.2 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 83.3 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Band form neutrophils/100 leukocytes in Blood by Manual count: 3 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 6164 (cells per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1656 (cells per microliter)\n- MCH [Entitic mass] by Automated count: 28.1 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 67 (percent)\n- Platelets [#/volume] in Blood by Automated count: 408 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 754 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18 (percent)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 300 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-28 00:00:00, ended at 2020-01-28 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-01 00:00:00, ended at 2020-02-01 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-04 00:00:00, ended at 2020-02-04 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of colon\n\n### Drug\n- loperamide hydrochloride 2 MG Oral Capsule, through Oral route, started on 2020-02-04, presumably until 2020-06-03, with intended 11 refill(s). Instructions: take 1 Kadiyala (2 mg total) by mouth every 4 hours as needed for Diarrhea\n- capecitabine 500 MG Oral Tablet, through Oral route, started on 2020-02-04, presumably until 2020-03-04, with intended 10 refill(s). Instructions: take 4 Tabs (2,000 mg total) by mouth 2 times a day Take 4 tabs twice daily x 7 days every other week. Cytotoxic: Take with food.\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2020-02-04, presumably until 2020-06-03, with intended 11 refill(s). Instructions: take 1 Tab (8 mg total) by mouth every 8 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-02-04 08:29:00, ended at 2020-02-04 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.22 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 86.2 (femtoliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 108 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.9 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.2 (percent)\n- MCHC [Mass/volume] by Automated count: 32.2 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.2 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 3.7 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 10.4 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 28.6 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.00 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 663 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 95 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.01 (million per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.2 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 10.1 (milligram per deciliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 30 (nanogram per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 123 (unit per liter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.95 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 2.14 (milligram per deciliter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.82 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.55 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 27.7 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 335 (thousand per microliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.38 (nanogram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 222 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 55.6 (percent)\n- Thyrotropin [Units/volume] in Serum or Plasma: 3.51 (micro-international unit per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of descending colon\n- Primary malignant neoplasm of colon\n- Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-02-04 08:35:26, ended at 2020-02-04 10:00:13\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' .008\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- loperamide hydrochloride 2 MG Oral Capsule, through Oral route, started on 2020-02-04, presumably until 2020-02-04, with intended 11 refill(s). Instructions: take 1 Dupre (2 mg total) by mouth every 4 hours as needed for Diarrhea\n- capecitabine 500 MG Oral Tablet, through Oral route, started on 2020-02-04, presumably until 2020-02-04, with intended 10 refill(s). Instructions: take 4 Tabs (2,000 mg total) by mouth 2 times a day Take 4 tabs twice daily x 7 days every other week. Cytotoxic: Take with food.\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2020-02-04, presumably until 2020-02-04, with intended 11 refill(s). Instructions: take 1 Tab (8 mg total) by mouth every 8 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-02-11 10:42:09, ended at 2020-02-11 12:09:05\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus without complication\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-12 00:00:00, ended at 2020-02-12 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-02-12 08:08:00, ended at 2020-02-12 10:42:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 235 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.66 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 271 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.86 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.1 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 60.0 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 115 (unit per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 127 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.6 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.7 (percent)\n- MCH [Entitic mass] by Automated count: 28.0 (picogram)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.72 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.26 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 594 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 2.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.3 (percent)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.85 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.8 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 86.6 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.89 (thousand per microliter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Primary malignant neoplasm of descending colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-02-12 08:22:59, ended at 2020-02-12 10:35:18\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' .008\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- doxycycline hyclate 100 MG Oral Tablet, through Oral route, started on 2020-02-12, presumably until 2020-02-26, with intended 3 refill(s). Instructions: take 1 Tab (100 mg total) by mouth 2 times a day for 14 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-02-25 00:00:00, ended at 2020-02-25 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-26 00:00:00, ended at 2020-02-26 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- hydroxyzine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2020-02-26, presumably until 2020-04-18, with intended 1 refill(s). Instructions: take 2 Tabs (50 mg total) by mouth 2 times a day Take 1 tab am & pm\n- clindamycin 0.01 MG/MG Topical Gel, through Topical route, started on 2020-02-26, presumably until 2020-10-08, with intended 10 refill(s). Instructions: by Topical route 2 times a day use thin film on affected area\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-02-26 08:27:00, ended at 2020-02-26 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 103 (unit per liter)\n- Body height: 6' 1.031\" (inch (US))\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.81 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 648 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.55 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.29 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 15.0 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 217 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.19 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 86.4 (femtoliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.6 (percent)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.4 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 59.9 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 100 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.4 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.0 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.1 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.81 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Anion gap in Serum or Plasma: 14 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.7 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 27.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 276 (milligram per deciliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Collection of blood specimen from a completely implantable venous access device\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2020-02-26, presumably until 2020-02-26\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2020-02-26, presumably until 2020-02-26\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2020-02-26, presumably until 2020-02-26\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2020-02-26, presumably until 2020-02-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-03-02 13:40:00, ended at 2020-03-02 15:34:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Erythrocytes [#/volume] in Blood by Automated count: 5.27 (million per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.62 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.8 (percent)\n- MCV [Entitic volume] by Automated count: 85.6 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 94 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 15.1 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.95 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 28.7 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 541 (unit per liter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Lactate [Moles/volume] in Blood: 2.0 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.7 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 192 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.1 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 83.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 139 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 14.4 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.26 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 12.07 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 110 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 2.5 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 6.6 (percent)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; initial, 31 minutes to 1 hour\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Collection of blood specimen from a completely implantable venous access device\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Fever\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2020-03-02, presumably until 2020-03-02\n- 1000 ML potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2020-03-02, presumably until 2020-03-02\n- 2 ML ondansetron 2 MG/ML Injection, started on 2020-03-02, presumably until 2020-03-02\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2020-03-02, presumably until 2020-03-02\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-03-02 15:35:00, ended at 2020-03-02 18:39:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest; 2 views\n\n### Condition\n- Fever\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2020-03-02 18:40:00, ended at 2020-03-04 13:12:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 2.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 0.53 (microgram of fibrinogen equivalent unit per milliliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 47.5 (second)\n- Basophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 544 (milligram per deciliter)\n- Glucose [Mass/volume] in Blood: 220 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 27.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.50 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 88.1 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 82 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 85 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.12 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 120 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Prothrombin time (PT): 14.0 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 474 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.55 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.94 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 150 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.1 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Thrombin time: 18.5 (second)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Monocytes/100 leukocytes in Blood by Automated count: 21.6 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 63.6 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.1 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.5 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.82 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n\n### Procedure\n- Hospital discharge day management; more than 30 minutes\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A detailed or comprehensive history; A detailed or comprehensive examination; and Medical decision making that is straightforward or of \n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n\n### Condition\n- Deficiency of macronutrients\n- Eruption\n- Fatigue\n- Nausea and vomiting\n- Obstruction of bile duct\n- Secondary thrombocytopenia\n- Sepsis\n- Disorder due to infection\n- Hypo-osmolality and or hyponatremia\n- Acquired absence of organ\n- Fever\n- Diabetes mellitus without complication\n- Disorder of digestive system\n- Hypokalemia\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2020-03-02, presumably until 2020-03-04\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2020-03-03, presumably until 2020-03-03\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2020-03-02, presumably until 2020-03-03\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2020-03-04, presumably until 2020-03-12, with intended 0 refill(s). Instructions: take 1 Tab (500 mg total) by mouth 2 times a day for 8 days\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2020-03-03, presumably until 2020-03-03\n- insulin detemir 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2020-03-02, presumably until 2020-03-03\n- doxycycline hyclate 100 MG Oral Capsule, through Oral route, started on 2020-03-02, presumably until 2020-03-04\n- clindamycin 0.01 MG/MG Topical Gel, through Topical route, started on 2020-03-02, presumably until 2020-03-04\n- amylase 120000 UNT / lipase 24000 UNT / protease 76000 UNT Delayed Release Oral Capsule, through Oral route, started on 2020-03-04, presumably until 2020-03-04\n- 50 ML magnesium sulfate 40 MG/ML Injection, through Intravenous route, started on 2020-03-03, presumably until 2020-03-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-03-10 00:00:00, ended at 2020-03-10 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-03-11 09:10:00, ended at 2020-03-11 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 32.4 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 157 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.3 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.6 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 83 (unit per liter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 7 (nanogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 46.0 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.26 (million per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 49.3 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.57 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.9 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.2 (percent)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.9 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 189 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.15 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 32.6 (percent)\n- MCV [Entitic volume] by Automated count: 87.5 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.83 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.25 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 562 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.6 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2020-03-11, presumably until 2020-03-11\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2020-03-11, presumably until 2020-03-11\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2020-03-11, presumably until 2020-03-11\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2020-03-11, presumably until 2020-03-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-03-17 14:29:59, ended at 2020-03-17 14:37:02\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus without complication\n\n### Drug\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2020-03-17, presumably until 2020-03-24, with intended 5 refill(s). Instructions: inject 25 Units subcutaneous (under the skin) daily in the evening\n- 3 ML insulin aspart, human 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2020-03-17, presumably until 2020-09-05, with intended 5 refill(s). Instructions: inject 10-14 Units subcutaneous (under the skin) 3 times a day 10 units with breakfast and dinner, 12 units with lunch, Add 2 units if BG>200\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-03-24 00:00:00, ended at 2020-03-24 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus without complication\n\n### Drug\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2020-03-24, presumably until 2020-06-03, with intended 3 refill(s). Instructions: inject 25 Units subcutaneous (under the skin) daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-03-25 08:49:00, ended at 2020-03-25 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.53 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.26 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.8 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 47.6 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 601 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 87.1 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.5 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 70 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 91 (unit per liter)\n- Body height: 6' 1.228\" (inch (US))\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 189 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.01 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.82 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 28.1 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 177 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 34.0 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.7 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.9 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.8 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.87 (thousand per microliter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2020-03-25, presumably until 2020-03-25\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2020-03-25, presumably until 2020-03-25\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2020-03-25, presumably until 2020-03-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-03-25 10:18:08, ended at 2020-03-25 10:36:20\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n- Neoplasm defined only by topography: Colon, NOS\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-01 15:42:57, ended at 2020-04-01 17:17:35\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: COVID-19\n- Nausea and vomiting\n- Primary diagnosis: Disorder of respiratory system\n- Type 2 diabetes mellitus\n- Obstruction of bile duct\n- Complication due to diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-04-04 08:05:00, ended at 2020-04-04 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Secondary malignant neoplasm of bone\n- Primary malignant neoplasm of descending colon\n- Secondary malignant neoplasm of left lung\n- Localized enlarged lymph nodes\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-08 00:00:00, ended at 2020-04-08 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-04-08 08:41:00, ended at 2020-04-08 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 28.3 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.1 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 116 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 6 (nanogram per milliliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 6.12 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 49.8 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.95 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 67.3 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.5 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.3 (percent)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 235 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.8 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 534 (unit per liter)\n- Body height: 6' .835\" (inch (US))\n- MCV [Entitic volume] by Automated count: 86.6 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.48 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.75 (million per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 85 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.80 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 77 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 16.3 (gram per deciliter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2020-04-08, presumably until 2020-04-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-08 09:43:03, ended at 2020-04-08 11:10:25\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.228\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-04-12 13:15:16, ended at 2020-04-12 13:15:22\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- COVID-19\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-04-15 00:00:00, ended at 2020-04-15 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Endoscopic retrograde cholangiopancreatography (ERCP); with removal and exchange of stent(s), biliary or pancreatic duct, including pre- and post-dilation and guide wire passage, when performed, including sphincterotomy, when performed, each stent exchang\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-04-15 00:00:00, ended at 2020-04-15 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for upper gastrointestinal endoscopic procedures, endoscope introduced proximal to duodenum; endoscopic retrograde cholangiopancreatography (ERCP)\n\n### Condition\n- Disorder caused by alcohol\n- Obstruction of bile duct\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2020-04-15, presumably until 2020-04-15\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2020-04-15, presumably until 2020-04-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-04-15 07:54:00, ended at 2020-04-15 11:43:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.75\" (inch (US))\n\n### Procedure\n- Endoscopic retrograde cholangiopancreatography (ERCP); with removal and exchange of stent(s), biliary or pancreatic duct, including pre- and post-dilation and guide wire passage, when performed, including sphincterotomy, when performed, each stent exchang\n- Endoscopic catheterization of the biliary ductal system, radiological supervision and interpretation\n\n### Condition\n- Gastritis\n- Hypoinsulinemia following procedure\n- Complication due to diabetes mellitus\n- Diabetes mellitus\n- Obstruction of bile duct\n- Secondary malignant neoplasm of bone\n- Acquired absence of organ\n- Disorder of digestive system\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-16 00:00:00, ended at 2020-04-16 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-18 00:00:00, ended at 2020-04-18 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- hydroxyzine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2020-04-18, presumably until 2020-04-25, with intended 1 refill(s). Instructions: take 2 Tabs (50 mg total) by mouth 2 times a day Take 1 tab am & pm\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-21 00:00:00, ended at 2020-04-21 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-22 00:00:00, ended at 2020-04-22 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n"}, "target": "Yes", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Malignant tumor of pancreas within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-07-29 14:58:00, ended at 2011-07-29 23:59:00\nThe patient in this visit was 34 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' .5\" (inch (US))\n\n### Procedure\n- Consultation and report on referred slides prepared elsewhere\n\n### Condition\n- Benign neoplasm of stomach\n- Carcinoma in situ of colon\n- Primary malignant neoplasm of colon\n- Benign neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2011-08-07 00:00:00, ended at 2011-08-07 00:00:00\nThe patient in this visit was 34 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- polyethylene glycol 3350 236000 MG / potassium chloride 2970 MG / sodium bicarbonate 6740 MG / sodium chloride 5860 MG / sodium sulfate 22740 MG Powder for Oral Solution, through Oral route, started on 2011-08-07, presumably until 2011-08-18, with intended 0 refill(s). Instructions: take 4,000 mL by mouth One Time.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-08-10 10:02:00, ended at 2011-08-10 13:29:00\nThe patient in this visit was 34 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1\" (inch (US))\n\n### Procedure\n- Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique\n- Endoscopic polypectomy of large intestine\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Endoscopic biopsy of large intestine\n- Colonoscopy, flexible; with biopsy, single or multiple\n\n### Condition\n- Benign neoplasm of rectum and anal canal\n- Primary malignant neoplasm of transverse colon\n- Benign neoplasm of colon\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-08-10, presumably until 2011-08-10\n- midazolam 1 MG/ML Injectable Solution, started on 2011-08-10, presumably until 2011-08-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-08-11 07:37:00, ended at 2011-08-18 12:30:00\nThe patient in this visit was 35 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 24.3 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.86 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 28.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.14 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.3 (percent)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 94.5 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.5 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.4 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Body height: 6' 1\" (inch (US))\n- Lymphocytes [#/volume] in Blood by Automated count: 0.84 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.47 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 250 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 159 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 74.1 (femtoliter)\n\n### Procedure\n- Rigid proctosigmoidoscopy\n- Molecular diagnostics; amplification, target, multiplex, first 2 nucleic acid sequences\n- Molecular diagnostics; interpretation and report\n- Molecular diagnostics; isolation or extraction of highly purified nucleic acid, each nucleic acid type (ie, DNA or RNA)\n- Laparoscopic total intra-abdominal colectomy\n- Molecular diagnostics; amplification, target, multiplex, each additional nucleic acid sequence beyond 2 (List separately in addition to code for primary procedure)\n- Other small-to-large intestinal anastomosis\n- Collection of venous blood by venipuncture\n- Molecular diagnostics; separation and identification by high resolution technique (eg, capillary electrophoresis), each nucleic acid preparation\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Benign neoplasm of colon\n- Neoplasm of intrapelvic lymph node\n- Neoplasm of intra-abdominal lymph nodes\n- Primary malignant neoplasm of colon\n- Primary malignant neoplasm of splenic flexure of colon\n- Anemia in neoplastic disease\n- Primary malignant neoplasm of rectosigmoid junction\n\n### Drug\n- psyllium, through Oral route, started on 2011-08-18, presumably until 2012-06-14. Instructions: take 1 Packet by mouth 3 times a day.\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2011-08-11, presumably until 2011-08-16\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2011-08-14, presumably until 2011-08-17\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2011-08-12, presumably until 2011-08-17\n- ispaghula husk, through Oral route, started on 2011-08-18, presumably until 2012-06-14. Instructions: take 1 Packet by mouth 3 times a day.\n- 2 ML ondansetron 2 MG/ML Injection, started on 2011-08-13, presumably until 2011-08-13\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2011-08-11, presumably until 2011-08-14\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-08-11, presumably until 2011-08-11\n- Plantago seed, through Oral route, started on 2011-08-18, presumably until 2012-06-14. Instructions: take 1 Packet by mouth 3 times a day.\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2011-08-13, presumably until 2011-08-14\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2011-08-14, presumably until 2011-08-14\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2011-08-13, presumably until 2012-02-14, with intended 2 refill(s). Instructions: take 1-2 Tabs by mouth every 6 hours as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-08-18 00:00:00, ended at 2011-08-18 00:00:00\nThe patient in this visit was 35 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-09-02 13:55:00, ended at 2011-09-02 23:59:00\nThe patient in this visit was 35 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.25\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign neoplasm of colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-09-14 15:07:00, ended at 2011-09-14 23:59:00\nThe patient in this visit was 35 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.25\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of colon\n- Benign neoplasm of colon\n\n### Drug\n- capecitabine 500 MG Oral Tablet, through Oral route, started on 2011-09-14, presumably until 2012-06-14, with intended 5 refill(s). Instructions: take 4 Tabs by mouth 2 times a day. Take 2 times daily for 2 weeks and then 1 week off.\n- ondansetron 8 MG Oral Tablet, through Oral route, presumably until 2012-06-14, with intended 1 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed. For nausea and vomiting.\n- lorazepam 1 MG Oral Tablet, through Oral route, presumably until 2012-06-14, with intended 2 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed. For nausea and vomiting.\n- prochlorperazine 10 MG Oral Tablet, through Oral route, presumably until 2012-06-14, with intended 2 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed. For nausea and vomiting.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-09-17 00:00:00, ended at 2011-09-17 00:00:00\nThe patient in this visit was 35 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-09-20 08:00:00, ended at 2011-09-20 13:19:00\nThe patient in this visit was 35 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 1 (nanogram per milliliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.22 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 21.7 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.0 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 20.3 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 99 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 100 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.61 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 30.6 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.75 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 51.9 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.3 (percent)\n- MCV [Entitic volume] by Automated count: 66.4 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.1 (percent)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.42 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 30.4 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 224 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.3 (thousand per microliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of colon\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2011-09-20, presumably until 2011-09-20\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2011-09-20, presumably until 2011-09-20\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2011-09-20, presumably until 2011-09-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-09-20 13:20:00, ended at 2011-09-20 23:59:00\nThe patient in this visit was 35 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of colon\n- Disorder of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-10-08 00:00:00, ended at 2011-10-08 00:00:00\nThe patient in this visit was 35 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-10-08 09:45:00, ended at 2011-10-08 11:10:00\nThe patient in this visit was 35 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.228\" (inch (US))\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Chromosome analysis, cytogenetic procedure AND/OR molecular biology method\n- Genetic counseling\n\n### Condition\n- Benign neoplasm of colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-10-12 12:00:00, ended at 2011-10-12 12:18:00\nThe patient in this visit was 35 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 3 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 44.1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.57 (thousand per microliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 2 (nanogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 21.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.11 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 31.2 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 35.9 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.4 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.6 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 16.4 (percent)\n- MCH [Entitic mass] by Automated count: 20.3 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 1.28 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 180 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.58 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 107 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 93 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 65.2 (femtoliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-10-12 12:19:00, ended at 2011-10-12 23:59:00\nThe patient in this visit was 35 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 2\" (inch (US))\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of colon\n- Benign neoplasm of colon\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2011-10-12, presumably until 2011-10-12\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2011-10-12, presumably until 2011-10-12\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2011-10-12, presumably until 2011-10-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-10-20 00:00:00, ended at 2011-10-20 00:00:00\nThe patient in this visit was 35 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-06-01 00:00:00, ended at 2012-06-01 00:00:00\nThe patient in this visit was 35 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-06-14 10:10:00, ended at 2012-06-14 13:39:00\nThe patient in this visit was 35 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 2\" (inch (US))\n\n### Procedure\n- Endoscopic polypectomy of large intestine\n- [Endoscopic] polypectomy of rectum\n- Sigmoidoscopy, flexible; with biopsy, single or multiple\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Benign neoplasm of colon\n- Benign neoplasm of rectum and anal canal\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2012-06-14, presumably until 2012-06-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-03-20 00:00:00, ended at 2013-03-20 00:00:00\nThe patient in this visit was 36 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2013-03-28 00:00:00, ended at 2013-03-28 00:00:00\nThe patient in this visit was 36 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- simethicone 66.7 MG/ML Oral Suspension, through Oral route, started on 2013-03-28, presumably until 2013-03-28\n- water 1000 MG/ML Irrigation Solution, through Topical route, started on 2013-03-28, presumably until 2013-03-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-28 09:47:00, ended at 2013-03-28 13:50:00\nThe patient in this visit was 36 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' .992\" (inch (US))\n\n### Procedure\n- [Endoscopic] polypectomy of rectum\n- Flexible fiberoptic sigmoidoscopy\n- Sigmoidoscopy, flexible; with biopsy, single or multiple\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Primary malignant neoplasm of colon\n- Benign neoplasm of rectum and anal canal\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2013-03-28, presumably until 2013-03-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-11-18 00:00:00, ended at 2014-11-18 00:00:00\nThe patient in this visit was 38 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-03-05 00:00:00, ended at 2016-03-05 00:00:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2018-03-29 14:20:00, ended at 2018-03-31 17:26:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- MCH [Entitic mass] by Automated count: 26.0 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.3 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 79.1 (femtoliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 32.6 (second)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.94 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 220 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Chromogranin A [Moles/volume] in Serum or Plasma: 49 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.95 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 58.7 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 98 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Body height: 6' 2\" (inch (US))\n- Hematocrit [Volume Fraction] of Blood by Automated count: 46.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 15.4 (gram per deciliter)\n- Prothrombin time (PT): 13.5 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 30.0 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 8 (nanogram per milliliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Lactate [Moles/volume] in Serum or Plasma: 1.0 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.04 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.00 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 46 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.7 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.8 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of rectosigmoid junction\n- Nausea and vomiting\n- Primary diagnosis: Intestinal obstruction\n- Primary malignant neoplasm of colon\n- Acquired absence of organ\n- Secondary malignant neoplasm of intra-abdominal lymph nodes\n- Primary malignant neoplasm of descending colon\n- Benign neoplasm of colon\n- Secondary malignant neoplasm of left lung\n- Benign neoplasm of transverse colon\n- Primary malignant neoplasm of splenic flexure of colon\n- Secondary malignant neoplasm of intrapelvic lymph nodes\n- Secondary malignant neoplasm of small intestine\n- Disorder of digestive system\n\n### Drug\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2018-03-29, presumably until 2018-03-31\n- barium sulfate, through Oral route, started on 2018-03-30, presumably until 2018-03-30\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2018-03-29, presumably until 2018-03-31\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-04-10 00:00:00, ended at 2018-04-10 00:00:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-04-10 08:42:18, ended at 2018-04-10 10:04:02\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 2.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Intestinal obstruction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-04-10 09:55:46, ended at 2018-04-10 11:10:59\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-10 11:13:00, ended at 2018-04-10 13:53:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 83 (unit per liter)\n- MCV [Entitic volume] by Automated count: 79.0 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.6 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.22 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 119 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 6.46 (million per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.6 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 213 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 51.1 (percent)\n- Hemoglobin [Mass/volume] in Blood: 16.4 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 25.4 (picogram)\n- Prothrombin time (PT): 13.1 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 59 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.0 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 27.8 (second)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 114 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-10 13:54:00, ended at 2018-04-10 18:24:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Intra-abdominal and pelvic swelling, mass and lump\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-04-10 18:25:00, ended at 2018-04-25 15:19:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Base excess in Arterial blood by calculation: 2.7 (millimole per liter)\n- Glucose [Mass/volume] in Blood: 250 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 308 (thousand per microliter)\n- Body height: 6' 2.016\" (inch (US))\n- Erythrocyte distribution width [Ratio] by Automated count: 16.7 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 634 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 80.6 (femtoliter)\n- Bicarbonate [Moles/volume] in Specimen: 26.1 (millimole per liter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.09 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.06 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 6.01 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Oxygen [Partial pressure] in Arterial blood: 155.0 (millimeter mercury column)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.9 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 95 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 15.3 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.1 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 99 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Prothrombin time (PT): 13.8 (second)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Carbon dioxide [Partial pressure] in Arterial blood: 35.8 (millimeter mercury column)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 25.9 (picogram)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 77 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 47.3 (percent)\n\n### Procedure\n- Computed tomography, abdomen and pelvis; without contrast material\n- Excision of Stomach, Via Natural or Artificial Opening Endoscopic, Diagnostic\n- Excision of Pancreas, Open Approach\n- Drainage of Peritoneal Cavity with Drainage Device, Percutaneous Approach\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Physical therapy evaluation: low complexity, requiring these components: A history with no personal factors and/or comorbidities that impact the plan of care; An examination of body system(s) using standardized tests and measures addressing 1-2 elements f\n- Collection of venous blood by venipuncture\n- Radiologic examination, abdomen; 1 view\n- Morphometric analysis, tumor\n- Excision of Aortic Lymphatic, Open Approach\n- Radiologic examination, chest; 2 views\n- Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple\n- Excision of Right Lobe Liver, Open Approach\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Sigmoidoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Excision of Duodenum, Open Approach\n- Radiologic examination, abdomen; 2 views\n- Destruction of Right Lobe Liver, Open Approach\n- Excision of Rectum, Via Natural or Artificial Opening Endoscopic, Diagnostic\n- Image-guided fluid collection drainage by catheter (eg, abscess, hematoma, seroma, lymphocele, cyst); peritoneal or retroperitoneal, percutaneous\n\n### Condition\n- Disorder of digestive system\n- Secondary malignant neoplasm of intra-abdominal lymph nodes\n- Secondary malignant neoplasm of small intestine\n- Adult hypertrophic pyloric stenosis\n- Gastrointestinal complication\n- Steatosis of liver\n- Benign neoplasm of colon\n- Rectal polyp\n- Acquired absence of organ\n- Primary malignant neoplasm of small intestine\n- Abnormal findings on diagnostic imaging of lung\n- Ascites\n- Benign neoplasm of rectum\n- Overlapping malignant neoplasm of pancreas\n- Abdominal distension, gaseous\n- Abscess of peritoneum\n- Late effect of complications of procedure\n- Primary malignant neoplasm of colon\n- Abdominal pain\n- Gastric polyp\n- Intestinal obstruction\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2018-04-10, presumably until 2018-04-13\n- 1 ML octreotide 0.1 MG/ML Injection, started on 2018-04-21, presumably until 2018-04-21\n- 2 ML fentanyl 0.05 MG/ML Injection, through Intravenous route, started on 2018-04-13, presumably until 2018-04-13\n- 2 ML prochlorperazine 5 MG/ML Injection, started on 2018-04-13, presumably until 2018-04-18\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2018-04-17, presumably until 2018-04-20\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-04-11, presumably until 2018-04-25\n- naloxone hydrochloride 0.4 MG/ML Injectable Solution, started on 2018-04-13, presumably until 2018-04-13\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2018-04-14, presumably until 2018-04-24\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-04-13, presumably until 2019-10-25, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 8 hours\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2018-04-16, presumably until 2018-04-16\n- diatrizoate, through Oral route, started on 2018-04-25, presumably until 2018-04-25\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-04-17, presumably until 2018-04-20\n- diatrizoic acid, through Oral route, started on 2018-04-25, presumably until 2018-04-25\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2018-04-14, presumably until 2018-04-21\n- piperacillin 4000 MG / tazobactam 500 MG Injection, through Intravenous route, started on 2018-04-20, presumably until 2018-04-20\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2018-04-20, presumably until 2018-04-24\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2018-04-14, presumably until 2018-04-15\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2018-04-13, presumably until 2018-04-13\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2018-04-13, presumably until 2018-05-08, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 6 hours as needed\n- 1000 ML glucose 50 MG/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2018-04-13, presumably until 2018-04-22\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2018-04-14, presumably until 2018-04-16\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-04-13, presumably until 2018-04-13\n- lidocaine hydrochloride 0.02 MG/MG Topical Gel, through Submucosal route, started on 2018-04-17, presumably until 2018-04-17\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2018-04-13, presumably until 2018-07-18, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 6 hours as needed\n- 50 ML magnesium sulfate 40 MG/ML Injection, through Intravenous route, started on 2018-04-17, presumably until 2018-04-21\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2018-04-23, presumably until 2018-05-02, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 7 days\n- hydromorphone hydrochloride 2 MG/ML Injectable Solution, through Intravenous route, started on 2018-04-13, presumably until 2018-04-13\n- 1 ML promethazine hydrochloride 25 MG/ML Injection, started on 2018-04-18, presumably until 2018-04-18\n- 0.5 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2018-04-13, presumably until 2018-04-13\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2018-04-23, presumably until 2018-04-23\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-04-12 00:00:00, ended at 2018-04-12 00:00:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for combined upper and lower gastrointestinal endoscopic procedures, endoscope introduced both proximal to and distal to the duodenum\n\n### Condition\n- Rectal polyp\n- Gastric polyp\n\n### Drug\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2018-04-12, presumably until 2018-04-12\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2018-04-12, presumably until 2018-04-12\n- 2 ML ondansetron 2 MG/ML Injection, started on 2018-04-12, presumably until 2018-04-12\n- succinylcholine chloride 20 MG/ML Injectable Solution, started on 2018-04-12, presumably until 2018-04-12\n- 2 ML alfentanil 0.5 MG/ML Injection, started on 2018-04-12, presumably until 2018-04-12\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2018-04-12, presumably until 2018-04-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-04-13 00:00:00, ended at 2018-04-13 00:00:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for intraperitoneal procedures in upper abdomen including laparoscopy; partial hepatectomy or management of liver hemorrhage (excluding liver biopsy)\n\n### Condition\n- Primary malignant neoplasm of transverse colon\n\n### Drug\n- 10 ML calcium chloride 100 MG/ML Injection, through Intravenous route, started on 2018-04-13, presumably until 2018-04-13\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2018-04-13, presumably until 2018-04-13\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2018-04-13, presumably until 2018-04-13\n- naloxone hydrochloride 0.4 MG/ML Injectable Solution, started on 2018-04-13, presumably until 2018-04-13\n- cefoxitin 1000 MG Injection, through Intravenous route, started on 2018-04-13, presumably until 2018-04-13\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2018-04-13, presumably until 2018-04-13\n- 10 ML methylene blue 5 MG/ML Injection, through Intravenous route, started on 2018-04-13, presumably until 2018-04-13\n- labetalol hydrochloride 5 MG/ML Injectable Solution, through Intravenous route, started on 2018-04-13, presumably until 2018-04-13\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2018-04-13, presumably until 2018-04-13\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2018-04-13, presumably until 2018-04-13\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2018-04-13, presumably until 2018-04-13\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2018-04-13, presumably until 2018-04-13\n- 2 ML ondansetron 2 MG/ML Injection, started on 2018-04-13, presumably until 2018-04-13\n- ketamine 100 MG/ML Injectable Solution, started on 2018-04-13, presumably until 2018-04-13\n- 250 ML lidocaine hydrochloride 8 MG/ML Injection, through Intravenous route, started on 2018-04-13, presumably until 2018-04-13\n- midazolam 1 MG/ML Injectable Solution, started on 2018-04-13, presumably until 2018-04-13\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2018-04-13, presumably until 2018-04-13\n- 2 ML alfentanil 0.5 MG/ML Injection, started on 2018-04-13, presumably until 2018-04-13\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2018-04-13, presumably until 2018-04-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-04-13 12:38:00, ended at 2018-04-13 12:38:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign neoplasm of colon\n- Primary malignant neoplasm of colon\n- Primary diagnosis: Intestinal obstruction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-04-20 00:00:00, ended at 2018-04-20 00:00:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-04-20, presumably until 2018-04-20\n- midazolam 1 MG/ML Injectable Solution, started on 2018-04-20, presumably until 2018-04-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-05-08 09:47:16, ended at 2018-05-08 11:06:42\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 2.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Epigastric pain\n- Primary malignant neoplasm of colon\n\n### Drug\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2018-05-08, presumably until 2018-07-18, with intended 1 refill(s). Instructions: take 1-2 Tabs by mouth every 6 hours as needed\n- metoclopramide 10 MG Oral Tablet, through Oral route, started on 2018-05-08, presumably until 2018-07-18, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-05-08 11:11:00, ended at 2018-05-08 23:59:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 96 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 53 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 124 (unit per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 31.4 (second)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.1 (percent)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.40 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 155 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 301 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Prothrombin time (PT): 13.6 (second)\n- MCH [Entitic mass] by Automated count: 24.9 (picogram)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.9 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 2 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.93 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.5 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 77.7 (femtoliter)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Epigastric pain\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-05-22 07:06:00, ended at 2018-05-22 23:59:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of duodenum\n- Epigastric pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-05-22 08:21:46, ended at 2018-05-22 12:20:05\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 2.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-05-26 00:00:00, ended at 2018-05-26 00:00:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of transverse colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-06-13 00:00:00, ended at 2018-06-13 00:00:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 20 ML epinephrine 0.005 MG/ML / lidocaine hydrochloride 20 MG/ML Injection, started on 2018-06-13, presumably until 2018-06-13\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-06-13, presumably until 2018-06-13\n- midazolam 1 MG/ML Injectable Solution, started on 2018-06-13, presumably until 2018-06-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-06-13 00:00:00, ended at 2018-06-13 00:00:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Intestinal obstruction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-06-13 14:13:00, ended at 2018-06-13 18:42:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.9 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.26 (million per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.87 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.1 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.72 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 64.7 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- INR in Blood by Coagulation assay: 1.0 (ratio)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 248 (thousand per microliter)\n- Body height: 6' 2\" (inch (US))\n- MCV [Entitic volume] by Automated count: 73.1 (femtoliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 21.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.9 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 31.6 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.1 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.4 (percent)\n- MCH [Entitic mass] by Automated count: 23.1 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 5.11 (thousand per microliter)\n\n### Procedure\n- Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the m\n- Insertion of Totally Implantable Vascular Access Device into Chest Subcutaneous Tissue and Fascia, Percutaneous Approach\n- Collection of venous blood by venipuncture\n- Fluoroscopic guidance for central venous access device placement, replacement (catheter only or complete), or removal (includes fluoroscopic guidance for vascular access and catheter manipulation, any necessary contrast injections through access site or c\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n- Insertion of tunneled centrally inserted central venous access device, with subcutaneous port; age 5 years or older\n\n### Condition\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-06-20 09:30:00, ended at 2018-06-20 23:59:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 114 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.75 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.06 (thousand per microliter)\n- Prothrombin time (PT): 13.7 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: <10 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.8 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 72.8 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.1 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 105 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.52 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 234 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 54.2 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 33.6 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.47 (million per microliter)\n- MCH [Entitic mass] by Automated count: 23.3 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.69 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 33.6 (second)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 2 (nanogram per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.5 (thousand per microliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of descending colon\n- Intestinal obstruction\n- Primary malignant neoplasm of transverse colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2018-06-20, presumably until 2018-06-20\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2018-06-20, presumably until 2018-06-20\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2018-06-20, presumably until 2018-06-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-06-20 10:19:33, ended at 2018-06-20 11:50:53\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 2.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neoplasm defined only by topography: Colon, NOS\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2018-06-20, presumably until 2018-08-02, with intended 1 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed For nausea and vomiting.\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2018-06-20, presumably until 2018-11-21, with intended 2 refill(s). Instructions: take 0.5 Tabs by mouth every 6 hours as needed For nausea and vomiting.\n- prochlorperazine 10 MG Oral Tablet, through Oral route, started on 2018-06-20, presumably until 2018-11-21, with intended 2 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed For nausea and vomiting.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-06-22 16:56:00, ended at 2018-06-22 23:59:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-06-23 00:00:00, ended at 2018-06-23 00:00:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, through Topical route, started on 2018-06-23, presumably until 2019-06-23, with intended 0 refill(s). Instructions: by Topical route as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-07-04 00:00:00, ended at 2018-07-04 00:00:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-07-04 12:21:00, ended at 2018-07-04 23:59:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.64 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.4 (percent)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 73.0 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.8 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 55.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.5 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 102 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.68 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 30.6 (percent)\n- aPTT in Platelet poor plasma by Coagulation assay: 29.9 (second)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.42 (million per microliter)\n- MCH [Entitic mass] by Automated count: 23.5 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 3.05 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 3 (nanogram per milliliter)\n- MCHC [Mass/volume] by Automated count: 32.2 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 191 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 137 (milligram per deciliter)\n- Prothrombin time (PT): 12.6 (second)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of descending colon\n- Primary malignant neoplasm of transverse colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2018-07-04, presumably until 2018-07-04\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-07-04, presumably until 2018-07-04\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2018-07-04, presumably until 2018-07-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-07-06 16:49:00, ended at 2018-07-06 23:59:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of splenic flexure of colon\n- Primary malignant neoplasm of colon\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-07-18 11:30:00, ended at 2018-07-18 23:59:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 178 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 23.3 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 48.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Prothrombin time (PT): 13.4 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 30.6 (second)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.30 (million per microliter)\n- MCV [Entitic volume] by Automated count: 73.7 (femtoliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 98 (unit per liter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.26 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.1 (percent)\n- MCHC [Mass/volume] by Automated count: 31.6 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 3 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.81 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 124 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.7 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.1 (percent)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.4 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 37.6 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.78 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.53 (thousand per microliter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of descending colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2018-07-18, presumably until 2018-07-18\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-07-18, presumably until 2018-07-18\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2018-07-18, presumably until 2018-07-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-07-20 16:10:00, ended at 2018-07-20 23:59:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-08-01 00:00:00, ended at 2018-08-01 00:00:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- olanzapine 5 MG Oral Tablet, through Oral route, started on 2018-08-01, presumably until 2018-08-21, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime Take 1 tab Q HS x 5 days after each infusion. Don't take with Ativan.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-01 11:12:00, ended at 2018-08-01 23:59:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 3 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.79 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.9 (percent)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.07 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 31.3 (percent)\n- MCH [Entitic mass] by Automated count: 23.9 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.0 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 73.3 (femtoliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 101 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.4 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.79 (thousand per microliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Body height: 6' 1.031\" (inch (US))\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.58 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.52 (million per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 54.3 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.9 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 103 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.2 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.6 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 186 (thousand per microliter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- lorazepam 2 MG/ML Injectable Solution, through Intravenous route, started on 2018-08-01, presumably until 2018-08-01\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2018-08-01, presumably until 2018-08-01\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-08-01, presumably until 2018-08-01\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2018-08-01, presumably until 2018-08-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-08-02 00:00:00, ended at 2018-08-02 00:00:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2018-08-02, presumably until 2019-10-25, with intended 2 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed For nausea and vomiting.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-03 16:30:00, ended at 2018-08-03 23:59:00\nThe patient in this visit was 41 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of splenic flexure of colon\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-14 12:20:00, ended at 2018-08-14 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of colon\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-15 10:53:00, ended at 2018-08-15 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Hemoglobin [Mass/volume] in Blood: 12.6 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.3 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.44 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Body height: 6' .835\" (inch (US))\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 173 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 159 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.6 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.3 (percent)\n- MCV [Entitic volume] by Automated count: 74.4 (femtoliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.80 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 3 (nanogram per milliliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.77 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 24.0 (picogram)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.26 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.0 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Prothrombin time (PT): 13.1 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 8.2 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 27.5 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 88 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 35.1 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 48.4 (percent)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of colon\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2018-08-15, presumably until 2018-08-15\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-08-15, presumably until 2018-08-15\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2018-08-15, presumably until 2018-08-15\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-08-15, presumably until 2018-08-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-08-15 11:19:37, ended at 2018-08-15 14:19:08\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-17 16:52:00, ended at 2018-08-17 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-08-21 00:00:00, ended at 2018-08-21 00:00:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- olanzapine 5 MG Oral Tablet, through Oral route, started on 2018-08-21, presumably until 2019-07-02, with intended 1 refill(s). Instructions: take 1 Tab by mouth every bedtime Take 1 tab Q HS x 5 days after each infusion. Don't take with Ativan.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-29 10:20:00, ended at 2018-08-29 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 3 (nanogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 74.4 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 101 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 37.5 (percent)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.89 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 148 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.68 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.40 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.4 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 167 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 47.5 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.2 (percent)\n- MCH [Entitic mass] by Automated count: 24.8 (picogram)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.6 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.6 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.12 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 144 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.9 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2018-08-29, presumably until 2018-08-29\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-08-29, presumably until 2018-08-29\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2018-08-29, presumably until 2018-08-29\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-08-29, presumably until 2018-08-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-31 16:01:00, ended at 2018-08-31 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-12 08:38:00, ended at 2018-09-12 11:10:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.44 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.5 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 75.9 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.3 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.76 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 29.7 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 55.8 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Prothrombin time (PT): 12.4 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.31 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 110 (unit per liter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 3 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.78 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 162 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 185 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 24.8 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 24.8 (second)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-09-12 09:05:43, ended at 2018-09-12 10:09:59\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' .835\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-12 11:11:00, ended at 2018-09-12 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-09-12, presumably until 2018-09-12\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2018-09-12, presumably until 2018-09-12\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-09-12, presumably until 2018-09-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-14 15:19:00, ended at 2018-09-14 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-26 11:50:00, ended at 2018-09-26 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Body height: 6' 1.504\" (inch (US))\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.78 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.4 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.3 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.79 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.5 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 31.9 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.64 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 53.3 (percent)\n- Platelets [#/volume] in Blood by Automated count: 162 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 146 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.18 (million per microliter)\n- MCH [Entitic mass] by Automated count: 25.2 (picogram)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 142 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 3 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 100 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 76.3 (femtoliter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.1 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.2 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.67 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.5 (millimole per liter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-09-26, presumably until 2018-09-26\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2018-09-26, presumably until 2018-09-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-28 15:57:00, ended at 2018-09-28 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-10-10 11:31:00, ended at 2018-10-10 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 40 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.13 (million per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.73 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.1 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 140 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.8 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 25.5 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 133 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 3 (nanogram per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 36.6 (percent)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.73 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.11 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 96 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.8 (percent)\n- MCV [Entitic volume] by Automated count: 77.5 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.75 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 47.7 (percent)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.0 (percent)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of descending colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2018-10-10, presumably until 2018-10-10\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-10-10, presumably until 2018-10-10\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2018-10-10, presumably until 2018-10-10\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-10-10, presumably until 2018-10-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-10-10 13:00:42, ended at 2018-10-10 15:02:01\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.543\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-10-12 18:43:00, ended at 2018-10-12 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-10-24 09:58:00, ended at 2018-10-24 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of colon\n- Abnormal findings on diagnostic imaging of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-10-24 12:13:13, ended at 2018-10-24 14:07:08\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.543\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-21 08:38:00, ended at 2018-11-21 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Disorder of digestive system\n- Acquired absence of organ\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-21 08:38:00, ended at 2018-11-21 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 179 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- No conditions.\n\n### Drug\n- barium sulfate, through Oral route, started on 2018-11-21, presumably until 2018-11-21\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-02-05 10:12:27, ended at 2019-02-05 11:31:01\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.819\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-02-05 12:54:00, ended at 2019-02-05 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.819\" (inch (US))\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of colon\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n- Primary malignant neoplasm of transverse colon\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2019-02-05, presumably until 2019-02-05\n- 0.5 ML meperidine hydrochloride 50 MG/ML Injection, started on 2019-02-05, presumably until 2019-02-05\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2019-02-05, presumably until 2019-02-05\n- 2 ML ondansetron 2 MG/ML Injection, started on 2019-02-05, presumably until 2019-02-05\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2019-02-05, presumably until 2019-02-05\n- methylprednisolone 125 MG Injection, started on 2019-02-05, presumably until 2019-02-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-02-26 12:37:00, ended at 2019-02-26 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.88 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.57 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.3 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 41.4 (percent)\n- MCV [Entitic volume] by Automated count: 81.7 (femtoliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 2 (nanogram per milliliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.63 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.0 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 108 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.81 (thousand per microliter)\n- Prothrombin time (PT): 13.0 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.5 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.7 (percent)\n- Globulin [Mass/volume] in Serum: 2.7 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 121 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 32.2 (second)\n- MCH [Entitic mass] by Automated count: 26.8 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 186 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.9 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.60 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 44.8 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of descending colon\n- Primary diagnosis: Primary malignant neoplasm of transverse colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2019-02-26, presumably until 2019-02-26\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2019-02-26, presumably until 2019-02-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-02-26 12:59:39, ended at 2019-02-26 17:00:57\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.819\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-15 00:00:00, ended at 2019-03-15 00:00:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of transverse colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-16 07:30:00, ended at 2019-03-16 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 48.6 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Accidental poisoning\n- Primary malignant neoplasm of colon\n- Poisoning by drug AND/OR medicinal substance\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-17 13:00:00, ended at 2019-03-17 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 2 (nanogram per milliliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.1 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 192 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.97 (thousand per microliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Platelets [#/volume] in Blood by Automated count: 169 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 15.8 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 36.1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.79 (million per microliter)\n- MCV [Entitic volume] by Automated count: 80.5 (femtoliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.72 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 46.6 (percent)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 50.7 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.7 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 14 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 112 (unit per liter)\n- Body height: 6' 1.504\" (inch (US))\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.53 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.77 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 27.3 (picogram)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of descending colon\n- Primary diagnosis: Primary malignant neoplasm of transverse colon\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2019-03-17, presumably until 2019-03-17\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2019-03-17, presumably until 2019-03-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-04-09 09:57:00, ended at 2019-04-09 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Globulin [Mass/volume] in Serum: 2.6 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.6 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 189 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.4 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.0 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 35.1 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 92 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.23 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 27.6 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.9 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 128 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.9 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 32.5 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.03 (million per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.88 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 84.5 (femtoliter)\n- Prothrombin time (PT): 13.2 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.64 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 45.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 2 (nanogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.5 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.62 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.09 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of colon\n- Primary malignant neoplasm of descending colon\n- Primary diagnosis: Primary malignant neoplasm of transverse colon\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2019-04-09, presumably until 2019-04-09\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2019-04-09, presumably until 2019-04-09\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2019-04-09, presumably until 2019-04-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-09 10:20:40, ended at 2019-04-09 11:08:08\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.819\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-04-30 09:07:00, ended at 2019-04-30 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2019-04-30, presumably until 2019-04-30\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2019-04-30, presumably until 2019-04-30\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-21 10:55:00, ended at 2019-05-21 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Erythrocytes [#/volume] in Blood by Automated count: 5.46 (million per microliter)\n- MCH [Entitic mass] by Automated count: 27.8 (picogram)\n- MCV [Entitic volume] by Automated count: 84.4 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 50.1 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 2 (nanogram per milliliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.21 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 129 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.60 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 87 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.87 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 15.2 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.1 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 36.2 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 46.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 158 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 2.2 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.06 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.8 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of transverse colon\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2019-05-21, presumably until 2019-05-21\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2019-05-21, presumably until 2019-05-21\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2019-05-21, presumably until 2019-05-21\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-21 11:11:47, ended at 2019-05-21 13:37:08\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.819\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-22 11:26:00, ended at 2019-05-22 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Abnormal findings on diagnostic imaging of lung\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-08 00:00:00, ended at 2019-06-08 00:00:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-11 07:07:00, ended at 2019-06-11 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Platelets [#/volume] in Blood by Automated count: 162 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 2 (nanogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.24 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 27.8 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.58 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.93 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.0 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 91 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 45.3 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.6 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 46.5 (percent)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 15.0 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 86.1 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.7 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.84 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 118 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 39.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.40 (million per microliter)\n- Globulin [Mass/volume] in Serum: 2.5 (gram per deciliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2019-06-11, presumably until 2019-06-11\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2019-06-11, presumably until 2019-06-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-11 07:46:03, ended at 2019-06-11 08:55:05\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.819\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-25 16:25:00, ended at 2019-06-25 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Disease of liver\n- Abnormal findings on diagnostic imaging of lung\n- Primary malignant neoplasm of colon\n- Disorder of pancreas\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-02 09:30:00, ended at 2019-07-02 12:05:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 3 (nanogram per milliliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.6 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.5 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.1 (percent)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 28.6 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.4 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.87 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.60 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 164 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.10 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 44.6 (percent)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 84.5 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.18 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 2.5 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 40.7 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 144 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 81 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 115 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.6 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.39 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-07-02 10:16:37, ended at 2019-07-02 11:16:50\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.268\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-02 12:06:00, ended at 2019-07-02 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of colon\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2019-07-02, presumably until 2019-07-02\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-30 14:00:00, ended at 2019-07-30 16:05:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 2.5 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.5 (percent)\n- MCV [Entitic volume] by Automated count: 84.6 (femtoliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.77 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.7 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.3 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 51.4 (percent)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.14 (million per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 2 (nanogram per milliliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.23 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 148 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 35.1 (percent)\n- MCH [Entitic mass] by Automated count: 28.4 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.53 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 172 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.20 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.22 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.6 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of colon\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-07-30 14:53:10, ended at 2019-07-30 15:46:45\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.268\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-30 16:06:00, ended at 2019-07-30 23:59:00\nThe patient in this visit was 42 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2019-07-30, presumably until 2019-07-30\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2019-07-30, presumably until 2019-07-30\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-16 00:00:00, ended at 2019-08-16 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-08-20 13:03:00, ended at 2019-08-20 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.7 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.2 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 84.5 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 45.5 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 4.4 (gram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 135 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 16.3 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 95 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.4 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.43 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 48.6 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.66 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.88 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 197 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.19 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.75 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 39.3 (percent)\n- MCH [Entitic mass] by Automated count: 28.3 (picogram)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 2 (nanogram per milliliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.82 (thousand per microliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2019-08-20, presumably until 2019-08-20\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2019-08-20, presumably until 2019-08-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-10 00:00:00, ended at 2019-09-10 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-09-10 12:00:00, ended at 2019-09-10 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 124 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.2 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 189 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 3 (nanogram per milliliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.1 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.26 (thousand per microliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.80 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.6 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.5 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.64 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 52 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.28 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.9 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 86.2 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.6 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 43.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 41.1 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.37 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2019-09-10, presumably until 2019-09-10\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2019-09-10, presumably until 2019-09-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-09-10 13:29:19, ended at 2019-09-10 15:37:13\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.268\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-25 00:00:00, ended at 2019-09-25 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 51.1 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-09-25 13:38:00, ended at 2019-09-25 14:26:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Disorder of adrenal gland\n- Primary malignant neoplasm of colon\n- Secondary malignant neoplasm of lung\n- Primary malignant neoplasm of descending colon\n- Localized enlarged lymph nodes\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-09-25 14:27:00, ended at 2019-09-25 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Accidental poisoning\n- Poisoning by drug AND/OR medicinal substance\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-01 08:33:00, ended at 2019-10-01 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 12.5 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 30.0 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 203 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 46.8 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.88 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 16.1 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 55.2 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 5 (nanogram per milliliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.6 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 237 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.87 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.16 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 97 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 49 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.42 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 218 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.5 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.26 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 86.3 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 29.7 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-01 08:50:28, ended at 2019-10-01 12:02:55\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.268\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-10-05 00:00:00, ended at 2019-10-05 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-22 11:43:00, ended at 2019-10-22 14:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 74 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 6 (nanogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.15 (million per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.83 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.8 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 87.2 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 44.9 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 228 (unit per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 240 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.90 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.0 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.28 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 29.5 (picogram)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.4 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.1 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.3 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 15.2 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.70 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 57.5 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.49 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 167 (thousand per microliter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-24 14:27:00, ended at 2019-10-24 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.68 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 157 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 49.2 (percent)\n- Hemoglobin [Mass/volume] in Blood: 16.4 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 28.9 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.4 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 278 (unit per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.35 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 86.6 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 8 (nanogram per milliliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.33 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 12.7 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.9 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.7 (percent)\n- Prothrombin time (PT): 12.0 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 53 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.87 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 59.7 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 1.05 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.27 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 137 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of colon\n- Primary malignant neoplasm of descending colon\n- Secondary malignant neoplasm of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-25 08:32:49, ended at 2019-10-25 11:16:33\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.228\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Secondary malignant neoplasm of left lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-10-29 00:00:00, ended at 2019-10-29 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neoplasm of colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-11-09 00:00:00, ended at 2019-11-09 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-11-12 12:00:00, ended at 2019-11-12 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 67 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.75 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 16.5 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.3 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 86.1 (femtoliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 56 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 10 (nanogram per milliliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 28.7 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 12.3 (percent)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 51.1 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.88 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 49.5 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.82 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 34.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 241 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.84 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 322 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 312 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.22 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of colon\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2019-11-12, presumably until 2019-11-12\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2019-11-12, presumably until 2019-11-12\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2019-11-12, presumably until 2019-11-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-11-13 09:00:00, ended at 2019-11-13 10:20:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 97 (milligram per deciliter)\n\n### Procedure\n- Therapeutic radiology simulation-aided field setting; complex\n\n### Condition\n- Secondary malignant neoplasm of left lung\n- Primary malignant neoplasm of rectosigmoid junction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-11-13 10:21:00, ended at 2019-11-13 10:21:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign neoplasm of colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-11-13 10:22:00, ended at 2019-11-13 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of colon\n\n### Drug\n- barium sulfate, through Oral route, started on 2019-11-13, presumably until 2019-11-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-11-13 10:22:00, ended at 2019-11-13 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-11-19 00:00:00, ended at 2019-11-19 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-11-20 00:00:00, ended at 2019-11-20 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- regorafenib 40 MG Oral Tablet, through Oral route, started on 2019-11-20, presumably until 2019-12-10, with intended 3 refill(s). Instructions: take 40 mg by mouth 2 times a day for 3 weeks on and 1 week off.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-11-21 00:00:00, ended at 2019-11-21 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of colon\n\n### Drug\n- regorafenib 40 MG Oral Tablet, through Oral route, started on 2019-11-21, presumably until 2020-01-08, with intended 3 refill(s). Instructions: take 40 mg by mouth 2 times a day for 3 weeks on and 1 week off.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2019-12-03 00:00:00, ended at 2019-12-03 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Abnormal findings on diagnostic imaging of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-10 10:20:00, ended at 2019-12-10 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Secondary malignant neoplasm of left lung\n- Primary malignant neoplasm of descending colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-17 09:20:00, ended at 2019-12-17 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 236 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.1 (percent)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 213 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.2 (picogram)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.06 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 28.7 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Anion gap in Serum or Plasma: 14 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.39 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.68 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 59.4 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 425 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 29 (nanogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.9 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 112 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 85.2 (femtoliter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.26 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 198 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 15.2 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.71 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.5 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.5 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-12-17 09:43:25, ended at 2019-12-17 13:19:34\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' .992\" (inch (US))\n- Hemoglobin A1c/Hemoglobin.total in Blood: 8.6 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-18 00:00:00, ended at 2019-12-18 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2019-12-18, presumably until 2019-12-21, with intended 2 refill(s). Instructions: take 1-2 Tabs (0.5-1 mg total) by mouth every 6 hours as needed For nausea and vomitting\n- capecitabine 500 MG Oral Tablet, started on 2019-12-18, presumably until 2019-12-20, with intended 3 refill(s). Instructions: 4 tabs (2000 mg) in the AM and the evening, for 7 days, then 7 days off\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2019-12-18, presumably until 2019-12-21, with intended 6 refill(s). Instructions: take 1 Tab (8 mg total) by mouth every 8 hours as needed (For nausea and vomitting)\n- prochlorperazine 10 MG Oral Tablet, through Oral route, started on 2019-12-18, presumably until 2019-12-21, with intended 6 refill(s). Instructions: take 1 Tab (10 mg total) by mouth every 6 hours as needed for Nausea/Vomiting\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-20 00:00:00, ended at 2019-12-20 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- capecitabine 500 MG Oral Tablet, started on 2019-12-20, presumably until 2019-12-21, with intended 3 refill(s). Instructions: 4 tabs (2000 mg) in the AM and the evening, for 7 days, then 7 days off\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-21 00:00:00, ended at 2019-12-21 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-25 00:00:00, ended at 2019-12-25 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-25 00:00:00, ended at 2019-12-25 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-26 00:00:00, ended at 2019-12-26 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-26 00:00:00, ended at 2019-12-26 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-26 12:03:00, ended at 2019-12-26 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- C reactive protein [Mass/volume] in Serum or Plasma: 4.8 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 15.3 (gram per deciliter)\n- Lutropin [Units/volume] in Serum or Plasma: 4.2 (milli-international unit per milliliter)\n- MCH [Entitic mass] by Automated count: 27.9 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 53.1 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.12 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.74 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 554 (unit per liter)\n- Anion gap in Serum or Plasma: 15 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.72 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- Testosterone [Mass/volume] in Serum or Plasma: 559 (nanogram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 161 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 96 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.48 (million per microliter)\n- Follitropin [Units/volume] in Serum or Plasma: 7.4 (milli-international unit per milliliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Corticotropin [Mass/volume] in Plasma: 58.8 (picogram per milliliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 46.9 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.6 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 266 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.0 (percent)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 9.0 (percent)\n- MCV [Entitic volume] by Automated count: 85.6 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 296 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.2 (gram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.18 (micro-international unit per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Cortisol [Mass/volume] in Serum or Plasma: 20.3 (microgram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.53 (thousand per microliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.40 (nanogram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.6 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 31.9 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.1 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 348 (milligram per deciliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n- Hyperglycemia\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2019-12-26, presumably until 2019-12-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-28 00:00:00, ended at 2019-12-28 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-02 00:00:00, ended at 2020-01-02 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 84 (unit per liter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter calculated)\n- Glucose [Mass/volume] in Serum or Plasma: 194 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.2 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 143 (unit per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 1.0 (calculated)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 614 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.86 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: NOT APPLICABLE (calculated)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-08 12:14:48, ended at 2020-01-08 14:10:15\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of colon\n\n### Drug\n- regorafenib 40 MG Oral Tablet, started on 2020-01-08, presumably until 2020-01-22, with intended 3 refill(s). Instructions: Take 1 tab in the morning and 2 tabs in the evening for 3 weeks on and 1 week off.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-08 13:45:00, ended at 2020-01-08 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 210 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 96 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.84 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 228 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.72 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 5.52 (micro-international unit per milliliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 2.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 12.8 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 49.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.3 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.2 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.66 (nanogram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 654 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.78 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.23 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.12 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 29.1 (percent)\n- MCV [Entitic volume] by Automated count: 83.9 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 51.2 (percent)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 40 (nanogram per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 16.2 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 27.7 (picogram)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 331 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.2 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.8 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.08 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 272 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Globulin [Mass/volume] in Serum: 4.4 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of colon\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-09 00:00:00, ended at 2020-01-09 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-11 00:00:00, ended at 2020-01-11 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2020-01-13 19:43:00, ended at 2020-01-16 10:16:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Acetaminophen [Presence] in Urine: <5.0 (microgram per milliliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.4 (percent)\n- Platelets [#/volume] in Blood by Automated count: 181 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 997 (unit per liter)\n- Anion gap in Serum or Plasma: 15 (millimole per liter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.60 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.74 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 324 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 60.9 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 235 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.64 (thousand per microliter)\n- Body height: 6' .835\" (inch (US))\n- Glucose [Mass/volume] in Blood: 345 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 83.8 (femtoliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.6 (percent)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 16.3 (gram per deciliter)\n- Prothrombin time (PT): 11.8 (second)\n- aPTT in Platelet poor plasma by Coagulation assay: 31.7 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 8.33 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 339 (milligram per deciliter)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.38 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.1 (percent)\n- MCH [Entitic mass] by Automated count: 28.1 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.80 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 48.3 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n\n### Procedure\n- Hospital discharge day management; more than 30 minutes\n- Dilation of Pancreatic Duct with Intraluminal Device, Via Natural or Artificial Opening Endoscopic\n- Endoscopic retrograde cholangiopancreatography (ERCP); with placement of endoscopic stent into biliary or pancreatic duct, including pre- and post-dilation and guide wire passage, when performed, including sphincterotomy, when performed, each stent\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n- Combined endoscopic catheterization of the biliary and pancreatic ductal systems, radiological supervision and interpretation\n- Dilation of Common Bile Duct with Intraluminal Device, Via Natural or Artificial Opening Endoscopic\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A problem focused interval history; A problem focused examination; Medical decision making that is straightforward or o\n\n### Condition\n- Acquired absence of spleen\n- Disorder of digestive system\n- Hepatic failure\n- Hypoinsulinemia following procedure\n- Jaundice\n- Hypokalemia\n- Secondary malignant neoplasm of right lung\n- Acquired absence of organ\n- Genetic predisposition\n- Secondary malignant neoplasm of left lung\n- Generalized abdominal pain\n- Primary diagnosis: Obstruction of bile duct\n- Pruritic rash\n- Primary malignant neoplasm of colon\n- Secondary malignant neoplasm of intra-abdominal lymph nodes\n\n### Drug\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2020-01-14, presumably until 2020-01-15\n- ondansetron 8 MG Oral Tablet, through Oral route, presumably until 2020-12-13, with intended 0 refill(s). Instructions: take 8 mg by mouth every 8 hours as needed\n- indomethacin 50 MG Rectal Suppository, through Rectal route, started on 2020-01-15, presumably until 2020-01-15\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2020-01-14, presumably until 2020-01-14\n- 3 ML insulin detemir 100 UNT/ML Pen Injector, through Subcutaneous route, presumably until 2020-03-17, with intended 0 refill(s). Instructions: inject 25 Units subcutaneous (under the skin) every bedtime\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2020-01-16, presumably until 2020-01-16\n- insulin glargine 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2020-01-14, presumably until 2020-01-15\n- amylase 120000 UNT / lipase 24000 UNT / protease 76000 UNT Delayed Release Oral Capsule, through Oral route, started on 2020-01-15, presumably until 2020-06-13, with intended 0 refill(s). Instructions: Take 3 caps by mouth 3 times a day with meals.\n- simethicone 80 MG Chewable Tablet, through Oral route, started on 2020-01-14, presumably until 2020-01-16\n- 3 ML insulin aspart, human 100 UNT/ML Pen Injector, through Subcutaneous route, presumably until 2020-03-17, with intended 0 refill(s). Instructions: inject 10 Units subcutaneous (under the skin) 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2020-01-15 00:00:00, ended at 2020-01-15 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for upper gastrointestinal endoscopic procedures, endoscope introduced proximal to duodenum; endoscopic retrograde cholangiopancreatography (ERCP)\n\n### Condition\n- Jaundice\n- Disorder caused by alcohol\n\n### Drug\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2020-01-15, presumably until 2020-01-15\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2020-01-15, presumably until 2020-01-15\n- 2 ML ondansetron 2 MG/ML Injection, started on 2020-01-15, presumably until 2020-01-15\n- midazolam 1 MG/ML Injectable Solution, started on 2020-01-15, presumably until 2020-01-15\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2020-01-15, presumably until 2020-01-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-01-15 00:00:00, ended at 2020-01-15 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Endoscopic retrograde cholangiopancreatography (ERCP); with placement of endoscopic stent into biliary or pancreatic duct, including pre- and post-dilation and guide wire passage, when performed, including sphincterotomy, when performed, each stent\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-16 00:00:00, ended at 2020-01-16 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2020-01-19 16:08:00, ended at 2020-01-22 18:14:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Glucose [Mass/volume] in Blood: 266 (milligram per deciliter)\n- Lactate [Moles/volume] in Blood: 1.2 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.1 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 84.6 (femtoliter)\n- Body height: 6' 1.228\" (inch (US))\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 44.4 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 16.5 (percent)\n- MCH [Entitic mass] by Automated count: 27.8 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 258 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Creatinine [Mass/volume] in Urine: 165.00 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.17 (thousand per microliter)\n- Osmolality of Urine: 883 (milliosmole per kilogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 17.1 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.57 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.0 (percent)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.05 (thousand per microliter)\n- Urate [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.33 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.6 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.9 (percent)\n- Osmolality of Serum or Plasma: 285 (milliosmole per kilogram)\n- Prothrombin time (PT): 13.4 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 1183 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 104 (unit per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.61 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 31.9 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 250 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 276 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.2 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Platelets [#/volume] in Blood by Automated count: 208 (thousand per microliter)\n- Sodium/Creatinine [Molar ratio] in Urine: 67 (millimole per liter)\n\n### Procedure\n- Combined endoscopic catheterization of the biliary and pancreatic ductal systems, radiological supervision and interpretation\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Hospital discharge day management; 30 minutes or less\n- Endoscopic catheterization of the biliary ductal system, radiological supervision and interpretation\n- Endoscopic retrograde cholangiopancreatography (ERCP); with removal and exchange of stent(s), biliary or pancreatic duct, including pre- and post-dilation and guide wire passage, when performed, including sphincterotomy, when performed, each stent exchang\n- Endoscopic cannulation of papilla with direct visualization of pancreatic/common bile duct(s) (List separately in addition to code(s) for primary procedure)\n- Dilation of Common Bile Duct with Intraluminal Device, Via Natural or Artificial Opening Endoscopic\n- Collection of venous blood by venipuncture\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Removal of Intraluminal Device from Hepatobiliary Duct, Via Natural or Artificial Opening Endoscopic\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Abdominal distension, gaseous\n- Benign neoplasm of colon\n- Hypo-osmolality and or hyponatremia\n- Secondary malignant neoplasm of bone\n- Secondary malignant neoplasm of intra-abdominal lymph nodes\n- Type 2 diabetes mellitus without complication\n- Secondary malignant neoplasm of unknown site\n- Acquired absence of organ\n- Primary diagnosis: Primary malignant neoplasm of colon\n- Fever\n- Obstruction of bile duct\n- Disorder of digestive system\n- Jaundice\n- Tachycardia\n- Hypoinsulinemia following procedure\n- Primary malignant neoplasm of descending colon\n- Pruritic rash\n- Cholangitis\n\n### Drug\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2020-01-20, presumably until 2020-01-20\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2020-01-20, presumably until 2020-01-20\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2020-01-19, presumably until 2020-01-27, with intended 0 refill(s). Instructions: take 1 Tab (500 mg total) by mouth 2 times a day for 5 days\n- calcium chloride 0.001 MEQ/ML / glucose 50 MG/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2020-01-19, presumably until 2020-01-20\n- cholestyramine resin 4000 MG Powder for Oral Suspension, through Oral route, started on 2020-01-19, presumably until 2020-01-21\n- metronidazole 500 MG Oral Tablet, through Oral route, started on 2020-01-20, presumably until 2020-01-25, with intended 0 refill(s). Instructions: take 1 Tab (500 mg total) by mouth every 8 hours for 7 doses\n- insulin glargine 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2020-01-19, presumably until 2020-01-21\n- amylase 120000 UNT / lipase 24000 UNT / protease 76000 UNT Delayed Release Oral Capsule, through Oral route, started on 2020-01-20, presumably until 2020-01-21\n- simethicone 80 MG Chewable Tablet, through Oral route, started on 2020-01-20, presumably until 2020-01-21\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2020-01-22 00:00:00, ended at 2020-01-22 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for upper gastrointestinal endoscopic procedures, endoscope introduced proximal to duodenum; endoscopic retrograde cholangiopancreatography (ERCP)\n\n### Condition\n- Obstruction of bile duct\n- Jaundice\n- Disorder caused by alcohol\n\n### Drug\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2020-01-22, presumably until 2020-01-22\n- midazolam 1 MG/ML Injectable Solution, started on 2020-01-22, presumably until 2020-01-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-01-22 00:00:00, ended at 2020-01-22 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Endoscopic cannulation of papilla with direct visualization of pancreatic/common bile duct(s) (List separately in addition to code(s) for primary procedure)\n- Endoscopic retrograde cholangiopancreatography (ERCP); with removal and exchange of stent(s), biliary or pancreatic duct, including pre- and post-dilation and guide wire passage, when performed, including sphincterotomy, when performed, each stent exchang\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-23 00:00:00, ended at 2020-01-23 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 109 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0 (cells per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 5.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 276 (cells per microliter)\n- Globulin [Mass/volume] in Serum: 5.0 (gram per deciliter calculated)\n- Hemoglobin [Mass/volume] in Blood: 14.5 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.0 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: NOT APPLICABLE (calculated)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 103 (unit per liter)\n- Band form neutrophils [#/volume] in Blood: 276 (cells per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 96 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.94 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.16 (million per liter)\n- Monocytes [#/volume] in Blood by Automated count: 828 (cells per microliter)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 9.4 (femtoliter)\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 0.6 (calculated)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.2 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 83.3 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Band form neutrophils/100 leukocytes in Blood by Manual count: 3 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 6164 (cells per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1656 (cells per microliter)\n- MCH [Entitic mass] by Automated count: 28.1 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 67 (percent)\n- Platelets [#/volume] in Blood by Automated count: 408 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 754 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18 (percent)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 300 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-28 00:00:00, ended at 2020-01-28 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-01 00:00:00, ended at 2020-02-01 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-04 00:00:00, ended at 2020-02-04 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of colon\n\n### Drug\n- loperamide hydrochloride 2 MG Oral Capsule, through Oral route, started on 2020-02-04, presumably until 2020-06-03, with intended 11 refill(s). Instructions: take 1 Kadiyala (2 mg total) by mouth every 4 hours as needed for Diarrhea\n- capecitabine 500 MG Oral Tablet, through Oral route, started on 2020-02-04, presumably until 2020-03-04, with intended 10 refill(s). Instructions: take 4 Tabs (2,000 mg total) by mouth 2 times a day Take 4 tabs twice daily x 7 days every other week. Cytotoxic: Take with food.\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2020-02-04, presumably until 2020-06-03, with intended 11 refill(s). Instructions: take 1 Tab (8 mg total) by mouth every 8 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-02-04 08:29:00, ended at 2020-02-04 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.22 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 86.2 (femtoliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 108 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.9 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.2 (percent)\n- MCHC [Mass/volume] by Automated count: 32.2 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.2 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 3.7 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 10.4 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 28.6 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.00 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 663 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 95 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.01 (million per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.2 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 10.1 (milligram per deciliter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 30 (nanogram per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 123 (unit per liter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.95 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 2.14 (milligram per deciliter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.82 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.55 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 27.7 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 335 (thousand per microliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.38 (nanogram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 222 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 55.6 (percent)\n- Thyrotropin [Units/volume] in Serum or Plasma: 3.51 (micro-international unit per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of descending colon\n- Primary malignant neoplasm of colon\n- Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-02-04 08:35:26, ended at 2020-02-04 10:00:13\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' .008\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- loperamide hydrochloride 2 MG Oral Capsule, through Oral route, started on 2020-02-04, presumably until 2020-02-04, with intended 11 refill(s). Instructions: take 1 Dupre (2 mg total) by mouth every 4 hours as needed for Diarrhea\n- capecitabine 500 MG Oral Tablet, through Oral route, started on 2020-02-04, presumably until 2020-02-04, with intended 10 refill(s). Instructions: take 4 Tabs (2,000 mg total) by mouth 2 times a day Take 4 tabs twice daily x 7 days every other week. Cytotoxic: Take with food.\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2020-02-04, presumably until 2020-02-04, with intended 11 refill(s). Instructions: take 1 Tab (8 mg total) by mouth every 8 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-02-11 10:42:09, ended at 2020-02-11 12:09:05\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 0\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus without complication\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-12 00:00:00, ended at 2020-02-12 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-02-12 08:08:00, ended at 2020-02-12 10:42:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 235 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.66 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 271 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.86 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.1 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 60.0 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 115 (unit per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 127 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.6 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.7 (percent)\n- MCH [Entitic mass] by Automated count: 28.0 (picogram)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.72 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.26 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 594 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 2.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.3 (percent)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.85 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.8 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 86.6 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.89 (thousand per microliter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Primary malignant neoplasm of descending colon\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-02-12 08:22:59, ended at 2020-02-12 10:35:18\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' .008\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- doxycycline hyclate 100 MG Oral Tablet, through Oral route, started on 2020-02-12, presumably until 2020-02-26, with intended 3 refill(s). Instructions: take 1 Tab (100 mg total) by mouth 2 times a day for 14 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-02-25 00:00:00, ended at 2020-02-25 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-26 00:00:00, ended at 2020-02-26 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- hydroxyzine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2020-02-26, presumably until 2020-04-18, with intended 1 refill(s). Instructions: take 2 Tabs (50 mg total) by mouth 2 times a day Take 1 tab am & pm\n- clindamycin 0.01 MG/MG Topical Gel, through Topical route, started on 2020-02-26, presumably until 2020-10-08, with intended 10 refill(s). Instructions: by Topical route 2 times a day use thin film on affected area\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-02-26 08:27:00, ended at 2020-02-26 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 103 (unit per liter)\n- Body height: 6' 1.031\" (inch (US))\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.81 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 648 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.55 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.29 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 15.0 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 217 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.19 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 86.4 (femtoliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.6 (percent)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.4 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 59.9 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 100 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.4 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.0 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.1 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.81 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Anion gap in Serum or Plasma: 14 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.7 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 27.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 276 (milligram per deciliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Collection of blood specimen from a completely implantable venous access device\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2020-02-26, presumably until 2020-02-26\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2020-02-26, presumably until 2020-02-26\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2020-02-26, presumably until 2020-02-26\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2020-02-26, presumably until 2020-02-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-03-02 13:40:00, ended at 2020-03-02 15:34:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Erythrocytes [#/volume] in Blood by Automated count: 5.27 (million per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.62 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.8 (percent)\n- MCV [Entitic volume] by Automated count: 85.6 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 94 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 15.1 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.95 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 28.7 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 541 (unit per liter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Lactate [Moles/volume] in Blood: 2.0 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.7 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 192 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.1 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 83.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 139 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 14.4 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.26 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 12.07 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 110 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 2.5 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 6.6 (percent)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; initial, 31 minutes to 1 hour\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Collection of blood specimen from a completely implantable venous access device\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Fever\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2020-03-02, presumably until 2020-03-02\n- 1000 ML potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2020-03-02, presumably until 2020-03-02\n- 2 ML ondansetron 2 MG/ML Injection, started on 2020-03-02, presumably until 2020-03-02\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2020-03-02, presumably until 2020-03-02\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-03-02 15:35:00, ended at 2020-03-02 18:39:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest; 2 views\n\n### Condition\n- Fever\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2020-03-02 18:40:00, ended at 2020-03-04 13:12:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 2.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma: 0.53 (microgram of fibrinogen equivalent unit per milliliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 47.5 (second)\n- Basophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 544 (milligram per deciliter)\n- Glucose [Mass/volume] in Blood: 220 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 27.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.50 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 88.1 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 82 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 85 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.12 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 120 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Prothrombin time (PT): 14.0 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 474 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.55 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.94 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 150 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.1 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Thrombin time: 18.5 (second)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Monocytes/100 leukocytes in Blood by Automated count: 21.6 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 63.6 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.1 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.5 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.82 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n\n### Procedure\n- Hospital discharge day management; more than 30 minutes\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A detailed or comprehensive history; A detailed or comprehensive examination; and Medical decision making that is straightforward or of \n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n\n### Condition\n- Deficiency of macronutrients\n- Eruption\n- Fatigue\n- Nausea and vomiting\n- Obstruction of bile duct\n- Secondary thrombocytopenia\n- Sepsis\n- Disorder due to infection\n- Hypo-osmolality and or hyponatremia\n- Acquired absence of organ\n- Fever\n- Diabetes mellitus without complication\n- Disorder of digestive system\n- Hypokalemia\n- Primary diagnosis: Primary malignant neoplasm of colon\n\n### Drug\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2020-03-02, presumably until 2020-03-04\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2020-03-03, presumably until 2020-03-03\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2020-03-02, presumably until 2020-03-03\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2020-03-04, presumably until 2020-03-12, with intended 0 refill(s). Instructions: take 1 Tab (500 mg total) by mouth 2 times a day for 8 days\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2020-03-03, presumably until 2020-03-03\n- insulin detemir 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2020-03-02, presumably until 2020-03-03\n- doxycycline hyclate 100 MG Oral Capsule, through Oral route, started on 2020-03-02, presumably until 2020-03-04\n- clindamycin 0.01 MG/MG Topical Gel, through Topical route, started on 2020-03-02, presumably until 2020-03-04\n- amylase 120000 UNT / lipase 24000 UNT / protease 76000 UNT Delayed Release Oral Capsule, through Oral route, started on 2020-03-04, presumably until 2020-03-04\n- 50 ML magnesium sulfate 40 MG/ML Injection, through Intravenous route, started on 2020-03-03, presumably until 2020-03-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-03-10 00:00:00, ended at 2020-03-10 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-03-11 09:10:00, ended at 2020-03-11 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 32.4 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 157 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.3 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.6 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 83 (unit per liter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 7 (nanogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 46.0 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.26 (million per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 49.3 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.57 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.9 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.2 (percent)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.9 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 189 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.15 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 32.6 (percent)\n- MCV [Entitic volume] by Automated count: 87.5 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.83 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.25 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 562 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.6 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2020-03-11, presumably until 2020-03-11\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2020-03-11, presumably until 2020-03-11\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2020-03-11, presumably until 2020-03-11\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2020-03-11, presumably until 2020-03-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-03-17 14:29:59, ended at 2020-03-17 14:37:02\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus without complication\n\n### Drug\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2020-03-17, presumably until 2020-03-24, with intended 5 refill(s). Instructions: inject 25 Units subcutaneous (under the skin) daily in the evening\n- 3 ML insulin aspart, human 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2020-03-17, presumably until 2020-09-05, with intended 5 refill(s). Instructions: inject 10-14 Units subcutaneous (under the skin) 3 times a day 10 units with breakfast and dinner, 12 units with lunch, Add 2 units if BG>200\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-03-24 00:00:00, ended at 2020-03-24 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus without complication\n\n### Drug\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2020-03-24, presumably until 2020-06-03, with intended 3 refill(s). Instructions: inject 25 Units subcutaneous (under the skin) daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-03-25 08:49:00, ended at 2020-03-25 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.53 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.26 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.8 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 47.6 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 601 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 87.1 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.5 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 70 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 91 (unit per liter)\n- Body height: 6' 1.228\" (inch (US))\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 189 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.01 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.82 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 28.1 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 177 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 34.0 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.7 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.9 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.8 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.87 (thousand per microliter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2020-03-25, presumably until 2020-03-25\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2020-03-25, presumably until 2020-03-25\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2020-03-25, presumably until 2020-03-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-03-25 10:18:08, ended at 2020-03-25 10:36:20\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n- Neoplasm defined only by topography: Colon, NOS\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-01 15:42:57, ended at 2020-04-01 17:17:35\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: COVID-19\n- Nausea and vomiting\n- Primary diagnosis: Disorder of respiratory system\n- Type 2 diabetes mellitus\n- Obstruction of bile duct\n- Complication due to diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-04-04 08:05:00, ended at 2020-04-04 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Secondary malignant neoplasm of bone\n- Primary malignant neoplasm of descending colon\n- Secondary malignant neoplasm of left lung\n- Localized enlarged lymph nodes\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-08 00:00:00, ended at 2020-04-08 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-04-08 08:41:00, ended at 2020-04-08 23:59:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 28.3 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.1 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 116 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 6 (nanogram per milliliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 6.12 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 49.8 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.95 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 67.3 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.5 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.3 (percent)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 235 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.8 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 534 (unit per liter)\n- Body height: 6' .835\" (inch (US))\n- MCV [Entitic volume] by Automated count: 86.6 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.48 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.75 (million per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 85 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.80 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 77 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 16.3 (gram per deciliter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2020-04-08, presumably until 2020-04-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-08 09:43:03, ended at 2020-04-08 11:10:25\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.228\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-04-12 13:15:16, ended at 2020-04-12 13:15:22\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- COVID-19\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-04-15 00:00:00, ended at 2020-04-15 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Endoscopic retrograde cholangiopancreatography (ERCP); with removal and exchange of stent(s), biliary or pancreatic duct, including pre- and post-dilation and guide wire passage, when performed, including sphincterotomy, when performed, each stent exchang\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-04-15 00:00:00, ended at 2020-04-15 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for upper gastrointestinal endoscopic procedures, endoscope introduced proximal to duodenum; endoscopic retrograde cholangiopancreatography (ERCP)\n\n### Condition\n- Disorder caused by alcohol\n- Obstruction of bile duct\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2020-04-15, presumably until 2020-04-15\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2020-04-15, presumably until 2020-04-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-04-15 07:54:00, ended at 2020-04-15 11:43:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 6' 1.75\" (inch (US))\n\n### Procedure\n- Endoscopic retrograde cholangiopancreatography (ERCP); with removal and exchange of stent(s), biliary or pancreatic duct, including pre- and post-dilation and guide wire passage, when performed, including sphincterotomy, when performed, each stent exchang\n- Endoscopic catheterization of the biliary ductal system, radiological supervision and interpretation\n\n### Condition\n- Gastritis\n- Hypoinsulinemia following procedure\n- Complication due to diabetes mellitus\n- Diabetes mellitus\n- Obstruction of bile duct\n- Secondary malignant neoplasm of bone\n- Acquired absence of organ\n- Disorder of digestive system\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-16 00:00:00, ended at 2020-04-16 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-18 00:00:00, ended at 2020-04-18 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- hydroxyzine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2020-04-18, presumably until 2020-04-25, with intended 1 refill(s). Instructions: take 2 Tabs (50 mg total) by mouth 2 times a day Take 1 tab am & pm\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-21 00:00:00, ended at 2020-04-21 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-22 00:00:00, ended at 2020-04-22 00:00:00\nThe patient in this visit was 43 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of descending colon\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Malignant tumor of pancreas within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of pancreatic_cancer means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "41e27fe329c755b90caae223f03ac7d3eb5e99761547c8b59493057cd88004e5", "prompt_hash": "00e1c001af87a1aa103ad5bdd843784a324d15b45fed7ea4d66f3e9795c3b253", "target_hash": "85a39ab345d672ff8ca9b9c6876f3adcacf45ee7c1e2dbd2408fd338bd55e07e", "exact_match": 0.0, "f1_gu_yn": [1, 0], "recall_gu_yn": [1, 0]}
{"doc_id": 2, "doc": {"person_id": 115968496, "visit_occurrence_id": 46171882, "death_date": "2014-03-29", "visit_concept_name": "Outpatient Visit", "visit_start_datetime": "2011-12-22 11:47:00", "visit_end_datetime": "2011-12-22 23:59:00", "visit_length_in_hours": 12.2, "integrated_visit_record": "## Visit\nThis visit record, was from Outpatient Visit, started at 2011-12-22 11:47:00, ended at 2011-12-22 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.3 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.08 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 250 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 123 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.3 (percent)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.19 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 31.0 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.0 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.9 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 42.1 (percent)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 61 (unit per liter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 101 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 33.4 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 24.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 98.0 (femtoliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 1.20 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.1 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.53 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 749, "patient_first_visit_date": "2008-09-11 06:46:00", "patient_last_visit_date": "2014-03-27 19:23:00", "end_obs_date": "2012-12-21", "hypertension_type": "new", "hypertension_one_year_diagnosis": 0, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "new", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "new", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "recurrent", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "recurrent", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "recurrent", "liver_cancer_one_year_diagnosis": 1, "visit_sequence_number": 97, "cumulated_visit_num": 97, "cumulated_approximate_token_count": 39125, "visit_cumulated": "## Visit\nThis visit record, was from Outpatient Visit, started at 2008-09-11 06:46:00, ended at 2008-09-11 14:50:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Leukocytes [#/volume] in Specimen by Automated count: 4.2 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.82 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.6 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 67.6 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.98 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.41 (thousand per microliter)\n- Body height: 5' 11.26\" (inch (US))\n- Neutrophils [#/volume] in Blood by Automated count: 2.81 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 258 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- MCV [Entitic volume] by Automated count: 85.0 (femtoliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 34.8 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.9 (percent)\n- MCH [Entitic mass] by Automated count: 29.5 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.8 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disease of liver\n\n### Drug\n- 2 ML fentanyl 0.05 MG/ML Injection, through Intravenous route, started on 2008-09-11, presumably until 2008-09-11\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2008-09-11, presumably until 2008-09-11\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2008-09-11, presumably until 2008-09-11\n- midazolam 1 MG/ML Injectable Solution, started on 2008-09-11, presumably until 2008-09-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-09-28 00:00:00, ended at 2008-09-28 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 86 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 53 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.8 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 436 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 109 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 85.9 (femtoliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.6 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.0 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.5 (percent)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.94 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 13.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.37 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 291 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 29.3 (picogram)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.2 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.37 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 76.5 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-10-24 00:00:00, ended at 2008-10-24 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.53 (million per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 191 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 217 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 70 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.3 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 46 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 30.4 (percent)\n- MCH [Entitic mass] by Automated count: 29.8 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 52.7 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.7 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 86.2 (femtoliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 102 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.12 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.1 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 1.94 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.6 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.5 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-11-15 00:00:00, ended at 2008-11-15 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 139 (unit per liter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 16.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.12 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 222 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.6 (percent)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.84 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.0 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.49 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.59 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 53.0 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 59 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 100 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.2 (percent)\n- MCH [Entitic mass] by Automated count: 30.4 (picogram)\n- MCV [Entitic volume] by Automated count: 87.9 (femtoliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.5 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 27.9 (percent)\n- MCHC [Mass/volume] by Automated count: 34.6 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-12-03 00:00:00, ended at 2008-12-03 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 127 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.4 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.39 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.1 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.7 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 45 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 55 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.91 (million per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.53 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 23.0 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 107 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.7 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.68 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.2 (percent)\n- MCH [Entitic mass] by Automated count: 30.9 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 314 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 89.9 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.5 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.4 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-12-24 00:00:00, ended at 2008-12-24 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 57 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 22.4 (percent)\n- Platelets [#/volume] in Blood by Automated count: 227 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 56 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 24.7 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 100 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.3 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.2 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 59.4 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.2 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.05 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.91 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 138 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.7 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 16.1 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-01-21 00:00:00, ended at 2009-01-21 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.3 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 49 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 99.5 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 227 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 112 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 107 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.8 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 61.4 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Anion gap in Serum or Plasma: 3 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 25.3 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.30 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.80 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 2.8 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 1.74 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.7 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 33.5 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-02-08 00:00:00, ended at 2009-02-08 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 97 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 106 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-02-19 00:00:00, ended at 2009-02-19 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoid syndrome\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-02-25 00:00:00, ended at 2009-02-25 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoid syndrome\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-03-21 00:00:00, ended at 2009-03-21 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoid syndrome\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-05-10 00:00:00, ended at 2009-05-10 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoid syndrome\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-05-21 00:00:00, ended at 2009-05-21 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 91 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.2 (percent)\n- MCV [Entitic volume] by Automated count: 93.7 (femtoliter)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 118 (milligram per deciliter)\n- Prothrombin time (PT): 12.9 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.7 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.2 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 38 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.50 (million per microliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.2 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 218 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 25.6 (second)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2009-06-05 08:27:00, ended at 2009-06-11 12:56:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 91 (unit per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 36.5 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 98 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.1 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 83 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Body height: 5' 11\" (inch (US))\n- Glucose [Mass/volume] in Serum or Plasma: 87 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 269 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 5.6 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.4 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.51 (million per microliter)\n- MCH [Entitic mass] by Automated count: 32.2 (picogram)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.19 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.4 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.3 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.3 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Prothrombin time (PT): 15.7 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.1 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- INR in Platelet poor plasma by Coagulation assay: 1.3 (ratio)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.2 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 95.4 (femtoliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n\n### Drug\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2009-06-05, presumably until 2009-06-07\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2009-06-06, presumably until 2009-06-06\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2009-06-11, presumably until 2009-06-11\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2009-06-10, presumably until 2009-06-10\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2009-06-06, presumably until 2009-06-10\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2009-06-06, presumably until 2009-06-06\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2009-06-11, presumably until 2009-08-30, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day. \n- heparin sodium, porcine 10000 UNT/ML Injectable Solution, started on 2009-06-06, presumably until 2009-06-11\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2009-06-07, presumably until 2009-06-07\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2009-06-06, presumably until 2009-06-06\n- 1000 ML glucose 50 MG/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2009-06-07, presumably until 2009-06-08\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2009-06-09, presumably until 2009-06-11\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2009-06-08, presumably until 2009-08-30, with quantity of 60.0, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2009-06-16 14:11:00, ended at 2009-07-04 12:20:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 1.8 (percent)\n- Basophils/100 leukocytes in Blood by Manual count: 1 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Manual count: 3 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.6 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.4 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.55 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 51 (unit per liter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.3 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.13 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 80 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Prothrombin time (PT): 14.9 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 663 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 5 (percent)\n- MCV [Entitic volume] by Automated count: 92.5 (femtoliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.6 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 987 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Basophils [#/volume] in Blood by Manual count: 0.1 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.97 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.8 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Manual count: 1.7 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Manual count: 9 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 93.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.0 (percent)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.1 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.7 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.51 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.2 (percent)\n- Lymphocytes [#/volume] in Blood by Manual count: 1.1 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 33.6 (second)\n- Amylase [Enzymatic activity/volume] in Serum or Plasma: 56 (unit per liter)\n- Body height: 5' 11\" (inch (US))\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.07 (millimole per liter)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- Neutrophils [#/volume] in Blood by Automated count: 9.65 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Manual count: 6.2 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.2 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2009-06-23, presumably until 2009-06-24\n- amylase 33200 UNT / lipase 10000 UNT / protease 37500 UNT Delayed Release Oral Capsule, through Oral route, started on 2009-06-19, presumably until 2010-07-04, with quantity of 60.0, with intended 1 refill(s). Instructions: take 2 Caps by mouth 3 times a day with meals. \n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2009-06-24, presumably until 2009-06-25\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2009-06-28, presumably until 2009-08-30, with quantity of 60.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily. \n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2009-06-16, presumably until 2009-07-03\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2009-06-16, presumably until 2009-06-27\n- diatrizoate, through Oral route, started on 2009-06-22, presumably until 2009-06-22\n- aspirin 325 MG Delayed Release Oral Tablet, through Oral route, started on 2009-06-20, presumably until 2010-07-04, with quantity of 60.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth every morning with breakfast. \n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2009-06-29, presumably until 2009-08-30, with quantity of 8.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- 500 ML glucose 50 MG/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2009-06-16, presumably until 2009-06-19\n- diatrizoic acid, through Oral route, started on 2009-06-22, presumably until 2009-06-22\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2009-06-17, presumably until 2009-06-17\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2009-06-24, presumably until 2009-06-26\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2009-06-16, presumably until 2009-06-27\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2009-06-22, presumably until 2009-06-23\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2009-06-18, presumably until 2009-06-19\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2009-06-18, presumably until 2009-07-03\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2009-07-03, presumably until 2009-07-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-08-23 00:00:00, ended at 2009-08-23 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-08-30 00:00:00, ended at 2009-08-30 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-08-30 07:39:00, ended at 2009-08-30 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.46 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 19.4 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 51 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 219 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 113 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.4 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 85.3 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.99 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 521 (thousand per microliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.8 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.3 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.84 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 46.2 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.0 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.36 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 31.5 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 27.7 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-10-31 09:01:00, ended at 2009-10-31 18:05:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- Selective catheter placement, arterial system; initial second order abdominal, pelvic, or lower extremity artery branch, within a vascular family\n- Angiography, selective, each additional vessel studied after basic examination, radiological supervision and interpretation (List separately in addition to code for primary procedure)\n- Arteriography of other intra-abdominal arteries\n- Angiography, visceral, selective or supraselective (with or without flush aortogram), radiological supervision and interpretation\n- Aortography\n- Selective catheter placement, arterial system; initial third order or more selective abdominal, pelvic, or lower extremity artery branch, within a vascular family\n- Scan of other sites\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n- Liver imaging (SPECT)\n- Selective catheter placement, arterial system; additional second order, third order, and beyond, abdominal, pelvic, or lower extremity artery branch, within a vascular family (List in addition to code for initial second or third order vessel as appropriat\n\n### Condition\n- Metastatic carcinoid tumor\n- Secondary malignant neoplasm of liver\n- Imaging of abdomen abnormal\n- Malignant carcinoid tumor\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2009-10-31, presumably until 2009-10-31\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-11-07 08:53:00, ended at 2009-11-07 21:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- Angiography, visceral, selective or supraselective (with or without flush aortogram), radiological supervision and interpretation\n- Arteriography of other intra-abdominal arteries\n- Supervision, handling, loading of radiation source\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n- Interstitial radiation source application, complex, includes supervision, handling, loading of radiation source, when performed\n- Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, onl\n- Radiopharmaceutical therapy, by intra-arterial particulate administration\n- Injection or instillation of radioisotopes\n- Selective catheter placement, arterial system; initial second order abdominal, pelvic, or lower extremity artery branch, within a vascular family\n- Insertion of catheter into artery\n\n### Condition\n- Imaging of abdomen abnormal\n- Secondary malignant neoplasm of liver\n- Primary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2009-11-22 00:00:00, ended at 2009-11-22 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2009-11-22, presumably until 2009-12-20, with quantity of 20.0. Instructions: take 1 Tab by mouth every 4 hours as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2009-12-20 08:50:03, ended at 2009-12-20 14:35:32\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-01-31 00:00:00, ended at 2010-01-31 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-01-31 08:54:00, ended at 2010-01-31 10:19:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen; with contrast material(s)\n\n### Condition\n- Disorder of lung\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-01-31 10:20:00, ended at 2010-01-31 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.5 (picogram)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.2 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.6 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.82 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 26.8 (second)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 374 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.82 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 68.1 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 230 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.7 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 117 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n- Prothrombin time (PT): 14.1 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 45 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.25 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.1 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.84 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.9 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 66 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.9 (percent)\n- MCV [Entitic volume] by Automated count: 87.5 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-14 09:23:00, ended at 2010-02-14 10:05:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 87 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.4 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.7 (picogram)\n- aPTT in Platelet poor plasma by Coagulation assay: 25.8 (second)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.06 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.55 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 40 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 485 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 61 (unit per liter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 86.9 (femtoliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.9 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.84 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.17 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.6 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 63.1 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 281 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.0 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.2 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Prothrombin time (PT): 13.3 (second)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-14 10:06:00, ended at 2010-02-14 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Primary malignant neoplasm of pancreas\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-05-05 00:00:00, ended at 2010-05-05 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-05-05 00:00:00, ended at 2010-05-05 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-09 11:45:00, ended at 2010-05-09 13:19:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 47 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.7 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.2 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 61 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.8 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.1 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.37 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 811 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.4 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.4 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.93 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 728 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 108 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.90 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.15 (million per microliter)\n- MCH [Entitic mass] by Automated count: 29.0 (picogram)\n- MCV [Entitic volume] by Automated count: 87.7 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 72.8 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-09 13:20:00, ended at 2010-05-09 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of pancreas\n- Malignant neoplastic disease\n- Primary malignant neoplasm of gastrointestinal tract\n- Secondary malignant neoplasm of liver\n- Malignant carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-16 10:24:00, ended at 2010-05-16 11:18:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 52 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.9 (percent)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.5 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.2 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.6 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 29.1 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 723 (thousand per microliter)\n- Prothrombin time (PT): 13.3 (second)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.85 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 142 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 853 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.85 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 86.9 (femtoliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 32.6 (second)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.7 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.96 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 75.1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-16 11:19:00, ended at 2010-05-16 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n- Primary malignant neoplasm of pancreas\n- Secondary malignant neoplasm of liver\n\n### Drug\n- amoxicillin 500 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2010-05-16, presumably until 2010-08-20, with quantity of 14.0, with intended 2 refill(s). Instructions: take by mouth. \n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, through Oral route, presumably until 2010-08-20. Instructions: take by mouth. \n- sulfamethoxazole 800 MG / trimethoprim 160 MG Oral Tablet, through Oral route, started on 2010-05-16, presumably until 2010-08-20, with quantity of 14.0, with intended 2 refill(s). Instructions: take by mouth. \n- zolpidem tartrate 10 MG Oral Tablet, through Oral route, presumably until 2010-08-20. Instructions: take by mouth. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-30 08:23:00, ended at 2010-05-30 08:53:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.8 (percent)\n- MCV [Entitic volume] by Automated count: 87.9 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 410 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 868 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.7 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.97 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 179 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.30 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.1 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.68 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.4 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 113 (unit per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.47 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.0 (picogram)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.4 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 22.0 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 55.8 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.18 (million per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 128 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-30 08:54:00, ended at 2010-05-30 15:02:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen; with contrast material(s)\n\n### Condition\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n- Lymphadenopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-30 15:03:00, ended at 2010-05-30 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of gastrointestinal tract\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n- Neoplasm of lymph node\n- Malignant carcinoid tumor\n- Primary malignant neoplasm of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-07-25 10:35:00, ended at 2010-07-25 11:42:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 114 (unit per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.2 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.9 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 89 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 1159 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.6 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.3 (percent)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Neutrophils/100 leukocytes in Blood by Automated count: 70.4 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 29.3 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 502 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 36.6 (second)\n- Monocytes [#/volume] in Blood by Automated count: 0.79 (thousand per microliter)\n- Prothrombin time (PT): 13.4 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.81 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 127 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.2 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 89.9 (femtoliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.85 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.1 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.97 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-07-25 11:43:00, ended at 2010-07-25 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of gastrointestinal tract\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n- Malignant carcinoid tumor\n- Primary malignant neoplasm of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-08-05 10:39:00, ended at 2010-08-05 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n- Computed tomography, pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen; without contrast material, followed by contrast material(s) and further sections\n\n### Condition\n- Neoplastic disease\n- Secondary malignant neoplasm of liver\n- Secondary malignant neoplasm of lung\n- Epigastric pain\n- Ascites\n- Imaging of musculoskeletal system abnormal\n- Malignant neoplastic disease\n- Lung field abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-08-08 10:17:00, ended at 2010-08-08 12:30:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 1482 (unit per liter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 7 (percent)\n- Monocytes/100 leukocytes in Blood by Manual count: 4 (percent)\n- Platelets [#/volume] in Blood by Automated count: 609 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 92 (unit per liter)\n- Basophils [#/volume] in Blood by Manual count: 0.1 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.4 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 142 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.9 (picogram)\n- Neutrophils [#/volume] in Blood by Manual count: 4.8 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.2 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.2 (percent)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.1 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Prothrombin time (PT): 13.6 (second)\n- aPTT in Platelet poor plasma by Coagulation assay: 30.3 (second)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.72 (million per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.6 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.1 (percent)\n- MCV [Entitic volume] by Automated count: 89.2 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 87 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 77 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Manual count: 1 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-08-08 12:31:00, ended at 2010-08-08 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n- Neoplasm of lymph node\n- Secondary malignant neoplasm of liver\n- Malignant carcinoid tumor\n- Primary malignant neoplasm of pancreas\n- Primary malignant neoplasm of gastrointestinal tract\n\n### Drug\n- capecitabine 500 MG Oral Tablet, through Oral route, started on 2010-08-08, presumably until 2011-08-08, with quantity of 84.0, with intended 0 refill(s). Instructions: take by mouth. 1500 mg po bid for 14 days then, 2 weeks off (28days cycle) #84 \n- temozolomide 140 MG Oral Capsule, through Oral route, started on 2010-08-08, presumably until 2012-01-26, with quantity of 10.0, with intended 0 refill(s). Instructions: take by mouth daily. 280 mg po daily D10 to D14 in 28 days cycle (140mg form 2 tabs ) #10 \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-08-18 12:20:00, ended at 2010-08-18 14:05:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of gastrointestinal tract\n- Secondary malignant neoplasm of liver\n- Primary malignant neoplasm of pancreas\n- Malignant neoplastic disease\n- Secondary malignant neoplastic disease\n- Malignant carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-08-18 14:06:00, ended at 2010-08-18 14:28:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 118 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.9 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 512 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.1 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.3 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- Neutrophils/100 leukocytes in Blood by Automated count: 76.9 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.82 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 33.9 (second)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.5 (percent)\n- MCV [Entitic volume] by Automated count: 92.9 (femtoliter)\n- Prothrombin time (PT): 15.1 (second)\n- Sodium [Moles/volume] in Serum or Plasma: 132 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 58 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.2 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.4 (percent)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.3 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 118 (unit per liter)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.63 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.08 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 1708 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.6 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.46 (million per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 26 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2010-08-18 14:29:00, ended at 2010-08-20 19:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 2.4 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n- Neutrophils/100 leukocytes in Blood by Manual count: 71 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 96 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 112 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.2 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.0 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.7 (percent)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.5 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 92.8 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.15 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Manual count: 5.5 (thousand per microliter)\n- Prothrombin time (PT): 15.0 (second)\n- Sodium [Moles/volume] in Serum or Plasma: 132 (millimole per liter)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: <0.8 (microgram per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 63 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 2.5 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.4 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 1.2 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 1945 (unit per liter)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- Platelets [#/volume] in Blood by Automated count: 511 (thousand per microliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.20 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 6 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.23 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.2 (percent)\n- Monocytes/100 leukocytes in Blood by Manual count: 16 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Body height: 5' 10.984\" (inch (US))\n- Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma: 604 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.6 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.6 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.15 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.0 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 97 (unit per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 69.2 (percent)\n- aPTT in Platelet poor plasma by Coagulation assay: 33.2 (second)\n\n### Procedure\n- Physical therapy evaluation\n- Abdominal paracentesis\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Injection of anesthetic agent into peripheral nerve for analgesia\n- Collection of venous blood by venipuncture\n\n### Condition\n- Abdominal pain\n- Malignant ascites\n- Loss of appetite\n- Malignant carcinoid tumor\n- Secondary malignant neoplasm of liver\n- Disorder of plasma protein metabolism\n- Lumbosacral spondylosis without myelopathy\n- Metastatic carcinoid tumor\n- Constipation\n- Portal hypertension\n- Acquired absence of organ\n- Neoplasm of digestive tract\n- Secondary malignant neoplasm of peritoneum\n- Thoracic spondylosis without myelopathy\n\n### Drug\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2010-08-20, presumably until 2010-11-07, with quantity of 30.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. \n- bupivacaine hydrochloride 2.5 MG/ML Injectable Solution, started on 2010-08-20, presumably until 2010-08-20\n- aspirin 325 MG Oral Tablet, through Oral route, presumably until 2013-06-23. Instructions: take 325 mg by mouth every morning with breakfast. \n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2010-08-19, presumably until 2010-11-07, with quantity of 60.0, with intended 3 refill(s). Instructions: take 1 Cap by mouth daily. \n- heparin sodium, porcine 10000 UNT/ML Injectable Solution, started on 2010-08-19, presumably until 2010-08-19\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2010-08-20, presumably until 2010-11-07, with quantity of 60.0, with intended 3 refill(s). Instructions: take 2 Tabs by mouth every bedtime as needed for Constipation. \n- 200 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2010-08-19, presumably until 2010-08-20\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2010-08-20, presumably until 2010-08-20\n- 1 ML morphine sulfate 2 MG/ML Prefilled Syringe, started on 2010-08-20, presumably until 2010-08-20\n- morphine sulfate 15 MG Extended Release Oral Tablet, through Oral route, started on 2010-08-18, presumably until 2011-02-16, with quantity of 60.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth every 12 hours. \n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2010-08-18, presumably until 2011-01-02, with quantity of 120.0, with intended 1 refill(s). Instructions: take 2 Tabs by mouth every 6 hours as needed for Pain. please hold for somnolence, Elon College  less than 8, altered mental status \n- midazolam 1 MG/ML Injectable Solution, started on 2010-08-20, presumably until 2010-08-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-08-31 00:00:00, ended at 2010-08-31 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-09-01 00:00:00, ended at 2010-09-01 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-09-01 09:44:00, ended at 2010-09-01 10:54:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of pancreas\n- Secondary malignant neoplastic disease\n- Abdominal pain\n- Primary malignant neoplasm of gastrointestinal tract\n- Malignant carcinoid tumor\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- spironolactone 50 MG Oral Tablet, through Oral route, started on 2010-09-01, presumably until 2010-11-07, with quantity of 30.0, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-09-01 10:55:00, ended at 2010-09-01 12:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Neutrophils/100 leukocytes in Blood by Manual count: 85 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 87 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 118 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 128 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.3 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 97.4 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 2411 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.2 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.0 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 21.3 (percent)\n- Monocytes/100 leukocytes in Blood by Manual count: 3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 5.7 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.07 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.9 (percent)\n- MCH [Entitic mass] by Automated count: 31.1 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 741 (thousand per microliter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.7 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Neutrophils [#/volume] in Blood by Manual count: 6.4 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 9 (percent)\n- MCHC [Mass/volume] by Automated count: 31.9 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Abdominal pain\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-09-08 17:12:00, ended at 2010-09-08 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Molecular diagnostics; isolation or extraction of highly purified nucleic acid, each nucleic acid type (ie, DNA or RNA)\n- Molecular diagnostics; amplification, target, each nucleic acid sequence\n- Molecular diagnostics; interpretation and report\n- Molecular diagnostics; lysis of cells prior to nucleic acid extraction (eg, stool specimens, paraffin embedded tissue), each specimen\n- Molecular diagnostics; separation by gel electrophoresis (eg, agarose, polyacrylamide), each nucleic acid preparation\n\n### Condition\n- Cholesterolosis of gallbladder\n- Chronic cholecystitis\n- Primary malignant neoplasm of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-09-12 09:53:00, ended at 2010-09-12 11:30:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of pancreas\n- Secondary malignant neoplasm of liver\n- Malignant carcinoid tumor\n- Malignant neoplastic disease\n- Primary malignant neoplasm of gastrointestinal tract\n\n### Drug\n- furosemide 40 MG Oral Tablet, through Oral route, started on 2010-09-12, presumably until 2010-11-07, with quantity of 30.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-09-12 11:31:00, ended at 2010-09-12 20:35:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- Procedure on single vessel\n- Venography, caval, inferior, with serialography, radiological supervision and interpretation\n- Angioplasty of other non-coronary vessel(s)\n- Insertion of non-drug-eluting peripheral (non-coronary) vessel stent(s)\n- Insertion of one vascular stent\n- Peritoneocentesis, abdominal paracentesis, or peritoneal lavage (diagnostic or therapeutic); initial\n- Transcatheter placement of an intravascular stent(s) (except coronary, carotid, vertebral, iliac, and lower extremity arteries), percutaneous; initial vessel\n- Introduction of catheter, superior or inferior vena cava\n- Diagnostic ultrasound of abdomen and retroperitoneum\n- Abdominal paracentesis\n- Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation\n- Transcatheter introduction of intravascular stent(s) (except coronary, carotid, vertebral, iliac, and lower extremity artery), percutaneous and/or open, radiological supervision and interpretation, each vessel\n- Venous catheterization, not elsewhere classified\n- Venography of vena cava\n\n### Condition\n- Ascites\n- Secondary malignant neoplasm of liver\n- Compression of vein\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-10-10 10:28:00, ended at 2010-10-10 11:09:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-10-10 11:10:00, ended at 2010-10-10 12:51:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Ascites\n- Benign carcinoid tumor\n- Primary malignant neoplasm of pancreas\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2010-10-10, presumably until 2011-01-02, with quantity of 15.0, with intended 6 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-10-10 12:52:00, ended at 2010-10-10 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, pelvis; 1 or 2 views\n- Radiologic examination, spine, lumbosacral; 2 or 3 views\n- Radiologic examination, sacrum and coccyx, minimum of 2 views\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-10-10 12:52:00, ended at 2010-10-10 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.07 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 71.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 647 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.4 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 62 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 107 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.8 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.75 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 98.2 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.7 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 1859 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 23.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.7 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 13.1 (percent)\n- MCH [Entitic mass] by Automated count: 33.0 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.0 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 26.2 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.3 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Prothrombin time (PT): 13.7 (second)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.29 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.3 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.80 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-03 10:14:00, ended at 2010-11-03 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen; without contrast material, followed by contrast material(s) and further sections\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, pelvis; with contrast material(s)\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n\n### Condition\n- Ascites\n- Malignant neoplastic disease\n- Disease of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-07 07:25:00, ended at 2010-11-07 08:14:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.44 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.5 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.8 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.01 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.22 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n- Anion gap in Serum or Plasma: 2 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.37 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 99.4 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.2 (gram per deciliter)\n- Prothrombin time (PT): 13.2 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 794 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 58 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.3 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 59.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 126 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.8 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 561 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 70 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 21.0 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 17.5 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.97 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 16.7 (percent)\n- MCH [Entitic mass] by Automated count: 33.5 (picogram)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-07 08:15:00, ended at 2010-11-07 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Ascites\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-05 10:19:00, ended at 2010-12-05 11:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.7 (percent)\n- MCV [Entitic volume] by Automated count: 100.9 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.13 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 75 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.7 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.40 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.1 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.10 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 74 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.3 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 33.1 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 1.06 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 78 (unit per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 419 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.6 (percent)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 58.4 (percent)\n- Prothrombin time (PT): 13.0 (second)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.39 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 534 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.3 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.0 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-05 12:00:00, ended at 2010-12-05 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-01 14:34:00, ended at 2011-01-01 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Lymphocytes [#/volume] in Blood by Automated count: 1.44 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 98.8 (femtoliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.6 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.8 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.2 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.1 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.5 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 132 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 55.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 438 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 84 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 272 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.23 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.39 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 25.8 (percent)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.1 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.11 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Prothrombin time (PT): 13.5 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 70 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-02 10:39:00, ended at 2011-01-02 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.276\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-21 10:13:00, ended at 2011-01-21 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Postprocedural state finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-01-23 00:00:00, ended at 2011-01-23 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-26 08:09:00, ended at 2011-01-26 08:55:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 93 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.21 (million per microliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 76 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.39 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.90 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.7 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.5 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 13.6 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 379 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.2 (percent)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 175 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 236 (unit per liter)\n- MCH [Entitic mass] by Automated count: 32.0 (picogram)\n- MCV [Entitic volume] by Automated count: 98.7 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 11.12 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.0 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.6 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 10.2 (percent)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Prothrombin time (PT): 13.0 (second)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-26 08:56:00, ended at 2011-01-26 10:49:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-26 10:50:00, ended at 2011-01-26 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; initial, 31 minutes to 1 hour\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, presumably until 2011-02-27. Instructions: take 1 Tab by mouth as needed \n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-01-26, presumably until 2011-01-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-02-27 12:04:00, ended at 2011-02-27 14:18:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.1 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.7 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 1.14 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 17.0 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 210 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.19 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 140 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.62 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 57 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.74 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 53.9 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.5 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 26.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 401 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Anion gap in Serum or Plasma: 2 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.9 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.3 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Prothrombin time (PT): 12.8 (second)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 96.6 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-02-27 14:19:00, ended at 2011-02-27 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n\n### Drug\n- zolpidem tartrate 10 MG Oral Tablet, through Oral route, started on 2011-02-27, presumably until 2011-08-26, with quantity of 30.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth every bedtime as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-03-27 11:11:00, ended at 2011-03-27 13:58:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 32.0 (percent)\n- MCV [Entitic volume] by Automated count: 94.3 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.95 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 209 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.8 (percent)\n- MCH [Entitic mass] by Automated count: 31.3 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 46.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 365 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 68 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.9 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.3 (thousand per microliter)\n- Prothrombin time (PT): 12.7 (second)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.46 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.2 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.68 (thousand per microliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 117 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- Monocytes/100 leukocytes in Blood by Automated count: 18.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.53 (million per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-03-27 13:59:00, ended at 2011-03-27 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n- Primary malignant neoplasm of islets of Langerhans\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-21 11:03:00, ended at 2011-04-21 11:36:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 77 (unit per liter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 144 (milligram per deciliter)\n- Prothrombin time (PT): 13.0 (second)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 189 (unit per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-21 11:37:00, ended at 2011-04-21 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Malignant neoplastic disease\n- Hypertrophy of breast\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-24 14:02:00, ended at 2011-04-24 15:56:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-24 15:57:00, ended at 2011-04-24 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Eosinophils [#/volume] in Blood by Automated count: 0.31 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 370 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 95.6 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.8 (percent)\n- MCH [Entitic mass] by Automated count: 31.5 (picogram)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.9 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.6 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.2 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 55.5 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.4 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.94 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.56 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.54 (thousand per microliter)\n- Prolactin [Mass/volume] in Serum or Plasma: 6 (nanogram per milliliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 3.08 (micro-international unit per milliliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 24.4 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.41 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-22 12:22:00, ended at 2011-05-22 14:05:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 59 (unit per liter)\n- Prothrombin time (PT): 13.8 (second)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 159 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 189 (unit per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-22 14:06:00, ended at 2011-05-22 15:07:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.772\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-22 15:08:00, ended at 2011-05-22 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.2 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 368 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.2 (percent)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.1 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.4 (picogram)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.36 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.4 (percent)\n- MCV [Entitic volume] by Automated count: 95.0 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 45.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.1 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 34.8 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.78 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.81 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.33 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-06-22 09:12:00, ended at 2011-06-22 10:05:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Lymphocytes [#/volume] in Blood by Automated count: 1.17 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 125 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 34.3 (percent)\n- MCV [Entitic volume] by Automated count: 96.1 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 49 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.1 (percent)\n- Prothrombin time (PT): 13.6 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 14.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 44.9 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.7 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.38 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.4 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 170 (unit per liter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- MCH [Entitic mass] by Automated count: 31.9 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 338 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.1 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 1.54 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 16.8 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-06-22 10:06:00, ended at 2011-06-22 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.772\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- zolpidem tartrate 10 MG Oral Tablet, through Oral route, started on 2011-06-22, presumably until 2011-11-24, with intended 3 refill(s). Instructions: take 1 Tab by mouth every bedtime as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-07-27 10:42:00, ended at 2011-07-27 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-07-31 07:59:00, ended at 2011-07-31 08:57:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 21.1 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.64 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.49 (thousand per microliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 78 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 186 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 3.6 (ratio)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 51 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.74 (million per microliter)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- Prothrombin time (PT): 13.4 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 58 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 15.0 (gram per deciliter)\n- Homocysteine [Moles/volume] in Serum or Plasma: 7.0 (micromole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 154 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.9 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.17 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 95.5 (femtoliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.0 (percent)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.3 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.7 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Lipoprotein a [Mass/volume] in Serum or Plasma: <5.0 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 309 (thousand per microliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 119 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 113 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 63.1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-07-31 08:58:00, ended at 2011-07-31 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-08-27 09:29:00, ended at 2011-08-27 10:20:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.7 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 354 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.62 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.9 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.8 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 198 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 98 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.4 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 62.4 (percent)\n- Prothrombin time (PT): 13.3 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 66 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.09 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.4 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.5 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 98.3 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.96 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.0 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.61 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-08-27 10:21:00, ended at 2011-08-27 12:05:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.26\" (inch (US))\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-09-28 09:45:00, ended at 2011-09-28 11:21:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.9 (percent)\n- MCV [Entitic volume] by Automated count: 96.3 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 61 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.64 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.56 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.2 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 53.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 315 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 28.1 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.24 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 79 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.3 (picogram)\n- Prothrombin time (PT): 13.6 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.4 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.18 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.4 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 158 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.7 (gram per deciliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-09-28 11:22:00, ended at 2011-09-28 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.26\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-10-19 00:00:00, ended at 2011-10-19 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-10-21 10:55:00, ended at 2011-10-21 12:20:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Disease of liver\n- Secondary malignant neoplasm of liver\n- Lymphadenopathy\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-10-21 12:21:00, ended at 2011-10-21 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 146 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 44.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 56 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.54 (million per microliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- MCV [Entitic volume] by Automated count: 97.3 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.26 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 55.5 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 30.7 (percent)\n- Prothrombin time (PT): 13.7 (second)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.5 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.81 (thousand per microliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 15.1 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 33.1 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 274 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.70 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-10-26 10:38:00, ended at 2011-10-26 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.26\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-10-28 00:00:00, ended at 2011-10-28 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- temozolomide 140 MG Oral Capsule, through Oral route, started on 2011-10-28, presumably until 2012-01-26, with intended 3 refill(s). Instructions: take  by mouth daily. Increased dose temodar 140mg 3 tabs (420mg total) po daily D10 to D14, #15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-11-19 00:00:00, ended at 2011-11-19 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-11-24 09:28:00, ended at 2011-11-24 09:47:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Hematocrit [Volume Fraction] of Blood by Automated count: 44.6 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.28 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 68.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 330 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 160 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.86 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 15.1 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.0 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 145 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.4 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.8 (picogram)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 59 (unit per liter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.3 (percent)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.61 (million per microliter)\n- MCV [Entitic volume] by Automated count: 96.8 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.75 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-11-24 09:48:00, ended at 2011-11-24 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.26\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplastic disease\n- Abdominal pain\n- Secondary malignant neoplasm of liver\n\n### Drug\n- zolpidem tartrate 10 MG Oral Tablet, through Oral route, started on 2011-11-24, presumably until 2012-02-26, with intended 3 refill(s). Instructions: take 1 Tab by mouth every bedtime as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-12-22 10:22:00, ended at 2011-12-22 11:46:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Disease of liver\n- Disorder of lung\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n- Lymphadenopathy\n- Imaging of abdomen abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-12-22 11:47:00, ended at 2011-12-22 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.3 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.08 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 250 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 123 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.3 (percent)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.19 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 31.0 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.0 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.9 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 42.1 (percent)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 61 (unit per liter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 101 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 33.4 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 24.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 98.0 (femtoliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 1.20 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.1 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.53 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Malignant tumor of pancreas within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2008-09-11 06:46:00, ended at 2008-09-11 14:50:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Leukocytes [#/volume] in Specimen by Automated count: 4.2 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.82 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.6 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 67.6 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.98 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.41 (thousand per microliter)\n- Body height: 5' 11.26\" (inch (US))\n- Neutrophils [#/volume] in Blood by Automated count: 2.81 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 258 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- MCV [Entitic volume] by Automated count: 85.0 (femtoliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 34.8 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.9 (percent)\n- MCH [Entitic mass] by Automated count: 29.5 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.8 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disease of liver\n\n### Drug\n- 2 ML fentanyl 0.05 MG/ML Injection, through Intravenous route, started on 2008-09-11, presumably until 2008-09-11\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2008-09-11, presumably until 2008-09-11\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2008-09-11, presumably until 2008-09-11\n- midazolam 1 MG/ML Injectable Solution, started on 2008-09-11, presumably until 2008-09-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-09-28 00:00:00, ended at 2008-09-28 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 86 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 53 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.8 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 436 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 109 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 85.9 (femtoliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.6 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.0 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.5 (percent)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.94 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 13.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.37 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 291 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 29.3 (picogram)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.2 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.37 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 76.5 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-10-24 00:00:00, ended at 2008-10-24 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.53 (million per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 191 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 217 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 70 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.3 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 46 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 30.4 (percent)\n- MCH [Entitic mass] by Automated count: 29.8 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 52.7 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.7 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 86.2 (femtoliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 102 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.12 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.1 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 1.94 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.6 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.5 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-11-15 00:00:00, ended at 2008-11-15 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 139 (unit per liter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 16.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.12 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 222 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.6 (percent)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.84 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.0 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.49 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.59 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 53.0 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 59 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 100 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.2 (percent)\n- MCH [Entitic mass] by Automated count: 30.4 (picogram)\n- MCV [Entitic volume] by Automated count: 87.9 (femtoliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.5 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 27.9 (percent)\n- MCHC [Mass/volume] by Automated count: 34.6 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-12-03 00:00:00, ended at 2008-12-03 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 127 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.4 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.39 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.1 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.7 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 45 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 55 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.91 (million per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.53 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 23.0 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 107 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.7 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.68 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.2 (percent)\n- MCH [Entitic mass] by Automated count: 30.9 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 314 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 89.9 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.5 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.4 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-12-24 00:00:00, ended at 2008-12-24 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 57 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 22.4 (percent)\n- Platelets [#/volume] in Blood by Automated count: 227 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 56 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 24.7 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 100 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.3 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.2 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 59.4 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.2 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.05 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.91 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 138 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.7 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 16.1 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-01-21 00:00:00, ended at 2009-01-21 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.3 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 49 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 99.5 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 227 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 112 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 107 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.8 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 61.4 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Anion gap in Serum or Plasma: 3 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 25.3 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.30 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.80 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 2.8 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 1.74 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.7 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 33.5 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-02-08 00:00:00, ended at 2009-02-08 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 97 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 106 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-02-19 00:00:00, ended at 2009-02-19 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoid syndrome\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-02-25 00:00:00, ended at 2009-02-25 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoid syndrome\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-03-21 00:00:00, ended at 2009-03-21 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoid syndrome\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-05-10 00:00:00, ended at 2009-05-10 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Carcinoid syndrome\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-05-21 00:00:00, ended at 2009-05-21 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 91 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.2 (percent)\n- MCV [Entitic volume] by Automated count: 93.7 (femtoliter)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 118 (milligram per deciliter)\n- Prothrombin time (PT): 12.9 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.7 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.2 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 38 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.50 (million per microliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.2 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 218 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 25.6 (second)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2009-06-05 08:27:00, ended at 2009-06-11 12:56:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 91 (unit per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 36.5 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 98 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.1 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 83 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Body height: 5' 11\" (inch (US))\n- Glucose [Mass/volume] in Serum or Plasma: 87 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 269 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 5.6 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.4 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.51 (million per microliter)\n- MCH [Entitic mass] by Automated count: 32.2 (picogram)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.19 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.4 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.3 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.3 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Prothrombin time (PT): 15.7 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.1 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- INR in Platelet poor plasma by Coagulation assay: 1.3 (ratio)\n- MCHC [Mass/volume] by Automated count: 34.3 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.2 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 95.4 (femtoliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n\n### Drug\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2009-06-05, presumably until 2009-06-07\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2009-06-06, presumably until 2009-06-06\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2009-06-11, presumably until 2009-06-11\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2009-06-10, presumably until 2009-06-10\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2009-06-06, presumably until 2009-06-10\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2009-06-06, presumably until 2009-06-06\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2009-06-11, presumably until 2009-08-30, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day. \n- heparin sodium, porcine 10000 UNT/ML Injectable Solution, started on 2009-06-06, presumably until 2009-06-11\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2009-06-07, presumably until 2009-06-07\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2009-06-06, presumably until 2009-06-06\n- 1000 ML glucose 50 MG/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2009-06-07, presumably until 2009-06-08\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2009-06-09, presumably until 2009-06-11\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2009-06-08, presumably until 2009-08-30, with quantity of 60.0, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2009-06-16 14:11:00, ended at 2009-07-04 12:20:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 1.8 (percent)\n- Basophils/100 leukocytes in Blood by Manual count: 1 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Manual count: 3 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.6 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.4 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.55 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 51 (unit per liter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.3 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.13 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 80 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Prothrombin time (PT): 14.9 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 663 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 5 (percent)\n- MCV [Entitic volume] by Automated count: 92.5 (femtoliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.6 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 987 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Basophils [#/volume] in Blood by Manual count: 0.1 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.97 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.8 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Manual count: 1.7 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Manual count: 9 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 93.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.0 (percent)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.1 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.7 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.51 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.2 (percent)\n- Lymphocytes [#/volume] in Blood by Manual count: 1.1 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 33.6 (second)\n- Amylase [Enzymatic activity/volume] in Serum or Plasma: 56 (unit per liter)\n- Body height: 5' 11\" (inch (US))\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.07 (millimole per liter)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- Neutrophils [#/volume] in Blood by Automated count: 9.65 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Manual count: 6.2 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.2 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2009-06-23, presumably until 2009-06-24\n- amylase 33200 UNT / lipase 10000 UNT / protease 37500 UNT Delayed Release Oral Capsule, through Oral route, started on 2009-06-19, presumably until 2010-07-04, with quantity of 60.0, with intended 1 refill(s). Instructions: take 2 Caps by mouth 3 times a day with meals. \n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2009-06-24, presumably until 2009-06-25\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2009-06-28, presumably until 2009-08-30, with quantity of 60.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily. \n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2009-06-16, presumably until 2009-07-03\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2009-06-16, presumably until 2009-06-27\n- diatrizoate, through Oral route, started on 2009-06-22, presumably until 2009-06-22\n- aspirin 325 MG Delayed Release Oral Tablet, through Oral route, started on 2009-06-20, presumably until 2010-07-04, with quantity of 60.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth every morning with breakfast. \n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2009-06-29, presumably until 2009-08-30, with quantity of 8.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- 500 ML glucose 50 MG/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2009-06-16, presumably until 2009-06-19\n- diatrizoic acid, through Oral route, started on 2009-06-22, presumably until 2009-06-22\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2009-06-17, presumably until 2009-06-17\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2009-06-24, presumably until 2009-06-26\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2009-06-16, presumably until 2009-06-27\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2009-06-22, presumably until 2009-06-23\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2009-06-18, presumably until 2009-06-19\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2009-06-18, presumably until 2009-07-03\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2009-07-03, presumably until 2009-07-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-08-23 00:00:00, ended at 2009-08-23 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-08-30 00:00:00, ended at 2009-08-30 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-08-30 07:39:00, ended at 2009-08-30 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.46 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 19.4 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 51 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 219 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 113 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.4 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 85.3 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.99 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 521 (thousand per microliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.8 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.3 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.84 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 46.2 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.0 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.36 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 31.5 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 27.7 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-10-31 09:01:00, ended at 2009-10-31 18:05:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- Selective catheter placement, arterial system; initial second order abdominal, pelvic, or lower extremity artery branch, within a vascular family\n- Angiography, selective, each additional vessel studied after basic examination, radiological supervision and interpretation (List separately in addition to code for primary procedure)\n- Arteriography of other intra-abdominal arteries\n- Angiography, visceral, selective or supraselective (with or without flush aortogram), radiological supervision and interpretation\n- Aortography\n- Selective catheter placement, arterial system; initial third order or more selective abdominal, pelvic, or lower extremity artery branch, within a vascular family\n- Scan of other sites\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n- Liver imaging (SPECT)\n- Selective catheter placement, arterial system; additional second order, third order, and beyond, abdominal, pelvic, or lower extremity artery branch, within a vascular family (List in addition to code for initial second or third order vessel as appropriat\n\n### Condition\n- Metastatic carcinoid tumor\n- Secondary malignant neoplasm of liver\n- Imaging of abdomen abnormal\n- Malignant carcinoid tumor\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2009-10-31, presumably until 2009-10-31\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-11-07 08:53:00, ended at 2009-11-07 21:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- Angiography, visceral, selective or supraselective (with or without flush aortogram), radiological supervision and interpretation\n- Arteriography of other intra-abdominal arteries\n- Supervision, handling, loading of radiation source\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n- Interstitial radiation source application, complex, includes supervision, handling, loading of radiation source, when performed\n- Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, onl\n- Radiopharmaceutical therapy, by intra-arterial particulate administration\n- Injection or instillation of radioisotopes\n- Selective catheter placement, arterial system; initial second order abdominal, pelvic, or lower extremity artery branch, within a vascular family\n- Insertion of catheter into artery\n\n### Condition\n- Imaging of abdomen abnormal\n- Secondary malignant neoplasm of liver\n- Primary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2009-11-22 00:00:00, ended at 2009-11-22 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2009-11-22, presumably until 2009-12-20, with quantity of 20.0. Instructions: take 1 Tab by mouth every 4 hours as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2009-12-20 08:50:03, ended at 2009-12-20 14:35:32\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-01-31 00:00:00, ended at 2010-01-31 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-01-31 08:54:00, ended at 2010-01-31 10:19:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen; with contrast material(s)\n\n### Condition\n- Disorder of lung\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-01-31 10:20:00, ended at 2010-01-31 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.5 (picogram)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.2 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.6 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.82 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 26.8 (second)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 374 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.82 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 68.1 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 230 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.7 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 117 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n- Prothrombin time (PT): 14.1 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 45 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.25 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.1 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.84 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.9 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 66 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.9 (percent)\n- MCV [Entitic volume] by Automated count: 87.5 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-14 09:23:00, ended at 2010-02-14 10:05:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 87 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.4 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.7 (picogram)\n- aPTT in Platelet poor plasma by Coagulation assay: 25.8 (second)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.06 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.55 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 40 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 485 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 61 (unit per liter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 86.9 (femtoliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.9 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.84 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.17 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.6 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 63.1 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 281 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.0 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.2 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Prothrombin time (PT): 13.3 (second)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-14 10:06:00, ended at 2010-02-14 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Primary malignant neoplasm of pancreas\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-05-05 00:00:00, ended at 2010-05-05 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-05-05 00:00:00, ended at 2010-05-05 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-09 11:45:00, ended at 2010-05-09 13:19:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 47 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.7 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.2 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 61 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.8 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.1 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.37 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 811 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.4 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.4 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.93 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 728 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 108 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.90 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.15 (million per microliter)\n- MCH [Entitic mass] by Automated count: 29.0 (picogram)\n- MCV [Entitic volume] by Automated count: 87.7 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 72.8 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-09 13:20:00, ended at 2010-05-09 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of pancreas\n- Malignant neoplastic disease\n- Primary malignant neoplasm of gastrointestinal tract\n- Secondary malignant neoplasm of liver\n- Malignant carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-16 10:24:00, ended at 2010-05-16 11:18:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 52 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.9 (percent)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.5 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.2 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.6 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 29.1 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 723 (thousand per microliter)\n- Prothrombin time (PT): 13.3 (second)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.85 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 142 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 853 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.85 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 86.9 (femtoliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 32.6 (second)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.7 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.96 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 75.1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-16 11:19:00, ended at 2010-05-16 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n- Primary malignant neoplasm of pancreas\n- Secondary malignant neoplasm of liver\n\n### Drug\n- amoxicillin 500 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2010-05-16, presumably until 2010-08-20, with quantity of 14.0, with intended 2 refill(s). Instructions: take by mouth. \n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, through Oral route, presumably until 2010-08-20. Instructions: take by mouth. \n- sulfamethoxazole 800 MG / trimethoprim 160 MG Oral Tablet, through Oral route, started on 2010-05-16, presumably until 2010-08-20, with quantity of 14.0, with intended 2 refill(s). Instructions: take by mouth. \n- zolpidem tartrate 10 MG Oral Tablet, through Oral route, presumably until 2010-08-20. Instructions: take by mouth. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-30 08:23:00, ended at 2010-05-30 08:53:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.8 (percent)\n- MCV [Entitic volume] by Automated count: 87.9 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 410 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 868 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.7 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.97 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 179 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.30 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.1 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.68 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.4 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 113 (unit per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.47 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.0 (picogram)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.4 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 22.0 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 55.8 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.18 (million per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 128 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-30 08:54:00, ended at 2010-05-30 15:02:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen; with contrast material(s)\n\n### Condition\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n- Lymphadenopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-30 15:03:00, ended at 2010-05-30 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of gastrointestinal tract\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n- Neoplasm of lymph node\n- Malignant carcinoid tumor\n- Primary malignant neoplasm of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-07-25 10:35:00, ended at 2010-07-25 11:42:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 114 (unit per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.2 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.9 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 89 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 1159 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.6 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.3 (percent)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Neutrophils/100 leukocytes in Blood by Automated count: 70.4 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 29.3 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 502 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 36.6 (second)\n- Monocytes [#/volume] in Blood by Automated count: 0.79 (thousand per microliter)\n- Prothrombin time (PT): 13.4 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.81 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 127 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.2 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 89.9 (femtoliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.85 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.1 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.97 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-07-25 11:43:00, ended at 2010-07-25 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of gastrointestinal tract\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n- Malignant carcinoid tumor\n- Primary malignant neoplasm of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-08-05 10:39:00, ended at 2010-08-05 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n- Computed tomography, pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen; without contrast material, followed by contrast material(s) and further sections\n\n### Condition\n- Neoplastic disease\n- Secondary malignant neoplasm of liver\n- Secondary malignant neoplasm of lung\n- Epigastric pain\n- Ascites\n- Imaging of musculoskeletal system abnormal\n- Malignant neoplastic disease\n- Lung field abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-08-08 10:17:00, ended at 2010-08-08 12:30:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 1482 (unit per liter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 7 (percent)\n- Monocytes/100 leukocytes in Blood by Manual count: 4 (percent)\n- Platelets [#/volume] in Blood by Automated count: 609 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 92 (unit per liter)\n- Basophils [#/volume] in Blood by Manual count: 0.1 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.4 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 142 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.9 (picogram)\n- Neutrophils [#/volume] in Blood by Manual count: 4.8 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.2 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.2 (percent)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.1 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Prothrombin time (PT): 13.6 (second)\n- aPTT in Platelet poor plasma by Coagulation assay: 30.3 (second)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.72 (million per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.6 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.1 (percent)\n- MCV [Entitic volume] by Automated count: 89.2 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 87 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 77 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Manual count: 1 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-08-08 12:31:00, ended at 2010-08-08 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n- Neoplasm of lymph node\n- Secondary malignant neoplasm of liver\n- Malignant carcinoid tumor\n- Primary malignant neoplasm of pancreas\n- Primary malignant neoplasm of gastrointestinal tract\n\n### Drug\n- capecitabine 500 MG Oral Tablet, through Oral route, started on 2010-08-08, presumably until 2011-08-08, with quantity of 84.0, with intended 0 refill(s). Instructions: take by mouth. 1500 mg po bid for 14 days then, 2 weeks off (28days cycle) #84 \n- temozolomide 140 MG Oral Capsule, through Oral route, started on 2010-08-08, presumably until 2012-01-26, with quantity of 10.0, with intended 0 refill(s). Instructions: take by mouth daily. 280 mg po daily D10 to D14 in 28 days cycle (140mg form 2 tabs ) #10 \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-08-18 12:20:00, ended at 2010-08-18 14:05:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of gastrointestinal tract\n- Secondary malignant neoplasm of liver\n- Primary malignant neoplasm of pancreas\n- Malignant neoplastic disease\n- Secondary malignant neoplastic disease\n- Malignant carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-08-18 14:06:00, ended at 2010-08-18 14:28:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 118 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.9 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 512 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.1 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.3 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- Neutrophils/100 leukocytes in Blood by Automated count: 76.9 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.82 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 33.9 (second)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.5 (percent)\n- MCV [Entitic volume] by Automated count: 92.9 (femtoliter)\n- Prothrombin time (PT): 15.1 (second)\n- Sodium [Moles/volume] in Serum or Plasma: 132 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 58 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.2 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.4 (percent)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.3 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 118 (unit per liter)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.63 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.08 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 1708 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.6 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.46 (million per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 26 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2010-08-18 14:29:00, ended at 2010-08-20 19:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 2.4 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n- Neutrophils/100 leukocytes in Blood by Manual count: 71 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 96 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 112 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.2 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.0 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.7 (percent)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.5 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 92.8 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.15 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Manual count: 5.5 (thousand per microliter)\n- Prothrombin time (PT): 15.0 (second)\n- Sodium [Moles/volume] in Serum or Plasma: 132 (millimole per liter)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: <0.8 (microgram per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 63 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 2.5 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.4 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 1.2 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 1945 (unit per liter)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- Platelets [#/volume] in Blood by Automated count: 511 (thousand per microliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.20 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 6 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.23 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.2 (percent)\n- Monocytes/100 leukocytes in Blood by Manual count: 16 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Body height: 5' 10.984\" (inch (US))\n- Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma: 604 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.6 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.6 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.15 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.0 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 97 (unit per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 69.2 (percent)\n- aPTT in Platelet poor plasma by Coagulation assay: 33.2 (second)\n\n### Procedure\n- Physical therapy evaluation\n- Abdominal paracentesis\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Injection of anesthetic agent into peripheral nerve for analgesia\n- Collection of venous blood by venipuncture\n\n### Condition\n- Abdominal pain\n- Malignant ascites\n- Loss of appetite\n- Malignant carcinoid tumor\n- Secondary malignant neoplasm of liver\n- Disorder of plasma protein metabolism\n- Lumbosacral spondylosis without myelopathy\n- Metastatic carcinoid tumor\n- Constipation\n- Portal hypertension\n- Acquired absence of organ\n- Neoplasm of digestive tract\n- Secondary malignant neoplasm of peritoneum\n- Thoracic spondylosis without myelopathy\n\n### Drug\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2010-08-20, presumably until 2010-11-07, with quantity of 30.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. \n- bupivacaine hydrochloride 2.5 MG/ML Injectable Solution, started on 2010-08-20, presumably until 2010-08-20\n- aspirin 325 MG Oral Tablet, through Oral route, presumably until 2013-06-23. Instructions: take 325 mg by mouth every morning with breakfast. \n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2010-08-19, presumably until 2010-11-07, with quantity of 60.0, with intended 3 refill(s). Instructions: take 1 Cap by mouth daily. \n- heparin sodium, porcine 10000 UNT/ML Injectable Solution, started on 2010-08-19, presumably until 2010-08-19\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2010-08-20, presumably until 2010-11-07, with quantity of 60.0, with intended 3 refill(s). Instructions: take 2 Tabs by mouth every bedtime as needed for Constipation. \n- 200 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2010-08-19, presumably until 2010-08-20\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2010-08-20, presumably until 2010-08-20\n- 1 ML morphine sulfate 2 MG/ML Prefilled Syringe, started on 2010-08-20, presumably until 2010-08-20\n- morphine sulfate 15 MG Extended Release Oral Tablet, through Oral route, started on 2010-08-18, presumably until 2011-02-16, with quantity of 60.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth every 12 hours. \n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2010-08-18, presumably until 2011-01-02, with quantity of 120.0, with intended 1 refill(s). Instructions: take 2 Tabs by mouth every 6 hours as needed for Pain. please hold for somnolence, Elon College  less than 8, altered mental status \n- midazolam 1 MG/ML Injectable Solution, started on 2010-08-20, presumably until 2010-08-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-08-31 00:00:00, ended at 2010-08-31 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-09-01 00:00:00, ended at 2010-09-01 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-09-01 09:44:00, ended at 2010-09-01 10:54:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of pancreas\n- Secondary malignant neoplastic disease\n- Abdominal pain\n- Primary malignant neoplasm of gastrointestinal tract\n- Malignant carcinoid tumor\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- spironolactone 50 MG Oral Tablet, through Oral route, started on 2010-09-01, presumably until 2010-11-07, with quantity of 30.0, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-09-01 10:55:00, ended at 2010-09-01 12:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Neutrophils/100 leukocytes in Blood by Manual count: 85 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 87 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 118 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 128 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.3 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 97.4 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 2411 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.2 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.0 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 21.3 (percent)\n- Monocytes/100 leukocytes in Blood by Manual count: 3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 5.7 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.07 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.9 (percent)\n- MCH [Entitic mass] by Automated count: 31.1 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 741 (thousand per microliter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.7 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Neutrophils [#/volume] in Blood by Manual count: 6.4 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 9 (percent)\n- MCHC [Mass/volume] by Automated count: 31.9 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Abdominal pain\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-09-08 17:12:00, ended at 2010-09-08 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Molecular diagnostics; isolation or extraction of highly purified nucleic acid, each nucleic acid type (ie, DNA or RNA)\n- Molecular diagnostics; amplification, target, each nucleic acid sequence\n- Molecular diagnostics; interpretation and report\n- Molecular diagnostics; lysis of cells prior to nucleic acid extraction (eg, stool specimens, paraffin embedded tissue), each specimen\n- Molecular diagnostics; separation by gel electrophoresis (eg, agarose, polyacrylamide), each nucleic acid preparation\n\n### Condition\n- Cholesterolosis of gallbladder\n- Chronic cholecystitis\n- Primary malignant neoplasm of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-09-12 09:53:00, ended at 2010-09-12 11:30:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of pancreas\n- Secondary malignant neoplasm of liver\n- Malignant carcinoid tumor\n- Malignant neoplastic disease\n- Primary malignant neoplasm of gastrointestinal tract\n\n### Drug\n- furosemide 40 MG Oral Tablet, through Oral route, started on 2010-09-12, presumably until 2010-11-07, with quantity of 30.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-09-12 11:31:00, ended at 2010-09-12 20:35:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- Procedure on single vessel\n- Venography, caval, inferior, with serialography, radiological supervision and interpretation\n- Angioplasty of other non-coronary vessel(s)\n- Insertion of non-drug-eluting peripheral (non-coronary) vessel stent(s)\n- Insertion of one vascular stent\n- Peritoneocentesis, abdominal paracentesis, or peritoneal lavage (diagnostic or therapeutic); initial\n- Transcatheter placement of an intravascular stent(s) (except coronary, carotid, vertebral, iliac, and lower extremity arteries), percutaneous; initial vessel\n- Introduction of catheter, superior or inferior vena cava\n- Diagnostic ultrasound of abdomen and retroperitoneum\n- Abdominal paracentesis\n- Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation\n- Transcatheter introduction of intravascular stent(s) (except coronary, carotid, vertebral, iliac, and lower extremity artery), percutaneous and/or open, radiological supervision and interpretation, each vessel\n- Venous catheterization, not elsewhere classified\n- Venography of vena cava\n\n### Condition\n- Ascites\n- Secondary malignant neoplasm of liver\n- Compression of vein\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-10-10 10:28:00, ended at 2010-10-10 11:09:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-10-10 11:10:00, ended at 2010-10-10 12:51:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Ascites\n- Benign carcinoid tumor\n- Primary malignant neoplasm of pancreas\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2010-10-10, presumably until 2011-01-02, with quantity of 15.0, with intended 6 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-10-10 12:52:00, ended at 2010-10-10 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, pelvis; 1 or 2 views\n- Radiologic examination, spine, lumbosacral; 2 or 3 views\n- Radiologic examination, sacrum and coccyx, minimum of 2 views\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-10-10 12:52:00, ended at 2010-10-10 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.07 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 71.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 647 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.4 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 62 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 107 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.8 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.75 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 98.2 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.7 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 1859 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 23.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.7 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 13.1 (percent)\n- MCH [Entitic mass] by Automated count: 33.0 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.0 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 26.2 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.3 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Prothrombin time (PT): 13.7 (second)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.29 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.3 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.80 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-03 10:14:00, ended at 2010-11-03 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen; without contrast material, followed by contrast material(s) and further sections\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, pelvis; with contrast material(s)\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n\n### Condition\n- Ascites\n- Malignant neoplastic disease\n- Disease of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-07 07:25:00, ended at 2010-11-07 08:14:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.44 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.5 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.8 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.01 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.22 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n- Anion gap in Serum or Plasma: 2 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.37 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 99.4 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.2 (gram per deciliter)\n- Prothrombin time (PT): 13.2 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 794 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 58 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.3 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 59.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 126 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.8 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 561 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 70 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 21.0 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 17.5 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.97 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 16.7 (percent)\n- MCH [Entitic mass] by Automated count: 33.5 (picogram)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-07 08:15:00, ended at 2010-11-07 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Ascites\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-05 10:19:00, ended at 2010-12-05 11:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.7 (percent)\n- MCV [Entitic volume] by Automated count: 100.9 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.13 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 75 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.7 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.40 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.1 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.10 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 74 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.3 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 33.1 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 1.06 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 78 (unit per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 419 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.6 (percent)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 58.4 (percent)\n- Prothrombin time (PT): 13.0 (second)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.39 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 534 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.3 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.0 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-05 12:00:00, ended at 2010-12-05 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-01 14:34:00, ended at 2011-01-01 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Lymphocytes [#/volume] in Blood by Automated count: 1.44 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 98.8 (femtoliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.6 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.8 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.2 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.1 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.5 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 132 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 55.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 438 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 84 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 272 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.23 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.39 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 25.8 (percent)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.1 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.11 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Prothrombin time (PT): 13.5 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 70 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-02 10:39:00, ended at 2011-01-02 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.276\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-21 10:13:00, ended at 2011-01-21 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Postprocedural state finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-01-23 00:00:00, ended at 2011-01-23 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-26 08:09:00, ended at 2011-01-26 08:55:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 93 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.21 (million per microliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 76 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.39 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.90 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.7 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.5 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 13.6 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 379 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.2 (percent)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 175 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 236 (unit per liter)\n- MCH [Entitic mass] by Automated count: 32.0 (picogram)\n- MCV [Entitic volume] by Automated count: 98.7 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 11.12 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.0 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.6 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 10.2 (percent)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Prothrombin time (PT): 13.0 (second)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-26 08:56:00, ended at 2011-01-26 10:49:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-26 10:50:00, ended at 2011-01-26 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; initial, 31 minutes to 1 hour\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, presumably until 2011-02-27. Instructions: take 1 Tab by mouth as needed \n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-01-26, presumably until 2011-01-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-02-27 12:04:00, ended at 2011-02-27 14:18:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.1 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.7 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 1.14 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 17.0 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 210 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.19 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 140 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.62 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 57 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.74 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 53.9 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.5 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 26.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 401 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Anion gap in Serum or Plasma: 2 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.9 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.3 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Prothrombin time (PT): 12.8 (second)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 96.6 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-02-27 14:19:00, ended at 2011-02-27 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n\n### Drug\n- zolpidem tartrate 10 MG Oral Tablet, through Oral route, started on 2011-02-27, presumably until 2011-08-26, with quantity of 30.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth every bedtime as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-03-27 11:11:00, ended at 2011-03-27 13:58:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 32.0 (percent)\n- MCV [Entitic volume] by Automated count: 94.3 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.95 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 209 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.8 (percent)\n- MCH [Entitic mass] by Automated count: 31.3 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 46.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 365 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 68 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.9 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.3 (thousand per microliter)\n- Prothrombin time (PT): 12.7 (second)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.46 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.2 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.68 (thousand per microliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 117 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- Monocytes/100 leukocytes in Blood by Automated count: 18.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.53 (million per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-03-27 13:59:00, ended at 2011-03-27 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n- Primary malignant neoplasm of islets of Langerhans\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-21 11:03:00, ended at 2011-04-21 11:36:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 77 (unit per liter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 144 (milligram per deciliter)\n- Prothrombin time (PT): 13.0 (second)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 189 (unit per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-21 11:37:00, ended at 2011-04-21 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Malignant neoplastic disease\n- Hypertrophy of breast\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-24 14:02:00, ended at 2011-04-24 15:56:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-24 15:57:00, ended at 2011-04-24 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Eosinophils [#/volume] in Blood by Automated count: 0.31 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 370 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 95.6 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.8 (percent)\n- MCH [Entitic mass] by Automated count: 31.5 (picogram)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.9 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.6 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.2 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 55.5 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.4 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.94 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.56 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.54 (thousand per microliter)\n- Prolactin [Mass/volume] in Serum or Plasma: 6 (nanogram per milliliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 3.08 (micro-international unit per milliliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 24.4 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.41 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-22 12:22:00, ended at 2011-05-22 14:05:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 59 (unit per liter)\n- Prothrombin time (PT): 13.8 (second)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 159 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 189 (unit per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-22 14:06:00, ended at 2011-05-22 15:07:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.772\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-22 15:08:00, ended at 2011-05-22 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.2 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 368 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.2 (percent)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.1 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.4 (picogram)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.36 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.4 (percent)\n- MCV [Entitic volume] by Automated count: 95.0 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 45.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.1 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 34.8 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.78 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.81 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.33 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-06-22 09:12:00, ended at 2011-06-22 10:05:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Lymphocytes [#/volume] in Blood by Automated count: 1.17 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 125 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 34.3 (percent)\n- MCV [Entitic volume] by Automated count: 96.1 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 49 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.1 (percent)\n- Prothrombin time (PT): 13.6 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 14.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 44.9 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.7 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.38 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.4 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 170 (unit per liter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- MCH [Entitic mass] by Automated count: 31.9 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 338 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.1 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 1.54 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 16.8 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-06-22 10:06:00, ended at 2011-06-22 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.772\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- zolpidem tartrate 10 MG Oral Tablet, through Oral route, started on 2011-06-22, presumably until 2011-11-24, with intended 3 refill(s). Instructions: take 1 Tab by mouth every bedtime as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-07-27 10:42:00, ended at 2011-07-27 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-07-31 07:59:00, ended at 2011-07-31 08:57:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 21.1 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.64 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.49 (thousand per microliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 78 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 186 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 3.6 (ratio)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 51 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.74 (million per microliter)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- Prothrombin time (PT): 13.4 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 58 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 15.0 (gram per deciliter)\n- Homocysteine [Moles/volume] in Serum or Plasma: 7.0 (micromole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 154 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.9 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.17 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 95.5 (femtoliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.0 (percent)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.3 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.7 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Lipoprotein a [Mass/volume] in Serum or Plasma: <5.0 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 309 (thousand per microliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 119 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 113 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 63.1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-07-31 08:58:00, ended at 2011-07-31 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-08-27 09:29:00, ended at 2011-08-27 10:20:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.7 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 354 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.62 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.9 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.8 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 198 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 98 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.4 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 62.4 (percent)\n- Prothrombin time (PT): 13.3 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 66 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.09 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.4 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.5 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 98.3 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.96 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.0 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.61 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-08-27 10:21:00, ended at 2011-08-27 12:05:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.26\" (inch (US))\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-09-28 09:45:00, ended at 2011-09-28 11:21:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.9 (percent)\n- MCV [Entitic volume] by Automated count: 96.3 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 61 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.64 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.56 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.2 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 53.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 315 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 28.1 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.24 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 79 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.3 (picogram)\n- Prothrombin time (PT): 13.6 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.4 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.18 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.4 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 158 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.7 (gram per deciliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-09-28 11:22:00, ended at 2011-09-28 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.26\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-10-19 00:00:00, ended at 2011-10-19 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-10-21 10:55:00, ended at 2011-10-21 12:20:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Disease of liver\n- Secondary malignant neoplasm of liver\n- Lymphadenopathy\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-10-21 12:21:00, ended at 2011-10-21 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 146 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 44.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 56 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.54 (million per microliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- MCV [Entitic volume] by Automated count: 97.3 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.26 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 55.5 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 30.7 (percent)\n- Prothrombin time (PT): 13.7 (second)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.5 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.81 (thousand per microliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 15.1 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 33.1 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 274 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.70 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-10-26 10:38:00, ended at 2011-10-26 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.26\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-10-28 00:00:00, ended at 2011-10-28 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Malignant neoplastic disease\n\n### Drug\n- temozolomide 140 MG Oral Capsule, through Oral route, started on 2011-10-28, presumably until 2012-01-26, with intended 3 refill(s). Instructions: take  by mouth daily. Increased dose temodar 140mg 3 tabs (420mg total) po daily D10 to D14, #15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-11-19 00:00:00, ended at 2011-11-19 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-11-24 09:28:00, ended at 2011-11-24 09:47:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Hematocrit [Volume Fraction] of Blood by Automated count: 44.6 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.28 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 68.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 330 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 160 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.86 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 15.1 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.0 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 145 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.4 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.8 (picogram)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 59 (unit per liter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.3 (percent)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.61 (million per microliter)\n- MCV [Entitic volume] by Automated count: 96.8 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.75 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-11-24 09:48:00, ended at 2011-11-24 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.26\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplastic disease\n- Abdominal pain\n- Secondary malignant neoplasm of liver\n\n### Drug\n- zolpidem tartrate 10 MG Oral Tablet, through Oral route, started on 2011-11-24, presumably until 2012-02-26, with intended 3 refill(s). Instructions: take 1 Tab by mouth every bedtime as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-12-22 10:22:00, ended at 2011-12-22 11:46:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Disease of liver\n- Disorder of lung\n- Malignant neoplastic disease\n- Secondary malignant neoplasm of liver\n- Lymphadenopathy\n- Imaging of abdomen abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-12-22 11:47:00, ended at 2011-12-22 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.3 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.08 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 250 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 123 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.3 (percent)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.19 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 31.0 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.0 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.9 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 42.1 (percent)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 61 (unit per liter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 101 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 33.4 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 24.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 98.0 (femtoliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 1.20 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.1 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.53 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Malignant tumor of pancreas within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of pancreatic_cancer means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "fa6a1cff776182bd0089f0bb2ab3fd35033356deb7bc6d841b9c191082a3845a", "prompt_hash": "a50538aa5eb197888488b7064db8b3fd04f035045c558932524b4c971bf70090", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
{"doc_id": 3, "doc": {"person_id": 115968682, "visit_occurrence_id": 131827326, "death_date": "2019-05-17", "visit_concept_name": "Pharmacy visit", "visit_start_datetime": "2019-03-11 00:00:00", "visit_end_datetime": "2019-03-11 00:00:00", "visit_length_in_hours": 0.0, "integrated_visit_record": "## Visit\nThis visit record, was from Pharmacy visit, started at 2019-03-11 00:00:00, ended at 2019-03-11 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- Abuse-Deterrent 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2019-03-11, presumably until 2019-03-12, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n\n", "approximate_token_count": 133, "patient_first_visit_date": "2010-08-04 12:40:00", "patient_last_visit_date": "2019-05-09 15:28:00", "end_obs_date": "2019-05-17", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 1, "obesity_type": "recurrent", "obesity_one_year_diagnosis": 1, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "recurrent", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "recurrent", "depressive_disorder_one_year_diagnosis": 1, "chronic_kidney_disease_type": "recurrent", "chronic_kidney_disease_one_year_diagnosis": 1, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "recurrent", "coronary_arteriosclerosis_one_year_diagnosis": 1, "type_ii_diabetes_type": "recurrent", "type_ii_diabetes_one_year_diagnosis": 1, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "recurrent", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "recurrent", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "recurrent", "heart_failure_one_year_diagnosis": 1, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 1, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "recurrent", "lung_cancer_one_year_diagnosis": 1, "liver_cancer_type": "recurrent", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 998, "cumulated_visit_num": 998, "cumulated_approximate_token_count": 262242, "visit_cumulated": "## Visit\nThis visit record, was from Outpatient Visit, started at 2010-08-04 12:40:00, ended at 2010-08-04 23:59:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation and report on referred material requiring preparation of slides\n- Morphometric analysis, tumor\n\n### Condition\n- Neoplasm of uncertain behavior of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-09-07 12:58:00, ended at 2010-09-07 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-09-08 00:00:00, ended at 2010-09-08 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Intra-abdominal and pelvic swelling, mass and lump\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-09-09 10:55:00, ended at 2010-09-09 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen; with contrast material(s)\n- Computed tomography, pelvis; with contrast material(s)\n\n### Condition\n- Intra-abdominal and pelvic swelling, mass and lump\n- Abnormal finding on evaluation procedure\n- Disorder of pancreas\n- Neoplastic disease\n- Neoplastic disease of uncertain behavior\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-09-16 09:05:00, ended at 2010-09-16 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-09-27 09:58:00, ended at 2010-09-27 12:45:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- Colonoscopy\n- Colonoscopy, flexible; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2010-09-27, presumably until 2010-09-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2010-09-28 05:45:00, ended at 2010-10-12 11:12:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: N/A (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.23 (million per microliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 500 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.0 (gram per deciliter)\n- Anion gap in Serum or Plasma: <2 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.7 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.3 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Body height: 5' 8.4\" (inch (US))\n- Globulin [Mass/volume] in Serum: 4.9 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 340 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.48 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 23.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 2.87 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 80.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.2 (percent)\n- INR in Platelet poor plasma by Coagulation assay: N/A (ratio)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.66 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.3 (millimole per liter)\n- Prothrombin time (PT): N/A (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 26.8 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 18.4 (percent)\n- Platelets [#/volume] in Blood by Automated count: 966 (thousand per microliter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.26 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.94 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.4 (percent)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 6.1 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.9 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 82.3 (femtoliter)\n\n### Procedure\n- Venous catheterization, not elsewhere classified\n- Selective catheter placement, arterial system; initial second order abdominal, pelvic, or lower extremity artery branch, within a vascular family\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Aortography\n- Transcatheter therapy, embolization, any method, radiological supervision and interpretation\n- Total splenectomy\n- Collection of venous blood by venipuncture\n- Open and other left hemicolectomy\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Distal subtotal pancreatectomy\n- Other endovascular procedures on other vessels\n- Angiography, visceral, selective or supraselective (with or without flush aortogram), radiological supervision and interpretation\n- Angiography through existing catheter for follow-up study for transcatheter therapy, embolization or infusion, other than for thrombolysis\n- Transcatheter occlusion or embolization (eg, for tumor destruction, to achieve hemostasis, to occlude a vascular malformation), percutaneous, any method, non-central nervous system, non-head or neck\n- Physical therapy evaluation\n- Radiologic examination, chest; single view, frontal\n- Arteriography of femoral and other lower extremity arteries\n- Continuous positive airway pressure ventilation (CPAP), initiation and management\n- Arteriography of other specified sites\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Excision or destruction of peritoneal tissue\n- Nephroureterectomy\n- Noninvasive ventilation\n\n### Condition\n- Acute postoperative pain\n- Low blood pressure\n- Pain in limb\n- Primary malignant neoplasm of abdomen\n- Primary malignant neoplasm of retroperitoneum\n- Atelectasis\n- Hyperkalemia\n- Portal hypertension\n- Venous thrombosis\n- Acute renal failure syndrome\n- Essential thrombocythemia\n- Imaging of thorax abnormal\n- Malnutrition (calorie)\n- Secondary malignant neoplastic disease\n- Cachexia\n- Hypovolemia\n- Primary malignant neoplasm of soft tissues of abdomen\n- Acquired hypothyroidism\n- Delirium\n- Obstructive sleep apnea syndrome\n- Thrombosis of superficial vein of lower limb\n- Acute posthemorrhagic anemia\n- Acute tubular necrosis\n- Leukocytosis\n- Postoperative infection\n- Swelling of limb\n- Acute vascular insufficiency of intestine\n- Blood coagulation disorder\n- Disorder of spleen\n- Secondary malignant neoplasm of intra-abdominal organs\n- Type 2 diabetes mellitus without complication\n- Essential hypertension\n- Imaging of abdomen abnormal\n- Obesity\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2010-09-28, presumably until 2010-10-10\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2010-09-30, presumably until 2010-09-30\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2010-10-12, presumably until 2010-10-12\n- metformin hydrochloride 500 MG Oral Tablet, through Oral route, started on 2010-10-10, presumably until 2010-10-12\n- cefoxitin 1000 MG Injection, through Intravenous route, started on 2010-09-29, presumably until 2010-09-29\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2010-09-29, presumably until 2010-10-11\n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2010-09-28, presumably until 2010-10-11. Instructions: take 20 mg by mouth every bedtime.\n- lisinopril 10 MG Oral Tablet, through Oral route, started on 2010-10-10, presumably until 2010-10-10\n- warfarin sodium 7.5 MG Oral Tablet, through Oral route, started on 2010-10-11, presumably until 2010-10-19, with quantity of 7.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n- 0.5 ML Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.068 MG/ML Injection, through Intramuscular route, started on 2010-10-10, presumably until 2010-10-10\n- cefazolin 1000 MG Injection, started on 2010-09-28, presumably until 2010-09-28\n- 0.8 ML enoxaparin sodium 150 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2010-10-11, presumably until 2010-10-13, with quantity of 7.0, with intended 0 refill(s). Instructions: 0.73 mL by SUBCUTANEOUS route every 12 hours. \n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2010-09-28, presumably until 2010-09-29\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2010-10-12, presumably until 2011-02-23, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily. \n- heparin sodium, porcine 10000 UNT/ML Injectable Solution, started on 2010-09-29, presumably until 2010-10-11\n- calcium chloride 0.001 MEQ/ML / glucose 50 MG/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2010-09-29, presumably until 2010-10-01\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2010-10-10, presumably until 2010-10-12\n- 0.5 ML meningococcal group A polysaccharide 0.1 MG/ML / meningococcal group C polysaccharide 0.1 MG/ML / meningococcal polysaccharide vaccine group W-135 0.1 MG/ML / meningococcal polysaccharide vaccine group Y 0.1 MG/ML Injection, through Subcutaneous route, started on 2010-10-10, presumably until 2010-10-10\n- insulin aspart, human 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2010-09-29, presumably until 2010-10-12\n- 1 ML vitamin K1 10 MG/ML Injection, through Intravenous route, started on 2010-10-03, presumably until 2010-10-03\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2010-10-10, presumably until 2010-10-10\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2010-10-09, presumably until 2010-10-12\n- 2 ML ondansetron 2 MG/ML Injection, started on 2010-09-28, presumably until 2010-09-29\n- acetaminophen 33.3 MG/ML / hydrocodone bitartrate 0.5 MG/ML Oral Solution, through Oral route, started on 2010-10-10, presumably until 2010-10-12\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2010-10-06, presumably until 2011-04-09, with quantity of 40.0, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 6 hours. \n- 0.5 ML Streptococcus pneumoniae type 1 capsular polysaccharide antigen 0.05 MG/ML / Streptococcus pneumoniae type 10A capsular polysaccharide antigen 0.05 MG/ML / Streptococcus pneumoniae type 11A capsular polysaccharide antigen 0.05 MG/ML / Streptococ..., started on 2010-10-10, presumably until 2010-10-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2010-10-13 00:00:00, ended at 2010-10-13 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.8 ML enoxaparin sodium 150 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2010-10-13, presumably until 2010-10-31, with quantity of 7.0, with intended 0 refill(s). Instructions: 0.73 mL by SUBCUTANEOUS route every 12 hours. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2010-10-17 00:00:00, ended at 2010-10-17 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2010-10-17, presumably until 2010-10-31, with quantity of 30.0, with intended 1 refill(s). Instructions: take 1-2 Tabs by mouth every 4 to 6 hours as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-10-19 09:55:00, ended at 2010-10-19 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- warfarin sodium 7.5 MG Oral Tablet, through Oral route, started on 2010-10-19, presumably until 2010-10-31, with quantity of 7.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-10-21 00:00:00, ended at 2010-10-21 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2010-10-26 21:05:00, ended at 2010-10-31 14:20:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 23.1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.47 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Prothrombin time (PT): 35.2 (second)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.2 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 27.6 (percent)\n- MCH [Entitic mass] by Automated count: 26.3 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 1.82 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 6.5 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 3.7 (ratio)\n- Neutrophils [#/volume] in Blood by Automated count: 9.97 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 78.1 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 80.5 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 81.7 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 132 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.1 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.5 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.5 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 846 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.5 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: <10 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.39 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.9 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 122 (unit per liter)\n- Body height: 5' 8.386\" (inch (US))\n- Eosinophils [#/volume] in Blood by Automated count: 0.62 (thousand per microliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.01 (nanogram per milliliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Incision of abdominal wall\n- Computed tomography, abdomen; without contrast material, followed by contrast material(s) and further sections\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Continuous positive airway pressure ventilation (CPAP), initiation and management\n- Computed tomography, pelvis; without contrast material, followed by contrast material(s) and further sections\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Obstructive sleep apnea syndrome\n- Persistent postoperative fistula\n- Type 2 diabetes mellitus without complication\n- Acquired absence of organ\n- Essential hypertension\n- Abdominal pain\n- Complication of surgical procedure\n- Malaise\n- Postoperative infection\n- Backache\n- Acute deep vein thrombosis of lower limb\n- Obesity\n- Acquired hypothyroidism\n- Cellulitis and abscess of trunk\n- Postprocedural state finding\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2010-10-27, presumably until 2010-10-28\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2010-10-30, presumably until 2010-10-30\n- warfarin sodium 5 MG Oral Tablet, through Oral route, started on 2010-10-31, presumably until 2011-04-26, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n- warfarin sodium 6 MG Oral Tablet, through Oral route, started on 2010-10-30, presumably until 2010-10-30\n- piperacillin 2000 MG / tazobactam 250 MG Injection, through Intravenous route, started on 2010-10-28, presumably until 2010-10-30\n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2010-10-27, presumably until 2010-10-30. Instructions: take 20 mg by mouth every bedtime.\n- diatrizoate, through Oral route, started on 2010-10-27, presumably until 2010-10-27\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2010-10-29, presumably until 2011-04-26, with quantity of 40.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily. \n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2010-10-27, presumably until 2010-10-31. Instructions: take 100 mcg by mouth daily.\n- diatrizoic acid, through Oral route, started on 2010-10-27, presumably until 2010-10-27\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2010-10-28, presumably until 2010-10-31\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2010-10-27, presumably until 2010-10-28\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2010-10-27, presumably until 2010-10-27\n- warfarin sodium 1 MG Oral Tablet, through Oral route, started on 2010-10-31, presumably until 2011-04-26, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2010-10-30, presumably until 2011-03-22, with quantity of 40.0, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 6 hours.\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2010-10-30, presumably until 2010-12-12, with quantity of 20.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours. \n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2010-10-29, presumably until 2010-10-30\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2010-10-26, presumably until 2010-10-30. Instructions: take 1-2 Tabs by mouth every 4 to 6 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-01 10:57:00, ended at 2010-11-01 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-02 08:17:00, ended at 2010-11-02 08:37:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.9 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 9.2 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Platelets [#/volume] in Blood by Automated count: 865 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- MCH [Entitic mass] by Automated count: 25.9 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.4 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.50 (million per microliter)\n- Globulin [Mass/volume] in Serum: 6.6 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.0 (gram per deciliter)\n- Prothrombin time (PT): 19.4 (second)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 10.0 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 27.9 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.7 (ratio)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.9 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 108 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 142 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 79.8 (femtoliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 46 (milliliter per minute per square meter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Intra-abdominal and pelvic swelling, mass and lump\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-02 08:38:00, ended at 2010-11-02 09:18:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Intra-abdominal and pelvic swelling, mass and lump\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-02 09:19:00, ended at 2010-11-02 12:35:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-02 12:36:00, ended at 2010-11-02 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-03 07:00:00, ended at 2010-11-03 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic radiology treatment planning; complex\n- Special treatment procedure (eg, total body irradiation, hemibody radiation, per oral or endocavitary irradiation)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-09 09:28:00, ended at 2010-11-09 10:01:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 80.8 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 981 (thousand per microliter)\n- Prothrombin time (PT): 19.6 (second)\n- Erythrocyte distribution width [Ratio] by Automated count: 23.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.56 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.8 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.8 (ratio)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.5 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 26.3 (picogram)\n- Hemoglobin [Mass/volume] in Blood: 9.4 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-09 10:02:00, ended at 2010-11-09 10:46:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-09 10:47:00, ended at 2010-11-09 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-11-16 00:00:00, ended at 2010-11-16 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2010-11-16, presumably until 2010-12-02, with quantity of 30.0, with intended 1 refill(s). Instructions: take 1-2 Tabs by mouth every 6 hours as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-23 08:32:00, ended at 2010-11-23 08:46:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 2.4 (ratio)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.9 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 82.1 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 602 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.1 (percent)\n- Prothrombin time (PT): 24.9 (second)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.7 (percent)\n- MCH [Entitic mass] by Automated count: 26.7 (picogram)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.66 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-23 08:47:00, ended at 2010-11-23 11:42:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-23 11:43:00, ended at 2010-11-23 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic radiology simulation-aided field setting; complex\n- Computed tomography guidance for placement of radiation therapy fields\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2010-12-02 00:00:00, ended at 2010-12-02 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2010-12-02, presumably until 2011-05-31, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 6 hours as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-02 07:00:00, ended at 2010-12-02 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-06 07:00:00, ended at 2010-12-06 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, onl\n- Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-07 12:15:00, ended at 2010-12-07 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Acute deep vein thrombosis of lower limb\n- Non-toxic uninodular goiter\n- Altered sensation of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-12-12 00:00:00, ended at 2010-12-12 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute deep vein thrombosis of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-12 13:56:00, ended at 2010-12-12 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic radiology port image(s)\n- Radiation treatment management, 5 treatments\n- Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, presumably until 2013-05-05. Instructions: take by mouth as needed \n- colchicine 0.6 MG Oral Tablet, through Oral route, presumably until 2016-05-15. Instructions: take 0.6 mg by mouth as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-12-13 00:00:00, ended at 2010-12-13 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-13 14:54:00, ended at 2010-12-13 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-14 15:13:00, ended at 2010-12-14 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-12-15 00:00:00, ended at 2010-12-15 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-15 15:01:00, ended at 2010-12-15 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- loperamide hydrochloride 2 MG Oral Tablet, through Oral route, presumably until 2011-06-02. Instructions: take 2 mg by mouth as needed Upt to 8/day \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-16 15:11:00, ended at 2010-12-16 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-19 14:46:00, ended at 2010-12-19 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment management, 5 treatments\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2010-12-19, presumably until 2010-12-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-20 13:37:00, ended at 2010-12-20 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic radiology port image(s)\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-21 09:09:00, ended at 2010-12-21 13:10:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-21 13:11:00, ended at 2010-12-21 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-23 13:03:00, ended at 2010-12-23 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-26 13:41:00, ended at 2010-12-26 14:01:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.32 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 7.7 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.5 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 16.5 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.8 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 96 (unit per liter)\n- Globulin [Mass/volume] in Serum: 5.1 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 90 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.7 (percent)\n- MCV [Entitic volume] by Automated count: 82.5 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 147 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.1 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 389 (thousand per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 51 (milliliter per minute per square meter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.0 (percent)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.9 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.68 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.49 (million per microliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.34 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 57.0 (percent)\n- MCH [Entitic mass] by Automated count: 26.5 (picogram)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-26 14:02:00, ended at 2010-12-26 14:57:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-27 13:57:00, ended at 2010-12-27 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Radiation treatment management, 5 treatments\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-28 08:41:00, ended at 2010-12-28 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-29 13:51:00, ended at 2010-12-29 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-30 14:16:00, ended at 2010-12-30 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-02 15:17:00, ended at 2011-01-02 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-03 14:15:00, ended at 2011-01-03 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic radiology port image(s)\n- Radiation treatment management, 5 treatments\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-04 06:34:00, ended at 2011-01-04 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-05 10:30:00, ended at 2011-01-05 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-09 14:52:00, ended at 2011-01-09 14:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hemoglobin [Mass/volume] in Blood: 11.8 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 26.9 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.4 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.46 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 23.5 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.81 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 262 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.1 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.4 (percent)\n- MCV [Entitic volume] by Automated count: 82.8 (femtoliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 17.6 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 2.6 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.40 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 30.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 1.19 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 45.6 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-09 15:00:00, ended at 2011-01-09 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-10 15:30:00, ended at 2011-01-10 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-11 15:11:00, ended at 2011-01-11 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment management, 5 treatments\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-12 15:06:00, ended at 2011-01-12 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-01-13 00:00:00, ended at 2011-01-13 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute deep vein thrombosis of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-13 11:30:00, ended at 2011-01-13 14:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Phlebitis of deep veins of lower extremity\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-01-13 13:29:17, ended at 2011-01-13 15:13:27\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute deep vein thrombosis of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-13 15:00:00, ended at 2011-01-13 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-16 14:43:00, ended at 2011-01-16 15:16:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.4 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 83.7 (femtoliter)\n- Neutrophils [#/volume] in Blood by Manual count: 2.1 (thousand per microliter)\n- Basophils [#/volume] in Blood by Manual count: 0.1 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.0 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.5 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 274 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Manual count: 3 (percent)\n- Monocytes [#/volume] in Blood by Manual count: 0.5 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.2 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 62 (percent)\n- Eosinophils/100 leukocytes in Blood by Manual count: 1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.69 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.7 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.3 (percent)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 16 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 24.2 (percent)\n- MCH [Entitic mass] by Automated count: 27.1 (picogram)\n- Monocytes/100 leukocytes in Blood by Manual count: 16 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-16 15:17:00, ended at 2011-01-16 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-17 15:03:00, ended at 2011-01-17 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Therapeutic radiology port image(s)\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-18 14:40:00, ended at 2011-01-18 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Radiation treatment management, 5 treatments\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-01-18 15:51:15, ended at 2011-01-18 17:10:45\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Altered sensation of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-19 15:18:00, ended at 2011-01-19 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-23 14:50:00, ended at 2011-01-23 15:25:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Lymphocytes/100 leukocytes in Blood by Automated count: 11.7 (percent)\n- MCH [Entitic mass] by Automated count: 27.2 (picogram)\n- MCV [Entitic volume] by Automated count: 84.2 (femtoliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 2.8 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.33 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 59.1 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.6 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 24.4 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.0 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 26.6 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 1.68 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 297 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.64 (million per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.76 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-23 15:26:00, ended at 2011-01-23 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-24 15:12:00, ended at 2011-01-24 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-25 15:12:00, ended at 2011-01-25 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-26 15:14:00, ended at 2011-01-26 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-02-08 09:40:00, ended at 2011-02-08 10:14:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-02-08 10:15:00, ended at 2011-02-08 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm of soft tissues\n- Acute deep vein thrombosis of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-02-23 09:57:00, ended at 2011-02-23 14:41:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Disorder of adrenal gland\n- Primary malignant neoplasm of soft tissues\n- Disorder of lung\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-02-23 14:42:00, ended at 2011-02-23 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, presumably until 2016-08-16. Instructions: take by mouth as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-02-28 09:54:00, ended at 2011-02-28 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Fine needle aspiration; with imaging guidance\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n- Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation\n\n### Condition\n- Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-03-06 12:54:00, ended at 2011-03-06 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Nerve conduction, amplitude and latency/velocity study, each nerve; motor, with F-wave study\n- Nerve conduction, amplitude and latency/velocity study, each nerve; sensory\n- Needle electromyography; limited study of muscles in 1 extremity or non-limb (axial) muscles (unilateral or bilateral), other than thoracic paraspinal, cranial nerve supplied muscles, or sphincters\n\n### Condition\n- Altered sensation of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-03-09 14:30:00, ended at 2011-03-09 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; lumbar\n\n### Condition\n- Displacement of lumbar intervertebral disc without myelopathy\n- Altered sensation of skin\n- Acquired spondylolisthesis\n- Lumbosacral spondylosis without myelopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-03-09 16:29:00, ended at 2011-03-09 17:13:43\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Altered sensation of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-03-22 00:00:00, ended at 2011-03-22 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2011-03-22, presumably until 2011-04-21, with quantity of 24.0, with intended 6 refill(s). Instructions: take 1 Tab by mouth 2 times a day. Take 2 (two) tabs PO, every 12 hours,  beginning the day before chemotherapy, the day of chemotherapy, and the day after chemotherapy, for a total of 6 doses. \n- prochlorperazine 10 MG Oral Tablet, through Oral route, started on 2011-03-22, presumably until 2012-01-10, with quantity of 30.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed for Nausea/Vomiting. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-03-22 12:15:00, ended at 2011-03-22 12:50:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.8 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.27 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 385 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 24.9 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.0 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 29.5 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.4 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.73 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 89.9 (femtoliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.64 (million per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.6 (percent)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.71 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.3 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-03-22 12:51:00, ended at 2011-03-22 18:57:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Altered sensation of skin\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n- Non-toxic uninodular goiter\n\n### Drug\n- metformin hydrochloride 500 MG Oral Tablet, through Oral route, presumably until 2011-10-17. Instructions: take 1,000 mg by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-03-22 18:58:00, ended at 2011-03-22 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm of soft tissues\n- Altered sensation of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-03-24 08:22:00, ended at 2011-03-24 08:29:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.46 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 11.2 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.5 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 17.6 (percent)\n- Platelets [#/volume] in Blood by Automated count: 401 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.74 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.9 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.63 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 13.9 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.4 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 132 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 30.0 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 2.66 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 58.5 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 10.0 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 143 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 23.8 (percent)\n- MCV [Entitic volume] by Automated count: 90.7 (femtoliter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.80 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-03-24 08:30:00, ended at 2011-03-24 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.008\" (inch (US))\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2011-03-24, presumably until 2011-03-24\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2011-03-24, presumably until 2011-03-24\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2011-03-24, presumably until 2011-04-21, with quantity of 32.0, with intended 0 refill(s). Instructions: take 2 Tabs by mouth. Take 8 mg (2 tabs) 12 hours prior to, morning of and 8 hours after chemotherapy. \n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-03-24, presumably until 2011-03-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-03-29 13:27:00, ended at 2011-03-29 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, lower extremity other than joint; without contrast material(s)\n- Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Altered sensation of skin\n- Edema\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-05 14:22:00, ended at 2011-04-05 14:29:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 92.0 (femtoliter)\n- Neutrophils [#/volume] in Blood by Manual count: 9.3 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 51 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.4 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 69 (percent)\n- Platelets [#/volume] in Blood by Automated count: 321 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.6 (percent)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.4 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 4 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.7 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.11 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 224 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.7 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 152 (unit per liter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 56 (milliliter per minute per square meter)\n- MCH [Entitic mass] by Automated count: 30.3 (picogram)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-05 14:30:00, ended at 2011-04-05 15:23:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-05 15:24:00, ended at 2011-04-05 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2011-04-05, presumably until 2011-04-05\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2011-04-05, presumably until 2011-04-05\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2011-04-05, presumably until 2011-04-05\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-04-05, presumably until 2011-04-05\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2011-04-05, presumably until 2011-04-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-17 12:10:00, ended at 2011-04-17 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of extremity veins including responses to compression and other maneuvers; unilateral or limited study\n\n### Condition\n- Anemia in neoplastic disease\n- Disorder of coccyx\n- Imaging of musculoskeletal system abnormal\n- Altered sensation of skin\n- Lumbosacral spondylosis without myelopathy\n- Displacement of lumbar intervertebral disc without myelopathy\n- Edema\n- Degeneration of intervertebral disc\n- Primary malignant neoplasm of retroperitoneum\n- Swelling of limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-04-17 15:08:00, ended at 2011-04-17 17:31:48\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Toxic polyneuropathy\n- Altered sensation of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-19 12:00:00, ended at 2011-04-19 12:21:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Collection of venous blood by venipuncture\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug provided in a facility (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2011-04-19, presumably until 2011-04-19\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2011-04-19, presumably until 2011-04-19\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-04-19, presumably until 2011-04-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-19 12:22:00, ended at 2011-04-19 12:57:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 51 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 185 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.8 (percent)\n- Monocytes/100 leukocytes in Blood by Manual count: 2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 483 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.7 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 31.3 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 16.1 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: >1000 (picogram per milliliter)\n- MCV [Entitic volume] by Automated count: 93.8 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.11 (million per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 56 (milliliter per minute per square meter)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Manual count: 15.8 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 75 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 368 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.3 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.88 (micro-international unit per milliliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.2 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Toxic polyneuropathy\n- Altered sensation of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-19 12:58:00, ended at 2011-04-19 14:29:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Toxic polyneuropathy\n- Acute deep vein thrombosis of lower limb\n- Altered sensation of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-19 14:30:00, ended at 2011-04-19 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Altered sensation of skin\n- Non-toxic uninodular goiter\n- Acute deep vein thrombosis of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-20 14:44:00, ended at 2011-04-20 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-04-20, presumably until 2011-04-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2011-04-21 00:00:00, ended at 2011-04-21 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2011-04-21, presumably until 2011-06-02, with quantity of 30.0, with intended 0 refill(s). Instructions: take 2 Tabs by mouth 2 times a day. On Day 1-3 of chemotherpy cycle (total of six doses) \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-04-26 00:00:00, ended at 2011-04-26 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-26 09:30:00, ended at 2011-04-26 13:21:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of extremity veins including responses to compression and other maneuvers; unilateral or limited study\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Phlebitis of deep veins of lower extremity\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-04-26 11:03:52, ended at 2011-04-26 12:14:24\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute deep vein thrombosis of lower limb\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, presumably until 2012-01-10. Instructions: take 0.5 mg by mouth every 4 hours as needed \n- ranitidine 150 MG Oral Tablet, through Oral route, presumably until 2011-06-30. Instructions: take 150 mg by mouth 2 times a day. \n- sucralfate 1000 MG Oral Tablet, through Oral route, presumably until 2011-07-01. Instructions: take by mouth 4 times a day. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-26 13:22:00, ended at 2011-04-26 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 56 (milliliter per minute per square meter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.8 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.3 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.04 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 302 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.86 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.2 (picogram)\n- MCV [Entitic volume] by Automated count: 90.2 (femtoliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 223 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 21.1 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.6 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- Neutrophils/100 leukocytes in Blood by Automated count: 93.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 22.78 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 68 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 118 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.1 (percent)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Prothrombin time (PT): 12.8 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 24.4 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-05-01 00:00:00, ended at 2011-05-01 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acquired spondylolisthesis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-02 07:02:00, ended at 2011-05-02 12:30:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- Fluoroscopic guidance for central venous access device placement, replacement (catheter only or complete), or removal (includes fluoroscopic guidance for vascular access and catheter manipulation, any necessary contrast injections through access site or c\n- Insertion of tunneled centrally inserted central venous access device, with subcutaneous port; age 5 years or older\n- Insertion of graft for vascular access\n\n### Condition\n- Malignant neoplastic disease\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2011-05-02, presumably until 2011-05-02\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-05-03 00:00:00, ended at 2011-05-03 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-03 10:20:00, ended at 2011-05-03 10:24:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2011-05-03, presumably until 2011-05-03\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2011-05-03, presumably until 2011-05-03\n- 2 ML ondansetron 2 MG/ML Injection, started on 2011-05-03, presumably until 2011-05-03\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-05-03, presumably until 2011-05-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-03 10:25:00, ended at 2011-05-03 10:48:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.2 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Manual count: 19.5 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.25 (million per microliter)\n- MCV [Entitic volume] by Automated count: 92.1 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 19.7 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 141 (unit per liter)\n- MCH [Entitic mass] by Automated count: 30.0 (picogram)\n- Neutrophils/100 leukocytes in Blood by Manual count: 70 (percent)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.9 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 232 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.6 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Manual count: 1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 535 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 56 (milliliter per minute per square meter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.9 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-03 10:49:00, ended at 2011-05-03 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Altered sensation of skin\n- Acute deep vein thrombosis of lower limb\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, through Topical route, started on 2011-05-03, presumably until 2011-06-02, with intended 3 refill(s). Instructions: 0.5 Inches by Topical route as needed Apply 60 minutes prior to port being accessed. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-04 13:10:00, ended at 2011-05-04 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-05-04, presumably until 2011-05-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-05-17 00:00:00, ended at 2011-05-17 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-05-17 00:00:00, ended at 2011-05-17 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Venous thrombosis\n\n### Drug\n- 1 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-05-17, presumably until 2011-05-28, with intended 2 refill(s). Instructions: inject 1 mL subcutaneous (under the skin) every 12 hours.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-17 07:39:00, ended at 2011-05-17 13:06:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Lymphadenopathy\n- Primary malignant neoplasm of soft tissues\n- Disorder of lung\n- Pleural effusion\n- Ascites\n- Embolism and thrombosis of the vena cava\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-17 13:07:00, ended at 2011-05-17 13:19:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 213 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 17.5 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 92.8 (femtoliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.2 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Manual count: 16.9 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 507 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.4 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 23.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 7.7 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 24.0 (percent)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.3 (picogram)\n- Monocytes/100 leukocytes in Blood by Manual count: 1 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.6 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.53 (million per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 138 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 2 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.0 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 71 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-17 13:20:00, ended at 2011-05-17 13:48:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Transfusion, blood or blood components\n\n### Condition\n- Altered sensation of skin\n- Primary malignant neoplasm of soft tissues\n- Acute deep vein thrombosis of lower limb\n- Venous thrombosis\n- Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-17 13:49:00, ended at 2011-05-17 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.008\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Altered sensation of skin\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- levothyroxine sodium 0.112 MG Oral Tablet, through Oral route, presumably until 2012-11-12. Instructions: take  by mouth.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-05-18 10:34:52, ended at 2011-05-18 15:52:30\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acquired spondylolisthesis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-18 13:22:00, ended at 2011-05-18 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Iron saturation [Mass Fraction] in Serum or Plasma: 8 (percent)\n- Iron [Mass/volume] in Serum or Plasma: 27 (microgram per deciliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 56 (nanogram per milliliter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 351 (microgram per deciliter)\n\n### Procedure\n- Transfusion, blood or blood components\n\n### Condition\n- Non-toxic uninodular goiter\n- Altered sensation of skin\n- Primary malignant neoplasm of soft tissues\n- Acute deep vein thrombosis of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-19 11:24:00, ended at 2011-05-19 15:45:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- Removal of foreign body from skin and/or subcutaneous tissue by incision\n- Removal of tunneled central venous access device, with subcutaneous port or pump, central or peripheral insertion\n\n### Condition\n- Embolism and thrombosis of the vena cava\n- Primary malignant neoplasm of retroperitoneum\n- Thrombosis of vein of trunk\n\n### Drug\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2011-05-19, presumably until 2011-05-19\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2011-05-19, presumably until 2011-05-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-24 11:04:00, ended at 2011-05-24 11:39:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 49 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 153 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.9 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.49 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.54 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 94.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 51 (milliliter per minute per square meter)\n- MCV [Entitic volume] by Automated count: 92.9 (femtoliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.4 (picogram)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 110 (unit per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 13.43 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 14.3 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 615 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.4 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.6 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 3.8 (percent)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 1.9 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Venous thrombosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-24 11:40:00, ended at 2011-05-24 12:56:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-24 12:57:00, ended at 2011-05-24 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.008\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2011-05-28 19:36:00, ended at 2011-06-02 15:15:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 106 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 18 (percent)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 3.09 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Manual count: 15 (percent)\n- Neutrophils/100 leukocytes in Blood by Manual count: 50 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- INR in Platelet poor plasma by Coagulation assay: 1.5 (ratio)\n- Prothrombin time (PT): 17.3 (second)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.56 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.4 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 19.1 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Manual count: 6 (percent)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.6 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.5 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Manual count: 5.2 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.9 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 13.26 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.7 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.8 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.11 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.7 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 40.2 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.47 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 12 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 1.5 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.7 (picogram)\n- MCV [Entitic volume] by Automated count: 93.8 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 5.9 (gram per deciliter)\n- Body height: 5' 6.142\" (inch (US))\n- Eosinophils [#/volume] in Blood by Manual count: 0.5 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Manual count: 1.3 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 80.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 628 (thousand per microliter)\n\n### Procedure\n- Continuous positive airway pressure ventilation (CPAP), initiation and management\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Physical therapy evaluation\n- Molecular diagnostics; interpretation and report\n- Molecular diagnostics; nucleic acid probe, each\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Molecular diagnostics; amplification, target, each nucleic acid sequence\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Computed tomographic angiography, head, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Duplex scan of extremity veins including responses to compression and other maneuvers; unilateral or limited study\n- Molecular diagnostics; isolation or extraction of highly purified nucleic acid, each nucleic acid type (ie, DNA or RNA)\n- Collection of venous blood by venipuncture\n- Computed tomographic angiography, chest (noncoronary), with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Computed tomographic angiography, neck, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n\n### Condition\n- Pain in limb\n- Thrombosis of vein of trunk\n- Acute thrombosis of subclavian vein\n- Arthropathy of knee joint\n- Localized osteoarthrosis uncertain if primary OR secondary\n- Altered sensation of skin\n- Coag./bleeding tests abnormal\n- Lymphadenopathy\n- Acquired absence of organ\n- Acquired hypothyroidism\n- Gout\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm of soft tissues\n- Disorder of gallbladder\n- Obesity\n- Obstructive sleep apnea syndrome\n- Pulmonary embolism with pulmonary infarction\n- Acute deep vein thrombosis of lower limb\n- Acute deep venous thrombosis of internal jugular vein\n- Disorder of lung\n- Embolism and thrombosis of the vena cava\n- Inflammatory disorder of digestive tract\n- Pleural effusion\n- Primary malignant neoplasm of retroperitoneum\n- Essential hypertension\n- Lung field abnormal\n- Type 2 diabetes mellitus without complication\n- Venous thrombosis\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2011-05-29, presumably until 2011-06-02\n- 1 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-05-29, presumably until 2011-06-02\n- warfarin sodium 5 MG Oral Tablet, through Oral route, presumably until 2011-06-02. Instructions: take 5 mg by mouth daily.\n- levothyroxine sodium 0.112 MG Oral Tablet, through Oral route, started on 2011-05-29, presumably until 2011-06-02\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2011-05-29, presumably until 2011-06-02\n- hydromorphone hydrochloride 4 MG Oral Tablet, through Oral route, started on 2011-05-31, presumably until 2011-11-29, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed.\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2011-05-31, presumably until 2011-06-09, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours.\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2011-05-30, presumably until 2011-10-17, with intended 2 refill(s). Instructions: take 1 Cap by mouth 2 times a day as needed for Constipation.\n- sucralfate 1000 MG Oral Tablet, through Oral route, started on 2011-05-29, presumably until 2011-05-30\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2011-05-30, presumably until 2011-05-30\n- colchicine 0.6 MG Oral Tablet, through Oral route, started on 2011-05-29, presumably until 2011-06-02\n- insulin aspart, human 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2011-05-30, presumably until 2011-06-02\n- 1 ML enoxaparin sodium 150 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-05-29, presumably until 2011-09-13, with intended 6 refill(s). Instructions: inject 1 mL subcutaneous (under the skin) Every Day.\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2011-05-29, presumably until 2011-06-02\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2011-05-30, presumably until 2011-05-31\n- 2 ML ondansetron 2 MG/ML Injection, started on 2011-05-28, presumably until 2011-05-30\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-05-29, presumably until 2011-06-02\n- prochlorperazine 5 MG Oral Tablet, through Oral route, started on 2011-05-30, presumably until 2011-05-30\n- sucralfate 100 MG/ML Oral Suspension, through Oral route, started on 2011-05-30, presumably until 2011-06-02\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2011-05-30, presumably until 2011-06-01\n- 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2011-05-30, presumably until 2011-05-30\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2011-05-30, presumably until 2011-05-30\n- simethicone 80 MG Chewable Tablet, through Oral route, started on 2011-05-29, presumably until 2011-06-02\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2011-05-28, presumably until 2011-05-30\n- 1 ML morphine sulfate 4 MG/ML Prefilled Syringe, started on 2011-05-28, presumably until 2011-05-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-05-31 00:00:00, ended at 2011-05-31 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Venous thrombosis\n- Pulmonary embolism with pulmonary infarction\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-06-07 00:00:00, ended at 2011-06-07 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary embolism with pulmonary infarction\n- Acute deep vein thrombosis of lower limb\n- Anemia\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-06-07 09:04:00, ended at 2011-06-07 09:48:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.3 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 6.3 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 1.19 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.3 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 130 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 8.1 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.2 (femtoliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 100 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.76 (million per microliter)\n- MCH [Entitic mass] by Automated count: 29.5 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 892 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 24.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.82 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 83.6 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 13.1 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 10.93 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.1 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-06-07 09:49:00, ended at 2011-06-07 10:29:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Non-toxic uninodular goiter\n- Altered sensation of skin\n- Pulmonary embolism with pulmonary infarction\n- Acute deep vein thrombosis of lower limb\n- Venous thrombosis\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-06-07 10:30:00, ended at 2011-06-07 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Transfusion, blood or blood components\n\n### Condition\n- Pulmonary embolism with pulmonary infarction\n- Primary malignant neoplasm of retroperitoneum\n- Anemia\n- Primary malignant neoplasm of soft tissues\n- Acute deep vein thrombosis of lower limb\n\n### Drug\n- 1 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-06-07, presumably until 2011-06-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-06-09 00:00:00, ended at 2011-06-09 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2011-06-07, presumably until 2011-07-01, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours. Note:  Rx was written by HSmith on 99999999.  Rx#0204.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-06-15 08:45:00, ended at 2011-06-15 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.157\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Pulmonary embolism with pulmonary infarction\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-06-21 07:46:00, ended at 2011-06-21 09:06:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.7 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 87 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.8 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.0 (percent)\n- MCHC [Mass/volume] by Automated count: 31.2 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.52 (million per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 56 (milliliter per minute per square meter)\n- MCV [Entitic volume] by Automated count: 90.3 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.98 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.3 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 120 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.26 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.2 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 8.01 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 76.2 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.23 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.5 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 824 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Primary malignant neoplasm of soft tissues\n- Pulmonary embolism with pulmonary infarction\n- Anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-06-21 09:07:00, ended at 2011-06-21 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.008\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2011-06-30 02:52:00, ended at 2011-07-01 13:30:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.5 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.97 (million per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.6 (percent)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood: 32 (percent)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 6.3 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.2 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.2 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 86.5 (femtoliter)\n- Hemoglobin [Mass/volume] in Blood: 8.3 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 669 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 25.6 (percent)\n- Hemoglobin [Mass/volume] in Blood by calculation: 10.9 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.1 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 1.07 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.88 (thousand per microliter)\n- Sodium [Moles/volume] in Blood: 136 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.0 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 83.8 (percent)\n- Potassium [Moles/volume] in Blood: 4.9 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.74 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug provided in a facility (List separately in addition to code for primary procedure)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Intestinal obstruction\n- Type 2 diabetes mellitus without complication\n- Obstructive sleep apnea syndrome\n- Primary malignant neoplasm of soft tissues\n- Abdominal pain\n- Ascites\n- Lymphadenopathy\n- Gout\n- Nausea and vomiting\n- Acquired hypothyroidism\n- Constipation\n- Epigastric pain\n- Pleural effusion\n- Paralytic ileus\n\n### Drug\n- levothyroxine sodium 0.112 MG Oral Tablet, through Oral route, started on 2011-06-30, presumably until 2011-07-01\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2011-06-30, presumably until 2011-07-01\n- hydromorphone hydrochloride 4 MG Oral Tablet, through Oral route, started on 2011-06-30, presumably until 2011-07-01\n- prochlorperazine 5 MG/ML Injectable Solution, started on 2011-06-30, presumably until 2011-06-30\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2011-06-30, presumably until 2011-10-27, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours. Note:  Rx was written by HSmith on 99999999.  Rx#0204.\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2011-06-30, presumably until 2011-07-01\n- 1 ML enoxaparin sodium 150 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-06-30, presumably until 2011-06-30\n- 2 ML ondansetron 2 MG/ML Injection, started on 2011-06-30, presumably until 2011-07-01\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2011-06-30, presumably until 2011-06-30\n- 1 ML hydromorphone hydrochloride 2 MG/ML Prefilled Syringe, started on 2011-06-30, presumably until 2011-06-30\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-06-30, presumably until 2011-07-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-07-12 00:00:00, ended at 2011-07-12 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-07-12 07:42:00, ended at 2011-07-12 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Intestinal obstruction\n- Imaging of abdomen abnormal\n- Primary malignant neoplasm of soft tissues\n- Disorder of lung\n- Ascites\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-07-17 11:27:00, ended at 2011-07-17 12:58:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.46 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.6 (percent)\n- Platelets [#/volume] in Blood by Automated count: 751 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.1 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 42 (milliliter per minute per square meter)\n- Glucose [Mass/volume] in Serum or Plasma: 108 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Amylase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Ferritin [Mass/volume] in Serum or Plasma: 8 (nanogram per milliliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.9 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.6 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.1 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.68 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 31.5 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.70 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 78.3 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.3 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.54 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 84 (unit per liter)\n- MCV [Entitic volume] by Automated count: 85.5 (femtoliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.0 (percent)\n- MCH [Entitic mass] by Automated count: 27.0 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-07-17 12:59:00, ended at 2011-07-17 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2011-08-02 13:53:00, ended at 2011-08-04 17:46:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 88 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.6 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Manual count: 5.1 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 34.0 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.9 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 18 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.1 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 1.0 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 82 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.79 (million per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Manual count: 1 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.4 (percent)\n- MCH [Entitic mass] by Automated count: 26.7 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.0 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 649 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.2 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.4 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 84.2 (femtoliter)\n- Base excess in Blood by calculation: 2.0 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Body height: 5' 7.008\" (inch (US))\n- Eosinophils/100 leukocytes in Blood by Manual count: 4 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.9 (percent)\n- Neutrophils/100 leukocytes in Blood by Manual count: 69 (percent)\n- Prothrombin time (PT): 18.2 (second)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Manual count: 0.1 (thousand per microliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.6 (ratio)\n- Monocytes/100 leukocytes in Blood by Manual count: 8 (percent)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Radiologic examination, abdomen; complete, including decubitus and/or erect views\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Vomiting\n- Acquired hypothyroidism\n- Acute deep venous thrombosis of internal jugular vein\n- Anuria\n- Dehydration\n- Inflammatory disorder of digestive tract\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm of soft tissues\n- Pulmonary embolism with pulmonary infarction\n- Obstructive sleep apnea syndrome\n- Venous thrombosis\n- Acute pyelonephritis without medullary necrosis\n- Imaging of abdomen abnormal\n- Pyelonephritis\n- Type 2 diabetes mellitus without complication\n- Nausea and vomiting\n- Acute deep vein thrombosis of lower limb\n- Gastric ulcer without hemorrhage, without perforation AND without obstruction\n- Hyperlipidemia\n- Altered sensation of skin\n- Disorder of kidney and/or ureter\n- Sepsis due to Streptococcus group D\n\n### Drug\n- levothyroxine sodium 0.112 MG Oral Tablet, through Oral route, started on 2011-08-03, presumably until 2011-08-04\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2011-08-03, presumably until 2011-08-03\n- sodium phosphate, dibasic 59.3 MG/ML / sodium phosphate, monobasic 161 MG/ML Enema, through Rectal route, started on 2011-08-03, presumably until 2011-08-03\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2011-08-03, presumably until 2011-08-04. Instructions: take by mouth daily.\n- metformin hydrochloride 500 MG Oral Tablet, through Oral route, started on 2011-08-03, presumably until 2011-08-03\n- magnesium citrate 58.2 MG/ML Oral Solution, through Oral route, started on 2011-08-03, presumably until 2011-08-03\n- ceftriaxone 1000 MG Injection, through Intravenous route, started on 2011-08-03, presumably until 2011-08-03\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2011-08-02, presumably until 2011-08-02\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2011-08-03, presumably until 2011-08-04\n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2011-08-03, presumably until 2011-08-03. Instructions: take 20 mg by mouth every bedtime. \n- prochlorperazine 5 MG/ML Injectable Solution, started on 2011-08-04, presumably until 2011-08-04\n- warfarin sodium 7.5 MG Oral Tablet, through Oral route, started on 2011-08-02, presumably until 2012-01-10. Instructions: take 7.5 mg by mouth. Tuesday, Thursday, Friday, Sunday\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2011-08-04, presumably until 2011-09-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n- colchicine 0.6 MG Oral Tablet, through Oral route, started on 2011-08-03, presumably until 2011-08-04. Instructions: take 0.6 mg by mouth daily. \n- 1 ML enoxaparin sodium 150 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-08-03, presumably until 2011-08-04\n- 2 ML ondansetron 2 MG/ML Injection, started on 2011-08-02, presumably until 2011-08-04\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2011-08-02, presumably until 2011-08-03\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-08-02, presumably until 2011-08-04\n- metoclopramide 10 MG Oral Tablet, through Oral route, started on 2011-08-04, presumably until 2011-10-17, with intended 1 refill(s). Instructions: take 1 Tab by mouth 3 times a day before meals.\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2011-08-02, presumably until 2011-08-02\n- 1 ML promethazine hydrochloride 25 MG/ML Injection, started on 2011-08-03, presumably until 2011-08-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-08-14 00:00:00, ended at 2011-08-14 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Pyelonephritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-08-14 09:26:00, ended at 2011-08-14 10:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.5 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.5 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.1 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.7 (thousand per microliter)\n- Amylase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.41 (million per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 26.8 (picogram)\n- MCV [Entitic volume] by Automated count: 83.6 (femtoliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 73 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.25 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.8 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.0 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 129 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.59 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 617 (thousand per microliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 51 (milliliter per minute per square meter)\n- Monocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 68.9 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-08-14 10:01:00, ended at 2011-08-14 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Venous thrombosis\n- Non-toxic uninodular goiter\n- Pulmonary embolism with pulmonary infarction\n- Pyelonephritis\n- Acute deep vein thrombosis of lower limb\n- Altered sensation of skin\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-08-17 14:42:00, ended at 2011-08-17 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-09-13 00:00:00, ended at 2011-09-13 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-09-13 12:17:00, ended at 2011-09-13 13:14:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocytes [#/volume] in Blood by Automated count: 4.57 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.69 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 114 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 81.3 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.83 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 73.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 10.1 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 446 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 107 (unit per liter)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.6 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 45 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.2 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 3.4 (ratio)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.60 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.4 (percent)\n- Prothrombin time (PT): 33.1 (second)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.8 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 13.2 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.2 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 27.7 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 8.4 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 38 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Primary malignant neoplasm of soft tissues\n- Pyelonephritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-09-13 13:15:00, ended at 2011-09-13 14:41:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-09-13 14:42:00, ended at 2011-09-13 17:48:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-09-13 17:49:00, ended at 2011-10-17 16:20:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 91 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.8 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.89 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 24.2 (percent)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 14 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 96 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 68 (milligram per deciliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 92 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.7 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 7.4 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.06 (micro-international unit per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 66 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.34 (millimole per liter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 38 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.3 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.5 (percent)\n- MCV [Entitic volume] by Automated count: 90.2 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.69 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 76.8 (percent)\n- aPTT in Platelet poor plasma by Coagulation assay: N/A (second)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 30 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.1 (picogram)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.2 (thousand per microliter)\n- INR in Platelet poor plasma by Coagulation assay: N/A (ratio)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Prothrombin time (PT): 33.6 (second)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 22 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 1.5 (thousand per microliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 14 (nanogram per milliliter)\n- Body height: 5' 7\" (inch (US))\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 266 (picogram per milliliter)\n- Eosinophils/100 leukocytes in Blood by Manual count: 2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 24.8 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.4 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Manual count: 19 (percent)\n- Neutrophils [#/volume] in Blood by Manual count: 8.9 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 72 (percent)\n- Triglyceride [Moles/volume] in Serum or Plasma: 56 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 96 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.7 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 7.26 (thousand per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 6.2 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 42 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.07 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 6 (percent)\n- Platelets [#/volume] in Blood by Automated count: 949 (thousand per microliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n\n### Procedure\n- Radiologic examination, gastrointestinal tract, upper; with or without delayed images, with KUB\n- Other lysis of peritoneal adhesions\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Physical therapy evaluation\n- Insertion of other (naso-)gastric tube\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Continuous positive airway pressure ventilation (CPAP), initiation and management\n- Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, without imaging guidance; age 5 years or older\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Dilation of esophagus, over guide wire\n- Collection of venous blood by venipuncture\n- Drainage of peritoneal abscess or localized peritonitis, exclusive of appendiceal abscess; percutaneous\n- Other endoscopy of small intestine\n- Radiologic examination, gastrointestinal tract, upper; with small intestine, includes multiple serial images\n- Packed blood cell transfusion\n- Radiologic examination, esophagus, including scout chest radiograph(s) and delayed image(s), when performed; single-contrast (eg, barium) study\n- Computed tomography, abdomen and pelvis; without contrast material\n- Total parenteral nutrition\n- Other cardiovascular stress test\n- Noninvasive ventilation\n- Abdominal paracentesis\n- Dilation of intestine\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Radiologic examination, chest; single view, frontal\n- Transfusion of other serum\n- Injection or infusion of oxazolidinone class of antibiotics\n- Computed tomography, thorax, diagnostic; without contrast material\n- Radiologic examination, abdomen; single anteroposterior view\n- Venous catheterization, not elsewhere classified\n- Anastomosis of small intestine to small intestine\n- Radiological guidance (ie, fluoroscopy, ultrasound, or computed tomography), for percutaneous drainage (eg, abscess, specimen collection), with placement of catheter, radiological supervision and interpretation\n\n### Condition\n- Acute deep venous thrombosis of internal jugular vein\n- Breathing painful\n- Dehydration\n- Loss of appetite\n- Obstruction of bile duct\n- Constipation\n- Essential hypertension\n- Abscess of peritoneum\n- Acquired hypothyroidism\n- Acute deep vein thrombosis of lower limb\n- Acute deep venous thrombosis of axillary vein\n- Altered sensation of skin\n- Ascites\n- Hypokalemia\n- Lung field abnormal\n- Nausea and vomiting\n- Non-toxic uninodular goiter\n- Paralytic ileus\n- Pleural effusion\n- Pulmonary embolism with pulmonary infarction\n- Radiation-induced disorder\n- Urinary tract infectious disease\n- Imaging of abdomen abnormal\n- Late effect of complications of procedure\n- Sepsis due to Streptococcus group D\n- Acute renal failure syndrome\n- Anemia\n- Gout\n- Intestinal volvulus\n- Old myocardial infarction\n- Acquired absence of organ\n- Acquired hypertrophic pyloric stenosis\n- Coag./bleeding tests abnormal\n- Diaphragmatic hernia\n- Disorder of lung\n- Inflammatory disorder of digestive tract\n- Intestinal obstruction\n- Ischemic heart disease\n- Venous thrombosis\n- Acute deep venous thrombosis of upper extremity\n- Late effect of radiation\n- Obstructive sleep apnea syndrome\n- Chronic deep venous thrombosis of internal jugular vein\n- Coronary arteriosclerosis\n- Peritoneal adhesions with obstruction\n- Type 2 diabetes mellitus without complication\n- Disorder due to infection\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- benzocaine 15 MG / menthol 3.6 MG Oral Lozenge, through Submucosal route, started on 2011-09-21, presumably until 2011-09-21\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2011-09-17, presumably until 2011-09-27\n- 50 ML sodium bicarbonate 84 MG/ML Injection, through Intravenous route, started on 2011-09-16, presumably until 2011-09-16\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2011-09-14, presumably until 2011-09-14\n- warfarin sodium 10 MG Oral Tablet, through Oral route, presumably until 2012-01-10. Instructions: take 10 mg by mouth. Monday, Wednesday, Saturday\n- levothyroxine sodium 0.112 MG Oral Tablet, through Oral route, started on 2011-09-13, presumably until 2011-09-19. Instructions: take  by mouth.\n- levothyroxine sodium 0.2 MG Injection, through Intravenous route, started on 2011-09-20, presumably until 2011-09-22\n- menthol, through Submucosal route, started on 2011-09-29, presumably until 2011-09-29\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2011-09-14, presumably until 2011-09-14. Instructions: take 0.5 mg by mouth every 4 hours as needed\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2011-09-17, presumably until 2011-09-19\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2011-09-13, presumably until 2011-10-17. Instructions: take by mouth daily.\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2011-09-14, presumably until 2011-10-15\n- warfarin sodium 3 MG Oral Tablet, through Oral route, started on 2011-09-15, presumably until 2011-09-15\n- levothyroxine sodium 0.5 MG Injection, through Intravenous route, started on 2011-09-20, presumably until 2011-09-26\n- benzocaine 140 MG/ML / butamben 20 MG/ML / tetracaine 20 MG/ML Mucosal Spray, through Topical route, started on 2011-09-20, presumably until 2011-09-25\n- lidocaine 40 MG/ML Topical Cream, through Topical route, started on 2011-09-16, presumably until 2011-09-16\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2011-09-15, presumably until 2011-10-04\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2011-09-19, presumably until 2011-09-24\n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2011-09-15, presumably until 2011-09-21. Instructions: take 20 mg by mouth every bedtime.\n- diatrizoate, through Oral route, started on 2011-10-06, presumably until 2011-10-13\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2011-10-05, presumably until 2011-10-17\n- cetylpyridinium, through Submucosal route, started on 2011-09-29, presumably until 2011-09-29\n- 5 ML metoprolol tartrate 1 MG/ML Injection, through Intravenous route, started on 2011-09-27, presumably until 2011-10-05\n- loperamide hydrochloride 2 MG Oral Tablet, through Oral route, started on 2011-10-17, presumably until 2011-10-27, with intended 0 refill(s). Instructions: take 2 mg by mouth as needed for Diarrhea (take 1 tab after each loose bowel movement/diarrhea. ).\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2011-09-13, presumably until 2011-09-19. Instructions: take 1 Cap by mouth 2 times a day as needed for Constipation.\n- linezolid 600 MG Oral Tablet, through Oral route, started on 2011-10-13, presumably until 2011-10-27, with intended 0 refill(s). Instructions: take 1 Tab by mouth Q12H.\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2011-10-05, presumably until 2012-01-10, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n- diatrizoic acid, through Oral route, started on 2011-10-06, presumably until 2011-10-13\n- colchicine 0.6 MG Oral Tablet, through Oral route, started on 2011-09-13, presumably until 2011-10-17. Instructions: take 0.6 mg by mouth daily.\n- soybean oil 200 MG/ML Injectable Suspension, through Intravenous route, started on 2011-09-17, presumably until 2011-10-11\n- insulin aspart, human 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2011-09-17, presumably until 2011-10-14\n- 0.8 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-10-02, presumably until 2011-11-01, with intended 0 refill(s). Instructions: inject 0.8 mL subcutaneous (under the skin) Q12H.\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2011-10-04, presumably until 2011-10-17\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2011-10-06, presumably until 2011-10-10\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2011-10-05, presumably until 2012-01-10, with intended 3 refill(s). Instructions: take 1 Tab by mouth every morning with breakfast.\n- 50 ML glucose 500 MG/ML Prefilled Syringe, through Intravenous route, started on 2011-09-13, presumably until 2011-09-13\n- 2 ML ondansetron 2 MG/ML Injection, started on 2011-09-13, presumably until 2011-10-17\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-09-13, presumably until 2011-10-04\n- metoclopramide 10 MG Oral Tablet, through Oral route, started on 2011-09-14, presumably until 2011-09-15\n- lidocaine 0.05 MG/MG Medicated Patch, through Topical route, started on 2011-10-03, presumably until 2011-10-16\n- 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2011-10-04, presumably until 2011-10-05\n- aspirin 300 MG Rectal Suppository, through Rectal route, started on 2011-09-20, presumably until 2011-10-04\n- nitroglycerin 0.4 MG Sublingual Tablet, through Sublingual route, started on 2011-09-18, presumably until 2011-09-18\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2011-09-19, presumably until 2011-09-19\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2011-09-30, presumably until 2011-10-05\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2011-09-18, presumably until 2011-10-16\n- metformin hydrochloride 850 MG Oral Tablet, through Oral route, presumably until 2011-10-17. Instructions: take 850 mg by mouth Evening.\n- lidocaine hydrochloride 20 MG/ML Injectable Solution, started on 2011-09-16, presumably until 2011-09-16\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2011-09-18, presumably until 2011-10-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-09-21 15:41:46, ended at 2011-09-21 17:18:52\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; supervision only, without interpretation and report\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; interpretation and report only\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation \n\n### Condition\n- Coronary arteriosclerosis\n- Electrocardiogram abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2011-10-20 04:30:00, ended at 2011-10-27 12:15:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Manual count: 0.3 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.96 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 20 (percent)\n- MCH [Entitic mass] by Automated count: 29.6 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 8.8 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Manual count: 3.0 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 56 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 26.3 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- Albumin [Mass/volume] in Serum or Plasma: 2.3 (gram per deciliter)\n- Body height: 5' 7\" (inch (US))\n- Magnesium [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 849 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 5.1 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.9 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Manual count: 5 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 21.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 90.1 (femtoliter)\n- Prothrombin time (PT): 14.3 (second)\n- aPTT in Platelet poor plasma by Coagulation assay: 30.5 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Manual count: 3 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 94 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Manual count: 16 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 96 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.2 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.39 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Manual count: 1.1 (thousand per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.8 (milligram per deciliter)\n\n### Procedure\n- Radiologic examination, abdomen; complete, including decubitus and/or erect views\n- Collection of venous blood by venipuncture\n- Radiologic examination, abdomen; single anteroposterior view\n\n### Condition\n- Acute deep venous thrombosis of internal jugular vein\n- Intestinal obstruction\n- Obstructive sleep apnea syndrome\n- Acquired hypothyroidism\n- Nausea and vomiting\n- Venous thrombosis\n- Constipation\n- Old myocardial infarction\n- Abdominal pain\n- Altered sensation of skin\n- Essential hypertension\n- Inflammatory disorder of digestive tract\n- Non-toxic uninodular goiter\n- Acute deep vein thrombosis of lower limb\n- Anemia\n- Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm of soft tissues of abdomen\n- Pulmonary embolism with pulmonary infarction\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2011-10-20, presumably until 2011-10-23\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2011-10-20, presumably until 2012-01-10, with intended 1 refill(s). Instructions: insert 1 Suppository into the rectum daily as needed (give as needed).\n- levothyroxine sodium 0.112 MG Oral Tablet, through Oral route, started on 2011-10-23, presumably until 2011-10-27\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2011-10-20, presumably until 2011-10-27\n- hydromorphone hydrochloride 4 MG Oral Tablet, through Oral route, started on 2011-10-26, presumably until 2012-04-24, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed for Pain.\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2011-10-20, presumably until 2012-04-24, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours.\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2011-10-27, presumably until 2012-01-10, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily.\n- linezolid 600 MG Oral Tablet, through Oral route, started on 2011-10-20, presumably until 2011-10-24\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2011-10-26, presumably until 2012-01-10, with intended 0 refill(s). Instructions: take 2 Tabs by mouth 2 times a day.\n- colchicine 0.6 MG Oral Tablet, through Oral route, started on 2011-10-22, presumably until 2011-10-27\n- 0.8 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-10-20, presumably until 2011-10-27\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2011-10-22, presumably until 2011-10-26\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2011-10-20, presumably until 2011-10-26\n- lactulose 667 MG/ML Oral Solution, through Oral route, started on 2011-10-24, presumably until 2011-10-25\n- 2 ML ondansetron 2 MG/ML Injection, started on 2011-10-21, presumably until 2011-10-26\n- water 1000 MG/ML Irrigation Solution, through Topical route, started on 2011-10-24, presumably until 2011-10-24\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2011-10-20, presumably until 2011-10-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2011-11-01 00:00:00, ended at 2011-11-01 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.8 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-11-01, presumably until 2011-12-11, with intended 0 refill(s). Instructions: inject 0.8 mL subcutaneous (under the skin) Q12H.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-11-06 10:10:00, ended at 2011-11-06 10:47:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Manual count: 2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 599 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.6 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.89 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 105 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 8 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.3 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.5 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 56 (milliliter per minute per square meter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 26.4 (percent)\n- Hemoglobin [Mass/volume] in Blood: 8.9 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 92 (unit per liter)\n- MCV [Entitic volume] by Automated count: 91.3 (femtoliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.6 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Manual count: 11 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 23.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.7 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 79 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Prothrombin time (PT): 14.9 (second)\n- MCH [Entitic mass] by Automated count: 30.7 (picogram)\n- Neutrophils [#/volume] in Blood by Manual count: 4.5 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.1 (thousand per microliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Acute deep venous thrombosis of internal jugular vein\n- Pulmonary embolism with pulmonary infarction\n- Nausea and vomiting\n- Pyelonephritis\n- Venous thrombosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-11-06 10:48:00, ended at 2011-11-06 12:24:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Intestinal obstruction\n- Pulmonary embolism with pulmonary infarction\n- Venous thrombosis\n- Nausea and vomiting\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Pyelonephritis\n- Acute deep venous thrombosis of internal jugular vein\n\n### Drug\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, presumably until 2012-01-10. Instructions: take 17 g by mouth One Time.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-11-06 12:25:00, ended at 2011-11-06 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-11-27 09:48:00, ended at 2011-11-27 10:48:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.9 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.99 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.0 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.5 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.6 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 50 (milliliter per minute per square meter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.8 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.0 (percent)\n- MCV [Entitic volume] by Automated count: 93.7 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.60 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.70 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- MCH [Entitic mass] by Automated count: 31.0 (picogram)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 123 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.61 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.1 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.3 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 499 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 92 (unit per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-11-27 10:49:00, ended at 2011-11-27 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.142\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Nausea and vomiting\n- Intestinal obstruction\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-12-11 00:00:00, ended at 2011-12-11 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute deep vein thrombosis of lower limb\n\n### Drug\n- 0.8 ML enoxaparin sodium 150 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-12-11, presumably until 2012-07-14, with intended 3 refill(s). Instructions: inject 0.83 mL subcutaneous (under the skin) daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-12-14 14:23:00, ended at 2011-12-14 14:44:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.26 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.8 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 113 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.2 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.9 (percent)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.69 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 45 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.2 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 16.6 (percent)\n- MCV [Entitic volume] by Automated count: 91.9 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 18.4 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.2 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.64 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 485 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 56 (milliliter per minute per square meter)\n- Glucose [Mass/volume] in Serum or Plasma: 102 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 63.4 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-12-14 14:45:00, ended at 2011-12-14 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-12-25 00:00:00, ended at 2011-12-25 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain in pelvis\n\n### Drug\n- menthol 0.0044 MG/MG / zinc oxide 0.206 MG/MG Topical Ointment, through Topical route, started on 2011-12-25, presumably until 2013-02-12, with intended 1 refill(s). Instructions: 1 Squirt by Topical route apply as directed. Apply to anus after each bowel movement for 1 week as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-12-25 11:10:00, ended at 2011-12-25 11:57:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 120 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.0 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.7 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.7 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.19 (million per microliter)\n- MCH [Entitic mass] by Automated count: 30.2 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 410 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 46 (milliliter per minute per square meter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 73.0 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 45 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.1 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 115 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.6 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.63 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.65 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 90.9 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.60 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-12-25 11:58:00, ended at 2011-12-25 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.142\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Intestinal obstruction\n- Anemia\n- Primary malignant neoplasm of soft tissues\n- Nausea and vomiting\n- Inflammatory disorder of digestive tract\n- Diarrhea\n- Pulmonary embolism with pulmonary infarction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-01-01 00:00:00, ended at 2012-01-01 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-01-01 00:00:00, ended at 2012-01-01 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-01-10 11:59:00, ended at 2012-01-10 12:32:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 127 (unit per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.8 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 108 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 44 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 50 (milliliter per minute per square meter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diarrhea\n- Nausea and vomiting\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-01-10 12:33:00, ended at 2012-01-10 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nausea and vomiting\n- Venous thrombosis\n- Intestinal obstruction\n- Acute deep vein thrombosis of lower limb\n- Altered sensation of skin\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm of soft tissues\n- Pulmonary embolism with pulmonary infarction\n- Inflammatory disorder of digestive tract\n- Pyelonephritis\n\n### Drug\n- escitalopram 10 MG Oral Tablet, through Oral route, started on 2012-01-10, presumably until 2012-06-07, with intended 11 refill(s). Instructions: take 1 Tab by mouth daily. Take 1/2 tablet for 3 days, then increase to whole tablet.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-02-05 07:15:00, ended at 2012-02-05 08:44:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Lung field abnormal\n- Primary malignant neoplasm of soft tissues\n- Imaging of gastrointestinal tract abnormal\n- Ascites\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-02-05 08:45:00, ended at 2012-02-05 08:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.25 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.6 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 172 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 10.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 435 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 46 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.1 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 56 (milliliter per minute per square meter)\n- MCV [Entitic volume] by Automated count: 89.7 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.99 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.7 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 30.0 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 101 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.73 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 72.2 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 140 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.1 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-02-05 09:00:00, ended at 2012-02-05 11:12:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-02-05 11:13:00, ended at 2012-02-05 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.535\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Intestinal obstruction\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-02-09 00:00:00, ended at 2012-02-09 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chest pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-02-13 00:00:00, ended at 2012-02-13 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chest pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-02-14 00:00:00, ended at 2012-02-14 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-02-14 08:49:00, ended at 2012-02-14 09:18:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocytes [#/volume] in Blood by Automated count: 3.42 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.6 (percent)\n- Platelets [#/volume] in Blood by Automated count: 416 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.8 (picogram)\n- MCV [Entitic volume] by Automated count: 89.7 (femtoliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.2 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Anemia\n- Primary malignant neoplasm of soft tissues\n- Diarrhea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-02-14 09:19:00, ended at 2012-02-14 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-02-14 13:11:35, ended at 2012-02-14 14:39:26\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Primary diagnosis: Coronary atherosclerosis\n\n### Drug\n- metoprolol tartrate 50 MG Oral Tablet, through Oral route, started on 2012-02-14, presumably until 2012-04-10, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth 2 times a day. Please ensure pt takes 6.25mg (1/4 tab) twice a day.\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2012-02-14, presumably until 2016-03-31, with intended 3 refill(s). Instructions: take 1 Tab by mouth Every Day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-02-15 15:42:00, ended at 2012-02-15 16:38:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diarrhea\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-02-16 10:46:00, ended at 2012-02-16 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diarrhea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-03-04 00:00:00, ended at 2012-03-04 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Depressive disorder\n- Inflammatory disorder of digestive tract\n- Primary malignant neoplasm of soft tissues\n- Radiation-induced disorder\n- Acute deep vein thrombosis of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2012-03-20 00:00:00, ended at 2012-03-20 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Coronary atherosclerosis\n- Essential hypertension\n\n### Drug\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2012-03-20, presumably until 2012-04-10, with intended 3 refill(s). Instructions: take 0.25 Tabs by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-03-29 00:00:00, ended at 2012-03-29 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-04-01 00:00:00, ended at 2012-04-01 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-04-01 07:52:00, ended at 2012-04-01 09:12:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n\n### Condition\n- Chronic deep venous thrombosis of internal jugular vein\n- Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-04-01 09:13:00, ended at 2012-04-01 11:16:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 113 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.8 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 29.7 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.66 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.7 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 5.1 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 436 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.9 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 56 (milliliter per minute per square meter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 72.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 7.2 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 10.6 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 139 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.51 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 90.0 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 38 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.4 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.49 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.50 (million per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-04-01 11:17:00, ended at 2012-04-01 11:39:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.142\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Pulmonary embolism with pulmonary infarction\n- Inflammatory disorder of digestive tract\n- Venous thrombosis\n- Acute deep vein thrombosis of lower limb\n- Radiation-induced disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-04-01 11:40:00, ended at 2012-04-01 12:41:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 38 (unit per liter)\n- Anion gap in Serum or Plasma: 3 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 139 (unit per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 56 (milliliter per minute per square meter)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-04-01 12:42:00, ended at 2012-04-01 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-04-02 00:00:00, ended at 2012-04-02 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n- Primary malignant neoplasm of soft tissues\n- Acute deep vein thrombosis of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-04-03 12:55:34, ended at 2012-04-03 14:11:19\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Inflammatory disorder of digestive tract\n- Radiation-induced disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-04-10 12:10:00, ended at 2012-04-10 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Inflammatory disorder of digestive tract\n- Radiation-induced disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-04-10 14:12:15, ended at 2012-04-10 15:05:26\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Coronary atherosclerosis\n\n### Drug\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2012-04-10, presumably until 2013-04-10, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-04-26 00:00:00, ended at 2012-04-26 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-04-26 07:06:00, ended at 2012-04-26 09:53:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomographic angiography, chest (noncoronary), with contrast material(s), including noncontrast images, if performed, and image postprocessing\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Malignant melanoma of skin\n- Acute deep vein thrombosis of lower limb\n- Venous thrombosis\n- Ascites\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-04-26 09:54:00, ended at 2012-04-26 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Venous thrombosis\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-04-29 00:00:00, ended at 2012-04-29 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-05-06 08:10:00, ended at 2012-05-06 08:34:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-05-06 08:35:00, ended at 2012-05-06 10:33:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Ascites\n- Lung field abnormal\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-05-06 10:34:00, ended at 2012-05-06 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Inflammatory disorder of digestive tract\n- Pulmonary embolism with pulmonary infarction\n- Primary malignant neoplasm of soft tissues\n- Radiation-induced disorder\n\n### Drug\n- hydromorphone hydrochloride 4 MG Oral Tablet, through Oral route, presumably until 2012-12-25. Instructions: take  by mouth Every Day.\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, presumably until 2012-07-08. Instructions: take 20 mg by mouth every 12 hours as needed.  \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-05-08 11:06:15, ended at 2012-05-08 17:43:45\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Insomnia\n\n### Drug\n- doxepin 10 MG/ML Oral Solution, through Oral route, started on 2012-05-08, presumably until 2012-07-08, with intended 1 refill(s). Instructions: take 3 mL by mouth every bedtime.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-05-16 00:00:00, ended at 2012-05-16 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Neoplasm of uncertain behavior of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2012-05-16 00:00:00, ended at 2012-05-16 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-toxic uninodular goiter\n- Acquired hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-05-16 11:11:23, ended at 2012-05-16 12:29:43\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; single lesion\n\n### Condition\n- Primary diagnosis: Neoplasm of uncertain behavior of skin\n- Scar conditions and fibrosis of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-05-29 12:58:30, ended at 2012-05-29 17:17:13\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-06-06 07:59:00, ended at 2012-06-06 09:11:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Prothrombin time (PT): 13.7 (second)\n- aPTT in Platelet poor plasma by Coagulation assay: 26.5 (second)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Non-toxic multinodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-06-06 09:12:00, ended at 2012-06-06 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Fine needle aspiration; with imaging guidance\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n- Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation\n\n### Condition\n- Non-toxic uninodular goiter\n- Hashimoto thyroiditis\n- Non-toxic multinodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-06-07 11:05:49, ended at 2012-06-07 11:26:14\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute deep vein thrombosis of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2012-06-28 00:00:00, ended at 2012-06-28 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2012-06-28, presumably until 2012-07-12, with intended 3 refill(s). Instructions: take 1 Olsen by mouth once a week.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-07-02 00:00:00, ended at 2012-07-02 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-07-02 13:24:00, ended at 2012-07-02 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Coronary arteriosclerosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-07-03 12:02:00, ended at 2012-07-03 14:01:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 16 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 164 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.71 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.7 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.41 (million per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.36 (thousand per microliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.1 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 466 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.0 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 97 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.81 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 50 (milliliter per minute per square meter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.4 (picogram)\n- Thyrotropin [Units/volume] in Serum or Plasma: 4.08 (milli-international unit per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 22 (nanogram per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 6 (nanogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.8 (percent)\n- MCV [Entitic volume] by Automated count: 90.3 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.2 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.9 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.1 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Vitamin D deficiency\n- Non-toxic uninodular goiter\n- Acquired hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-07-03 14:02:00, ended at 2012-07-03 14:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm of soft tissues\n- Acquired hypothyroidism\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-07-03 15:00:00, ended at 2012-07-03 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-07-08 09:34:00, ended at 2012-07-08 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- Genetic counseling\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, presumably until 2012-12-25. Instructions: take 10 mg by mouth every 12 hours as needed.  \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-07-10 00:00:00, ended at 2012-07-10 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-07-10 00:00:00, ended at 2012-07-10 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-07-12 00:00:00, ended at 2012-07-12 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2012-07-12, presumably until 2012-09-04, with intended 3 refill(s). Instructions: take 1 Trammell by mouth once a week.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-07-19 00:00:00, ended at 2012-07-19 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-08-07 10:24:00, ended at 2012-08-07 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 12 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.63 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.7 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 13.3 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.8 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.4 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 116 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.4 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 157 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.73 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.70 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 451 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 28.5 (picogram)\n- MCV [Entitic volume] by Automated count: 87.1 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.88 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 71.3 (percent)\n- Globulin [Mass/volume] in Serum: 4.4 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 50 (milliliter per minute per square meter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.3 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-08-08 08:19:00, ended at 2012-08-08 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Abdominal pain\n- Ascites\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-08-08 12:59:54, ended at 2012-08-08 16:09:36\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-08-08 14:12:06, ended at 2012-08-08 14:50:25\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic ischemic heart disease\n\n### Drug\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2012-08-08, presumably until 2012-11-28, with intended 12 refill(s). Instructions: take 0.5 Tabs by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-08-27 15:00:00, ended at 2012-08-27 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-08-28 11:58:25, ended at 2012-08-28 12:58:54\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Diarrhea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-08-28 13:03:00, ended at 2012-08-28 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 23 (nanogram per milliliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 12 (nanogram per milliliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 11 (nanogram per milliliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Diarrhea\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-08-29 13:41:00, ended at 2012-08-29 13:45:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diarrhea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-08-29 13:46:00, ended at 2012-08-29 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diarrhea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-08-30 00:00:00, ended at 2012-08-30 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of intestine\n\n### Drug\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2012-09-20, presumably until 2012-10-18, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-09-04 00:00:00, ended at 2012-09-04 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2012-09-04, presumably until 2013-05-13, with intended 3 refill(s). Instructions: take 1 Robbins by mouth once a week.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-09-10 08:41:00, ended at 2012-09-10 12:25:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- Other nonoperative measurements and examinations\n- Breath hydrogen or methane test (eg, for detection of lactase deficiency, fructose intolerance, bacterial overgrowth, or oro-cecal gastrointestinal transit)\n\n### Condition\n- Abdominal pain\n- Essential hypertension\n- Type 2 diabetes mellitus without complication\n- Hyperlipidemia\n\n### Drug\n- lactulose 667 MG/ML Oral Solution, through Oral route, started on 2012-09-10, presumably until 2012-09-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-09-16 00:00:00, ended at 2012-09-16 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of intestine\n\n### Drug\n- rifaximin 200 MG Oral Tablet, through Oral route, started on 2012-09-16, presumably until 2012-10-14, with intended 0 refill(s). Instructions: take 2 Tabs by mouth 3 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-10-14 00:00:00, ended at 2012-10-14 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-10-14 10:50:00, ended at 2012-10-14 12:16:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Monocytes [#/volume] in Blood by Automated count: 0.81 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.82 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 475 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- MCV [Entitic volume] by Automated count: 88.9 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.4 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.9 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 10.9 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.4 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 101 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.4 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 157 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 50 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.5 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 73.8 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.59 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.9 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 29.0 (picogram)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-10-14 12:17:00, ended at 2012-10-14 13:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-10-14 14:00:00, ended at 2012-10-14 14:54:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-10-14 14:55:00, ended at 2012-10-14 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Radiation-induced disorder\n- Primary malignant neoplasm of soft tissues\n- Inflammatory disorder of digestive tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-10-16 11:01:06, ended at 2012-10-16 16:12:56\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-10-18 00:00:00, ended at 2012-10-18 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Radiation-induced disorder\n- Inflammatory disorder of digestive tract\n- Diarrhea\n\n### Drug\n- mesalamine 800 MG Delayed Release Oral Tablet, through Oral route, started on 2012-10-18, presumably until 2013-03-10, with intended 3 refill(s). Instructions: take 3 Tabs by mouth Every Day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-10-18 11:15:54, ended at 2012-10-18 11:55:04\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Diarrhea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-10-18 14:13:00, ended at 2012-10-18 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of extremity veins including responses to compression and other maneuvers; unilateral or limited study\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Acute deep venous thrombosis of internal jugular vein\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-10-23 00:00:00, ended at 2012-10-23 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Crohn's disease of small intestine\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-11-06 08:00:00, ended at 2012-11-06 08:49:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Kidney stone\n- Primary malignant neoplasm of soft tissues\n- Ascites\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-11-06 08:50:00, ended at 2012-11-06 08:50:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diarrhea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-11-06 08:51:00, ended at 2012-11-06 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 16 (nanogram per milliliter)\n- MCV [Entitic volume] by Automated count: 88.8 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.7 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.1 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.0 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 4.02 (milli-international unit per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 23 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 148 (unit per liter)\n- MCH [Entitic mass] by Automated count: 30.0 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 7 (nanogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.35 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 55 (milliliter per minute per square meter)\n- Glucose [Mass/volume] in Serum or Plasma: 88 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 393 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Inflammatory disorder of digestive tract\n- Radiation-induced disorder\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-11-06 10:09:03, ended at 2012-11-06 10:55:20\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n- Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-11-06 15:05:05, ended at 2012-11-06 16:02:48\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-11-11 00:00:00, ended at 2012-11-11 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-11-11 08:41:00, ended at 2012-11-11 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-11-12 00:00:00, ended at 2012-11-12 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diarrhea\n- Primary diagnosis: Acquired hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.112 MG Oral Tablet, through Oral route, started on 2012-11-12, presumably until 2013-05-01, with intended 3 refill(s). Instructions: take 1 Tab by mouth as directed. Take 1.5 pills on Sun, 1 pill Mon-Sat\n- amylase 120000 UNT / lipase 24000 UNT / protease 76000 UNT Delayed Release Oral Capsule, through Oral route, started on 2012-11-12, presumably until 2013-02-12, with intended 3 refill(s). Instructions: take 1-2 Caps by mouth 3 times a day with meals.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-11-13 00:00:00, ended at 2012-11-13 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-11-13 00:00:00, ended at 2012-11-13 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-11-13 00:00:00, ended at 2012-11-13 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vitamin D deficiency\n\n### Drug\n- cholecalciferol 0.125 MG Oral Tablet, through Oral route, started on 2012-11-13, presumably until 2013-02-12, with intended 3 refill(s). Instructions: take 5,000 Units by mouth Every Day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-11-13 09:17:01, ended at 2012-11-13 12:17:07\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute deep vein thrombosis of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2012-11-28 00:00:00, ended at 2012-11-28 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic ischemic heart disease\n\n### Drug\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2012-11-28, presumably until 2013-11-28, with intended 11 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-12-24 08:53:01, ended at 2012-12-24 09:29:13\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abdominal pain\n\n### Drug\n- gabapentin 300 MG Oral Tablet, through Oral route, started on 2012-12-24, presumably until 2013-02-12, with intended 3 refill(s). Instructions: take 1 Tab by mouth 3 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-12-25 12:02:59, ended at 2012-12-25 16:00:36\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2012-12-25 14:49:00, ended at 2012-12-26 17:45:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 40 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: N/A (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 200 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.2 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.3 (percent)\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.79 (milli-international unit per liter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 119 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.82 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 89.6 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 70.7 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.5 (percent)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 0.9 (nanogram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.09 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.49 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 51.9 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 43 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 102 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.87 (thousand per microliter)\n- Prothrombin time (PT): 14.2 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 62 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 76 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.9 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.2 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.2 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 446 (thousand per microliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 87 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; supervision only, without interpretation and report\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; interpretation and report only\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; tracing only, without interpretation and report\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation \n\n### Condition\n- Inflammatory disorder of digestive tract\n- Anemia\n- Type 2 diabetes mellitus without complication\n- Acute deep vein thrombosis of lower limb\n- Diarrhea\n- Hyperlipidemia\n- Acute myocardial infarction\n- Chronic ischemic heart disease\n- Coronary atherosclerosis\n- Disorder of kidney and/or ureter\n- Essential hypertension\n- Obesity\n- Acquired hypothyroidism\n- Primary diagnosis: Chest pain\n- Coronary arteriosclerosis\n- Pulmonary embolism with pulmonary infarction\n- Obstructive sleep apnea syndrome\n- Vitamin D deficiency\n- Radiation-induced disorder\n\n### Drug\n- levothyroxine sodium 0.112 MG Oral Tablet, through Oral route, started on 2012-12-26, presumably until 2012-12-26\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2012-12-26, presumably until 2012-12-26\n- hydromorphone hydrochloride 4 MG Oral Tablet, through Oral route, presumably until 2015-10-01. Instructions: take 8 mg by mouth as needed (only as needed only takes it 3 times a month). Every 72 hours\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2012-12-25, presumably until 2012-12-25\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2012-12-25, presumably until 2012-12-25\n- colchicine 0.6 MG Oral Tablet, through Oral route, started on 2012-12-26, presumably until 2012-12-26\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2012-12-26, presumably until 2012-12-26\n- mesalamine 400 MG Delayed Release Oral Tablet, through Oral route, started on 2012-12-26, presumably until 2012-12-26\n- amylase 120000 UNT / lipase 24000 UNT / protease 76000 UNT Delayed Release Oral Capsule, through Oral route, started on 2012-12-26, presumably until 2012-12-26\n- 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, presumably until 2015-10-01. Instructions: take 20 mg by mouth as needed. Only takes about 3 times a month\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2012-12-26, presumably until 2012-12-26\n- clopidogrel 75 MG Oral Tablet, through Oral route, started on 2012-12-25, presumably until 2012-12-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-01-23 00:00:00, ended at 2013-01-23 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-01-29 13:06:33, ended at 2013-01-29 13:50:08\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Coronary atherosclerosis\n- Chronic ischemic heart disease\n- Primary diagnosis: Chest pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-02-06 08:55:47, ended at 2013-02-06 09:56:44\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Generally unwell\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-06 10:19:00, ended at 2013-02-06 12:47:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 190 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.58 (million per microliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 6 (nanogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 69.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 468 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 4.22 (milli-international unit per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.91 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.2 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.8 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 15 (nanogram per milliliter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 88.8 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.7 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.12 (thousand per microliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 9 (nanogram per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 38 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 55 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 28.0 (picogram)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- MCHC [Mass/volume] by Automated count: 31.5 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.75 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Non-toxic uninodular goiter\n- Crohn's disease of small intestine\n- Vitamin D deficiency\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-06 12:48:00, ended at 2013-02-06 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Ascites\n- Pathological fracture of vertebra\n- Acquired renal cystic disease\n- Closed fracture lumbar vertebra\n- Kidney stone\n- Lung field abnormal\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-10 08:55:00, ended at 2013-02-10 10:11:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Post-surgical malabsorption\n- Primary diagnosis: Closed fracture\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2013-02-10, presumably until 2015-03-29, with intended 6 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-10 10:12:00, ended at 2013-02-10 16:43:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.142\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-02-10 15:03:01, ended at 2013-02-10 16:34:28\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Generalized abdominal pain\n- Iron deficiency anemia\n- Primary diagnosis: Post-surgical malabsorption\n- Diarrhea\n- Flatulence, eructation and gas pain\n- Megaloblastic anemia due to vitamin B-12 deficiency\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-10 16:44:00, ended at 2013-02-10 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Ferritin [Mass/volume] in Serum or Plasma: 3 (nanogram per milliliter)\n- Iron [Mass/volume] in Serum or Plasma: 27 (microgram per deciliter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 256 (picogram per milliliter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 398 (microgram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 7 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Post-surgical malabsorption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-12 09:14:00, ended at 2013-02-12 19:30:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hematocrit [Volume Fraction] of Blood: 31 (percent)\n- Sodium [Moles/volume] in Blood: 141 (millimole per liter)\n- Body height: 5' 6.5\" (inch (US))\n- Potassium [Moles/volume] in Blood: 4.8 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 10.5 (gram per deciliter)\n\n### Procedure\n- Coronary arteriography using two catheters\n- Collection of venous blood by venipuncture\n- Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation\n\n### Condition\n- Pure hypercholesterolemia\n- Essential hypertension\n- Angina pectoris\n- Abnormal results of cardiovascular function studies\n- Coronary arteriosclerosis\n- Old myocardial infarction\n- Obesity\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- diazepam 5 MG Oral Tablet, through Oral route, started on 2013-02-12, presumably until 2013-02-12\n- aspirin 325 MG Oral Tablet, through Oral route, started on 2013-02-12, presumably until 2013-02-12\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-02-12, presumably until 2013-02-12\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2013-02-12, presumably until 2013-02-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-14 09:45:00, ended at 2013-02-14 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine)\n\n### Condition\n- Disorder of bone and articular cartilage\n- Disorder of endocrine system\n- Closed fracture\n- Osteoporosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2013-02-18 00:00:00, ended at 2013-02-18 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acquired hypothyroidism\n- Primary diagnosis: Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-02-19 00:00:00, ended at 2013-02-19 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-10 12:25:00, ended at 2013-03-10 18:35:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- MCV [Entitic volume] by Automated count: 90.3 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.3 (percent)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 527 (picogram per milliliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 4 (nanogram per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 82 (milligram per deciliter)\n- Iron [Mass/volume] in Serum or Plasma: 38 (microgram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.2 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 20.9 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.15 (thousand per microliter)\n- Reticulocytes [#/volume] in Blood by Automated count: 44.3 (thousand per microliter)\n- Reticulocytes/100 erythrocytes in Blood by Automated count: 1.16 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.6 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.1 (gram per deciliter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 420 (microgram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.2 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.58 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 435 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.4 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 183 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.9 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 38 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.81 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 9 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.30 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of iron metabolism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-03-10 14:11:38, ended at 2013-03-10 15:19:51\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diarrhea\n- Primary diagnosis: Generalized abdominal pain\n- Iron deficiency anemia\n- Flatulence, eructation and gas pain\n- Post-surgical malabsorption\n\n### Drug\n- amitriptyline hydrochloride 10 MG Oral Tablet, through Oral route, started on 2013-03-10, presumably until 2013-05-05, with intended 2 refill(s). Instructions: take 1 Tab by mouth every bedtime.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-10 18:36:00, ended at 2013-03-10 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; thoracic\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; cervical\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; lumbar\n\n### Condition\n- Pathological fracture of vertebra\n- Primary malignant neoplasm of soft tissues\n- Abnormal findings on diagnostic imaging of skull and head\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-11 13:18:00, ended at 2013-03-11 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.961\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of iron metabolism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-03-12 09:57:34, ended at 2013-03-12 16:34:53\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Malaise\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-03-18 00:00:00, ended at 2013-03-18 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Post-surgical malabsorption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-04-25 00:00:00, ended at 2013-04-25 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Coronary atherosclerosis\n\n### Drug\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2013-04-25, presumably until 2014-05-12, with intended 11 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2013-05-01 00:00:00, ended at 2013-05-01 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acquired hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.137 MG Oral Tablet, through Oral route, started on 2013-05-01, presumably until 2014-05-01, with intended 3 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-05-01 00:00:00, ended at 2013-05-01 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-01 09:23:00, ended at 2013-05-01 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 5.34 (milli-international unit per liter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 19 (nanogram per milliliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 19 (nanogram per milliliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Non-toxic uninodular goiter\n- Vitamin D deficiency\n- Post-surgical malabsorption\n- Disorder of iron metabolism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-05-01 10:01:20, ended at 2013-05-01 10:58:03\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n- Acquired hypothyroidism\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-02 09:23:00, ended at 2013-05-02 14:22:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Anemia\n- Acquired hypothyroidism\n- Diarrhea\n- Iron deficiency anemia\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2013-05-02, presumably until 2013-05-02\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2013-05-02, presumably until 2013-05-02\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-05-02, presumably until 2013-05-02\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2013-05-02, presumably until 2013-05-02\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-05-02, presumably until 2013-05-02\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2013-05-02, presumably until 2013-05-02\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-02 14:23:00, ended at 2013-05-02 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n\n### Condition\n- Non-toxic multinodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-05-05 00:00:00, ended at 2013-05-05 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-05 08:00:00, ended at 2013-05-05 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Anemia\n- Primary diagnosis: Iron deficiency anemia\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2013-05-05, presumably until 2013-05-05\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-05-05, presumably until 2013-05-05\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2013-05-05, presumably until 2013-05-05\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2013-05-05, presumably until 2013-05-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-05-05 12:31:58, ended at 2013-05-05 14:00:52\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diarrhea\n- Nausea and vomiting\n- Mineral deficiency\n- Primary diagnosis: Post-surgical malabsorption\n- Generalized abdominal pain\n\n### Drug\n- zinc sulfate 220 MG Oral Capsule, through Oral route, started on 2013-05-05, presumably until 2014-03-18, with intended 1 refill(s). Instructions: take 1 Cap by mouth daily.\n- amitriptyline hydrochloride 10 MG Oral Tablet, through Oral route, started on 2013-05-05, presumably until 2013-06-03, with intended 2 refill(s). Instructions: take 3 Tabs by mouth every bedtime.\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2013-05-05, presumably until 2014-04-11, with intended 2 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed for Nausea.\n- dicyclomine hydrochloride 10 MG Oral Capsule, through Oral route, started on 2013-05-05, presumably until 2013-08-11, with intended 2 refill(s). Instructions: take 1 Cap by mouth 4 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-06 12:47:00, ended at 2013-05-06 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Anemia\n- Primary diagnosis: Iron deficiency anemia\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2013-05-06, presumably until 2013-05-06\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2013-05-06, presumably until 2013-05-06\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-05-06, presumably until 2013-05-06\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2013-05-06, presumably until 2013-05-06\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-07 08:05:00, ended at 2013-05-07 16:29:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-05-07 15:09:19, ended at 2013-05-07 16:17:14\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chest pain\n- Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-07 16:30:00, ended at 2013-05-07 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 14 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 29.4 (picogram)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.61 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.76 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.3 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 89.8 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 68.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 425 (thousand per microliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 22 (nanogram per milliliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 22 (nanogram per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 50 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.1 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.53 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.30 (million per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 46 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 165 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.7 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.8 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.7 (percent)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 8.10 (milli-international unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.9 (percent)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Acquired hypothyroidism\n- Anemia\n- Diarrhea\n- Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Iron deficiency anemia\n- Vitamin D deficiency\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2013-05-07, presumably until 2013-05-07\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2013-05-07, presumably until 2013-05-07\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-05-07, presumably until 2013-05-07\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-05-07, presumably until 2013-05-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-08 14:20:00, ended at 2013-05-08 14:47:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 175 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.32 (million per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.70 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 20.8 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.4 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.6 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.02 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.28 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.7 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.2 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 29.0 (picogram)\n- MCV [Entitic volume] by Automated count: 89.7 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 64.7 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 438 (thousand per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 55 (milliliter per minute per square meter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.8 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-08 14:48:00, ended at 2013-05-08 16:22:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-08 16:23:00, ended at 2013-05-08 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Primary diagnosis: Iron deficiency anemia\n- Anemia\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2013-05-08, presumably until 2013-05-08\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2013-05-08, presumably until 2013-05-08\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-05-08, presumably until 2013-05-08\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-05-08, presumably until 2013-05-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-09 08:00:00, ended at 2013-05-09 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Ferritin [Mass/volume] in Serum or Plasma: 239 (nanogram per milliliter)\n- Iron [Mass/volume] in Serum or Plasma: 529 (microgram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 162 (percent)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 326 (microgram per deciliter)\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Collection of venous blood by venipuncture\n\n### Condition\n- Anemia\n- Primary diagnosis: Iron deficiency anemia\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2013-05-09, presumably until 2013-05-09\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2013-05-09, presumably until 2013-05-09\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-05-09, presumably until 2013-05-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2013-05-13 00:00:00, ended at 2013-05-13 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2013-05-13, presumably until 2013-08-05, with intended 1 refill(s). Instructions: take 1 Cap by mouth as directed. Take twice/week x 4 weeks then once/week x 3 months.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-05-16 00:00:00, ended at 2013-05-16 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-19 08:00:00, ended at 2013-05-19 09:16:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Mononeuritis\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-19 09:17:00, ended at 2013-05-19 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 424 (picogram per milliliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.2 (nanogram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.69 (milli-international unit per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Mononeuritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-06-03 14:26:43, ended at 2013-06-03 16:31:26\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Generalized abdominal pain\n- Diarrhea\n- Primary diagnosis: Disorder of the peripheral nervous system\n\n### Drug\n- amitriptyline hydrochloride 10 MG Oral Tablet, through Oral route, started on 2013-06-03, presumably until 2013-08-11, with intended 3 refill(s). Instructions: take 5 Tabs by mouth every bedtime.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-04 10:58:00, ended at 2013-06-04 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 502 (picogram per milliliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 5.3 (percent)\n- Ferritin [Mass/volume] in Serum or Plasma: 62 (nanogram per milliliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of the peripheral nervous system\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-07-10 00:00:00, ended at 2013-07-10 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-10 09:03:00, ended at 2013-07-10 13:14:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocytes [#/volume] in Blood by Automated count: 3.97 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Iron [Mass/volume] in Serum or Plasma: 73 (microgram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.3 (percent)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 21 (nanogram per milliliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.3 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 112 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 101 (milligram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 24 (percent)\n- MCV [Entitic volume] by Automated count: 94.8 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.76 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 63.9 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.6 (percent)\n- Platelets [#/volume] in Blood by Automated count: 368 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 193 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 9 (nanogram per milliliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.5 (percent)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.4 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 144 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 26 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Body height: 5' 6.5\" (inch (US))\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 55 (milliliter per minute per square meter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 302 (microgram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.2 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 3.20 (thousand per microliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 12 (nanogram per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Ferritin [Mass/volume] in Serum or Plasma: 43 (nanogram per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.0 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.92 (thousand per microliter)\n\n### Procedure\n- Other nonoperative measurements and examinations\n- Collection of venous blood by venipuncture\n- Breath hydrogen or methane test (eg, for detection of lactase deficiency, fructose intolerance, bacterial overgrowth, or oro-cecal gastrointestinal transit)\n\n### Condition\n- Anemia\n- Diarrhea\n- Hyperlipidemia\n- Vitamin D deficiency\n- Essential hypertension\n- Acquired hypothyroidism\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-11 14:40:00, ended at 2013-07-11 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-07-14 12:20:46, ended at 2013-07-14 13:31:27\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Diarrhea\n- Flatulence, eructation and gas pain\n- Nausea\n- Disorder of intestine\n\n### Drug\n- cholestyramine resin 4000 MG Powder for Oral Suspension, through Oral route, started on 2013-07-14, presumably until 2013-10-13, with intended 1 refill(s). Instructions: take 4 g by mouth every other day.\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2013-07-14, presumably until 2013-08-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-07-21 00:00:00, ended at 2013-07-21 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-08-05 00:00:00, ended at 2013-08-05 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2013-08-05, presumably until 2013-08-07, with intended 1 refill(s). Instructions: take 1 Cap by mouth as directed. Take twice/week x 4 weeks then once/week x 3 months.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2013-08-07 00:00:00, ended at 2013-08-07 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2013-08-07, presumably until 2013-09-19, with intended 0 refill(s). Instructions: take 1 Cap by mouth as directed. Take twice/week x 4 weeks then once/week x 3 months.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-08-07 15:04:39, ended at 2013-08-07 16:18:32\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-08-07 15:33:00, ended at 2013-08-07 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.7 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 33 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 175 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 16.3 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.6 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 69.6 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 112 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 50 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.5 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 144 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.91 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.5 (percent)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 95.9 (femtoliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.6 (percent)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.25 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.7 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.87 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 331 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.4 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.23 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-08-08 16:16:00, ended at 2013-08-08 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Lung field abnormal\n- Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm of soft tissues of abdomen\n- Ascites\n- Closed fracture\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-08-11 08:00:00, ended at 2013-08-11 08:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-08-11 09:00:00, ended at 2013-08-11 12:45:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-08-11 12:46:00, ended at 2013-08-11 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Needle electromyography, each extremity, with related paraspinal areas, when performed, done with nerve conduction, amplitude and latency/velocity study; limited (List separately in addition to code for primary procedure)\n- Nerve conduction studies; 7-8 studies\n\n### Condition\n- Inflammatory and toxic neuropathy\n- Disorder of the peripheral nervous system\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-08-12 12:03:00, ended at 2013-08-12 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Electrocardiogram abnormal\n- Anemia\n- Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Iron deficiency anemia\n- Acquired hypothyroidism\n- Chest pain\n- Diarrhea\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2013-08-12, presumably until 2013-08-12\n- 2 ML iron-dextran complex 50 MG/ML Injection, started on 2013-08-12, presumably until 2013-08-12\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2013-08-12, presumably until 2013-08-12\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2013-08-12, presumably until 2013-08-12\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2013-08-12, presumably until 2013-08-12\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-08-12, presumably until 2013-08-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-08-13 13:15:40, ended at 2013-08-13 14:08:58\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Acquired hypothyroidism\n- Primary diagnosis: Disorder of the peripheral nervous system\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-08-13 14:51:00, ended at 2013-08-13 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-09 12:07:00, ended at 2013-09-09 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Diarrhea\n- Primary malignant neoplasm of soft tissues\n- Anemia\n- Primary diagnosis: Iron deficiency anemia\n- Acquired hypothyroidism\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-09-09, presumably until 2013-09-09\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-09-09, presumably until 2013-09-09\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2013-09-09, presumably until 2013-09-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-10 11:30:00, ended at 2013-09-10 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Cardiac arrhythmia\n- Anemia\n- Chest pain\n- Electrocardiogram abnormal\n- Primary diagnosis: Iron deficiency anemia\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2013-09-10, presumably until 2013-09-10\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-09-10, presumably until 2013-09-10\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2013-09-10, presumably until 2013-09-10\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-09-10, presumably until 2013-09-10\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2013-09-10, presumably until 2013-09-10\n- methylprednisolone 125 MG Injection, started on 2013-09-10, presumably until 2013-09-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-09-10 15:14:29, ended at 2013-09-10 17:23:51\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-11 11:30:00, ended at 2013-09-11 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Anemia\n- Primary diagnosis: Iron deficiency anemia\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2013-09-11, presumably until 2013-09-11\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2013-09-11, presumably until 2013-09-11\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-09-11, presumably until 2013-09-11\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-09-11, presumably until 2013-09-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-12 11:30:00, ended at 2013-09-12 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Iron deficiency anemia\n- Anemia\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2013-09-12, presumably until 2013-09-12\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2013-09-12, presumably until 2013-09-12\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-09-12, presumably until 2013-09-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-13 07:30:00, ended at 2013-09-13 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, any joint of lower extremity; without contrast material(s), followed by contrast material(s) and further sequences\n\n### Condition\n- Joint pain\n- Osteoarthritis of knee\n- Disorder of musculoskeletal system\n- Sprain of cruciate ligament of knee\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-15 11:30:00, ended at 2013-09-15 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Primary diagnosis: Iron deficiency anemia\n- Anemia\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2013-09-15, presumably until 2013-09-15\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2013-09-15, presumably until 2013-09-15\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-09-15, presumably until 2013-09-15\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2013-09-15, presumably until 2013-09-15\n- methylprednisolone 125 MG Injection, started on 2013-09-15, presumably until 2013-09-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-09-19 00:00:00, ended at 2013-09-19 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2013-09-19, presumably until 2014-02-24, with intended 0 refill(s). Instructions: take 1 Cap by mouth as directed. Take twice/week x 8 weeks then once/week x 3 months.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-09-23 00:00:00, ended at 2013-09-23 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Coronary atherosclerosis\n- Primary malignant neoplasm of soft tissues\n- Iron deficiency anemia\n- Disorder of musculoskeletal system\n- Primary diagnosis: Sprain of cruciate ligament of knee\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-09-30 12:42:31, ended at 2013-09-30 15:32:27\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Osteoarthritis of knee\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-30 12:44:00, ended at 2013-09-30 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, knee; 3 views\n- Bone length studies (orthoroentgenogram, scanogram)\n\n### Condition\n- Osteoarthritis of knee\n- Joint pain\n- Loose body in knee\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-13 14:51:00, ended at 2013-10-13 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 5.5 (percent)\n\n### Procedure\n- Pre-surgery evaluation\n- Collection of venous blood by venipuncture\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Old myocardial infarction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-10-21 13:05:42, ended at 2013-10-21 14:30:57\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Flatulence, eructation and gas pain\n- Primary diagnosis: Post-surgical malabsorption\n- Diarrhea\n- Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-10-22 10:03:58, ended at 2013-10-22 11:50:10\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Osteoarthritis\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-11-05 13:19:51, ended at 2013-11-05 13:45:04\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Senile hyperkeratosis\n- Primary diagnosis: Benign neoplasm of skin of trunk\n- Onychomycosis due to dermatophyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-11-06 09:44:00, ended at 2013-11-06 10:46:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Anemia\n- Primary diagnosis: Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-11-06 10:47:00, ended at 2013-11-06 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.79 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 111 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 109 (milligram per deciliter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 244 (microgram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 127 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.74 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Reticulocytes/100 erythrocytes in Blood by Automated count: 1.75 (percent)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 135 (nanogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.0 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.6 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Iron [Mass/volume] in Serum or Plasma: 75 (microgram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 76.6 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.72 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.82 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.4 (percent)\n- Reticulocytes [#/volume] in Blood by Automated count: 64.9 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Hemoglobin [Mass/volume] in Blood: 12.3 (gram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 31 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.5 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 11.0 (percent)\n- MCH [Entitic mass] by Automated count: 33.0 (picogram)\n- MCV [Entitic volume] by Automated count: 99.5 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 300 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-11-06 13:59:14, ended at 2013-11-06 15:09:05\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2013-11-07 00:00:00, ended at 2013-11-07 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-11-07 10:20:52, ended at 2013-11-07 10:46:07\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-11-07 10:53:00, ended at 2013-11-07 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 7 (nanogram per milliliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.25 (milli-international unit per liter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 34 (nanogram per milliliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 27 (nanogram per milliliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Vitamin D deficiency\n- Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-11-27 09:03:47, ended at 2013-11-27 17:46:01\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-11-27 11:05:07, ended at 2013-11-27 13:51:17\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-12-10 14:14:02, ended at 2013-12-10 15:09:25\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- Pre-surgery evaluation\n\n### Condition\n- Primary diagnosis: Primary cardiomyopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-12-11 10:12:12, ended at 2013-12-11 17:21:20\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-12-15 00:00:00, ended at 2013-12-15 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic ischemic heart disease\n\n### Drug\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2013-12-15, presumably until 2014-11-18, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-01-16 00:00:00, ended at 2014-01-16 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-06 14:29:00, ended at 2014-02-06 16:19:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 56 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.2 (percent)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 273 (microgram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 28 (percent)\n- MCH [Entitic mass] by Automated count: 32.9 (picogram)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 17.0 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.5 (percent)\n- Reticulocytes/100 erythrocytes in Blood by Automated count: 1.57 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 148 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.77 (million per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 55 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.9 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 370 (thousand per microliter)\n- Iron [Mass/volume] in Serum or Plasma: 76 (microgram per deciliter)\n- Reticulocytes [#/volume] in Blood by Automated count: 59.3 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.9 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.4 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 98.8 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 72.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 135 (nanogram per milliliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.34 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.70 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-06 16:20:00, ended at 2014-02-06 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Lymphadenopathy\n- Primary malignant neoplasm of soft tissues of abdomen\n- Ascites\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-09 09:00:00, ended at 2014-02-09 10:14:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.496\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Old myocardial infarction\n- Radiation-induced disorder\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Inflammatory disorder of digestive tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-09 10:15:00, ended at 2014-02-09 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.496\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Old myocardial infarction\n- Inflammatory disorder of digestive tract\n- Radiation-induced disorder\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-10 09:45:00, ended at 2014-02-10 11:11:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-10 11:12:00, ended at 2014-02-10 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-02-11 13:10:49, ended at 2014-02-11 13:53:47\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of the peripheral nervous system\n- Primary malignant neoplasm of soft tissues\n- Acquired hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-11 14:56:00, ended at 2014-02-11 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-19 12:43:00, ended at 2014-02-20 12:28:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 135 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.91 (million per microliter)\n- MCV [Entitic volume] by Automated count: 99.8 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.6 (percent)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.12 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 71.0 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Body height: 5' 6\" (inch (US))\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 33.2 (picogram)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.1 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.20 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 324 (thousand per microliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 77 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.9 (percent)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.03 (thousand per microliter)\n- Prothrombin time (PT): 13.7 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.9 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.0 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Monocytes [#/volume] in Blood by Automated count: 0.68 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.8 (gram per deciliter)\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Ultrasonography of digestive system\n- Endoscopy and biopsy of upper gastrointestinal tract\n- Collection of venous blood by venipuncture\n- Radiologic examination, chest; single view, frontal\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s) (includes endoscopic ultrasound examination of the esophagus, stomach, and either the duodenum or a surgicall\n\n### Condition\n- Acute postoperative pain\n- Conduction disorder of the heart\n- Neoplasm of uncertain behavior of digestive organ\n- Primary diagnosis: Postprocedural state finding\n- Cardiac arrhythmia\n- Localized swelling, mass and lump, trunk\n- Neoplasm of intra-abdominal lymph nodes\n- Atelectasis\n- Coronary arteriosclerosis\n- Lung field abnormal\n- Abdominal pain\n- Hyperlipidemia\n- Post-surgical hypoinsulinemia\n- Secondary diabetes mellitus\n- Acquired hypothyroidism\n- Obstructive sleep apnea syndrome\n- Lymphadenopathy\n- Ascites\n- Electrocardiogram abnormal\n- Old myocardial infarction\n\n### Drug\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2014-02-20, presumably until 2014-03-18, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2014-02-20, presumably until 2014-02-20\n- levothyroxine sodium 0.137 MG Oral Tablet, through Oral route, started on 2014-02-20, presumably until 2014-02-20\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-02-19, presumably until 2014-02-20\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2014-02-19, presumably until 2014-02-20\n- 100 ML metronidazole 5 MG/ML Injection, through Intravenous route, started on 2014-02-19, presumably until 2014-02-20\n- midazolam 1 MG/ML Injectable Solution, started on 2014-02-19, presumably until 2014-02-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-02-24 00:00:00, ended at 2014-02-24 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2014-02-24, presumably until 2014-06-05, with intended 0 refill(s). Instructions: take 1 Cap by mouth as directed. Take twice/week x 8 weeks then once/week x 3 months.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-02 14:19:00, ended at 2014-03-02 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.142\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-04 12:36:00, ended at 2014-03-04 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-10 09:00:00, ended at 2014-03-10 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Lymphadenopathy\n- Primary malignant neoplasm of soft tissues of abdomen\n- Neoplasm of lymph node\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-03-13 00:00:00, ended at 2014-03-13 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-18 10:49:00, ended at 2014-03-18 11:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.142\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-18 12:00:00, ended at 2014-03-18 15:13:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- ciprofloxacin 250 MG Oral Tablet, presumably until 2014-04-01. Instructions: Take 250 mg by mouth twice daily. For 2 days for prophylaxis.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-18 15:14:00, ended at 2014-03-18 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.142\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-03-23 00:00:00, ended at 2014-03-23 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-27 17:07:00, ended at 2014-03-27 18:56:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-27 18:57:00, ended at 2014-03-27 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, upper extremity, other than joint; without contrast material(s), followed by contrast material(s) and further sequences\n\n### Condition\n- Disorder of bone and articular cartilage\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-01 08:12:00, ended at 2014-04-01 10:14:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-01 10:15:00, ended at 2014-04-01 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-02 13:51:00, ended at 2014-04-02 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n\n### Condition\n- Non-toxic multinodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-04-08 00:00:00, ended at 2014-04-08 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- MCH [Entitic mass] by Automated count: 33.0 (picogram)\n- aPTT in Platelet poor plasma by Coagulation assay: 29.4 (second)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.1 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.2 (percent)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.4 (thousand per microliter)\n- Prothrombin time (PT): 12.7 (second)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Body height: 5' 6.5\" (inch (US))\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- Platelets [#/volume] in Blood by Automated count: 273 (thousand per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 55 (milliliter per minute per square meter)\n- Glucose [Mass/volume] in Serum or Plasma: 102 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 98.1 (femtoliter)\n- Hemoglobin [Mass/volume] in Blood: 12.9 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 33 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.90 (million per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Pre-surgery evaluation\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-04-08 00:00:00, ended at 2014-04-08 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-08 13:00:00, ended at 2014-04-08 16:38:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-08 16:39:00, ended at 2014-04-08 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2014-04-09 00:00:00, ended at 2014-04-09 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for thoracotomy procedures involving lungs, pleura, diaphragm, and mediastinum (including surgical thoracoscopy); utilizing 1 lung ventilation\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, started on 2014-04-09, presumably until 2014-04-09\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2014-04-09, presumably until 2014-04-09\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2014-04-09, presumably until 2014-04-09\n- cefazolin 1000 MG Injection, started on 2014-04-09, presumably until 2014-04-09\n- remifentanil 2 MG Injection, through Intravenous route, started on 2014-04-09, presumably until 2014-04-09\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2014-04-09, presumably until 2014-04-09\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2014-04-09, presumably until 2014-04-09\n- 2 ML ondansetron 2 MG/ML Injection, started on 2014-04-09, presumably until 2014-04-09\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-04-09, presumably until 2014-04-09\n- midazolam 1 MG/ML Injectable Solution, started on 2014-04-09, presumably until 2014-04-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2014-04-09 00:00:00, ended at 2014-04-09 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 10 ML bupivacaine hydrochloride 5 MG/ML Injection, started on 2014-04-09, presumably until 2014-04-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2014-04-09 05:19:00, ended at 2014-04-11 14:25:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 31 (milligram per deciliter)\n- Body height: 5' 6\" (inch (US))\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.6 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 79.1 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.32 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 33.1 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.8 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 291 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.4 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.1 (percent)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 159 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.0 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 99.3 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.17 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.3 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 8.21 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.3 (milligram per deciliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 366 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.63 (million per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 113 (millimole per liter)\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Collection of venous blood by venipuncture\n- Thoracoscopic wedge resection of lung\n- Duplex scan of extremity veins including responses to compression and other maneuvers; unilateral or limited study\n- Pathology consultation during surgery; first tissue block, with frozen section(s), single specimen\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Excision of regional lymph nodes\n- Radiologic examination, chest; single view, frontal\n- Physical therapy evaluation\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Noninvasive ventilation\n- Other endoscopy of small intestine\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n\n### Condition\n- Benign hypertensive renal disease with renal failure\n- Edema\n- Anxiety state\n- Gout\n- Non-toxic uninodular goiter\n- Vitamin D deficiency\n- Electrocardiogram abnormal\n- Hyperlipidemia\n- Lung field abnormal\n- Type 2 diabetes mellitus without complication\n- Disorder of thyroid gland\n- Erythema of skin\n- Secondary malignant neoplasm of lung\n- Acquired hypothyroidism\n- Ascites\n- Chronic pain\n- Depressive disorder\n- Nausea and vomiting\n- Primary cardiomyopathy\n- Chronic ischemic heart disease\n- Coronary atherosclerosis\n- Gastroesophageal reflux disease\n- Chronic kidney disease\n- Iron deficiency anemia\n- Obstructive sleep apnea syndrome\n- Old myocardial infarction\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Acute postoperative pain\n- Acute pulmonary edema\n- Disorder of the peripheral nervous system\n- Congestive heart failure\n\n### Drug\n- benzocaine 15 MG / menthol 3.6 MG Oral Lozenge, through Submucosal route, started on 2014-04-10, presumably until 2014-04-11\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-04-09, presumably until 2014-04-10\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2014-04-09, presumably until 2014-04-09\n- 1 ML ketorolac tromethamine 30 MG/ML Injection, started on 2014-04-09, presumably until 2014-04-10\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2014-04-09, presumably until 2014-04-11\n- magnesium citrate 58.2 MG/ML Oral Solution, through Oral route, started on 2014-04-11, presumably until 2014-04-11\n- naloxone hydrochloride 0.4 MG/ML Injectable Solution, started on 2014-04-09, presumably until 2014-04-09\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2014-04-10, presumably until 2014-04-11\n- albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution, through Inhalation, started on 2014-04-09, presumably until 2014-04-11\n- cefazolin 1000 MG Injection, through Intravenous route, started on 2014-04-09, presumably until 2014-04-10\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2014-04-09, presumably until 2014-06-05, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily.\n- lisinopril 2.5 MG Oral Tablet, through Oral route, started on 2014-04-11, presumably until 2014-04-11\n- magnesium hydroxide 80 MG/ML Oral Suspension, through Oral route, started on 2014-04-11, presumably until 2014-04-11\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2014-04-09, presumably until 2014-04-11\n- colchicine 0.6 MG Oral Tablet, through Oral route, started on 2014-04-10, presumably until 2014-04-11\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2014-04-09, presumably until 2014-04-10\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2014-04-11, presumably until 2014-04-11\n- 2 ML ondansetron 2 MG/ML Injection, started on 2014-04-09, presumably until 2014-04-10\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2014-04-09, presumably until 2014-04-09\n- levothyroxine sodium 0.137 MG Oral Tablet, through Oral route, started on 2014-04-10, presumably until 2014-04-11\n- magnesium sulfate 20 MG/ML Injection, through Intravenous route, started on 2014-04-10, presumably until 2014-04-10\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2014-04-11, presumably until 2015-04-11, with intended 2 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed for Nausea.\n- ketamine 100 MG/ML Injectable Solution, started on 2014-04-09, presumably until 2014-04-09\n- gabapentin 600 MG Oral Tablet, through Oral route, started on 2014-04-09, presumably until 2014-04-11\n- 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2014-04-09, presumably until 2014-04-09\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2014-04-10, presumably until 2014-10-08, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain.\n- calcium carbonate 1250 MG Oral Tablet, through Oral route, presumably until 2015-08-04. Instructions: take 2 Tabs by mouth daily.\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2014-04-10, presumably until 2014-04-11\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2014-04-09, presumably until 2014-04-09\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2014-04-09, presumably until 2014-04-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-04-14 00:00:00, ended at 2014-04-14 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-04-20 00:00:00, ended at 2014-04-20 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-04-21 15:26:16, ended at 2014-04-21 16:16:21\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diarrhea\n- Abdominal pain\n- Primary diagnosis: Post-surgical malabsorption\n- Dysuria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-22 13:04:00, ended at 2014-04-22 13:04:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 55 (milliliter per minute per square meter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.2 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.1 (thousand per microliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 31 (nanogram per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.45 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 11.3 (gram per deciliter)\n- Prothrombin time (PT): 14.2 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 36 (nanogram per milliliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 5 (nanogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 32.8 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 668 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 99.2 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 117 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Post-surgical malabsorption\n- Vitamin D deficiency\n- Dysuria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-22 13:05:00, ended at 2014-04-22 13:56:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Imaging of thorax abnormal\n- Postprocedural state finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-22 13:57:00, ended at 2014-04-22 14:56:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Postprocedural state finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-22 14:57:00, ended at 2014-04-22 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-04-27 00:00:00, ended at 2014-04-27 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-05-05 00:00:00, ended at 2014-05-05 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Mineral deficiency\n- Diarrhea\n- Primary diagnosis: Post-surgical malabsorption\n- Vitamin deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-05-12 00:00:00, ended at 2014-05-12 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic ischemic heart disease\n\n### Drug\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2014-05-12, presumably until 2015-09-10, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-05-12 00:00:00, ended at 2014-05-12 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acquired hypothyroidism\n- Primary diagnosis: Non-toxic uninodular goiter\n\n### Drug\n- levothyroxine sodium 0.137 MG Oral Tablet, started on 2014-05-12, presumably until 2014-05-18, with intended 0 refill(s). Instructions: TAKE 1 TABLET ORALLY EVERY MORNING BEFORE BREAKFAST\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2014-05-18 00:00:00, ended at 2014-05-18 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acquired hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.137 MG Oral Tablet, started on 2014-05-18, presumably until 2014-06-05, with intended 0 refill(s). Instructions: TAKE 1 TABLET ORALLY EVERY MORNING BEFORE BREAKFAST\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-06-05 08:46:56, ended at 2014-06-05 09:14:20\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n- Acquired hypothyroidism\n- Primary diagnosis: Non-toxic uninodular goiter\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2014-06-05, presumably until 2014-08-12, with intended 5 refill(s). Instructions: take 1 Simonton by mouth once a week.\n- levothyroxine sodium 0.137 MG Oral Tablet, started on 2014-06-05, presumably until 2015-04-20, with intended 3 refill(s). Instructions: TAKE 1 TABLET ORALLY EVERY MORNING BEFORE BREAKFAST\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-06-05 10:21:06, ended at 2014-06-05 11:20:44\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Scar conditions and fibrosis of skin\n- Benign neoplasm of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-06-10 14:08:34, ended at 2014-06-10 15:15:06\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary cardiomyopathy\n- Takotsubo cardiomyopathy\n- Primary diagnosis: Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-06-11 13:02:48, ended at 2014-06-11 14:15:04\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-07-08 09:12:49, ended at 2014-07-08 10:02:41\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Generally unwell\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-20 07:29:00, ended at 2014-07-20 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Imaging result abnormal\n- Postprocedural state finding\n- Lymphadenopathy\n- Imaging of musculoskeletal system abnormal\n- Solitary nodule of lung\n- Acquired absence of organ\n- Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-07-27 00:00:00, ended at 2014-07-27 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-27 08:00:00, ended at 2014-07-27 08:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-27 09:00:00, ended at 2014-07-27 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-08-10 14:02:20, ended at 2014-08-10 15:39:32\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Diarrhea\n\n### Drug\n- Streptococcus thermophilus, through Oral route, started on 2014-08-10, presumably until 2014-12-07, with intended 3 refill(s). Instructions: take 1 Cap by mouth Every Day. Please take medication 1/2 hour before eating daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-11 12:15:00, ended at 2014-08-11 12:42:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 114 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 247 (microgram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.2 (percent)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 20 (nanogram per milliliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.14 (milli-international unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.18 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.37 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 67.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 105 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.2 (percent)\n- MCV [Entitic volume] by Automated count: 97.5 (femtoliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.72 (million per microliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 23 (percent)\n- Ferritin [Mass/volume] in Serum or Plasma: 118 (nanogram per milliliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.5 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 362 (thousand per microliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 20 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 116 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Iron [Mass/volume] in Serum or Plasma: 57 (microgram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.3 (percent)\n- Globulin [Mass/volume] in Serum: 4.4 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.4 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Acquired hypothyroidism\n- Vitamin D deficiency\n- Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-11 12:43:00, ended at 2014-08-11 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n- Iron deficiency anemia\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Acquired hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-08-12 00:00:00, ended at 2014-08-12 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2014-08-12, presumably until 2014-08-14, with intended 5 refill(s). Instructions: take 1 Hodges by mouth once a week.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-08-14 00:00:00, ended at 2014-08-14 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2014-08-14, presumably until 2015-01-31, with intended 5 refill(s). Instructions: take 1 Cap by mouth 2 times a week.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2014-09-04 00:00:00, ended at 2014-09-04 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-26 15:26:10, ended at 2014-10-26 16:11:06\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes\n\n### Condition\n- Vitamin D deficiency\n- Primary diagnosis: Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-10-26 15:27:47, ended at 2014-10-26 17:04:44\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Abdominal pain\n- Chronic pain\n- Iron deficiency anemia\n- Primary diagnosis: Diarrhea\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-27 07:10:00, ended at 2014-10-27 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Ascites\n- Localized swelling, mass and lump, trunk\n- Postprocedural state finding\n- Lymphadenopathy\n- Primary malignant neoplasm of soft tissues\n- Disorder of pericardium\n- Solitary nodule of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-28 09:42:00, ended at 2014-10-28 11:14:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-28 11:15:00, ended at 2014-10-28 12:18:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 115 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 273 (microgram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.93 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 32 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.3 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 20.0 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.45 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.96 (million per microliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 22 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.9 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 67.8 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.7 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.0 (picogram)\n- MCV [Entitic volume] by Automated count: 96.3 (femtoliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.0 (nanogram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.1 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 42 (milliliter per minute per square meter)\n- Iron [Mass/volume] in Serum or Plasma: 60 (microgram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 358 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 90 (nanogram per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 128 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.2 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Iron deficiency anemia\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-28 12:19:00, ended at 2014-10-28 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-10-30 00:00:00, ended at 2014-10-30 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-11-12 13:05:41, ended at 2014-11-12 14:02:34\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-11-18 00:00:00, ended at 2014-11-18 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic ischemic heart disease\n\n### Drug\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2014-11-18, presumably until 2015-11-23, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-12-07 14:40:00, ended at 2014-12-07 17:11:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Urine: <5 (milligram per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 114 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Albumin/Creatinine [Mass Ratio] in Urine: <30 (milligram per gram)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 5.5 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Nausea and vomiting\n- Post-surgical malabsorption\n- Type 2 diabetes mellitus without complication\n- Abdominal pain\n- Diarrhea\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-12-07 15:15:13, ended at 2014-12-07 16:12:13\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-12-07 15:48:15, ended at 2014-12-07 17:05:49\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Post-surgical malabsorption\n- Primary diagnosis: Diarrhea\n- Abdominal pain\n- Nausea and vomiting\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-12-07 18:11:00, ended at 2014-12-07 20:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diarrhea\n- Abdominal pain\n- Nausea and vomiting\n- Post-surgical malabsorption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-12-07 21:00:00, ended at 2014-12-07 21:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Abdominal pain\n- Post-surgical malabsorption\n- Diarrhea\n- Nausea and vomiting\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-12-07 21:00:00, ended at 2014-12-07 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diarrhea\n- Nausea and vomiting\n- Post-surgical malabsorption\n- Abdominal pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-12-07 21:00:00, ended at 2014-12-07 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Abdominal pain\n- Post-surgical malabsorption\n- Nausea and vomiting\n- Diarrhea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-01-07 00:00:00, ended at 2015-01-07 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-01-25 00:00:00, ended at 2015-01-25 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-01-27 12:23:00, ended at 2015-01-27 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Monocytes [#/volume] in Blood by Automated count: 0.82 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.9 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.5 (percent)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 307 (microgram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.18 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n- Ferritin [Mass/volume] in Serum or Plasma: 66 (nanogram per milliliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.15 (million per microliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 21 (percent)\n- MCV [Entitic volume] by Automated count: 97.8 (femtoliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 5 (nanogram per milliliter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Iron [Mass/volume] in Serum or Plasma: 65 (microgram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.6 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 71.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 357 (thousand per microliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 35 (nanogram per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.6 (percent)\n- MCH [Entitic mass] by Automated count: 32.8 (picogram)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 30 (nanogram per milliliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.5 (percent)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.6 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.41 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Vitamin D deficiency\n- Iron deficiency anemia\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-01-31 00:00:00, ended at 2015-01-31 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acquired hypothyroidism\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2015-01-31, presumably until 2015-04-20, with intended 5 refill(s). Instructions: take 1 Cap by mouth 2 times a week.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-02-01 10:18:00, ended at 2015-02-01 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Ascites\n- Spondylolisthesis\n- Acquired spondylolisthesis\n- Spondylosis without myelopathy\n- Solitary nodule of lung\n- Disorder of back\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-02-03 00:00:00, ended at 2015-02-03 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-02-03 00:00:00, ended at 2015-02-03 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-02-03 09:30:00, ended at 2015-02-03 10:23:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-02-03 10:24:00, ended at 2015-02-03 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-03-01 09:03:00, ended at 2015-03-01 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Lung field abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-03-03 00:00:00, ended at 2015-03-03 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-03-03 08:54:00, ended at 2015-03-03 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-03-09 10:22:33, ended at 2015-03-09 11:17:09\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.276\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of lung\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-03-29 00:00:00, ended at 2015-03-29 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, started on 2015-03-29, presumably until 2016-03-27, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY WITH MEALS.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-04-01 09:58:00, ended at 2015-04-02 09:52:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Computed tomography guidance for, and monitoring of, parenchymal tissue ablation\n- CT of thorax with contrast\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Collection of venous blood by venipuncture\n- Radiologic examination, chest; single view, frontal\n- Percutaneous ablation of lung lesion or tissue\n- Ablation therapy for reduction or eradication of 1 or more pulmonary tumor(s) including pleura or chest wall when involved by tumor extension, percutaneous, including imaging guidance when performed, unilateral; radiofrequency\n\n### Condition\n- Chronic ischemic heart disease\n- Lung field abnormal\n- Secondary malignant neoplasm of lung\n- Takotsubo cardiomyopathy\n- Non-toxic uninodular goiter\n- Type 2 diabetes mellitus without complication\n- Coronary arteriosclerosis\n- Electrocardiogram abnormal\n- Old myocardial infarction\n- Primary malignant neoplasm of soft tissues\n- Vitamin D deficiency\n- Disorder of the peripheral nervous system\n- Essential hypertension\n- Obstructive sleep apnea syndrome\n- Pneumothorax\n- Primary malignant neoplasm of retroperitoneum\n- Solitary nodule of lung\n- Iron deficiency anemia\n- Acquired absence of organ\n- Acquired hypothyroidism\n- Cardiac arrhythmia\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2015-04-01, presumably until 2015-04-02\n- cefazolin 1000 MG Injection, started on 2015-04-01, presumably until 2015-04-01\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2015-04-01, presumably until 2015-04-01\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2015-04-02, presumably until 2015-04-02\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2015-04-01, presumably until 2015-04-02\n- 2 ML ondansetron 2 MG/ML Injection, started on 2015-04-01, presumably until 2015-04-01\n- 1 ML hydromorphone hydrochloride 2 MG/ML Prefilled Syringe, started on 2015-04-01, presumably until 2015-04-01\n- levothyroxine sodium 0.137 MG Oral Tablet, through Oral route, started on 2015-04-02, presumably until 2015-04-02\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2015-04-01, presumably until 2015-04-01\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2015-04-01, presumably until 2015-04-02\n- 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2015-04-01, presumably until 2015-04-01\n- midazolam 1 MG/ML Injectable Solution, started on 2015-04-01, presumably until 2015-04-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-04-02 10:08:00, ended at 2015-04-02 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n\n### Condition\n- Non-toxic multinodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-04-19 14:27:35, ended at 2015-04-19 15:51:01\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Diarrhea\n- Primary malignant neoplasm of soft tissues\n- Post-surgical malabsorption\n\n### Drug\n- bismuth subsalicylate 262 MG Chewable Tablet, through Oral route, started on 2015-04-19, presumably until 2015-08-04, with intended 5 refill(s). Instructions: take 2 Tabs by mouth every 6 hours.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-04-20 09:43:06, ended at 2015-04-20 10:12:12\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acquired hypothyroidism\n- Vitamin D deficiency\n- Non-toxic uninodular goiter\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2015-04-20, presumably until 2015-07-23, with intended 6 refill(s). Instructions: take 1 Cap by mouth 2 times a week.\n- levothyroxine sodium 0.137 MG Oral Tablet, started on 2015-04-20, presumably until 2015-07-23, with intended 4 refill(s). Instructions: TAKE 1 TABLET ORALLY EVERY MORNING BEFORE BREAKFAST\n- ondansetron 4 MG Oral Tablet, through Oral route, presumably until 2016-02-11, with intended 0 refill(s). Instructions: take  by mouth.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-04-20 10:16:00, ended at 2015-04-20 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Iron saturation [Mass Fraction] in Serum or Plasma: 31 (percent)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.8 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.20 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.2 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.03 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 346 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.6 (percent)\n- MCV [Entitic volume] by Automated count: 98.3 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.84 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.86 (million per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 71.4 (nanogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.0 (percent)\n- Iron [Mass/volume] in Serum or Plasma: 75 (microgram per deciliter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 243 (microgram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.9 (picogram)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.7 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.3 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.5 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.39 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.5 (percent)\n- Thyrotropin [Units/volume] in Serum or Plasma: 3.49 (micro-international unit per milliliter)\n- IgA [Mass/volume] in Serum or Plasma: 298 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Vitamin D deficiency\n- Diarrhea\n- Iron deficiency anemia\n- Acquired hypothyroidism\n- Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-05-06 11:51:00, ended at 2015-05-06 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Imaging of abdomen abnormal\n- Imaging of gastrointestinal tract abnormal\n- Secondary malignant neoplasm of lung\n- Lymphadenopathy\n- Lung field abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-05-07 11:22:00, ended at 2015-05-07 12:50:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- diclofenac sodium 0.01 MG/MG Topical Gel, started on 2015-05-06, presumably until 2015-11-01, with intended 0 refill(s)\n- levofloxacin 500 MG Oral Tablet, started on 2015-04-26, presumably until 2015-08-04, with intended 0 refill(s)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-05-07 12:51:00, ended at 2015-05-07 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-07-02 00:00:00, ended at 2015-07-02 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-07-15 17:03:00, ended at 2015-07-15 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, any joint of upper extremity; without contrast material(s), followed by contrast material(s) and further sequences\n\n### Condition\n- Synovitis and tenosynovitis\n- Ganglion of joint\n- Sprain of wrist\n- Wrist joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-07-18 00:00:00, ended at 2015-07-18 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Enthesopathy\n- Ganglion cyst\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-07-23 00:00:00, ended at 2015-07-23 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-07-23 00:00:00, ended at 2015-07-23 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n- Primary diagnosis: Acquired hypothyroidism\n- Non-toxic uninodular goiter\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2015-07-23, presumably until 2016-08-28, with intended 6 refill(s). Instructions: take 1 Cap by mouth as directed Take 3 x/ week x 4 weeks then 2x/week\n- levothyroxine sodium 0.137 MG Oral Tablet, started on 2015-07-23, presumably until 2015-11-05, with intended 4 refill(s). Instructions: Take 1.5 pills on Sun, 1 pill Mon-Sat\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-08-02 11:35:00, ended at 2015-08-02 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Lung field abnormal\n- Lymphadenopathy\n- Disease of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-08-02 14:26:43, ended at 2015-08-02 15:36:34\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign neoplasm of skin\n- Chromosomal disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-08-04 00:00:00, ended at 2015-08-04 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-08-04 00:00:00, ended at 2015-08-04 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-08-04 00:00:00, ended at 2015-08-04 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Stool: TNP (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diarrhea\n- Primary diagnosis: Post-surgical malabsorption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-08-04 09:25:00, ended at 2015-08-04 13:36:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, wrist; complete, minimum of 3 views\n\n### Condition\n- Post-surgical malabsorption\n- Primary cardiomyopathy\n- Wrist joint pain\n- Primary malignant neoplasm of soft tissues\n- Takotsubo cardiomyopathy\n- Diarrhea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-08-04 10:15:34, ended at 2015-08-04 11:30:16\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sprain of wrist\n- Primary diagnosis: Synovitis and tenosynovitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-08-04 11:59:04, ended at 2015-08-04 13:31:32\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-08-04 11:59:43, ended at 2015-08-04 16:53:27\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.496\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-08-04 13:37:00, ended at 2015-08-04 17:05:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.2 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14.8 (percent)\n- MCV [Entitic volume] by Automated count: 98.0 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.2 (gram per deciliter)\n- Prothrombin time (PT): 12.7 (second)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.9 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.0 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 74.2 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 108 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Globulin [Mass/volume] in Serum: 4.8 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.13 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.8 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 29.4 (second)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.6 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.64 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.10 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 97 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 356 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-08-04 15:09:59, ended at 2015-08-04 15:54:42\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Post-surgical malabsorption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-08-04 16:12:17, ended at 2015-08-04 16:35:02\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary cardiomyopathy\n- Takotsubo cardiomyopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-08-04 17:06:00, ended at 2015-08-04 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Thiamine [Moles/volume] in Serum or Plasma: 6 (nanomole per liter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 7 (nanogram per milliliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 37 (nanogram per milliliter)\n- Erythrocyte sedimentation rate: 48 (millimeter per hour)\n- Ferritin [Mass/volume] in Serum or Plasma: 63.3 (nanogram per milliliter)\n- Iron [Mass/volume] in Serum or Plasma: 49 (microgram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 18 (percent)\n- Retinol [Mass/volume] in Serum or Plasma: 63.4 (microgram per deciliter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 268 (microgram per deciliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 44 (nanogram per milliliter)\n- Folate [Mass/volume] in Red Blood Cells: 212 (nanogram per milliliter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 546 (picogram per milliliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Diarrhea\n- Post-surgical malabsorption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-08-11 11:35:00, ended at 2015-08-11 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen; with contrast material(s)\n\n### Condition\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-08-19 13:56:26, ended at 2015-08-19 15:45:40\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 101 - 200 (per high power field)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: Full Field (per high power field)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Primary diagnosis: Dysuria\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- nitrofurantoin, macrocrystals 25 MG / nitrofurantoin, monohydrate 75 MG Oral Capsule, through Oral route, started on 2015-08-19, presumably until 2015-08-26, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day for 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-08-19 15:35:00, ended at 2015-08-19 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocytes [#/volume] in Blood by Automated count: 3.76 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.2 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.3 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 96.3 (femtoliter)\n- Prothrombin time (PT): 13.8 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 37 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 5.0 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 108 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.9 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.9 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 12 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.5 (picogram)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 98 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 369 (thousand per microliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Dysuria\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-08-24 00:00:00, ended at 2015-08-24 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-08-26 12:53:00, ended at 2015-08-26 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Disease of liver\n- Primary malignant neoplasm of retroperitoneum\n- Secondary malignant neoplasm of liver\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-08-30 09:03:04, ended at 2015-08-30 11:26:46\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.709\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neoplastic disease\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-09-07 00:00:00, ended at 2015-09-07 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Thiamine deficiency\n\n### Drug\n- thiamine 100 MG Oral Tablet, through Oral route, started on 2015-09-08, presumably until 2019-01-22, with intended 3 refill(s). Instructions: take 1 Tab by mouth Every Day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-09-10 00:00:00, ended at 2015-09-10 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic ischemic heart disease\n\n### Drug\n- carvedilol 3.125 MG Oral Tablet, started on 2015-09-11, presumably until 2016-11-28, with intended 3 refill(s). Instructions: TAKE 1 TABLET ORALLY TWICE DAILY WITH MEALS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2015-09-24 00:00:00, ended at 2015-09-24 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n- Anesthesia for intraperitoneal procedures in upper abdomen including laparoscopy; partial hepatectomy or management of liver hemorrhage (excluding liver biopsy)\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Coronary atherosclerosis\n- Type 2 diabetes mellitus without complication\n- Acquired hypothyroidism\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, through Intravenous route, started on 2015-09-24, presumably until 2015-09-24\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2015-09-24, presumably until 2015-09-24\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2015-09-24, presumably until 2015-09-24\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2015-09-24, presumably until 2015-09-24\n- cefoxitin 1000 MG Injection, through Intravenous route, started on 2015-09-24, presumably until 2015-09-24\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2015-09-24, presumably until 2015-09-24\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2015-09-24, presumably until 2015-09-24\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2015-09-24, presumably until 2015-09-24\n- 2 ML ondansetron 2 MG/ML Injection, started on 2015-09-24, presumably until 2015-09-24\n- ketamine 100 MG/ML Injectable Solution, started on 2015-09-24, presumably until 2015-09-24\n- gabapentin 100 MG Oral Capsule, through Oral route, started on 2015-09-24, presumably until 2015-09-24\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2015-09-24, presumably until 2015-09-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2015-09-24 00:00:00, ended at 2015-09-24 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Injection(s), anesthetic agent(s) and/or steroid; other peripheral nerve or branch\n\n### Condition\n- Acute postoperative pain\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2015-09-24, presumably until 2015-09-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2015-09-24 06:55:00, ended at 2015-10-01 12:30:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 73 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 99.9 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 88 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.3 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 326 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 144 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.52 (million per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Glucose [Mass/volume] in Blood: 169 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.2 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.5 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Prothrombin time (PT): 14.6 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Body height: 5' 6.5\" (inch (US))\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCH [Entitic mass] by Automated count: 32.5 (picogram)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 111 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.3 (thousand per microliter)\n\n### Procedure\n- Physical therapy evaluation\n- Other lysis of peritoneal adhesions\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Radiologic examination, abdomen; single anteroposterior view\n- Collection of venous blood by venipuncture\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Occupational therapy evaluation\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Partial hepatectomy\n\n### Condition\n- Abdominal pain\n- Coronary arteriosclerosis\n- Gastroesophageal reflux disease\n- Essential hypertension\n- Old myocardial infarction\n- Primary malignant neoplasm of soft tissues\n- Acquired hypothyroidism\n- Primary diagnosis: Acute postoperative pain\n- Secondary malignant neoplasm of liver\n- Acute renal failure syndrome\n- Peritoneal adhesion\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2015-09-24, presumably until 2015-09-28\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2015-09-29, presumably until 2015-09-29\n- levothyroxine sodium 0.112 MG Oral Tablet, through Oral route, started on 2015-09-25, presumably until 2015-10-01\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2015-09-24, presumably until 2015-10-01\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2015-09-29, presumably until 2015-10-01\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2015-09-27, presumably until 2016-01-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2015-09-27, presumably until 2015-09-30\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2015-09-29, presumably until 2015-09-29\n- levothyroxine sodium 0.025 MG Oral Tablet, through Oral route, started on 2015-09-25, presumably until 2015-10-01\n- oxycodone hydrochloride 10 MG Oral Tablet, through Oral route, started on 2015-09-30, presumably until 2015-11-10, with intended 0 refill(s). Instructions: take 1 Tab by mouth Q3H PRN (pain)\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2015-09-25, presumably until 2015-10-01\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2015-09-27, presumably until 2015-09-30\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2015-09-24, presumably until 2015-09-26\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2015-09-24, presumably until 2016-01-10, with intended 0 refill(s). Instructions: take 1 Cap by mouth 3 times a day\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2015-09-24, presumably until 2015-09-29\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2015-09-29, presumably until 2015-10-30, with intended 0 refill(s). Instructions: take 1 Packet by mouth daily\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2015-09-26, presumably until 2015-10-01\n- 2 ML ondansetron 2 MG/ML Injection, started on 2015-09-24, presumably until 2015-10-01\n- 1 ML hydromorphone hydrochloride 2 MG/ML Prefilled Syringe, started on 2015-09-24, presumably until 2015-09-26\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2015-09-24, presumably until 2015-09-24\n- ketamine 100 MG/ML Injectable Solution, started on 2015-09-24, presumably until 2015-09-24\n- 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2015-09-26, presumably until 2015-09-30\n- 12 HR oxycodone hydrochloride 30 MG Extended Release Oral Tablet, through Oral route, started on 2015-09-30, presumably until 2015-09-30, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2015-09-25, presumably until 2015-10-01, with intended 0 refill(s). Instructions: take 1-3 Tabs by mouth Q3H PRN for Pain\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2015-09-25, presumably until 2015-09-25\n- 1 ML promethazine hydrochloride 25 MG/ML Injection, started on 2015-09-24, presumably until 2015-09-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-10-05 12:12:30, ended at 2015-10-05 12:48:24\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.472\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-10-06 13:08:36, ended at 2015-10-06 14:15:28\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Wrist joint pain\n\n### Drug\n- Abuse-Deterrent 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, started on 2015-10-01, presumably until 2015-10-06, with intended 0 refill(s)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-10-06 15:24:02, ended at 2015-10-06 17:54:51\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Post-surgical malabsorption\n- Wrist joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-10-15 00:00:00, ended at 2015-10-15 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Post-surgical malabsorption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-10-25 16:24:19, ended at 2015-10-25 17:02:02\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.315\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-10-26 00:00:00, ended at 2015-10-26 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Post-surgical malabsorption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-10-29 07:40:00, ended at 2015-10-29 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Ascites\n- Primary malignant neoplasm of trunk\n- Abnormal findings on diagnostic imaging of lung\n- Malignant neoplasm of connective and soft tissue of abdomen\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-11-01 00:00:00, ended at 2015-11-01 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-11-01 00:00:00, ended at 2015-11-01 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-11-01 10:13:19, ended at 2015-11-01 12:15:29\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-11-01 10:15:00, ended at 2015-11-01 14:28:16\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-11-02 06:16:00, ended at 2015-11-02 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- MCH [Entitic mass] by Automated count: 30.3 (picogram)\n- MCHC [Mass/volume] by Automated count: 31.3 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.54 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 32 (nanogram per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 13.4 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 40 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 103 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.7 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.2 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 67.7 (percent)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 37 (nanogram per milliliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.58 (thousand per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 66.8 (nanogram per milliliter)\n- Globulin [Mass/volume] in Serum: 4.9 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 9 (percent)\n- MCV [Entitic volume] by Automated count: 96.8 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.2 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 92 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.27 (million per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.7 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 5 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Iron [Mass/volume] in Serum or Plasma: 24 (microgram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 7.1 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.10 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.91 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 394 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 16.10 (micro-international unit per milliliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hypothyroidism\n- Primary malignant neoplasm of soft tissues\n- Vitamin D deficiency\n- Iron deficiency anemia\n- Post-surgical malabsorption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-11-03 00:00:00, ended at 2015-11-03 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-11-05 00:00:00, ended at 2015-11-05 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n\n### Drug\n- levothyroxine sodium 0.175 MG Oral Tablet, through Oral route, started on 2015-11-05, presumably until 2015-12-29, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-11-10 00:00:00, ended at 2015-11-10 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- oxycodone hydrochloride 10 MG Oral Tablet, through Oral route, started on 2015-11-10, presumably until 2016-01-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-11-23 00:00:00, ended at 2015-11-23 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- lisinopril 5 MG Oral Tablet, started on 2015-11-23, presumably until 2016-12-13, with intended 10 refill(s). Instructions: TAKE 1 TABLET ORALLY DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-12-17 11:48:00, ended at 2015-12-17 12:58:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.70 (million per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 53.7 (nanogram per milliliter)\n- Globulin [Mass/volume] in Serum: 4.8 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.2 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 73.1 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 13 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 6.89 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14.9 (percent)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Prothrombin time (PT): 13.3 (second)\n- aPTT in Platelet poor plasma by Coagulation assay: 27.0 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.5 (percent)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- MCV [Entitic volume] by Automated count: 93.9 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.97 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.18 (micro-international unit per milliliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 98 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.8 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 103 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.3 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.4 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.40 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 358 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Iron [Mass/volume] in Serum or Plasma: 39 (microgram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Dysuria\n- Thiamine deficiency\n- Neoplastic disease of uncertain behavior\n- Essential hypertension\n- Primary malignant neoplasm\n- Primary malignant neoplasm of soft tissues\n- Iron deficiency anemia\n- Post-surgical malabsorption\n- Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-12-17 12:14:56, ended at 2015-12-17 12:49:51\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Primary diagnosis: Iron deficiency anemia\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-12-17 12:59:00, ended at 2015-12-17 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Iron deficiency anemia\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2015-12-17, presumably until 2015-12-17\n- methylprednisolone 40 MG Injection, started on 2015-12-17, presumably until 2015-12-17\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2015-12-17, presumably until 2015-12-17\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2015-12-17, presumably until 2015-12-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-12-18 08:57:00, ended at 2015-12-18 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Iron deficiency anemia\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2015-12-18, presumably until 2015-12-18\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2015-12-18, presumably until 2015-12-18\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2015-12-18, presumably until 2015-12-18\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2015-12-18, presumably until 2015-12-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-12-22 12:14:00, ended at 2015-12-22 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Abnormal findings on diagnostic imaging of lung\n- Disorder of kidney and/or ureter\n- Malignant neoplasm of connective and soft tissue of abdomen\n- Primary malignant neoplasm of trunk\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-12-27 00:00:00, ended at 2015-12-27 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prednisone 10 MG Oral Tablet, started on 2015-12-27, presumably until 2016-01-10, with intended 0 refill(s). Instructions: Take 50 mg po on day 1, 40 mg po on day 2, 30 mg po on day 3, 20 mg po on day 4, 10 mg po on day 5\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-12-27 13:02:00, ended at 2015-12-27 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.69 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 319 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 17 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.4 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 100 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.9 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.92 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 93.2 (femtoliter)\n- Prothrombin time (PT): 14.2 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Ferritin [Mass/volume] in Serum or Plasma: 151.0 (nanogram per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.4 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 78.5 (percent)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 11.0 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.2 (percent)\n- Iron [Mass/volume] in Serum or Plasma: 21 (microgram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.61 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 31.8 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.80 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.9 (gram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 5 (percent)\n- MCH [Entitic mass] by Automated count: 29.6 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Iron deficiency anemia\n- Post-surgical malabsorption\n- Primary malignant neoplasm of soft tissues\n- Dysuria\n- Primary malignant neoplasm\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-12-27 13:29:14, ended at 2015-12-27 15:24:40\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-12-27 14:48:33, ended at 2015-12-27 16:30:26\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.748\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-12-29 00:00:00, ended at 2015-12-29 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.175 MG Oral Tablet, started on 2015-12-29, presumably until 2016-02-07, with intended 1 refill(s). Instructions: TAKE 1 TABLET ORALLY IN THE MORNING BEFORE BREAKFAST\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-12-29 00:00:00, ended at 2015-12-29 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-01-10 16:49:00, ended at 2016-01-11 14:48:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocytes [#/volume] in Blood by Automated count: 4.03 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 105 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.8 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- MCHC [Mass/volume] by Automated count: 32.0 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 53 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.7 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.92 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.7 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 75.8 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Erythrocyte sedimentation rate: 40 (millimeter per hour)\n- MCH [Entitic mass] by Automated count: 30.0 (picogram)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.7 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 3 - 5 (per high power field)\n- Neutrophils [#/volume] in Blood by Automated count: 5.51 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.3 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 93.7 (femtoliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.1 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 394 (thousand per microliter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Initial observation care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination \n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Anorectal disorder\n- Fever\n- Hypothyroidism\n- Essential hypertension\n- Obstructive sleep apnea syndrome\n- Residual hemorrhoidal skin tags\n- Thrombosed external hemorrhoids\n- Acquired hypothyroidism\n- Cardiomyopathy\n- Post-surgical malabsorption\n- Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplasm of lung\n- Disorder of kidney and/or ureter\n- Old myocardial infarction\n- Primary diagnosis: Pain\n- Secondary malignant neoplastic disease\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2016-01-11, presumably until 2016-01-11\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2016-01-10, presumably until 2016-01-10\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2016-01-11, presumably until 2016-02-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2016-01-11, presumably until 2016-02-17, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day as needed for Constipation\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2016-01-11, presumably until 2016-01-11\n- levothyroxine sodium 0.025 MG Oral Tablet, through Oral route, started on 2016-01-11, presumably until 2016-01-11\n- oxycodone hydrochloride 10 MG Oral Tablet, through Oral route, started on 2016-01-11, presumably until 2016-02-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed (pain)\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2016-01-20, presumably until 2016-04-17, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2016-01-11, presumably until 2016-02-17, with intended 0 refill(s). Instructions: take 1 Packet by mouth daily as needed\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2016-01-11, presumably until 2016-01-11\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2016-01-11, presumably until 2016-01-11\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-01-10, presumably until 2016-01-10\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2016-01-10, presumably until 2016-01-10\n- lidocaine hydrochloride 0.02 MG/MG Topical Gel, started on 2016-01-11, presumably until 2016-08-23, with intended 0 refill(s). Instructions: Apply liberally to anus 3-4x daily as needed for pain\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2016-01-11, presumably until 2016-01-11\n- 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2016-01-10, presumably until 2016-01-10\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2016-01-10, presumably until 2016-01-11\n- prednisone 20 MG Oral Tablet, through Oral route, started on 2016-01-11, presumably until 2016-01-11\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2016-01-11, presumably until 2016-01-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-01-26 00:00:00, ended at 2016-01-26 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-01-31 00:00:00, ended at 2016-01-31 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n- Acquired hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-01-31 00:00:00, ended at 2016-01-31 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-02-01 00:00:00, ended at 2016-02-01 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n\n### Drug\n- levothyroxine sodium 0.175 MG Oral Tablet, through Oral route, started on 2016-02-01, presumably until 2016-02-07, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-02-03 00:00:00, ended at 2016-02-03 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-toxic uninodular goiter\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.2 MG Oral Tablet, through Oral route, started on 2016-02-07, presumably until 2016-03-06, with intended 2 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-02-03 00:00:00, ended at 2016-02-03 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-02-03 07:58:00, ended at 2016-02-03 10:42:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 113 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Non-toxic uninodular goiter\n- Inflammatory disorder of digestive tract\n- Radiation-induced disorder\n- Solitary nodule of lung\n- Vitamin D deficiency\n- Absent kidney\n- Acquired absence of organ\n- Abnormal findings on diagnostic imaging of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-02-03 10:43:00, ended at 2016-02-03 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 35 (nanogram per milliliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 35 (nanogram per milliliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 11.20 (micro-international unit per milliliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Non-toxic uninodular goiter\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-02-04 00:00:00, ended at 2016-02-04 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Osteoarthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-02-08 00:00:00, ended at 2016-02-08 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-02-11 00:00:00, ended at 2016-02-11 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-toxic uninodular goiter\n- Vitamin D deficiency\n\n### Drug\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2016-02-11, presumably until 2016-03-21, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours\n- oxycodone hydrochloride 10 MG Oral Tablet, through Oral route, started on 2016-02-11, presumably until 2016-03-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed (pain)\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2016-02-11, presumably until 2016-08-24, with intended 1 refill(s). Instructions: take 2 Tabs by mouth 3 times a day as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-02-15 13:20:33, ended at 2016-02-15 15:18:40\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.535\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-02-16 00:00:00, ended at 2016-02-16 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-02-16 12:22:00, ended at 2016-02-16 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s), followed by contrast material(s) and further sequences\n\n### Condition\n- Abscess of buttock\n- Disorder of bone\n- Mononeuropathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-02-17 09:46:44, ended at 2016-02-17 10:42:55\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Electrocardiogram abnormal\n- Disorder of soft tissue\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2013-10-24, presumably until 2016-02-17, with intended 0 refill(s)\n- hydromorphone hydrochloride 4 MG Oral Tablet, through Oral route, started on 2015-04-09, presumably until 2016-03-12, with intended 0 refill(s). Instructions: take 2 mg by mouth every 6 hours as needed \n- colchicine 0.6 MG Oral Tablet, started on 2013-10-06, presumably until 2016-02-17, with intended 0 refill(s)\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2016-02-02, presumably until 2016-02-17, with intended 0 refill(s). Instructions: take 5 mg by mouth\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, started on 2016-01-11, presumably until 2016-02-17, with intended 0 refill(s)\n- aspirin 81 MG Chewable Tablet, through Oral route, presumably until 2016-02-17, with intended 0 refill(s). Instructions: take 81 mg by mouth\n- triamcinolone acetonide 0.25 MG/ML Topical Cream, through Topical route, started on 2013-09-05, presumably until 2016-02-17, with intended 0 refill(s). Instructions: by Topical route as needed \n- Abuse-Deterrent 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, started on 2016-02-11, presumably until 2016-02-17, with intended 0 refill(s)\n- ondansetron 8 MG Disintegrating Oral Tablet, through Oral route, presumably until 2016-02-17, with intended 0 refill(s). Instructions: take 8 mg by mouth\n- hydrocortisone acetate 25 MG Rectal Suppository, through Rectal route, started on 2016-01-06, presumably until 2017-11-07, with intended 0 refill(s). Instructions: insert 25 mg into the rectum\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-03-03 09:07:12, ended at 2016-03-03 13:59:05\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Post-surgical malabsorption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-03 11:00:00, ended at 2016-03-03 12:19:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n\n### Condition\n- Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-03 12:20:00, ended at 2016-03-03 13:43:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Abnormal findings on diagnostic imaging of urinary organs\n- Dysuria\n- Primary malignant neoplasm\n- Primary malignant neoplasm of soft tissues\n- Vitamin D deficiency\n- Iron deficiency anemia\n- Abnormal findings on diagnostic imaging of lung\n- Hypothyroidism\n- Osteoarthritis\n- Abnormal findings diagnostic imaging of liver+biliary tract\n- Malignant neoplasm of connective and soft tissue of pelvis\n- Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-03 13:44:00, ended at 2016-03-03 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 2 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.7 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.9 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.4 (picogram)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 11.6 (gram per deciliter)\n- Iron [Mass/volume] in Serum or Plasma: 23 (microgram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.3 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 53.1 (nanogram per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5.1 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 9.66 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.11 (micro-international unit per milliliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.1 (nanogram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 93 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 131 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 11 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 112 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.4 (percent)\n- MCV [Entitic volume] by Automated count: 92.8 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 89.0 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 5.7 (millimole per liter)\n- Prothrombin time (PT): 13.7 (second)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.81 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 333 (thousand per microliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 7 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm\n- Dysuria\n- Neoplasm of uncertain behavior of soft tissues\n- Primary malignant neoplasm of soft tissues\n- Vitamin D deficiency\n- Iron deficiency anemia\n- Hypothyroidism\n- Disorder of soft tissue\n- Osteoarthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-03-06 08:45:06, ended at 2016-03-06 11:46:31\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.496\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-03-06 10:02:09, ended at 2016-03-06 12:47:44\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.496\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-03-06 12:23:26, ended at 2016-03-06 12:59:12\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-toxic uninodular goiter\n- Primary diagnosis: Hypothyroidism\n- Vitamin D deficiency\n\n### Drug\n- cholecalciferol 1.25 MG Oral Capsule, through Oral route, started on 2016-03-06, presumably until 2017-08-23, with intended 3 refill(s). Instructions: take 1 Cap by mouth 2 times a week\n- levothyroxine sodium 0.2 MG Oral Tablet, through Oral route, started on 2016-03-06, presumably until 2016-10-06, with intended 3 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2016-03-07 00:00:00, ended at 2016-03-07 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for all procedures on the integumentary system, muscles and nerves of head, neck, and posterior trunk, not otherwise specified\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2016-03-07, presumably until 2016-03-07\n- cefazolin 1000 MG Injection, started on 2016-03-07, presumably until 2016-03-07\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2016-03-07, presumably until 2016-03-07\n- vasopressin (USP) 20 UNT/ML Injectable Solution, through Intravenous route, started on 2016-03-07, presumably until 2016-03-07\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2016-03-07, presumably until 2016-03-07\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-03-07, presumably until 2016-03-07\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-03-07, presumably until 2016-03-07\n- succinylcholine chloride 20 MG/ML Injectable Solution, started on 2016-03-07, presumably until 2016-03-07\n- midazolam 1 MG/ML Injectable Solution, started on 2016-03-07, presumably until 2016-03-07\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2016-03-07, presumably until 2016-03-07\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2016-03-07, presumably until 2016-03-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2016-03-07 00:00:00, ended at 2016-03-07 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 10 ML bupivacaine hydrochloride 2.5 MG/ML / epinephrine 0.005 MG/ML Injection, started on 2016-03-07, presumably until 2016-03-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2016-03-07 05:45:00, ended at 2016-03-09 14:22:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.1 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 315 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 18.9 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 93.4 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 147 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.1 (picogram)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.70 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.5 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Body height: 5' 6\" (inch (US))\n- Erythrocyte distribution width [Ratio] by Automated count: 17.5 (percent)\n\n### Procedure\n- Excision of Buttock Subcutaneous Tissue and Fascia, Open Approach\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Physical therapy evaluation\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Occupational therapy evaluation\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Collection of venous blood by venipuncture\n\n### Condition\n- Electrocardiogram abnormal\n- Gastroesophageal reflux disease without esophagitis\n- Heart failure\n- Bradycardia\n- Disorder of digestive system\n- Major depression, single episode\n- Secondary malignant neoplastic disease\n- Vitamin D deficiency\n- Absent kidney\n- Acquired absence of organ\n- Iron deficiency anemia\n- Old myocardial infarction\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Malignant neoplasm of connective and soft tissue of pelvis\n- Obstructive sleep apnea syndrome\n- Osteoarthritis\n- Chest pain\n- Chronic gout without tophus\n- Disorder of soft tissue\n- Essential hypertension\n- Hypothyroidism\n- Type 2 diabetes mellitus without complication\n- Acquired absence of spleen\n- Atherosclerosis of coronary artery without angina pectoris\n- Hyperkalemia\n- Primary malignant neoplasm\n\n### Drug\n- benzocaine 15 MG / menthol 3.6 MG Oral Lozenge, through Submucosal route, started on 2016-03-07, presumably until 2016-03-07\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2016-03-07, presumably until 2016-03-07\n- thiamine 100 MG Oral Tablet, through Oral route, started on 2016-03-07, presumably until 2016-03-09\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2016-03-08, presumably until 2016-03-09\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2016-03-08, presumably until 2016-03-09\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2016-03-08, presumably until 2016-03-30, with intended 0 refill(s). Instructions: inject 0.4 mL subcutaneous (under the skin) Every Day\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2016-03-07, presumably until 2016-03-09\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2016-03-07, presumably until 2016-03-07\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2016-03-08, presumably until 2016-03-09\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2016-03-07, presumably until 2016-03-09\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-03-07, presumably until 2016-03-08\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2016-03-07, presumably until 2016-03-08\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-03-07, presumably until 2016-03-08\n- 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2016-03-08, presumably until 2016-03-09\n- 12 HR oxycodone hydrochloride 30 MG Extended Release Oral Tablet, through Oral route, started on 2016-03-09, presumably until 2016-03-23, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2016-03-07, presumably until 2016-03-13, with intended 0 refill(s). Instructions: take 1-4 Tabs by mouth Q3H PRN\n- ascorbic acid 500 MG Oral Tablet, through Oral route, started on 2016-03-07, presumably until 2016-03-09\n- aluminum hydroxide 40 MG/ML / magnesium hydroxide 40 MG/ML / simethicone 4 MG/ML Oral Suspension, through Oral route, started on 2016-03-08, presumably until 2016-03-08\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2016-03-08, presumably until 2016-03-09\n- 1 ML promethazine hydrochloride 25 MG/ML Injection, started on 2016-03-07, presumably until 2016-03-07\n- hydrocortisone acetate 25 MG Rectal Suppository, through Rectal route, started on 2016-03-07, presumably until 2016-03-08\n- cefazolin 2000 MG Injection, through Intravenous route, started on 2016-03-07, presumably until 2016-03-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-03-12 00:00:00, ended at 2016-03-12 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydromorphone hydrochloride 4 MG Oral Tablet, through Oral route, started on 2016-03-12, presumably until 2016-03-12, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth every 6 hours as needed for Pain\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-03-13 00:00:00, ended at 2016-03-13 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- oxycodone hydrochloride 10 MG Oral Tablet, through Oral route, started on 2016-03-13, presumably until 2016-03-21, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 3 to 4 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-03-20 00:00:00, ended at 2016-03-20 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2016-03-20, presumably until 2016-08-06, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-03-20 00:00:00, ended at 2016-03-20 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-03-20 00:00:00, ended at 2016-03-20 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-03-20 08:57:08, ended at 2016-03-20 11:39:36\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.496\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Electrocardiogram abnormal\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-20 10:43:00, ended at 2016-03-20 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.8 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.72 (million per microliter)\n- Follitropin [Units/volume] in Serum or Plasma: 44.1 (milli-international unit per milliliter)\n- Urate [Mass/volume] in Serum or Plasma: 4.7 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Anion gap in Serum or Plasma: 2 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.3 (gram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 30.7 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.6 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.18 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 179 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.8 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 11.4 (percent)\n- MCH [Entitic mass] by Automated count: 30.4 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 394 (thousand per microliter)\n- Prothrombin time (PT): 13.8 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.78 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 76.3 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 125 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.8 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.3 (percent)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-03-21 00:00:00, ended at 2016-03-21 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2016-03-21, presumably until 2016-04-06, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours\n- oxycodone hydrochloride 10 MG Oral Tablet, through Oral route, started on 2016-03-21, presumably until 2016-04-06, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 3 to 4 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-03-22 11:55:08, ended at 2016-03-22 12:53:55\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-03-27 00:00:00, ended at 2016-03-27 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2016-03-27, presumably until 2016-03-31, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-30 08:56:00, ended at 2016-03-30 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Abnormal findings on diagnostic imaging of lung\n- Primary malignant neoplasm of soft tissues\n- Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-31 08:36:00, ended at 2016-03-31 15:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 10.9 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.02 (thousand per microliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 46 (unit per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.7 (percent)\n- Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma: 164 (picogram per milliliter)\n- Prothrombin time (PT): 14.2 (second)\n- Creatine kinase.MB [Mass/volume] in Serum or Plasma: 0.9 (nanogram per milliliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.62 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.3 (percent)\n- Body height: 5' 6.5\" (inch (US))\n- Leukocytes [#/volume] in Specimen by Automated count: 8.4 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 17.5 (percent)\n- MCH [Entitic mass] by Automated count: 30.2 (picogram)\n- MCV [Entitic volume] by Automated count: 94.9 (femtoliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.46 (thousand per microliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.4 (percent)\n- MCHC [Mass/volume] by Automated count: 31.8 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 71.9 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.73 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 339 (thousand per microliter)\n\n### Procedure\n- Insertion of Infusion Device into Superior Vena Cava, Percutaneous Approach\n- Fluoroscopy of Superior Vena Cava, Guidance\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Insertion of Tunneled Vascular Access Device into Chest Subcutaneous Tissue and Fascia, Open Approach\n- Fluoroscopic guidance for central venous access device placement, replacement (catheter only or complete), or removal (includes fluoroscopic guidance for vascular access and catheter manipulation, any necessary contrast injections through access site or c\n- Insertion of tunneled centrally inserted central venous access device, with subcutaneous port; age 5 years or older\n- Collection of venous blood by venipuncture\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Secondary malignant neoplastic disease\n- Primary malignant neoplasm of soft tissues\n- Absent kidney\n- Disorder due to and following accidental poisoning\n- Disorder due to and following drug poisoning\n- Essential hypertension\n- Gout\n- Hypothyroidism\n- Acquired absence of organ\n- Electrocardiogram abnormal\n- Obstructive sleep apnea syndrome\n- Secondary malignant neoplasm of lung\n- Obesity\n\n### Drug\n- aspirin 325 MG Oral Tablet, through Oral route, started on 2016-03-31, presumably until 2016-04-17, with intended 0 refill(s). Instructions: take 325 mg by mouth every morning with breakfast\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2016-03-31, presumably until 2016-03-31\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-03-31, presumably until 2016-03-31\n- nitroglycerin 0.4 MG Sublingual Tablet, through Sublingual route, started on 2016-03-31, presumably until 2016-03-31\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-31 15:48:00, ended at 2016-03-31 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 55.8 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Disorder due to and following accidental poisoning\n- Disorder due to and following drug poisoning\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-04-03 00:00:00, ended at 2016-04-03 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amoxicillin 875 MG Oral Tablet, through Oral route, started on 2016-04-03, presumably until 2016-04-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-04-05 00:00:00, ended at 2016-04-05 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2016-04-06, presumably until 2016-04-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours\n- oxycodone hydrochloride 10 MG Oral Tablet, through Oral route, started on 2016-04-06, presumably until 2016-04-13, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 to 6 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-04-11 14:56:00, ended at 2016-04-12 11:52:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bicarbonate [Moles/volume] in Specimen: 22.7 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.9 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 73.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 319 (thousand per microliter)\n- Prothrombin time (PT): 14.4 (second)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.27 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 81 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.9 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 13.1 (percent)\n- MCH [Entitic mass] by Automated count: 31.1 (picogram)\n- aPTT in Platelet poor plasma by Coagulation assay: 30.3 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.7 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.05 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.8 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.35 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 10.4 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.15 (thousand per microliter)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 20 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 114 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 95.3 (femtoliter)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 17 (millimeter mercury column)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Base excess in Blood by calculation: -3 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 44.2 (millimeter mercury column)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.3 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Computed tomographic angiography, chest (noncoronary), with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Initial observation care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination \n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug provided in a facility (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n\n### Condition\n- Chest pain\n- Primary diagnosis: Thrombosed external hemorrhoids\n- Abnormal findings on diagnostic imaging of lung\n- Old myocardial infarction\n- Generalized ischemic myocardial dysfunction\n- Obstructive sleep apnea syndrome\n- Primary malignant neoplasm of soft tissues\n- Type 2 diabetes mellitus without complication\n- Absent kidney\n- Atherosclerosis of coronary artery without angina pectoris\n- Electrocardiogram abnormal\n- Neck pain\n- Secondary malignant neoplasm of lung\n- Acquired absence of organ\n- Acquired absence of spleen\n- Acute deep venous thrombosis of internal jugular vein\n- Essential hypertension\n- Hypothyroidism\n- Disorder of digestive system\n\n### Drug\n- levothyroxine sodium 0.088 MG Oral Tablet, through Oral route, started on 2016-04-12, presumably until 2016-04-12\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2016-04-11, presumably until 2016-04-11\n- amoxicillin 250 MG Oral Capsule, through Oral route, started on 2016-04-11, presumably until 2016-04-12\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2016-04-11, presumably until 2016-04-11\n- 0.8 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2016-04-11, presumably until 2016-05-01, with intended 0 refill(s). Instructions: inject 0.8 mL subcutaneous (under the skin) every 12 hours\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2016-04-12, presumably until 2016-04-17, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed (pain)\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2016-04-12, presumably until 2016-04-12\n- carvedilol 6.25 MG Oral Tablet, through Oral route, started on 2016-04-11, presumably until 2016-04-12\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-04-11, presumably until 2016-04-11\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2016-04-11, presumably until 2016-04-12\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-04-11, presumably until 2016-04-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-04-12 00:00:00, ended at 2016-04-12 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- rivaroxaban 20 MG Oral Tablet, through Oral route, started on 2016-04-12, presumably until 2016-08-02, with intended 3 refill(s). Instructions: take 20 mg by mouth Every Day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-04-13 12:56:00, ended at 2016-04-13 18:14:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- Removal of Tunneled Vascular Access Device from Trunk Subcutaneous Tissue and Fascia, Open Approach\n- Fluoroscopy of Superior Vena Cava, Guidance\n- Fluoroscopic guidance for central venous access device placement, replacement (catheter only or complete), or removal (includes fluoroscopic guidance for vascular access and catheter manipulation, any necessary contrast injections through access site or c\n- Insertion of Infusion Device into Superior Vena Cava, Percutaneous Approach\n- Replacement, complete, of a tunneled centrally inserted central venous access device, with subcutaneous port, through same venous access\n- Insertion of Tunneled Vascular Access Device into Chest Subcutaneous Tissue and Fascia, Open Approach\n\n### Condition\n- Complication associated with vascular device\n- Essential hypertension\n- Old myocardial infarction\n- Adverse effect of prosthetic device\n- Pain due to internal prosthetic device\n- Secondary malignant neoplasm of lung\n- Acquired absence of organ\n- Obesity\n- Obstructive sleep apnea syndrome\n- Absent kidney\n- Complication of surgical procedure\n- Gout\n- Hypothyroidism\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2016-04-13, presumably until 2016-04-13\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2016-04-13, presumably until 2016-04-13\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-04-13, presumably until 2016-04-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-04-14 00:00:00, ended at 2016-04-14 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-04-17 00:00:00, ended at 2016-04-17 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-04-17, presumably until 2017-04-17, with intended 3 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2016-04-17, presumably until 2016-08-18, with intended 2 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2016-04-17, presumably until 2016-05-08, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n- prochlorperazine 10 MG Oral Tablet, through Oral route, started on 2016-04-17, presumably until 2016-04-17, with intended 3 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed for Nausea/Vomiting\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-04-17 00:00:00, ended at 2016-04-17 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prochlorperazine 10 MG Oral Tablet, through Oral route, started on 2016-04-17, presumably until 2016-07-15, with intended 3 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed for Nausea/Vomiting\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-04-17 07:57:00, ended at 2016-04-17 08:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 31 (nanogram per milliliter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.8 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 97 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 19 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.21 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 63.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 381 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.31 (thousand per microliter)\n- Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma: 12 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.2 (percent)\n- MCH [Entitic mass] by Automated count: 30.9 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 123 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.2 (percent)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.49 (million per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.33 (micro-international unit per milliliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.5 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCV [Entitic volume] by Automated count: 95.1 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Urate [Mass/volume] in Serum or Plasma: 4.8 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 36.5 (second)\n- Globulin [Mass/volume] in Serum: 5.0 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.67 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 20.4 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 54.4 (nanogram per milliliter)\n- Iron [Mass/volume] in Serum or Plasma: 41 (microgram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.2 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.91 (thousand per microliter)\n- Prothrombin time (PT): 13.9 (second)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 31 (nanogram per milliliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Iron deficiency anemia\n- Hypothyroidism\n- Non-toxic uninodular goiter\n- Vitamin D deficiency\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-04-17 08:28:48, ended at 2016-04-17 10:43:25\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.961\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2016-04-17, presumably until 2016-05-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2016-04-17, presumably until 2016-07-03, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth daily\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2016-04-17, presumably until 2016-05-15, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-04-17 09:00:00, ended at 2016-04-17 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration; intravenous, push technique, each additional substance/drug (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Dysuria\n- Iron deficiency anemia\n- Hypothyroidism\n- Primary malignant neoplasm\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-04-17, presumably until 2016-04-17\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2016-04-17, presumably until 2016-04-17\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-04-17, presumably until 2016-04-17\n- 5 ML doxorubicin hydrochloride 2 MG/ML Injection, through Intravenous route, started on 2016-04-17, presumably until 2016-04-17\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2016-04-17, presumably until 2016-04-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-04-18 14:30:00, ended at 2016-04-18 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Intravenous infusion, hydration; initial, 31 minutes to 1 hour\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2016-04-18, presumably until 2016-04-18\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-04-18, presumably until 2016-04-18\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-04-18, presumably until 2016-04-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-04-19 00:00:00, ended at 2016-04-19 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-04-20 00:00:00, ended at 2016-04-20 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-04-21 00:00:00, ended at 2016-04-21 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-04-24 00:00:00, ended at 2016-04-24 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-04-24 00:00:00, ended at 2016-04-24 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- levofloxacin 500 MG Oral Tablet, through Oral route, started on 2016-04-24, presumably until 2016-04-29, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily for 5 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-04-24 07:00:00, ended at 2016-04-24 11:43:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Lymphocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 281 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 109 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.7 (percent)\n- MCH [Entitic mass] by Automated count: 30.3 (picogram)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 62.8 (percent)\n- MCV [Entitic volume] by Automated count: 93.1 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.51 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 119 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 16.8 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.1 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 1.2 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 11 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.6 (percent)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.6 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 14.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Primary malignant neoplasm\n- Primary malignant neoplasm of soft tissues\n- Dysuria\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-04-24, presumably until 2016-04-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-04-24 08:36:38, ended at 2016-04-24 10:09:41\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.961\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute mastoiditis without complications\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-04-24 11:44:00, ended at 2016-04-24 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomographic angiography, neck, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Computed tomographic angiography, head, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n\n### Condition\n- Acute deep venous thrombosis of internal jugular vein\n- Headache\n- Abnormal findings on diagnostic imaging of lung\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-04-24, presumably until 2016-04-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-04-28 00:00:00, ended at 2016-04-28 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-01 00:00:00, ended at 2016-05-01 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-01 00:00:00, ended at 2016-05-01 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.4 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.2 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.1 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 299 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.23 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 95.2 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.88 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 62.8 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.59 (million per microliter)\n- MCH [Entitic mass] by Automated count: 30.9 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 3.73 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 20.7 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.9 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-01 00:00:00, ended at 2016-05-01 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-01 00:00:00, ended at 2016-05-01 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- trazodone hydrochloride 50 MG Oral Tablet, started on 2016-05-01, presumably until 2016-08-16, with intended 2 refill(s). Instructions: Take 1 to 2 tabs at bedtime.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-01 07:24:00, ended at 2016-05-01 07:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.2 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.1 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 95.2 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 114 (milligram per deciliter)\n- Prothrombin time (PT): 18.7 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 92 (unit per liter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma: 14 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 299 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.4 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.59 (million per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Urate [Mass/volume] in Serum or Plasma: 5.2 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.9 (picogram)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hypothyroidism\n- Dysuria\n- Iron deficiency anemia\n- Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-01 07:43:00, ended at 2016-05-01 08:11:25\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.961\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-01 08:00:00, ended at 2016-05-01 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Hypothyroidism\n- Primary malignant neoplasm of soft tissues\n- Iron deficiency anemia\n- Dysuria\n- Primary malignant neoplasm\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-05-01, presumably until 2016-05-01\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-05-01, presumably until 2016-05-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-05 00:00:00, ended at 2016-05-05 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-08 00:00:00, ended at 2016-05-08 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-08 00:00:00, ended at 2016-05-08 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration; intravenous, push technique, each additional substance/drug (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Dysuria\n- Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Fatigue\n- Primary malignant neoplasm\n- Iron deficiency anemia\n- Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-05-08 00:00:00, ended at 2016-05-08 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2016-05-08, presumably until 2016-05-29, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2016-05-08, presumably until 2016-11-06, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2016-05-08, presumably until 2017-05-08, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, through Topical route, started on 2016-05-08, presumably until 2016-08-15, with intended 2 refill(s). Instructions: by Topical route as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-08 07:10:00, ended at 2016-05-08 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.0 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.49 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 13.2 (percent)\n- MCV [Entitic volume] by Automated count: 95.9 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 443 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.08 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.93 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.81 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 22.4 (percent)\n- Urate [Mass/volume] in Serum or Plasma: 4.7 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 34 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 14 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.7 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 84 (unit per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 62.8 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.4 (picogram)\n- aPTT in Platelet poor plasma by Coagulation assay: 59.6 (second)\n- Glucose [Mass/volume] in Serum or Plasma: 124 (milligram per deciliter)\n- Prothrombin time (PT): 19.4 (second)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.1 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.07 (thousand per microliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration; intravenous, push technique, each additional substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-05-08, presumably until 2016-05-08\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2016-05-08, presumably until 2016-05-08\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-05-08, presumably until 2016-05-08\n- 5 ML doxorubicin hydrochloride 2 MG/ML Injection, through Intravenous route, started on 2016-05-08, presumably until 2016-05-08\n- dexamethasone phosphate 4 MG/ML Injectable Solution, through Intravenous route, started on 2016-05-08, presumably until 2016-05-08, with intended 0 refill(s). Instructions: 2.5 mL by Intravenous route One Time\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-08 08:09:30, ended at 2016-05-08 10:11:52\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-09 13:10:00, ended at 2016-05-09 14:23:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2016-05-09, presumably until 2016-05-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-09 14:24:00, ended at 2016-05-09 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Ultrasound, limited, joint or other nonvascular extremity structure(s) (eg, joint space, peri-articular tendon[s], muscle[s], nerve[s], other soft-tissue structure[s], or soft-tissue mass[es]), real-time with image documentation\n\n### Condition\n- Localized swelling, mass and lump, trunk\n- Primary malignant neoplasm\n- Primary malignant neoplasm of skin of trunk\n- Iron deficiency anemia\n- Hypothyroidism\n- Neoplastic disease\n- Primary malignant neoplasm of soft tissues\n- Dysuria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-12 00:00:00, ended at 2016-05-12 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-15 00:00:00, ended at 2016-05-15 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2016-05-15, presumably until 2016-05-15, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n- 72 HR scopolamine 0.0139 MG/HR Transdermal System, through Transdermal route, started on 2016-05-15, presumably until 2017-05-15, with intended 2 refill(s). Instructions: apply 1 Patch to skin every 72 hours\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-15 00:00:00, ended at 2016-05-15 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-15 07:00:00, ended at 2016-05-15 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.87 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.7 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.75 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 85.7 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.44 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 12.7 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.98 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.7 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 121 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.0 (picogram)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 166 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.6 (percent)\n- Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.7 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 10.86 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Prothrombin time (PT): 22.5 (second)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5.9 (percent)\n- MCV [Entitic volume] by Automated count: 95.2 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 297 (thousand per microliter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Dysuria\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-05-15, presumably until 2016-05-15\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-05-15, presumably until 2016-05-15\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2016-05-15, presumably until 2016-05-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-15 08:17:17, ended at 2016-05-15 10:00:47\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2016-05-15, presumably until 2016-06-05, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-15 15:19:12, ended at 2016-05-15 17:29:40\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-16 00:00:00, ended at 2016-05-16 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- melatonin 1 MG Oral Tablet, through Oral route, started on 2016-05-16, presumably until 2016-08-23, with intended 3 refill(s). Instructions: take 1 Tab by mouth every bedtime\n- methylphenidate hydrochloride 5 MG Oral Tablet, through Oral route, started on 2016-05-16, presumably until 2016-11-12, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-26 00:00:00, ended at 2016-05-26 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-26 14:15:00, ended at 2016-05-26 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplasm of lung\n- Abnormal findings on diagnostic imaging of lung\n- Secondary malignant neoplasm of left lung\n- Secondary malignant neoplasm of right lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-29 08:00:00, ended at 2016-05-29 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 91 (unit per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Urate [Mass/volume] in Serum or Plasma: 4.2 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.2 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 71.4 (percent)\n- aPTT in Platelet poor plasma by Coagulation assay: 35.7 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 116 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.5 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.92 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.35 (million per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.6 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 356 (thousand per microliter)\n- Prothrombin time (PT): 13.6 (second)\n- Eosinophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma: 12 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.9 (percent)\n- MCV [Entitic volume] by Automated count: 96.4 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 26 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Monocytes [#/volume] in Blood by Automated count: 1.34 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 16.3 (percent)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.81 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.5 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 5.86 (thousand per microliter)\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Hypothyroidism\n- Primary malignant neoplasm of soft tissues\n- Essential hypertension\n- Type 2 diabetes mellitus without complication\n- Gastroesophageal reflux disease without esophagitis\n- Hyperlipidemia\n- Primary malignant neoplasm\n- Dysuria\n- Iron deficiency anemia\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-05-29, presumably until 2016-05-29\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2016-05-29, presumably until 2016-05-29\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-05-29, presumably until 2016-05-29\n- 5 ML doxorubicin hydrochloride 2 MG/ML Injection, through Intravenous route, started on 2016-05-29, presumably until 2016-05-29\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2016-05-29, presumably until 2016-05-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-29 09:16:39, ended at 2016-05-29 11:00:30\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neoplasm defined only by topography: Connective, Subcutaneous and other soft tissues, NOS\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2016-05-29, presumably until 2016-07-18, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-30 13:10:00, ended at 2016-05-30 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2016-05-30, presumably until 2016-05-30\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-02 00:00:00, ended at 2016-06-02 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-05 00:00:00, ended at 2016-06-05 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Iron saturation [Mass Fraction] in Serum or Plasma: 25 (percent)\n- Ferritin [Mass/volume] in Serum or Plasma: 167.0 (nanogram per milliliter)\n- Iron [Mass/volume] in Serum or Plasma: 68 (microgram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-06-05 00:00:00, ended at 2016-06-05 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2016-06-05, presumably until 2016-07-18, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-06-05 08:00:00, ended at 2016-06-05 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 288 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5.2 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 161 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.99 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.71 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 88.7 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 28 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.64 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 13.6 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 115 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.3 (percent)\n- MCH [Entitic mass] by Automated count: 32.2 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.58 (micro-international unit per milliliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 12.04 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- MCV [Entitic volume] by Automated count: 97.9 (femtoliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.87 (milligram per deciliter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Hypothyroidism\n- Iron deficiency anemia\n- Primary malignant neoplasm of soft tissues\n- Non-toxic uninodular goiter\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-06-05, presumably until 2016-06-05\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-06-05, presumably until 2016-06-05\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-06-05, presumably until 2016-06-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-06-05 08:32:00, ended at 2016-06-05 10:19:36\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-08 00:00:00, ended at 2016-06-08 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-15 00:00:00, ended at 2016-06-15 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-19 00:00:00, ended at 2016-06-19 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-19 00:00:00, ended at 2016-06-19 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- levofloxacin 500 MG Oral Tablet, through Oral route, started on 2016-06-19, presumably until 2016-06-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily for 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-06-19 07:00:00, ended at 2016-06-19 09:31:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hemoglobin [Mass/volume] in Blood: 11.0 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.6 (picogram)\n- MCV [Entitic volume] by Automated count: 99.2 (femtoliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 348 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 104 (unit per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.1 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.75 (thousand per microliter)\n- Urate [Mass/volume] in Serum or Plasma: 4.5 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.6 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.6 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 77.3 (percent)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 21.0 (percent)\n- Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma: 10 (unit per liter)\n- Monocytes [#/volume] in Blood by Automated count: 1.08 (thousand per microliter)\n- Prothrombin time (PT): 19.1 (second)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.89 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.39 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 125 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.6 (percent)\n- aPTT in Platelet poor plasma by Coagulation assay: 36.2 (second)\n- Neutrophils [#/volume] in Blood by Automated count: 6.68 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.82 (micro-international unit per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n- Collection of venous blood by venipuncture\n\n### Condition\n- Non-toxic uninodular goiter\n- Hypothyroidism\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-06-19 08:19:48, ended at 2016-06-19 09:30:02\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.157\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-06-19 09:32:00, ended at 2016-06-19 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Fever\n- Cough\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-20 00:00:00, ended at 2016-06-20 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- benzonatate 100 MG Oral Capsule, through Oral route, started on 2016-06-20, presumably until 2016-07-03, with intended 0 refill(s). Instructions: take 1 Cap by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-30 00:00:00, ended at 2016-06-30 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-03 00:00:00, ended at 2016-07-03 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-03 00:00:00, ended at 2016-07-03 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2016-07-03, presumably until 2016-08-23, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth daily\n- 12 HR dextromethorphan hydrobromide 30 MG / guaifenesin 600 MG Extended Release Oral Tablet, through Oral route, started on 2016-07-03, presumably until 2016-08-23, with intended 1 refill(s). Instructions: take 1 Tab by mouth every 12 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-07-03 07:10:00, ended at 2016-07-03 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma: <10 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.9 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 37.6 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 100 (unit per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Body height: 5' 5.157\" (inch (US))\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.90 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.30 (million per microliter)\n- Prothrombin time (PT): 18.9 (second)\n- Urate [Mass/volume] in Serum or Plasma: 4.1 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.90 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 11.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.80 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.10 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.0 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 72.4 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.7 (percent)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 379 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 120 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.7 (percent)\n- MCH [Entitic mass] by Automated count: 33.0 (picogram)\n- MCV [Entitic volume] by Automated count: 99.0 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.8 (percent)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Dysuria\n- Gastroesophageal reflux disease without esophagitis\n- Primary malignant neoplasm\n- Hypothyroidism\n- Essential hypertension\n- Type 2 diabetes mellitus without complication\n- Iron deficiency anemia\n- Hyperlipidemia\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-07-03, presumably until 2016-07-03\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2016-07-03, presumably until 2016-07-03\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-07-03, presumably until 2016-07-03\n- 5 ML doxorubicin hydrochloride 2 MG/ML Injection, through Intravenous route, started on 2016-07-03, presumably until 2016-07-03\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2016-07-03, presumably until 2016-07-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-07-03 08:33:01, ended at 2016-07-03 09:36:27\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- azithromycin 250 MG Oral Tablet, through Oral route, started on 2016-07-04, presumably until 2016-07-09, with intended 0 refill(s). Instructions: take 1 Tab by mouth as directed for 5 days 2 tabs on day 1, then 1 tab daily thereafter\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-04 00:00:00, ended at 2016-07-04 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Fever\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Acute upper respiratory infection\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-04 00:00:00, ended at 2016-07-04 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute upper respiratory infection\n- Fever\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-07-04 12:48:00, ended at 2016-07-04 13:19:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 5 (nanogram per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 3.3 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 10.7 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.38 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.0 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.2 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.7 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.35 (million per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 10.46 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 91.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 387 (thousand per microliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 34 (nanogram per milliliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 29 (nanogram per milliliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 55.1 (nanogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.3 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.8 (percent)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 49 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.5 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 99.5 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Iron [Mass/volume] in Serum or Plasma: 153 (microgram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Dysuria\n- Iron deficiency anemia\n- Fever\n- Primary malignant neoplasm of soft tissues\n- Vitamin D deficiency\n- Acute upper respiratory infection\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-07-04 13:20:00, ended at 2016-07-04 15:22:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2016-07-04, presumably until 2016-07-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-07-04 15:23:00, ended at 2016-07-04 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-10 00:00:00, ended at 2016-07-10 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-11 00:00:00, ended at 2016-07-11 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-11 00:00:00, ended at 2016-07-11 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-07-11 08:00:00, ended at 2016-07-11 10:06:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Neutrophils/100 leukocytes in Blood by Automated count: 74.6 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Ferritin [Mass/volume] in Serum or Plasma: 154.5 (nanogram per milliliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 28 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.62 (thousand per microliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 4 (nanogram per milliliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 6 (percent)\n- MCH [Entitic mass] by Automated count: 32.3 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 3.71 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.04 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.5 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.9 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 26 (nanogram per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 10.4 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.0 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 30 (nanogram per milliliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.5 (percent)\n- Iron [Mass/volume] in Serum or Plasma: 17 (microgram per deciliter)\n- MCV [Entitic volume] by Automated count: 99.8 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 127 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.22 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.44 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.4 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 209 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 119 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.1 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.4 (percent)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Vitamin D deficiency\n- Iron deficiency anemia\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-07-11, presumably until 2016-07-11\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-07-11, presumably until 2016-07-11\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-07-11, presumably until 2016-07-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-07-11 09:02:31, ended at 2016-07-11 14:43:53\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-07-11 10:07:00, ended at 2016-07-11 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Radiologic examination, abdomen; single anteroposterior view\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Abdominal pain\n- Hypothyroidism\n- Intestinal obstruction\n- Gastroesophageal reflux disease without esophagitis\n- Essential hypertension\n- Primary malignant neoplasm of soft tissues\n- Type 2 diabetes mellitus without complication\n- Dysuria\n- Primary malignant neoplasm\n- Hyperlipidemia\n- Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-07-15 00:00:00, ended at 2016-07-15 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prochlorperazine 10 MG Oral Tablet, started on 2016-07-17, presumably until 2017-05-16, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY 8 HOURS AS NEEDED FOR NAUSEA OR VOMITING\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-07-18 00:00:00, ended at 2016-07-18 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2016-07-18, presumably until 2016-11-17, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2016-07-18, presumably until 2016-08-15, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-19 00:00:00, ended at 2016-07-19 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-21 00:00:00, ended at 2016-07-21 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-24 00:00:00, ended at 2016-07-24 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-25 00:00:00, ended at 2016-07-25 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-07-25 07:10:00, ended at 2016-07-25 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 461 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 75.1 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.1 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.6 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.1 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 33.2 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Prothrombin time (PT): 16.0 (second)\n- Urate [Mass/volume] in Serum or Plasma: 4.7 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 34.8 (second)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.1 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.5 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.87 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.56 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.27 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 10.9 (gram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.1 (percent)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.57 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 97 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma: <10 (unit per liter)\n- MCV [Entitic volume] by Automated count: 100.2 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 114 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.82 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.24 (micro-international unit per milliliter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration; intravenous, push technique, each additional substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Non-toxic uninodular goiter\n- Hypothyroidism\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-07-25, presumably until 2016-07-25\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2016-07-25, presumably until 2016-07-25\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-07-25, presumably until 2016-07-25\n- 5 ML doxorubicin hydrochloride 2 MG/ML Injection, through Intravenous route, started on 2016-07-25, presumably until 2016-07-25\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2016-07-25, presumably until 2016-07-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-07-25 07:42:57, ended at 2016-07-25 11:57:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.157\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-26 00:00:00, ended at 2016-07-26 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-26 00:00:00, ended at 2016-07-26 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-07-26 13:22:00, ended at 2016-07-26 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2016-07-26, presumably until 2016-07-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-28 00:00:00, ended at 2016-07-28 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-07-31 15:10:00, ended at 2016-08-01 18:23:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.27 (million per microliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 51 - 100 (per high power field)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.6 (thousand per microliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 166 (unit per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Glucose [Mass/volume] in Serum or Plasma: 132 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.9 (percent)\n- Neutrophils/100 leukocytes in Blood by Manual count: 71 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 33 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 33.1 (picogram)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 100.7 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 3 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.06 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1 (percent)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 226 (thousand per microliter)\n- Prothrombin time (PT): 14.9 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.17 (thousand per microliter)\n- Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma: <30 (picogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.95 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.2 (percent)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.28 (thousand per microliter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Initial observation care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination \n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Computed tomographic angiography, chest (noncoronary), with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Collection of venous blood by venipuncture\n- Magnetic resonance (eg, proton) imaging, lower extremity other than joint; without contrast material(s), followed by contrast material(s) and further sequences\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Magnetic resonance (eg, proton) imaging, lower extremity other than joint; without contrast material(s)\n- Physical therapy evaluation\n\n### Condition\n- Abnormal heart beat\n- Old myocardial infarction\n- Postoperative state\n- Primary malignant neoplasm of retroperitoneum\n- Urinary tract infectious disease\n- Abnormal findings on diagnostic imaging of lung\n- Pulmonary embolism\n- Ventricular premature complex\n- Chest pain\n- Electrocardiogram abnormal\n- Secondary malignant neoplasm of nervous system\n- Essential hypertension\n- Hypothyroidism\n- Obstructive sleep apnea syndrome\n- Primary diagnosis: Dyspnea\n\n### Drug\n- thiamine 100 MG Oral Tablet, through Oral route, started on 2016-08-01, presumably until 2016-08-01\n- warfarin sodium 5 MG Oral Tablet, through Oral route, started on 2016-08-01, presumably until 2016-08-02, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- nitrofurantoin, macrocrystals 25 MG / nitrofurantoin, monohydrate 75 MG Oral Capsule, through Oral route, started on 2016-08-01, presumably until 2016-08-06, with intended 0 refill(s). Instructions: take 1 Puthenveetil by mouth every 12 hours for 5 days\n- pantoprazole 20 MG Delayed Release Oral Tablet, through Oral route, started on 2016-07-31, presumably until 2016-07-31\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2016-08-01, presumably until 2016-08-01\n- ceftriaxone 1000 MG Injection, through Intravenous route, started on 2016-07-31, presumably until 2016-07-31\n- lisinopril 10 MG Oral Tablet, through Oral route, started on 2016-08-01, presumably until 2016-08-01\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2016-07-31, presumably until 2016-08-01\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2016-07-31, presumably until 2016-07-31\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2016-08-01, presumably until 2016-08-01\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2016-07-31, presumably until 2016-07-31\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2016-08-01, presumably until 2016-08-01\n- 0.8 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2016-08-01, presumably until 2016-08-06, with intended 1 refill(s). Instructions: inject 0.8 mL subcutaneous (under the skin) every 12 hours\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2016-07-31, presumably until 2016-08-01\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-08-01, presumably until 2016-08-01\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2016-08-01, presumably until 2016-08-01\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-07-31, presumably until 2016-08-01\n- prochlorperazine 5 MG Oral Tablet, through Oral route, started on 2016-07-31, presumably until 2016-08-01\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2016-07-31, presumably until 2016-08-01\n- rivaroxaban 20 MG Oral Tablet, through Oral route, started on 2016-07-31, presumably until 2016-07-31\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-08-02 00:00:00, ended at 2016-08-02 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- dexamethasone 4 MG Oral Tablet, started on 2016-08-02, presumably until 2017-01-15, with intended 1 refill(s). Instructions: Take one 4mg tab the day before and the day after chemotherapy.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-08-02 08:02:56, ended at 2016-08-02 11:49:44\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.157\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2016-08-02, presumably until 2016-12-04, with intended 3 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-08-03 00:00:00, ended at 2016-08-03 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-08-07 00:00:00, ended at 2016-08-07 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-08-08 00:00:00, ended at 2016-08-08 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Pain due to neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-08-15 00:00:00, ended at 2016-08-15 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2016-08-15, presumably until 2016-09-27, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, through Topical route, started on 2016-08-15, presumably until 2017-08-15, with intended 2 refill(s). Instructions: by Topical route as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-15 07:59:00, ended at 2016-08-15 09:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.96 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.32 (million per microliter)\n- Iron [Mass/volume] in Serum or Plasma: 64 (microgram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 14 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.1 (percent)\n- MCV [Entitic volume] by Automated count: 100.4 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.2 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 35 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 119 (unit per liter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 30 (nanogram per milliliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 23 (percent)\n- Platelets [#/volume] in Blood by Automated count: 479 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 5 (nanogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Ferritin [Mass/volume] in Serum or Plasma: 55.5 (nanogram per milliliter)\n- MCH [Entitic mass] by Automated count: 32.6 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 1.24 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 11.24 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 83.2 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.3 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.4 (percent)\n- MCHC [Mass/volume] by Automated count: 32.4 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.8 (gram per deciliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.1 (nanogram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 119 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.95 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.37 (micro-international unit per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 13.5 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hypothyroidism\n- Dysuria\n- Hyperlipidemia\n- Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm\n- Vitamin D deficiency\n- Non-toxic uninodular goiter\n- Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-08-15 08:42:20, ended at 2016-08-15 11:23:42\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.157\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-15 10:00:00, ended at 2016-08-15 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.157\" (inch (US))\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2016-08-15, presumably until 2016-08-15\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2016-08-15, presumably until 2016-08-15\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-08-15, presumably until 2016-08-15\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2016-08-15, presumably until 2016-08-15\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-08-15, presumably until 2016-08-15\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-08-15, presumably until 2016-08-15\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2016-08-15, presumably until 2016-08-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-16 08:07:00, ended at 2016-08-16 13:23:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Abnormal findings on diagnostic imaging of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-16 13:24:00, ended at 2016-08-16 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2016-08-16, presumably until 2016-08-16\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-08-16 13:57:28, ended at 2016-08-16 14:34:06\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Takotsubo cardiomyopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-08-18 00:00:00, ended at 2016-08-18 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- docusate sodium 100 MG Oral Capsule, started on 2016-08-18, presumably until 2018-07-06, with intended 0 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-08-18 00:00:00, ended at 2016-08-18 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of intestine\n- Post-surgical malabsorption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-08-21 00:00:00, ended at 2016-08-21 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Melena\n- Primary diagnosis: Anorectal disorder\n- Post-surgical malabsorption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-08-23 13:04:57, ended at 2016-08-23 14:48:39\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Melena\n- Hypothyroidism\n- Essential hypertension\n- Obstructive sleep apnea syndrome\n\n### Drug\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, presumably until 2019-04-16, with intended 0 refill(s). Instructions: take 81 mg by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-24 00:00:00, ended at 2016-08-24 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for lower intestinal endoscopic procedures, endoscope introduced distal to duodenum\n\n### Condition\n- Hemorrhoids\n- Diarrhea\n- Essential hypertension\n- Melena\n\n### Drug\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2016-08-24, presumably until 2016-08-24\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2016-08-24, presumably until 2016-08-24\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2016-08-24, presumably until 2016-08-24\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-08-24, presumably until 2016-08-24\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-08-24, presumably until 2016-08-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-24 07:32:00, ended at 2016-08-24 10:06:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Sigmoidoscopy, flexible; with biopsy, single or multiple\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Excision of Sigmoid Colon, Via Natural or Artificial Opening Endoscopic, Diagnostic\n- Sigmoidoscopy, flexible; with control of bleeding, any method\n\n### Condition\n- Diarrhea\n- Cardiomyopathy\n- Disorder of intestine\n- Hemorrhoids\n- Type 2 diabetes mellitus without complication\n- Vitamin D deficiency\n- Old myocardial infarction\n- Takotsubo cardiomyopathy\n- Melena\n- Dyspnea\n- Hypothyroidism\n\n### Drug\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-08-24, presumably until 2016-08-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-08-28 00:00:00, ended at 2016-08-28 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, started on 2016-08-28, presumably until 2017-03-12, with intended 3 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH TWICE WEEKLY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-08-29 00:00:00, ended at 2016-08-29 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Pulmonary embolism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-30 07:10:00, ended at 2016-08-30 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 105 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.8 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 76.2 (percent)\n- Urate [Mass/volume] in Serum or Plasma: 4.5 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 11 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Hemoglobin [Mass/volume] in Blood: 10.2 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.7 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.84 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 33.5 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 7.84 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Prothrombin time (PT): 15.4 (second)\n- aPTT in Platelet poor plasma by Coagulation assay: 35.8 (second)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.0 (percent)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 138 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 101.8 (femtoliter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.03 (million per microliter)\n- Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma: <10 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.9 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.3 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.00 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.32 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 319 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Dysuria\n- Pulmonary embolism\n- Type 2 diabetes mellitus without complication\n- Ascites\n- Hypothyroidism\n- Primary malignant neoplasm of soft tissues\n- Essential hypertension\n- Iron deficiency anemia\n- Secondary malignant neoplasm of left lung\n- Primary malignant neoplasm\n- Secondary malignant neoplasm of right lung\n- Gastroesophageal reflux disease without esophagitis\n- Hyperlipidemia\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2016-08-30, presumably until 2016-08-30\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-08-30, presumably until 2016-08-30\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2016-08-30, presumably until 2016-08-30\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-08-30, presumably until 2016-08-30\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-08-30, presumably until 2016-08-30\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-08-30, presumably until 2016-08-30\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-08-30 07:55:06, ended at 2016-08-30 10:42:32\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- mupirocin 0.02 MG/MG Topical Ointment, started on 2016-08-18, presumably until 2017-11-08, with intended 0 refill(s). Instructions: Apply to affected area BID prn rash\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-31 08:00:00, ended at 2016-08-31 11:09:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 55.4 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Disorder due to and following accidental poisoning\n- Disorder due to and following drug poisoning\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-31 11:10:00, ended at 2016-08-31 14:29:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Acquired absence of organ\n- Absent kidney\n- Solitary nodule of lung\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-31 14:30:00, ended at 2016-08-31 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2016-08-31, presumably until 2016-08-31\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-09-11 00:00:00, ended at 2016-09-11 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of intestine\n- Primary diagnosis: Post-surgical malabsorption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-09-27 11:57:00, ended at 2016-09-27 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.8 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 95.1 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 108 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.92 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 1.7 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.2 (percent)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 102.4 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 33.1 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 9.46 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 153 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.9 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.28 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 33 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.86 (million per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 12 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.3 (percent)\n- Platelets [#/volume] in Blood by Automated count: 370 (thousand per microliter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Disorder of intestine\n- Post-surgical malabsorption\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2016-09-27, presumably until 2016-09-27\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-09-27, presumably until 2016-09-27\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2016-09-27, presumably until 2016-09-27\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-09-27, presumably until 2016-09-27\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-09-27, presumably until 2016-09-27\n- prochlorperazine 10 MG Oral Tablet, through Oral route, started on 2016-09-27, presumably until 2016-09-27\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-09-27, presumably until 2016-09-27\n- 0.6 ML pegfilgrastim 10 MG/ML Injection, through Subcutaneous route, started on 2016-09-27, presumably until 2016-09-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-09-27 12:25:43, ended at 2016-09-27 14:20:18\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2016-09-27, presumably until 2016-11-17, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-09-28 00:00:00, ended at 2016-09-28 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Insomnia\n\n### Drug\n- amitriptyline hydrochloride 75 MG Oral Tablet, through Oral route, started on 2016-09-28, presumably until 2017-05-24, with intended 3 refill(s). Instructions: take 1 Tab by mouth every bedtime as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-09-28 14:30:39, ended at 2016-09-28 14:58:23\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; single lesion\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Primary diagnosis: Neoplastic disease of uncertain behavior\n- Hyperpigmentation of skin\n- Secondary malignant neoplasm of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-10-05 00:00:00, ended at 2016-10-05 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-10-05 00:00:00, ended at 2016-10-05 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n- Non-toxic uninodular goiter\n\n### Drug\n- levothyroxine sodium 0.2 MG Oral Tablet, through Oral route, started on 2016-10-06, presumably until 2017-05-10, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast Take additional 1/2 tab on Sundays, total 7.5 tabs a week\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-10-12 00:00:00, ended at 2016-10-12 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-10-14 14:30:00, ended at 2016-10-14 15:09:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Magnetic resonance (eg, proton) imaging, lower extremity other than joint; without contrast material(s), followed by contrast material(s) and further sequences\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Type 2 diabetes mellitus without complication\n- Postoperative state\n- Dysuria\n- Primary malignant neoplasm of soft tissues\n- Hypothyroidism\n- Primary malignant neoplasm\n- Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-10-14 15:10:00, ended at 2016-10-14 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.32 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 1.8 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 147 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.91 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 96.0 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 38 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- MCHC [Mass/volume] by Automated count: 31.4 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 149 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.2 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.84 (million per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.28 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 463 (thousand per microliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 32.3 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 102.8 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.26 (micro-international unit per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.8 (percent)\n- Ferritin [Mass/volume] in Serum or Plasma: 62.7 (nanogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.2 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 16.0 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 15.38 (thousand per microliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Ascites\n- Non-toxic uninodular goiter\n- Hypothyroidism\n- Essential hypertension\n- Hyperlipidemia\n- Secondary malignant neoplasm of left lung\n- Dysuria\n- Gastroesophageal reflux disease without esophagitis\n- Primary malignant neoplasm of soft tissues\n- Type 2 diabetes mellitus without complication\n- Iron deficiency anemia\n- Primary malignant neoplasm\n- Secondary malignant neoplasm of right lung\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2016-10-14, presumably until 2016-10-14\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-10-14, presumably until 2016-10-14\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-10-14, presumably until 2016-10-14\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-10-14, presumably until 2016-10-14\n- prochlorperazine 10 MG Oral Tablet, through Oral route, started on 2016-10-14, presumably until 2016-10-14\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-10-14, presumably until 2016-10-14\n- 0.6 ML pegfilgrastim 10 MG/ML Injection, through Subcutaneous route, started on 2016-10-14, presumably until 2016-10-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-10-19 00:00:00, ended at 2016-10-19 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prednisone 2 MG Delayed Release Oral Tablet, started on 2016-10-19, presumably until 2016-11-03, with intended 0 refill(s). Instructions: Take 8 mg on day 1, 6 mg on day 2, 4 mg on day 3, 2 mg on day 4\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-10-30 00:00:00, ended at 2016-10-30 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, started on 2016-10-31, presumably until 2017-01-23, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY WITH MEALS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-10-30 08:30:00, ended at 2016-10-30 08:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Secondary malignant neoplasm of lung\n- Disorder of pancreas\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-10-30 09:00:00, ended at 2016-10-30 12:09:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.11 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 6.4 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.47 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 14.66 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 150 (unit per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 44 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 109 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 31.0 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 106.2 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.90 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.6 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.92 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 9.6 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.0 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 84.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 468 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 17.3 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 33.0 (picogram)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-10-30, presumably until 2016-10-30\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-30 10:00:17, ended at 2016-10-30 10:32:42\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-10-30 12:10:00, ended at 2016-10-30 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Dysuria\n- Gastroesophageal reflux disease without esophagitis\n- Primary malignant neoplasm of soft tissues\n- Type 2 diabetes mellitus without complication\n- Essential hypertension\n- Hypothyroidism\n- Primary malignant neoplasm\n- Ascites\n- Hyperlipidemia\n- Iron deficiency anemia\n- Secondary malignant neoplasm of right lung\n- Secondary malignant neoplasm of left lung\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2016-10-30, presumably until 2016-10-30\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-10-30, presumably until 2016-10-30\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2016-10-30, presumably until 2016-10-30\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-10-30, presumably until 2016-10-30\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2016-10-30, presumably until 2016-10-30\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-10-30, presumably until 2016-10-30\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-10-30, presumably until 2016-10-30\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-30 12:47:33, ended at 2016-10-30 16:25:56\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.8 ML filgrastim 0.6 MG/ML Prefilled Syringe, started on 2016-10-30, presumably until 2017-07-12, with intended 2 refill(s). Instructions: 384 mL by Injection route every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-11-03 00:00:00, ended at 2016-11-03 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- prednisone 2 MG Delayed Release Oral Tablet, started on 2016-11-03, presumably until 2016-12-23, with intended 0 refill(s). Instructions: Take 8 mg on day 1, 6 mg on day 2, 4 mg on day 3, 2 mg on day 4\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-11-06 00:00:00, ended at 2016-11-06 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2016-11-06, presumably until 2017-12-19, with intended 6 refill(s). Instructions: take 1 Tab by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-11-17 00:00:00, ended at 2016-11-17 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2016-11-17, presumably until 2017-03-12, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2016-11-17, presumably until 2017-01-15, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-11-18 00:00:00, ended at 2016-11-18 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-11-18 09:00:00, ended at 2016-11-18 15:37:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 26.6 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 8.7 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 90.2 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 156 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 7.02 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.6 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 105 (unit per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Iron [Mass/volume] in Serum or Plasma: 33 (microgram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.57 (million per microliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 11 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.44 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.17 (micro-international unit per milliliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.8 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 33.7 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 3.3 (percent)\n- Platelets [#/volume] in Blood by Automated count: 501 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.92 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5.6 (percent)\n- MCV [Entitic volume] by Automated count: 103.6 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.26 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Hypothyroidism\n- Non-toxic uninodular goiter\n- Iron deficiency anemia\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2016-11-18, presumably until 2016-11-18\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-11-18, presumably until 2016-11-18\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-11-18, presumably until 2016-11-18\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2016-11-18, presumably until 2016-11-18\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2016-11-18, presumably until 2016-11-18\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-11-18, presumably until 2016-11-18\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-11-18, presumably until 2016-11-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2016-11-18 15:48:00, ended at 2016-11-18 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Dyspnea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-11-19 11:00:00, ended at 2016-11-19 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Transfusion, blood or blood components\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2016-11-19, presumably until 2016-11-19\n- 10 ML furosemide 10 MG/ML Injection, started on 2016-11-19, presumably until 2016-11-19\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-11-19, presumably until 2016-11-19\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2016-11-19, presumably until 2016-11-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-11-28 00:00:00, ended at 2016-11-28 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Generalized ischemic myocardial dysfunction\n\n### Drug\n- carvedilol 3.125 MG Oral Tablet, started on 2016-11-28, presumably until 2017-04-20, with intended 3 refill(s). Instructions: pt only taking it once a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-01 11:10:00, ended at 2016-12-01 12:29:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Ascites\n- Secondary malignant neoplasm of lung\n- Localized enlarged lymph nodes\n- Primary malignant neoplasm of retroperitoneum\n- Secondary malignant neoplasm of adrenal gland\n- Secondary malignant neoplastic disease\n- Intestinal obstruction\n- Secondary malignant neoplasm of right lung\n- Acquired absence of organ\n- Secondary malignant neoplasm of left lung\n- Absent kidney\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-12-01, presumably until 2016-12-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-01 12:30:00, ended at 2016-12-01 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 16.0 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.32 (million per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 87 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 87 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 31.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 99.0 (femtoliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.15 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 21.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 298 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 5.9 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 7.9 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.8 (percent)\n- MCH [Entitic mass] by Automated count: 31.4 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.5 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.94 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.4 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.35 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 61.2 (percent)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 111 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.88 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Gastroesophageal reflux disease without esophagitis\n- Hyperlipidemia\n- Iron deficiency anemia\n- Secondary malignant neoplasm of left lung\n- Primary malignant neoplasm\n- Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplasm of right lung\n- Type 2 diabetes mellitus without complication\n- Dysuria\n- Hypothyroidism\n- Ascites\n- Essential hypertension\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2016-12-01, presumably until 2016-12-01\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-12-01, presumably until 2016-12-01\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-12-01, presumably until 2016-12-01\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2016-12-01, presumably until 2016-12-01\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-12-01, presumably until 2016-12-01\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-12-01, presumably until 2016-12-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-12-01 13:35:21, ended at 2016-12-01 16:18:18\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-04 00:00:00, ended at 2016-12-04 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Nausea\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-12-04, presumably until 2017-03-12, with intended 3 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-12-04 00:00:00, ended at 2016-12-04 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- dabigatran etexilate 150 MG Oral Capsule, started on 2016-12-06, presumably until 2017-02-16, with intended 0 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-13 00:00:00, ended at 2016-12-13 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-12-13 00:00:00, ended at 2016-12-13 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2016-12-13, presumably until 2017-11-14, with intended 9 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-12-23 00:00:00, ended at 2016-12-23 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- prednisone 2 MG Delayed Release Oral Tablet, started on 2016-12-23, presumably until 2017-01-15, with intended 0 refill(s). Instructions: Take 8 mg on day 1, 6 mg on day 2, 4 mg on day 3, 2 mg on day 4\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-23 10:12:00, ended at 2016-12-23 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 184 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 124 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 123 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.59 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.96 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.15 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.2 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 7 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.10 (million per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.7 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.7 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Leukocytes [#/volume] in Body fluid by Manual count: 1 (milli-international unit per milliliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.4 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 27 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 20 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 98.3 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 2.2 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.44 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 43 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2016-12-23, presumably until 2016-12-23\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-12-23, presumably until 2016-12-23\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2016-12-23, presumably until 2016-12-23\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-12-23, presumably until 2016-12-23\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-12-23, presumably until 2016-12-23\n- 0.6 ML pegfilgrastim 10 MG/ML Injection, through Subcutaneous route, started on 2016-12-23, presumably until 2016-12-23\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-01-05 00:00:00, ended at 2017-01-05 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- dabigatran etexilate 150 MG Oral Capsule, started on 2017-01-08, presumably until 2017-03-12, with intended 0 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-01-15 00:00:00, ended at 2017-01-15 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-15 07:21:00, ended at 2017-01-15 07:49:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Splitting of blood or blood products, each unit\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Transfusion, blood or blood components\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Disorder of pancreas\n- Primary malignant neoplasm of retroperitoneum\n- Secondary malignant neoplasm of left lung\n- Disorder of adrenal gland\n- Secondary malignant neoplasm of lung\n- Localized enlarged lymph nodes\n- Secondary malignant neoplasm of right lung\n- Secondary malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-15 07:50:00, ended at 2017-01-15 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 49 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 88 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 161 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 18 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 17 (percent)\n- MCHC [Mass/volume] by Automated count: 31.9 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 38 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 27.9 (percent)\n- Hemoglobin [Mass/volume] in Blood: 8.9 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.9 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 100.5 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 224 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.08 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 21.8 (percent)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.66 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.1 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.90 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 17 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Leukocytes [#/volume] in Body fluid by Manual count: 3 (milli-international unit per milliliter)\n- MCH [Entitic mass] by Automated count: 32.0 (picogram)\n- Monocytes [#/volume] in Blood by Manual count: 0.66 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.78 (million per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Transfusion, blood or blood components\n- Splitting of blood or blood products, each unit\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Secondary malignant neoplasm of right lung\n- Type 2 diabetes mellitus without complication\n- Gastroesophageal reflux disease without esophagitis\n- Hypothyroidism\n- Essential hypertension\n- Primary malignant neoplasm\n- Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplasm of left lung\n- Iron deficiency anemia\n- Ascites\n- Hyperlipidemia\n- Dysuria\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-01-15, presumably until 2017-01-15\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2017-01-15, presumably until 2017-01-15\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2017-01-15, presumably until 2017-01-15\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-01-15, presumably until 2017-01-15\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2017-01-15, presumably until 2017-01-15\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-01-15, presumably until 2017-01-15\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-01-15, presumably until 2017-01-15\n- 0.6 ML pegfilgrastim 10 MG/ML Injection, through Subcutaneous route, started on 2017-01-15, presumably until 2017-01-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-01-15 09:02:27, ended at 2017-01-15 10:41:09\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2017-01-15, presumably until 2017-02-05, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily 40 mg daily x 1, 30 mg daily x 1 , 20 mg daily x 1, 10 mg daily x 1, 5 mg daily x 1.\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2017-01-15, presumably until 2017-02-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-01-23 00:00:00, ended at 2017-01-23 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2017-01-23, presumably until 2017-11-25, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day Take 1 tab by mouth twice daily with meals.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-01-26 00:00:00, ended at 2017-01-26 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-26 08:18:00, ended at 2017-01-26 10:02:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 42.3 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Disorder due to and following drug poisoning\n- Rheumatic tricuspid valve regurgitation\n- Disorder due to and following accidental poisoning\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-26 10:03:00, ended at 2017-01-26 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 81 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.40 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.5 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.2 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 113 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.96 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.1 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 112 (millimole per liter)\n- Platelets [#/volume] in Blood by Automated count: 147 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 0.98 (thousand per microliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.42 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 97.6 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 63.0 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 231 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 27.1 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.7 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 1.6 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.5 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.2 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-27 11:30:00, ended at 2017-01-27 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.5 ML filgrastim 0.6 MG/ML Prefilled Syringe, started on 2017-01-27, presumably until 2017-01-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-02-05 00:00:00, ended at 2017-02-05 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-02-05 00:00:00, ended at 2017-02-05 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-02-05 00:00:00, ended at 2017-02-05 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2017-02-05, presumably until 2017-08-22, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily 40 mg daily x 1, 30 mg daily x 1 , 20 mg daily x 1, 10 mg daily x 1, 5 mg daily x 1.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-02-05 00:00:00, ended at 2017-02-05 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-02-05 10:31:00, ended at 2017-02-05 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.2 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.67 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.85 (thousand per microliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 16.0 (percent)\n- MCV [Entitic volume] by Automated count: 97.3 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 19.9 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.85 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.0 (percent)\n- MCH [Entitic mass] by Automated count: 31.9 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 62.6 (percent)\n- Platelets [#/volume] in Blood by Automated count: 56 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 113 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.68 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.3 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 192 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 112 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.87 (million per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.4 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.3 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Collection of venous blood by venipuncture\n- Transfusion, blood or blood components\n\n### Condition\n- Hypothyroidism\n- Essential hypertension\n- Ascites\n- Hyperlipidemia\n- Primary malignant neoplasm\n- Secondary malignant neoplasm of left lung\n- Type 2 diabetes mellitus without complication\n- Gastroesophageal reflux disease without esophagitis\n- Dysuria\n- Iron deficiency anemia\n- Secondary malignant neoplasm of right lung\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2017-02-05, presumably until 2017-02-05\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-02-05, presumably until 2017-02-05\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-02-05, presumably until 2017-02-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-02-05 11:30:29, ended at 2017-02-05 12:53:31\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.984\" (inch (US))\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Transfusion, blood or blood components\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Iron deficiency anemia\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-02-10 14:00:00, ended at 2017-02-10 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocyte distribution width [Ratio] by Automated count: 22.4 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 115 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.3 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.2 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.85 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.8 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.3 (milligram per deciliter)\n- Leukocytes [#/volume] in Body fluid by Manual count: 1 (milli-international unit per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 11 (percent)\n- Neutrophils/100 leukocytes in Blood by Manual count: 58 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 17 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.93 (million per microliter)\n- MCV [Entitic volume] by Automated count: 98.1 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.99 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 22 (percent)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.5 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 116 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.50 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 169 (unit per liter)\n- Platelets [#/volume] in Blood by Automated count: 253 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n\n### Procedure\n- Application of on-body injector (includes cannula insertion) for timed subcutaneous injection\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-02-10, presumably until 2017-02-10\n- 2 ML prochlorperazine 5 MG/ML Injection, started on 2017-02-10, presumably until 2017-02-10\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2017-02-10, presumably until 2017-02-10\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2017-02-10, presumably until 2017-02-10\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-02-10, presumably until 2017-02-10\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-02-10, presumably until 2017-02-10\n- 0.6 ML pegfilgrastim 10 MG/ML Injection, through Subcutaneous route, started on 2017-02-10, presumably until 2017-02-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-02-14 00:00:00, ended at 2017-02-14 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2017-02-14, presumably until 2017-04-05, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-02-16 00:00:00, ended at 2017-02-16 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2017-02-16, presumably until 2017-05-24, with intended 5 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-02-20 00:00:00, ended at 2017-02-20 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Finding of frequency of urination\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-02-21 00:00:00, ended at 2017-02-21 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-toxic uninodular goiter\n- Vitamin D deficiency\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-02-22 00:00:00, ended at 2017-02-22 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cystitis\n\n### Drug\n- sulfamethoxazole 800 MG / trimethoprim 160 MG Oral Tablet, through Oral route, started on 2017-02-22, presumably until 2017-03-04, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-02-22 00:00:00, ended at 2017-02-22 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cystitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-03-12 00:00:00, ended at 2017-03-12 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.8 ML filgrastim 0.6 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2017-03-14, presumably until 2017-07-12, with intended 5 refill(s). Instructions: inject 0.8 mL subcutaneous (under the skin) daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-03-12 07:37:00, ended at 2017-03-12 09:17:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Acquired absence of organ\n- Secondary malignant neoplasm of left lung\n- Absent kidney\n- Secondary malignant neoplasm of right lung\n- Vitamin D deficiency\n- Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplastic disease\n- Secondary malignant neoplasm of adrenal gland\n- Secondary malignant neoplasm of lung\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-03-12, presumably until 2017-03-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-03-12 09:18:00, ended at 2017-03-12 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 45.2 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Disorder due to and following drug poisoning\n- Disorder due to and following accidental poisoning\n- Primary malignant neoplasm of soft tissues\n- Rheumatic tricuspid valve regurgitation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-03-12 12:46:42, ended at 2017-03-12 14:18:18\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Takotsubo cardiomyopathy\n- Primary diagnosis: Cardiomyopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-03-12 14:36:42, ended at 2017-03-12 16:32:10\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2017-03-12, presumably until 2017-06-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-03-12 15:49:23, ended at 2017-03-12 17:52:34\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-03-13 00:00:00, ended at 2017-03-13 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cystitis\n\n### Drug\n- nitrofurantoin, macrocrystals 50 MG Oral Capsule, through Oral route, started on 2017-03-13, presumably until 2017-06-10, with intended 2 refill(s). Instructions: take 1 Baxley by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-03-13 08:00:00, ended at 2017-03-13 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Ascites\n- Dysuria\n- Iron deficiency anemia\n- Secondary malignant neoplasm of right lung\n- Essential hypertension\n- Hyperlipidemia\n- Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplasm of left lung\n- Hypothyroidism\n- Type 2 diabetes mellitus without complication\n- Primary malignant neoplasm\n- Gastroesophageal reflux disease without esophagitis\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-03-13, presumably until 2017-03-13\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2017-03-13, presumably until 2017-03-13\n- 2 ML prochlorperazine 5 MG/ML Injection, started on 2017-03-13, presumably until 2017-03-13\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2017-03-13, presumably until 2017-03-13\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2017-03-13, presumably until 2017-03-13\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-03-13, presumably until 2017-03-13\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-03-13, presumably until 2017-03-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-03-14 00:00:00, ended at 2017-03-14 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-04-05 00:00:00, ended at 2017-04-05 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2017-04-05, presumably until 2017-06-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-07 11:20:00, ended at 2017-04-07 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.4 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.87 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 35.8 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.53 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 27.5 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 33.2 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 31.6 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 111 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 26.3 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 0.61 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 198 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.38 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 8.5 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Anion gap in Serum or Plasma: 3 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 113 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.7 (percent)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 175 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 1.9 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 110.2 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.64 (thousand per microliter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Anemia\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-04-07, presumably until 2017-04-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-04-08 00:00:00, ended at 2017-04-08 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-08 08:17:00, ended at 2017-04-08 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Transfusion, blood or blood components\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Collection of venous blood by venipuncture\n\n### Condition\n- Anemia\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.5 ML filgrastim 0.6 MG/ML Prefilled Syringe, started on 2017-04-08, presumably until 2017-04-08\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-04-08, presumably until 2017-04-08\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-04-08, presumably until 2017-04-08\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2017-04-08, presumably until 2017-04-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-04-09 00:00:00, ended at 2017-04-09 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-14 14:42:00, ended at 2017-04-14 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 111 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 101 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 200 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.4 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.44 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.2 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.78 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.2 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 23.5 (percent)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.94 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 18.4 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.0 (percent)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 33.2 (picogram)\n- MCV [Entitic volume] by Automated count: 102.2 (femtoliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.95 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.1 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.32 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 325 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.1 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 11.4 (gram per deciliter)\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-04-14, presumably until 2017-04-14\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2017-04-14, presumably until 2017-04-14\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2017-04-14, presumably until 2017-04-14\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-04-14, presumably until 2017-04-14\n- prochlorperazine 10 MG Oral Tablet, through Oral route, started on 2017-04-14, presumably until 2017-04-14\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-04-14, presumably until 2017-04-14\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2017-04-14, presumably until 2017-04-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-04-20 00:00:00, ended at 2017-04-20 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Generalized ischemic myocardial dysfunction\n\n### Drug\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2017-04-20, presumably until 2017-09-05, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals pt only taking it once a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-05-10 00:00:00, ended at 2017-05-10 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.025 MG Oral Tablet, through Oral route, started on 2017-05-10, presumably until 2017-07-12, with intended 3 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast Take daily with the 200 mcg tablet\n- levothyroxine sodium 0.2 MG Oral Tablet, through Oral route, started on 2017-05-10, presumably until 2017-07-12, with intended 3 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast Take daily with 25 mcg tablet\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-05-10 00:00:00, ended at 2017-05-10 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Folate [Mass/volume] in Red Blood Cells: 290 (nanogram per milliliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 0.9 (nanogram per deciliter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 562 (picogram per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-05-10 00:00:00, ended at 2017-05-10 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-05-10 07:35:00, ended at 2017-05-10 09:25:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Non-toxic multinodular goiter\n- Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-05-10 07:35:00, ended at 2017-05-10 09:25:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-05-10, presumably until 2017-05-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-05-10 09:26:00, ended at 2017-05-10 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.14 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 33.7 (picogram)\n- MCV [Entitic volume] by Automated count: 103.8 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 164 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.1 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.3 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 2.8 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 43 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 162 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 32 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.1 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 17 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.90 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.70 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 84 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.48 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 9.05 (micro-international unit per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.04 (milligram per deciliter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Acquired hypothyroidism\n- Non-toxic uninodular goiter\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-05-10, presumably until 2017-05-10\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2017-05-10, presumably until 2017-05-10\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2017-05-10, presumably until 2017-05-10\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2017-05-10, presumably until 2017-05-10\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-05-10, presumably until 2017-05-10\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-05-10, presumably until 2017-05-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-05-10 10:34:40, ended at 2017-05-10 11:47:59\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.984\" (inch (US))\n- Triiodothyronine (T3) Free [Mass/volume] in Serum or Plasma: 1.9 (picogram per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Acquired hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-05-11 00:00:00, ended at 2017-05-11 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 41.2 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-05-11 07:00:00, ended at 2017-05-11 13:24:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Transfusion, blood or blood components\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Takotsubo cardiomyopathy\n- Cardiomyopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-05-11 13:25:00, ended at 2017-05-11 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Transfusion, blood or blood components\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2017-05-11, presumably until 2017-05-11\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-05-11, presumably until 2017-05-11\n- 0.8 ML filgrastim 0.6 MG/ML Prefilled Syringe, started on 2017-05-11, presumably until 2017-05-11\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-05-11, presumably until 2017-05-11\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2017-05-11, presumably until 2017-05-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-05-12 09:10:00, ended at 2017-05-12 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.8 ML filgrastim 0.6 MG/ML Prefilled Syringe, started on 2017-05-12, presumably until 2017-05-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-05-16 00:00:00, ended at 2017-05-16 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Nausea and vomiting\n\n### Drug\n- prochlorperazine 10 MG Oral Tablet, started on 2017-05-16, presumably until 2018-07-10, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY 8 HOURS AS NEEDED FOR NAUSEA OR VOMITING\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-05-24 00:00:00, ended at 2017-05-24 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- amitriptyline hydrochloride 75 MG Oral Tablet, through Oral route, started on 2017-05-25, presumably until 2017-10-22, with intended 3 refill(s). Instructions: take 1 Tab by mouth every bedtime as needed\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2017-05-25, presumably until 2017-11-29, with intended 5 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-06-08 00:00:00, ended at 2017-06-08 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2017-06-08, presumably until 2017-06-15, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-06-08 00:00:00, ended at 2017-06-08 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2017-06-08, presumably until 2017-09-18, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2017-06-08, presumably until 2017-08-20, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-08 10:43:00, ended at 2017-06-08 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 169 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 100.0 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.3 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.3 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.02 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Triiodothyronine (T3) Free [Mass/volume] in Serum or Plasma: 2.1 (picogram per milliliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 6.12 (micro-international unit per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.09 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 23.0 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.68 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 281 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.00 (million per microliter)\n- MCH [Entitic mass] by Automated count: 33.4 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.68 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.6 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 97 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.0 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 18.3 (percent)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hypothyroidism\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-06-08, presumably until 2017-06-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-08 11:28:16, ended at 2017-06-08 12:11:22\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2017-06-08, presumably until 2017-06-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-08 13:01:05, ended at 2017-06-08 14:13:21\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.984\" (inch (US))\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n- Benign neoplasm of left adrenal gland\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-09 12:17:00, ended at 2017-06-09 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-06-09, presumably until 2017-06-09\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2017-06-09, presumably until 2017-06-09\n- 2 ML prochlorperazine 5 MG/ML Injection, started on 2017-06-09, presumably until 2017-06-09\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2017-06-09, presumably until 2017-06-09\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2017-06-09, presumably until 2017-06-09\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-06-09, presumably until 2017-06-09\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-06-09, presumably until 2017-06-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-06-11 00:00:00, ended at 2017-06-11 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-11 12:41:58, ended at 2017-06-11 13:15:24\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Cardiomyopathy\n- Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-07-10 12:18:00, ended at 2017-07-10 13:53:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Secondary malignant neoplasm of lung\n- Non-toxic uninodular goiter\n- Disorder of pancreas\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-07-10 13:54:00, ended at 2017-07-10 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n\n### Condition\n- Non-toxic uninodular goiter\n- Non-toxic multinodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-07-12 00:00:00, ended at 2017-07-12 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-07-12 08:30:00, ended at 2017-07-12 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 129 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.9 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.75 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.7 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 123 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 27.2 (percent)\n- MCH [Entitic mass] by Automated count: 34.7 (picogram)\n- Calcium [Mass/volume] in Serum or Plasma: 8.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.60 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.62 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 59 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.9 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.96 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 298 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.0 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.4 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 73.9 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 6.41 (micro-international unit per milliliter)\n- Triiodothyronine (T3) Free [Mass/volume] in Serum or Plasma: 1.8 (picogram per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.94 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 104.5 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n\n### Procedure\n- Transfusion, blood or blood components\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Osteoporosis\n- Iron deficiency anemia due to blood loss\n- Hypothyroidism\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-07-12, presumably until 2017-07-12\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-07-12, presumably until 2017-07-12\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2017-07-12, presumably until 2017-07-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-07-12 09:38:25, ended at 2017-07-12 10:32:02\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.984\" (inch (US))\n- Ferritin [Mass/volume] in Serum or Plasma: 46.7 (nanogram per milliliter)\n- Triiodothyronine (T3) Free [Mass/volume] in Serum or Plasma: 1.6 (picogram per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Osteoporosis\n- Primary diagnosis: Iron deficiency anemia due to blood loss\n- Hypothyroidism\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2017-07-12, presumably until 2017-07-16, with intended 6 refill(s). Instructions: take 1 Tab by mouth every 12 hours as needed\n- levothyroxine sodium 0.125 MG Oral Capsule, through Oral route, started on 2017-07-12, presumably until 2017-07-20, with intended 6 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n- temozolomide 140 MG Oral Capsule, through Oral route, started on 2017-07-12, presumably until 2017-08-20, with intended 6 refill(s). Instructions: take 1 Cap by mouth daily Daily x 21 days, off 1 week\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-07-16 00:00:00, ended at 2017-07-16 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Nausea\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2017-07-16, presumably until 2017-12-19, with intended 6 refill(s). Instructions: take 1 Tab by mouth as directed Take 1 tablet one hour before taking Temodar.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-07-20 00:00:00, ended at 2017-07-20 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- levothyroxine sodium 0.175 MG Oral Tablet, through Oral route, started on 2017-07-20, presumably until 2018-01-25, with intended 3 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast Total 275 mcg (100 + 175 mcg pills)\n- levothyroxine sodium 0.125 MG Oral Capsule, through Oral route, started on 2017-07-20, presumably until 2017-07-26, with intended 3 refill(s). Instructions: take 2 Caps by mouth every day Patient with absorption issues.\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2017-07-20, presumably until 2018-01-25, with intended 3 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast Total 275 mcg (100 + 175 mcg pills)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-07-26 00:00:00, ended at 2017-07-26 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypothyroidism\n- Primary diagnosis: Intestinal malabsorption\n\n### Drug\n- levothyroxine sodium 0.125 MG Oral Capsule, through Oral route, started on 2017-07-26, presumably until 2017-09-05, with intended 3 refill(s). Instructions: take 2 Caps by mouth every day Patient with absorption issues.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-08-05 00:00:00, ended at 2017-08-05 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, started on 2017-08-16, presumably until 2017-11-25, with intended 0 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH TWICE A WEEK\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-10 00:00:00, ended at 2017-08-10 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-20 00:00:00, ended at 2017-08-20 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Cortisol [Mass/volume] in Serum or Plasma: 4.9 (microgram per deciliter)\n- Testosterone Free/Testosterone.total in Serum or Plasma: 0.1 (nanogram per deciliter)\n- Testosterone [Mass/volume] in Serum or Plasma: 8 (nanogram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-20 00:00:00, ended at 2017-08-20 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- temozolomide 100 MG Oral Capsule, through Oral route, started on 2017-08-20, presumably until 2017-11-09, with intended 5 refill(s). Instructions: take 1 Cap by mouth daily\n- temozolomide 20 MG Oral Capsule, through Oral route, started on 2017-08-20, presumably until 2017-11-09, with intended 5 refill(s). Instructions: take 1 Cap by mouth daily To take with Temozolomide 100 mg capsule\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-08-20 00:00:00, ended at 2017-08-20 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2017-08-20, presumably until 2017-10-10, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-20 07:47:00, ended at 2017-08-20 08:49:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Secondary malignant neoplasm of lung\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-20 08:50:00, ended at 2017-08-20 10:41:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 115 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.3 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 116 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 11.0 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.7 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.68 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 301 (thousand per microliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 4 (nanogram per milliliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.32 (million per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.47 (micro-international unit per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 17 (nanogram per milliliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.63 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 33.1 (picogram)\n- MCV [Entitic volume] by Automated count: 100.9 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 21.6 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.0 (percent)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 21 (nanogram per milliliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.5 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.83 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 69.4 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.04 (milligram per deciliter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplasm of lung\n- Vitamin D deficiency\n- Hypothyroidism\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-08-20, presumably until 2017-08-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-22 00:00:00, ended at 2017-08-22 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2017-08-22, presumably until 2017-12-19, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-22 00:00:00, ended at 2017-08-22 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2017-08-22, presumably until 2017-11-19, with intended 3 refill(s). Instructions: take 1 Dunbar by mouth once a week\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-09-03 00:00:00, ended at 2017-09-03 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Iron deficiency anemia\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- folic acid 1 MG Oral Tablet, through Oral route, started on 2017-09-03, presumably until 2017-11-19, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-05 07:00:00, ended at 2017-09-05 09:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine)\n\n### Condition\n- Iron deficiency anemia due to blood loss\n- Disorder of bone\n- Osteoporosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-05 08:45:08, ended at 2017-09-05 09:46:40\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.748\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-05 10:00:00, ended at 2017-09-05 14:09:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 41.8 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Generalized ischemic myocardial dysfunction\n- Osteoporosis\n- Primary malignant neoplasm of soft tissues\n- Cardiomyopathy\n- Iron deficiency anemia\n- Iron deficiency anemia due to blood loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-05 11:57:56, ended at 2017-09-05 13:19:29\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Cardiomyopathy\n- Generalized ischemic myocardial dysfunction\n\n### Drug\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2017-09-05, presumably until 2018-07-27, with intended 6 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-05 14:10:00, ended at 2017-09-05 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Hypothyroidism\n- Primary malignant neoplasm of soft tissues\n- Vitamin D deficiency\n- Iron deficiency anemia\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2017-09-05, presumably until 2017-09-05\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-09-05, presumably until 2017-09-05\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-09-05, presumably until 2017-09-05\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-09-05, presumably until 2017-09-05\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2017-09-05, presumably until 2017-09-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-09-18 00:00:00, ended at 2017-09-18 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2017-09-18, presumably until 2017-11-09, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-28 07:30:00, ended at 2017-09-28 07:35:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Osteoporosis\n- Hypothyroidism\n- Non-toxic uninodular goiter\n- Secondary malignant neoplasm of lung\n- Vitamin D deficiency\n- Iron deficiency anemia\n- Primary malignant neoplasm of retroperitoneum\n- Anemia due to and following chemotherapy\n- Disorder of adrenal gland\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-28 07:36:00, ended at 2017-09-28 09:09:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 117 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Disorder of bone\n- Primary malignant neoplasm of soft tissues\n- Abnormal findings on diagnostic imaging of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-28 09:10:00, ended at 2017-09-28 14:29:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.24 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.93 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.7 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.83 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 280 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 97 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 21.7 (percent)\n- MCH [Entitic mass] by Automated count: 33.1 (picogram)\n- Triiodothyronine (T3) Free [Mass/volume] in Serum or Plasma: 1.4 (picogram per milliliter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 894 (picogram per milliliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 6.71 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 110 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.5 (percent)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.4 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.06 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 100.4 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 77.1 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 14 (unit per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.50 (micro-international unit per milliliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 105.3 (nanogram per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-28 09:39:52, ended at 2017-09-28 10:25:54\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.53 (micro-international unit per milliliter)\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Osteoporosis\n- Vitamin D deficiency\n- Disorder of adrenal gland\n- Non-toxic uninodular goiter\n- Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-28 12:24:01, ended at 2017-09-28 15:37:04\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.984\" (inch (US))\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Intravenous infusion, hydration; initial, 31 minutes to 1 hour\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-28 14:30:00, ended at 2017-09-28 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, hydration; initial, 31 minutes to 1 hour\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Hypothyroidism\n- Primary malignant neoplasm of soft tissues\n- Vitamin D deficiency\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-09-28, presumably until 2017-09-28\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-09-28, presumably until 2017-09-28\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2017-09-28, presumably until 2017-09-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-10-03 00:00:00, ended at 2017-10-03 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-10-10 00:00:00, ended at 2017-10-10 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2017-10-10, presumably until 2017-10-29, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-10-17 00:00:00, ended at 2017-10-17 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-10-22 00:00:00, ended at 2017-10-22 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amitriptyline hydrochloride 75 MG Oral Tablet, started on 2017-10-23, presumably until 2017-11-21, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY NIGHT AT BEDTIME AS NEEDED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-10-25 00:00:00, ended at 2017-10-25 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Impaired renal function disorder\n- Acquired absence of organ\n- Absent kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-10-29 00:00:00, ended at 2017-10-29 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2017-10-29, presumably until 2017-10-31, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-10-31 00:00:00, ended at 2017-10-31 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2017-10-31, presumably until 2017-12-19, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-07 00:00:00, ended at 2017-11-07 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hemorrhoids\n\n### Drug\n- mupirocin 0.02 MG/MG Topical Ointment, started on 2017-11-08, presumably until 2017-11-09, with intended 1 refill(s). Instructions: Apply to affected area BID prn rash\n- hydrocortisone acetate 25 MG Rectal Suppository, through Rectal route, started on 2017-11-07, presumably until 2017-11-19, with intended 3 refill(s). Instructions: insert 1 Suppository into the rectum daily as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-09 00:00:00, ended at 2017-11-09 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-11-09 08:22:00, ended at 2017-11-09 10:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 111 (milligram per deciliter)\n\n### Procedure\n- Transfusion, blood or blood components\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Secondary malignant neoplasm of lung\n- Secondary malignant neoplastic disease\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-11-09 08:22:00, ended at 2017-11-09 10:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-11-09 11:00:00, ended at 2017-11-09 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 139 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.3 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.6 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.08 (micro-international unit per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 66 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 105.3 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.53 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 84 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.97 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.0 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.70 (million per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.52 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 21.1 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 83.9 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.48 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 34.3 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 297 (thousand per microliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.4 (percent)\n\n### Procedure\n- Transfusion, blood or blood components\n\n### Condition\n- Hypothyroidism\n- Vitamin D deficiency\n- Disorder of pancreas\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-11-09, presumably until 2017-11-09\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-11-09, presumably until 2017-11-09\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2017-11-09, presumably until 2017-11-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-09 12:13:02, ended at 2017-11-09 14:14:42\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Cortisol [Mass/volume] in Serum or Plasma: 2.5 (microgram per deciliter)\n- Body height: 5' 5.984\" (inch (US))\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of pancreas\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- temozolomide 100 MG Oral Capsule, through Oral route, started on 2017-11-09, presumably until 2018-02-06, with intended 5 refill(s). Instructions: take 1 Cap by mouth daily\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, through Oral route, started on 2017-11-09, presumably until 2018-02-20, with intended 1 refill(s). Instructions: take 1-2 Caps by mouth 3 times a day with meals\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2017-11-09, presumably until 2017-12-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n- mupirocin 0.02 MG/MG Topical Ointment, started on 2017-11-09, presumably until 2018-04-26, with intended 2 refill(s). Instructions: Apply to affected area BID prn rash\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-11-13 00:00:00, ended at 2017-11-13 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2017-11-13, presumably until 2017-11-13, with intended 9 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-11-14 00:00:00, ended at 2017-11-14 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2017-11-14, presumably until 2017-12-19, with intended 9 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-19 08:52:21, ended at 2017-11-19 10:09:42\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Absent kidney\n- Chronic kidney disease stage 3\n- Acquired absence of organ\n- Primary diagnosis: Blood chemistry abnormal\n- Essential hypertension\n- Vitamin D deficiency\n\n### Drug\n- hydrocortisone 25 MG/ML Topical Cream, started on 2016-01-06, presumably until 2018-09-10, with intended 0 refill(s). Instructions: Apply to external hemorrhoid BID prn pain\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-11-19 10:14:00, ended at 2017-11-19 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Microalbumin/Creatinine [Mass Ratio] in Urine: <10 (milligram per gram)\n- Albumin [Mass/volume] in Urine: 8 (milligram per liter)\n- Protein/Creatinine [Mass Ratio] in Urine: 0.39 (milligram per milligram)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 49 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 131.00 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 6 - 10 (per high power field)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Acquired absence of organ\n- Blood chemistry abnormal\n- Vitamin D deficiency\n- Absent kidney\n- Primary malignant neoplasm of soft tissues\n- Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-21 00:00:00, ended at 2017-11-21 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-11-21 00:00:00, ended at 2017-11-21 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amitriptyline hydrochloride 75 MG Oral Tablet, started on 2017-11-22, presumably until 2017-12-19, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY NIGHT AT BEDTIME AS NEEDED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-11-25 00:00:00, ended at 2017-11-25 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2017-11-26, presumably until 2018-01-30, with intended 2 refill(s). Instructions: take 1 Cap by mouth 2 times per week\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-11-25 00:00:00, ended at 2017-11-25 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2017-11-26, presumably until 2018-01-25, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day Take 1 tab by mouth twice daily with meals.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-11-29 00:00:00, ended at 2017-11-29 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- dabigatran etexilate 150 MG Oral Capsule, started on 2017-12-03, presumably until 2017-12-30, with intended 0 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-30 00:00:00, ended at 2017-11-30 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- nitrofurantoin, macrocrystals 50 MG Oral Capsule, through Oral route, started on 2017-11-30, presumably until 2018-03-19, with intended 5 refill(s). Instructions: take 1 Zapanta by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-12-11 00:00:00, ended at 2017-12-11 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2017-12-11, presumably until 2018-04-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-12-17 00:00:00, ended at 2017-12-17 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-12-19 00:00:00, ended at 2017-12-19 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nausea\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2017-12-24, presumably until 2018-03-12, with intended 6 refill(s). Instructions: take 1 Tab by mouth as directed Take 1 tablet one hour before taking Temodar.\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2017-12-24, presumably until 2018-06-06, with intended 6 refill(s). Instructions: take 1 Tab by mouth every day\n- amitriptyline hydrochloride 75 MG Oral Tablet, through Oral route, started on 2017-12-24, presumably until 2018-01-29, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime as needed\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2017-12-24, presumably until 2018-01-25, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2017-12-24, presumably until 2018-01-16, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-12-19 00:00:00, ended at 2017-12-19 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2017-12-19, presumably until 2018-06-24, with intended 9 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-12-30 00:00:00, ended at 2017-12-30 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- dabigatran etexilate 150 MG Oral Capsule, started on 2017-12-31, presumably until 2018-01-25, with intended 0 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-01-15 08:08:19, ended at 2018-01-15 08:57:35\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; single lesion\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Verruca vulgaris\n- Primary diagnosis: Neoplastic disease of uncertain behavior\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-01-15 12:00:00, ended at 2018-01-15 12:02:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 131 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Neoplastic disease of uncertain behavior\n- Verruca vulgaris\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-01-15, presumably until 2018-01-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-01-15 12:03:00, ended at 2018-01-15 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-01-16 11:28:00, ended at 2018-01-16 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 18 (nanogram per milliliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.64 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.1 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 97.6 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.47 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 10.9 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 65 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.3 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 22 (nanogram per milliliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 12.9 (nanogram per milliliter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 271 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.3 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.9 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Urate [Mass/volume] in Serum or Plasma: 5.4 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 81 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.15 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.5 (percent)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 197 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.66 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.84 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.30 (micro-international unit per milliliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 164 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.8 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 73.6 (percent)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 4 (nanogram per milliliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.5 (percent)\n- Haptoglobin [Mass/volume] in Serum or Plasma: 182 (milligram per deciliter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Hypothyroidism\n- Primary malignant neoplasm of soft tissues\n- Vitamin D deficiency\n- Blood chemistry abnormal\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-01-16, presumably until 2018-01-16\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-01-16 12:22:08, ended at 2018-01-16 14:17:45\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.496\" (inch (US))\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 93 (unit per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Amylase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Blood chemistry abnormal\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Vitamin D deficiency\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-01-16, presumably until 2018-03-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-01-25 00:00:00, ended at 2018-01-25 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n- Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.175 MG Oral Tablet, through Oral route, started on 2018-01-25, presumably until 2018-03-27, with intended 3 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast Total 275 mcg (100 + 175 mcg pills)\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2018-01-25, presumably until 2018-03-27, with intended 3 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast Total 275 mcg (100 + 175 mcg pills)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-01-25 00:00:00, ended at 2018-01-25 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2018-01-25, presumably until 2018-04-26, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2018-01-25, presumably until 2018-03-19, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-01-25 00:00:00, ended at 2018-01-25 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2018-01-29, presumably until 2018-04-26, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day Take 1 tab by mouth twice daily with meals.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-01-28 00:00:00, ended at 2018-01-28 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-01-29 00:00:00, ended at 2018-01-29 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amitriptyline hydrochloride 75 MG Oral Tablet, through Oral route, started on 2018-01-29, presumably until 2018-04-26, with intended 5 refill(s). Instructions: take 1 Tab by mouth every bedtime as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-01-30 00:00:00, ended at 2018-01-30 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2018-01-31, presumably until 2018-02-20, with intended 2 refill(s). Instructions: take 1 Cap by mouth 2 times per week\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-02-06 00:00:00, ended at 2018-02-06 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- temozolomide 100 MG Oral Capsule, through Oral route, started on 2018-02-06, presumably until 2018-06-05, with intended 5 refill(s). Instructions: take 1 Cap by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-02-20 00:00:00, ended at 2018-02-20 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, started on 2018-02-21, presumably until 2018-04-26, with intended 0 refill(s). Instructions: TAKE 1 TO 2 CAPSULES BY MOUTH THREE TIMES DAILY WITH MEALS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-02-20 00:00:00, ended at 2018-02-20 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2018-02-20, presumably until 2018-03-27, with intended 2 refill(s). Instructions: take 1 Cap by mouth 3 times a week\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-03-04 00:00:00, ended at 2018-03-04 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- dabigatran etexilate 150 MG Oral Capsule, started on 2018-03-05, presumably until 2018-04-02, with intended 0 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-04 13:34:00, ended at 2018-03-04 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neoplasm of uncertain behavior of skin\n- Chronic kidney disease stage 3\n- Hypothyroidism\n- Vitamin D deficiency\n- Primary malignant neoplasm of soft tissues\n- Anemia due to and following chemotherapy\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-03-04, presumably until 2018-03-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-03-11 00:00:00, ended at 2018-03-11 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-03-13, presumably until 2018-04-25, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-03-12 00:00:00, ended at 2018-03-12 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Nausea\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2018-03-12, presumably until 2018-04-25, with intended 6 refill(s). Instructions: take 1 Tab by mouth as directed Take 1 tablet one hour before taking Temodar.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-03-19 00:00:00, ended at 2018-03-19 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-19 13:14:00, ended at 2018-03-19 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 17 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 17 (nanogram per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 114 (unit per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Low blood pressure\n- Renal agenesis\n- Chronic kidney disease stage 3\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-03-19 13:41:55, ended at 2018-03-19 15:27:09\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease stage 3\n- Low blood pressure\n- Renal agenesis\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-03-20 00:00:00, ended at 2018-03-20 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-20 08:30:00, ended at 2018-03-20 08:42:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cardiomyopathy\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-03-20, presumably until 2018-03-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-20 08:43:00, ended at 2018-03-20 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 143 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-21 07:10:00, ended at 2018-03-21 09:56:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 17 (nanogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 113 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 148 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.1 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.56 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 23.1 (percent)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.91 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 110.2 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 17 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.98 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 42 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.53 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.8 (percent)\n- Thyrotropin [Units/volume] in Serum or Plasma: 4.61 (micro-international unit per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.1 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 27.9 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.9 (percent)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.1 (nanogram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 96 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 9.1 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.47 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 36.0 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 75.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 243 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Vitamin D deficiency\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-03-21, presumably until 2018-03-21\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-03-21 08:23:49, ended at 2018-03-21 09:55:06\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.496\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-21 09:57:00, ended at 2018-03-21 14:45:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-21 14:46:00, ended at 2018-03-21 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 42.3 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Accidental poisoning\n- Poisoning by drug AND/OR medicinal substance\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-03-22 00:00:00, ended at 2018-03-22 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of retroperitoneum\n- Chronic kidney disease stage 3\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-03-22 00:00:00, ended at 2018-03-22 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n- Vitamin D deficiency\n- Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.15 MG Oral Capsule, started on 2018-03-27, presumably until 2018-06-12, with intended 11 refill(s). Instructions: Take 125 mcg + 150 mcg = total of 275 mcg cap daily\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2018-03-27, presumably until 2018-05-28, with intended 2 refill(s). Instructions: take 1 Cap by mouth every other day\n- levothyroxine sodium 0.125 MG Oral Capsule, started on 2018-03-27, presumably until 2018-06-12, with intended 11 refill(s). Instructions: Take 125 mcg + 150 mcg = total of 275 mcg cap daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-03-22 08:56:09, ended at 2018-03-22 09:51:43\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.496\" (inch (US))\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; single lesion\n- Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; each separate/additional lesion (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Neoplasm of uncertain behavior of skin\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-03-22, presumably until 2018-03-22\n- 1 ML epinephrine 1 MG/ML Injection, started on 2018-03-22, presumably until 2018-03-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-22 10:20:00, ended at 2018-03-22 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Transfusion, blood or blood components\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Chronic kidney disease stage 3\n- Primary malignant neoplasm of retroperitoneum\n- Anemia due to and following chemotherapy\n\n### Drug\n- 0.6 ML darbepoetin alfa 0.5 MG/ML Prefilled Syringe, started on 2018-03-22, presumably until 2018-03-22\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-03-22, presumably until 2018-03-22\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-03-22, presumably until 2018-03-22\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2018-03-22, presumably until 2018-03-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-04-01 00:00:00, ended at 2018-04-01 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Reticulocytes [#/volume] in Blood by Automated count: 63.1 (thousand per microliter)\n- Reticulocytes/100 erythrocytes in Blood by Automated count: 1.84 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-01 11:25:00, ended at 2018-04-01 14:49:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Neutrophils/100 leukocytes in Blood by Automated count: 79.5 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 104 (unit per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 17 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.1 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 4.9 (percent)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 978 (picogram per milliliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 25.5 (percent)\n- Folate [Mass/volume] in Red Blood Cells: 319 (nanogram per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 132 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 105.0 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.43 (million per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 158.6 (nanogram per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 11.9 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Iron [Mass/volume] in Serum or Plasma: 44 (microgram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.25 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 34.8 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 4.05 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 221 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.01 (micro-international unit per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.98 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.74 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.0 (percent)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Chronic kidney disease stage 3\n- Iron deficiency anemia\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-04-01 12:25:17, ended at 2018-04-01 13:03:39\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Iron deficiency anemia\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-04-01 12:58:54, ended at 2018-04-01 15:16:42\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.496\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-01 14:50:00, ended at 2018-04-01 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n\n### Condition\n- Primary diagnosis: Iron deficiency anemia\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-04-01, presumably until 2018-04-01\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-04-01, presumably until 2018-04-01\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-04-01, presumably until 2018-04-01\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2018-04-01, presumably until 2018-04-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-04-02 00:00:00, ended at 2018-04-02 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2018-04-02, presumably until 2018-05-06, with intended 3 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-04-03 00:00:00, ended at 2018-04-03 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Bronchitis\n\n### Drug\n- levofloxacin 500 MG Oral Tablet, through Oral route, started on 2018-04-03, presumably until 2018-04-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-04-19 00:00:00, ended at 2018-04-19 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-23 11:49:00, ended at 2018-04-23 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.91 (million per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 89.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 253 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Iron [Mass/volume] in Serum or Plasma: 50 (microgram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.1 (percent)\n- MCV [Entitic volume] by Automated count: 106.5 (femtoliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 301.6 (nanogram per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 133 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.87 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.71 (micro-international unit per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.0 (percent)\n- MCH [Entitic mass] by Automated count: 35.2 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 19 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.8 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 11 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.10 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.3 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.2 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 104 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 21.7 (percent)\n- Globulin [Mass/volume] in Serum: 4.4 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Chronic kidney disease stage 3\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-04-23 13:25:04, ended at 2018-04-23 14:20:37\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Ventricular premature complex\n- Bifascicular block\n- Electrocardiogram abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-04-24 00:00:00, ended at 2018-04-24 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 10 ML bupivacaine hydrochloride 5 MG/ML Injection, started on 2018-04-24, presumably until 2018-04-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-04-24 00:00:00, ended at 2018-04-24 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on the integumentary system on the extremities, anterior trunk and perineum; not otherwise specified\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Primary malignant neoplasm of retroperitoneum\n- Essential hypertension\n- Obstructive sleep apnea syndrome\n\n### Drug\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2018-04-24, presumably until 2018-04-24\n- cefazolin 1000 MG Injection, started on 2018-04-24, presumably until 2018-04-24\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2018-04-24, presumably until 2018-04-24\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2018-04-24, presumably until 2018-04-24\n- 2 ML ondansetron 2 MG/ML Injection, started on 2018-04-24, presumably until 2018-04-24\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-04-24, presumably until 2018-04-24\n- midazolam 1 MG/ML Injectable Solution, started on 2018-04-24, presumably until 2018-04-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-24 09:34:00, ended at 2018-04-24 15:15:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- Excision of Chest Subcutaneous Tissue and Fascia, Open Approach\n- Repair, intermediate, wounds of scalp, axillae, trunk and/or extremities (excluding hands and feet); 7.6 cm to 12.5 cm\n- Repair Chest Subcutaneous Tissue and Fascia, Open Approach\n- Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter 3.1 to 4.0 cm\n\n### Condition\n- Secondary malignant neoplasm of lung\n- Primary malignant neoplasm of retroperitoneum\n- Secondary malignant neoplastic disease\n\n### Drug\n- 0.5 ML meperidine hydrochloride 50 MG/ML Injection, started on 2018-04-24, presumably until 2018-04-24\n- 2 ML ondansetron 2 MG/ML Injection, started on 2018-04-24, presumably until 2018-04-24\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2018-04-24, presumably until 2018-07-06, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-04-25 00:00:00, ended at 2018-04-25 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Neck pain\n- Primary malignant neoplasm of soft tissues\n- Nausea\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2018-04-25, presumably until 2018-05-31, with intended 6 refill(s). Instructions: take 1 Tab by mouth as directed Take 1 tablet one hour before taking Temodar daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-04-25 09:48:45, ended at 2018-04-25 11:10:11\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.496\" (inch (US))\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Nausea\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2018-04-25, presumably until 2018-04-25, with intended 6 refill(s). Instructions: take 1 Tab by mouth as directed Take 1 tablet one hour before taking Temodar.\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-04-25, presumably until 2018-06-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-25 11:18:00, ended at 2018-04-25 15:05:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Chronic kidney disease stage 3\n- Vitamin D deficiency\n- Primary malignant neoplasm of soft tissues\n- Hypothyroidism\n\n### Drug\n- 0.6 ML darbepoetin alfa 0.5 MG/ML Prefilled Syringe, started on 2018-04-25, presumably until 2018-04-25\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-04-25, presumably until 2018-04-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-25 15:06:00, ended at 2018-04-25 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n\n### Condition\n- Nausea\n- Neck pain\n- Chronic kidney disease stage 3\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-04-26 00:00:00, ended at 2018-04-26 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2018-04-26, presumably until 2018-07-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2018-04-26, presumably until 2018-06-19, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-04-26 00:00:00, ended at 2018-04-26 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-toxic uninodular goiter\n- Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.15 MG Oral Capsule, started on 2018-04-26, presumably until 2018-04-26, with intended 11 refill(s). Instructions: Take 125 mcg + 150 mcg = total of 275 mcg cap daily\n- levothyroxine sodium 0.125 MG Oral Capsule, started on 2018-04-26, presumably until 2018-04-26, with intended 11 refill(s). Instructions: Take 125 mcg + 150 mcg = total of 275 mcg cap daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-04-26 00:00:00, ended at 2018-04-26 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, started on 2018-04-26, presumably until 2018-05-28, with intended 0 refill(s). Instructions: TAKE 1 TO 2 CAPSULES BY MOUTH THREE TIMES DAILY WITH MEALS\n- amitriptyline hydrochloride 75 MG Oral Tablet, through Oral route, started on 2018-04-26, presumably until 2018-06-12, with intended 5 refill(s). Instructions: take 1 Tab by mouth every bedtime as needed\n- mupirocin 0.02 MG/MG Topical Ointment, started on 2018-04-26, presumably until 2018-09-10, with intended 2 refill(s). Instructions: Apply to affected area BID prn rash\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2018-04-26, presumably until 2018-09-14, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day Take 1 tab by mouth twice daily with meals.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-05-06 00:00:00, ended at 2018-05-06 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-05-06 00:00:00, ended at 2018-05-06 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2018-05-07, presumably until 2018-07-26, with intended 3 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-05-06 09:42:34, ended at 2018-05-06 11:03:39\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.496\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Hypothyroidism\n- Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-05-16 00:00:00, ended at 2018-05-16 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-05-28 00:00:00, ended at 2018-05-28 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-toxic uninodular goiter\n- Hypothyroidism\n- Vitamin D deficiency\n\n### Drug\n- levothyroxine sodium 0.15 MG Oral Capsule, started on 2018-05-28, presumably until 2018-05-28, with intended 11 refill(s). Instructions: Take 125 mcg + 150 mcg = total of 275 mcg cap daily\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2018-05-29, presumably until 2018-09-11, with intended 2 refill(s). Instructions: take 1 Cap by mouth every other day\n- levothyroxine sodium 0.125 MG Oral Capsule, started on 2018-05-28, presumably until 2018-05-28, with intended 11 refill(s). Instructions: Take 125 mcg + 150 mcg = total of 275 mcg cap daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-05-28 00:00:00, ended at 2018-05-28 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, started on 2018-05-28, presumably until 2018-07-06, with intended 0 refill(s). Instructions: TAKE 1 TO 2 CAPSULES BY MOUTH THREE TIMES DAILY WITH MEALS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-05-31 00:00:00, ended at 2018-05-31 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Nausea\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2018-05-31, presumably until 2018-06-12, with intended 6 refill(s). Instructions: take 1 Tab by mouth as directed Take 1 tablet one hour before taking Temodar daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-06-03 07:46:00, ended at 2018-06-03 12:25:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-06-03 07:46:00, ended at 2018-06-03 12:25:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 177 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-06-03 10:37:27, ended at 2018-06-03 11:15:15\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary diagnosis: Chronic kidney disease stage 3\n- Essential hypertension\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-06-03 12:26:00, ended at 2018-06-03 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 93 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- Iron [Mass/volume] in Serum or Plasma: 46 (microgram per deciliter)\n- MCH [Entitic mass] by Automated count: 36.6 (picogram)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.3 (percent)\n- Platelets [#/volume] in Blood by Automated count: 268 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 5.8 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Ferritin [Mass/volume] in Serum or Plasma: 167.2 (nanogram per milliliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 16 (percent)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.01 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 107.9 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.8 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.2 (nanogram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 155 (milligram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.88 (micro-international unit per milliliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.74 (million per microliter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Hypothyroidism\n- Vitamin D deficiency\n- Primary malignant neoplasm of soft tissues\n- Chronic kidney disease stage 3\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-06-03, presumably until 2018-06-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-06-03 13:29:31, ended at 2018-06-03 14:18:27\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.496\" (inch (US))\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 55 (unit per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-06-04 13:40:00, ended at 2018-06-05 20:36:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 107.4 (femtoliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 246 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 36.6 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 274 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.89 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.22 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 99 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 40 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.3 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 8.45 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 95.7 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.69 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.8 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.9 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 1.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Body height: 5' 5.945\" (inch (US))\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n\n### Procedure\n- Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n\n### Condition\n- Nausea\n- Old myocardial infarction\n- Chronic kidney disease stage 2\n- Iron deficiency anemia\n- Secondary malignant neoplasm of lung\n- Acquired absence of organ\n- Takotsubo cardiomyopathy\n- Acute insomnia\n- Hypothyroidism\n- Obesity\n- Vitamin D deficiency\n- Obstructive sleep apnea syndrome\n- Secondary malignant neoplasm of intra-abdominal lymph nodes\n- Absent kidney\n- Chronic systolic heart failure\n- Disorder of pancreas\n- Chronic congestive heart failure\n- Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- thiamine 100 MG Oral Tablet, through Oral route, started on 2018-06-05, presumably until 2018-06-05\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, through Oral route, started on 2018-06-04, presumably until 2018-06-05\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2018-06-05, presumably until 2018-06-05\n- 50 ML famotidine 0.4 MG/ML Injection, through Intravenous route, started on 2018-06-04, presumably until 2018-06-04\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2018-06-04, presumably until 2018-06-04\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-06-05, presumably until 2018-06-05\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-06-04, presumably until 2018-06-05\n- prednisone 2.5 MG Oral Tablet, through Oral route, started on 2018-06-05, presumably until 2018-06-05\n- hydrocortisone 25 MG/ML Topical Cream, through Topical route, started on 2018-06-04, presumably until 2018-06-05\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-06-04, presumably until 2018-06-04\n- amitriptyline hydrochloride 75 MG Oral Tablet, through Oral route, started on 2018-06-04, presumably until 2018-06-04\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2018-06-05, presumably until 2018-06-05\n- levothyroxine sodium 0.025 MG Oral Tablet, through Oral route, started on 2018-06-05, presumably until 2018-06-05\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-06-04, presumably until 2018-06-05\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-06-05, presumably until 2018-06-05\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2018-06-04, presumably until 2018-06-04\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2018-06-04, presumably until 2018-06-05\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2018-06-04, presumably until 2018-06-05\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2018-06-04, presumably until 2018-06-04\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2018-06-04, presumably until 2018-06-04\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2018-06-04, presumably until 2018-06-05\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2018-06-05, presumably until 2018-06-05\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2018-06-04, presumably until 2018-06-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-06-06 00:00:00, ended at 2018-06-06 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-06-06, presumably until 2018-07-05, with intended 6 refill(s). Instructions: take 1 Tab by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-06-07 00:00:00, ended at 2018-06-07 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-11 00:00:00, ended at 2018-06-11 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2018-06-13, presumably until 2018-06-13, with intended 2 refill(s). Instructions: take 1 Cap by mouth every other day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-11 00:00:00, ended at 2018-06-11 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-06-12, presumably until 2018-08-01, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-06-12 00:00:00, ended at 2018-06-12 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n- Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.125 MG Oral Tablet, started on 2018-06-12, presumably until 2018-07-26, with intended 11 refill(s). Instructions: Take 150 mcg tab + 125 mcg tab = total of 275 mcg dose, daily before breakfast\n- levothyroxine sodium 0.15 MG Oral Tablet, through Oral route, started on 2018-06-12, presumably until 2018-07-26, with intended 11 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast Take 150 mcg tab + 125 mcg tab = total of 275 mcg dose daily before breakfast\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-06-12 00:00:00, ended at 2018-06-12 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nausea\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2018-06-12, presumably until 2018-06-27, with intended 6 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n- amitriptyline hydrochloride 75 MG Oral Tablet, through Oral route, started on 2018-06-12, presumably until 2018-06-12, with intended 5 refill(s). Instructions: take 1 Tab by mouth every bedtime as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-12 00:00:00, ended at 2018-06-12 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amitriptyline hydrochloride 75 MG Oral Tablet, started on 2018-06-12, presumably until 2018-07-06, with intended 5 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY NIGHT AT BEDTIME AS NEEDED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-06-19 00:00:00, ended at 2018-06-19 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2018-06-19, presumably until 2018-08-19, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-23 00:00:00, ended at 2018-06-23 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- lisinopril 5 MG Oral Tablet, started on 2018-06-24, presumably until 2018-12-23, with intended 1 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-27 00:00:00, ended at 2018-06-27 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2018-06-28, presumably until 2018-06-28, with intended 5 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-28 00:00:00, ended at 2018-06-28 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2018-06-28, presumably until 2018-08-19, with intended 5 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-29 00:00:00, ended at 2018-06-29 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2018-07-01, presumably until 2018-07-01, with intended 2 refill(s). Instructions: take 1 Cap by mouth every other day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-07-05 10:08:17, ended at 2018-07-05 11:24:54\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-07-05 12:18:00, ended at 2018-07-06 17:44:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 141 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 4.1 (percent)\n- MCH [Entitic mass] by Automated count: 37.1 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 1.46 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 24.3 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 8.28 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 63 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 47 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.4 (gram per deciliter)\n- Iron [Mass/volume] in Serum or Plasma: 79 (microgram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.8 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 108.9 (femtoliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 4.49 (micro-international unit per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.08 (milligram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 30 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 94.4 (percent)\n- Body height: 5' 5.157\" (inch (US))\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.1 (nanogram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 208 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.76 (million per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 509.1 (nanogram per milliliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.0 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.34 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 306 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n\n### Procedure\n- Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach\n- Hospital discharge day management; more than 30 minutes\n\n### Condition\n- Hypothyroidism\n- Post-surgical malabsorption\n- Atherosclerosis of coronary artery without angina pectoris\n- Chronic congestive heart failure\n- Insomnia\n- Nausea\n- Secondary malignant neoplasm of bone\n- Vitamin D deficiency\n- Generalized ischemic myocardial dysfunction\n- Acquired absence of spleen\n- Chronic kidney disease stage 3\n- Hypertensive heart and renal disease with (congestive) heart failure\n- Obstructive sleep apnea syndrome\n- Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplasm of intra-abdominal lymph nodes\n- Type 2 diabetes mellitus\n- Acquired absence of organ\n- Cardiomyopathy\n- Primary malignant neoplasm of retroperitoneum\n- Acute insomnia\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Headache\n- Chronic systolic heart failure\n- Secondary malignant neoplasm of left lung\n- Anemia in neoplastic disease\n- Disorder of pancreas\n- Secondary malignant neoplastic disease\n- Absent kidney\n- Asthenia\n\n### Drug\n- thiamine 100 MG Oral Tablet, through Oral route, started on 2018-07-06, presumably until 2018-07-06\n- 50 ML famotidine 0.4 MG/ML Injection, through Intravenous route, started on 2018-07-05, presumably until 2018-07-05\n- olanzapine 2.5 MG Oral Tablet, through Oral route, started on 2018-07-05, presumably until 2018-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime as needed (nausea, insomnia)\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-07-05, presumably until 2018-09-10, with intended 6 refill(s). Instructions: take 1 Tab by mouth every day While on prednisone\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-07-06, presumably until 2018-07-06\n- prednisone 2.5 MG Oral Tablet, through Oral route, started on 2018-07-06, presumably until 2018-07-06\n- hydrocortisone 25 MG/ML Topical Cream, through Topical route, started on 2018-07-06, presumably until 2018-07-06\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-07-05, presumably until 2018-07-05\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2018-07-06, presumably until 2018-07-06\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2018-07-06, presumably until 2018-07-06\n- levothyroxine sodium 0.025 MG Oral Tablet, through Oral route, started on 2018-07-06, presumably until 2018-07-06, with intended 0 refill(s). Instructions: take 11 Tabs by mouth every morning before breakfast\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-07-05, presumably until 2018-07-06\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2018-07-05, presumably until 2018-07-05\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2018-07-05, presumably until 2018-07-06\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2018-07-05, presumably until 2018-07-06\n- prochlorperazine 5 MG Oral Tablet, through Oral route, started on 2018-07-06, presumably until 2018-07-06\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2018-07-05, presumably until 2018-07-05\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2018-07-05, presumably until 2018-07-06\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2018-07-06, presumably until 2018-07-06\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2018-07-05, presumably until 2018-07-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-07-10 00:00:00, ended at 2018-07-10 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nausea and vomiting\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- prochlorperazine 10 MG Oral Tablet, started on 2018-07-10, presumably until 2019-03-20, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY 8 HOURS AS NEEDED FOR NAUSEA OR VOMITING\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-07-11 00:00:00, ended at 2018-07-11 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2018-07-11, presumably until 2018-08-19, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-07-25 10:54:38, ended at 2018-07-25 11:30:54\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n- Benign neoplasm of adrenal gland\n- Osteoporosis\n- Nausea\n- Vitamin D deficiency\n- Cancer-related fatigue\n- Hypothyroidism\n- Insomnia\n\n### Drug\n- levothyroxine sodium 0.15 MG Oral Capsule, started on 2018-06-15, presumably until 2018-07-30, with intended 0 refill(s)\n- levothyroxine sodium 0.125 MG Oral Capsule, started on 2018-06-15, presumably until 2018-07-26, with intended 0 refill(s)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-07-26 00:00:00, ended at 2018-07-26 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypothyroidism\n- Primary diagnosis: Non-toxic uninodular goiter\n\n### Drug\n- levothyroxine sodium 0.15 MG Oral Capsule, started on 2018-07-30, presumably until 2018-08-12, with intended 3 refill(s). Instructions: Tirosint 150 mcg , take 2 capsules by mouth daily = total of 300 mcg per day\n- levothyroxine sodium 0.15 MG Oral Tablet, started on 2018-07-30, presumably until 2018-09-13, with intended 3 refill(s). Instructions: Levothyroxine 150 mcg tablet, take 2 tabs by mouth before breakfast daily = total of 300 mcg per day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-07-26 00:00:00, ended at 2018-07-26 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-07-26 07:46:00, ended at 2018-07-26 10:19:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 133 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-07-26 10:20:00, ended at 2018-07-26 12:39:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 80 (unit per liter)\n- Iron [Mass/volume] in Serum or Plasma: 178 (microgram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.06 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 5 (nanogram per milliliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.99 (million per microliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 62 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.38 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 29 (nanogram per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 151 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 148 (milligram per deciliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 24 (nanogram per milliliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.6 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.9 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 36.6 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 6.71 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 81.4 (percent)\n- Thyrotropin [Units/volume] in Serum or Plasma: 6.78 (micro-international unit per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 76 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.11 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 26.3 (percent)\n- Ferritin [Mass/volume] in Serum or Plasma: 878.5 (nanogram per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 4.6 (percent)\n- Platelets [#/volume] in Blood by Automated count: 198 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.2 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 109.0 (femtoliter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Vitamin D deficiency\n- Chronic kidney disease stage 3\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm of retroperitoneum\n- Hypothyroidism\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-07-26 11:04:52, ended at 2018-07-26 11:59:35\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2018-07-26, presumably until 2019-04-16, with intended 3 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n- 72 HR scopolamine 0.0139 MG/HR Transdermal System, through Transdermal route, started on 2018-07-26, presumably until 2018-07-27, with intended 3 refill(s). Instructions: apply 1 Patch to skin every 72 hours\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-07-26 12:40:00, ended at 2018-07-27 18:30:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.92 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 216 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.24 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.2 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.33 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.5 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.9 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.2 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 132 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 26.1 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 2.7 (percent)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.6 (gram per deciliter)\n- Left ventricular Ejection fraction: 39.6 (percent)\n- MCH [Entitic mass] by Automated count: 36.6 (picogram)\n- MCV [Entitic volume] by Automated count: 109.1 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 200 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 3.4 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 93.7 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 92 (unit per liter)\n- Body height: 5' 4.961\" (inch (US))\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.61 (million per microliter)\n\n### Procedure\n- Initial observation care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination \n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; initiation of prolonged chemotherapy infusion (more than 8 hours), requiring use of a portable or implantable pump\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Chemotherapy administration; intravenous, push technique, single or initial substance/drug\n\n### Condition\n- Pain due to neoplastic disease\n- Secondary malignant neoplasm of lymph node\n- Chronic congestive heart failure\n- Chronic kidney disease stage 3\n- Generalized ischemic myocardial dysfunction\n- Anemia in neoplastic disease\n- Chronic systolic heart failure\n- Secondary malignant neoplasm of lung\n- Electrocardiogram abnormal\n- Major depression, single episode\n- Cardiomyopathy\n- Disorder of pancreas\n- Non-toxic uninodular goiter\n- Hypothyroidism\n- Nausea\n- Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm of retroperitoneum\n- Secondary malignant neoplasm of bone\n- Vitamin D deficiency\n- Post-surgical malabsorption\n\n### Drug\n- thiamine 100 MG Oral Tablet, through Oral route, started on 2018-07-26, presumably until 2018-07-27\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, through Oral route, started on 2018-07-26, presumably until 2018-08-01, with intended 0 refill(s). Instructions: take by mouth\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2018-07-27, presumably until 2018-07-27\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2018-07-26, presumably until 2018-07-26\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-07-27, presumably until 2018-07-27\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-07-26, presumably until 2019-04-14, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 6 hours as needed for Pain (headache)\n- prednisone 2.5 MG Oral Tablet, through Oral route, started on 2018-07-27, presumably until 2018-07-27\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-07-26, presumably until 2018-07-26\n- amitriptyline hydrochloride 25 MG Oral Tablet, through Oral route, started on 2018-07-26, presumably until 2018-07-27\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2018-07-27, presumably until 2018-07-27\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2018-07-27, presumably until 2018-07-27\n- levothyroxine sodium 0.025 MG Oral Tablet, through Oral route, started on 2018-07-27, presumably until 2018-07-27\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2018-07-29, presumably until 2018-07-29, with intended 0 refill(s). Instructions: inject 0.6 mL subcutaneous (under the skin) One Time With Dr. Cunningham on 7/02\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2018-07-26, presumably until 2018-07-26\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-07-26, presumably until 2018-07-27\n- prochlorperazine 10 MG Oral Tablet, through Oral route, started on 2018-07-27, presumably until 2018-07-27\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2018-07-26, presumably until 2018-07-26\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2018-07-26, presumably until 2018-08-19, with intended 0 refill(s). Instructions: Take 1 tab in the Am and 2 tabs in the PM as previously prescribed by cardiology\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2018-07-26, presumably until 2018-07-27\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2018-07-26, presumably until 2018-07-26\n- loratadine 10 MG Oral Tablet, through Oral route, started on 2018-07-28, presumably until 2018-08-07, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily For 10 days with neulasta to prevent bone pain\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2018-07-26, presumably until 2018-07-26\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2018-07-26, presumably until 2018-07-27\n- 72 HR scopolamine 0.0139 MG/HR Transdermal System, through Transdermal route, started on 2018-07-26, presumably until 2018-09-10, with intended 3 refill(s). Instructions: apply 1 Patch to skin every 72 hours\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2018-07-27, presumably until 2018-07-27\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2018-07-26, presumably until 2018-07-26\n- magnesium sulfate 40 MG/ML Injection, through Intravenous route, started on 2018-07-27, presumably until 2018-07-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-08-01 00:00:00, ended at 2018-08-01 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, started on 2018-08-01, presumably until 2019-01-22, with intended 1 refill(s). Instructions: Take 1-2 caps TID with meals\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-08-01, presumably until 2018-08-19, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-08-01 00:00:00, ended at 2018-08-01 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, through Oral route, started on 2018-08-01, presumably until 2018-08-01, with intended 0 refill(s). Instructions: take by mouth\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-08-01, presumably until 2018-08-01, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-19 09:03:00, ended at 2018-08-19 14:33:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 55 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 25.2 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.38 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 36.0 (picogram)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.4 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 16.1 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 78.6 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.2 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.4 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.0 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Iron [Mass/volume] in Serum or Plasma: 170 (microgram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 65 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 85 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 133 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.51 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 150 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.04 (million per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.37 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.7 (percent)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 30 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.01 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- MCV [Entitic volume] by Automated count: 107.4 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Ferritin [Mass/volume] in Serum or Plasma: 1379.2 (nanogram per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 4.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 211 (thousand per microliter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm of retroperitoneum\n- Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-08-19 10:42:51, ended at 2018-08-19 11:19:28\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Generalized ischemic myocardial dysfunction\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2018-08-19, presumably until 2018-11-24, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2018-08-19, presumably until 2018-12-13, with intended 5 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed for Nausea\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2018-08-19, presumably until 2018-11-03, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-08-19, presumably until 2018-09-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n- carvedilol 3.125 MG Oral Tablet, started on 2018-08-19, presumably until 2018-08-20, with intended 3 refill(s). Instructions: Take 1 tab in the Am and 2 tabs in the PM as previously prescribed by cardiology\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-19 14:34:00, ended at 2018-08-20 20:04:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 3.3 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 145 (unit per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 113 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 35.4 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.00 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.37 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 212 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.4 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 92 (unit per liter)\n- Body height: 5' 4.961\" (inch (US))\n- Lymphocytes/100 leukocytes in Blood by Automated count: 3.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.7 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.0 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.37 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 108.3 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 93.8 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 25.3 (percent)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 28 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 214 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.4 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 10.67 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 18 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.13 (million per microliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Secondary malignant neoplasm of lung\n- Hypothyroidism\n- Takotsubo cardiomyopathy\n- Chronic kidney disease stage 3\n- Secondary malignant neoplasm of bone\n- Secondary malignant neoplasm of intrapelvic lymph nodes\n- Chronic kidney disease due to hypertension\n- Non-toxic uninodular goiter\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- thiamine 100 MG Oral Tablet, through Oral route, started on 2018-08-20, presumably until 2018-08-20\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, through Oral route, started on 2018-08-19, presumably until 2018-08-20\n- 50 ML famotidine 0.4 MG/ML Injection, through Intravenous route, started on 2018-08-19, presumably until 2018-08-19\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-08-20, presumably until 2018-08-20\n- prednisone 2.5 MG Oral Tablet, through Oral route, started on 2018-08-20, presumably until 2018-08-20\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-08-19, presumably until 2018-08-19\n- amitriptyline hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-08-19, presumably until 2018-08-19\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2018-08-20, presumably until 2018-08-20\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2018-08-20, presumably until 2018-08-20, with intended 0 refill(s). Instructions: inject 0.6 mL subcutaneous (under the skin) One Time 24-72 hours after chemotherapy\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-08-19, presumably until 2018-08-20\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-08-20, presumably until 2018-08-20\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2018-08-19, presumably until 2018-08-19\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2018-08-19, presumably until 2018-08-20\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2018-08-19, presumably until 2018-08-20\n- loratadine 10 MG Oral Tablet, through Oral route, started on 2018-08-20, presumably until 2019-04-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily (over the counter) take for 10 days during neulasta for bone pain\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2018-08-19, presumably until 2018-08-19\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2018-08-20, presumably until 2018-08-20\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2018-08-19, presumably until 2018-08-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-08-20 00:00:00, ended at 2018-08-20 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Generalized ischemic myocardial dysfunction\n\n### Drug\n- carvedilol 3.125 MG Oral Tablet, started on 2018-08-20, presumably until 2019-02-25, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY MORNING AND 2 TABLETS BY MOUTH EVERY EVENING\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-09-09 00:00:00, ended at 2018-09-09 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2018-09-11, presumably until 2018-09-12, with intended 11 refill(s). Instructions: take 1 Cap by mouth every other day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-09-09 00:00:00, ended at 2018-09-09 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amitriptyline hydrochloride 25 MG Oral Tablet, started on 2018-09-10, presumably until 2018-09-14, with intended 0 refill(s). Instructions: Start 25mg po nightly at bedtime, in 1 week increase to 50mg for 1 week then increase to 75mg.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-09-10 00:00:00, ended at 2018-09-10 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-09-10, presumably until 2019-01-22, with intended 6 refill(s). Instructions: take 1 Tab by mouth every day While on prednisone\n- hydrocortisone 25 MG/ML Topical Cream, started on 2018-09-10, presumably until 2019-04-14, with intended 2 refill(s). Instructions: Apply to external hemorrhoid BID prn pain\n- mupirocin 0.02 MG/MG Topical Ointment, started on 2018-09-10, presumably until 2019-04-14, with intended 2 refill(s). Instructions: Apply to affected area BID prn rash\n- 72 HR scopolamine 0.0139 MG/HR Transdermal System, through Transdermal route, started on 2018-09-10, presumably until 2018-12-14, with intended 3 refill(s). Instructions: apply 1 Patch to skin every 72 hours\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-09-10 00:00:00, ended at 2018-09-10 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, started on 2018-09-12, presumably until 2018-09-19, with intended 3 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH EVERY OTHER DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-09-11 00:00:00, ended at 2018-09-11 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2018-09-11, presumably until 2018-09-12, with intended 2 refill(s). Instructions: take 1 Cap by mouth every other day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-12 07:35:00, ended at 2018-09-12 09:49:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 40.2 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Generalized ischemic myocardial dysfunction\n- Cardiomyopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-12 09:50:00, ended at 2018-09-12 12:27:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-12 09:50:00, ended at 2018-09-12 12:27:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 128 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Secondary malignant neoplasm of right lung\n- Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplasm of left lung\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-12 12:28:00, ended at 2018-09-12 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 173 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 18 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.03 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Ferritin [Mass/volume] in Serum or Plasma: 1367.7 (nanogram per milliliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.08 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 112.3 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 78.5 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.5 (percent)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 52 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.44 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.78 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 233 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.89 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 123 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 37.1 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 48 (unit per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 70 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 23.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.7 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 35 (milligram per deciliter)\n- Iron [Mass/volume] in Serum or Plasma: 137 (microgram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.4 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 6.0 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.7 (percent)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Hypothyroidism\n- Primary malignant neoplasm of retroperitoneum\n- Visual disturbance\n- Chronic kidney disease stage 3\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-09-13 14:55:30, ended at 2018-09-13 16:25:22\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Intraocular pressure of left eye: 17 (millimeter mercury column)\n- Intraocular pressure of right eye: 16 (millimeter mercury column)\n\n### Procedure\n- Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; retina\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Tear film insufficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-09-13 17:15:00, ended at 2018-09-15 11:06:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 2 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 113 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.77 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 234 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 163 (unit per liter)\n- Body height: 5' 5\" (inch (US))\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 75 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 31 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.7 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 36.7 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 232 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 24.0 (percent)\n- Leukocytes [#/volume] in Body fluid by Manual count: 1 (milli-international unit per milliliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.15 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 71 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.2 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.01 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.9 (percent)\n- MCV [Entitic volume] by Automated count: 111.4 (femtoliter)\n\n### Procedure\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach\n- Hospital discharge day management; more than 30 minutes\n\n### Condition\n- Acquired absence of organ\n- Acquired absence of spleen\n- Atherosclerosis of coronary artery without angina pectoris\n- Pain due to neoplastic disease\n- Suicidal thoughts\n- Absent kidney\n- Generalized ischemic myocardial dysfunction\n- Insomnia\n- Iron deficiency anemia\n- Chronic kidney disease due to hypertension\n- Secondary malignant neoplasm of lymph node\n- Anemia in neoplastic disease\n- Cardiomyopathy\n- Disorder of digestive system\n- Hypothyroidism\n- Post-surgical malabsorption\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplasm of lung\n- Vitamin D deficiency\n- Disorder of pancreas\n- Old myocardial infarction\n- Chronic kidney disease stage 3\n- Major depression, single episode\n- Nausea\n- Obesity\n- Secondary malignant neoplasm of bone\n\n### Drug\n- thiamine 100 MG Oral Tablet, through Oral route, started on 2018-09-14, presumably until 2018-09-15\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, through Oral route, started on 2018-09-13, presumably until 2018-09-15\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2018-09-14, presumably until 2018-09-15\n- 50 ML famotidine 0.4 MG/ML Injection, through Intravenous route, started on 2018-09-13, presumably until 2018-09-13\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2018-09-13, presumably until 2018-09-14\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-09-14, presumably until 2018-09-15\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-09-13, presumably until 2018-09-13\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2018-09-14, presumably until 2018-09-14\n- amitriptyline hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-09-13, presumably until 2019-04-14, with intended 0 refill(s). Instructions: take 75 mg by mouth every bedtime \n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2018-09-14, presumably until 2018-09-15\n- levothyroxine sodium 0.025 MG Oral Tablet, through Oral route, started on 2018-09-14, presumably until 2018-09-15\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2018-09-14, presumably until 2018-09-15\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-09-14, presumably until 2018-09-15\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2018-09-13, presumably until 2018-09-14\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2018-09-13, presumably until 2018-09-15\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2018-09-13, presumably until 2018-09-15\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2018-09-13, presumably until 2018-09-13\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2018-09-13, presumably until 2019-01-13, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals.\n- 72 HR scopolamine 0.0139 MG/HR Transdermal System, through Transdermal route, started on 2018-09-14, presumably until 2018-09-14\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2018-09-14, presumably until 2018-09-15\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2018-09-13, presumably until 2018-09-13\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2018-09-14, presumably until 2018-09-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-09-19 00:00:00, ended at 2018-09-19 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2018-09-19, presumably until 2018-10-17, with intended 3 refill(s). Instructions: take 1 Cap by mouth 3 times a week\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-09-25 13:38:34, ended at 2018-09-25 14:54:06\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Chest pain\n- Electrocardiogram abnormal\n- Ventricular premature complex\n- Old myocardial infarction\n- Primary diagnosis: Cardiomyopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-10-11 07:29:00, ended at 2018-10-11 13:38:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.62 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 3.4 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.3 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 81.8 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 41 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.01 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.9 (percent)\n- MCV [Entitic volume] by Automated count: 118.0 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 68 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 37.5 (picogram)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 111 (millimole per liter)\n- Ferritin [Mass/volume] in Serum or Plasma: 837.0 (nanogram per milliliter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.8 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.33 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 31.8 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 146 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 147 (milligram per deciliter)\n- Iron [Mass/volume] in Serum or Plasma: 118 (microgram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.30 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.04 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 225 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 21.8 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease stage 3\n- Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-10-11 13:39:00, ended at 2018-10-12 17:49:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 218 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.94 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Body height: 5' 5.354\" (inch (US))\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration; intravenous, push technique, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Pain due to neoplastic disease\n- Primary malignant neoplasm of soft tissues\n- Insomnia\n- Nausea\n- Secondary malignant neoplasm of lung\n- Secondary malignant neoplasm of bone\n- Secondary malignant neoplasm of lymph node\n- Hypothyroidism\n- Polyneuropathy\n- Primary diagnosis: Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- epoetin alfa 20000 UNT/ML Injectable Solution, started on 2018-10-11, presumably until 2018-10-11\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, through Oral route, started on 2018-10-11, presumably until 2018-10-12\n- 2 ML prochlorperazine 5 MG/ML Injection, started on 2018-10-11, presumably until 2018-10-11\n- 50 ML famotidine 0.4 MG/ML Injection, through Intravenous route, started on 2018-10-11, presumably until 2018-10-11\n- Abuse-Deterrent 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2018-10-12, presumably until 2018-10-12\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-10-11, presumably until 2018-10-12\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-10-11, presumably until 2018-10-11\n- vitamin B12 1 MG/ML Injectable Solution, started on 2018-10-11, presumably until 2018-10-12\n- amitriptyline hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-10-11, presumably until 2018-10-11\n- 0.5 ML influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 an..., through Intramuscular route, started on 2018-10-11, presumably until 2018-10-11\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-10-11, presumably until 2018-10-11\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-10-12, presumably until 2018-10-12\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2018-10-11, presumably until 2018-10-11\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2018-10-11, presumably until 2018-10-12\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2018-10-11, presumably until 2018-10-12\n- levothyroxine sodium 0.137 MG Oral Tablet, through Oral route, started on 2018-10-12, presumably until 2018-10-12\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2018-10-11, presumably until 2018-10-12\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2018-10-11, presumably until 2018-10-11\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2018-10-11, presumably until 2018-10-12\n- magnesium chloride 598 MG Delayed Release Oral Tablet, through Oral route, started on 2018-10-12, presumably until 2018-10-12\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2018-10-12, presumably until 2018-10-12\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2018-10-11, presumably until 2018-10-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-10-17 00:00:00, ended at 2018-10-17 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, started on 2018-10-17, presumably until 2018-10-17, with intended 3 refill(s). Instructions: Take 1 capsule ,  every other day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-10-17 00:00:00, ended at 2018-10-17 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, started on 2018-10-18, presumably until 2019-02-14, with intended 3 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH EVERY OTHER DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-10-30 00:00:00, ended at 2018-10-30 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-10-31, presumably until 2019-01-24, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-31 00:00:00, ended at 2018-10-31 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-01 00:00:00, ended at 2018-11-01 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-01 00:00:00, ended at 2018-11-01 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-01 00:00:00, ended at 2018-11-01 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-01 07:40:00, ended at 2018-11-01 08:27:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Neutrophils/100 leukocytes in Blood by Automated count: 77.1 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 49 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.1 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 112.1 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 889.4 (nanogram per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 145 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 190 (thousand per microliter)\n- Thiamine pyrophosphate [Moles/volume] in Blood: 194 (nanomole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.95 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.9 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5.5 (percent)\n- MCH [Entitic mass] by Automated count: 36.7 (picogram)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.3 (percent)\n- Iron [Mass/volume] in Serum or Plasma: 127 (microgram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.50 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.47 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 64 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 184 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.97 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 16.1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.02 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 27.0 (percent)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n- Polyneuropathy\n- Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-01 08:28:00, ended at 2018-11-01 16:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 154 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-01 08:28:00, ended at 2018-11-01 16:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-11-01 13:40:25, ended at 2018-11-01 15:14:33\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.961\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- magnesium oxide 400 MG Oral Capsule, through Oral route, started on 2018-11-01, presumably until 2019-04-14, with intended 3 refill(s). Instructions: take 400 mg by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-11-01 15:19:16, ended at 2018-11-01 16:28:34\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.961\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cancer-related fatigue\n- Nausea\n- Primary diagnosis: Pain due to neoplastic disease\n\n### Drug\n- Abuse-Deterrent 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2018-11-01, presumably until 2019-01-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- methylphenidate hydrochloride 5 MG Oral Tablet, through Oral route, started on 2018-11-01, presumably until 2019-01-24, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day as needed (fatigue)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-11-01 17:00:00, ended at 2018-11-03 13:09:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 26.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.4 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5 (percent)\n- MCV [Entitic volume] by Automated count: 112.1 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 96.4 (percent)\n- Body height: 5' 3.78\" (inch (US))\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Monocytes [#/volume] in Blood by Manual count: 1.17 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 91 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.83 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.22 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 60 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.017 (nanogram per milliliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.00 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 227 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.7 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.7 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.59 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 37.2 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 10 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 10.33 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 30 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 170 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 187 (thousand per microliter)\n\n### Procedure\n- Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)\n- Hospital discharge day management; more than 30 minutes\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Chronic kidney disease stage 3\n- Pain due to neoplastic disease\n- Acquired absence of organ\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Disorder of pancreas\n- Hypothyroidism\n- Insomnia\n- Obstructive sleep apnea syndrome\n- Old myocardial infarction\n- Polyneuropathy\n- Chronic congestive heart failure\n- Hypertensive heart and renal disease with (congestive) heart failure\n- Major depression, single episode\n- Atherosclerosis of coronary artery without angina pectoris\n- Chronic systolic heart failure\n- Absent kidney\n- Chronic gout without tophus\n- Disorder of digestive system\n- Electrocardiogram abnormal\n- Secondary malignant neoplasm of bone\n- Acquired absence of spleen\n- Chest pain\n- Post-surgical malabsorption\n- Primary malignant neoplasm of retroperitoneum\n- Type 2 diabetes mellitus\n- Iron deficiency anemia\n- Nausea\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplasm of lung\n- Vitamin D deficiency\n- Secondary malignant neoplasm of lymph nodes of multiple sites\n- Takotsubo cardiomyopathy\n\n### Drug\n- epoetin alfa 20000 UNT/ML Injectable Solution, started on 2018-11-01, presumably until 2018-11-01\n- thiamine 100 MG Oral Tablet, through Oral route, started on 2018-11-02, presumably until 2018-11-03\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, through Oral route, started on 2018-11-01, presumably until 2018-11-03\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2018-11-02, presumably until 2018-11-03\n- 50 ML famotidine 0.4 MG/ML Injection, through Intravenous route, started on 2018-11-01, presumably until 2018-11-01\n- Abuse-Deterrent 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2018-11-02, presumably until 2018-11-03\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2018-11-02, presumably until 2018-11-02\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-11-02, presumably until 2018-11-03\n- 0.5 ML varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML Injection, through Intramuscular route, started on 2018-11-02, presumably until 2018-11-02\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-11-02, presumably until 2018-11-02\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2018-11-02, presumably until 2018-11-03\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-11-01, presumably until 2018-11-01\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2018-11-02, presumably until 2018-11-03\n- vitamin B12 1 MG/ML Injectable Solution, started on 2018-11-01, presumably until 2018-11-03\n- amitriptyline hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-11-01, presumably until 2018-11-02\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2018-11-02, presumably until 2018-11-03\n- levothyroxine sodium 0.025 MG Oral Tablet, through Oral route, started on 2018-11-02, presumably until 2018-11-03\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-12-14, with intended 0 refill(s). Instructions: take 2 Tabs by mouth daily\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-11-01, presumably until 2018-11-01\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2018-11-01, presumably until 2018-11-02\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2018-11-01, presumably until 2018-11-03\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2018-11-01, presumably until 2018-11-03\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2018-11-01, presumably until 2018-11-01\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2018-11-01, presumably until 2018-11-03\n- aluminum hydroxide 40 MG/ML / magnesium hydroxide 40 MG/ML / simethicone 4 MG/ML Oral Suspension, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2018-11-02, presumably until 2018-11-03\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2018-11-01, presumably until 2018-11-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-06 00:00:00, ended at 2018-11-06 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-11-18 00:00:00, ended at 2018-11-18 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- levothyroxine sodium 0.137 MG Oral Capsule, through Oral route, started on 2018-11-21, presumably until 2018-11-21, with intended 0 refill(s). Instructions: take 2.0073 Caps by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-18 00:00:00, ended at 2018-11-18 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- levothyroxine sodium 0.137 MG Oral Capsule, through Oral route, started on 2018-11-18, presumably until 2019-02-14, with intended 3 refill(s). Instructions: take 2.0073 Caps by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-22 10:30:00, ended at 2018-11-22 14:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.42 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 184 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.5 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.13 (milligram per deciliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 940.8 (nanogram per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 9.6 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.8 (percent)\n- MCV [Entitic volume] by Automated count: 113.2 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 86.8 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 166 (unit per liter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 70 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.49 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.2 (percent)\n- Iron [Mass/volume] in Serum or Plasma: 107 (microgram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 55 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.24 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 192 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 81 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 24.9 (percent)\n- MCH [Entitic mass] by Automated count: 38.6 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.84 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Chronic kidney disease stage 3\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-11-22 10:51:32, ended at 2018-11-22 11:52:36\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.551\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Obstructive sleep apnea syndrome\n- Primary malignant neoplasm of soft tissues\n- Disorder of pancreas\n- Generalized ischemic myocardial dysfunction\n- Hypothyroidism\n- Iron deficiency anemia\n- Non-toxic uninodular goiter\n- Atherosclerosis of coronary artery without angina pectoris\n- Chronic kidney disease stage 3\n- Takotsubo cardiomyopathy\n- Post-surgical malabsorption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-11-22 14:19:33, ended at 2018-11-22 15:02:15\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.551\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-22 15:00:00, ended at 2018-11-22 16:15:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 51.3 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Poisoning by drug AND/OR medicinal substance\n- Accidental poisoning\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-22 16:16:00, ended at 2018-11-22 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.157\" (inch (US))\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2018-11-22, presumably until 2018-11-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-11-23 14:45:00, ended at 2018-11-24 19:10:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 78 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 165 (unit per liter)\n- Body height: 5' 5.157\" (inch (US))\n- Erythrocyte distribution width [Ratio] by Automated count: 24.4 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 38.3 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 8.84 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Glucose [Mass/volume] in Blood: 244 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 286 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.22 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.94 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.2 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 115.9 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 96.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.60 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 212 (thousand per microliter)\n\n### Procedure\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Hospital discharge day management; 30 minutes or less\n- Introduction of Monoclonal Antibody into Central Vein, Percutaneous Approach\n\n### Condition\n- Disorder of pancreas\n- Hypothyroidism\n- Old myocardial infarction\n- Primary diagnosis: Chronic kidney disease stage 3\n- Essential hypertension\n- Secondary malignant neoplasm of bone\n- Cardiomyopathy\n- Vitamin D deficiency\n- Pain due to neoplastic disease\n- Atherosclerosis of coronary artery without angina pectoris\n- Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplasm of lung\n- Iron deficiency anemia\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- epoetin alfa 20000 UNT/ML Injectable Solution, started on 2018-11-23, presumably until 2018-11-23\n- thiamine 100 MG Oral Tablet, through Oral route, started on 2018-11-24, presumably until 2018-11-24\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, through Oral route, started on 2018-11-23, presumably until 2018-11-24\n- Abuse-Deterrent 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2018-11-24, presumably until 2018-11-24\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2018-11-24, presumably until 2018-12-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed (for nausea or anxiety)\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-11-24, presumably until 2018-11-24\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-11-24, presumably until 2018-11-24\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2018-11-24, presumably until 2018-11-24\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-11-23, presumably until 2018-11-23\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2018-11-24, presumably until 2018-11-24\n- amitriptyline hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-11-23, presumably until 2018-11-23\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2018-11-23, presumably until 2018-11-23\n- prochlorperazine 10 MG Oral Tablet, through Oral route, started on 2018-11-24, presumably until 2018-11-24\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2018-11-23, presumably until 2018-11-23\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2018-11-23, presumably until 2018-11-24\n- 2 ML ondansetron 2 MG/ML Injection, started on 2018-11-23, presumably until 2018-11-23\n- levothyroxine sodium 0.137 MG Oral Tablet, through Oral route, started on 2018-11-24, presumably until 2018-11-24\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2018-11-23, presumably until 2018-11-24\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2018-11-23, presumably until 2018-11-23\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2018-11-23, presumably until 2018-11-24\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2018-11-24, presumably until 2018-11-24\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2018-11-23, presumably until 2018-11-23\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-25 00:00:00, ended at 2018-11-25 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Polyneuropathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-25 00:00:00, ended at 2018-11-25 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-11-25 11:26:43, ended at 2018-11-25 14:07:45\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.354\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Polyneuropathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-25 15:17:00, ended at 2018-11-25 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2018-11-25, presumably until 2018-11-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-02 00:00:00, ended at 2018-12-02 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-05 08:14:00, ended at 2018-12-05 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- MCH [Entitic mass] by Automated count: 37.5 (picogram)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.12 (million per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 1101.8 (nanogram per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 114.2 (femtoliter)\n- Iron [Mass/volume] in Serum or Plasma: 152 (microgram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.6 (percent)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 53 (percent)\n- Platelets [#/volume] in Blood by Automated count: 122 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.0 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 29.0 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Night blindness\n- Chronic kidney disease stage 3\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-12-05 08:39:37, ended at 2018-12-05 10:36:20\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.551\" (inch (US))\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 91 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.30 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 177 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 208 (unit per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Night blindness\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-12-06 00:00:00, ended at 2018-12-06 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 20 MG/ML Injectable Solution, started on 2018-12-06, presumably until 2018-12-06\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-06 00:00:00, ended at 2018-12-06 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for closed chest procedures; (including bronchoscopy) not otherwise specified\n\n### Condition\n- Obstructive sleep apnea syndrome\n- Gastroesophageal reflux disease without esophagitis\n- Secondary malignant neoplasm of left lung\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2018-12-06, presumably until 2018-12-06\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2018-12-06, presumably until 2018-12-06\n- cefazolin 1000 MG Injection, started on 2018-12-06, presumably until 2018-12-06\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2018-12-06, presumably until 2018-12-06\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2018-12-06, presumably until 2018-12-06\n- 2 ML ondansetron 2 MG/ML Injection, started on 2018-12-06, presumably until 2018-12-06\n- midazolam 1 MG/ML Injectable Solution, started on 2018-12-06, presumably until 2018-12-06\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-06 06:13:00, ended at 2018-12-07 09:36:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n- INR in Blood by Coagulation assay: 1.1 (ratio)\n\n### Procedure\n- Radiologic examination, chest; single view\n- Ablation therapy for reduction or eradication of 1 or more pulmonary tumor(s) including pleura or chest wall when involved by tumor extension, percutaneous, including imaging guidance when performed, unilateral; cryoablation\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Autoimmune thyroiditis\n- Generalized ischemic myocardial dysfunction\n- Obstructive sleep apnea syndrome\n- Old myocardial infarction\n- Primary malignant neoplasm of pancreas\n- Absent kidney\n- Acquired absence of organ\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Chronic kidney disease stage 3\n- Secondary malignant neoplasm of left lung\n- Abnormal findings on diagnostic imaging of lung\n- Acquired absence of spleen\n- Secondary malignant neoplasm of lung\n- Atherosclerosis of coronary artery without angina pectoris\n- Chronic kidney disease due to hypertension\n- Iron deficiency anemia\n- Obesity\n- Primary malignant neoplasm of retroperitoneum\n- Type 2 diabetes mellitus\n\n### Drug\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, through Oral route, started on 2018-12-07, presumably until 2018-12-07\n- Abuse-Deterrent 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2018-12-06, presumably until 2018-12-07\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-12-06, presumably until 2018-12-06\n- levothyroxine sodium 0.125 MG Oral Tablet, through Oral route, started on 2018-12-07, presumably until 2018-12-07\n- amitriptyline hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-12-06, presumably until 2018-12-06\n- levothyroxine sodium 0.025 MG Oral Tablet, through Oral route, started on 2018-12-07, presumably until 2018-12-07\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2018-12-06, presumably until 2018-12-06\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-12-06, presumably until 2018-12-06\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2018-12-06, presumably until 2018-12-06\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2018-12-06, presumably until 2018-12-06\n- levofloxacin 500 MG Oral Tablet, through Oral route, started on 2018-12-03, presumably until 2019-01-22, with intended 0 refill(s). Instructions: take 500 mg by mouth daily Take for 1 week\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2018-12-06, presumably until 2018-12-06\n- 2 ML ondansetron 2 MG/ML Injection, started on 2018-12-06, presumably until 2018-12-06\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-12-06, presumably until 2018-12-06\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2018-12-07, presumably until 2018-12-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-12 00:00:00, ended at 2018-12-12 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-12 07:47:00, ended at 2018-12-12 14:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 163 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 89.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 52 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 110.8 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.4 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 141 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 26.8 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.9 (percent)\n- Retinol [Mass/volume] in Serum or Plasma: 5.9 (microgram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 184 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.92 (thousand per microliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.57 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.5 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.28 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.8 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.00 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 37.8 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.0 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.79 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 151 (thousand per microliter)\n\n### Procedure\n- Therapeutic radiology treatment planning; complex\n- Special treatment procedure (eg, total body irradiation, hemibody radiation, per oral or endocavitary irradiation)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplastic disease\n- Night blindness\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-12 07:47:00, ended at 2018-12-12 14:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; thoracic\n\n### Condition\n- Malignant neoplasm of connective and soft tissue of thorax\n- Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm of trunk\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-12-12, presumably until 2018-12-12\n- gadobenate, through Intravenous route, started on 2018-12-12, presumably until 2018-12-12\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2018-12-12, presumably until 2018-12-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-12 07:47:00, ended at 2018-12-12 14:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-12 07:47:00, ended at 2018-12-12 14:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 144 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-12 07:47:00, ended at 2018-12-12 14:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-12 15:00:00, ended at 2018-12-12 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Ferritin [Mass/volume] in Serum or Plasma: 788.2 (nanogram per milliliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 14 (percent)\n- Iron [Mass/volume] in Serum or Plasma: 31 (microgram per deciliter)\n- Body height: 5' 4.567\" (inch (US))\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n- Chronic kidney disease stage 3\n\n### Drug\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2018-12-12, presumably until 2018-12-12\n- 2 ML ondansetron 2 MG/ML Injection, started on 2018-12-12, presumably until 2018-12-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-13 00:00:00, ended at 2018-12-13 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2018-12-13, presumably until 2019-01-03, with intended 2 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-13 07:15:00, ended at 2018-12-13 16:23:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Unlisted procedure, medical radiation physics, dosimetry and treatment devices, and special services\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-12-13 16:24:00, ended at 2018-12-14 21:44:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Urine: 62.65 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.22 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 39.0 (picogram)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 334 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 167 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 157 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 9.62 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 114.9 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.2 (millimole per liter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.08 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Body height: 5' 5.748\" (inch (US))\n- Erythrocytes [#/volume] in Blood by Automated count: 2.44 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.0 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 96.5 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Sodium/Creatinine [Molar ratio] in Urine: 163 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: >1000 (picogram per milliliter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 66 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.7 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 26.9 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.0 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n\n### Procedure\n- Hospital discharge day management; more than 30 minutes\n- Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach\n\n### Condition\n- Acquired absence of organ\n- Chronic congestive heart failure\n- Obstructive sleep apnea syndrome\n- Atherosclerosis of coronary artery without angina pectoris\n- Cardiomyopathy\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Polyneuropathy due to drug\n- Vitamin D deficiency\n- Major depression, single episode\n- Pain due to neoplastic disease\n- Urinary tract infectious disease\n- Anemia in neoplastic disease\n- Hypothyroidism\n- Old myocardial infarction\n- Primary malignant neoplasm of soft tissues\n- Post-surgical malabsorption\n- Secondary malignant neoplasm of lung\n- Type 2 diabetes mellitus\n- Absent kidney\n- Acquired absence of spleen\n- Chronic kidney disease stage 3\n- Chronic systolic heart failure\n- Takotsubo cardiomyopathy\n- Anemia due to and following chemotherapy\n- Nausea\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- epoetin alfa 20000 UNT/ML Injectable Solution, started on 2018-12-13, presumably until 2018-12-13\n- thiamine 100 MG Oral Tablet, through Oral route, started on 2018-12-14, presumably until 2018-12-14\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, through Oral route, started on 2018-12-13, presumably until 2018-12-14\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2018-12-14, presumably until 2018-12-14\n- 2 ML prochlorperazine 5 MG/ML Injection, started on 2018-12-14, presumably until 2018-12-14\n- Abuse-Deterrent 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2018-12-14, presumably until 2018-12-14\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2018-12-14, presumably until 2019-01-03, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed (for nausea or anxiety)\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2018-12-13, presumably until 2018-12-13\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-12-14, presumably until 2018-12-14\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2018-12-14, presumably until 2019-02-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-12-13, presumably until 2018-12-13\n- amitriptyline hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-12-13, presumably until 2018-12-13\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2018-12-14, presumably until 2018-12-14\n- levothyroxine sodium 0.025 MG Oral Tablet, through Oral route, started on 2018-12-14, presumably until 2018-12-14\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2018-12-14, presumably until 2018-12-14\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-12-13, presumably until 2018-12-13\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2018-12-13, presumably until 2018-12-13\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2018-12-13, presumably until 2018-12-14\n- levofloxacin 500 MG Oral Tablet, through Oral route, started on 2018-12-14, presumably until 2018-12-14\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2018-12-13, presumably until 2018-12-14\n- magnesium lactate 84 MG Extended Release Oral Tablet, through Oral route, started on 2018-12-14, presumably until 2018-12-14\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2018-12-13, presumably until 2018-12-13\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2018-12-13, presumably until 2018-12-14\n- 72 HR scopolamine 0.0139 MG/HR Transdermal System, through Transdermal route, started on 2018-12-14, presumably until 2019-01-13, with intended 3 refill(s). Instructions: apply 1 Patch to skin every 72 hours\n- aluminum hydroxide 40 MG/ML / magnesium hydroxide 40 MG/ML / simethicone 4 MG/ML Oral Suspension, through Oral route, started on 2018-12-14, presumably until 2018-12-14\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2018-12-14, presumably until 2018-12-14\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2018-12-13, presumably until 2018-12-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-15 14:36:00, ended at 2018-12-15 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2018-12-15, presumably until 2018-12-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-17 04:20:00, ended at 2018-12-17 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan\n- Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, onl\n- Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications\n\n### Condition\n- Secondary malignant neoplastic disease\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-12-21 00:00:00, ended at 2018-12-21 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- lisinopril 5 MG Oral Tablet, started on 2018-12-21, presumably until 2018-12-21, with intended 0 refill(s). Instructions: GENERIC FOR ZESTRIL--- TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-23 00:00:00, ended at 2018-12-23 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- lisinopril 5 MG Oral Tablet, started on 2018-12-23, presumably until 2019-01-24, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY (evening)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-23 14:54:00, ended at 2018-12-23 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereotactic body radiation therapy, treatment management, per treatment course, to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions\n- Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions\n- Therapeutic radiology simulation-aided field setting; simple\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Secondary malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-24 00:00:00, ended at 2018-12-24 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 68 (unit per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-24 08:35:00, ended at 2018-12-24 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions\n\n### Condition\n- Chronic kidney disease stage 3\n- Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplastic disease\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-25 08:42:00, ended at 2018-12-25 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions\n\n### Condition\n- Secondary malignant neoplastic disease\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-26 10:42:00, ended at 2018-12-26 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions\n\n### Condition\n- Secondary malignant neoplastic disease\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-27 08:45:00, ended at 2018-12-27 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions\n\n### Condition\n- Secondary malignant neoplastic disease\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-01-03 11:49:00, ended at 2019-01-03 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 68 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.8 (percent)\n- MCH [Entitic mass] by Automated count: 38.8 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.8 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.43 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 77.3 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 4.3 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 158 (unit per liter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.8 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.11 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 1566.2 (nanogram per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.0 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 153 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.79 (million per microliter)\n- Iron [Mass/volume] in Serum or Plasma: 119 (microgram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.30 (thousand per microliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 24.5 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 152 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 117.6 (femtoliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Body height: 5' 4.055\" (inch (US))\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.22 (milligram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 47 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n- Chronic kidney disease stage 3\n\n### Drug\n- 50 ML famotidine 0.4 MG/ML Injection, through Intravenous route, started on 2019-01-03, presumably until 2019-01-03\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2019-01-03, presumably until 2019-01-03\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2019-01-03, presumably until 2019-01-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-01-03 12:40:41, ended at 2019-01-03 15:19:59\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.961\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2019-01-03, presumably until 2019-02-14, with intended 1 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed (for nausea or anxiety)\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2019-01-03, presumably until 2019-04-14, with intended 2 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-01-13 00:00:00, ended at 2019-01-13 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- Abuse-Deterrent 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2019-01-14, presumably until 2019-02-10, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-13 00:00:00, ended at 2019-01-13 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Nausea and vomiting\n\n### Drug\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2019-01-13, presumably until 2019-01-24, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals.\n- 72 HR scopolamine 0.0139 MG/HR Transdermal System, through Transdermal route, started on 2019-01-13, presumably until 2019-03-12, with intended 3 refill(s). Instructions: apply 1 Patch to skin every 72 hours\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-01-13 00:00:00, ended at 2019-01-13 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, started on 2019-01-13, presumably until 2019-01-24, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY WITH MEALS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-01-21 00:00:00, ended at 2019-01-21 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2019-01-22, presumably until 2019-01-24, with intended 0 refill(s). Instructions: GENERIC FOR PROTONIX--- TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-22 00:00:00, ended at 2019-01-22 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Dysuria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-01-22 08:52:04, ended at 2019-01-22 10:45:17\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.528\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Pain due to neoplastic disease\n- Primary diagnosis: Polyneuropathy\n\n### Drug\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2019-01-22, presumably until 2019-02-14, with intended 0 refill(s). Instructions: take 1 Cap by mouth 3 times a day Start at 300mg TID. If this improves your symptoms we may consider 600 mg at bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-01-23 08:36:00, ended at 2019-01-23 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-01-23 08:36:00, ended at 2019-01-23 08:36:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 197 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-01-24 00:00:00, ended at 2019-01-24 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- methylphenidate hydrochloride 5 MG Oral Tablet, through Oral route, started on 2019-01-24, presumably until 2019-07-23, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day as needed (fatigue)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-01-24 00:00:00, ended at 2019-01-24 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2019-01-24, presumably until 2019-01-26, with intended 11 refill(s). Instructions: take 1 Tab by mouth daily\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2019-01-24, presumably until 2019-02-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2019-01-24, presumably until 2019-04-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-01-24 00:00:00, ended at 2019-01-24 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- lisinopril 5 MG Oral Tablet, started on 2019-01-24, presumably until 2019-03-01, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY (evening)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-24 00:00:00, ended at 2019-01-24 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- methylphenidate hydrochloride 5 MG Oral Tablet, through Oral route, started on 2019-01-24, presumably until 2019-02-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day as needed (fatigue)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-01-24 12:26:00, ended at 2019-01-24 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.22 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCH [Entitic mass] by Automated count: 38.1 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 239 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 100 (unit per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.57 (million per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 843 (nanogram per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 84.2 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.9 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 259 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.3 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.3 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.42 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 117.9 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.11 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5.8 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.9 (percent)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Dysuria\n- Primary malignant neoplasm of retroperitoneum\n- Chronic kidney disease stage 3\n\n### Drug\n- epoetin alfa 20000 UNT/ML Injectable Solution, started on 2019-01-24, presumably until 2019-01-24\n- 0.5 ML varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML Injection, through Intramuscular route, started on 2019-01-24, presumably until 2019-01-24\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2019-01-24, presumably until 2019-01-24\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2019-01-24, presumably until 2019-01-24\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2019-01-24, presumably until 2019-01-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-01-24 13:25:06, ended at 2019-01-24 15:06:42\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.528\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-01-26 00:00:00, ended at 2019-01-26 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2019-01-27, presumably until 2019-04-14, with intended 11 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-02-10 00:00:00, ended at 2019-02-10 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- Abuse-Deterrent 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2019-02-12, presumably until 2019-03-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-11 00:00:00, ended at 2019-02-11 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, through Oral route, started on 2019-02-11, presumably until 2019-03-01, with intended 2 refill(s). Instructions: take 1-2 Caps by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-02-13 15:56:00, ended at 2019-02-13 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen; without contrast material\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-14 00:00:00, ended at 2019-02-14 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-14 00:00:00, ended at 2019-02-14 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperglycemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-14 00:00:00, ended at 2019-02-14 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-02-14 00:00:00, ended at 2019-02-14 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.2 MG Oral Capsule, through Oral route, started on 2019-02-14, presumably until 2019-03-31, with intended 3 refill(s). Instructions: take 1 Cap by mouth every day Take with 100 mcg daily\n- levothyroxine sodium 0.1 MG Oral Capsule, through Oral route, started on 2019-02-14, presumably until 2019-03-31, with intended 3 refill(s). Instructions: take 1 Cap by mouth every day Take with 200 mcg daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-02-14 09:11:00, ended at 2019-02-14 10:12:44\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.276\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cancer-related fatigue\n- Nausea\n- Primary diagnosis: Pain due to neoplastic disease\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2019-02-14, presumably until 2019-04-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n- methylphenidate hydrochloride 5 MG Oral Tablet, through Oral route, started on 2019-02-14, presumably until 2019-08-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day as needed (fatigue)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-02-14 11:59:00, ended at 2019-02-14 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Ferritin [Mass/volume] in Serum or Plasma: 924 (nanogram per milliliter)\n- Sodium [Moles/volume] in Serum or Plasma: 127 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Protein/Creatinine [Mass Ratio] in Urine: 0.21 (milligram per milligram)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.1 (gram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCV [Entitic volume] by Automated count: 115.2 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 28 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 116 (unit per liter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 1615 (picogram per milliliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.7 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.3 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.2 (percent)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 15.0 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 71.48 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n- Retinol [Mass/volume] in Serum or Plasma: 6.1 (microgram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 485 (milligram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 51 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.8 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.75 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.91 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 81.6 (percent)\n- Platelets [#/volume] in Blood by Automated count: 180 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5.0 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.40 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 94 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.97 (million per microliter)\n- Iron [Mass/volume] in Serum or Plasma: 94 (microgram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.36 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 37.4 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Declotting by thrombolytic agent of implanted vascular access device or catheter\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Chronic kidney disease stage 3\n- Disorder of kidney and/or ureter\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- epoetin alfa 20000 UNT/ML Injectable Solution, started on 2019-02-14, presumably until 2019-02-14\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2019-02-14, presumably until 2019-02-14\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2019-02-14, presumably until 2019-02-14\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2019-02-14, presumably until 2019-02-14\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2019-02-14, presumably until 2019-02-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-20 00:00:00, ended at 2019-02-20 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of nervous system due to type 2 diabetes mellitus\n- Vitamin A deficiency\n- Post-surgical malabsorption\n\n### Drug\n- ubidecarenone, through Oral route, started on 2019-02-20, presumably until 2019-04-14, with intended 3 refill(s). Instructions: take 1 Hudgins by mouth every 12 hours\n- vitamin K1, through Oral route, started on 2019-02-20, presumably until 2019-04-14, with intended 3 refill(s). Instructions: take 1 Kiser by mouth every 12 hours\n- folic acid, through Oral route, started on 2019-02-20, presumably until 2019-04-14, with intended 3 refill(s). Instructions: take 1 Vale by mouth every 12 hours\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-25 00:00:00, ended at 2019-02-25 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.53 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.4 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Anion gap in Serum or Plasma: 20 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 638 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 28 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 126 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 91 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 116 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 15 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-02-25 07:50:00, ended at 2019-02-25 13:40:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hemoglobin [Mass/volume] in Blood: 12.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 115.9 (femtoliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.34 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.6 (thousand per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 943 (nanogram per milliliter)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 38.0 (picogram)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.5 (percent)\n- Iron [Mass/volume] in Serum or Plasma: 78 (microgram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.7 (percent)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 43 (percent)\n- Platelets [#/volume] in Blood by Automated count: 164 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Chronic kidney disease stage 3\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-02-25 08:07:00, ended at 2019-02-25 09:02:47\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 16 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 126 (millimole per liter)\n- Phosphate [Mass/volume] in Serum or Plasma: 2.8 (milligram per deciliter)\n- Body height: 5' 5\" (inch (US))\n- Creatinine [Mass/volume] in Serum or Plasma: 1.49 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 639 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 92 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 28 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 18 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Chronic kidney disease stage 3\n- Hypo-osmolality and or hyponatremia\n- Primary diagnosis: Acute renal failure syndrome\n- Hyperglycemia\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2019-02-25 13:41:00, ended at 2019-03-01 15:30:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Corticotropin [Mass/volume] in Plasma: 14.4 (picogram per milliliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.7 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 6.73 (thousand per microliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.34 (million per microliter)\n- Glutamate decarboxylase 65 Ab [Units/volume] in Serum by Immunoassay: <5 (international unit per milliliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.7 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.32 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.017 (nanogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 31 (milligram per deciliter)\n- Base excess in Blood by calculation: -9 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 0.75 (nanogram per deciliter)\n- C peptide [Mass/volume] in Serum or Plasma: 1.37 (nanogram per milliliter)\n- Glucose [Mass/volume] in Blood: 466 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.3 (percent)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 10.6 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 2.9 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.1 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Glutamate decarboxylase 65 Ab [Moles/volume] in Serum: 0.01 (nanomole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 4.0 (percent)\n- MCH [Entitic mass] by Automated count: 38.1 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 164 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Body height: 5' 5\" (inch (US))\n- Creatinine [Mass/volume] in Serum or Plasma: 1.63 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 687 (milligram per deciliter)\n- Insulin Ab [Units/volume] in Serum by Radioimmunoassay (RIA): <0.4 (unit per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.0 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 117.3 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.78 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 84.0 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Islet cell 512 Ab [Units/volume] in Serum: SEE BELOW (unit per milliliter)\n\n### Procedure\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; initial, 31 minutes to 1 hour\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination\n- Hospital discharge day management; more than 30 minutes\n- Collection of venous blood by venipuncture\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Radiologic examination, chest; 2 views\n- Physical therapy evaluation: low complexity, requiring these components: A history with no personal factors and/or comorbidities that impact the plan of care; An examination of body system(s) using standardized tests and measures addressing 1-2 elements f\n- Occupational therapy evaluation, moderate complexity, requiring these components: An occupational profile and medical and therapy history, which includes an expanded review of medical and/or therapy records and additional review of physical, cognitive, or\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Absent kidney\n- Acquired absence of organ\n- Acquired absence of spleen\n- Asthenia\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Electrocardiogram abnormal\n- Hypertensive heart and renal disease with (congestive) heart failure\n- Old myocardial infarction\n- Polyneuropathy due to type 2 diabetes mellitus\n- Vitamin A deficiency\n- Chronic congestive heart failure\n- Disorder of pancreas\n- Hypoinsulinemia following procedure\n- Insomnia\n- Conduction disorder of the heart\n- Diabetic ketoacidosis without coma\n- Drug-induced diabetes mellitus\n- Hypothyroidism\n- Mild protein-calorie malnutrition (weight for age 75-89 percent of standard)\n- Pain due to neoplastic disease\n- Abdominal pain\n- Hyperosmolar coma due to type 2 diabetes mellitus\n- Hyperosmolarity\n- Polyneuropathy due to drug\n- Secondary malignant neoplasm of left lung\n- Atherosclerosis of coronary artery without angina pectoris\n- Hypo-osmolality and or hyponatremia\n- Post-surgical malabsorption\n- Vitamin D deficiency\n- Chronic systolic heart failure\n- Disorder of digestive system\n- Fatigue\n- Hyperglycemia due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n- Acute renal failure syndrome\n- Anemia in neoplastic disease\n- Diabetes mellitus without complication\n- Dyspnea\n- Primary diagnosis: Hyperglycemia\n- Major depression, single episode\n- Malaise\n- Nausea\n- Primary malignant neoplasm of retroperitoneum\n- Chronic kidney disease stage 3\n- Essential hypertension\n- Obesity\n- Obstructive sleep apnea syndrome\n- Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplasm of bone\n- Dehydration\n- Gout\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2019-02-26, presumably until 2019-02-26\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, through Oral route, started on 2019-02-26, presumably until 2019-02-28\n- 3 ML insulin isophane, human 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2019-02-28, presumably until 2019-03-01, with intended 0 refill(s). Instructions: inject 14 Units subcutaneous (under the skin) 2 times a day\n- Abuse-Deterrent 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2019-02-26, presumably until 2019-03-01\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2019-02-25, presumably until 2019-02-28\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2019-02-26, presumably until 2019-03-01\n- 1000 ML potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2019-02-25, presumably until 2019-02-25\n- 3 ML insulin lispro 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2019-02-28, presumably until 2019-03-03, with intended 0 refill(s). Instructions: inject 1-25 Units subcutaneous (under the skin) 3 times a day before meals Inject according to the printed scale given to you at the hospital\n- amitriptyline hydrochloride 75 MG Oral Tablet, through Oral route, started on 2019-02-25, presumably until 2019-02-28\n- amylase 180000 UNT / lipase 36000 UNT / protease 114000 UNT Delayed Release Oral Capsule, through Oral route, started on 2019-02-28, presumably until 2019-03-03, with intended 1 refill(s). Instructions: Take 1 capsule with each meal (3 times a day) and 1 capsule with each snack up to 3 times a day. Take capsules whole with a generous amount of liquid. Do not crush or chew\n- insulin isophane, human 100 UNT/ML Injectable Suspension, through Subcutaneous route, started on 2019-02-26, presumably until 2019-03-01\n- levothyroxine sodium 0.1 MG Injection, through Intravenous route, started on 2019-02-27, presumably until 2019-03-01\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2019-02-26, presumably until 2019-03-01\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2019-02-26, presumably until 2019-03-01\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2019-02-25, presumably until 2019-02-26\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2019-02-25, presumably until 2019-03-01\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2019-03-01, presumably until 2019-03-01\n- lisinopril 5 MG Oral Tablet, started on 2019-03-01, presumably until 2019-04-16, with intended 3 refill(s). Instructions: STOP taking this medication until your kidney function is normal (creatinine of 1 or less on your labs) or until Dr. Tran tells you to restart it  Take 1 tablet by mouth daily (evening)\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2017-11-12, presumably until 2019-04-16, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning And 2 tablets orally in the PM\n- carvedilol 6.25 MG Oral Tablet, through Oral route, started on 2019-02-26, presumably until 2019-03-01\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2019-03-01, presumably until 2019-03-03, with intended 0 refill(s). Instructions: inject 25 Units subcutaneous (under the skin) daily in the evening\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2019-02-25, presumably until 2019-03-01\n- isopropyl alcohol 0.7 ML/ML Medicated Pad, started on 2019-02-27, presumably until 2019-03-03, with intended 0 refill(s). Instructions: 1 Each by Misc.(Non-Drug; Combo Route) route 4 times a day before meals and bedtime\n- glucagon (rDNA) 1 MG Injection, through Intramuscular route, started on 2019-02-27, presumably until 2019-04-16, with intended 0 refill(s). Instructions: inject 1 mg into a muscle as needed\n- 72 HR scopolamine 0.0139 MG/HR Transdermal System, through Transdermal route, started on 2019-02-28, presumably until 2019-02-28\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2019-02-27, presumably until 2019-03-01\n- glucose 4000 MG Chewable Tablet, through Oral route, started on 2019-03-01, presumably until 2019-03-03, with intended 0 refill(s). Instructions: take 4-8 Tabs by mouth as needed for Low blood sugar You should keep sugar with you at all times. You can use juice or dextrose (glucose) tablets. The tablets can be bought over the counter at most pharmacies. If you are using juice, substitute an equivalent amount of carbohydrates (in grams) with juice. See instructions provided by diabetes educator nurse.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-03 00:00:00, ended at 2019-03-03 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperosmolarity\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n- Chronic kidney disease stage 3\n\n### Drug\n- 3 ML insulin lispro 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2019-03-03, presumably until 2019-04-14, with intended 2 refill(s). Instructions: inject 1-25 Units subcutaneous (under the skin) 3 times a day before meals Inject according to the printed scale given to you at the hospital\n- amylase 180000 UNT / lipase 36000 UNT / protease 114000 UNT Delayed Release Oral Capsule, started on 2019-03-03, presumably until 2019-03-06, with intended 3 refill(s). Instructions: Take 1 capsule with each meal (3 times a day) and 1 capsule with each snack up to 3 times a day.   Take capsules whole with a generous amount of liquid. Do not crush or chew\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2019-03-03, presumably until 2019-04-11, with intended 0 refill(s). Instructions: inject 25 Units subcutaneous (under the skin) daily in the evening\n- isopropyl alcohol 0.7 ML/ML Medicated Pad, started on 2019-03-03, presumably until 2019-04-14, with intended 6 refill(s). Instructions: 1 Each by Misc.(Non-Drug; Combo Route) route 4 times a day before meals and bedtime\n- glucose 4000 MG Chewable Tablet, through Oral route, started on 2019-03-03, presumably until 2019-04-16, with intended 1 refill(s). Instructions: take 4-8 Tabs by mouth as needed for Low blood sugar You should keep sugar with you at all times. You can use juice or dextrose (glucose) tablets. The tablets can be bought over the counter at most pharmacies. If you are using juice, substitute an equivalent amount of carbohydrates (in grams) with juice. See instructions provided by diabetes educator nurse.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-03-03 00:00:00, ended at 2019-03-03 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, started on 2019-03-03, presumably until 2019-04-16, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY 8 HOURS AS NEEDED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-06 00:00:00, ended at 2019-03-06 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amylase 180000 UNT / lipase 36000 UNT / protease 114000 UNT Delayed Release Oral Capsule, started on 2019-03-06, presumably until 2019-04-16, with intended 3 refill(s). Instructions: Take 1 capsule with each meal (3 times a day) and 1 capsule with each snack up to 3 times a day.   Take capsules whole with a generous amount of liquid. Do not crush or chew\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-06 13:59:45, ended at 2019-03-06 14:59:24\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.039\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Pain due to neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-07 00:00:00, ended at 2019-03-07 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-07 12:18:00, ended at 2019-03-07 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- Ferritin [Mass/volume] in Serum or Plasma: 794 (nanogram per milliliter)\n- Iron [Mass/volume] in Serum or Plasma: 99 (microgram per deciliter)\n- MCH [Entitic mass] by Automated count: 37.0 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 59 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.7 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.89 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.0 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.29 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 6.5 (percent)\n- MCV [Entitic volume] by Automated count: 117.6 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 74.4 (percent)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 62 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.1 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 31.5 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.06 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.53 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 109 (unit per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.8 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 66 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.27 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Platelets [#/volume] in Blood by Automated count: 162 (thousand per microliter)\n\n### Procedure\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Collection of venous blood by venipuncture\n- Declotting by thrombolytic agent of implanted vascular access device or catheter\n\n### Condition\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n- Candidiasis\n- Localized infection of skin AND/OR subcutaneous tissue\n- Primary malignant neoplasm of soft tissues\n- Anemia of chronic disease\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm of retroperitoneum\n- Actinic keratosis\n- Chronic kidney disease stage 3\n- Hypertrophic condition of skin\n- Pain due to neoplastic disease\n- Neoplasm of uncertain behavior of skin\n- Complication due to diabetes mellitus\n- Eruption\n- Hypothyroidism\n- Chronic ulcer of skin\n- Tear film insufficiency\n\n### Drug\n- epoetin alfa 20000 UNT/ML Injectable Solution, started on 2019-03-07, presumably until 2019-03-07\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2019-03-07, presumably until 2019-03-07\n- levothyroxine sodium 0.3 MG Oral Tablet, through Oral route, started on 2019-03-07, presumably until 2019-03-07\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2019-03-07, presumably until 2019-03-07\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2019-03-07, presumably until 2019-03-07\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2019-03-07, presumably until 2019-03-07\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2019-03-07, presumably until 2019-03-07\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2019-03-07, presumably until 2019-03-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-03-10 00:00:00, ended at 2019-03-10 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- prednisone 5 MG Oral Tablet, started on 2019-03-10, presumably until 2019-04-11, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-11 00:00:00, ended at 2019-03-11 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Eruption\n- Hyperosmolarity\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Primary malignant neoplasm of soft tissues\n- Chronic kidney disease stage 3\n- Type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-03-11 00:00:00, ended at 2019-03-11 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- Abuse-Deterrent 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2019-03-11, presumably until 2019-03-12, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Malignant tumor of pancreas within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-08-04 12:40:00, ended at 2010-08-04 23:59:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation and report on referred material requiring preparation of slides\n- Morphometric analysis, tumor\n\n### Condition\n- Neoplasm of uncertain behavior of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-09-07 12:58:00, ended at 2010-09-07 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-09-08 00:00:00, ended at 2010-09-08 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Intra-abdominal and pelvic swelling, mass and lump\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-09-09 10:55:00, ended at 2010-09-09 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen; with contrast material(s)\n- Computed tomography, pelvis; with contrast material(s)\n\n### Condition\n- Intra-abdominal and pelvic swelling, mass and lump\n- Abnormal finding on evaluation procedure\n- Disorder of pancreas\n- Neoplastic disease\n- Neoplastic disease of uncertain behavior\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-09-16 09:05:00, ended at 2010-09-16 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-09-27 09:58:00, ended at 2010-09-27 12:45:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- Colonoscopy\n- Colonoscopy, flexible; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2010-09-27, presumably until 2010-09-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2010-09-28 05:45:00, ended at 2010-10-12 11:12:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: N/A (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.23 (million per microliter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 500 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.0 (gram per deciliter)\n- Anion gap in Serum or Plasma: <2 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.7 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.3 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Body height: 5' 8.4\" (inch (US))\n- Globulin [Mass/volume] in Serum: 4.9 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 340 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.48 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 23.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 2.87 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 80.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.2 (percent)\n- INR in Platelet poor plasma by Coagulation assay: N/A (ratio)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.66 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.3 (millimole per liter)\n- Prothrombin time (PT): N/A (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 26.8 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 18.4 (percent)\n- Platelets [#/volume] in Blood by Automated count: 966 (thousand per microliter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.26 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.94 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.4 (percent)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 6.1 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.9 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 82.3 (femtoliter)\n\n### Procedure\n- Venous catheterization, not elsewhere classified\n- Selective catheter placement, arterial system; initial second order abdominal, pelvic, or lower extremity artery branch, within a vascular family\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Aortography\n- Transcatheter therapy, embolization, any method, radiological supervision and interpretation\n- Total splenectomy\n- Collection of venous blood by venipuncture\n- Open and other left hemicolectomy\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Distal subtotal pancreatectomy\n- Other endovascular procedures on other vessels\n- Angiography, visceral, selective or supraselective (with or without flush aortogram), radiological supervision and interpretation\n- Angiography through existing catheter for follow-up study for transcatheter therapy, embolization or infusion, other than for thrombolysis\n- Transcatheter occlusion or embolization (eg, for tumor destruction, to achieve hemostasis, to occlude a vascular malformation), percutaneous, any method, non-central nervous system, non-head or neck\n- Physical therapy evaluation\n- Radiologic examination, chest; single view, frontal\n- Arteriography of femoral and other lower extremity arteries\n- Continuous positive airway pressure ventilation (CPAP), initiation and management\n- Arteriography of other specified sites\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Excision or destruction of peritoneal tissue\n- Nephroureterectomy\n- Noninvasive ventilation\n\n### Condition\n- Acute postoperative pain\n- Low blood pressure\n- Pain in limb\n- Primary malignant neoplasm of abdomen\n- Primary malignant neoplasm of retroperitoneum\n- Atelectasis\n- Hyperkalemia\n- Portal hypertension\n- Venous thrombosis\n- Acute renal failure syndrome\n- Essential thrombocythemia\n- Imaging of thorax abnormal\n- Malnutrition (calorie)\n- Secondary malignant neoplastic disease\n- Cachexia\n- Hypovolemia\n- Primary malignant neoplasm of soft tissues of abdomen\n- Acquired hypothyroidism\n- Delirium\n- Obstructive sleep apnea syndrome\n- Thrombosis of superficial vein of lower limb\n- Acute posthemorrhagic anemia\n- Acute tubular necrosis\n- Leukocytosis\n- Postoperative infection\n- Swelling of limb\n- Acute vascular insufficiency of intestine\n- Blood coagulation disorder\n- Disorder of spleen\n- Secondary malignant neoplasm of intra-abdominal organs\n- Type 2 diabetes mellitus without complication\n- Essential hypertension\n- Imaging of abdomen abnormal\n- Obesity\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2010-09-28, presumably until 2010-10-10\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2010-09-30, presumably until 2010-09-30\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2010-10-12, presumably until 2010-10-12\n- metformin hydrochloride 500 MG Oral Tablet, through Oral route, started on 2010-10-10, presumably until 2010-10-12\n- cefoxitin 1000 MG Injection, through Intravenous route, started on 2010-09-29, presumably until 2010-09-29\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2010-09-29, presumably until 2010-10-11\n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2010-09-28, presumably until 2010-10-11. Instructions: take 20 mg by mouth every bedtime.\n- lisinopril 10 MG Oral Tablet, through Oral route, started on 2010-10-10, presumably until 2010-10-10\n- warfarin sodium 7.5 MG Oral Tablet, through Oral route, started on 2010-10-11, presumably until 2010-10-19, with quantity of 7.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n- 0.5 ML Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.068 MG/ML Injection, through Intramuscular route, started on 2010-10-10, presumably until 2010-10-10\n- cefazolin 1000 MG Injection, started on 2010-09-28, presumably until 2010-09-28\n- 0.8 ML enoxaparin sodium 150 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2010-10-11, presumably until 2010-10-13, with quantity of 7.0, with intended 0 refill(s). Instructions: 0.73 mL by SUBCUTANEOUS route every 12 hours. \n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2010-09-28, presumably until 2010-09-29\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2010-10-12, presumably until 2011-02-23, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily. \n- heparin sodium, porcine 10000 UNT/ML Injectable Solution, started on 2010-09-29, presumably until 2010-10-11\n- calcium chloride 0.001 MEQ/ML / glucose 50 MG/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2010-09-29, presumably until 2010-10-01\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2010-10-10, presumably until 2010-10-12\n- 0.5 ML meningococcal group A polysaccharide 0.1 MG/ML / meningococcal group C polysaccharide 0.1 MG/ML / meningococcal polysaccharide vaccine group W-135 0.1 MG/ML / meningococcal polysaccharide vaccine group Y 0.1 MG/ML Injection, through Subcutaneous route, started on 2010-10-10, presumably until 2010-10-10\n- insulin aspart, human 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2010-09-29, presumably until 2010-10-12\n- 1 ML vitamin K1 10 MG/ML Injection, through Intravenous route, started on 2010-10-03, presumably until 2010-10-03\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2010-10-10, presumably until 2010-10-10\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2010-10-09, presumably until 2010-10-12\n- 2 ML ondansetron 2 MG/ML Injection, started on 2010-09-28, presumably until 2010-09-29\n- acetaminophen 33.3 MG/ML / hydrocodone bitartrate 0.5 MG/ML Oral Solution, through Oral route, started on 2010-10-10, presumably until 2010-10-12\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2010-10-06, presumably until 2011-04-09, with quantity of 40.0, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 6 hours. \n- 0.5 ML Streptococcus pneumoniae type 1 capsular polysaccharide antigen 0.05 MG/ML / Streptococcus pneumoniae type 10A capsular polysaccharide antigen 0.05 MG/ML / Streptococcus pneumoniae type 11A capsular polysaccharide antigen 0.05 MG/ML / Streptococ..., started on 2010-10-10, presumably until 2010-10-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2010-10-13 00:00:00, ended at 2010-10-13 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.8 ML enoxaparin sodium 150 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2010-10-13, presumably until 2010-10-31, with quantity of 7.0, with intended 0 refill(s). Instructions: 0.73 mL by SUBCUTANEOUS route every 12 hours. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2010-10-17 00:00:00, ended at 2010-10-17 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2010-10-17, presumably until 2010-10-31, with quantity of 30.0, with intended 1 refill(s). Instructions: take 1-2 Tabs by mouth every 4 to 6 hours as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-10-19 09:55:00, ended at 2010-10-19 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- warfarin sodium 7.5 MG Oral Tablet, through Oral route, started on 2010-10-19, presumably until 2010-10-31, with quantity of 7.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-10-21 00:00:00, ended at 2010-10-21 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2010-10-26 21:05:00, ended at 2010-10-31 14:20:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 23.1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.47 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Prothrombin time (PT): 35.2 (second)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.2 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 27.6 (percent)\n- MCH [Entitic mass] by Automated count: 26.3 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 1.82 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 6.5 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 3.7 (ratio)\n- Neutrophils [#/volume] in Blood by Automated count: 9.97 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 78.1 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 80.5 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 81.7 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 132 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.1 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.5 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.5 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 846 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.5 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: <10 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.39 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.9 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 122 (unit per liter)\n- Body height: 5' 8.386\" (inch (US))\n- Eosinophils [#/volume] in Blood by Automated count: 0.62 (thousand per microliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.01 (nanogram per milliliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Incision of abdominal wall\n- Computed tomography, abdomen; without contrast material, followed by contrast material(s) and further sections\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Continuous positive airway pressure ventilation (CPAP), initiation and management\n- Computed tomography, pelvis; without contrast material, followed by contrast material(s) and further sections\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Obstructive sleep apnea syndrome\n- Persistent postoperative fistula\n- Type 2 diabetes mellitus without complication\n- Acquired absence of organ\n- Essential hypertension\n- Abdominal pain\n- Complication of surgical procedure\n- Malaise\n- Postoperative infection\n- Backache\n- Acute deep vein thrombosis of lower limb\n- Obesity\n- Acquired hypothyroidism\n- Cellulitis and abscess of trunk\n- Postprocedural state finding\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2010-10-27, presumably until 2010-10-28\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2010-10-30, presumably until 2010-10-30\n- warfarin sodium 5 MG Oral Tablet, through Oral route, started on 2010-10-31, presumably until 2011-04-26, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n- warfarin sodium 6 MG Oral Tablet, through Oral route, started on 2010-10-30, presumably until 2010-10-30\n- piperacillin 2000 MG / tazobactam 250 MG Injection, through Intravenous route, started on 2010-10-28, presumably until 2010-10-30\n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2010-10-27, presumably until 2010-10-30. Instructions: take 20 mg by mouth every bedtime.\n- diatrizoate, through Oral route, started on 2010-10-27, presumably until 2010-10-27\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2010-10-29, presumably until 2011-04-26, with quantity of 40.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily. \n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2010-10-27, presumably until 2010-10-31. Instructions: take 100 mcg by mouth daily.\n- diatrizoic acid, through Oral route, started on 2010-10-27, presumably until 2010-10-27\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2010-10-28, presumably until 2010-10-31\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2010-10-27, presumably until 2010-10-28\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2010-10-27, presumably until 2010-10-27\n- warfarin sodium 1 MG Oral Tablet, through Oral route, started on 2010-10-31, presumably until 2011-04-26, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2010-10-30, presumably until 2011-03-22, with quantity of 40.0, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 6 hours.\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2010-10-30, presumably until 2010-12-12, with quantity of 20.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours. \n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2010-10-29, presumably until 2010-10-30\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2010-10-26, presumably until 2010-10-30. Instructions: take 1-2 Tabs by mouth every 4 to 6 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-01 10:57:00, ended at 2010-11-01 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-02 08:17:00, ended at 2010-11-02 08:37:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.9 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 9.2 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Platelets [#/volume] in Blood by Automated count: 865 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- MCH [Entitic mass] by Automated count: 25.9 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.4 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.50 (million per microliter)\n- Globulin [Mass/volume] in Serum: 6.6 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.0 (gram per deciliter)\n- Prothrombin time (PT): 19.4 (second)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 10.0 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 27.9 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.7 (ratio)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.9 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 108 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 142 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 79.8 (femtoliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 46 (milliliter per minute per square meter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Intra-abdominal and pelvic swelling, mass and lump\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-02 08:38:00, ended at 2010-11-02 09:18:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Intra-abdominal and pelvic swelling, mass and lump\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-02 09:19:00, ended at 2010-11-02 12:35:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-02 12:36:00, ended at 2010-11-02 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-03 07:00:00, ended at 2010-11-03 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic radiology treatment planning; complex\n- Special treatment procedure (eg, total body irradiation, hemibody radiation, per oral or endocavitary irradiation)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-09 09:28:00, ended at 2010-11-09 10:01:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 80.8 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 981 (thousand per microliter)\n- Prothrombin time (PT): 19.6 (second)\n- Erythrocyte distribution width [Ratio] by Automated count: 23.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.56 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.8 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.8 (ratio)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.5 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 26.3 (picogram)\n- Hemoglobin [Mass/volume] in Blood: 9.4 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-09 10:02:00, ended at 2010-11-09 10:46:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-09 10:47:00, ended at 2010-11-09 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-11-16 00:00:00, ended at 2010-11-16 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2010-11-16, presumably until 2010-12-02, with quantity of 30.0, with intended 1 refill(s). Instructions: take 1-2 Tabs by mouth every 6 hours as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-23 08:32:00, ended at 2010-11-23 08:46:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 2.4 (ratio)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.9 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 82.1 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 602 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.1 (percent)\n- Prothrombin time (PT): 24.9 (second)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.7 (percent)\n- MCH [Entitic mass] by Automated count: 26.7 (picogram)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.66 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-23 08:47:00, ended at 2010-11-23 11:42:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-23 11:43:00, ended at 2010-11-23 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic radiology simulation-aided field setting; complex\n- Computed tomography guidance for placement of radiation therapy fields\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2010-12-02 00:00:00, ended at 2010-12-02 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2010-12-02, presumably until 2011-05-31, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 6 hours as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-02 07:00:00, ended at 2010-12-02 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-06 07:00:00, ended at 2010-12-06 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, onl\n- Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-07 12:15:00, ended at 2010-12-07 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Acute deep vein thrombosis of lower limb\n- Non-toxic uninodular goiter\n- Altered sensation of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-12-12 00:00:00, ended at 2010-12-12 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute deep vein thrombosis of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-12 13:56:00, ended at 2010-12-12 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic radiology port image(s)\n- Radiation treatment management, 5 treatments\n- Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, presumably until 2013-05-05. Instructions: take by mouth as needed \n- colchicine 0.6 MG Oral Tablet, through Oral route, presumably until 2016-05-15. Instructions: take 0.6 mg by mouth as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-12-13 00:00:00, ended at 2010-12-13 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-13 14:54:00, ended at 2010-12-13 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-14 15:13:00, ended at 2010-12-14 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-12-15 00:00:00, ended at 2010-12-15 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-15 15:01:00, ended at 2010-12-15 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- loperamide hydrochloride 2 MG Oral Tablet, through Oral route, presumably until 2011-06-02. Instructions: take 2 mg by mouth as needed Upt to 8/day \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-16 15:11:00, ended at 2010-12-16 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-19 14:46:00, ended at 2010-12-19 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment management, 5 treatments\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2010-12-19, presumably until 2010-12-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-20 13:37:00, ended at 2010-12-20 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic radiology port image(s)\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-21 09:09:00, ended at 2010-12-21 13:10:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-21 13:11:00, ended at 2010-12-21 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-23 13:03:00, ended at 2010-12-23 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-26 13:41:00, ended at 2010-12-26 14:01:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.32 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 7.7 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.5 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 16.5 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.8 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 96 (unit per liter)\n- Globulin [Mass/volume] in Serum: 5.1 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 90 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.7 (percent)\n- MCV [Entitic volume] by Automated count: 82.5 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 147 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.1 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 389 (thousand per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 51 (milliliter per minute per square meter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.0 (percent)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.9 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.68 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.49 (million per microliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.34 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 57.0 (percent)\n- MCH [Entitic mass] by Automated count: 26.5 (picogram)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-26 14:02:00, ended at 2010-12-26 14:57:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-27 13:57:00, ended at 2010-12-27 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Radiation treatment management, 5 treatments\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-28 08:41:00, ended at 2010-12-28 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-29 13:51:00, ended at 2010-12-29 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-30 14:16:00, ended at 2010-12-30 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-02 15:17:00, ended at 2011-01-02 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-03 14:15:00, ended at 2011-01-03 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic radiology port image(s)\n- Radiation treatment management, 5 treatments\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-04 06:34:00, ended at 2011-01-04 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-05 10:30:00, ended at 2011-01-05 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-09 14:52:00, ended at 2011-01-09 14:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hemoglobin [Mass/volume] in Blood: 11.8 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 26.9 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.4 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.46 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 23.5 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.81 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 262 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.1 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.4 (percent)\n- MCV [Entitic volume] by Automated count: 82.8 (femtoliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 17.6 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 2.6 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.40 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 30.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 1.19 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 45.6 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-09 15:00:00, ended at 2011-01-09 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-10 15:30:00, ended at 2011-01-10 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-11 15:11:00, ended at 2011-01-11 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment management, 5 treatments\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-12 15:06:00, ended at 2011-01-12 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-01-13 00:00:00, ended at 2011-01-13 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute deep vein thrombosis of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-13 11:30:00, ended at 2011-01-13 14:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Phlebitis of deep veins of lower extremity\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-01-13 13:29:17, ended at 2011-01-13 15:13:27\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute deep vein thrombosis of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-13 15:00:00, ended at 2011-01-13 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-16 14:43:00, ended at 2011-01-16 15:16:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.4 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 83.7 (femtoliter)\n- Neutrophils [#/volume] in Blood by Manual count: 2.1 (thousand per microliter)\n- Basophils [#/volume] in Blood by Manual count: 0.1 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.0 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.5 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 274 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Manual count: 3 (percent)\n- Monocytes [#/volume] in Blood by Manual count: 0.5 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.2 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 62 (percent)\n- Eosinophils/100 leukocytes in Blood by Manual count: 1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.69 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.7 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.3 (percent)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 16 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 24.2 (percent)\n- MCH [Entitic mass] by Automated count: 27.1 (picogram)\n- Monocytes/100 leukocytes in Blood by Manual count: 16 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-16 15:17:00, ended at 2011-01-16 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-17 15:03:00, ended at 2011-01-17 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Therapeutic radiology port image(s)\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-18 14:40:00, ended at 2011-01-18 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Radiation treatment management, 5 treatments\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-01-18 15:51:15, ended at 2011-01-18 17:10:45\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Altered sensation of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-19 15:18:00, ended at 2011-01-19 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-23 14:50:00, ended at 2011-01-23 15:25:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Lymphocytes/100 leukocytes in Blood by Automated count: 11.7 (percent)\n- MCH [Entitic mass] by Automated count: 27.2 (picogram)\n- MCV [Entitic volume] by Automated count: 84.2 (femtoliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 2.8 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.33 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 59.1 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.6 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 24.4 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.0 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 26.6 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 1.68 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 297 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.64 (million per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.76 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-23 15:26:00, ended at 2011-01-23 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-24 15:12:00, ended at 2011-01-24 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-25 15:12:00, ended at 2011-01-25 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-26 15:14:00, ended at 2011-01-26 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-02-08 09:40:00, ended at 2011-02-08 10:14:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-02-08 10:15:00, ended at 2011-02-08 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm of soft tissues\n- Acute deep vein thrombosis of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-02-23 09:57:00, ended at 2011-02-23 14:41:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Disorder of adrenal gland\n- Primary malignant neoplasm of soft tissues\n- Disorder of lung\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-02-23 14:42:00, ended at 2011-02-23 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, presumably until 2016-08-16. Instructions: take by mouth as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-02-28 09:54:00, ended at 2011-02-28 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Fine needle aspiration; with imaging guidance\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n- Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation\n\n### Condition\n- Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-03-06 12:54:00, ended at 2011-03-06 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Nerve conduction, amplitude and latency/velocity study, each nerve; motor, with F-wave study\n- Nerve conduction, amplitude and latency/velocity study, each nerve; sensory\n- Needle electromyography; limited study of muscles in 1 extremity or non-limb (axial) muscles (unilateral or bilateral), other than thoracic paraspinal, cranial nerve supplied muscles, or sphincters\n\n### Condition\n- Altered sensation of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-03-09 14:30:00, ended at 2011-03-09 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; lumbar\n\n### Condition\n- Displacement of lumbar intervertebral disc without myelopathy\n- Altered sensation of skin\n- Acquired spondylolisthesis\n- Lumbosacral spondylosis without myelopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-03-09 16:29:00, ended at 2011-03-09 17:13:43\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Altered sensation of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-03-22 00:00:00, ended at 2011-03-22 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2011-03-22, presumably until 2011-04-21, with quantity of 24.0, with intended 6 refill(s). Instructions: take 1 Tab by mouth 2 times a day. Take 2 (two) tabs PO, every 12 hours,  beginning the day before chemotherapy, the day of chemotherapy, and the day after chemotherapy, for a total of 6 doses. \n- prochlorperazine 10 MG Oral Tablet, through Oral route, started on 2011-03-22, presumably until 2012-01-10, with quantity of 30.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed for Nausea/Vomiting. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-03-22 12:15:00, ended at 2011-03-22 12:50:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.8 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.27 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 385 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 24.9 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.0 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 29.5 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.4 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.73 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 89.9 (femtoliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.64 (million per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.6 (percent)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.71 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.3 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-03-22 12:51:00, ended at 2011-03-22 18:57:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Altered sensation of skin\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n- Non-toxic uninodular goiter\n\n### Drug\n- metformin hydrochloride 500 MG Oral Tablet, through Oral route, presumably until 2011-10-17. Instructions: take 1,000 mg by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-03-22 18:58:00, ended at 2011-03-22 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm of soft tissues\n- Altered sensation of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-03-24 08:22:00, ended at 2011-03-24 08:29:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.46 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 11.2 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.5 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 17.6 (percent)\n- Platelets [#/volume] in Blood by Automated count: 401 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.74 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.9 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.63 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 13.9 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.4 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 132 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 30.0 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 2.66 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 58.5 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 10.0 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 143 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 23.8 (percent)\n- MCV [Entitic volume] by Automated count: 90.7 (femtoliter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.80 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-03-24 08:30:00, ended at 2011-03-24 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.008\" (inch (US))\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2011-03-24, presumably until 2011-03-24\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2011-03-24, presumably until 2011-03-24\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2011-03-24, presumably until 2011-04-21, with quantity of 32.0, with intended 0 refill(s). Instructions: take 2 Tabs by mouth. Take 8 mg (2 tabs) 12 hours prior to, morning of and 8 hours after chemotherapy. \n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-03-24, presumably until 2011-03-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-03-29 13:27:00, ended at 2011-03-29 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, lower extremity other than joint; without contrast material(s)\n- Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Altered sensation of skin\n- Edema\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-05 14:22:00, ended at 2011-04-05 14:29:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 92.0 (femtoliter)\n- Neutrophils [#/volume] in Blood by Manual count: 9.3 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 51 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.4 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 69 (percent)\n- Platelets [#/volume] in Blood by Automated count: 321 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.6 (percent)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.4 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 4 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.7 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.11 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 224 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.7 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 152 (unit per liter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 56 (milliliter per minute per square meter)\n- MCH [Entitic mass] by Automated count: 30.3 (picogram)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-05 14:30:00, ended at 2011-04-05 15:23:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-05 15:24:00, ended at 2011-04-05 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2011-04-05, presumably until 2011-04-05\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2011-04-05, presumably until 2011-04-05\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2011-04-05, presumably until 2011-04-05\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-04-05, presumably until 2011-04-05\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2011-04-05, presumably until 2011-04-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-17 12:10:00, ended at 2011-04-17 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of extremity veins including responses to compression and other maneuvers; unilateral or limited study\n\n### Condition\n- Anemia in neoplastic disease\n- Disorder of coccyx\n- Imaging of musculoskeletal system abnormal\n- Altered sensation of skin\n- Lumbosacral spondylosis without myelopathy\n- Displacement of lumbar intervertebral disc without myelopathy\n- Edema\n- Degeneration of intervertebral disc\n- Primary malignant neoplasm of retroperitoneum\n- Swelling of limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-04-17 15:08:00, ended at 2011-04-17 17:31:48\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Toxic polyneuropathy\n- Altered sensation of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-19 12:00:00, ended at 2011-04-19 12:21:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Collection of venous blood by venipuncture\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug provided in a facility (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2011-04-19, presumably until 2011-04-19\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2011-04-19, presumably until 2011-04-19\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-04-19, presumably until 2011-04-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-19 12:22:00, ended at 2011-04-19 12:57:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 51 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 185 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.8 (percent)\n- Monocytes/100 leukocytes in Blood by Manual count: 2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 483 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.7 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 31.3 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 16.1 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: >1000 (picogram per milliliter)\n- MCV [Entitic volume] by Automated count: 93.8 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.11 (million per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 56 (milliliter per minute per square meter)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Manual count: 15.8 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 75 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 368 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.3 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.88 (micro-international unit per milliliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.2 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Toxic polyneuropathy\n- Altered sensation of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-19 12:58:00, ended at 2011-04-19 14:29:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Toxic polyneuropathy\n- Acute deep vein thrombosis of lower limb\n- Altered sensation of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-19 14:30:00, ended at 2011-04-19 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Altered sensation of skin\n- Non-toxic uninodular goiter\n- Acute deep vein thrombosis of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-20 14:44:00, ended at 2011-04-20 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-04-20, presumably until 2011-04-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2011-04-21 00:00:00, ended at 2011-04-21 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2011-04-21, presumably until 2011-06-02, with quantity of 30.0, with intended 0 refill(s). Instructions: take 2 Tabs by mouth 2 times a day. On Day 1-3 of chemotherpy cycle (total of six doses) \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-04-26 00:00:00, ended at 2011-04-26 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-26 09:30:00, ended at 2011-04-26 13:21:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of extremity veins including responses to compression and other maneuvers; unilateral or limited study\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Phlebitis of deep veins of lower extremity\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-04-26 11:03:52, ended at 2011-04-26 12:14:24\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute deep vein thrombosis of lower limb\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, presumably until 2012-01-10. Instructions: take 0.5 mg by mouth every 4 hours as needed \n- ranitidine 150 MG Oral Tablet, through Oral route, presumably until 2011-06-30. Instructions: take 150 mg by mouth 2 times a day. \n- sucralfate 1000 MG Oral Tablet, through Oral route, presumably until 2011-07-01. Instructions: take by mouth 4 times a day. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-04-26 13:22:00, ended at 2011-04-26 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 56 (milliliter per minute per square meter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.8 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.3 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.04 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 302 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.86 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.2 (picogram)\n- MCV [Entitic volume] by Automated count: 90.2 (femtoliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 223 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 21.1 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.6 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- Neutrophils/100 leukocytes in Blood by Automated count: 93.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 22.78 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 68 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 118 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.1 (percent)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Prothrombin time (PT): 12.8 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 24.4 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-05-01 00:00:00, ended at 2011-05-01 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acquired spondylolisthesis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-02 07:02:00, ended at 2011-05-02 12:30:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- Fluoroscopic guidance for central venous access device placement, replacement (catheter only or complete), or removal (includes fluoroscopic guidance for vascular access and catheter manipulation, any necessary contrast injections through access site or c\n- Insertion of tunneled centrally inserted central venous access device, with subcutaneous port; age 5 years or older\n- Insertion of graft for vascular access\n\n### Condition\n- Malignant neoplastic disease\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2011-05-02, presumably until 2011-05-02\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-05-03 00:00:00, ended at 2011-05-03 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-03 10:20:00, ended at 2011-05-03 10:24:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2011-05-03, presumably until 2011-05-03\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2011-05-03, presumably until 2011-05-03\n- 2 ML ondansetron 2 MG/ML Injection, started on 2011-05-03, presumably until 2011-05-03\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-05-03, presumably until 2011-05-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-03 10:25:00, ended at 2011-05-03 10:48:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.2 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Manual count: 19.5 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.25 (million per microliter)\n- MCV [Entitic volume] by Automated count: 92.1 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 19.7 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 141 (unit per liter)\n- MCH [Entitic mass] by Automated count: 30.0 (picogram)\n- Neutrophils/100 leukocytes in Blood by Manual count: 70 (percent)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.9 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 232 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.6 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Manual count: 1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 535 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 56 (milliliter per minute per square meter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.9 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-03 10:49:00, ended at 2011-05-03 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Altered sensation of skin\n- Acute deep vein thrombosis of lower limb\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, through Topical route, started on 2011-05-03, presumably until 2011-06-02, with intended 3 refill(s). Instructions: 0.5 Inches by Topical route as needed Apply 60 minutes prior to port being accessed. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-04 13:10:00, ended at 2011-05-04 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-05-04, presumably until 2011-05-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-05-17 00:00:00, ended at 2011-05-17 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-05-17 00:00:00, ended at 2011-05-17 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Venous thrombosis\n\n### Drug\n- 1 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-05-17, presumably until 2011-05-28, with intended 2 refill(s). Instructions: inject 1 mL subcutaneous (under the skin) every 12 hours.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-17 07:39:00, ended at 2011-05-17 13:06:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Lymphadenopathy\n- Primary malignant neoplasm of soft tissues\n- Disorder of lung\n- Pleural effusion\n- Ascites\n- Embolism and thrombosis of the vena cava\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-17 13:07:00, ended at 2011-05-17 13:19:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 213 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 17.5 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 92.8 (femtoliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.2 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Manual count: 16.9 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 507 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.4 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 23.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 7.7 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 24.0 (percent)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.3 (picogram)\n- Monocytes/100 leukocytes in Blood by Manual count: 1 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.6 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.53 (million per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 138 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 2 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.0 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 71 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-17 13:20:00, ended at 2011-05-17 13:48:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Transfusion, blood or blood components\n\n### Condition\n- Altered sensation of skin\n- Primary malignant neoplasm of soft tissues\n- Acute deep vein thrombosis of lower limb\n- Venous thrombosis\n- Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-17 13:49:00, ended at 2011-05-17 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.008\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Altered sensation of skin\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- levothyroxine sodium 0.112 MG Oral Tablet, through Oral route, presumably until 2012-11-12. Instructions: take  by mouth.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-05-18 10:34:52, ended at 2011-05-18 15:52:30\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acquired spondylolisthesis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-18 13:22:00, ended at 2011-05-18 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Iron saturation [Mass Fraction] in Serum or Plasma: 8 (percent)\n- Iron [Mass/volume] in Serum or Plasma: 27 (microgram per deciliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 56 (nanogram per milliliter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 351 (microgram per deciliter)\n\n### Procedure\n- Transfusion, blood or blood components\n\n### Condition\n- Non-toxic uninodular goiter\n- Altered sensation of skin\n- Primary malignant neoplasm of soft tissues\n- Acute deep vein thrombosis of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-19 11:24:00, ended at 2011-05-19 15:45:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- Removal of foreign body from skin and/or subcutaneous tissue by incision\n- Removal of tunneled central venous access device, with subcutaneous port or pump, central or peripheral insertion\n\n### Condition\n- Embolism and thrombosis of the vena cava\n- Primary malignant neoplasm of retroperitoneum\n- Thrombosis of vein of trunk\n\n### Drug\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2011-05-19, presumably until 2011-05-19\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2011-05-19, presumably until 2011-05-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-24 11:04:00, ended at 2011-05-24 11:39:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 49 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 153 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.9 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.49 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.54 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 94.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 51 (milliliter per minute per square meter)\n- MCV [Entitic volume] by Automated count: 92.9 (femtoliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.4 (picogram)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 110 (unit per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 13.43 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 14.3 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 615 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.4 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.6 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 3.8 (percent)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 1.9 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Venous thrombosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-24 11:40:00, ended at 2011-05-24 12:56:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-24 12:57:00, ended at 2011-05-24 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.008\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2011-05-28 19:36:00, ended at 2011-06-02 15:15:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 106 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 18 (percent)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 3.09 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Manual count: 15 (percent)\n- Neutrophils/100 leukocytes in Blood by Manual count: 50 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- INR in Platelet poor plasma by Coagulation assay: 1.5 (ratio)\n- Prothrombin time (PT): 17.3 (second)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.56 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.4 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 19.1 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Manual count: 6 (percent)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.6 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.5 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Manual count: 5.2 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.9 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 13.26 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.7 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.8 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.11 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.7 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 40.2 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.47 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 12 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 1.5 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.7 (picogram)\n- MCV [Entitic volume] by Automated count: 93.8 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 5.9 (gram per deciliter)\n- Body height: 5' 6.142\" (inch (US))\n- Eosinophils [#/volume] in Blood by Manual count: 0.5 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Manual count: 1.3 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 80.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 628 (thousand per microliter)\n\n### Procedure\n- Continuous positive airway pressure ventilation (CPAP), initiation and management\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Physical therapy evaluation\n- Molecular diagnostics; interpretation and report\n- Molecular diagnostics; nucleic acid probe, each\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Molecular diagnostics; amplification, target, each nucleic acid sequence\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Computed tomographic angiography, head, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Duplex scan of extremity veins including responses to compression and other maneuvers; unilateral or limited study\n- Molecular diagnostics; isolation or extraction of highly purified nucleic acid, each nucleic acid type (ie, DNA or RNA)\n- Collection of venous blood by venipuncture\n- Computed tomographic angiography, chest (noncoronary), with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Computed tomographic angiography, neck, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n\n### Condition\n- Pain in limb\n- Thrombosis of vein of trunk\n- Acute thrombosis of subclavian vein\n- Arthropathy of knee joint\n- Localized osteoarthrosis uncertain if primary OR secondary\n- Altered sensation of skin\n- Coag./bleeding tests abnormal\n- Lymphadenopathy\n- Acquired absence of organ\n- Acquired hypothyroidism\n- Gout\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm of soft tissues\n- Disorder of gallbladder\n- Obesity\n- Obstructive sleep apnea syndrome\n- Pulmonary embolism with pulmonary infarction\n- Acute deep vein thrombosis of lower limb\n- Acute deep venous thrombosis of internal jugular vein\n- Disorder of lung\n- Embolism and thrombosis of the vena cava\n- Inflammatory disorder of digestive tract\n- Pleural effusion\n- Primary malignant neoplasm of retroperitoneum\n- Essential hypertension\n- Lung field abnormal\n- Type 2 diabetes mellitus without complication\n- Venous thrombosis\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2011-05-29, presumably until 2011-06-02\n- 1 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-05-29, presumably until 2011-06-02\n- warfarin sodium 5 MG Oral Tablet, through Oral route, presumably until 2011-06-02. Instructions: take 5 mg by mouth daily.\n- levothyroxine sodium 0.112 MG Oral Tablet, through Oral route, started on 2011-05-29, presumably until 2011-06-02\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2011-05-29, presumably until 2011-06-02\n- hydromorphone hydrochloride 4 MG Oral Tablet, through Oral route, started on 2011-05-31, presumably until 2011-11-29, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed.\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2011-05-31, presumably until 2011-06-09, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours.\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2011-05-30, presumably until 2011-10-17, with intended 2 refill(s). Instructions: take 1 Cap by mouth 2 times a day as needed for Constipation.\n- sucralfate 1000 MG Oral Tablet, through Oral route, started on 2011-05-29, presumably until 2011-05-30\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2011-05-30, presumably until 2011-05-30\n- colchicine 0.6 MG Oral Tablet, through Oral route, started on 2011-05-29, presumably until 2011-06-02\n- insulin aspart, human 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2011-05-30, presumably until 2011-06-02\n- 1 ML enoxaparin sodium 150 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-05-29, presumably until 2011-09-13, with intended 6 refill(s). Instructions: inject 1 mL subcutaneous (under the skin) Every Day.\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2011-05-29, presumably until 2011-06-02\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2011-05-30, presumably until 2011-05-31\n- 2 ML ondansetron 2 MG/ML Injection, started on 2011-05-28, presumably until 2011-05-30\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-05-29, presumably until 2011-06-02\n- prochlorperazine 5 MG Oral Tablet, through Oral route, started on 2011-05-30, presumably until 2011-05-30\n- sucralfate 100 MG/ML Oral Suspension, through Oral route, started on 2011-05-30, presumably until 2011-06-02\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2011-05-30, presumably until 2011-06-01\n- 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2011-05-30, presumably until 2011-05-30\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2011-05-30, presumably until 2011-05-30\n- simethicone 80 MG Chewable Tablet, through Oral route, started on 2011-05-29, presumably until 2011-06-02\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2011-05-28, presumably until 2011-05-30\n- 1 ML morphine sulfate 4 MG/ML Prefilled Syringe, started on 2011-05-28, presumably until 2011-05-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-05-31 00:00:00, ended at 2011-05-31 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Venous thrombosis\n- Pulmonary embolism with pulmonary infarction\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-06-07 00:00:00, ended at 2011-06-07 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Pulmonary embolism with pulmonary infarction\n- Acute deep vein thrombosis of lower limb\n- Anemia\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-06-07 09:04:00, ended at 2011-06-07 09:48:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.3 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 6.3 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 1.19 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.3 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 130 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 8.1 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.2 (femtoliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 100 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.76 (million per microliter)\n- MCH [Entitic mass] by Automated count: 29.5 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 892 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 24.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.82 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 83.6 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 13.1 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 10.93 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.1 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-06-07 09:49:00, ended at 2011-06-07 10:29:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Non-toxic uninodular goiter\n- Altered sensation of skin\n- Pulmonary embolism with pulmonary infarction\n- Acute deep vein thrombosis of lower limb\n- Venous thrombosis\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-06-07 10:30:00, ended at 2011-06-07 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Transfusion, blood or blood components\n\n### Condition\n- Pulmonary embolism with pulmonary infarction\n- Primary malignant neoplasm of retroperitoneum\n- Anemia\n- Primary malignant neoplasm of soft tissues\n- Acute deep vein thrombosis of lower limb\n\n### Drug\n- 1 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-06-07, presumably until 2011-06-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-06-09 00:00:00, ended at 2011-06-09 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2011-06-07, presumably until 2011-07-01, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours. Note:  Rx was written by HSmith on 99999999.  Rx#0204.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-06-15 08:45:00, ended at 2011-06-15 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.157\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Pulmonary embolism with pulmonary infarction\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-06-21 07:46:00, ended at 2011-06-21 09:06:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.7 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 87 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.8 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.0 (percent)\n- MCHC [Mass/volume] by Automated count: 31.2 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.52 (million per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 56 (milliliter per minute per square meter)\n- MCV [Entitic volume] by Automated count: 90.3 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.98 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.3 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 120 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.26 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.2 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 8.01 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 76.2 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.23 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.5 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 824 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Primary malignant neoplasm of soft tissues\n- Pulmonary embolism with pulmonary infarction\n- Anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-06-21 09:07:00, ended at 2011-06-21 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7.008\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2011-06-30 02:52:00, ended at 2011-07-01 13:30:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.5 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.97 (million per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.6 (percent)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood: 32 (percent)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 6.3 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.2 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.2 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 86.5 (femtoliter)\n- Hemoglobin [Mass/volume] in Blood: 8.3 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 669 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 25.6 (percent)\n- Hemoglobin [Mass/volume] in Blood by calculation: 10.9 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.1 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 1.07 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.88 (thousand per microliter)\n- Sodium [Moles/volume] in Blood: 136 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.0 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 83.8 (percent)\n- Potassium [Moles/volume] in Blood: 4.9 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.74 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug provided in a facility (List separately in addition to code for primary procedure)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Intestinal obstruction\n- Type 2 diabetes mellitus without complication\n- Obstructive sleep apnea syndrome\n- Primary malignant neoplasm of soft tissues\n- Abdominal pain\n- Ascites\n- Lymphadenopathy\n- Gout\n- Nausea and vomiting\n- Acquired hypothyroidism\n- Constipation\n- Epigastric pain\n- Pleural effusion\n- Paralytic ileus\n\n### Drug\n- levothyroxine sodium 0.112 MG Oral Tablet, through Oral route, started on 2011-06-30, presumably until 2011-07-01\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2011-06-30, presumably until 2011-07-01\n- hydromorphone hydrochloride 4 MG Oral Tablet, through Oral route, started on 2011-06-30, presumably until 2011-07-01\n- prochlorperazine 5 MG/ML Injectable Solution, started on 2011-06-30, presumably until 2011-06-30\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2011-06-30, presumably until 2011-10-27, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours. Note:  Rx was written by HSmith on 99999999.  Rx#0204.\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2011-06-30, presumably until 2011-07-01\n- 1 ML enoxaparin sodium 150 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-06-30, presumably until 2011-06-30\n- 2 ML ondansetron 2 MG/ML Injection, started on 2011-06-30, presumably until 2011-07-01\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2011-06-30, presumably until 2011-06-30\n- 1 ML hydromorphone hydrochloride 2 MG/ML Prefilled Syringe, started on 2011-06-30, presumably until 2011-06-30\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-06-30, presumably until 2011-07-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-07-12 00:00:00, ended at 2011-07-12 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-07-12 07:42:00, ended at 2011-07-12 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Intestinal obstruction\n- Imaging of abdomen abnormal\n- Primary malignant neoplasm of soft tissues\n- Disorder of lung\n- Ascites\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-07-17 11:27:00, ended at 2011-07-17 12:58:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.46 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.6 (percent)\n- Platelets [#/volume] in Blood by Automated count: 751 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.1 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 42 (milliliter per minute per square meter)\n- Glucose [Mass/volume] in Serum or Plasma: 108 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Amylase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Ferritin [Mass/volume] in Serum or Plasma: 8 (nanogram per milliliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.9 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.6 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.1 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.68 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 31.5 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.70 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 78.3 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.3 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.54 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 84 (unit per liter)\n- MCV [Entitic volume] by Automated count: 85.5 (femtoliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.0 (percent)\n- MCH [Entitic mass] by Automated count: 27.0 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-07-17 12:59:00, ended at 2011-07-17 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2011-08-02 13:53:00, ended at 2011-08-04 17:46:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 88 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.6 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Manual count: 5.1 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 34.0 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.9 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 18 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.1 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 1.0 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 82 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.79 (million per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Manual count: 1 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.4 (percent)\n- MCH [Entitic mass] by Automated count: 26.7 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.0 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 649 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.2 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.4 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 84.2 (femtoliter)\n- Base excess in Blood by calculation: 2.0 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Body height: 5' 7.008\" (inch (US))\n- Eosinophils/100 leukocytes in Blood by Manual count: 4 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.9 (percent)\n- Neutrophils/100 leukocytes in Blood by Manual count: 69 (percent)\n- Prothrombin time (PT): 18.2 (second)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Manual count: 0.1 (thousand per microliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.6 (ratio)\n- Monocytes/100 leukocytes in Blood by Manual count: 8 (percent)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Radiologic examination, abdomen; complete, including decubitus and/or erect views\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Vomiting\n- Acquired hypothyroidism\n- Acute deep venous thrombosis of internal jugular vein\n- Anuria\n- Dehydration\n- Inflammatory disorder of digestive tract\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm of soft tissues\n- Pulmonary embolism with pulmonary infarction\n- Obstructive sleep apnea syndrome\n- Venous thrombosis\n- Acute pyelonephritis without medullary necrosis\n- Imaging of abdomen abnormal\n- Pyelonephritis\n- Type 2 diabetes mellitus without complication\n- Nausea and vomiting\n- Acute deep vein thrombosis of lower limb\n- Gastric ulcer without hemorrhage, without perforation AND without obstruction\n- Hyperlipidemia\n- Altered sensation of skin\n- Disorder of kidney and/or ureter\n- Sepsis due to Streptococcus group D\n\n### Drug\n- levothyroxine sodium 0.112 MG Oral Tablet, through Oral route, started on 2011-08-03, presumably until 2011-08-04\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2011-08-03, presumably until 2011-08-03\n- sodium phosphate, dibasic 59.3 MG/ML / sodium phosphate, monobasic 161 MG/ML Enema, through Rectal route, started on 2011-08-03, presumably until 2011-08-03\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2011-08-03, presumably until 2011-08-04. Instructions: take by mouth daily.\n- metformin hydrochloride 500 MG Oral Tablet, through Oral route, started on 2011-08-03, presumably until 2011-08-03\n- magnesium citrate 58.2 MG/ML Oral Solution, through Oral route, started on 2011-08-03, presumably until 2011-08-03\n- ceftriaxone 1000 MG Injection, through Intravenous route, started on 2011-08-03, presumably until 2011-08-03\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2011-08-02, presumably until 2011-08-02\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2011-08-03, presumably until 2011-08-04\n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2011-08-03, presumably until 2011-08-03. Instructions: take 20 mg by mouth every bedtime. \n- prochlorperazine 5 MG/ML Injectable Solution, started on 2011-08-04, presumably until 2011-08-04\n- warfarin sodium 7.5 MG Oral Tablet, through Oral route, started on 2011-08-02, presumably until 2012-01-10. Instructions: take 7.5 mg by mouth. Tuesday, Thursday, Friday, Sunday\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2011-08-04, presumably until 2011-09-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n- colchicine 0.6 MG Oral Tablet, through Oral route, started on 2011-08-03, presumably until 2011-08-04. Instructions: take 0.6 mg by mouth daily. \n- 1 ML enoxaparin sodium 150 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-08-03, presumably until 2011-08-04\n- 2 ML ondansetron 2 MG/ML Injection, started on 2011-08-02, presumably until 2011-08-04\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2011-08-02, presumably until 2011-08-03\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-08-02, presumably until 2011-08-04\n- metoclopramide 10 MG Oral Tablet, through Oral route, started on 2011-08-04, presumably until 2011-10-17, with intended 1 refill(s). Instructions: take 1 Tab by mouth 3 times a day before meals.\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2011-08-02, presumably until 2011-08-02\n- 1 ML promethazine hydrochloride 25 MG/ML Injection, started on 2011-08-03, presumably until 2011-08-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-08-14 00:00:00, ended at 2011-08-14 00:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Pyelonephritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-08-14 09:26:00, ended at 2011-08-14 10:00:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.5 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.5 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.1 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.7 (thousand per microliter)\n- Amylase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.41 (million per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 26.8 (picogram)\n- MCV [Entitic volume] by Automated count: 83.6 (femtoliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 73 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.25 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.8 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.0 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 129 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.59 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 617 (thousand per microliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 51 (milliliter per minute per square meter)\n- Monocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 68.9 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-08-14 10:01:00, ended at 2011-08-14 23:59:00\nThe patient in this visit was 50 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Venous thrombosis\n- Non-toxic uninodular goiter\n- Pulmonary embolism with pulmonary infarction\n- Pyelonephritis\n- Acute deep vein thrombosis of lower limb\n- Altered sensation of skin\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-08-17 14:42:00, ended at 2011-08-17 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-09-13 00:00:00, ended at 2011-09-13 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-09-13 12:17:00, ended at 2011-09-13 13:14:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocytes [#/volume] in Blood by Automated count: 4.57 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.69 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 114 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 81.3 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.83 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 73.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 10.1 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 446 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 107 (unit per liter)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.6 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 45 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.2 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 3.4 (ratio)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.60 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.4 (percent)\n- Prothrombin time (PT): 33.1 (second)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.8 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 13.2 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.2 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 27.7 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 8.4 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 38 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Primary malignant neoplasm of soft tissues\n- Pyelonephritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-09-13 13:15:00, ended at 2011-09-13 14:41:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-09-13 14:42:00, ended at 2011-09-13 17:48:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-09-13 17:49:00, ended at 2011-10-17 16:20:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 91 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.8 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.89 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 24.2 (percent)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 14 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 96 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 68 (milligram per deciliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 92 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.7 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 7.4 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.06 (micro-international unit per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 66 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.34 (millimole per liter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 38 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.3 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.5 (percent)\n- MCV [Entitic volume] by Automated count: 90.2 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.69 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 76.8 (percent)\n- aPTT in Platelet poor plasma by Coagulation assay: N/A (second)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 30 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.1 (picogram)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.2 (thousand per microliter)\n- INR in Platelet poor plasma by Coagulation assay: N/A (ratio)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Prothrombin time (PT): 33.6 (second)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 22 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 1.5 (thousand per microliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 14 (nanogram per milliliter)\n- Body height: 5' 7\" (inch (US))\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 266 (picogram per milliliter)\n- Eosinophils/100 leukocytes in Blood by Manual count: 2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 24.8 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.4 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Manual count: 19 (percent)\n- Neutrophils [#/volume] in Blood by Manual count: 8.9 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 72 (percent)\n- Triglyceride [Moles/volume] in Serum or Plasma: 56 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 96 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.7 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 7.26 (thousand per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 6.2 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 42 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.07 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 6 (percent)\n- Platelets [#/volume] in Blood by Automated count: 949 (thousand per microliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n\n### Procedure\n- Radiologic examination, gastrointestinal tract, upper; with or without delayed images, with KUB\n- Other lysis of peritoneal adhesions\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Physical therapy evaluation\n- Insertion of other (naso-)gastric tube\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Continuous positive airway pressure ventilation (CPAP), initiation and management\n- Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, without imaging guidance; age 5 years or older\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Dilation of esophagus, over guide wire\n- Collection of venous blood by venipuncture\n- Drainage of peritoneal abscess or localized peritonitis, exclusive of appendiceal abscess; percutaneous\n- Other endoscopy of small intestine\n- Radiologic examination, gastrointestinal tract, upper; with small intestine, includes multiple serial images\n- Packed blood cell transfusion\n- Radiologic examination, esophagus, including scout chest radiograph(s) and delayed image(s), when performed; single-contrast (eg, barium) study\n- Computed tomography, abdomen and pelvis; without contrast material\n- Total parenteral nutrition\n- Other cardiovascular stress test\n- Noninvasive ventilation\n- Abdominal paracentesis\n- Dilation of intestine\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Radiologic examination, chest; single view, frontal\n- Transfusion of other serum\n- Injection or infusion of oxazolidinone class of antibiotics\n- Computed tomography, thorax, diagnostic; without contrast material\n- Radiologic examination, abdomen; single anteroposterior view\n- Venous catheterization, not elsewhere classified\n- Anastomosis of small intestine to small intestine\n- Radiological guidance (ie, fluoroscopy, ultrasound, or computed tomography), for percutaneous drainage (eg, abscess, specimen collection), with placement of catheter, radiological supervision and interpretation\n\n### Condition\n- Acute deep venous thrombosis of internal jugular vein\n- Breathing painful\n- Dehydration\n- Loss of appetite\n- Obstruction of bile duct\n- Constipation\n- Essential hypertension\n- Abscess of peritoneum\n- Acquired hypothyroidism\n- Acute deep vein thrombosis of lower limb\n- Acute deep venous thrombosis of axillary vein\n- Altered sensation of skin\n- Ascites\n- Hypokalemia\n- Lung field abnormal\n- Nausea and vomiting\n- Non-toxic uninodular goiter\n- Paralytic ileus\n- Pleural effusion\n- Pulmonary embolism with pulmonary infarction\n- Radiation-induced disorder\n- Urinary tract infectious disease\n- Imaging of abdomen abnormal\n- Late effect of complications of procedure\n- Sepsis due to Streptococcus group D\n- Acute renal failure syndrome\n- Anemia\n- Gout\n- Intestinal volvulus\n- Old myocardial infarction\n- Acquired absence of organ\n- Acquired hypertrophic pyloric stenosis\n- Coag./bleeding tests abnormal\n- Diaphragmatic hernia\n- Disorder of lung\n- Inflammatory disorder of digestive tract\n- Intestinal obstruction\n- Ischemic heart disease\n- Venous thrombosis\n- Acute deep venous thrombosis of upper extremity\n- Late effect of radiation\n- Obstructive sleep apnea syndrome\n- Chronic deep venous thrombosis of internal jugular vein\n- Coronary arteriosclerosis\n- Peritoneal adhesions with obstruction\n- Type 2 diabetes mellitus without complication\n- Disorder due to infection\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- benzocaine 15 MG / menthol 3.6 MG Oral Lozenge, through Submucosal route, started on 2011-09-21, presumably until 2011-09-21\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2011-09-17, presumably until 2011-09-27\n- 50 ML sodium bicarbonate 84 MG/ML Injection, through Intravenous route, started on 2011-09-16, presumably until 2011-09-16\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2011-09-14, presumably until 2011-09-14\n- warfarin sodium 10 MG Oral Tablet, through Oral route, presumably until 2012-01-10. Instructions: take 10 mg by mouth. Monday, Wednesday, Saturday\n- levothyroxine sodium 0.112 MG Oral Tablet, through Oral route, started on 2011-09-13, presumably until 2011-09-19. Instructions: take  by mouth.\n- levothyroxine sodium 0.2 MG Injection, through Intravenous route, started on 2011-09-20, presumably until 2011-09-22\n- menthol, through Submucosal route, started on 2011-09-29, presumably until 2011-09-29\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2011-09-14, presumably until 2011-09-14. Instructions: take 0.5 mg by mouth every 4 hours as needed\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2011-09-17, presumably until 2011-09-19\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2011-09-13, presumably until 2011-10-17. Instructions: take by mouth daily.\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2011-09-14, presumably until 2011-10-15\n- warfarin sodium 3 MG Oral Tablet, through Oral route, started on 2011-09-15, presumably until 2011-09-15\n- levothyroxine sodium 0.5 MG Injection, through Intravenous route, started on 2011-09-20, presumably until 2011-09-26\n- benzocaine 140 MG/ML / butamben 20 MG/ML / tetracaine 20 MG/ML Mucosal Spray, through Topical route, started on 2011-09-20, presumably until 2011-09-25\n- lidocaine 40 MG/ML Topical Cream, through Topical route, started on 2011-09-16, presumably until 2011-09-16\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2011-09-15, presumably until 2011-10-04\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2011-09-19, presumably until 2011-09-24\n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2011-09-15, presumably until 2011-09-21. Instructions: take 20 mg by mouth every bedtime.\n- diatrizoate, through Oral route, started on 2011-10-06, presumably until 2011-10-13\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2011-10-05, presumably until 2011-10-17\n- cetylpyridinium, through Submucosal route, started on 2011-09-29, presumably until 2011-09-29\n- 5 ML metoprolol tartrate 1 MG/ML Injection, through Intravenous route, started on 2011-09-27, presumably until 2011-10-05\n- loperamide hydrochloride 2 MG Oral Tablet, through Oral route, started on 2011-10-17, presumably until 2011-10-27, with intended 0 refill(s). Instructions: take 2 mg by mouth as needed for Diarrhea (take 1 tab after each loose bowel movement/diarrhea. ).\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2011-09-13, presumably until 2011-09-19. Instructions: take 1 Cap by mouth 2 times a day as needed for Constipation.\n- linezolid 600 MG Oral Tablet, through Oral route, started on 2011-10-13, presumably until 2011-10-27, with intended 0 refill(s). Instructions: take 1 Tab by mouth Q12H.\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2011-10-05, presumably until 2012-01-10, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n- diatrizoic acid, through Oral route, started on 2011-10-06, presumably until 2011-10-13\n- colchicine 0.6 MG Oral Tablet, through Oral route, started on 2011-09-13, presumably until 2011-10-17. Instructions: take 0.6 mg by mouth daily.\n- soybean oil 200 MG/ML Injectable Suspension, through Intravenous route, started on 2011-09-17, presumably until 2011-10-11\n- insulin aspart, human 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2011-09-17, presumably until 2011-10-14\n- 0.8 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-10-02, presumably until 2011-11-01, with intended 0 refill(s). Instructions: inject 0.8 mL subcutaneous (under the skin) Q12H.\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2011-10-04, presumably until 2011-10-17\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2011-10-06, presumably until 2011-10-10\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2011-10-05, presumably until 2012-01-10, with intended 3 refill(s). Instructions: take 1 Tab by mouth every morning with breakfast.\n- 50 ML glucose 500 MG/ML Prefilled Syringe, through Intravenous route, started on 2011-09-13, presumably until 2011-09-13\n- 2 ML ondansetron 2 MG/ML Injection, started on 2011-09-13, presumably until 2011-10-17\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-09-13, presumably until 2011-10-04\n- metoclopramide 10 MG Oral Tablet, through Oral route, started on 2011-09-14, presumably until 2011-09-15\n- lidocaine 0.05 MG/MG Medicated Patch, through Topical route, started on 2011-10-03, presumably until 2011-10-16\n- 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2011-10-04, presumably until 2011-10-05\n- aspirin 300 MG Rectal Suppository, through Rectal route, started on 2011-09-20, presumably until 2011-10-04\n- nitroglycerin 0.4 MG Sublingual Tablet, through Sublingual route, started on 2011-09-18, presumably until 2011-09-18\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2011-09-19, presumably until 2011-09-19\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2011-09-30, presumably until 2011-10-05\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2011-09-18, presumably until 2011-10-16\n- metformin hydrochloride 850 MG Oral Tablet, through Oral route, presumably until 2011-10-17. Instructions: take 850 mg by mouth Evening.\n- lidocaine hydrochloride 20 MG/ML Injectable Solution, started on 2011-09-16, presumably until 2011-09-16\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2011-09-18, presumably until 2011-10-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-09-21 15:41:46, ended at 2011-09-21 17:18:52\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; supervision only, without interpretation and report\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; interpretation and report only\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation \n\n### Condition\n- Coronary arteriosclerosis\n- Electrocardiogram abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2011-10-20 04:30:00, ended at 2011-10-27 12:15:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Manual count: 0.3 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.96 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 20 (percent)\n- MCH [Entitic mass] by Automated count: 29.6 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 8.8 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Manual count: 3.0 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 56 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 26.3 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- Albumin [Mass/volume] in Serum or Plasma: 2.3 (gram per deciliter)\n- Body height: 5' 7\" (inch (US))\n- Magnesium [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 849 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 5.1 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.9 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Manual count: 5 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 21.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 90.1 (femtoliter)\n- Prothrombin time (PT): 14.3 (second)\n- aPTT in Platelet poor plasma by Coagulation assay: 30.5 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Manual count: 3 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 94 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Manual count: 16 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 96 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.2 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.39 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Manual count: 1.1 (thousand per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.8 (milligram per deciliter)\n\n### Procedure\n- Radiologic examination, abdomen; complete, including decubitus and/or erect views\n- Collection of venous blood by venipuncture\n- Radiologic examination, abdomen; single anteroposterior view\n\n### Condition\n- Acute deep venous thrombosis of internal jugular vein\n- Intestinal obstruction\n- Obstructive sleep apnea syndrome\n- Acquired hypothyroidism\n- Nausea and vomiting\n- Venous thrombosis\n- Constipation\n- Old myocardial infarction\n- Abdominal pain\n- Altered sensation of skin\n- Essential hypertension\n- Inflammatory disorder of digestive tract\n- Non-toxic uninodular goiter\n- Acute deep vein thrombosis of lower limb\n- Anemia\n- Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm of soft tissues of abdomen\n- Pulmonary embolism with pulmonary infarction\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2011-10-20, presumably until 2011-10-23\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2011-10-20, presumably until 2012-01-10, with intended 1 refill(s). Instructions: insert 1 Suppository into the rectum daily as needed (give as needed).\n- levothyroxine sodium 0.112 MG Oral Tablet, through Oral route, started on 2011-10-23, presumably until 2011-10-27\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2011-10-20, presumably until 2011-10-27\n- hydromorphone hydrochloride 4 MG Oral Tablet, through Oral route, started on 2011-10-26, presumably until 2012-04-24, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed for Pain.\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2011-10-20, presumably until 2012-04-24, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours.\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2011-10-27, presumably until 2012-01-10, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily.\n- linezolid 600 MG Oral Tablet, through Oral route, started on 2011-10-20, presumably until 2011-10-24\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2011-10-26, presumably until 2012-01-10, with intended 0 refill(s). Instructions: take 2 Tabs by mouth 2 times a day.\n- colchicine 0.6 MG Oral Tablet, through Oral route, started on 2011-10-22, presumably until 2011-10-27\n- 0.8 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-10-20, presumably until 2011-10-27\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2011-10-22, presumably until 2011-10-26\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2011-10-20, presumably until 2011-10-26\n- lactulose 667 MG/ML Oral Solution, through Oral route, started on 2011-10-24, presumably until 2011-10-25\n- 2 ML ondansetron 2 MG/ML Injection, started on 2011-10-21, presumably until 2011-10-26\n- water 1000 MG/ML Irrigation Solution, through Topical route, started on 2011-10-24, presumably until 2011-10-24\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2011-10-20, presumably until 2011-10-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2011-11-01 00:00:00, ended at 2011-11-01 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.8 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-11-01, presumably until 2011-12-11, with intended 0 refill(s). Instructions: inject 0.8 mL subcutaneous (under the skin) Q12H.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-11-06 10:10:00, ended at 2011-11-06 10:47:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Manual count: 2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 599 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.6 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.89 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 105 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 8 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.3 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.5 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 56 (milliliter per minute per square meter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 26.4 (percent)\n- Hemoglobin [Mass/volume] in Blood: 8.9 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 92 (unit per liter)\n- MCV [Entitic volume] by Automated count: 91.3 (femtoliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.6 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Manual count: 11 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 23.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.7 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 79 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Prothrombin time (PT): 14.9 (second)\n- MCH [Entitic mass] by Automated count: 30.7 (picogram)\n- Neutrophils [#/volume] in Blood by Manual count: 4.5 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.1 (thousand per microliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Acute deep venous thrombosis of internal jugular vein\n- Pulmonary embolism with pulmonary infarction\n- Nausea and vomiting\n- Pyelonephritis\n- Venous thrombosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-11-06 10:48:00, ended at 2011-11-06 12:24:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Intestinal obstruction\n- Pulmonary embolism with pulmonary infarction\n- Venous thrombosis\n- Nausea and vomiting\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Pyelonephritis\n- Acute deep venous thrombosis of internal jugular vein\n\n### Drug\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, presumably until 2012-01-10. Instructions: take 17 g by mouth One Time.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-11-06 12:25:00, ended at 2011-11-06 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-11-27 09:48:00, ended at 2011-11-27 10:48:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.9 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.99 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.0 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.5 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.6 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 50 (milliliter per minute per square meter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.8 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.0 (percent)\n- MCV [Entitic volume] by Automated count: 93.7 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.60 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.70 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- MCH [Entitic mass] by Automated count: 31.0 (picogram)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 123 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.61 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.1 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.3 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 499 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 92 (unit per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-11-27 10:49:00, ended at 2011-11-27 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.142\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Nausea and vomiting\n- Intestinal obstruction\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-12-11 00:00:00, ended at 2011-12-11 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute deep vein thrombosis of lower limb\n\n### Drug\n- 0.8 ML enoxaparin sodium 150 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-12-11, presumably until 2012-07-14, with intended 3 refill(s). Instructions: inject 0.83 mL subcutaneous (under the skin) daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-12-14 14:23:00, ended at 2011-12-14 14:44:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.26 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.8 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 113 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.2 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.9 (percent)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.69 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 45 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.2 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 16.6 (percent)\n- MCV [Entitic volume] by Automated count: 91.9 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 18.4 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.2 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.64 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 485 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 56 (milliliter per minute per square meter)\n- Glucose [Mass/volume] in Serum or Plasma: 102 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 63.4 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-12-14 14:45:00, ended at 2011-12-14 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-12-25 00:00:00, ended at 2011-12-25 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain in pelvis\n\n### Drug\n- menthol 0.0044 MG/MG / zinc oxide 0.206 MG/MG Topical Ointment, through Topical route, started on 2011-12-25, presumably until 2013-02-12, with intended 1 refill(s). Instructions: 1 Squirt by Topical route apply as directed. Apply to anus after each bowel movement for 1 week as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-12-25 11:10:00, ended at 2011-12-25 11:57:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 120 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.0 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.7 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.7 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.19 (million per microliter)\n- MCH [Entitic mass] by Automated count: 30.2 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 410 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 46 (milliliter per minute per square meter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 73.0 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 45 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.1 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 115 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.6 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.63 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.65 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 90.9 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.60 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-12-25 11:58:00, ended at 2011-12-25 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.142\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Intestinal obstruction\n- Anemia\n- Primary malignant neoplasm of soft tissues\n- Nausea and vomiting\n- Inflammatory disorder of digestive tract\n- Diarrhea\n- Pulmonary embolism with pulmonary infarction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-01-01 00:00:00, ended at 2012-01-01 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-01-01 00:00:00, ended at 2012-01-01 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-01-10 11:59:00, ended at 2012-01-10 12:32:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 127 (unit per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.8 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 108 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 44 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 50 (milliliter per minute per square meter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diarrhea\n- Nausea and vomiting\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-01-10 12:33:00, ended at 2012-01-10 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nausea and vomiting\n- Venous thrombosis\n- Intestinal obstruction\n- Acute deep vein thrombosis of lower limb\n- Altered sensation of skin\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm of soft tissues\n- Pulmonary embolism with pulmonary infarction\n- Inflammatory disorder of digestive tract\n- Pyelonephritis\n\n### Drug\n- escitalopram 10 MG Oral Tablet, through Oral route, started on 2012-01-10, presumably until 2012-06-07, with intended 11 refill(s). Instructions: take 1 Tab by mouth daily. Take 1/2 tablet for 3 days, then increase to whole tablet.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-02-05 07:15:00, ended at 2012-02-05 08:44:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Lung field abnormal\n- Primary malignant neoplasm of soft tissues\n- Imaging of gastrointestinal tract abnormal\n- Ascites\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-02-05 08:45:00, ended at 2012-02-05 08:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.25 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.6 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 172 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 10.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 435 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 46 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.1 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 56 (milliliter per minute per square meter)\n- MCV [Entitic volume] by Automated count: 89.7 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.99 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.7 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 30.0 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 101 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.73 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 72.2 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 140 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.1 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-02-05 09:00:00, ended at 2012-02-05 11:12:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-02-05 11:13:00, ended at 2012-02-05 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.535\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Intestinal obstruction\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-02-09 00:00:00, ended at 2012-02-09 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chest pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-02-13 00:00:00, ended at 2012-02-13 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chest pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-02-14 00:00:00, ended at 2012-02-14 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-02-14 08:49:00, ended at 2012-02-14 09:18:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocytes [#/volume] in Blood by Automated count: 3.42 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.6 (percent)\n- Platelets [#/volume] in Blood by Automated count: 416 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.8 (picogram)\n- MCV [Entitic volume] by Automated count: 89.7 (femtoliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.2 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Anemia\n- Primary malignant neoplasm of soft tissues\n- Diarrhea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-02-14 09:19:00, ended at 2012-02-14 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-02-14 13:11:35, ended at 2012-02-14 14:39:26\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Primary diagnosis: Coronary atherosclerosis\n\n### Drug\n- metoprolol tartrate 50 MG Oral Tablet, through Oral route, started on 2012-02-14, presumably until 2012-04-10, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth 2 times a day. Please ensure pt takes 6.25mg (1/4 tab) twice a day.\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2012-02-14, presumably until 2016-03-31, with intended 3 refill(s). Instructions: take 1 Tab by mouth Every Day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-02-15 15:42:00, ended at 2012-02-15 16:38:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diarrhea\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-02-16 10:46:00, ended at 2012-02-16 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diarrhea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-03-04 00:00:00, ended at 2012-03-04 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Depressive disorder\n- Inflammatory disorder of digestive tract\n- Primary malignant neoplasm of soft tissues\n- Radiation-induced disorder\n- Acute deep vein thrombosis of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2012-03-20 00:00:00, ended at 2012-03-20 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Coronary atherosclerosis\n- Essential hypertension\n\n### Drug\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2012-03-20, presumably until 2012-04-10, with intended 3 refill(s). Instructions: take 0.25 Tabs by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-03-29 00:00:00, ended at 2012-03-29 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-04-01 00:00:00, ended at 2012-04-01 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-04-01 07:52:00, ended at 2012-04-01 09:12:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n\n### Condition\n- Chronic deep venous thrombosis of internal jugular vein\n- Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-04-01 09:13:00, ended at 2012-04-01 11:16:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 113 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.8 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 29.7 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.66 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.7 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 5.1 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 436 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.9 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 56 (milliliter per minute per square meter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 72.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 7.2 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 10.6 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 139 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.51 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 90.0 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 38 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.4 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.49 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.50 (million per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-04-01 11:17:00, ended at 2012-04-01 11:39:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.142\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Pulmonary embolism with pulmonary infarction\n- Inflammatory disorder of digestive tract\n- Venous thrombosis\n- Acute deep vein thrombosis of lower limb\n- Radiation-induced disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-04-01 11:40:00, ended at 2012-04-01 12:41:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 38 (unit per liter)\n- Anion gap in Serum or Plasma: 3 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 139 (unit per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 56 (milliliter per minute per square meter)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-04-01 12:42:00, ended at 2012-04-01 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-04-02 00:00:00, ended at 2012-04-02 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n- Primary malignant neoplasm of soft tissues\n- Acute deep vein thrombosis of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-04-03 12:55:34, ended at 2012-04-03 14:11:19\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Inflammatory disorder of digestive tract\n- Radiation-induced disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-04-10 12:10:00, ended at 2012-04-10 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Inflammatory disorder of digestive tract\n- Radiation-induced disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-04-10 14:12:15, ended at 2012-04-10 15:05:26\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Coronary atherosclerosis\n\n### Drug\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2012-04-10, presumably until 2013-04-10, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-04-26 00:00:00, ended at 2012-04-26 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-04-26 07:06:00, ended at 2012-04-26 09:53:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomographic angiography, chest (noncoronary), with contrast material(s), including noncontrast images, if performed, and image postprocessing\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Malignant melanoma of skin\n- Acute deep vein thrombosis of lower limb\n- Venous thrombosis\n- Ascites\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-04-26 09:54:00, ended at 2012-04-26 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Venous thrombosis\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-04-29 00:00:00, ended at 2012-04-29 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-05-06 08:10:00, ended at 2012-05-06 08:34:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-05-06 08:35:00, ended at 2012-05-06 10:33:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Ascites\n- Lung field abnormal\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-05-06 10:34:00, ended at 2012-05-06 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Inflammatory disorder of digestive tract\n- Pulmonary embolism with pulmonary infarction\n- Primary malignant neoplasm of soft tissues\n- Radiation-induced disorder\n\n### Drug\n- hydromorphone hydrochloride 4 MG Oral Tablet, through Oral route, presumably until 2012-12-25. Instructions: take  by mouth Every Day.\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, presumably until 2012-07-08. Instructions: take 20 mg by mouth every 12 hours as needed.  \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-05-08 11:06:15, ended at 2012-05-08 17:43:45\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Insomnia\n\n### Drug\n- doxepin 10 MG/ML Oral Solution, through Oral route, started on 2012-05-08, presumably until 2012-07-08, with intended 1 refill(s). Instructions: take 3 mL by mouth every bedtime.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-05-16 00:00:00, ended at 2012-05-16 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Neoplasm of uncertain behavior of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2012-05-16 00:00:00, ended at 2012-05-16 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-toxic uninodular goiter\n- Acquired hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-05-16 11:11:23, ended at 2012-05-16 12:29:43\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; single lesion\n\n### Condition\n- Primary diagnosis: Neoplasm of uncertain behavior of skin\n- Scar conditions and fibrosis of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-05-29 12:58:30, ended at 2012-05-29 17:17:13\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-06-06 07:59:00, ended at 2012-06-06 09:11:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Prothrombin time (PT): 13.7 (second)\n- aPTT in Platelet poor plasma by Coagulation assay: 26.5 (second)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Non-toxic multinodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-06-06 09:12:00, ended at 2012-06-06 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Fine needle aspiration; with imaging guidance\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n- Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation\n\n### Condition\n- Non-toxic uninodular goiter\n- Hashimoto thyroiditis\n- Non-toxic multinodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-06-07 11:05:49, ended at 2012-06-07 11:26:14\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute deep vein thrombosis of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2012-06-28 00:00:00, ended at 2012-06-28 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2012-06-28, presumably until 2012-07-12, with intended 3 refill(s). Instructions: take 1 Olsen by mouth once a week.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-07-02 00:00:00, ended at 2012-07-02 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-07-02 13:24:00, ended at 2012-07-02 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Coronary arteriosclerosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-07-03 12:02:00, ended at 2012-07-03 14:01:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 16 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 164 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.71 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.7 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.41 (million per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.36 (thousand per microliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.1 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 466 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.0 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 97 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.81 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 50 (milliliter per minute per square meter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.4 (picogram)\n- Thyrotropin [Units/volume] in Serum or Plasma: 4.08 (milli-international unit per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 22 (nanogram per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 6 (nanogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.8 (percent)\n- MCV [Entitic volume] by Automated count: 90.3 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.2 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.9 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.1 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Vitamin D deficiency\n- Non-toxic uninodular goiter\n- Acquired hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-07-03 14:02:00, ended at 2012-07-03 14:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm of soft tissues\n- Acquired hypothyroidism\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-07-03 15:00:00, ended at 2012-07-03 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-07-08 09:34:00, ended at 2012-07-08 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- Genetic counseling\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, presumably until 2012-12-25. Instructions: take 10 mg by mouth every 12 hours as needed.  \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-07-10 00:00:00, ended at 2012-07-10 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-07-10 00:00:00, ended at 2012-07-10 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-07-12 00:00:00, ended at 2012-07-12 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2012-07-12, presumably until 2012-09-04, with intended 3 refill(s). Instructions: take 1 Trammell by mouth once a week.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-07-19 00:00:00, ended at 2012-07-19 00:00:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-08-07 10:24:00, ended at 2012-08-07 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 12 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.63 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.7 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 13.3 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.8 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.4 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 116 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.4 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 157 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.73 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.70 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 451 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 28.5 (picogram)\n- MCV [Entitic volume] by Automated count: 87.1 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.88 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 71.3 (percent)\n- Globulin [Mass/volume] in Serum: 4.4 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 50 (milliliter per minute per square meter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.3 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-08-08 08:19:00, ended at 2012-08-08 23:59:00\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Abdominal pain\n- Ascites\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-08-08 12:59:54, ended at 2012-08-08 16:09:36\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-08-08 14:12:06, ended at 2012-08-08 14:50:25\nThe patient in this visit was 51 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic ischemic heart disease\n\n### Drug\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2012-08-08, presumably until 2012-11-28, with intended 12 refill(s). Instructions: take 0.5 Tabs by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-08-27 15:00:00, ended at 2012-08-27 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-08-28 11:58:25, ended at 2012-08-28 12:58:54\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Diarrhea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-08-28 13:03:00, ended at 2012-08-28 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 23 (nanogram per milliliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 12 (nanogram per milliliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 11 (nanogram per milliliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Diarrhea\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-08-29 13:41:00, ended at 2012-08-29 13:45:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diarrhea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-08-29 13:46:00, ended at 2012-08-29 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diarrhea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-08-30 00:00:00, ended at 2012-08-30 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of intestine\n\n### Drug\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2012-09-20, presumably until 2012-10-18, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-09-04 00:00:00, ended at 2012-09-04 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2012-09-04, presumably until 2013-05-13, with intended 3 refill(s). Instructions: take 1 Robbins by mouth once a week.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-09-10 08:41:00, ended at 2012-09-10 12:25:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- Other nonoperative measurements and examinations\n- Breath hydrogen or methane test (eg, for detection of lactase deficiency, fructose intolerance, bacterial overgrowth, or oro-cecal gastrointestinal transit)\n\n### Condition\n- Abdominal pain\n- Essential hypertension\n- Type 2 diabetes mellitus without complication\n- Hyperlipidemia\n\n### Drug\n- lactulose 667 MG/ML Oral Solution, through Oral route, started on 2012-09-10, presumably until 2012-09-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-09-16 00:00:00, ended at 2012-09-16 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of intestine\n\n### Drug\n- rifaximin 200 MG Oral Tablet, through Oral route, started on 2012-09-16, presumably until 2012-10-14, with intended 0 refill(s). Instructions: take 2 Tabs by mouth 3 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-10-14 00:00:00, ended at 2012-10-14 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-10-14 10:50:00, ended at 2012-10-14 12:16:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Monocytes [#/volume] in Blood by Automated count: 0.81 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.82 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 475 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- MCV [Entitic volume] by Automated count: 88.9 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.4 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.9 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 10.9 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.4 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 101 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.4 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 157 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 50 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.5 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 73.8 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.59 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.9 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 29.0 (picogram)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-10-14 12:17:00, ended at 2012-10-14 13:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-10-14 14:00:00, ended at 2012-10-14 14:54:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-10-14 14:55:00, ended at 2012-10-14 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Radiation-induced disorder\n- Primary malignant neoplasm of soft tissues\n- Inflammatory disorder of digestive tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-10-16 11:01:06, ended at 2012-10-16 16:12:56\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-10-18 00:00:00, ended at 2012-10-18 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Radiation-induced disorder\n- Inflammatory disorder of digestive tract\n- Diarrhea\n\n### Drug\n- mesalamine 800 MG Delayed Release Oral Tablet, through Oral route, started on 2012-10-18, presumably until 2013-03-10, with intended 3 refill(s). Instructions: take 3 Tabs by mouth Every Day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-10-18 11:15:54, ended at 2012-10-18 11:55:04\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Diarrhea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-10-18 14:13:00, ended at 2012-10-18 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of extremity veins including responses to compression and other maneuvers; unilateral or limited study\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Acute deep venous thrombosis of internal jugular vein\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-10-23 00:00:00, ended at 2012-10-23 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Crohn's disease of small intestine\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-11-06 08:00:00, ended at 2012-11-06 08:49:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Kidney stone\n- Primary malignant neoplasm of soft tissues\n- Ascites\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-11-06 08:50:00, ended at 2012-11-06 08:50:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diarrhea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-11-06 08:51:00, ended at 2012-11-06 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 16 (nanogram per milliliter)\n- MCV [Entitic volume] by Automated count: 88.8 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.7 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.1 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.0 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 4.02 (milli-international unit per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 23 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 148 (unit per liter)\n- MCH [Entitic mass] by Automated count: 30.0 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 7 (nanogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.35 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 55 (milliliter per minute per square meter)\n- Glucose [Mass/volume] in Serum or Plasma: 88 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 393 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Inflammatory disorder of digestive tract\n- Radiation-induced disorder\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-11-06 10:09:03, ended at 2012-11-06 10:55:20\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n- Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-11-06 15:05:05, ended at 2012-11-06 16:02:48\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-11-11 00:00:00, ended at 2012-11-11 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-11-11 08:41:00, ended at 2012-11-11 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-11-12 00:00:00, ended at 2012-11-12 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diarrhea\n- Primary diagnosis: Acquired hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.112 MG Oral Tablet, through Oral route, started on 2012-11-12, presumably until 2013-05-01, with intended 3 refill(s). Instructions: take 1 Tab by mouth as directed. Take 1.5 pills on Sun, 1 pill Mon-Sat\n- amylase 120000 UNT / lipase 24000 UNT / protease 76000 UNT Delayed Release Oral Capsule, through Oral route, started on 2012-11-12, presumably until 2013-02-12, with intended 3 refill(s). Instructions: take 1-2 Caps by mouth 3 times a day with meals.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-11-13 00:00:00, ended at 2012-11-13 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-11-13 00:00:00, ended at 2012-11-13 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-11-13 00:00:00, ended at 2012-11-13 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vitamin D deficiency\n\n### Drug\n- cholecalciferol 0.125 MG Oral Tablet, through Oral route, started on 2012-11-13, presumably until 2013-02-12, with intended 3 refill(s). Instructions: take 5,000 Units by mouth Every Day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-11-13 09:17:01, ended at 2012-11-13 12:17:07\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute deep vein thrombosis of lower limb\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2012-11-28 00:00:00, ended at 2012-11-28 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic ischemic heart disease\n\n### Drug\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2012-11-28, presumably until 2013-11-28, with intended 11 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-12-24 08:53:01, ended at 2012-12-24 09:29:13\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abdominal pain\n\n### Drug\n- gabapentin 300 MG Oral Tablet, through Oral route, started on 2012-12-24, presumably until 2013-02-12, with intended 3 refill(s). Instructions: take 1 Tab by mouth 3 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-12-25 12:02:59, ended at 2012-12-25 16:00:36\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2012-12-25 14:49:00, ended at 2012-12-26 17:45:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 40 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: N/A (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 200 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.2 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.3 (percent)\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.79 (milli-international unit per liter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 119 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.82 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 89.6 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 70.7 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.5 (percent)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 0.9 (nanogram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.09 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.49 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 51.9 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 43 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 102 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.87 (thousand per microliter)\n- Prothrombin time (PT): 14.2 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 62 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 76 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.9 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.2 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.2 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 446 (thousand per microliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 87 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; supervision only, without interpretation and report\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; interpretation and report only\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; tracing only, without interpretation and report\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation \n\n### Condition\n- Inflammatory disorder of digestive tract\n- Anemia\n- Type 2 diabetes mellitus without complication\n- Acute deep vein thrombosis of lower limb\n- Diarrhea\n- Hyperlipidemia\n- Acute myocardial infarction\n- Chronic ischemic heart disease\n- Coronary atherosclerosis\n- Disorder of kidney and/or ureter\n- Essential hypertension\n- Obesity\n- Acquired hypothyroidism\n- Primary diagnosis: Chest pain\n- Coronary arteriosclerosis\n- Pulmonary embolism with pulmonary infarction\n- Obstructive sleep apnea syndrome\n- Vitamin D deficiency\n- Radiation-induced disorder\n\n### Drug\n- levothyroxine sodium 0.112 MG Oral Tablet, through Oral route, started on 2012-12-26, presumably until 2012-12-26\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2012-12-26, presumably until 2012-12-26\n- hydromorphone hydrochloride 4 MG Oral Tablet, through Oral route, presumably until 2015-10-01. Instructions: take 8 mg by mouth as needed (only as needed only takes it 3 times a month). Every 72 hours\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2012-12-25, presumably until 2012-12-25\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2012-12-25, presumably until 2012-12-25\n- colchicine 0.6 MG Oral Tablet, through Oral route, started on 2012-12-26, presumably until 2012-12-26\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2012-12-26, presumably until 2012-12-26\n- mesalamine 400 MG Delayed Release Oral Tablet, through Oral route, started on 2012-12-26, presumably until 2012-12-26\n- amylase 120000 UNT / lipase 24000 UNT / protease 76000 UNT Delayed Release Oral Capsule, through Oral route, started on 2012-12-26, presumably until 2012-12-26\n- 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, presumably until 2015-10-01. Instructions: take 20 mg by mouth as needed. Only takes about 3 times a month\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2012-12-26, presumably until 2012-12-26\n- clopidogrel 75 MG Oral Tablet, through Oral route, started on 2012-12-25, presumably until 2012-12-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-01-23 00:00:00, ended at 2013-01-23 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-01-29 13:06:33, ended at 2013-01-29 13:50:08\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Coronary atherosclerosis\n- Chronic ischemic heart disease\n- Primary diagnosis: Chest pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-02-06 08:55:47, ended at 2013-02-06 09:56:44\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Generally unwell\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-06 10:19:00, ended at 2013-02-06 12:47:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 190 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.58 (million per microliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 6 (nanogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 69.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 468 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 4.22 (milli-international unit per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.91 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.2 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.8 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 15 (nanogram per milliliter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 88.8 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.7 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.12 (thousand per microliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 9 (nanogram per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 38 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 55 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 28.0 (picogram)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- MCHC [Mass/volume] by Automated count: 31.5 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.75 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Non-toxic uninodular goiter\n- Crohn's disease of small intestine\n- Vitamin D deficiency\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-06 12:48:00, ended at 2013-02-06 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Ascites\n- Pathological fracture of vertebra\n- Acquired renal cystic disease\n- Closed fracture lumbar vertebra\n- Kidney stone\n- Lung field abnormal\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-10 08:55:00, ended at 2013-02-10 10:11:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Post-surgical malabsorption\n- Primary diagnosis: Closed fracture\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2013-02-10, presumably until 2015-03-29, with intended 6 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-10 10:12:00, ended at 2013-02-10 16:43:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.142\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-02-10 15:03:01, ended at 2013-02-10 16:34:28\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Generalized abdominal pain\n- Iron deficiency anemia\n- Primary diagnosis: Post-surgical malabsorption\n- Diarrhea\n- Flatulence, eructation and gas pain\n- Megaloblastic anemia due to vitamin B-12 deficiency\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-10 16:44:00, ended at 2013-02-10 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Ferritin [Mass/volume] in Serum or Plasma: 3 (nanogram per milliliter)\n- Iron [Mass/volume] in Serum or Plasma: 27 (microgram per deciliter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 256 (picogram per milliliter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 398 (microgram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 7 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Post-surgical malabsorption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-12 09:14:00, ended at 2013-02-12 19:30:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hematocrit [Volume Fraction] of Blood: 31 (percent)\n- Sodium [Moles/volume] in Blood: 141 (millimole per liter)\n- Body height: 5' 6.5\" (inch (US))\n- Potassium [Moles/volume] in Blood: 4.8 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 10.5 (gram per deciliter)\n\n### Procedure\n- Coronary arteriography using two catheters\n- Collection of venous blood by venipuncture\n- Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation\n\n### Condition\n- Pure hypercholesterolemia\n- Essential hypertension\n- Angina pectoris\n- Abnormal results of cardiovascular function studies\n- Coronary arteriosclerosis\n- Old myocardial infarction\n- Obesity\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- diazepam 5 MG Oral Tablet, through Oral route, started on 2013-02-12, presumably until 2013-02-12\n- aspirin 325 MG Oral Tablet, through Oral route, started on 2013-02-12, presumably until 2013-02-12\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-02-12, presumably until 2013-02-12\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2013-02-12, presumably until 2013-02-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-14 09:45:00, ended at 2013-02-14 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine)\n\n### Condition\n- Disorder of bone and articular cartilage\n- Disorder of endocrine system\n- Closed fracture\n- Osteoporosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2013-02-18 00:00:00, ended at 2013-02-18 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acquired hypothyroidism\n- Primary diagnosis: Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-02-19 00:00:00, ended at 2013-02-19 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-10 12:25:00, ended at 2013-03-10 18:35:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- MCV [Entitic volume] by Automated count: 90.3 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.3 (percent)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 527 (picogram per milliliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 4 (nanogram per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 82 (milligram per deciliter)\n- Iron [Mass/volume] in Serum or Plasma: 38 (microgram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.2 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 20.9 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.15 (thousand per microliter)\n- Reticulocytes [#/volume] in Blood by Automated count: 44.3 (thousand per microliter)\n- Reticulocytes/100 erythrocytes in Blood by Automated count: 1.16 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.6 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.1 (gram per deciliter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 420 (microgram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.2 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.58 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 435 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.4 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 183 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.9 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 38 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.81 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 9 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.30 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of iron metabolism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-03-10 14:11:38, ended at 2013-03-10 15:19:51\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diarrhea\n- Primary diagnosis: Generalized abdominal pain\n- Iron deficiency anemia\n- Flatulence, eructation and gas pain\n- Post-surgical malabsorption\n\n### Drug\n- amitriptyline hydrochloride 10 MG Oral Tablet, through Oral route, started on 2013-03-10, presumably until 2013-05-05, with intended 2 refill(s). Instructions: take 1 Tab by mouth every bedtime.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-10 18:36:00, ended at 2013-03-10 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; thoracic\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; cervical\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; lumbar\n\n### Condition\n- Pathological fracture of vertebra\n- Primary malignant neoplasm of soft tissues\n- Abnormal findings on diagnostic imaging of skull and head\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-11 13:18:00, ended at 2013-03-11 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.961\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of iron metabolism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-03-12 09:57:34, ended at 2013-03-12 16:34:53\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Malaise\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-03-18 00:00:00, ended at 2013-03-18 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Post-surgical malabsorption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-04-25 00:00:00, ended at 2013-04-25 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Coronary atherosclerosis\n\n### Drug\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2013-04-25, presumably until 2014-05-12, with intended 11 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2013-05-01 00:00:00, ended at 2013-05-01 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acquired hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.137 MG Oral Tablet, through Oral route, started on 2013-05-01, presumably until 2014-05-01, with intended 3 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-05-01 00:00:00, ended at 2013-05-01 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-01 09:23:00, ended at 2013-05-01 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 5.34 (milli-international unit per liter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 19 (nanogram per milliliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 19 (nanogram per milliliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Non-toxic uninodular goiter\n- Vitamin D deficiency\n- Post-surgical malabsorption\n- Disorder of iron metabolism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-05-01 10:01:20, ended at 2013-05-01 10:58:03\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n- Acquired hypothyroidism\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-02 09:23:00, ended at 2013-05-02 14:22:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Anemia\n- Acquired hypothyroidism\n- Diarrhea\n- Iron deficiency anemia\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2013-05-02, presumably until 2013-05-02\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2013-05-02, presumably until 2013-05-02\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-05-02, presumably until 2013-05-02\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2013-05-02, presumably until 2013-05-02\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-05-02, presumably until 2013-05-02\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2013-05-02, presumably until 2013-05-02\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-02 14:23:00, ended at 2013-05-02 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n\n### Condition\n- Non-toxic multinodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-05-05 00:00:00, ended at 2013-05-05 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-05 08:00:00, ended at 2013-05-05 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Anemia\n- Primary diagnosis: Iron deficiency anemia\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2013-05-05, presumably until 2013-05-05\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-05-05, presumably until 2013-05-05\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2013-05-05, presumably until 2013-05-05\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2013-05-05, presumably until 2013-05-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-05-05 12:31:58, ended at 2013-05-05 14:00:52\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diarrhea\n- Nausea and vomiting\n- Mineral deficiency\n- Primary diagnosis: Post-surgical malabsorption\n- Generalized abdominal pain\n\n### Drug\n- zinc sulfate 220 MG Oral Capsule, through Oral route, started on 2013-05-05, presumably until 2014-03-18, with intended 1 refill(s). Instructions: take 1 Cap by mouth daily.\n- amitriptyline hydrochloride 10 MG Oral Tablet, through Oral route, started on 2013-05-05, presumably until 2013-06-03, with intended 2 refill(s). Instructions: take 3 Tabs by mouth every bedtime.\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2013-05-05, presumably until 2014-04-11, with intended 2 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed for Nausea.\n- dicyclomine hydrochloride 10 MG Oral Capsule, through Oral route, started on 2013-05-05, presumably until 2013-08-11, with intended 2 refill(s). Instructions: take 1 Cap by mouth 4 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-06 12:47:00, ended at 2013-05-06 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Anemia\n- Primary diagnosis: Iron deficiency anemia\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2013-05-06, presumably until 2013-05-06\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2013-05-06, presumably until 2013-05-06\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-05-06, presumably until 2013-05-06\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2013-05-06, presumably until 2013-05-06\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-07 08:05:00, ended at 2013-05-07 16:29:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-05-07 15:09:19, ended at 2013-05-07 16:17:14\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chest pain\n- Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-07 16:30:00, ended at 2013-05-07 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 14 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 29.4 (picogram)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.61 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.76 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.3 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 89.8 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 68.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 425 (thousand per microliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 22 (nanogram per milliliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 22 (nanogram per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 50 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.1 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.53 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.30 (million per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 46 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 165 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.7 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.8 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.7 (percent)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 8.10 (milli-international unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.9 (percent)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Acquired hypothyroidism\n- Anemia\n- Diarrhea\n- Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Iron deficiency anemia\n- Vitamin D deficiency\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2013-05-07, presumably until 2013-05-07\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2013-05-07, presumably until 2013-05-07\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-05-07, presumably until 2013-05-07\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-05-07, presumably until 2013-05-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-08 14:20:00, ended at 2013-05-08 14:47:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 175 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.32 (million per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.70 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 20.8 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.4 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.6 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.02 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.28 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.7 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.2 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 29.0 (picogram)\n- MCV [Entitic volume] by Automated count: 89.7 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 64.7 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 438 (thousand per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 55 (milliliter per minute per square meter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.8 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-08 14:48:00, ended at 2013-05-08 16:22:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-08 16:23:00, ended at 2013-05-08 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Primary diagnosis: Iron deficiency anemia\n- Anemia\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2013-05-08, presumably until 2013-05-08\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2013-05-08, presumably until 2013-05-08\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-05-08, presumably until 2013-05-08\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-05-08, presumably until 2013-05-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-09 08:00:00, ended at 2013-05-09 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Ferritin [Mass/volume] in Serum or Plasma: 239 (nanogram per milliliter)\n- Iron [Mass/volume] in Serum or Plasma: 529 (microgram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 162 (percent)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 326 (microgram per deciliter)\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Collection of venous blood by venipuncture\n\n### Condition\n- Anemia\n- Primary diagnosis: Iron deficiency anemia\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2013-05-09, presumably until 2013-05-09\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2013-05-09, presumably until 2013-05-09\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-05-09, presumably until 2013-05-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2013-05-13 00:00:00, ended at 2013-05-13 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2013-05-13, presumably until 2013-08-05, with intended 1 refill(s). Instructions: take 1 Cap by mouth as directed. Take twice/week x 4 weeks then once/week x 3 months.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-05-16 00:00:00, ended at 2013-05-16 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-19 08:00:00, ended at 2013-05-19 09:16:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Mononeuritis\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-19 09:17:00, ended at 2013-05-19 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 424 (picogram per milliliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.2 (nanogram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.69 (milli-international unit per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Mononeuritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-06-03 14:26:43, ended at 2013-06-03 16:31:26\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Generalized abdominal pain\n- Diarrhea\n- Primary diagnosis: Disorder of the peripheral nervous system\n\n### Drug\n- amitriptyline hydrochloride 10 MG Oral Tablet, through Oral route, started on 2013-06-03, presumably until 2013-08-11, with intended 3 refill(s). Instructions: take 5 Tabs by mouth every bedtime.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-04 10:58:00, ended at 2013-06-04 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 502 (picogram per milliliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 5.3 (percent)\n- Ferritin [Mass/volume] in Serum or Plasma: 62 (nanogram per milliliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of the peripheral nervous system\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-07-10 00:00:00, ended at 2013-07-10 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-10 09:03:00, ended at 2013-07-10 13:14:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocytes [#/volume] in Blood by Automated count: 3.97 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Iron [Mass/volume] in Serum or Plasma: 73 (microgram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.3 (percent)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 21 (nanogram per milliliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.3 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 112 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 101 (milligram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 24 (percent)\n- MCV [Entitic volume] by Automated count: 94.8 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.76 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 63.9 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.6 (percent)\n- Platelets [#/volume] in Blood by Automated count: 368 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 193 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 9 (nanogram per milliliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.5 (percent)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.4 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 144 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 26 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Body height: 5' 6.5\" (inch (US))\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 55 (milliliter per minute per square meter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 302 (microgram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.2 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 3.20 (thousand per microliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 12 (nanogram per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Ferritin [Mass/volume] in Serum or Plasma: 43 (nanogram per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.0 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.92 (thousand per microliter)\n\n### Procedure\n- Other nonoperative measurements and examinations\n- Collection of venous blood by venipuncture\n- Breath hydrogen or methane test (eg, for detection of lactase deficiency, fructose intolerance, bacterial overgrowth, or oro-cecal gastrointestinal transit)\n\n### Condition\n- Anemia\n- Diarrhea\n- Hyperlipidemia\n- Vitamin D deficiency\n- Essential hypertension\n- Acquired hypothyroidism\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-11 14:40:00, ended at 2013-07-11 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-07-14 12:20:46, ended at 2013-07-14 13:31:27\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Diarrhea\n- Flatulence, eructation and gas pain\n- Nausea\n- Disorder of intestine\n\n### Drug\n- cholestyramine resin 4000 MG Powder for Oral Suspension, through Oral route, started on 2013-07-14, presumably until 2013-10-13, with intended 1 refill(s). Instructions: take 4 g by mouth every other day.\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2013-07-14, presumably until 2013-08-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-07-21 00:00:00, ended at 2013-07-21 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-08-05 00:00:00, ended at 2013-08-05 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2013-08-05, presumably until 2013-08-07, with intended 1 refill(s). Instructions: take 1 Cap by mouth as directed. Take twice/week x 4 weeks then once/week x 3 months.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2013-08-07 00:00:00, ended at 2013-08-07 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2013-08-07, presumably until 2013-09-19, with intended 0 refill(s). Instructions: take 1 Cap by mouth as directed. Take twice/week x 4 weeks then once/week x 3 months.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-08-07 15:04:39, ended at 2013-08-07 16:18:32\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-08-07 15:33:00, ended at 2013-08-07 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.7 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 33 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 175 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 16.3 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.6 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 69.6 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 112 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 50 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.5 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 144 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.91 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.5 (percent)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 95.9 (femtoliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.6 (percent)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.25 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.7 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.87 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 331 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.4 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.23 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-08-08 16:16:00, ended at 2013-08-08 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Lung field abnormal\n- Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm of soft tissues of abdomen\n- Ascites\n- Closed fracture\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-08-11 08:00:00, ended at 2013-08-11 08:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-08-11 09:00:00, ended at 2013-08-11 12:45:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-08-11 12:46:00, ended at 2013-08-11 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Needle electromyography, each extremity, with related paraspinal areas, when performed, done with nerve conduction, amplitude and latency/velocity study; limited (List separately in addition to code for primary procedure)\n- Nerve conduction studies; 7-8 studies\n\n### Condition\n- Inflammatory and toxic neuropathy\n- Disorder of the peripheral nervous system\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-08-12 12:03:00, ended at 2013-08-12 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Electrocardiogram abnormal\n- Anemia\n- Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Iron deficiency anemia\n- Acquired hypothyroidism\n- Chest pain\n- Diarrhea\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2013-08-12, presumably until 2013-08-12\n- 2 ML iron-dextran complex 50 MG/ML Injection, started on 2013-08-12, presumably until 2013-08-12\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2013-08-12, presumably until 2013-08-12\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2013-08-12, presumably until 2013-08-12\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2013-08-12, presumably until 2013-08-12\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-08-12, presumably until 2013-08-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-08-13 13:15:40, ended at 2013-08-13 14:08:58\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Acquired hypothyroidism\n- Primary diagnosis: Disorder of the peripheral nervous system\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-08-13 14:51:00, ended at 2013-08-13 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-09 12:07:00, ended at 2013-09-09 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Diarrhea\n- Primary malignant neoplasm of soft tissues\n- Anemia\n- Primary diagnosis: Iron deficiency anemia\n- Acquired hypothyroidism\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-09-09, presumably until 2013-09-09\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-09-09, presumably until 2013-09-09\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2013-09-09, presumably until 2013-09-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-10 11:30:00, ended at 2013-09-10 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Cardiac arrhythmia\n- Anemia\n- Chest pain\n- Electrocardiogram abnormal\n- Primary diagnosis: Iron deficiency anemia\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2013-09-10, presumably until 2013-09-10\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-09-10, presumably until 2013-09-10\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2013-09-10, presumably until 2013-09-10\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-09-10, presumably until 2013-09-10\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2013-09-10, presumably until 2013-09-10\n- methylprednisolone 125 MG Injection, started on 2013-09-10, presumably until 2013-09-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-09-10 15:14:29, ended at 2013-09-10 17:23:51\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-11 11:30:00, ended at 2013-09-11 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Anemia\n- Primary diagnosis: Iron deficiency anemia\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2013-09-11, presumably until 2013-09-11\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2013-09-11, presumably until 2013-09-11\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-09-11, presumably until 2013-09-11\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-09-11, presumably until 2013-09-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-12 11:30:00, ended at 2013-09-12 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Iron deficiency anemia\n- Anemia\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2013-09-12, presumably until 2013-09-12\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2013-09-12, presumably until 2013-09-12\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-09-12, presumably until 2013-09-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-13 07:30:00, ended at 2013-09-13 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, any joint of lower extremity; without contrast material(s), followed by contrast material(s) and further sequences\n\n### Condition\n- Joint pain\n- Osteoarthritis of knee\n- Disorder of musculoskeletal system\n- Sprain of cruciate ligament of knee\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-15 11:30:00, ended at 2013-09-15 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Primary diagnosis: Iron deficiency anemia\n- Anemia\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2013-09-15, presumably until 2013-09-15\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2013-09-15, presumably until 2013-09-15\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-09-15, presumably until 2013-09-15\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2013-09-15, presumably until 2013-09-15\n- methylprednisolone 125 MG Injection, started on 2013-09-15, presumably until 2013-09-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-09-19 00:00:00, ended at 2013-09-19 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2013-09-19, presumably until 2014-02-24, with intended 0 refill(s). Instructions: take 1 Cap by mouth as directed. Take twice/week x 8 weeks then once/week x 3 months.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-09-23 00:00:00, ended at 2013-09-23 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Coronary atherosclerosis\n- Primary malignant neoplasm of soft tissues\n- Iron deficiency anemia\n- Disorder of musculoskeletal system\n- Primary diagnosis: Sprain of cruciate ligament of knee\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-09-30 12:42:31, ended at 2013-09-30 15:32:27\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Osteoarthritis of knee\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-30 12:44:00, ended at 2013-09-30 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, knee; 3 views\n- Bone length studies (orthoroentgenogram, scanogram)\n\n### Condition\n- Osteoarthritis of knee\n- Joint pain\n- Loose body in knee\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-13 14:51:00, ended at 2013-10-13 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 5.5 (percent)\n\n### Procedure\n- Pre-surgery evaluation\n- Collection of venous blood by venipuncture\n\n### Condition\n- Acute deep vein thrombosis of lower limb\n- Old myocardial infarction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-10-21 13:05:42, ended at 2013-10-21 14:30:57\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Flatulence, eructation and gas pain\n- Primary diagnosis: Post-surgical malabsorption\n- Diarrhea\n- Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-10-22 10:03:58, ended at 2013-10-22 11:50:10\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Osteoarthritis\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-11-05 13:19:51, ended at 2013-11-05 13:45:04\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Senile hyperkeratosis\n- Primary diagnosis: Benign neoplasm of skin of trunk\n- Onychomycosis due to dermatophyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-11-06 09:44:00, ended at 2013-11-06 10:46:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Anemia\n- Primary diagnosis: Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-11-06 10:47:00, ended at 2013-11-06 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.79 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 111 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 109 (milligram per deciliter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 244 (microgram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 127 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.74 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Reticulocytes/100 erythrocytes in Blood by Automated count: 1.75 (percent)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 135 (nanogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.0 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.6 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Iron [Mass/volume] in Serum or Plasma: 75 (microgram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 76.6 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.72 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.82 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.4 (percent)\n- Reticulocytes [#/volume] in Blood by Automated count: 64.9 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Hemoglobin [Mass/volume] in Blood: 12.3 (gram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 31 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.5 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 11.0 (percent)\n- MCH [Entitic mass] by Automated count: 33.0 (picogram)\n- MCV [Entitic volume] by Automated count: 99.5 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 300 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-11-06 13:59:14, ended at 2013-11-06 15:09:05\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2013-11-07 00:00:00, ended at 2013-11-07 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-11-07 10:20:52, ended at 2013-11-07 10:46:07\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-11-07 10:53:00, ended at 2013-11-07 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 7 (nanogram per milliliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.25 (milli-international unit per liter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 34 (nanogram per milliliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 27 (nanogram per milliliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Vitamin D deficiency\n- Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-11-27 09:03:47, ended at 2013-11-27 17:46:01\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-11-27 11:05:07, ended at 2013-11-27 13:51:17\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-12-10 14:14:02, ended at 2013-12-10 15:09:25\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- Pre-surgery evaluation\n\n### Condition\n- Primary diagnosis: Primary cardiomyopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-12-11 10:12:12, ended at 2013-12-11 17:21:20\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-12-15 00:00:00, ended at 2013-12-15 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic ischemic heart disease\n\n### Drug\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2013-12-15, presumably until 2014-11-18, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-01-16 00:00:00, ended at 2014-01-16 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-06 14:29:00, ended at 2014-02-06 16:19:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 56 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.2 (percent)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 273 (microgram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 28 (percent)\n- MCH [Entitic mass] by Automated count: 32.9 (picogram)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 17.0 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.5 (percent)\n- Reticulocytes/100 erythrocytes in Blood by Automated count: 1.57 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 148 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.77 (million per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 55 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.9 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 370 (thousand per microliter)\n- Iron [Mass/volume] in Serum or Plasma: 76 (microgram per deciliter)\n- Reticulocytes [#/volume] in Blood by Automated count: 59.3 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.9 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.4 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 98.8 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 72.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 135 (nanogram per milliliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.34 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.70 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-06 16:20:00, ended at 2014-02-06 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Lymphadenopathy\n- Primary malignant neoplasm of soft tissues of abdomen\n- Ascites\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-09 09:00:00, ended at 2014-02-09 10:14:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.496\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Old myocardial infarction\n- Radiation-induced disorder\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Inflammatory disorder of digestive tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-09 10:15:00, ended at 2014-02-09 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.496\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Old myocardial infarction\n- Inflammatory disorder of digestive tract\n- Radiation-induced disorder\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-10 09:45:00, ended at 2014-02-10 11:11:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-10 11:12:00, ended at 2014-02-10 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-02-11 13:10:49, ended at 2014-02-11 13:53:47\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of the peripheral nervous system\n- Primary malignant neoplasm of soft tissues\n- Acquired hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-11 14:56:00, ended at 2014-02-11 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-19 12:43:00, ended at 2014-02-20 12:28:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 135 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.91 (million per microliter)\n- MCV [Entitic volume] by Automated count: 99.8 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.6 (percent)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.12 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 71.0 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Body height: 5' 6\" (inch (US))\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 33.2 (picogram)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.1 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.20 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 324 (thousand per microliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 77 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.9 (percent)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.03 (thousand per microliter)\n- Prothrombin time (PT): 13.7 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.9 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.0 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Monocytes [#/volume] in Blood by Automated count: 0.68 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.8 (gram per deciliter)\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Ultrasonography of digestive system\n- Endoscopy and biopsy of upper gastrointestinal tract\n- Collection of venous blood by venipuncture\n- Radiologic examination, chest; single view, frontal\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s) (includes endoscopic ultrasound examination of the esophagus, stomach, and either the duodenum or a surgicall\n\n### Condition\n- Acute postoperative pain\n- Conduction disorder of the heart\n- Neoplasm of uncertain behavior of digestive organ\n- Primary diagnosis: Postprocedural state finding\n- Cardiac arrhythmia\n- Localized swelling, mass and lump, trunk\n- Neoplasm of intra-abdominal lymph nodes\n- Atelectasis\n- Coronary arteriosclerosis\n- Lung field abnormal\n- Abdominal pain\n- Hyperlipidemia\n- Post-surgical hypoinsulinemia\n- Secondary diabetes mellitus\n- Acquired hypothyroidism\n- Obstructive sleep apnea syndrome\n- Lymphadenopathy\n- Ascites\n- Electrocardiogram abnormal\n- Old myocardial infarction\n\n### Drug\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2014-02-20, presumably until 2014-03-18, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2014-02-20, presumably until 2014-02-20\n- levothyroxine sodium 0.137 MG Oral Tablet, through Oral route, started on 2014-02-20, presumably until 2014-02-20\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-02-19, presumably until 2014-02-20\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2014-02-19, presumably until 2014-02-20\n- 100 ML metronidazole 5 MG/ML Injection, through Intravenous route, started on 2014-02-19, presumably until 2014-02-20\n- midazolam 1 MG/ML Injectable Solution, started on 2014-02-19, presumably until 2014-02-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-02-24 00:00:00, ended at 2014-02-24 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2014-02-24, presumably until 2014-06-05, with intended 0 refill(s). Instructions: take 1 Cap by mouth as directed. Take twice/week x 8 weeks then once/week x 3 months.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-02 14:19:00, ended at 2014-03-02 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.142\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-04 12:36:00, ended at 2014-03-04 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-10 09:00:00, ended at 2014-03-10 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Lymphadenopathy\n- Primary malignant neoplasm of soft tissues of abdomen\n- Neoplasm of lymph node\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-03-13 00:00:00, ended at 2014-03-13 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-18 10:49:00, ended at 2014-03-18 11:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.142\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-18 12:00:00, ended at 2014-03-18 15:13:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- ciprofloxacin 250 MG Oral Tablet, presumably until 2014-04-01. Instructions: Take 250 mg by mouth twice daily. For 2 days for prophylaxis.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-18 15:14:00, ended at 2014-03-18 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.142\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-03-23 00:00:00, ended at 2014-03-23 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-27 17:07:00, ended at 2014-03-27 18:56:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-03-27 18:57:00, ended at 2014-03-27 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, upper extremity, other than joint; without contrast material(s), followed by contrast material(s) and further sequences\n\n### Condition\n- Disorder of bone and articular cartilage\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-01 08:12:00, ended at 2014-04-01 10:14:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-01 10:15:00, ended at 2014-04-01 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-02 13:51:00, ended at 2014-04-02 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n\n### Condition\n- Non-toxic multinodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-04-08 00:00:00, ended at 2014-04-08 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- MCH [Entitic mass] by Automated count: 33.0 (picogram)\n- aPTT in Platelet poor plasma by Coagulation assay: 29.4 (second)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.1 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.2 (percent)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.4 (thousand per microliter)\n- Prothrombin time (PT): 12.7 (second)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Body height: 5' 6.5\" (inch (US))\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- Platelets [#/volume] in Blood by Automated count: 273 (thousand per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 55 (milliliter per minute per square meter)\n- Glucose [Mass/volume] in Serum or Plasma: 102 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 98.1 (femtoliter)\n- Hemoglobin [Mass/volume] in Blood: 12.9 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 33 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.90 (million per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Pre-surgery evaluation\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-04-08 00:00:00, ended at 2014-04-08 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-08 13:00:00, ended at 2014-04-08 16:38:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-08 16:39:00, ended at 2014-04-08 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2014-04-09 00:00:00, ended at 2014-04-09 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for thoracotomy procedures involving lungs, pleura, diaphragm, and mediastinum (including surgical thoracoscopy); utilizing 1 lung ventilation\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, started on 2014-04-09, presumably until 2014-04-09\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2014-04-09, presumably until 2014-04-09\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2014-04-09, presumably until 2014-04-09\n- cefazolin 1000 MG Injection, started on 2014-04-09, presumably until 2014-04-09\n- remifentanil 2 MG Injection, through Intravenous route, started on 2014-04-09, presumably until 2014-04-09\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2014-04-09, presumably until 2014-04-09\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2014-04-09, presumably until 2014-04-09\n- 2 ML ondansetron 2 MG/ML Injection, started on 2014-04-09, presumably until 2014-04-09\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-04-09, presumably until 2014-04-09\n- midazolam 1 MG/ML Injectable Solution, started on 2014-04-09, presumably until 2014-04-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2014-04-09 00:00:00, ended at 2014-04-09 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 10 ML bupivacaine hydrochloride 5 MG/ML Injection, started on 2014-04-09, presumably until 2014-04-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2014-04-09 05:19:00, ended at 2014-04-11 14:25:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 31 (milligram per deciliter)\n- Body height: 5' 6\" (inch (US))\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.6 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 79.1 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.32 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 33.1 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.8 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 291 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.4 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.1 (percent)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 159 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.0 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 99.3 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.17 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.3 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 8.21 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.3 (milligram per deciliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 366 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.63 (million per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 113 (millimole per liter)\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Collection of venous blood by venipuncture\n- Thoracoscopic wedge resection of lung\n- Duplex scan of extremity veins including responses to compression and other maneuvers; unilateral or limited study\n- Pathology consultation during surgery; first tissue block, with frozen section(s), single specimen\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Excision of regional lymph nodes\n- Radiologic examination, chest; single view, frontal\n- Physical therapy evaluation\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Noninvasive ventilation\n- Other endoscopy of small intestine\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n\n### Condition\n- Benign hypertensive renal disease with renal failure\n- Edema\n- Anxiety state\n- Gout\n- Non-toxic uninodular goiter\n- Vitamin D deficiency\n- Electrocardiogram abnormal\n- Hyperlipidemia\n- Lung field abnormal\n- Type 2 diabetes mellitus without complication\n- Disorder of thyroid gland\n- Erythema of skin\n- Secondary malignant neoplasm of lung\n- Acquired hypothyroidism\n- Ascites\n- Chronic pain\n- Depressive disorder\n- Nausea and vomiting\n- Primary cardiomyopathy\n- Chronic ischemic heart disease\n- Coronary atherosclerosis\n- Gastroesophageal reflux disease\n- Chronic kidney disease\n- Iron deficiency anemia\n- Obstructive sleep apnea syndrome\n- Old myocardial infarction\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Acute postoperative pain\n- Acute pulmonary edema\n- Disorder of the peripheral nervous system\n- Congestive heart failure\n\n### Drug\n- benzocaine 15 MG / menthol 3.6 MG Oral Lozenge, through Submucosal route, started on 2014-04-10, presumably until 2014-04-11\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-04-09, presumably until 2014-04-10\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2014-04-09, presumably until 2014-04-09\n- 1 ML ketorolac tromethamine 30 MG/ML Injection, started on 2014-04-09, presumably until 2014-04-10\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2014-04-09, presumably until 2014-04-11\n- magnesium citrate 58.2 MG/ML Oral Solution, through Oral route, started on 2014-04-11, presumably until 2014-04-11\n- naloxone hydrochloride 0.4 MG/ML Injectable Solution, started on 2014-04-09, presumably until 2014-04-09\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2014-04-10, presumably until 2014-04-11\n- albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution, through Inhalation, started on 2014-04-09, presumably until 2014-04-11\n- cefazolin 1000 MG Injection, through Intravenous route, started on 2014-04-09, presumably until 2014-04-10\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2014-04-09, presumably until 2014-06-05, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily.\n- lisinopril 2.5 MG Oral Tablet, through Oral route, started on 2014-04-11, presumably until 2014-04-11\n- magnesium hydroxide 80 MG/ML Oral Suspension, through Oral route, started on 2014-04-11, presumably until 2014-04-11\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2014-04-09, presumably until 2014-04-11\n- colchicine 0.6 MG Oral Tablet, through Oral route, started on 2014-04-10, presumably until 2014-04-11\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2014-04-09, presumably until 2014-04-10\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2014-04-11, presumably until 2014-04-11\n- 2 ML ondansetron 2 MG/ML Injection, started on 2014-04-09, presumably until 2014-04-10\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2014-04-09, presumably until 2014-04-09\n- levothyroxine sodium 0.137 MG Oral Tablet, through Oral route, started on 2014-04-10, presumably until 2014-04-11\n- magnesium sulfate 20 MG/ML Injection, through Intravenous route, started on 2014-04-10, presumably until 2014-04-10\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2014-04-11, presumably until 2015-04-11, with intended 2 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed for Nausea.\n- ketamine 100 MG/ML Injectable Solution, started on 2014-04-09, presumably until 2014-04-09\n- gabapentin 600 MG Oral Tablet, through Oral route, started on 2014-04-09, presumably until 2014-04-11\n- 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2014-04-09, presumably until 2014-04-09\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2014-04-10, presumably until 2014-10-08, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain.\n- calcium carbonate 1250 MG Oral Tablet, through Oral route, presumably until 2015-08-04. Instructions: take 2 Tabs by mouth daily.\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2014-04-10, presumably until 2014-04-11\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2014-04-09, presumably until 2014-04-09\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2014-04-09, presumably until 2014-04-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-04-14 00:00:00, ended at 2014-04-14 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-04-20 00:00:00, ended at 2014-04-20 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-04-21 15:26:16, ended at 2014-04-21 16:16:21\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diarrhea\n- Abdominal pain\n- Primary diagnosis: Post-surgical malabsorption\n- Dysuria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-22 13:04:00, ended at 2014-04-22 13:04:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 55 (milliliter per minute per square meter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.2 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.1 (thousand per microliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 31 (nanogram per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.45 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 11.3 (gram per deciliter)\n- Prothrombin time (PT): 14.2 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 36 (nanogram per milliliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 5 (nanogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 32.8 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 668 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 99.2 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 117 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Post-surgical malabsorption\n- Vitamin D deficiency\n- Dysuria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-22 13:05:00, ended at 2014-04-22 13:56:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Imaging of thorax abnormal\n- Postprocedural state finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-22 13:57:00, ended at 2014-04-22 14:56:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Postprocedural state finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-22 14:57:00, ended at 2014-04-22 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-04-27 00:00:00, ended at 2014-04-27 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-05-05 00:00:00, ended at 2014-05-05 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Mineral deficiency\n- Diarrhea\n- Primary diagnosis: Post-surgical malabsorption\n- Vitamin deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-05-12 00:00:00, ended at 2014-05-12 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic ischemic heart disease\n\n### Drug\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2014-05-12, presumably until 2015-09-10, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-05-12 00:00:00, ended at 2014-05-12 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acquired hypothyroidism\n- Primary diagnosis: Non-toxic uninodular goiter\n\n### Drug\n- levothyroxine sodium 0.137 MG Oral Tablet, started on 2014-05-12, presumably until 2014-05-18, with intended 0 refill(s). Instructions: TAKE 1 TABLET ORALLY EVERY MORNING BEFORE BREAKFAST\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2014-05-18 00:00:00, ended at 2014-05-18 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acquired hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.137 MG Oral Tablet, started on 2014-05-18, presumably until 2014-06-05, with intended 0 refill(s). Instructions: TAKE 1 TABLET ORALLY EVERY MORNING BEFORE BREAKFAST\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-06-05 08:46:56, ended at 2014-06-05 09:14:20\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n- Acquired hypothyroidism\n- Primary diagnosis: Non-toxic uninodular goiter\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2014-06-05, presumably until 2014-08-12, with intended 5 refill(s). Instructions: take 1 Simonton by mouth once a week.\n- levothyroxine sodium 0.137 MG Oral Tablet, started on 2014-06-05, presumably until 2015-04-20, with intended 3 refill(s). Instructions: TAKE 1 TABLET ORALLY EVERY MORNING BEFORE BREAKFAST\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-06-05 10:21:06, ended at 2014-06-05 11:20:44\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Scar conditions and fibrosis of skin\n- Benign neoplasm of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-06-10 14:08:34, ended at 2014-06-10 15:15:06\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary cardiomyopathy\n- Takotsubo cardiomyopathy\n- Primary diagnosis: Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-06-11 13:02:48, ended at 2014-06-11 14:15:04\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-07-08 09:12:49, ended at 2014-07-08 10:02:41\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Generally unwell\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-20 07:29:00, ended at 2014-07-20 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Imaging result abnormal\n- Postprocedural state finding\n- Lymphadenopathy\n- Imaging of musculoskeletal system abnormal\n- Solitary nodule of lung\n- Acquired absence of organ\n- Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-07-27 00:00:00, ended at 2014-07-27 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-27 08:00:00, ended at 2014-07-27 08:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-27 09:00:00, ended at 2014-07-27 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-08-10 14:02:20, ended at 2014-08-10 15:39:32\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Diarrhea\n\n### Drug\n- Streptococcus thermophilus, through Oral route, started on 2014-08-10, presumably until 2014-12-07, with intended 3 refill(s). Instructions: take 1 Cap by mouth Every Day. Please take medication 1/2 hour before eating daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-11 12:15:00, ended at 2014-08-11 12:42:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 114 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 247 (microgram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.2 (percent)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 20 (nanogram per milliliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.14 (milli-international unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.18 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.37 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 67.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 105 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.2 (percent)\n- MCV [Entitic volume] by Automated count: 97.5 (femtoliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.72 (million per microliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 23 (percent)\n- Ferritin [Mass/volume] in Serum or Plasma: 118 (nanogram per milliliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.5 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 362 (thousand per microliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 20 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 116 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Iron [Mass/volume] in Serum or Plasma: 57 (microgram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.3 (percent)\n- Globulin [Mass/volume] in Serum: 4.4 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.4 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Acquired hypothyroidism\n- Vitamin D deficiency\n- Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-11 12:43:00, ended at 2014-08-11 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n- Iron deficiency anemia\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Acquired hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-08-12 00:00:00, ended at 2014-08-12 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2014-08-12, presumably until 2014-08-14, with intended 5 refill(s). Instructions: take 1 Hodges by mouth once a week.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-08-14 00:00:00, ended at 2014-08-14 00:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2014-08-14, presumably until 2015-01-31, with intended 5 refill(s). Instructions: take 1 Cap by mouth 2 times a week.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2014-09-04 00:00:00, ended at 2014-09-04 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-26 15:26:10, ended at 2014-10-26 16:11:06\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes\n\n### Condition\n- Vitamin D deficiency\n- Primary diagnosis: Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-10-26 15:27:47, ended at 2014-10-26 17:04:44\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Abdominal pain\n- Chronic pain\n- Iron deficiency anemia\n- Primary diagnosis: Diarrhea\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-27 07:10:00, ended at 2014-10-27 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Ascites\n- Localized swelling, mass and lump, trunk\n- Postprocedural state finding\n- Lymphadenopathy\n- Primary malignant neoplasm of soft tissues\n- Disorder of pericardium\n- Solitary nodule of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-28 09:42:00, ended at 2014-10-28 11:14:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-28 11:15:00, ended at 2014-10-28 12:18:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 115 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 273 (microgram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.93 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 32 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.3 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 20.0 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.45 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.96 (million per microliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 22 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.9 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 67.8 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.7 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.0 (picogram)\n- MCV [Entitic volume] by Automated count: 96.3 (femtoliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.0 (nanogram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.1 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 42 (milliliter per minute per square meter)\n- Iron [Mass/volume] in Serum or Plasma: 60 (microgram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 358 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 90 (nanogram per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 128 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.2 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Iron deficiency anemia\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-28 12:19:00, ended at 2014-10-28 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-10-30 00:00:00, ended at 2014-10-30 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-11-12 13:05:41, ended at 2014-11-12 14:02:34\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2014-11-18 00:00:00, ended at 2014-11-18 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic ischemic heart disease\n\n### Drug\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2014-11-18, presumably until 2015-11-23, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-12-07 14:40:00, ended at 2014-12-07 17:11:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Urine: <5 (milligram per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 114 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Albumin/Creatinine [Mass Ratio] in Urine: <30 (milligram per gram)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 5.5 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Nausea and vomiting\n- Post-surgical malabsorption\n- Type 2 diabetes mellitus without complication\n- Abdominal pain\n- Diarrhea\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-12-07 15:15:13, ended at 2014-12-07 16:12:13\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-12-07 15:48:15, ended at 2014-12-07 17:05:49\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Post-surgical malabsorption\n- Primary diagnosis: Diarrhea\n- Abdominal pain\n- Nausea and vomiting\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-12-07 18:11:00, ended at 2014-12-07 20:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diarrhea\n- Abdominal pain\n- Nausea and vomiting\n- Post-surgical malabsorption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-12-07 21:00:00, ended at 2014-12-07 21:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Abdominal pain\n- Post-surgical malabsorption\n- Diarrhea\n- Nausea and vomiting\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-12-07 21:00:00, ended at 2014-12-07 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diarrhea\n- Nausea and vomiting\n- Post-surgical malabsorption\n- Abdominal pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-12-07 21:00:00, ended at 2014-12-07 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Abdominal pain\n- Post-surgical malabsorption\n- Nausea and vomiting\n- Diarrhea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-01-07 00:00:00, ended at 2015-01-07 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-01-25 00:00:00, ended at 2015-01-25 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-01-27 12:23:00, ended at 2015-01-27 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Monocytes [#/volume] in Blood by Automated count: 0.82 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.9 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.5 (percent)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 307 (microgram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.18 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n- Ferritin [Mass/volume] in Serum or Plasma: 66 (nanogram per milliliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.15 (million per microliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 21 (percent)\n- MCV [Entitic volume] by Automated count: 97.8 (femtoliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 5 (nanogram per milliliter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Iron [Mass/volume] in Serum or Plasma: 65 (microgram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.6 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 71.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 357 (thousand per microliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 35 (nanogram per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.6 (percent)\n- MCH [Entitic mass] by Automated count: 32.8 (picogram)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 30 (nanogram per milliliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.5 (percent)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.6 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.41 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Vitamin D deficiency\n- Iron deficiency anemia\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-01-31 00:00:00, ended at 2015-01-31 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acquired hypothyroidism\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2015-01-31, presumably until 2015-04-20, with intended 5 refill(s). Instructions: take 1 Cap by mouth 2 times a week.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-02-01 10:18:00, ended at 2015-02-01 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Ascites\n- Spondylolisthesis\n- Acquired spondylolisthesis\n- Spondylosis without myelopathy\n- Solitary nodule of lung\n- Disorder of back\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-02-03 00:00:00, ended at 2015-02-03 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-02-03 00:00:00, ended at 2015-02-03 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-02-03 09:30:00, ended at 2015-02-03 10:23:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-02-03 10:24:00, ended at 2015-02-03 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-03-01 09:03:00, ended at 2015-03-01 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Lung field abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-03-03 00:00:00, ended at 2015-03-03 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-03-03 08:54:00, ended at 2015-03-03 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-03-09 10:22:33, ended at 2015-03-09 11:17:09\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.276\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of lung\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-03-29 00:00:00, ended at 2015-03-29 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, started on 2015-03-29, presumably until 2016-03-27, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY WITH MEALS.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-04-01 09:58:00, ended at 2015-04-02 09:52:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Computed tomography guidance for, and monitoring of, parenchymal tissue ablation\n- CT of thorax with contrast\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Collection of venous blood by venipuncture\n- Radiologic examination, chest; single view, frontal\n- Percutaneous ablation of lung lesion or tissue\n- Ablation therapy for reduction or eradication of 1 or more pulmonary tumor(s) including pleura or chest wall when involved by tumor extension, percutaneous, including imaging guidance when performed, unilateral; radiofrequency\n\n### Condition\n- Chronic ischemic heart disease\n- Lung field abnormal\n- Secondary malignant neoplasm of lung\n- Takotsubo cardiomyopathy\n- Non-toxic uninodular goiter\n- Type 2 diabetes mellitus without complication\n- Coronary arteriosclerosis\n- Electrocardiogram abnormal\n- Old myocardial infarction\n- Primary malignant neoplasm of soft tissues\n- Vitamin D deficiency\n- Disorder of the peripheral nervous system\n- Essential hypertension\n- Obstructive sleep apnea syndrome\n- Pneumothorax\n- Primary malignant neoplasm of retroperitoneum\n- Solitary nodule of lung\n- Iron deficiency anemia\n- Acquired absence of organ\n- Acquired hypothyroidism\n- Cardiac arrhythmia\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2015-04-01, presumably until 2015-04-02\n- cefazolin 1000 MG Injection, started on 2015-04-01, presumably until 2015-04-01\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2015-04-01, presumably until 2015-04-01\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2015-04-02, presumably until 2015-04-02\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2015-04-01, presumably until 2015-04-02\n- 2 ML ondansetron 2 MG/ML Injection, started on 2015-04-01, presumably until 2015-04-01\n- 1 ML hydromorphone hydrochloride 2 MG/ML Prefilled Syringe, started on 2015-04-01, presumably until 2015-04-01\n- levothyroxine sodium 0.137 MG Oral Tablet, through Oral route, started on 2015-04-02, presumably until 2015-04-02\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2015-04-01, presumably until 2015-04-01\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2015-04-01, presumably until 2015-04-02\n- 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2015-04-01, presumably until 2015-04-01\n- midazolam 1 MG/ML Injectable Solution, started on 2015-04-01, presumably until 2015-04-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-04-02 10:08:00, ended at 2015-04-02 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n\n### Condition\n- Non-toxic multinodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-04-19 14:27:35, ended at 2015-04-19 15:51:01\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Diarrhea\n- Primary malignant neoplasm of soft tissues\n- Post-surgical malabsorption\n\n### Drug\n- bismuth subsalicylate 262 MG Chewable Tablet, through Oral route, started on 2015-04-19, presumably until 2015-08-04, with intended 5 refill(s). Instructions: take 2 Tabs by mouth every 6 hours.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-04-20 09:43:06, ended at 2015-04-20 10:12:12\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acquired hypothyroidism\n- Vitamin D deficiency\n- Non-toxic uninodular goiter\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2015-04-20, presumably until 2015-07-23, with intended 6 refill(s). Instructions: take 1 Cap by mouth 2 times a week.\n- levothyroxine sodium 0.137 MG Oral Tablet, started on 2015-04-20, presumably until 2015-07-23, with intended 4 refill(s). Instructions: TAKE 1 TABLET ORALLY EVERY MORNING BEFORE BREAKFAST\n- ondansetron 4 MG Oral Tablet, through Oral route, presumably until 2016-02-11, with intended 0 refill(s). Instructions: take  by mouth.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-04-20 10:16:00, ended at 2015-04-20 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Iron saturation [Mass Fraction] in Serum or Plasma: 31 (percent)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.8 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.20 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.2 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.03 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 346 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.6 (percent)\n- MCV [Entitic volume] by Automated count: 98.3 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.84 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.86 (million per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 71.4 (nanogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.0 (percent)\n- Iron [Mass/volume] in Serum or Plasma: 75 (microgram per deciliter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 243 (microgram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.9 (picogram)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.7 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.3 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.5 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.39 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.5 (percent)\n- Thyrotropin [Units/volume] in Serum or Plasma: 3.49 (micro-international unit per milliliter)\n- IgA [Mass/volume] in Serum or Plasma: 298 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Vitamin D deficiency\n- Diarrhea\n- Iron deficiency anemia\n- Acquired hypothyroidism\n- Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-05-06 11:51:00, ended at 2015-05-06 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Imaging of abdomen abnormal\n- Imaging of gastrointestinal tract abnormal\n- Secondary malignant neoplasm of lung\n- Lymphadenopathy\n- Lung field abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-05-07 11:22:00, ended at 2015-05-07 12:50:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- diclofenac sodium 0.01 MG/MG Topical Gel, started on 2015-05-06, presumably until 2015-11-01, with intended 0 refill(s)\n- levofloxacin 500 MG Oral Tablet, started on 2015-04-26, presumably until 2015-08-04, with intended 0 refill(s)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-05-07 12:51:00, ended at 2015-05-07 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-07-02 00:00:00, ended at 2015-07-02 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-07-15 17:03:00, ended at 2015-07-15 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, any joint of upper extremity; without contrast material(s), followed by contrast material(s) and further sequences\n\n### Condition\n- Synovitis and tenosynovitis\n- Ganglion of joint\n- Sprain of wrist\n- Wrist joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-07-18 00:00:00, ended at 2015-07-18 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Enthesopathy\n- Ganglion cyst\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-07-23 00:00:00, ended at 2015-07-23 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-07-23 00:00:00, ended at 2015-07-23 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n- Primary diagnosis: Acquired hypothyroidism\n- Non-toxic uninodular goiter\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2015-07-23, presumably until 2016-08-28, with intended 6 refill(s). Instructions: take 1 Cap by mouth as directed Take 3 x/ week x 4 weeks then 2x/week\n- levothyroxine sodium 0.137 MG Oral Tablet, started on 2015-07-23, presumably until 2015-11-05, with intended 4 refill(s). Instructions: Take 1.5 pills on Sun, 1 pill Mon-Sat\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-08-02 11:35:00, ended at 2015-08-02 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Lung field abnormal\n- Lymphadenopathy\n- Disease of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-08-02 14:26:43, ended at 2015-08-02 15:36:34\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign neoplasm of skin\n- Chromosomal disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-08-04 00:00:00, ended at 2015-08-04 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-08-04 00:00:00, ended at 2015-08-04 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-08-04 00:00:00, ended at 2015-08-04 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Stool: TNP (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Diarrhea\n- Primary diagnosis: Post-surgical malabsorption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-08-04 09:25:00, ended at 2015-08-04 13:36:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, wrist; complete, minimum of 3 views\n\n### Condition\n- Post-surgical malabsorption\n- Primary cardiomyopathy\n- Wrist joint pain\n- Primary malignant neoplasm of soft tissues\n- Takotsubo cardiomyopathy\n- Diarrhea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-08-04 10:15:34, ended at 2015-08-04 11:30:16\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sprain of wrist\n- Primary diagnosis: Synovitis and tenosynovitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-08-04 11:59:04, ended at 2015-08-04 13:31:32\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-08-04 11:59:43, ended at 2015-08-04 16:53:27\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.496\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-08-04 13:37:00, ended at 2015-08-04 17:05:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.2 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14.8 (percent)\n- MCV [Entitic volume] by Automated count: 98.0 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.2 (gram per deciliter)\n- Prothrombin time (PT): 12.7 (second)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.9 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.0 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 74.2 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 108 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Globulin [Mass/volume] in Serum: 4.8 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.13 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.8 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 29.4 (second)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.6 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.64 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.10 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 97 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 356 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-08-04 15:09:59, ended at 2015-08-04 15:54:42\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Post-surgical malabsorption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-08-04 16:12:17, ended at 2015-08-04 16:35:02\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary cardiomyopathy\n- Takotsubo cardiomyopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-08-04 17:06:00, ended at 2015-08-04 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Thiamine [Moles/volume] in Serum or Plasma: 6 (nanomole per liter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 7 (nanogram per milliliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 37 (nanogram per milliliter)\n- Erythrocyte sedimentation rate: 48 (millimeter per hour)\n- Ferritin [Mass/volume] in Serum or Plasma: 63.3 (nanogram per milliliter)\n- Iron [Mass/volume] in Serum or Plasma: 49 (microgram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 18 (percent)\n- Retinol [Mass/volume] in Serum or Plasma: 63.4 (microgram per deciliter)\n- Iron binding capacity [Mass/volume] in Serum or Plasma: 268 (microgram per deciliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 44 (nanogram per milliliter)\n- Folate [Mass/volume] in Red Blood Cells: 212 (nanogram per milliliter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 546 (picogram per milliliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Diarrhea\n- Post-surgical malabsorption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-08-11 11:35:00, ended at 2015-08-11 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen; with contrast material(s)\n\n### Condition\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-08-19 13:56:26, ended at 2015-08-19 15:45:40\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 101 - 200 (per high power field)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: Full Field (per high power field)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Primary diagnosis: Dysuria\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- nitrofurantoin, macrocrystals 25 MG / nitrofurantoin, monohydrate 75 MG Oral Capsule, through Oral route, started on 2015-08-19, presumably until 2015-08-26, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day for 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-08-19 15:35:00, ended at 2015-08-19 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocytes [#/volume] in Blood by Automated count: 3.76 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.2 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.3 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 96.3 (femtoliter)\n- Prothrombin time (PT): 13.8 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 37 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 5.0 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 108 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.9 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.9 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 12 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.5 (picogram)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 98 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 369 (thousand per microliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Dysuria\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-08-24 00:00:00, ended at 2015-08-24 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-08-26 12:53:00, ended at 2015-08-26 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Disease of liver\n- Primary malignant neoplasm of retroperitoneum\n- Secondary malignant neoplasm of liver\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-08-30 09:03:04, ended at 2015-08-30 11:26:46\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.709\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neoplastic disease\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2015-09-07 00:00:00, ended at 2015-09-07 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Thiamine deficiency\n\n### Drug\n- thiamine 100 MG Oral Tablet, through Oral route, started on 2015-09-08, presumably until 2019-01-22, with intended 3 refill(s). Instructions: take 1 Tab by mouth Every Day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-09-10 00:00:00, ended at 2015-09-10 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic ischemic heart disease\n\n### Drug\n- carvedilol 3.125 MG Oral Tablet, started on 2015-09-11, presumably until 2016-11-28, with intended 3 refill(s). Instructions: TAKE 1 TABLET ORALLY TWICE DAILY WITH MEALS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2015-09-24 00:00:00, ended at 2015-09-24 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n- Anesthesia for intraperitoneal procedures in upper abdomen including laparoscopy; partial hepatectomy or management of liver hemorrhage (excluding liver biopsy)\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Coronary atherosclerosis\n- Type 2 diabetes mellitus without complication\n- Acquired hypothyroidism\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, through Intravenous route, started on 2015-09-24, presumably until 2015-09-24\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2015-09-24, presumably until 2015-09-24\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2015-09-24, presumably until 2015-09-24\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2015-09-24, presumably until 2015-09-24\n- cefoxitin 1000 MG Injection, through Intravenous route, started on 2015-09-24, presumably until 2015-09-24\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2015-09-24, presumably until 2015-09-24\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2015-09-24, presumably until 2015-09-24\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2015-09-24, presumably until 2015-09-24\n- 2 ML ondansetron 2 MG/ML Injection, started on 2015-09-24, presumably until 2015-09-24\n- ketamine 100 MG/ML Injectable Solution, started on 2015-09-24, presumably until 2015-09-24\n- gabapentin 100 MG Oral Capsule, through Oral route, started on 2015-09-24, presumably until 2015-09-24\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2015-09-24, presumably until 2015-09-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2015-09-24 00:00:00, ended at 2015-09-24 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Injection(s), anesthetic agent(s) and/or steroid; other peripheral nerve or branch\n\n### Condition\n- Acute postoperative pain\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2015-09-24, presumably until 2015-09-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2015-09-24 06:55:00, ended at 2015-10-01 12:30:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 73 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 99.9 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 88 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.3 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 326 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 144 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.52 (million per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Glucose [Mass/volume] in Blood: 169 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.2 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.5 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Prothrombin time (PT): 14.6 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Body height: 5' 6.5\" (inch (US))\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCH [Entitic mass] by Automated count: 32.5 (picogram)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 111 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.3 (thousand per microliter)\n\n### Procedure\n- Physical therapy evaluation\n- Other lysis of peritoneal adhesions\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Radiologic examination, abdomen; single anteroposterior view\n- Collection of venous blood by venipuncture\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Occupational therapy evaluation\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Partial hepatectomy\n\n### Condition\n- Abdominal pain\n- Coronary arteriosclerosis\n- Gastroesophageal reflux disease\n- Essential hypertension\n- Old myocardial infarction\n- Primary malignant neoplasm of soft tissues\n- Acquired hypothyroidism\n- Primary diagnosis: Acute postoperative pain\n- Secondary malignant neoplasm of liver\n- Acute renal failure syndrome\n- Peritoneal adhesion\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2015-09-24, presumably until 2015-09-28\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2015-09-29, presumably until 2015-09-29\n- levothyroxine sodium 0.112 MG Oral Tablet, through Oral route, started on 2015-09-25, presumably until 2015-10-01\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2015-09-24, presumably until 2015-10-01\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2015-09-29, presumably until 2015-10-01\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2015-09-27, presumably until 2016-01-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2015-09-27, presumably until 2015-09-30\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2015-09-29, presumably until 2015-09-29\n- levothyroxine sodium 0.025 MG Oral Tablet, through Oral route, started on 2015-09-25, presumably until 2015-10-01\n- oxycodone hydrochloride 10 MG Oral Tablet, through Oral route, started on 2015-09-30, presumably until 2015-11-10, with intended 0 refill(s). Instructions: take 1 Tab by mouth Q3H PRN (pain)\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2015-09-25, presumably until 2015-10-01\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2015-09-27, presumably until 2015-09-30\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2015-09-24, presumably until 2015-09-26\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2015-09-24, presumably until 2016-01-10, with intended 0 refill(s). Instructions: take 1 Cap by mouth 3 times a day\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2015-09-24, presumably until 2015-09-29\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2015-09-29, presumably until 2015-10-30, with intended 0 refill(s). Instructions: take 1 Packet by mouth daily\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2015-09-26, presumably until 2015-10-01\n- 2 ML ondansetron 2 MG/ML Injection, started on 2015-09-24, presumably until 2015-10-01\n- 1 ML hydromorphone hydrochloride 2 MG/ML Prefilled Syringe, started on 2015-09-24, presumably until 2015-09-26\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2015-09-24, presumably until 2015-09-24\n- ketamine 100 MG/ML Injectable Solution, started on 2015-09-24, presumably until 2015-09-24\n- 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2015-09-26, presumably until 2015-09-30\n- 12 HR oxycodone hydrochloride 30 MG Extended Release Oral Tablet, through Oral route, started on 2015-09-30, presumably until 2015-09-30, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2015-09-25, presumably until 2015-10-01, with intended 0 refill(s). Instructions: take 1-3 Tabs by mouth Q3H PRN for Pain\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2015-09-25, presumably until 2015-09-25\n- 1 ML promethazine hydrochloride 25 MG/ML Injection, started on 2015-09-24, presumably until 2015-09-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-10-05 12:12:30, ended at 2015-10-05 12:48:24\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.472\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-10-06 13:08:36, ended at 2015-10-06 14:15:28\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Wrist joint pain\n\n### Drug\n- Abuse-Deterrent 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, started on 2015-10-01, presumably until 2015-10-06, with intended 0 refill(s)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-10-06 15:24:02, ended at 2015-10-06 17:54:51\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Post-surgical malabsorption\n- Wrist joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-10-15 00:00:00, ended at 2015-10-15 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Post-surgical malabsorption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-10-25 16:24:19, ended at 2015-10-25 17:02:02\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.315\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-10-26 00:00:00, ended at 2015-10-26 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Post-surgical malabsorption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-10-29 07:40:00, ended at 2015-10-29 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Ascites\n- Primary malignant neoplasm of trunk\n- Abnormal findings on diagnostic imaging of lung\n- Malignant neoplasm of connective and soft tissue of abdomen\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-11-01 00:00:00, ended at 2015-11-01 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-11-01 00:00:00, ended at 2015-11-01 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-11-01 10:13:19, ended at 2015-11-01 12:15:29\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-11-01 10:15:00, ended at 2015-11-01 14:28:16\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-11-02 06:16:00, ended at 2015-11-02 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- MCH [Entitic mass] by Automated count: 30.3 (picogram)\n- MCHC [Mass/volume] by Automated count: 31.3 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.54 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 32 (nanogram per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 13.4 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 40 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 103 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.7 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.2 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 67.7 (percent)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 37 (nanogram per milliliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.58 (thousand per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 66.8 (nanogram per milliliter)\n- Globulin [Mass/volume] in Serum: 4.9 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 9 (percent)\n- MCV [Entitic volume] by Automated count: 96.8 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.2 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 92 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.27 (million per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.7 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 5 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Iron [Mass/volume] in Serum or Plasma: 24 (microgram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 7.1 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.10 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.91 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 394 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 16.10 (micro-international unit per milliliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hypothyroidism\n- Primary malignant neoplasm of soft tissues\n- Vitamin D deficiency\n- Iron deficiency anemia\n- Post-surgical malabsorption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-11-03 00:00:00, ended at 2015-11-03 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-11-05 00:00:00, ended at 2015-11-05 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n\n### Drug\n- levothyroxine sodium 0.175 MG Oral Tablet, through Oral route, started on 2015-11-05, presumably until 2015-12-29, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-11-10 00:00:00, ended at 2015-11-10 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- oxycodone hydrochloride 10 MG Oral Tablet, through Oral route, started on 2015-11-10, presumably until 2016-01-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-11-23 00:00:00, ended at 2015-11-23 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- lisinopril 5 MG Oral Tablet, started on 2015-11-23, presumably until 2016-12-13, with intended 10 refill(s). Instructions: TAKE 1 TABLET ORALLY DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-12-17 11:48:00, ended at 2015-12-17 12:58:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.70 (million per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 53.7 (nanogram per milliliter)\n- Globulin [Mass/volume] in Serum: 4.8 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.1 (ratio)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.2 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 73.1 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 13 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 6.89 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 14.9 (percent)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Prothrombin time (PT): 13.3 (second)\n- aPTT in Platelet poor plasma by Coagulation assay: 27.0 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.5 (percent)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- MCV [Entitic volume] by Automated count: 93.9 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.97 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.18 (micro-international unit per milliliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 98 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.8 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 103 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.3 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.4 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.40 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 358 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Iron [Mass/volume] in Serum or Plasma: 39 (microgram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Dysuria\n- Thiamine deficiency\n- Neoplastic disease of uncertain behavior\n- Essential hypertension\n- Primary malignant neoplasm\n- Primary malignant neoplasm of soft tissues\n- Iron deficiency anemia\n- Post-surgical malabsorption\n- Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-12-17 12:14:56, ended at 2015-12-17 12:49:51\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Primary diagnosis: Iron deficiency anemia\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-12-17 12:59:00, ended at 2015-12-17 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Iron deficiency anemia\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2015-12-17, presumably until 2015-12-17\n- methylprednisolone 40 MG Injection, started on 2015-12-17, presumably until 2015-12-17\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2015-12-17, presumably until 2015-12-17\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2015-12-17, presumably until 2015-12-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-12-18 08:57:00, ended at 2015-12-18 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Iron deficiency anemia\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2015-12-18, presumably until 2015-12-18\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2015-12-18, presumably until 2015-12-18\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2015-12-18, presumably until 2015-12-18\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2015-12-18, presumably until 2015-12-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-12-22 12:14:00, ended at 2015-12-22 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Abnormal findings on diagnostic imaging of lung\n- Disorder of kidney and/or ureter\n- Malignant neoplasm of connective and soft tissue of abdomen\n- Primary malignant neoplasm of trunk\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-12-27 00:00:00, ended at 2015-12-27 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prednisone 10 MG Oral Tablet, started on 2015-12-27, presumably until 2016-01-10, with intended 0 refill(s). Instructions: Take 50 mg po on day 1, 40 mg po on day 2, 30 mg po on day 3, 20 mg po on day 4, 10 mg po on day 5\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-12-27 13:02:00, ended at 2015-12-27 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.69 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 319 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 17 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.4 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 100 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.9 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.92 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 93.2 (femtoliter)\n- Prothrombin time (PT): 14.2 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Ferritin [Mass/volume] in Serum or Plasma: 151.0 (nanogram per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.4 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 78.5 (percent)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 11.0 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.2 (percent)\n- Iron [Mass/volume] in Serum or Plasma: 21 (microgram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.61 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 31.8 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.80 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.9 (gram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 5 (percent)\n- MCH [Entitic mass] by Automated count: 29.6 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Iron deficiency anemia\n- Post-surgical malabsorption\n- Primary malignant neoplasm of soft tissues\n- Dysuria\n- Primary malignant neoplasm\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-12-27 13:29:14, ended at 2015-12-27 15:24:40\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-12-27 14:48:33, ended at 2015-12-27 16:30:26\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.748\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-12-29 00:00:00, ended at 2015-12-29 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.175 MG Oral Tablet, started on 2015-12-29, presumably until 2016-02-07, with intended 1 refill(s). Instructions: TAKE 1 TABLET ORALLY IN THE MORNING BEFORE BREAKFAST\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-12-29 00:00:00, ended at 2015-12-29 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-01-10 16:49:00, ended at 2016-01-11 14:48:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocytes [#/volume] in Blood by Automated count: 4.03 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 105 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.8 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- MCHC [Mass/volume] by Automated count: 32.0 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 53 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.7 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.92 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.7 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 75.8 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Erythrocyte sedimentation rate: 40 (millimeter per hour)\n- MCH [Entitic mass] by Automated count: 30.0 (picogram)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.7 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 3 - 5 (per high power field)\n- Neutrophils [#/volume] in Blood by Automated count: 5.51 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.3 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 93.7 (femtoliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.1 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 394 (thousand per microliter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Initial observation care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination \n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Anorectal disorder\n- Fever\n- Hypothyroidism\n- Essential hypertension\n- Obstructive sleep apnea syndrome\n- Residual hemorrhoidal skin tags\n- Thrombosed external hemorrhoids\n- Acquired hypothyroidism\n- Cardiomyopathy\n- Post-surgical malabsorption\n- Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplasm of lung\n- Disorder of kidney and/or ureter\n- Old myocardial infarction\n- Primary diagnosis: Pain\n- Secondary malignant neoplastic disease\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2016-01-11, presumably until 2016-01-11\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2016-01-10, presumably until 2016-01-10\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2016-01-11, presumably until 2016-02-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2016-01-11, presumably until 2016-02-17, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day as needed for Constipation\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2016-01-11, presumably until 2016-01-11\n- levothyroxine sodium 0.025 MG Oral Tablet, through Oral route, started on 2016-01-11, presumably until 2016-01-11\n- oxycodone hydrochloride 10 MG Oral Tablet, through Oral route, started on 2016-01-11, presumably until 2016-02-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed (pain)\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2016-01-20, presumably until 2016-04-17, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2016-01-11, presumably until 2016-02-17, with intended 0 refill(s). Instructions: take 1 Packet by mouth daily as needed\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2016-01-11, presumably until 2016-01-11\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2016-01-11, presumably until 2016-01-11\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-01-10, presumably until 2016-01-10\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2016-01-10, presumably until 2016-01-10\n- lidocaine hydrochloride 0.02 MG/MG Topical Gel, started on 2016-01-11, presumably until 2016-08-23, with intended 0 refill(s). Instructions: Apply liberally to anus 3-4x daily as needed for pain\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2016-01-11, presumably until 2016-01-11\n- 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2016-01-10, presumably until 2016-01-10\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2016-01-10, presumably until 2016-01-11\n- prednisone 20 MG Oral Tablet, through Oral route, started on 2016-01-11, presumably until 2016-01-11\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2016-01-11, presumably until 2016-01-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-01-26 00:00:00, ended at 2016-01-26 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-01-31 00:00:00, ended at 2016-01-31 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n- Acquired hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-01-31 00:00:00, ended at 2016-01-31 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-02-01 00:00:00, ended at 2016-02-01 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n\n### Drug\n- levothyroxine sodium 0.175 MG Oral Tablet, through Oral route, started on 2016-02-01, presumably until 2016-02-07, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-02-03 00:00:00, ended at 2016-02-03 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-toxic uninodular goiter\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.2 MG Oral Tablet, through Oral route, started on 2016-02-07, presumably until 2016-03-06, with intended 2 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-02-03 00:00:00, ended at 2016-02-03 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-02-03 07:58:00, ended at 2016-02-03 10:42:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 113 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Non-toxic uninodular goiter\n- Inflammatory disorder of digestive tract\n- Radiation-induced disorder\n- Solitary nodule of lung\n- Vitamin D deficiency\n- Absent kidney\n- Acquired absence of organ\n- Abnormal findings on diagnostic imaging of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-02-03 10:43:00, ended at 2016-02-03 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 35 (nanogram per milliliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 35 (nanogram per milliliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 11.20 (micro-international unit per milliliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Non-toxic uninodular goiter\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-02-04 00:00:00, ended at 2016-02-04 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Osteoarthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-02-08 00:00:00, ended at 2016-02-08 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-02-11 00:00:00, ended at 2016-02-11 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-toxic uninodular goiter\n- Vitamin D deficiency\n\n### Drug\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2016-02-11, presumably until 2016-03-21, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours\n- oxycodone hydrochloride 10 MG Oral Tablet, through Oral route, started on 2016-02-11, presumably until 2016-03-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed (pain)\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2016-02-11, presumably until 2016-08-24, with intended 1 refill(s). Instructions: take 2 Tabs by mouth 3 times a day as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-02-15 13:20:33, ended at 2016-02-15 15:18:40\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.535\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-02-16 00:00:00, ended at 2016-02-16 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-02-16 12:22:00, ended at 2016-02-16 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s), followed by contrast material(s) and further sequences\n\n### Condition\n- Abscess of buttock\n- Disorder of bone\n- Mononeuropathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-02-17 09:46:44, ended at 2016-02-17 10:42:55\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Electrocardiogram abnormal\n- Disorder of soft tissue\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2013-10-24, presumably until 2016-02-17, with intended 0 refill(s)\n- hydromorphone hydrochloride 4 MG Oral Tablet, through Oral route, started on 2015-04-09, presumably until 2016-03-12, with intended 0 refill(s). Instructions: take 2 mg by mouth every 6 hours as needed \n- colchicine 0.6 MG Oral Tablet, started on 2013-10-06, presumably until 2016-02-17, with intended 0 refill(s)\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2016-02-02, presumably until 2016-02-17, with intended 0 refill(s). Instructions: take 5 mg by mouth\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, started on 2016-01-11, presumably until 2016-02-17, with intended 0 refill(s)\n- aspirin 81 MG Chewable Tablet, through Oral route, presumably until 2016-02-17, with intended 0 refill(s). Instructions: take 81 mg by mouth\n- triamcinolone acetonide 0.25 MG/ML Topical Cream, through Topical route, started on 2013-09-05, presumably until 2016-02-17, with intended 0 refill(s). Instructions: by Topical route as needed \n- Abuse-Deterrent 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, started on 2016-02-11, presumably until 2016-02-17, with intended 0 refill(s)\n- ondansetron 8 MG Disintegrating Oral Tablet, through Oral route, presumably until 2016-02-17, with intended 0 refill(s). Instructions: take 8 mg by mouth\n- hydrocortisone acetate 25 MG Rectal Suppository, through Rectal route, started on 2016-01-06, presumably until 2017-11-07, with intended 0 refill(s). Instructions: insert 25 mg into the rectum\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-03-03 09:07:12, ended at 2016-03-03 13:59:05\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Post-surgical malabsorption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-03 11:00:00, ended at 2016-03-03 12:19:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n\n### Condition\n- Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-03 12:20:00, ended at 2016-03-03 13:43:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Abnormal findings on diagnostic imaging of urinary organs\n- Dysuria\n- Primary malignant neoplasm\n- Primary malignant neoplasm of soft tissues\n- Vitamin D deficiency\n- Iron deficiency anemia\n- Abnormal findings on diagnostic imaging of lung\n- Hypothyroidism\n- Osteoarthritis\n- Abnormal findings diagnostic imaging of liver+biliary tract\n- Malignant neoplasm of connective and soft tissue of pelvis\n- Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-03 13:44:00, ended at 2016-03-03 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 2 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.7 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.9 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.4 (picogram)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 11.6 (gram per deciliter)\n- Iron [Mass/volume] in Serum or Plasma: 23 (microgram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.3 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 53.1 (nanogram per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5.1 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 9.66 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.11 (micro-international unit per milliliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.1 (nanogram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 93 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 131 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 11 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 112 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.4 (percent)\n- MCV [Entitic volume] by Automated count: 92.8 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 89.0 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 5.7 (millimole per liter)\n- Prothrombin time (PT): 13.7 (second)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.81 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 333 (thousand per microliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 7 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm\n- Dysuria\n- Neoplasm of uncertain behavior of soft tissues\n- Primary malignant neoplasm of soft tissues\n- Vitamin D deficiency\n- Iron deficiency anemia\n- Hypothyroidism\n- Disorder of soft tissue\n- Osteoarthritis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-03-06 08:45:06, ended at 2016-03-06 11:46:31\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.496\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-03-06 10:02:09, ended at 2016-03-06 12:47:44\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.496\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-03-06 12:23:26, ended at 2016-03-06 12:59:12\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-toxic uninodular goiter\n- Primary diagnosis: Hypothyroidism\n- Vitamin D deficiency\n\n### Drug\n- cholecalciferol 1.25 MG Oral Capsule, through Oral route, started on 2016-03-06, presumably until 2017-08-23, with intended 3 refill(s). Instructions: take 1 Cap by mouth 2 times a week\n- levothyroxine sodium 0.2 MG Oral Tablet, through Oral route, started on 2016-03-06, presumably until 2016-10-06, with intended 3 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2016-03-07 00:00:00, ended at 2016-03-07 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for all procedures on the integumentary system, muscles and nerves of head, neck, and posterior trunk, not otherwise specified\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2016-03-07, presumably until 2016-03-07\n- cefazolin 1000 MG Injection, started on 2016-03-07, presumably until 2016-03-07\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2016-03-07, presumably until 2016-03-07\n- vasopressin (USP) 20 UNT/ML Injectable Solution, through Intravenous route, started on 2016-03-07, presumably until 2016-03-07\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2016-03-07, presumably until 2016-03-07\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-03-07, presumably until 2016-03-07\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-03-07, presumably until 2016-03-07\n- succinylcholine chloride 20 MG/ML Injectable Solution, started on 2016-03-07, presumably until 2016-03-07\n- midazolam 1 MG/ML Injectable Solution, started on 2016-03-07, presumably until 2016-03-07\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2016-03-07, presumably until 2016-03-07\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2016-03-07, presumably until 2016-03-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2016-03-07 00:00:00, ended at 2016-03-07 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 10 ML bupivacaine hydrochloride 2.5 MG/ML / epinephrine 0.005 MG/ML Injection, started on 2016-03-07, presumably until 2016-03-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2016-03-07 05:45:00, ended at 2016-03-09 14:22:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.1 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 315 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 18.9 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 93.4 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 147 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.1 (picogram)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.70 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.5 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Body height: 5' 6\" (inch (US))\n- Erythrocyte distribution width [Ratio] by Automated count: 17.5 (percent)\n\n### Procedure\n- Excision of Buttock Subcutaneous Tissue and Fascia, Open Approach\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Physical therapy evaluation\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Occupational therapy evaluation\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Collection of venous blood by venipuncture\n\n### Condition\n- Electrocardiogram abnormal\n- Gastroesophageal reflux disease without esophagitis\n- Heart failure\n- Bradycardia\n- Disorder of digestive system\n- Major depression, single episode\n- Secondary malignant neoplastic disease\n- Vitamin D deficiency\n- Absent kidney\n- Acquired absence of organ\n- Iron deficiency anemia\n- Old myocardial infarction\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Malignant neoplasm of connective and soft tissue of pelvis\n- Obstructive sleep apnea syndrome\n- Osteoarthritis\n- Chest pain\n- Chronic gout without tophus\n- Disorder of soft tissue\n- Essential hypertension\n- Hypothyroidism\n- Type 2 diabetes mellitus without complication\n- Acquired absence of spleen\n- Atherosclerosis of coronary artery without angina pectoris\n- Hyperkalemia\n- Primary malignant neoplasm\n\n### Drug\n- benzocaine 15 MG / menthol 3.6 MG Oral Lozenge, through Submucosal route, started on 2016-03-07, presumably until 2016-03-07\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2016-03-07, presumably until 2016-03-07\n- thiamine 100 MG Oral Tablet, through Oral route, started on 2016-03-07, presumably until 2016-03-09\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2016-03-08, presumably until 2016-03-09\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2016-03-08, presumably until 2016-03-09\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2016-03-08, presumably until 2016-03-30, with intended 0 refill(s). Instructions: inject 0.4 mL subcutaneous (under the skin) Every Day\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2016-03-07, presumably until 2016-03-09\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2016-03-07, presumably until 2016-03-07\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2016-03-08, presumably until 2016-03-09\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2016-03-07, presumably until 2016-03-09\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-03-07, presumably until 2016-03-08\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2016-03-07, presumably until 2016-03-08\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-03-07, presumably until 2016-03-08\n- 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2016-03-08, presumably until 2016-03-09\n- 12 HR oxycodone hydrochloride 30 MG Extended Release Oral Tablet, through Oral route, started on 2016-03-09, presumably until 2016-03-23, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2016-03-07, presumably until 2016-03-13, with intended 0 refill(s). Instructions: take 1-4 Tabs by mouth Q3H PRN\n- ascorbic acid 500 MG Oral Tablet, through Oral route, started on 2016-03-07, presumably until 2016-03-09\n- aluminum hydroxide 40 MG/ML / magnesium hydroxide 40 MG/ML / simethicone 4 MG/ML Oral Suspension, through Oral route, started on 2016-03-08, presumably until 2016-03-08\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2016-03-08, presumably until 2016-03-09\n- 1 ML promethazine hydrochloride 25 MG/ML Injection, started on 2016-03-07, presumably until 2016-03-07\n- hydrocortisone acetate 25 MG Rectal Suppository, through Rectal route, started on 2016-03-07, presumably until 2016-03-08\n- cefazolin 2000 MG Injection, through Intravenous route, started on 2016-03-07, presumably until 2016-03-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-03-12 00:00:00, ended at 2016-03-12 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydromorphone hydrochloride 4 MG Oral Tablet, through Oral route, started on 2016-03-12, presumably until 2016-03-12, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth every 6 hours as needed for Pain\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-03-13 00:00:00, ended at 2016-03-13 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- oxycodone hydrochloride 10 MG Oral Tablet, through Oral route, started on 2016-03-13, presumably until 2016-03-21, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 3 to 4 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-03-20 00:00:00, ended at 2016-03-20 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2016-03-20, presumably until 2016-08-06, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-03-20 00:00:00, ended at 2016-03-20 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-03-20 00:00:00, ended at 2016-03-20 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-03-20 08:57:08, ended at 2016-03-20 11:39:36\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.496\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Electrocardiogram abnormal\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-20 10:43:00, ended at 2016-03-20 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.8 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.72 (million per microliter)\n- Follitropin [Units/volume] in Serum or Plasma: 44.1 (milli-international unit per milliliter)\n- Urate [Mass/volume] in Serum or Plasma: 4.7 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Anion gap in Serum or Plasma: 2 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.3 (gram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 30.7 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.6 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.18 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 179 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.8 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 11.4 (percent)\n- MCH [Entitic mass] by Automated count: 30.4 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 394 (thousand per microliter)\n- Prothrombin time (PT): 13.8 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.78 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 76.3 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 125 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.8 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.3 (percent)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-03-21 00:00:00, ended at 2016-03-21 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2016-03-21, presumably until 2016-04-06, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours\n- oxycodone hydrochloride 10 MG Oral Tablet, through Oral route, started on 2016-03-21, presumably until 2016-04-06, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 3 to 4 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-03-22 11:55:08, ended at 2016-03-22 12:53:55\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-03-27 00:00:00, ended at 2016-03-27 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2016-03-27, presumably until 2016-03-31, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-30 08:56:00, ended at 2016-03-30 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Abnormal findings on diagnostic imaging of lung\n- Primary malignant neoplasm of soft tissues\n- Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-31 08:36:00, ended at 2016-03-31 15:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 10.9 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.02 (thousand per microliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 46 (unit per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.7 (percent)\n- Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma: 164 (picogram per milliliter)\n- Prothrombin time (PT): 14.2 (second)\n- Creatine kinase.MB [Mass/volume] in Serum or Plasma: 0.9 (nanogram per milliliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.62 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.3 (percent)\n- Body height: 5' 6.5\" (inch (US))\n- Leukocytes [#/volume] in Specimen by Automated count: 8.4 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 17.5 (percent)\n- MCH [Entitic mass] by Automated count: 30.2 (picogram)\n- MCV [Entitic volume] by Automated count: 94.9 (femtoliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.46 (thousand per microliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.4 (percent)\n- MCHC [Mass/volume] by Automated count: 31.8 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 71.9 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.73 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 339 (thousand per microliter)\n\n### Procedure\n- Insertion of Infusion Device into Superior Vena Cava, Percutaneous Approach\n- Fluoroscopy of Superior Vena Cava, Guidance\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Insertion of Tunneled Vascular Access Device into Chest Subcutaneous Tissue and Fascia, Open Approach\n- Fluoroscopic guidance for central venous access device placement, replacement (catheter only or complete), or removal (includes fluoroscopic guidance for vascular access and catheter manipulation, any necessary contrast injections through access site or c\n- Insertion of tunneled centrally inserted central venous access device, with subcutaneous port; age 5 years or older\n- Collection of venous blood by venipuncture\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Secondary malignant neoplastic disease\n- Primary malignant neoplasm of soft tissues\n- Absent kidney\n- Disorder due to and following accidental poisoning\n- Disorder due to and following drug poisoning\n- Essential hypertension\n- Gout\n- Hypothyroidism\n- Acquired absence of organ\n- Electrocardiogram abnormal\n- Obstructive sleep apnea syndrome\n- Secondary malignant neoplasm of lung\n- Obesity\n\n### Drug\n- aspirin 325 MG Oral Tablet, through Oral route, started on 2016-03-31, presumably until 2016-04-17, with intended 0 refill(s). Instructions: take 325 mg by mouth every morning with breakfast\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2016-03-31, presumably until 2016-03-31\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-03-31, presumably until 2016-03-31\n- nitroglycerin 0.4 MG Sublingual Tablet, through Sublingual route, started on 2016-03-31, presumably until 2016-03-31\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-03-31 15:48:00, ended at 2016-03-31 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 55.8 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Disorder due to and following accidental poisoning\n- Disorder due to and following drug poisoning\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-04-03 00:00:00, ended at 2016-04-03 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amoxicillin 875 MG Oral Tablet, through Oral route, started on 2016-04-03, presumably until 2016-04-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-04-05 00:00:00, ended at 2016-04-05 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- 12 HR oxycodone hydrochloride 20 MG Extended Release Oral Tablet, through Oral route, started on 2016-04-06, presumably until 2016-04-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 12 hours\n- oxycodone hydrochloride 10 MG Oral Tablet, through Oral route, started on 2016-04-06, presumably until 2016-04-13, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 to 6 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-04-11 14:56:00, ended at 2016-04-12 11:52:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bicarbonate [Moles/volume] in Specimen: 22.7 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.9 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 73.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 319 (thousand per microliter)\n- Prothrombin time (PT): 14.4 (second)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.27 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 81 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.9 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 13.1 (percent)\n- MCH [Entitic mass] by Automated count: 31.1 (picogram)\n- aPTT in Platelet poor plasma by Coagulation assay: 30.3 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.7 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.05 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.8 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.35 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 10.4 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.15 (thousand per microliter)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 20 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 114 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 95.3 (femtoliter)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 17 (millimeter mercury column)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Base excess in Blood by calculation: -3 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 44.2 (millimeter mercury column)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.3 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Computed tomographic angiography, chest (noncoronary), with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Initial observation care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination \n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug provided in a facility (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n\n### Condition\n- Chest pain\n- Primary diagnosis: Thrombosed external hemorrhoids\n- Abnormal findings on diagnostic imaging of lung\n- Old myocardial infarction\n- Generalized ischemic myocardial dysfunction\n- Obstructive sleep apnea syndrome\n- Primary malignant neoplasm of soft tissues\n- Type 2 diabetes mellitus without complication\n- Absent kidney\n- Atherosclerosis of coronary artery without angina pectoris\n- Electrocardiogram abnormal\n- Neck pain\n- Secondary malignant neoplasm of lung\n- Acquired absence of organ\n- Acquired absence of spleen\n- Acute deep venous thrombosis of internal jugular vein\n- Essential hypertension\n- Hypothyroidism\n- Disorder of digestive system\n\n### Drug\n- levothyroxine sodium 0.088 MG Oral Tablet, through Oral route, started on 2016-04-12, presumably until 2016-04-12\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2016-04-11, presumably until 2016-04-11\n- amoxicillin 250 MG Oral Capsule, through Oral route, started on 2016-04-11, presumably until 2016-04-12\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2016-04-11, presumably until 2016-04-11\n- 0.8 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2016-04-11, presumably until 2016-05-01, with intended 0 refill(s). Instructions: inject 0.8 mL subcutaneous (under the skin) every 12 hours\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2016-04-12, presumably until 2016-04-17, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed (pain)\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2016-04-12, presumably until 2016-04-12\n- carvedilol 6.25 MG Oral Tablet, through Oral route, started on 2016-04-11, presumably until 2016-04-12\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-04-11, presumably until 2016-04-11\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2016-04-11, presumably until 2016-04-12\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-04-11, presumably until 2016-04-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-04-12 00:00:00, ended at 2016-04-12 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- rivaroxaban 20 MG Oral Tablet, through Oral route, started on 2016-04-12, presumably until 2016-08-02, with intended 3 refill(s). Instructions: take 20 mg by mouth Every Day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-04-13 12:56:00, ended at 2016-04-13 18:14:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- Removal of Tunneled Vascular Access Device from Trunk Subcutaneous Tissue and Fascia, Open Approach\n- Fluoroscopy of Superior Vena Cava, Guidance\n- Fluoroscopic guidance for central venous access device placement, replacement (catheter only or complete), or removal (includes fluoroscopic guidance for vascular access and catheter manipulation, any necessary contrast injections through access site or c\n- Insertion of Infusion Device into Superior Vena Cava, Percutaneous Approach\n- Replacement, complete, of a tunneled centrally inserted central venous access device, with subcutaneous port, through same venous access\n- Insertion of Tunneled Vascular Access Device into Chest Subcutaneous Tissue and Fascia, Open Approach\n\n### Condition\n- Complication associated with vascular device\n- Essential hypertension\n- Old myocardial infarction\n- Adverse effect of prosthetic device\n- Pain due to internal prosthetic device\n- Secondary malignant neoplasm of lung\n- Acquired absence of organ\n- Obesity\n- Obstructive sleep apnea syndrome\n- Absent kidney\n- Complication of surgical procedure\n- Gout\n- Hypothyroidism\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2016-04-13, presumably until 2016-04-13\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2016-04-13, presumably until 2016-04-13\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-04-13, presumably until 2016-04-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-04-14 00:00:00, ended at 2016-04-14 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-04-17 00:00:00, ended at 2016-04-17 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-04-17, presumably until 2017-04-17, with intended 3 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2016-04-17, presumably until 2016-08-18, with intended 2 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2016-04-17, presumably until 2016-05-08, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n- prochlorperazine 10 MG Oral Tablet, through Oral route, started on 2016-04-17, presumably until 2016-04-17, with intended 3 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed for Nausea/Vomiting\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-04-17 00:00:00, ended at 2016-04-17 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prochlorperazine 10 MG Oral Tablet, through Oral route, started on 2016-04-17, presumably until 2016-07-15, with intended 3 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed for Nausea/Vomiting\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-04-17 07:57:00, ended at 2016-04-17 08:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 31 (nanogram per milliliter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.8 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 97 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 19 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.21 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 63.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 381 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.31 (thousand per microliter)\n- Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma: 12 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.2 (percent)\n- MCH [Entitic mass] by Automated count: 30.9 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 123 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.2 (percent)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.49 (million per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.33 (micro-international unit per milliliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.5 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCV [Entitic volume] by Automated count: 95.1 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Urate [Mass/volume] in Serum or Plasma: 4.8 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 36.5 (second)\n- Globulin [Mass/volume] in Serum: 5.0 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.67 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 20.4 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 54.4 (nanogram per milliliter)\n- Iron [Mass/volume] in Serum or Plasma: 41 (microgram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.2 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.91 (thousand per microliter)\n- Prothrombin time (PT): 13.9 (second)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 31 (nanogram per milliliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Iron deficiency anemia\n- Hypothyroidism\n- Non-toxic uninodular goiter\n- Vitamin D deficiency\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-04-17 08:28:48, ended at 2016-04-17 10:43:25\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.961\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2016-04-17, presumably until 2016-05-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2016-04-17, presumably until 2016-07-03, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth daily\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2016-04-17, presumably until 2016-05-15, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-04-17 09:00:00, ended at 2016-04-17 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration; intravenous, push technique, each additional substance/drug (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Dysuria\n- Iron deficiency anemia\n- Hypothyroidism\n- Primary malignant neoplasm\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-04-17, presumably until 2016-04-17\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2016-04-17, presumably until 2016-04-17\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-04-17, presumably until 2016-04-17\n- 5 ML doxorubicin hydrochloride 2 MG/ML Injection, through Intravenous route, started on 2016-04-17, presumably until 2016-04-17\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2016-04-17, presumably until 2016-04-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-04-18 14:30:00, ended at 2016-04-18 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Intravenous infusion, hydration; initial, 31 minutes to 1 hour\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2016-04-18, presumably until 2016-04-18\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-04-18, presumably until 2016-04-18\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-04-18, presumably until 2016-04-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-04-19 00:00:00, ended at 2016-04-19 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-04-20 00:00:00, ended at 2016-04-20 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-04-21 00:00:00, ended at 2016-04-21 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-04-24 00:00:00, ended at 2016-04-24 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-04-24 00:00:00, ended at 2016-04-24 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- levofloxacin 500 MG Oral Tablet, through Oral route, started on 2016-04-24, presumably until 2016-04-29, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily for 5 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-04-24 07:00:00, ended at 2016-04-24 11:43:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Lymphocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 281 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 109 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.7 (percent)\n- MCH [Entitic mass] by Automated count: 30.3 (picogram)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 62.8 (percent)\n- MCV [Entitic volume] by Automated count: 93.1 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.51 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 119 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 16.8 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.1 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 1.2 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 11 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.6 (percent)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.6 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 14.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Primary malignant neoplasm\n- Primary malignant neoplasm of soft tissues\n- Dysuria\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-04-24, presumably until 2016-04-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-04-24 08:36:38, ended at 2016-04-24 10:09:41\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.961\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute mastoiditis without complications\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-04-24 11:44:00, ended at 2016-04-24 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomographic angiography, neck, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Computed tomographic angiography, head, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n\n### Condition\n- Acute deep venous thrombosis of internal jugular vein\n- Headache\n- Abnormal findings on diagnostic imaging of lung\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-04-24, presumably until 2016-04-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-04-28 00:00:00, ended at 2016-04-28 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-01 00:00:00, ended at 2016-05-01 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-01 00:00:00, ended at 2016-05-01 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.4 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.2 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.1 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 299 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.23 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 95.2 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.88 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 62.8 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.59 (million per microliter)\n- MCH [Entitic mass] by Automated count: 30.9 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 3.73 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 20.7 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.9 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-01 00:00:00, ended at 2016-05-01 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-01 00:00:00, ended at 2016-05-01 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- trazodone hydrochloride 50 MG Oral Tablet, started on 2016-05-01, presumably until 2016-08-16, with intended 2 refill(s). Instructions: Take 1 to 2 tabs at bedtime.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-01 07:24:00, ended at 2016-05-01 07:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.2 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.1 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 95.2 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 114 (milligram per deciliter)\n- Prothrombin time (PT): 18.7 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 92 (unit per liter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma: 14 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 299 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.4 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.59 (million per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Urate [Mass/volume] in Serum or Plasma: 5.2 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.9 (picogram)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hypothyroidism\n- Dysuria\n- Iron deficiency anemia\n- Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-01 07:43:00, ended at 2016-05-01 08:11:25\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.961\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-01 08:00:00, ended at 2016-05-01 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Hypothyroidism\n- Primary malignant neoplasm of soft tissues\n- Iron deficiency anemia\n- Dysuria\n- Primary malignant neoplasm\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-05-01, presumably until 2016-05-01\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-05-01, presumably until 2016-05-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-05 00:00:00, ended at 2016-05-05 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-08 00:00:00, ended at 2016-05-08 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-08 00:00:00, ended at 2016-05-08 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration; intravenous, push technique, each additional substance/drug (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Dysuria\n- Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Fatigue\n- Primary malignant neoplasm\n- Iron deficiency anemia\n- Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-05-08 00:00:00, ended at 2016-05-08 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2016-05-08, presumably until 2016-05-29, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2016-05-08, presumably until 2016-11-06, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2016-05-08, presumably until 2017-05-08, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, through Topical route, started on 2016-05-08, presumably until 2016-08-15, with intended 2 refill(s). Instructions: by Topical route as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-08 07:10:00, ended at 2016-05-08 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.0 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.49 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 13.2 (percent)\n- MCV [Entitic volume] by Automated count: 95.9 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 443 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.08 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.93 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.81 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 22.4 (percent)\n- Urate [Mass/volume] in Serum or Plasma: 4.7 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 34 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 14 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.7 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 84 (unit per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 62.8 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.4 (picogram)\n- aPTT in Platelet poor plasma by Coagulation assay: 59.6 (second)\n- Glucose [Mass/volume] in Serum or Plasma: 124 (milligram per deciliter)\n- Prothrombin time (PT): 19.4 (second)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.1 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.07 (thousand per microliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration; intravenous, push technique, each additional substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-05-08, presumably until 2016-05-08\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2016-05-08, presumably until 2016-05-08\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-05-08, presumably until 2016-05-08\n- 5 ML doxorubicin hydrochloride 2 MG/ML Injection, through Intravenous route, started on 2016-05-08, presumably until 2016-05-08\n- dexamethasone phosphate 4 MG/ML Injectable Solution, through Intravenous route, started on 2016-05-08, presumably until 2016-05-08, with intended 0 refill(s). Instructions: 2.5 mL by Intravenous route One Time\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-08 08:09:30, ended at 2016-05-08 10:11:52\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-09 13:10:00, ended at 2016-05-09 14:23:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2016-05-09, presumably until 2016-05-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-09 14:24:00, ended at 2016-05-09 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Ultrasound, limited, joint or other nonvascular extremity structure(s) (eg, joint space, peri-articular tendon[s], muscle[s], nerve[s], other soft-tissue structure[s], or soft-tissue mass[es]), real-time with image documentation\n\n### Condition\n- Localized swelling, mass and lump, trunk\n- Primary malignant neoplasm\n- Primary malignant neoplasm of skin of trunk\n- Iron deficiency anemia\n- Hypothyroidism\n- Neoplastic disease\n- Primary malignant neoplasm of soft tissues\n- Dysuria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-12 00:00:00, ended at 2016-05-12 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-15 00:00:00, ended at 2016-05-15 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2016-05-15, presumably until 2016-05-15, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n- 72 HR scopolamine 0.0139 MG/HR Transdermal System, through Transdermal route, started on 2016-05-15, presumably until 2017-05-15, with intended 2 refill(s). Instructions: apply 1 Patch to skin every 72 hours\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-15 00:00:00, ended at 2016-05-15 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-15 07:00:00, ended at 2016-05-15 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.87 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.7 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.75 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 85.7 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.44 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 12.7 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.98 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.7 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 121 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.0 (picogram)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 166 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.6 (percent)\n- Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.7 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 10.86 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Prothrombin time (PT): 22.5 (second)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5.9 (percent)\n- MCV [Entitic volume] by Automated count: 95.2 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 297 (thousand per microliter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Dysuria\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-05-15, presumably until 2016-05-15\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-05-15, presumably until 2016-05-15\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2016-05-15, presumably until 2016-05-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-15 08:17:17, ended at 2016-05-15 10:00:47\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2016-05-15, presumably until 2016-06-05, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-15 15:19:12, ended at 2016-05-15 17:29:40\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-16 00:00:00, ended at 2016-05-16 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- melatonin 1 MG Oral Tablet, through Oral route, started on 2016-05-16, presumably until 2016-08-23, with intended 3 refill(s). Instructions: take 1 Tab by mouth every bedtime\n- methylphenidate hydrochloride 5 MG Oral Tablet, through Oral route, started on 2016-05-16, presumably until 2016-11-12, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-05-26 00:00:00, ended at 2016-05-26 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-26 14:15:00, ended at 2016-05-26 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplasm of lung\n- Abnormal findings on diagnostic imaging of lung\n- Secondary malignant neoplasm of left lung\n- Secondary malignant neoplasm of right lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-29 08:00:00, ended at 2016-05-29 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 91 (unit per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Urate [Mass/volume] in Serum or Plasma: 4.2 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.2 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 71.4 (percent)\n- aPTT in Platelet poor plasma by Coagulation assay: 35.7 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 116 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.5 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.92 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.35 (million per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.6 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 356 (thousand per microliter)\n- Prothrombin time (PT): 13.6 (second)\n- Eosinophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma: 12 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.9 (percent)\n- MCV [Entitic volume] by Automated count: 96.4 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 26 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Monocytes [#/volume] in Blood by Automated count: 1.34 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 16.3 (percent)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.81 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.5 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 5.86 (thousand per microliter)\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Hypothyroidism\n- Primary malignant neoplasm of soft tissues\n- Essential hypertension\n- Type 2 diabetes mellitus without complication\n- Gastroesophageal reflux disease without esophagitis\n- Hyperlipidemia\n- Primary malignant neoplasm\n- Dysuria\n- Iron deficiency anemia\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-05-29, presumably until 2016-05-29\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2016-05-29, presumably until 2016-05-29\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-05-29, presumably until 2016-05-29\n- 5 ML doxorubicin hydrochloride 2 MG/ML Injection, through Intravenous route, started on 2016-05-29, presumably until 2016-05-29\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2016-05-29, presumably until 2016-05-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-05-29 09:16:39, ended at 2016-05-29 11:00:30\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neoplasm defined only by topography: Connective, Subcutaneous and other soft tissues, NOS\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2016-05-29, presumably until 2016-07-18, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-05-30 13:10:00, ended at 2016-05-30 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2016-05-30, presumably until 2016-05-30\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-02 00:00:00, ended at 2016-06-02 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-05 00:00:00, ended at 2016-06-05 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Iron saturation [Mass Fraction] in Serum or Plasma: 25 (percent)\n- Ferritin [Mass/volume] in Serum or Plasma: 167.0 (nanogram per milliliter)\n- Iron [Mass/volume] in Serum or Plasma: 68 (microgram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-06-05 00:00:00, ended at 2016-06-05 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2016-06-05, presumably until 2016-07-18, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-06-05 08:00:00, ended at 2016-06-05 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 288 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5.2 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 161 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.99 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.71 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 88.7 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 28 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.64 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 13.6 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 115 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.3 (percent)\n- MCH [Entitic mass] by Automated count: 32.2 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.58 (micro-international unit per milliliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 4.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 12.04 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- MCV [Entitic volume] by Automated count: 97.9 (femtoliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.87 (milligram per deciliter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Hypothyroidism\n- Iron deficiency anemia\n- Primary malignant neoplasm of soft tissues\n- Non-toxic uninodular goiter\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-06-05, presumably until 2016-06-05\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-06-05, presumably until 2016-06-05\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-06-05, presumably until 2016-06-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-06-05 08:32:00, ended at 2016-06-05 10:19:36\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-08 00:00:00, ended at 2016-06-08 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-15 00:00:00, ended at 2016-06-15 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-19 00:00:00, ended at 2016-06-19 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-19 00:00:00, ended at 2016-06-19 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- levofloxacin 500 MG Oral Tablet, through Oral route, started on 2016-06-19, presumably until 2016-06-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily for 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-06-19 07:00:00, ended at 2016-06-19 09:31:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hemoglobin [Mass/volume] in Blood: 11.0 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.6 (picogram)\n- MCV [Entitic volume] by Automated count: 99.2 (femtoliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 348 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 104 (unit per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.1 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.75 (thousand per microliter)\n- Urate [Mass/volume] in Serum or Plasma: 4.5 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.6 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.6 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 77.3 (percent)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 21.0 (percent)\n- Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma: 10 (unit per liter)\n- Monocytes [#/volume] in Blood by Automated count: 1.08 (thousand per microliter)\n- Prothrombin time (PT): 19.1 (second)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.89 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.39 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 125 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.6 (percent)\n- aPTT in Platelet poor plasma by Coagulation assay: 36.2 (second)\n- Neutrophils [#/volume] in Blood by Automated count: 6.68 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.82 (micro-international unit per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n- Collection of venous blood by venipuncture\n\n### Condition\n- Non-toxic uninodular goiter\n- Hypothyroidism\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-06-19 08:19:48, ended at 2016-06-19 09:30:02\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.157\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-06-19 09:32:00, ended at 2016-06-19 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Fever\n- Cough\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-20 00:00:00, ended at 2016-06-20 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- benzonatate 100 MG Oral Capsule, through Oral route, started on 2016-06-20, presumably until 2016-07-03, with intended 0 refill(s). Instructions: take 1 Cap by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-06-30 00:00:00, ended at 2016-06-30 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-03 00:00:00, ended at 2016-07-03 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-03 00:00:00, ended at 2016-07-03 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2016-07-03, presumably until 2016-08-23, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth daily\n- 12 HR dextromethorphan hydrobromide 30 MG / guaifenesin 600 MG Extended Release Oral Tablet, through Oral route, started on 2016-07-03, presumably until 2016-08-23, with intended 1 refill(s). Instructions: take 1 Tab by mouth every 12 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-07-03 07:10:00, ended at 2016-07-03 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma: <10 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.9 (gram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 37.6 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 100 (unit per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Body height: 5' 5.157\" (inch (US))\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.90 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.30 (million per microliter)\n- Prothrombin time (PT): 18.9 (second)\n- Urate [Mass/volume] in Serum or Plasma: 4.1 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.90 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 11.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.80 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.10 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.0 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 72.4 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.7 (percent)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 379 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 120 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.7 (percent)\n- MCH [Entitic mass] by Automated count: 33.0 (picogram)\n- MCV [Entitic volume] by Automated count: 99.0 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.8 (percent)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Dysuria\n- Gastroesophageal reflux disease without esophagitis\n- Primary malignant neoplasm\n- Hypothyroidism\n- Essential hypertension\n- Type 2 diabetes mellitus without complication\n- Iron deficiency anemia\n- Hyperlipidemia\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-07-03, presumably until 2016-07-03\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2016-07-03, presumably until 2016-07-03\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-07-03, presumably until 2016-07-03\n- 5 ML doxorubicin hydrochloride 2 MG/ML Injection, through Intravenous route, started on 2016-07-03, presumably until 2016-07-03\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2016-07-03, presumably until 2016-07-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-07-03 08:33:01, ended at 2016-07-03 09:36:27\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- azithromycin 250 MG Oral Tablet, through Oral route, started on 2016-07-04, presumably until 2016-07-09, with intended 0 refill(s). Instructions: take 1 Tab by mouth as directed for 5 days 2 tabs on day 1, then 1 tab daily thereafter\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-04 00:00:00, ended at 2016-07-04 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Fever\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Acute upper respiratory infection\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-04 00:00:00, ended at 2016-07-04 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acute upper respiratory infection\n- Fever\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-07-04 12:48:00, ended at 2016-07-04 13:19:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 5 (nanogram per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 3.3 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 10.7 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.38 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.0 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.2 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 5.7 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.35 (million per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 10.46 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 91.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 387 (thousand per microliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 34 (nanogram per milliliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 29 (nanogram per milliliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 55.1 (nanogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.3 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.8 (percent)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 49 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.5 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 99.5 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Iron [Mass/volume] in Serum or Plasma: 153 (microgram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Dysuria\n- Iron deficiency anemia\n- Fever\n- Primary malignant neoplasm of soft tissues\n- Vitamin D deficiency\n- Acute upper respiratory infection\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-07-04 13:20:00, ended at 2016-07-04 15:22:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2016-07-04, presumably until 2016-07-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-07-04 15:23:00, ended at 2016-07-04 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-10 00:00:00, ended at 2016-07-10 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-11 00:00:00, ended at 2016-07-11 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-11 00:00:00, ended at 2016-07-11 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-07-11 08:00:00, ended at 2016-07-11 10:06:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Neutrophils/100 leukocytes in Blood by Automated count: 74.6 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Ferritin [Mass/volume] in Serum or Plasma: 154.5 (nanogram per milliliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 28 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.62 (thousand per microliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 4 (nanogram per milliliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 6 (percent)\n- MCH [Entitic mass] by Automated count: 32.3 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 3.71 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.04 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.5 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.9 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 26 (nanogram per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 10.4 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.0 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 30 (nanogram per milliliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.5 (percent)\n- Iron [Mass/volume] in Serum or Plasma: 17 (microgram per deciliter)\n- MCV [Entitic volume] by Automated count: 99.8 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 127 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.22 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.44 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.4 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 209 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 119 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.1 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.4 (percent)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Vitamin D deficiency\n- Iron deficiency anemia\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-07-11, presumably until 2016-07-11\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-07-11, presumably until 2016-07-11\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-07-11, presumably until 2016-07-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-07-11 09:02:31, ended at 2016-07-11 14:43:53\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-07-11 10:07:00, ended at 2016-07-11 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Radiologic examination, abdomen; single anteroposterior view\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Abdominal pain\n- Hypothyroidism\n- Intestinal obstruction\n- Gastroesophageal reflux disease without esophagitis\n- Essential hypertension\n- Primary malignant neoplasm of soft tissues\n- Type 2 diabetes mellitus without complication\n- Dysuria\n- Primary malignant neoplasm\n- Hyperlipidemia\n- Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-07-15 00:00:00, ended at 2016-07-15 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prochlorperazine 10 MG Oral Tablet, started on 2016-07-17, presumably until 2017-05-16, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY 8 HOURS AS NEEDED FOR NAUSEA OR VOMITING\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-07-18 00:00:00, ended at 2016-07-18 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2016-07-18, presumably until 2016-11-17, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2016-07-18, presumably until 2016-08-15, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-19 00:00:00, ended at 2016-07-19 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-21 00:00:00, ended at 2016-07-21 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-24 00:00:00, ended at 2016-07-24 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-25 00:00:00, ended at 2016-07-25 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-07-25 07:10:00, ended at 2016-07-25 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 461 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 75.1 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.1 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.6 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.1 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 33.2 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Prothrombin time (PT): 16.0 (second)\n- Urate [Mass/volume] in Serum or Plasma: 4.7 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 34.8 (second)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.1 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.5 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.87 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.56 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.27 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 10.9 (gram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.1 (percent)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.57 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 97 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma: <10 (unit per liter)\n- MCV [Entitic volume] by Automated count: 100.2 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 114 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.82 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.24 (micro-international unit per milliliter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration; intravenous, push technique, each additional substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Non-toxic uninodular goiter\n- Hypothyroidism\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-07-25, presumably until 2016-07-25\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2016-07-25, presumably until 2016-07-25\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-07-25, presumably until 2016-07-25\n- 5 ML doxorubicin hydrochloride 2 MG/ML Injection, through Intravenous route, started on 2016-07-25, presumably until 2016-07-25\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2016-07-25, presumably until 2016-07-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-07-25 07:42:57, ended at 2016-07-25 11:57:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.157\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-26 00:00:00, ended at 2016-07-26 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-26 00:00:00, ended at 2016-07-26 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-07-26 13:22:00, ended at 2016-07-26 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2016-07-26, presumably until 2016-07-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-07-28 00:00:00, ended at 2016-07-28 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2016-07-31 15:10:00, ended at 2016-08-01 18:23:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.27 (million per microliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 51 - 100 (per high power field)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.6 (thousand per microliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 166 (unit per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Glucose [Mass/volume] in Serum or Plasma: 132 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.9 (percent)\n- Neutrophils/100 leukocytes in Blood by Manual count: 71 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 33 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 33.1 (picogram)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 100.7 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 3 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.06 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1 (percent)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 226 (thousand per microliter)\n- Prothrombin time (PT): 14.9 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.17 (thousand per microliter)\n- Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma: <30 (picogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.95 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.2 (percent)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.28 (thousand per microliter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Initial observation care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination \n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Computed tomographic angiography, chest (noncoronary), with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Collection of venous blood by venipuncture\n- Magnetic resonance (eg, proton) imaging, lower extremity other than joint; without contrast material(s), followed by contrast material(s) and further sequences\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Magnetic resonance (eg, proton) imaging, lower extremity other than joint; without contrast material(s)\n- Physical therapy evaluation\n\n### Condition\n- Abnormal heart beat\n- Old myocardial infarction\n- Postoperative state\n- Primary malignant neoplasm of retroperitoneum\n- Urinary tract infectious disease\n- Abnormal findings on diagnostic imaging of lung\n- Pulmonary embolism\n- Ventricular premature complex\n- Chest pain\n- Electrocardiogram abnormal\n- Secondary malignant neoplasm of nervous system\n- Essential hypertension\n- Hypothyroidism\n- Obstructive sleep apnea syndrome\n- Primary diagnosis: Dyspnea\n\n### Drug\n- thiamine 100 MG Oral Tablet, through Oral route, started on 2016-08-01, presumably until 2016-08-01\n- warfarin sodium 5 MG Oral Tablet, through Oral route, started on 2016-08-01, presumably until 2016-08-02, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- nitrofurantoin, macrocrystals 25 MG / nitrofurantoin, monohydrate 75 MG Oral Capsule, through Oral route, started on 2016-08-01, presumably until 2016-08-06, with intended 0 refill(s). Instructions: take 1 Puthenveetil by mouth every 12 hours for 5 days\n- pantoprazole 20 MG Delayed Release Oral Tablet, through Oral route, started on 2016-07-31, presumably until 2016-07-31\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2016-08-01, presumably until 2016-08-01\n- ceftriaxone 1000 MG Injection, through Intravenous route, started on 2016-07-31, presumably until 2016-07-31\n- lisinopril 10 MG Oral Tablet, through Oral route, started on 2016-08-01, presumably until 2016-08-01\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2016-07-31, presumably until 2016-08-01\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2016-07-31, presumably until 2016-07-31\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2016-08-01, presumably until 2016-08-01\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2016-07-31, presumably until 2016-07-31\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2016-08-01, presumably until 2016-08-01\n- 0.8 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2016-08-01, presumably until 2016-08-06, with intended 1 refill(s). Instructions: inject 0.8 mL subcutaneous (under the skin) every 12 hours\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2016-07-31, presumably until 2016-08-01\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-08-01, presumably until 2016-08-01\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2016-08-01, presumably until 2016-08-01\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-07-31, presumably until 2016-08-01\n- prochlorperazine 5 MG Oral Tablet, through Oral route, started on 2016-07-31, presumably until 2016-08-01\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2016-07-31, presumably until 2016-08-01\n- rivaroxaban 20 MG Oral Tablet, through Oral route, started on 2016-07-31, presumably until 2016-07-31\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-08-02 00:00:00, ended at 2016-08-02 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- dexamethasone 4 MG Oral Tablet, started on 2016-08-02, presumably until 2017-01-15, with intended 1 refill(s). Instructions: Take one 4mg tab the day before and the day after chemotherapy.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-08-02 08:02:56, ended at 2016-08-02 11:49:44\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.157\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2016-08-02, presumably until 2016-12-04, with intended 3 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-08-03 00:00:00, ended at 2016-08-03 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-08-07 00:00:00, ended at 2016-08-07 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-08-08 00:00:00, ended at 2016-08-08 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Pain due to neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-08-15 00:00:00, ended at 2016-08-15 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2016-08-15, presumably until 2016-09-27, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, through Topical route, started on 2016-08-15, presumably until 2017-08-15, with intended 2 refill(s). Instructions: by Topical route as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-15 07:59:00, ended at 2016-08-15 09:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.96 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.32 (million per microliter)\n- Iron [Mass/volume] in Serum or Plasma: 64 (microgram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 14 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.1 (percent)\n- MCV [Entitic volume] by Automated count: 100.4 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.2 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 35 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 119 (unit per liter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 30 (nanogram per milliliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 23 (percent)\n- Platelets [#/volume] in Blood by Automated count: 479 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 5 (nanogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Ferritin [Mass/volume] in Serum or Plasma: 55.5 (nanogram per milliliter)\n- MCH [Entitic mass] by Automated count: 32.6 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 1.24 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 11.24 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 83.2 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.3 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.4 (percent)\n- MCHC [Mass/volume] by Automated count: 32.4 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.8 (gram per deciliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.1 (nanogram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 119 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.95 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.37 (micro-international unit per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 13.5 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hypothyroidism\n- Dysuria\n- Hyperlipidemia\n- Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm\n- Vitamin D deficiency\n- Non-toxic uninodular goiter\n- Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-08-15 08:42:20, ended at 2016-08-15 11:23:42\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.157\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-15 10:00:00, ended at 2016-08-15 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.157\" (inch (US))\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2016-08-15, presumably until 2016-08-15\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2016-08-15, presumably until 2016-08-15\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-08-15, presumably until 2016-08-15\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2016-08-15, presumably until 2016-08-15\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-08-15, presumably until 2016-08-15\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-08-15, presumably until 2016-08-15\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2016-08-15, presumably until 2016-08-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-16 08:07:00, ended at 2016-08-16 13:23:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Abnormal findings on diagnostic imaging of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-16 13:24:00, ended at 2016-08-16 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2016-08-16, presumably until 2016-08-16\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-08-16 13:57:28, ended at 2016-08-16 14:34:06\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Takotsubo cardiomyopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-08-18 00:00:00, ended at 2016-08-18 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- docusate sodium 100 MG Oral Capsule, started on 2016-08-18, presumably until 2018-07-06, with intended 0 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-08-18 00:00:00, ended at 2016-08-18 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of intestine\n- Post-surgical malabsorption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-08-21 00:00:00, ended at 2016-08-21 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Melena\n- Primary diagnosis: Anorectal disorder\n- Post-surgical malabsorption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-08-23 13:04:57, ended at 2016-08-23 14:48:39\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Melena\n- Hypothyroidism\n- Essential hypertension\n- Obstructive sleep apnea syndrome\n\n### Drug\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, presumably until 2019-04-16, with intended 0 refill(s). Instructions: take 81 mg by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-24 00:00:00, ended at 2016-08-24 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for lower intestinal endoscopic procedures, endoscope introduced distal to duodenum\n\n### Condition\n- Hemorrhoids\n- Diarrhea\n- Essential hypertension\n- Melena\n\n### Drug\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2016-08-24, presumably until 2016-08-24\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2016-08-24, presumably until 2016-08-24\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2016-08-24, presumably until 2016-08-24\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-08-24, presumably until 2016-08-24\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-08-24, presumably until 2016-08-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-24 07:32:00, ended at 2016-08-24 10:06:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Sigmoidoscopy, flexible; with biopsy, single or multiple\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Excision of Sigmoid Colon, Via Natural or Artificial Opening Endoscopic, Diagnostic\n- Sigmoidoscopy, flexible; with control of bleeding, any method\n\n### Condition\n- Diarrhea\n- Cardiomyopathy\n- Disorder of intestine\n- Hemorrhoids\n- Type 2 diabetes mellitus without complication\n- Vitamin D deficiency\n- Old myocardial infarction\n- Takotsubo cardiomyopathy\n- Melena\n- Dyspnea\n- Hypothyroidism\n\n### Drug\n- 2 ML ondansetron 2 MG/ML Injection, started on 2016-08-24, presumably until 2016-08-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-08-28 00:00:00, ended at 2016-08-28 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, started on 2016-08-28, presumably until 2017-03-12, with intended 3 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH TWICE WEEKLY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-08-29 00:00:00, ended at 2016-08-29 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Pulmonary embolism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-30 07:10:00, ended at 2016-08-30 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 105 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.8 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 76.2 (percent)\n- Urate [Mass/volume] in Serum or Plasma: 4.5 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 11 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Hemoglobin [Mass/volume] in Blood: 10.2 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.7 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.84 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 33.5 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 7.84 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Prothrombin time (PT): 15.4 (second)\n- aPTT in Platelet poor plasma by Coagulation assay: 35.8 (second)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.0 (percent)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 138 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 101.8 (femtoliter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.03 (million per microliter)\n- Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma: <10 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.9 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.3 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.00 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.32 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 319 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Dysuria\n- Pulmonary embolism\n- Type 2 diabetes mellitus without complication\n- Ascites\n- Hypothyroidism\n- Primary malignant neoplasm of soft tissues\n- Essential hypertension\n- Iron deficiency anemia\n- Secondary malignant neoplasm of left lung\n- Primary malignant neoplasm\n- Secondary malignant neoplasm of right lung\n- Gastroesophageal reflux disease without esophagitis\n- Hyperlipidemia\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2016-08-30, presumably until 2016-08-30\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-08-30, presumably until 2016-08-30\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2016-08-30, presumably until 2016-08-30\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-08-30, presumably until 2016-08-30\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-08-30, presumably until 2016-08-30\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-08-30, presumably until 2016-08-30\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-08-30 07:55:06, ended at 2016-08-30 10:42:32\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- mupirocin 0.02 MG/MG Topical Ointment, started on 2016-08-18, presumably until 2017-11-08, with intended 0 refill(s). Instructions: Apply to affected area BID prn rash\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-31 08:00:00, ended at 2016-08-31 11:09:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 55.4 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Disorder due to and following accidental poisoning\n- Disorder due to and following drug poisoning\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-31 11:10:00, ended at 2016-08-31 14:29:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Acquired absence of organ\n- Absent kidney\n- Solitary nodule of lung\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-08-31 14:30:00, ended at 2016-08-31 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2016-08-31, presumably until 2016-08-31\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-09-11 00:00:00, ended at 2016-09-11 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of intestine\n- Primary diagnosis: Post-surgical malabsorption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-09-27 11:57:00, ended at 2016-09-27 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.8 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 95.1 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 108 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.92 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 1.7 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.2 (percent)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 102.4 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 33.1 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 9.46 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 153 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.9 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.28 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 33 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.86 (million per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 12 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.3 (percent)\n- Platelets [#/volume] in Blood by Automated count: 370 (thousand per microliter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Disorder of intestine\n- Post-surgical malabsorption\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2016-09-27, presumably until 2016-09-27\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-09-27, presumably until 2016-09-27\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2016-09-27, presumably until 2016-09-27\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-09-27, presumably until 2016-09-27\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-09-27, presumably until 2016-09-27\n- prochlorperazine 10 MG Oral Tablet, through Oral route, started on 2016-09-27, presumably until 2016-09-27\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-09-27, presumably until 2016-09-27\n- 0.6 ML pegfilgrastim 10 MG/ML Injection, through Subcutaneous route, started on 2016-09-27, presumably until 2016-09-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-09-27 12:25:43, ended at 2016-09-27 14:20:18\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2016-09-27, presumably until 2016-11-17, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-09-28 00:00:00, ended at 2016-09-28 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Insomnia\n\n### Drug\n- amitriptyline hydrochloride 75 MG Oral Tablet, through Oral route, started on 2016-09-28, presumably until 2017-05-24, with intended 3 refill(s). Instructions: take 1 Tab by mouth every bedtime as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-09-28 14:30:39, ended at 2016-09-28 14:58:23\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; single lesion\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Primary diagnosis: Neoplastic disease of uncertain behavior\n- Hyperpigmentation of skin\n- Secondary malignant neoplasm of skin\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-10-05 00:00:00, ended at 2016-10-05 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-10-05 00:00:00, ended at 2016-10-05 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n- Non-toxic uninodular goiter\n\n### Drug\n- levothyroxine sodium 0.2 MG Oral Tablet, through Oral route, started on 2016-10-06, presumably until 2017-05-10, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast Take additional 1/2 tab on Sundays, total 7.5 tabs a week\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-10-12 00:00:00, ended at 2016-10-12 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-10-14 14:30:00, ended at 2016-10-14 15:09:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Magnetic resonance (eg, proton) imaging, lower extremity other than joint; without contrast material(s), followed by contrast material(s) and further sequences\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Type 2 diabetes mellitus without complication\n- Postoperative state\n- Dysuria\n- Primary malignant neoplasm of soft tissues\n- Hypothyroidism\n- Primary malignant neoplasm\n- Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-10-14 15:10:00, ended at 2016-10-14 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.32 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 1.8 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 147 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.91 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 96.0 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 38 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- MCHC [Mass/volume] by Automated count: 31.4 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 149 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.2 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.84 (million per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.28 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 463 (thousand per microliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 32.3 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 102.8 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.26 (micro-international unit per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.8 (percent)\n- Ferritin [Mass/volume] in Serum or Plasma: 62.7 (nanogram per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.2 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 16.0 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 15.38 (thousand per microliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Ascites\n- Non-toxic uninodular goiter\n- Hypothyroidism\n- Essential hypertension\n- Hyperlipidemia\n- Secondary malignant neoplasm of left lung\n- Dysuria\n- Gastroesophageal reflux disease without esophagitis\n- Primary malignant neoplasm of soft tissues\n- Type 2 diabetes mellitus without complication\n- Iron deficiency anemia\n- Primary malignant neoplasm\n- Secondary malignant neoplasm of right lung\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2016-10-14, presumably until 2016-10-14\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-10-14, presumably until 2016-10-14\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-10-14, presumably until 2016-10-14\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-10-14, presumably until 2016-10-14\n- prochlorperazine 10 MG Oral Tablet, through Oral route, started on 2016-10-14, presumably until 2016-10-14\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-10-14, presumably until 2016-10-14\n- 0.6 ML pegfilgrastim 10 MG/ML Injection, through Subcutaneous route, started on 2016-10-14, presumably until 2016-10-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-10-19 00:00:00, ended at 2016-10-19 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prednisone 2 MG Delayed Release Oral Tablet, started on 2016-10-19, presumably until 2016-11-03, with intended 0 refill(s). Instructions: Take 8 mg on day 1, 6 mg on day 2, 4 mg on day 3, 2 mg on day 4\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-10-30 00:00:00, ended at 2016-10-30 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, started on 2016-10-31, presumably until 2017-01-23, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY WITH MEALS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-10-30 08:30:00, ended at 2016-10-30 08:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Secondary malignant neoplasm of lung\n- Disorder of pancreas\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-10-30 09:00:00, ended at 2016-10-30 12:09:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.11 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 6.4 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.47 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 14.66 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 150 (unit per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 44 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 109 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 31.0 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 106.2 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.90 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.6 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.92 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 9.6 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.0 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 84.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 468 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 17.3 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 33.0 (picogram)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-10-30, presumably until 2016-10-30\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-30 10:00:17, ended at 2016-10-30 10:32:42\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-10-30 12:10:00, ended at 2016-10-30 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Dysuria\n- Gastroesophageal reflux disease without esophagitis\n- Primary malignant neoplasm of soft tissues\n- Type 2 diabetes mellitus without complication\n- Essential hypertension\n- Hypothyroidism\n- Primary malignant neoplasm\n- Ascites\n- Hyperlipidemia\n- Iron deficiency anemia\n- Secondary malignant neoplasm of right lung\n- Secondary malignant neoplasm of left lung\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2016-10-30, presumably until 2016-10-30\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-10-30, presumably until 2016-10-30\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2016-10-30, presumably until 2016-10-30\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-10-30, presumably until 2016-10-30\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2016-10-30, presumably until 2016-10-30\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-10-30, presumably until 2016-10-30\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-10-30, presumably until 2016-10-30\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-10-30 12:47:33, ended at 2016-10-30 16:25:56\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.8 ML filgrastim 0.6 MG/ML Prefilled Syringe, started on 2016-10-30, presumably until 2017-07-12, with intended 2 refill(s). Instructions: 384 mL by Injection route every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-11-03 00:00:00, ended at 2016-11-03 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- prednisone 2 MG Delayed Release Oral Tablet, started on 2016-11-03, presumably until 2016-12-23, with intended 0 refill(s). Instructions: Take 8 mg on day 1, 6 mg on day 2, 4 mg on day 3, 2 mg on day 4\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-11-06 00:00:00, ended at 2016-11-06 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2016-11-06, presumably until 2017-12-19, with intended 6 refill(s). Instructions: take 1 Tab by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-11-17 00:00:00, ended at 2016-11-17 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2016-11-17, presumably until 2017-03-12, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2016-11-17, presumably until 2017-01-15, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-11-18 00:00:00, ended at 2016-11-18 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-11-18 09:00:00, ended at 2016-11-18 15:37:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 26.6 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 8.7 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 90.2 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 156 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 7.02 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.6 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 105 (unit per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Iron [Mass/volume] in Serum or Plasma: 33 (microgram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 18.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.57 (million per microliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 11 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.44 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.17 (micro-international unit per milliliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.8 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 33.7 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 3.3 (percent)\n- Platelets [#/volume] in Blood by Automated count: 501 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.92 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5.6 (percent)\n- MCV [Entitic volume] by Automated count: 103.6 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.26 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Hypothyroidism\n- Non-toxic uninodular goiter\n- Iron deficiency anemia\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2016-11-18, presumably until 2016-11-18\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-11-18, presumably until 2016-11-18\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-11-18, presumably until 2016-11-18\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2016-11-18, presumably until 2016-11-18\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2016-11-18, presumably until 2016-11-18\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-11-18, presumably until 2016-11-18\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-11-18, presumably until 2016-11-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2016-11-18 15:48:00, ended at 2016-11-18 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Dyspnea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-11-19 11:00:00, ended at 2016-11-19 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Transfusion, blood or blood components\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2016-11-19, presumably until 2016-11-19\n- 10 ML furosemide 10 MG/ML Injection, started on 2016-11-19, presumably until 2016-11-19\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-11-19, presumably until 2016-11-19\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2016-11-19, presumably until 2016-11-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-11-28 00:00:00, ended at 2016-11-28 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Generalized ischemic myocardial dysfunction\n\n### Drug\n- carvedilol 3.125 MG Oral Tablet, started on 2016-11-28, presumably until 2017-04-20, with intended 3 refill(s). Instructions: pt only taking it once a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-01 11:10:00, ended at 2016-12-01 12:29:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Ascites\n- Secondary malignant neoplasm of lung\n- Localized enlarged lymph nodes\n- Primary malignant neoplasm of retroperitoneum\n- Secondary malignant neoplasm of adrenal gland\n- Secondary malignant neoplastic disease\n- Intestinal obstruction\n- Secondary malignant neoplasm of right lung\n- Acquired absence of organ\n- Secondary malignant neoplasm of left lung\n- Absent kidney\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-12-01, presumably until 2016-12-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-01 12:30:00, ended at 2016-12-01 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 16.0 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.32 (million per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 87 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 87 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 31.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 99.0 (femtoliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.15 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 21.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 298 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 5.9 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 7.9 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.8 (percent)\n- MCH [Entitic mass] by Automated count: 31.4 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.5 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.94 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.4 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.35 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 61.2 (percent)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 111 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.88 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Gastroesophageal reflux disease without esophagitis\n- Hyperlipidemia\n- Iron deficiency anemia\n- Secondary malignant neoplasm of left lung\n- Primary malignant neoplasm\n- Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplasm of right lung\n- Type 2 diabetes mellitus without complication\n- Dysuria\n- Hypothyroidism\n- Ascites\n- Essential hypertension\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2016-12-01, presumably until 2016-12-01\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2016-12-01, presumably until 2016-12-01\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-12-01, presumably until 2016-12-01\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2016-12-01, presumably until 2016-12-01\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-12-01, presumably until 2016-12-01\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-12-01, presumably until 2016-12-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-12-01 13:35:21, ended at 2016-12-01 16:18:18\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-04 00:00:00, ended at 2016-12-04 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Nausea\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-12-04, presumably until 2017-03-12, with intended 3 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-12-04 00:00:00, ended at 2016-12-04 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- dabigatran etexilate 150 MG Oral Capsule, started on 2016-12-06, presumably until 2017-02-16, with intended 0 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-12-13 00:00:00, ended at 2016-12-13 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-12-13 00:00:00, ended at 2016-12-13 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2016-12-13, presumably until 2017-11-14, with intended 9 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2016-12-23 00:00:00, ended at 2016-12-23 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- prednisone 2 MG Delayed Release Oral Tablet, started on 2016-12-23, presumably until 2017-01-15, with intended 0 refill(s). Instructions: Take 8 mg on day 1, 6 mg on day 2, 4 mg on day 3, 2 mg on day 4\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2016-12-23 10:12:00, ended at 2016-12-23 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 184 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 124 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 123 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.59 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.96 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.15 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.2 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 7 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.10 (million per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.7 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.7 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Leukocytes [#/volume] in Body fluid by Manual count: 1 (milli-international unit per milliliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.4 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 27 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 20 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 98.3 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 2.2 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.44 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 43 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2016-12-23, presumably until 2016-12-23\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2016-12-23, presumably until 2016-12-23\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2016-12-23, presumably until 2016-12-23\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2016-12-23, presumably until 2016-12-23\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2016-12-23, presumably until 2016-12-23\n- 0.6 ML pegfilgrastim 10 MG/ML Injection, through Subcutaneous route, started on 2016-12-23, presumably until 2016-12-23\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-01-05 00:00:00, ended at 2017-01-05 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- dabigatran etexilate 150 MG Oral Capsule, started on 2017-01-08, presumably until 2017-03-12, with intended 0 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-01-15 00:00:00, ended at 2017-01-15 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-15 07:21:00, ended at 2017-01-15 07:49:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Splitting of blood or blood products, each unit\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Transfusion, blood or blood components\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Disorder of pancreas\n- Primary malignant neoplasm of retroperitoneum\n- Secondary malignant neoplasm of left lung\n- Disorder of adrenal gland\n- Secondary malignant neoplasm of lung\n- Localized enlarged lymph nodes\n- Secondary malignant neoplasm of right lung\n- Secondary malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-15 07:50:00, ended at 2017-01-15 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 49 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 88 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 161 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 18 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 17 (percent)\n- MCHC [Mass/volume] by Automated count: 31.9 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 38 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 27.9 (percent)\n- Hemoglobin [Mass/volume] in Blood: 8.9 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.9 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 100.5 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 224 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.08 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 21.8 (percent)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.66 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.1 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.90 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 17 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Leukocytes [#/volume] in Body fluid by Manual count: 3 (milli-international unit per milliliter)\n- MCH [Entitic mass] by Automated count: 32.0 (picogram)\n- Monocytes [#/volume] in Blood by Manual count: 0.66 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.78 (million per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Transfusion, blood or blood components\n- Splitting of blood or blood products, each unit\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Secondary malignant neoplasm of right lung\n- Type 2 diabetes mellitus without complication\n- Gastroesophageal reflux disease without esophagitis\n- Hypothyroidism\n- Essential hypertension\n- Primary malignant neoplasm\n- Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplasm of left lung\n- Iron deficiency anemia\n- Ascites\n- Hyperlipidemia\n- Dysuria\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-01-15, presumably until 2017-01-15\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2017-01-15, presumably until 2017-01-15\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2017-01-15, presumably until 2017-01-15\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-01-15, presumably until 2017-01-15\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2017-01-15, presumably until 2017-01-15\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-01-15, presumably until 2017-01-15\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-01-15, presumably until 2017-01-15\n- 0.6 ML pegfilgrastim 10 MG/ML Injection, through Subcutaneous route, started on 2017-01-15, presumably until 2017-01-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-01-15 09:02:27, ended at 2017-01-15 10:41:09\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2017-01-15, presumably until 2017-02-05, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily 40 mg daily x 1, 30 mg daily x 1 , 20 mg daily x 1, 10 mg daily x 1, 5 mg daily x 1.\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2017-01-15, presumably until 2017-02-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-01-23 00:00:00, ended at 2017-01-23 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2017-01-23, presumably until 2017-11-25, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day Take 1 tab by mouth twice daily with meals.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-01-26 00:00:00, ended at 2017-01-26 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-26 08:18:00, ended at 2017-01-26 10:02:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 42.3 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Disorder due to and following drug poisoning\n- Rheumatic tricuspid valve regurgitation\n- Disorder due to and following accidental poisoning\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-26 10:03:00, ended at 2017-01-26 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 81 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.40 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.5 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.2 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 113 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.96 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.1 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 112 (millimole per liter)\n- Platelets [#/volume] in Blood by Automated count: 147 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 0.98 (thousand per microliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.42 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 97.6 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 63.0 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 231 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 27.1 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.7 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 1.6 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.5 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.2 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-01-27 11:30:00, ended at 2017-01-27 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.5 ML filgrastim 0.6 MG/ML Prefilled Syringe, started on 2017-01-27, presumably until 2017-01-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-02-05 00:00:00, ended at 2017-02-05 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-02-05 00:00:00, ended at 2017-02-05 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-02-05 00:00:00, ended at 2017-02-05 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2017-02-05, presumably until 2017-08-22, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily 40 mg daily x 1, 30 mg daily x 1 , 20 mg daily x 1, 10 mg daily x 1, 5 mg daily x 1.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-02-05 00:00:00, ended at 2017-02-05 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-02-05 10:31:00, ended at 2017-02-05 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.2 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.67 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.85 (thousand per microliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 16.0 (percent)\n- MCV [Entitic volume] by Automated count: 97.3 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 19.9 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.85 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.0 (percent)\n- MCH [Entitic mass] by Automated count: 31.9 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 62.6 (percent)\n- Platelets [#/volume] in Blood by Automated count: 56 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 113 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.68 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.3 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 192 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 112 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.87 (million per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.4 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.3 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Collection of venous blood by venipuncture\n- Transfusion, blood or blood components\n\n### Condition\n- Hypothyroidism\n- Essential hypertension\n- Ascites\n- Hyperlipidemia\n- Primary malignant neoplasm\n- Secondary malignant neoplasm of left lung\n- Type 2 diabetes mellitus without complication\n- Gastroesophageal reflux disease without esophagitis\n- Dysuria\n- Iron deficiency anemia\n- Secondary malignant neoplasm of right lung\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2017-02-05, presumably until 2017-02-05\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-02-05, presumably until 2017-02-05\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-02-05, presumably until 2017-02-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-02-05 11:30:29, ended at 2017-02-05 12:53:31\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.984\" (inch (US))\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Transfusion, blood or blood components\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Iron deficiency anemia\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-02-10 14:00:00, ended at 2017-02-10 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocyte distribution width [Ratio] by Automated count: 22.4 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 115 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.3 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.2 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.85 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.8 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.3 (milligram per deciliter)\n- Leukocytes [#/volume] in Body fluid by Manual count: 1 (milli-international unit per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 11 (percent)\n- Neutrophils/100 leukocytes in Blood by Manual count: 58 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 17 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.93 (million per microliter)\n- MCV [Entitic volume] by Automated count: 98.1 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.99 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 22 (percent)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.5 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 116 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.50 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 169 (unit per liter)\n- Platelets [#/volume] in Blood by Automated count: 253 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n\n### Procedure\n- Application of on-body injector (includes cannula insertion) for timed subcutaneous injection\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-02-10, presumably until 2017-02-10\n- 2 ML prochlorperazine 5 MG/ML Injection, started on 2017-02-10, presumably until 2017-02-10\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2017-02-10, presumably until 2017-02-10\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2017-02-10, presumably until 2017-02-10\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-02-10, presumably until 2017-02-10\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-02-10, presumably until 2017-02-10\n- 0.6 ML pegfilgrastim 10 MG/ML Injection, through Subcutaneous route, started on 2017-02-10, presumably until 2017-02-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-02-14 00:00:00, ended at 2017-02-14 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2017-02-14, presumably until 2017-04-05, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-02-16 00:00:00, ended at 2017-02-16 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2017-02-16, presumably until 2017-05-24, with intended 5 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-02-20 00:00:00, ended at 2017-02-20 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Finding of frequency of urination\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-02-21 00:00:00, ended at 2017-02-21 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-toxic uninodular goiter\n- Vitamin D deficiency\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-02-22 00:00:00, ended at 2017-02-22 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cystitis\n\n### Drug\n- sulfamethoxazole 800 MG / trimethoprim 160 MG Oral Tablet, through Oral route, started on 2017-02-22, presumably until 2017-03-04, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-02-22 00:00:00, ended at 2017-02-22 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cystitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-03-12 00:00:00, ended at 2017-03-12 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.8 ML filgrastim 0.6 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2017-03-14, presumably until 2017-07-12, with intended 5 refill(s). Instructions: inject 0.8 mL subcutaneous (under the skin) daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-03-12 07:37:00, ended at 2017-03-12 09:17:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Acquired absence of organ\n- Secondary malignant neoplasm of left lung\n- Absent kidney\n- Secondary malignant neoplasm of right lung\n- Vitamin D deficiency\n- Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplastic disease\n- Secondary malignant neoplasm of adrenal gland\n- Secondary malignant neoplasm of lung\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-03-12, presumably until 2017-03-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-03-12 09:18:00, ended at 2017-03-12 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 45.2 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Disorder due to and following drug poisoning\n- Disorder due to and following accidental poisoning\n- Primary malignant neoplasm of soft tissues\n- Rheumatic tricuspid valve regurgitation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-03-12 12:46:42, ended at 2017-03-12 14:18:18\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Takotsubo cardiomyopathy\n- Primary diagnosis: Cardiomyopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-03-12 14:36:42, ended at 2017-03-12 16:32:10\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2017-03-12, presumably until 2017-06-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-03-12 15:49:23, ended at 2017-03-12 17:52:34\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-03-13 00:00:00, ended at 2017-03-13 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cystitis\n\n### Drug\n- nitrofurantoin, macrocrystals 50 MG Oral Capsule, through Oral route, started on 2017-03-13, presumably until 2017-06-10, with intended 2 refill(s). Instructions: take 1 Baxley by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-03-13 08:00:00, ended at 2017-03-13 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Ascites\n- Dysuria\n- Iron deficiency anemia\n- Secondary malignant neoplasm of right lung\n- Essential hypertension\n- Hyperlipidemia\n- Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplasm of left lung\n- Hypothyroidism\n- Type 2 diabetes mellitus without complication\n- Primary malignant neoplasm\n- Gastroesophageal reflux disease without esophagitis\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-03-13, presumably until 2017-03-13\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2017-03-13, presumably until 2017-03-13\n- 2 ML prochlorperazine 5 MG/ML Injection, started on 2017-03-13, presumably until 2017-03-13\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2017-03-13, presumably until 2017-03-13\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2017-03-13, presumably until 2017-03-13\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-03-13, presumably until 2017-03-13\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-03-13, presumably until 2017-03-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-03-14 00:00:00, ended at 2017-03-14 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-04-05 00:00:00, ended at 2017-04-05 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2017-04-05, presumably until 2017-06-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-07 11:20:00, ended at 2017-04-07 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.4 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.87 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 35.8 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.53 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 27.5 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 33.2 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 31.6 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 111 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 26.3 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 0.61 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 198 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.38 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 8.5 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Anion gap in Serum or Plasma: 3 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 113 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.7 (percent)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 175 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 1.9 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 110.2 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.64 (thousand per microliter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Anemia\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-04-07, presumably until 2017-04-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-04-08 00:00:00, ended at 2017-04-08 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-08 08:17:00, ended at 2017-04-08 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Transfusion, blood or blood components\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Collection of venous blood by venipuncture\n\n### Condition\n- Anemia\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.5 ML filgrastim 0.6 MG/ML Prefilled Syringe, started on 2017-04-08, presumably until 2017-04-08\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-04-08, presumably until 2017-04-08\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-04-08, presumably until 2017-04-08\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2017-04-08, presumably until 2017-04-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-04-09 00:00:00, ended at 2017-04-09 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-04-14 14:42:00, ended at 2017-04-14 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 111 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 101 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 200 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.4 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.44 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.2 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.78 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.2 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 23.5 (percent)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.94 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 18.4 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.0 (percent)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 33.2 (picogram)\n- MCV [Entitic volume] by Automated count: 102.2 (femtoliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.95 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.1 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.32 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 325 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.1 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 11.4 (gram per deciliter)\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-04-14, presumably until 2017-04-14\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2017-04-14, presumably until 2017-04-14\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2017-04-14, presumably until 2017-04-14\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-04-14, presumably until 2017-04-14\n- prochlorperazine 10 MG Oral Tablet, through Oral route, started on 2017-04-14, presumably until 2017-04-14\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-04-14, presumably until 2017-04-14\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2017-04-14, presumably until 2017-04-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-04-20 00:00:00, ended at 2017-04-20 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Generalized ischemic myocardial dysfunction\n\n### Drug\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2017-04-20, presumably until 2017-09-05, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals pt only taking it once a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-05-10 00:00:00, ended at 2017-05-10 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.025 MG Oral Tablet, through Oral route, started on 2017-05-10, presumably until 2017-07-12, with intended 3 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast Take daily with the 200 mcg tablet\n- levothyroxine sodium 0.2 MG Oral Tablet, through Oral route, started on 2017-05-10, presumably until 2017-07-12, with intended 3 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast Take daily with 25 mcg tablet\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-05-10 00:00:00, ended at 2017-05-10 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Folate [Mass/volume] in Red Blood Cells: 290 (nanogram per milliliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 0.9 (nanogram per deciliter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 562 (picogram per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-05-10 00:00:00, ended at 2017-05-10 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-05-10 07:35:00, ended at 2017-05-10 09:25:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Non-toxic multinodular goiter\n- Non-toxic uninodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-05-10 07:35:00, ended at 2017-05-10 09:25:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-05-10, presumably until 2017-05-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-05-10 09:26:00, ended at 2017-05-10 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.14 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 33.7 (picogram)\n- MCV [Entitic volume] by Automated count: 103.8 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 164 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.1 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.3 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 2.8 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 43 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 162 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 32 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.1 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 17 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.90 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.70 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 84 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.48 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 9.05 (micro-international unit per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.04 (milligram per deciliter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Acquired hypothyroidism\n- Non-toxic uninodular goiter\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-05-10, presumably until 2017-05-10\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2017-05-10, presumably until 2017-05-10\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2017-05-10, presumably until 2017-05-10\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2017-05-10, presumably until 2017-05-10\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-05-10, presumably until 2017-05-10\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-05-10, presumably until 2017-05-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-05-10 10:34:40, ended at 2017-05-10 11:47:59\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.984\" (inch (US))\n- Triiodothyronine (T3) Free [Mass/volume] in Serum or Plasma: 1.9 (picogram per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Acquired hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-05-11 00:00:00, ended at 2017-05-11 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 41.2 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-05-11 07:00:00, ended at 2017-05-11 13:24:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Transfusion, blood or blood components\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Takotsubo cardiomyopathy\n- Cardiomyopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-05-11 13:25:00, ended at 2017-05-11 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Transfusion, blood or blood components\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2017-05-11, presumably until 2017-05-11\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-05-11, presumably until 2017-05-11\n- 0.8 ML filgrastim 0.6 MG/ML Prefilled Syringe, started on 2017-05-11, presumably until 2017-05-11\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-05-11, presumably until 2017-05-11\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2017-05-11, presumably until 2017-05-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-05-12 09:10:00, ended at 2017-05-12 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.8 ML filgrastim 0.6 MG/ML Prefilled Syringe, started on 2017-05-12, presumably until 2017-05-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-05-16 00:00:00, ended at 2017-05-16 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Nausea and vomiting\n\n### Drug\n- prochlorperazine 10 MG Oral Tablet, started on 2017-05-16, presumably until 2018-07-10, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY 8 HOURS AS NEEDED FOR NAUSEA OR VOMITING\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-05-24 00:00:00, ended at 2017-05-24 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- amitriptyline hydrochloride 75 MG Oral Tablet, through Oral route, started on 2017-05-25, presumably until 2017-10-22, with intended 3 refill(s). Instructions: take 1 Tab by mouth every bedtime as needed\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2017-05-25, presumably until 2017-11-29, with intended 5 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-06-08 00:00:00, ended at 2017-06-08 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2017-06-08, presumably until 2017-06-15, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-06-08 00:00:00, ended at 2017-06-08 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2017-06-08, presumably until 2017-09-18, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2017-06-08, presumably until 2017-08-20, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-08 10:43:00, ended at 2017-06-08 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 169 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 100.0 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.3 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.3 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.02 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Triiodothyronine (T3) Free [Mass/volume] in Serum or Plasma: 2.1 (picogram per milliliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 6.12 (micro-international unit per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.09 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 23.0 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.68 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 281 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.00 (million per microliter)\n- MCH [Entitic mass] by Automated count: 33.4 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.68 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.6 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 97 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.0 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 18.3 (percent)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hypothyroidism\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-06-08, presumably until 2017-06-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-08 11:28:16, ended at 2017-06-08 12:11:22\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- amoxicillin 875 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2017-06-08, presumably until 2017-06-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day for 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-08 13:01:05, ended at 2017-06-08 14:13:21\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.984\" (inch (US))\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n- Benign neoplasm of left adrenal gland\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-06-09 12:17:00, ended at 2017-06-09 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2017-06-09, presumably until 2017-06-09\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2017-06-09, presumably until 2017-06-09\n- 2 ML prochlorperazine 5 MG/ML Injection, started on 2017-06-09, presumably until 2017-06-09\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2017-06-09, presumably until 2017-06-09\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2017-06-09, presumably until 2017-06-09\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-06-09, presumably until 2017-06-09\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-06-09, presumably until 2017-06-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-06-11 00:00:00, ended at 2017-06-11 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-06-11 12:41:58, ended at 2017-06-11 13:15:24\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Cardiomyopathy\n- Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-07-10 12:18:00, ended at 2017-07-10 13:53:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Secondary malignant neoplasm of lung\n- Non-toxic uninodular goiter\n- Disorder of pancreas\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-07-10 13:54:00, ended at 2017-07-10 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n\n### Condition\n- Non-toxic uninodular goiter\n- Non-toxic multinodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-07-12 00:00:00, ended at 2017-07-12 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-07-12 08:30:00, ended at 2017-07-12 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 129 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.9 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.75 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.7 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 123 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 27.2 (percent)\n- MCH [Entitic mass] by Automated count: 34.7 (picogram)\n- Calcium [Mass/volume] in Serum or Plasma: 8.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.60 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.62 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 59 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 22.9 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.96 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 298 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.0 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.4 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 73.9 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 6.41 (micro-international unit per milliliter)\n- Triiodothyronine (T3) Free [Mass/volume] in Serum or Plasma: 1.8 (picogram per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.94 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 104.5 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n\n### Procedure\n- Transfusion, blood or blood components\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Osteoporosis\n- Iron deficiency anemia due to blood loss\n- Hypothyroidism\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-07-12, presumably until 2017-07-12\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-07-12, presumably until 2017-07-12\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2017-07-12, presumably until 2017-07-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-07-12 09:38:25, ended at 2017-07-12 10:32:02\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.984\" (inch (US))\n- Ferritin [Mass/volume] in Serum or Plasma: 46.7 (nanogram per milliliter)\n- Triiodothyronine (T3) Free [Mass/volume] in Serum or Plasma: 1.6 (picogram per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Osteoporosis\n- Primary diagnosis: Iron deficiency anemia due to blood loss\n- Hypothyroidism\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2017-07-12, presumably until 2017-07-16, with intended 6 refill(s). Instructions: take 1 Tab by mouth every 12 hours as needed\n- levothyroxine sodium 0.125 MG Oral Capsule, through Oral route, started on 2017-07-12, presumably until 2017-07-20, with intended 6 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n- temozolomide 140 MG Oral Capsule, through Oral route, started on 2017-07-12, presumably until 2017-08-20, with intended 6 refill(s). Instructions: take 1 Cap by mouth daily Daily x 21 days, off 1 week\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-07-16 00:00:00, ended at 2017-07-16 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Nausea\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2017-07-16, presumably until 2017-12-19, with intended 6 refill(s). Instructions: take 1 Tab by mouth as directed Take 1 tablet one hour before taking Temodar.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-07-20 00:00:00, ended at 2017-07-20 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- levothyroxine sodium 0.175 MG Oral Tablet, through Oral route, started on 2017-07-20, presumably until 2018-01-25, with intended 3 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast Total 275 mcg (100 + 175 mcg pills)\n- levothyroxine sodium 0.125 MG Oral Capsule, through Oral route, started on 2017-07-20, presumably until 2017-07-26, with intended 3 refill(s). Instructions: take 2 Caps by mouth every day Patient with absorption issues.\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2017-07-20, presumably until 2018-01-25, with intended 3 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast Total 275 mcg (100 + 175 mcg pills)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-07-26 00:00:00, ended at 2017-07-26 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypothyroidism\n- Primary diagnosis: Intestinal malabsorption\n\n### Drug\n- levothyroxine sodium 0.125 MG Oral Capsule, through Oral route, started on 2017-07-26, presumably until 2017-09-05, with intended 3 refill(s). Instructions: take 2 Caps by mouth every day Patient with absorption issues.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-08-05 00:00:00, ended at 2017-08-05 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, started on 2017-08-16, presumably until 2017-11-25, with intended 0 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH TWICE A WEEK\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-10 00:00:00, ended at 2017-08-10 00:00:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-20 00:00:00, ended at 2017-08-20 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Cortisol [Mass/volume] in Serum or Plasma: 4.9 (microgram per deciliter)\n- Testosterone Free/Testosterone.total in Serum or Plasma: 0.1 (nanogram per deciliter)\n- Testosterone [Mass/volume] in Serum or Plasma: 8 (nanogram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-20 00:00:00, ended at 2017-08-20 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- temozolomide 100 MG Oral Capsule, through Oral route, started on 2017-08-20, presumably until 2017-11-09, with intended 5 refill(s). Instructions: take 1 Cap by mouth daily\n- temozolomide 20 MG Oral Capsule, through Oral route, started on 2017-08-20, presumably until 2017-11-09, with intended 5 refill(s). Instructions: take 1 Cap by mouth daily To take with Temozolomide 100 mg capsule\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-08-20 00:00:00, ended at 2017-08-20 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2017-08-20, presumably until 2017-10-10, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-20 07:47:00, ended at 2017-08-20 08:49:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Secondary malignant neoplasm of lung\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-20 08:50:00, ended at 2017-08-20 10:41:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 115 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.3 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 116 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 11.0 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.7 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.68 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 301 (thousand per microliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 4 (nanogram per milliliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.32 (million per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.47 (micro-international unit per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 17 (nanogram per milliliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.63 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 33.1 (picogram)\n- MCV [Entitic volume] by Automated count: 100.9 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 21.6 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.0 (percent)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 21 (nanogram per milliliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.5 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.83 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 69.4 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.04 (milligram per deciliter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplasm of lung\n- Vitamin D deficiency\n- Hypothyroidism\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-08-20, presumably until 2017-08-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-22 00:00:00, ended at 2017-08-22 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2017-08-22, presumably until 2017-12-19, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-22 00:00:00, ended at 2017-08-22 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2017-08-22, presumably until 2017-11-19, with intended 3 refill(s). Instructions: take 1 Dunbar by mouth once a week\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-09-03 00:00:00, ended at 2017-09-03 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Iron deficiency anemia\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- folic acid 1 MG Oral Tablet, through Oral route, started on 2017-09-03, presumably until 2017-11-19, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-05 07:00:00, ended at 2017-09-05 09:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine)\n\n### Condition\n- Iron deficiency anemia due to blood loss\n- Disorder of bone\n- Osteoporosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-05 08:45:08, ended at 2017-09-05 09:46:40\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.748\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-05 10:00:00, ended at 2017-09-05 14:09:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 41.8 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Generalized ischemic myocardial dysfunction\n- Osteoporosis\n- Primary malignant neoplasm of soft tissues\n- Cardiomyopathy\n- Iron deficiency anemia\n- Iron deficiency anemia due to blood loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-05 11:57:56, ended at 2017-09-05 13:19:29\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Cardiomyopathy\n- Generalized ischemic myocardial dysfunction\n\n### Drug\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2017-09-05, presumably until 2018-07-27, with intended 6 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-05 14:10:00, ended at 2017-09-05 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Hypothyroidism\n- Primary malignant neoplasm of soft tissues\n- Vitamin D deficiency\n- Iron deficiency anemia\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2017-09-05, presumably until 2017-09-05\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-09-05, presumably until 2017-09-05\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-09-05, presumably until 2017-09-05\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-09-05, presumably until 2017-09-05\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2017-09-05, presumably until 2017-09-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-09-18 00:00:00, ended at 2017-09-18 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2017-09-18, presumably until 2017-11-09, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-28 07:30:00, ended at 2017-09-28 07:35:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Osteoporosis\n- Hypothyroidism\n- Non-toxic uninodular goiter\n- Secondary malignant neoplasm of lung\n- Vitamin D deficiency\n- Iron deficiency anemia\n- Primary malignant neoplasm of retroperitoneum\n- Anemia due to and following chemotherapy\n- Disorder of adrenal gland\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-28 07:36:00, ended at 2017-09-28 09:09:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 117 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Disorder of bone\n- Primary malignant neoplasm of soft tissues\n- Abnormal findings on diagnostic imaging of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-28 09:10:00, ended at 2017-09-28 14:29:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.24 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.93 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.7 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.83 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 280 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 97 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 21.7 (percent)\n- MCH [Entitic mass] by Automated count: 33.1 (picogram)\n- Triiodothyronine (T3) Free [Mass/volume] in Serum or Plasma: 1.4 (picogram per milliliter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 894 (picogram per milliliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 6.71 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 110 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.5 (percent)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.4 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.06 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 100.4 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 77.1 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 14 (unit per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.50 (micro-international unit per milliliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 105.3 (nanogram per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-28 09:39:52, ended at 2017-09-28 10:25:54\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.53 (micro-international unit per milliliter)\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Osteoporosis\n- Vitamin D deficiency\n- Disorder of adrenal gland\n- Non-toxic uninodular goiter\n- Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-09-28 12:24:01, ended at 2017-09-28 15:37:04\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.984\" (inch (US))\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Intravenous infusion, hydration; initial, 31 minutes to 1 hour\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-28 14:30:00, ended at 2017-09-28 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, hydration; initial, 31 minutes to 1 hour\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Hypothyroidism\n- Primary malignant neoplasm of soft tissues\n- Vitamin D deficiency\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-09-28, presumably until 2017-09-28\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2017-09-28, presumably until 2017-09-28\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2017-09-28, presumably until 2017-09-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-10-03 00:00:00, ended at 2017-10-03 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-10-10 00:00:00, ended at 2017-10-10 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2017-10-10, presumably until 2017-10-29, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-10-17 00:00:00, ended at 2017-10-17 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-10-22 00:00:00, ended at 2017-10-22 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amitriptyline hydrochloride 75 MG Oral Tablet, started on 2017-10-23, presumably until 2017-11-21, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY NIGHT AT BEDTIME AS NEEDED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-10-25 00:00:00, ended at 2017-10-25 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Impaired renal function disorder\n- Acquired absence of organ\n- Absent kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-10-29 00:00:00, ended at 2017-10-29 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2017-10-29, presumably until 2017-10-31, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-10-31 00:00:00, ended at 2017-10-31 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2017-10-31, presumably until 2017-12-19, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-07 00:00:00, ended at 2017-11-07 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hemorrhoids\n\n### Drug\n- mupirocin 0.02 MG/MG Topical Ointment, started on 2017-11-08, presumably until 2017-11-09, with intended 1 refill(s). Instructions: Apply to affected area BID prn rash\n- hydrocortisone acetate 25 MG Rectal Suppository, through Rectal route, started on 2017-11-07, presumably until 2017-11-19, with intended 3 refill(s). Instructions: insert 1 Suppository into the rectum daily as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-09 00:00:00, ended at 2017-11-09 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-11-09 08:22:00, ended at 2017-11-09 10:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 111 (milligram per deciliter)\n\n### Procedure\n- Transfusion, blood or blood components\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Secondary malignant neoplasm of lung\n- Secondary malignant neoplastic disease\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-11-09 08:22:00, ended at 2017-11-09 10:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-11-09 11:00:00, ended at 2017-11-09 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 139 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.3 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.6 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.08 (micro-international unit per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 66 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 105.3 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.53 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 84 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.97 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.0 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.70 (million per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.52 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 21.1 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 83.9 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.48 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 34.3 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 297 (thousand per microliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.4 (percent)\n\n### Procedure\n- Transfusion, blood or blood components\n\n### Condition\n- Hypothyroidism\n- Vitamin D deficiency\n- Disorder of pancreas\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2017-11-09, presumably until 2017-11-09\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2017-11-09, presumably until 2017-11-09\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2017-11-09, presumably until 2017-11-09\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-09 12:13:02, ended at 2017-11-09 14:14:42\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Cortisol [Mass/volume] in Serum or Plasma: 2.5 (microgram per deciliter)\n- Body height: 5' 5.984\" (inch (US))\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of pancreas\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- temozolomide 100 MG Oral Capsule, through Oral route, started on 2017-11-09, presumably until 2018-02-06, with intended 5 refill(s). Instructions: take 1 Cap by mouth daily\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, through Oral route, started on 2017-11-09, presumably until 2018-02-20, with intended 1 refill(s). Instructions: take 1-2 Caps by mouth 3 times a day with meals\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2017-11-09, presumably until 2017-12-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n- mupirocin 0.02 MG/MG Topical Ointment, started on 2017-11-09, presumably until 2018-04-26, with intended 2 refill(s). Instructions: Apply to affected area BID prn rash\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-11-13 00:00:00, ended at 2017-11-13 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2017-11-13, presumably until 2017-11-13, with intended 9 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-11-14 00:00:00, ended at 2017-11-14 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2017-11-14, presumably until 2017-12-19, with intended 9 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-19 08:52:21, ended at 2017-11-19 10:09:42\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Absent kidney\n- Chronic kidney disease stage 3\n- Acquired absence of organ\n- Primary diagnosis: Blood chemistry abnormal\n- Essential hypertension\n- Vitamin D deficiency\n\n### Drug\n- hydrocortisone 25 MG/ML Topical Cream, started on 2016-01-06, presumably until 2018-09-10, with intended 0 refill(s). Instructions: Apply to external hemorrhoid BID prn pain\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-11-19 10:14:00, ended at 2017-11-19 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Microalbumin/Creatinine [Mass Ratio] in Urine: <10 (milligram per gram)\n- Albumin [Mass/volume] in Urine: 8 (milligram per liter)\n- Protein/Creatinine [Mass Ratio] in Urine: 0.39 (milligram per milligram)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 49 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 131.00 (milligram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 6 - 10 (per high power field)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Acquired absence of organ\n- Blood chemistry abnormal\n- Vitamin D deficiency\n- Absent kidney\n- Primary malignant neoplasm of soft tissues\n- Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-21 00:00:00, ended at 2017-11-21 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-11-21 00:00:00, ended at 2017-11-21 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amitriptyline hydrochloride 75 MG Oral Tablet, started on 2017-11-22, presumably until 2017-12-19, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY NIGHT AT BEDTIME AS NEEDED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-11-25 00:00:00, ended at 2017-11-25 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2017-11-26, presumably until 2018-01-30, with intended 2 refill(s). Instructions: take 1 Cap by mouth 2 times per week\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-11-25 00:00:00, ended at 2017-11-25 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2017-11-26, presumably until 2018-01-25, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day Take 1 tab by mouth twice daily with meals.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-11-29 00:00:00, ended at 2017-11-29 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- dabigatran etexilate 150 MG Oral Capsule, started on 2017-12-03, presumably until 2017-12-30, with intended 0 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-30 00:00:00, ended at 2017-11-30 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- nitrofurantoin, macrocrystals 50 MG Oral Capsule, through Oral route, started on 2017-11-30, presumably until 2018-03-19, with intended 5 refill(s). Instructions: take 1 Zapanta by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-12-11 00:00:00, ended at 2017-12-11 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2017-12-11, presumably until 2018-04-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-12-17 00:00:00, ended at 2017-12-17 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-12-19 00:00:00, ended at 2017-12-19 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nausea\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2017-12-24, presumably until 2018-03-12, with intended 6 refill(s). Instructions: take 1 Tab by mouth as directed Take 1 tablet one hour before taking Temodar.\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2017-12-24, presumably until 2018-06-06, with intended 6 refill(s). Instructions: take 1 Tab by mouth every day\n- amitriptyline hydrochloride 75 MG Oral Tablet, through Oral route, started on 2017-12-24, presumably until 2018-01-29, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime as needed\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2017-12-24, presumably until 2018-01-25, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2017-12-24, presumably until 2018-01-16, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-12-19 00:00:00, ended at 2017-12-19 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2017-12-19, presumably until 2018-06-24, with intended 9 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-12-30 00:00:00, ended at 2017-12-30 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- dabigatran etexilate 150 MG Oral Capsule, started on 2017-12-31, presumably until 2018-01-25, with intended 0 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-01-15 08:08:19, ended at 2018-01-15 08:57:35\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; single lesion\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Verruca vulgaris\n- Primary diagnosis: Neoplastic disease of uncertain behavior\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-01-15 12:00:00, ended at 2018-01-15 12:02:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 131 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Neoplastic disease of uncertain behavior\n- Verruca vulgaris\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-01-15, presumably until 2018-01-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-01-15 12:03:00, ended at 2018-01-15 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-01-16 11:28:00, ended at 2018-01-16 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 18 (nanogram per milliliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.64 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.1 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 97.6 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.47 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 10.9 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 65 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.3 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 22 (nanogram per milliliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 12.9 (nanogram per milliliter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 271 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.3 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.9 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Urate [Mass/volume] in Serum or Plasma: 5.4 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 81 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.15 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.5 (percent)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 197 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.66 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.84 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.30 (micro-international unit per milliliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 164 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.8 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 73.6 (percent)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 4 (nanogram per milliliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.5 (percent)\n- Haptoglobin [Mass/volume] in Serum or Plasma: 182 (milligram per deciliter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Hypothyroidism\n- Primary malignant neoplasm of soft tissues\n- Vitamin D deficiency\n- Blood chemistry abnormal\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-01-16, presumably until 2018-01-16\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-01-16 12:22:08, ended at 2018-01-16 14:17:45\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.496\" (inch (US))\n- Lipase [Enzymatic activity/volume] in Serum or Plasma: 93 (unit per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Amylase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Blood chemistry abnormal\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Vitamin D deficiency\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-01-16, presumably until 2018-03-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-01-25 00:00:00, ended at 2018-01-25 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n- Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.175 MG Oral Tablet, through Oral route, started on 2018-01-25, presumably until 2018-03-27, with intended 3 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast Total 275 mcg (100 + 175 mcg pills)\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2018-01-25, presumably until 2018-03-27, with intended 3 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast Total 275 mcg (100 + 175 mcg pills)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-01-25 00:00:00, ended at 2018-01-25 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2018-01-25, presumably until 2018-04-26, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2018-01-25, presumably until 2018-03-19, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-01-25 00:00:00, ended at 2018-01-25 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2018-01-29, presumably until 2018-04-26, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day Take 1 tab by mouth twice daily with meals.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-01-28 00:00:00, ended at 2018-01-28 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-01-29 00:00:00, ended at 2018-01-29 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amitriptyline hydrochloride 75 MG Oral Tablet, through Oral route, started on 2018-01-29, presumably until 2018-04-26, with intended 5 refill(s). Instructions: take 1 Tab by mouth every bedtime as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-01-30 00:00:00, ended at 2018-01-30 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2018-01-31, presumably until 2018-02-20, with intended 2 refill(s). Instructions: take 1 Cap by mouth 2 times per week\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-02-06 00:00:00, ended at 2018-02-06 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- temozolomide 100 MG Oral Capsule, through Oral route, started on 2018-02-06, presumably until 2018-06-05, with intended 5 refill(s). Instructions: take 1 Cap by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-02-20 00:00:00, ended at 2018-02-20 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, started on 2018-02-21, presumably until 2018-04-26, with intended 0 refill(s). Instructions: TAKE 1 TO 2 CAPSULES BY MOUTH THREE TIMES DAILY WITH MEALS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-02-20 00:00:00, ended at 2018-02-20 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2018-02-20, presumably until 2018-03-27, with intended 2 refill(s). Instructions: take 1 Cap by mouth 3 times a week\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-03-04 00:00:00, ended at 2018-03-04 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- dabigatran etexilate 150 MG Oral Capsule, started on 2018-03-05, presumably until 2018-04-02, with intended 0 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-04 13:34:00, ended at 2018-03-04 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neoplasm of uncertain behavior of skin\n- Chronic kidney disease stage 3\n- Hypothyroidism\n- Vitamin D deficiency\n- Primary malignant neoplasm of soft tissues\n- Anemia due to and following chemotherapy\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-03-04, presumably until 2018-03-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-03-11 00:00:00, ended at 2018-03-11 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-03-13, presumably until 2018-04-25, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-03-12 00:00:00, ended at 2018-03-12 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Nausea\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2018-03-12, presumably until 2018-04-25, with intended 6 refill(s). Instructions: take 1 Tab by mouth as directed Take 1 tablet one hour before taking Temodar.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-03-19 00:00:00, ended at 2018-03-19 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-19 13:14:00, ended at 2018-03-19 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 17 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 17 (nanogram per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 114 (unit per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Low blood pressure\n- Renal agenesis\n- Chronic kidney disease stage 3\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-03-19 13:41:55, ended at 2018-03-19 15:27:09\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease stage 3\n- Low blood pressure\n- Renal agenesis\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-03-20 00:00:00, ended at 2018-03-20 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-20 08:30:00, ended at 2018-03-20 08:42:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cardiomyopathy\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-03-20, presumably until 2018-03-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-20 08:43:00, ended at 2018-03-20 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 143 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-21 07:10:00, ended at 2018-03-21 09:56:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 17 (nanogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 113 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 148 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.1 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.56 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 23.1 (percent)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.91 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 110.2 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 17 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.98 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 42 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.53 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.8 (percent)\n- Thyrotropin [Units/volume] in Serum or Plasma: 4.61 (micro-international unit per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.1 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 27.9 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.9 (percent)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.1 (nanogram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 96 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 9.1 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.47 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 36.0 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 75.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 243 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Vitamin D deficiency\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-03-21, presumably until 2018-03-21\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-03-21 08:23:49, ended at 2018-03-21 09:55:06\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.496\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-21 09:57:00, ended at 2018-03-21 14:45:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-21 14:46:00, ended at 2018-03-21 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 42.3 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Accidental poisoning\n- Poisoning by drug AND/OR medicinal substance\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-03-22 00:00:00, ended at 2018-03-22 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of retroperitoneum\n- Chronic kidney disease stage 3\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-03-22 00:00:00, ended at 2018-03-22 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n- Vitamin D deficiency\n- Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.15 MG Oral Capsule, started on 2018-03-27, presumably until 2018-06-12, with intended 11 refill(s). Instructions: Take 125 mcg + 150 mcg = total of 275 mcg cap daily\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2018-03-27, presumably until 2018-05-28, with intended 2 refill(s). Instructions: take 1 Cap by mouth every other day\n- levothyroxine sodium 0.125 MG Oral Capsule, started on 2018-03-27, presumably until 2018-06-12, with intended 11 refill(s). Instructions: Take 125 mcg + 150 mcg = total of 275 mcg cap daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-03-22 08:56:09, ended at 2018-03-22 09:51:43\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.496\" (inch (US))\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; single lesion\n- Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; each separate/additional lesion (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Neoplasm of uncertain behavior of skin\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2018-03-22, presumably until 2018-03-22\n- 1 ML epinephrine 1 MG/ML Injection, started on 2018-03-22, presumably until 2018-03-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-03-22 10:20:00, ended at 2018-03-22 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Transfusion, blood or blood components\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Chronic kidney disease stage 3\n- Primary malignant neoplasm of retroperitoneum\n- Anemia due to and following chemotherapy\n\n### Drug\n- 0.6 ML darbepoetin alfa 0.5 MG/ML Prefilled Syringe, started on 2018-03-22, presumably until 2018-03-22\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-03-22, presumably until 2018-03-22\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-03-22, presumably until 2018-03-22\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2018-03-22, presumably until 2018-03-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-04-01 00:00:00, ended at 2018-04-01 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Reticulocytes [#/volume] in Blood by Automated count: 63.1 (thousand per microliter)\n- Reticulocytes/100 erythrocytes in Blood by Automated count: 1.84 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Iron deficiency anemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-01 11:25:00, ended at 2018-04-01 14:49:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Neutrophils/100 leukocytes in Blood by Automated count: 79.5 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 104 (unit per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 17 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.1 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 4.9 (percent)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 978 (picogram per milliliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 25.5 (percent)\n- Folate [Mass/volume] in Red Blood Cells: 319 (nanogram per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 132 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 105.0 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.43 (million per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 158.6 (nanogram per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 11.9 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Iron [Mass/volume] in Serum or Plasma: 44 (microgram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.25 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 34.8 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 4.05 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 221 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.01 (micro-international unit per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.98 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.74 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.0 (percent)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Chronic kidney disease stage 3\n- Iron deficiency anemia\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-04-01 12:25:17, ended at 2018-04-01 13:03:39\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Iron deficiency anemia\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-04-01 12:58:54, ended at 2018-04-01 15:16:42\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.496\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-01 14:50:00, ended at 2018-04-01 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n\n### Condition\n- Primary diagnosis: Iron deficiency anemia\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-04-01, presumably until 2018-04-01\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-04-01, presumably until 2018-04-01\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-04-01, presumably until 2018-04-01\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2018-04-01, presumably until 2018-04-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-04-02 00:00:00, ended at 2018-04-02 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2018-04-02, presumably until 2018-05-06, with intended 3 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-04-03 00:00:00, ended at 2018-04-03 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Bronchitis\n\n### Drug\n- levofloxacin 500 MG Oral Tablet, through Oral route, started on 2018-04-03, presumably until 2018-04-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily for 10 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-04-19 00:00:00, ended at 2018-04-19 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-23 11:49:00, ended at 2018-04-23 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.91 (million per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 89.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 253 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Iron [Mass/volume] in Serum or Plasma: 50 (microgram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.1 (percent)\n- MCV [Entitic volume] by Automated count: 106.5 (femtoliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 301.6 (nanogram per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 133 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.87 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.71 (micro-international unit per milliliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.0 (percent)\n- MCH [Entitic mass] by Automated count: 35.2 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 19 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.8 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 11 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.10 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.3 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.2 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 104 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 21.7 (percent)\n- Globulin [Mass/volume] in Serum: 4.4 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Chronic kidney disease stage 3\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-04-23 13:25:04, ended at 2018-04-23 14:20:37\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Ventricular premature complex\n- Bifascicular block\n- Electrocardiogram abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-04-24 00:00:00, ended at 2018-04-24 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 10 ML bupivacaine hydrochloride 5 MG/ML Injection, started on 2018-04-24, presumably until 2018-04-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-04-24 00:00:00, ended at 2018-04-24 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on the integumentary system on the extremities, anterior trunk and perineum; not otherwise specified\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Primary malignant neoplasm of retroperitoneum\n- Essential hypertension\n- Obstructive sleep apnea syndrome\n\n### Drug\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2018-04-24, presumably until 2018-04-24\n- cefazolin 1000 MG Injection, started on 2018-04-24, presumably until 2018-04-24\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2018-04-24, presumably until 2018-04-24\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2018-04-24, presumably until 2018-04-24\n- 2 ML ondansetron 2 MG/ML Injection, started on 2018-04-24, presumably until 2018-04-24\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-04-24, presumably until 2018-04-24\n- midazolam 1 MG/ML Injectable Solution, started on 2018-04-24, presumably until 2018-04-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-24 09:34:00, ended at 2018-04-24 15:15:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- Excision of Chest Subcutaneous Tissue and Fascia, Open Approach\n- Repair, intermediate, wounds of scalp, axillae, trunk and/or extremities (excluding hands and feet); 7.6 cm to 12.5 cm\n- Repair Chest Subcutaneous Tissue and Fascia, Open Approach\n- Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter 3.1 to 4.0 cm\n\n### Condition\n- Secondary malignant neoplasm of lung\n- Primary malignant neoplasm of retroperitoneum\n- Secondary malignant neoplastic disease\n\n### Drug\n- 0.5 ML meperidine hydrochloride 50 MG/ML Injection, started on 2018-04-24, presumably until 2018-04-24\n- 2 ML ondansetron 2 MG/ML Injection, started on 2018-04-24, presumably until 2018-04-24\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2018-04-24, presumably until 2018-07-06, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-04-25 00:00:00, ended at 2018-04-25 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Neck pain\n- Primary malignant neoplasm of soft tissues\n- Nausea\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2018-04-25, presumably until 2018-05-31, with intended 6 refill(s). Instructions: take 1 Tab by mouth as directed Take 1 tablet one hour before taking Temodar daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-04-25 09:48:45, ended at 2018-04-25 11:10:11\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.496\" (inch (US))\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Nausea\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2018-04-25, presumably until 2018-04-25, with intended 6 refill(s). Instructions: take 1 Tab by mouth as directed Take 1 tablet one hour before taking Temodar.\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-04-25, presumably until 2018-06-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-25 11:18:00, ended at 2018-04-25 15:05:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Chronic kidney disease stage 3\n- Vitamin D deficiency\n- Primary malignant neoplasm of soft tissues\n- Hypothyroidism\n\n### Drug\n- 0.6 ML darbepoetin alfa 0.5 MG/ML Prefilled Syringe, started on 2018-04-25, presumably until 2018-04-25\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-04-25, presumably until 2018-04-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-04-25 15:06:00, ended at 2018-04-25 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation\n\n### Condition\n- Nausea\n- Neck pain\n- Chronic kidney disease stage 3\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-04-26 00:00:00, ended at 2018-04-26 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2018-04-26, presumably until 2018-07-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2018-04-26, presumably until 2018-06-19, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-04-26 00:00:00, ended at 2018-04-26 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-toxic uninodular goiter\n- Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.15 MG Oral Capsule, started on 2018-04-26, presumably until 2018-04-26, with intended 11 refill(s). Instructions: Take 125 mcg + 150 mcg = total of 275 mcg cap daily\n- levothyroxine sodium 0.125 MG Oral Capsule, started on 2018-04-26, presumably until 2018-04-26, with intended 11 refill(s). Instructions: Take 125 mcg + 150 mcg = total of 275 mcg cap daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-04-26 00:00:00, ended at 2018-04-26 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, started on 2018-04-26, presumably until 2018-05-28, with intended 0 refill(s). Instructions: TAKE 1 TO 2 CAPSULES BY MOUTH THREE TIMES DAILY WITH MEALS\n- amitriptyline hydrochloride 75 MG Oral Tablet, through Oral route, started on 2018-04-26, presumably until 2018-06-12, with intended 5 refill(s). Instructions: take 1 Tab by mouth every bedtime as needed\n- mupirocin 0.02 MG/MG Topical Ointment, started on 2018-04-26, presumably until 2018-09-10, with intended 2 refill(s). Instructions: Apply to affected area BID prn rash\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2018-04-26, presumably until 2018-09-14, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day Take 1 tab by mouth twice daily with meals.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-05-06 00:00:00, ended at 2018-05-06 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-05-06 00:00:00, ended at 2018-05-06 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2018-05-07, presumably until 2018-07-26, with intended 3 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-05-06 09:42:34, ended at 2018-05-06 11:03:39\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.496\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Hypothyroidism\n- Postoperative state\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-05-16 00:00:00, ended at 2018-05-16 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-05-28 00:00:00, ended at 2018-05-28 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Non-toxic uninodular goiter\n- Hypothyroidism\n- Vitamin D deficiency\n\n### Drug\n- levothyroxine sodium 0.15 MG Oral Capsule, started on 2018-05-28, presumably until 2018-05-28, with intended 11 refill(s). Instructions: Take 125 mcg + 150 mcg = total of 275 mcg cap daily\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2018-05-29, presumably until 2018-09-11, with intended 2 refill(s). Instructions: take 1 Cap by mouth every other day\n- levothyroxine sodium 0.125 MG Oral Capsule, started on 2018-05-28, presumably until 2018-05-28, with intended 11 refill(s). Instructions: Take 125 mcg + 150 mcg = total of 275 mcg cap daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-05-28 00:00:00, ended at 2018-05-28 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, started on 2018-05-28, presumably until 2018-07-06, with intended 0 refill(s). Instructions: TAKE 1 TO 2 CAPSULES BY MOUTH THREE TIMES DAILY WITH MEALS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-05-31 00:00:00, ended at 2018-05-31 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Nausea\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2018-05-31, presumably until 2018-06-12, with intended 6 refill(s). Instructions: take 1 Tab by mouth as directed Take 1 tablet one hour before taking Temodar daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-06-03 07:46:00, ended at 2018-06-03 12:25:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-06-03 07:46:00, ended at 2018-06-03 12:25:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 177 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-06-03 10:37:27, ended at 2018-06-03 11:15:15\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary diagnosis: Chronic kidney disease stage 3\n- Essential hypertension\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-06-03 12:26:00, ended at 2018-06-03 23:59:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 93 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- Iron [Mass/volume] in Serum or Plasma: 46 (microgram per deciliter)\n- MCH [Entitic mass] by Automated count: 36.6 (picogram)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.3 (percent)\n- Platelets [#/volume] in Blood by Automated count: 268 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 5.8 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Ferritin [Mass/volume] in Serum or Plasma: 167.2 (nanogram per milliliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 16 (percent)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.01 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 107.9 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.8 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.2 (nanogram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 155 (milligram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.88 (micro-international unit per milliliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.74 (million per microliter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Hypothyroidism\n- Vitamin D deficiency\n- Primary malignant neoplasm of soft tissues\n- Chronic kidney disease stage 3\n\n### Drug\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-06-03, presumably until 2018-06-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-06-03 13:29:31, ended at 2018-06-03 14:18:27\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.496\" (inch (US))\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 55 (unit per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-06-04 13:40:00, ended at 2018-06-05 20:36:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 107.4 (femtoliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 246 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 36.6 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 274 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.89 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.22 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 99 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 40 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.3 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 8.45 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 95.7 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.69 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.8 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.9 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 1.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Body height: 5' 5.945\" (inch (US))\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n\n### Procedure\n- Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n\n### Condition\n- Nausea\n- Old myocardial infarction\n- Chronic kidney disease stage 2\n- Iron deficiency anemia\n- Secondary malignant neoplasm of lung\n- Acquired absence of organ\n- Takotsubo cardiomyopathy\n- Acute insomnia\n- Hypothyroidism\n- Obesity\n- Vitamin D deficiency\n- Obstructive sleep apnea syndrome\n- Secondary malignant neoplasm of intra-abdominal lymph nodes\n- Absent kidney\n- Chronic systolic heart failure\n- Disorder of pancreas\n- Chronic congestive heart failure\n- Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- thiamine 100 MG Oral Tablet, through Oral route, started on 2018-06-05, presumably until 2018-06-05\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, through Oral route, started on 2018-06-04, presumably until 2018-06-05\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2018-06-05, presumably until 2018-06-05\n- 50 ML famotidine 0.4 MG/ML Injection, through Intravenous route, started on 2018-06-04, presumably until 2018-06-04\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2018-06-04, presumably until 2018-06-04\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-06-05, presumably until 2018-06-05\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-06-04, presumably until 2018-06-05\n- prednisone 2.5 MG Oral Tablet, through Oral route, started on 2018-06-05, presumably until 2018-06-05\n- hydrocortisone 25 MG/ML Topical Cream, through Topical route, started on 2018-06-04, presumably until 2018-06-05\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-06-04, presumably until 2018-06-04\n- amitriptyline hydrochloride 75 MG Oral Tablet, through Oral route, started on 2018-06-04, presumably until 2018-06-04\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2018-06-05, presumably until 2018-06-05\n- levothyroxine sodium 0.025 MG Oral Tablet, through Oral route, started on 2018-06-05, presumably until 2018-06-05\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-06-04, presumably until 2018-06-05\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-06-05, presumably until 2018-06-05\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2018-06-04, presumably until 2018-06-04\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2018-06-04, presumably until 2018-06-05\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2018-06-04, presumably until 2018-06-05\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2018-06-04, presumably until 2018-06-04\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2018-06-04, presumably until 2018-06-04\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2018-06-04, presumably until 2018-06-05\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2018-06-05, presumably until 2018-06-05\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2018-06-04, presumably until 2018-06-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-06-06 00:00:00, ended at 2018-06-06 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-06-06, presumably until 2018-07-05, with intended 6 refill(s). Instructions: take 1 Tab by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-06-07 00:00:00, ended at 2018-06-07 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-11 00:00:00, ended at 2018-06-11 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2018-06-13, presumably until 2018-06-13, with intended 2 refill(s). Instructions: take 1 Cap by mouth every other day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-11 00:00:00, ended at 2018-06-11 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-06-12, presumably until 2018-08-01, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-06-12 00:00:00, ended at 2018-06-12 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n- Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.125 MG Oral Tablet, started on 2018-06-12, presumably until 2018-07-26, with intended 11 refill(s). Instructions: Take 150 mcg tab + 125 mcg tab = total of 275 mcg dose, daily before breakfast\n- levothyroxine sodium 0.15 MG Oral Tablet, through Oral route, started on 2018-06-12, presumably until 2018-07-26, with intended 11 refill(s). Instructions: take 1 Tab by mouth every morning before breakfast Take 150 mcg tab + 125 mcg tab = total of 275 mcg dose daily before breakfast\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-06-12 00:00:00, ended at 2018-06-12 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nausea\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2018-06-12, presumably until 2018-06-27, with intended 6 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n- amitriptyline hydrochloride 75 MG Oral Tablet, through Oral route, started on 2018-06-12, presumably until 2018-06-12, with intended 5 refill(s). Instructions: take 1 Tab by mouth every bedtime as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-12 00:00:00, ended at 2018-06-12 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amitriptyline hydrochloride 75 MG Oral Tablet, started on 2018-06-12, presumably until 2018-07-06, with intended 5 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY NIGHT AT BEDTIME AS NEEDED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-06-19 00:00:00, ended at 2018-06-19 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2018-06-19, presumably until 2018-08-19, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-23 00:00:00, ended at 2018-06-23 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- lisinopril 5 MG Oral Tablet, started on 2018-06-24, presumably until 2018-12-23, with intended 1 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-27 00:00:00, ended at 2018-06-27 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2018-06-28, presumably until 2018-06-28, with intended 5 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-28 00:00:00, ended at 2018-06-28 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2018-06-28, presumably until 2018-08-19, with intended 5 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-29 00:00:00, ended at 2018-06-29 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2018-07-01, presumably until 2018-07-01, with intended 2 refill(s). Instructions: take 1 Cap by mouth every other day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-07-05 10:08:17, ended at 2018-07-05 11:24:54\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-07-05 12:18:00, ended at 2018-07-06 17:44:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 141 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 4.1 (percent)\n- MCH [Entitic mass] by Automated count: 37.1 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 1.46 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 24.3 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 8.28 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 63 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 47 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.4 (gram per deciliter)\n- Iron [Mass/volume] in Serum or Plasma: 79 (microgram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.8 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 108.9 (femtoliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 4.49 (micro-international unit per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.08 (milligram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 30 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 94.4 (percent)\n- Body height: 5' 5.157\" (inch (US))\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.1 (nanogram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 208 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.76 (million per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 509.1 (nanogram per milliliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.0 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.34 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 306 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n\n### Procedure\n- Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach\n- Hospital discharge day management; more than 30 minutes\n\n### Condition\n- Hypothyroidism\n- Post-surgical malabsorption\n- Atherosclerosis of coronary artery without angina pectoris\n- Chronic congestive heart failure\n- Insomnia\n- Nausea\n- Secondary malignant neoplasm of bone\n- Vitamin D deficiency\n- Generalized ischemic myocardial dysfunction\n- Acquired absence of spleen\n- Chronic kidney disease stage 3\n- Hypertensive heart and renal disease with (congestive) heart failure\n- Obstructive sleep apnea syndrome\n- Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplasm of intra-abdominal lymph nodes\n- Type 2 diabetes mellitus\n- Acquired absence of organ\n- Cardiomyopathy\n- Primary malignant neoplasm of retroperitoneum\n- Acute insomnia\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Headache\n- Chronic systolic heart failure\n- Secondary malignant neoplasm of left lung\n- Anemia in neoplastic disease\n- Disorder of pancreas\n- Secondary malignant neoplastic disease\n- Absent kidney\n- Asthenia\n\n### Drug\n- thiamine 100 MG Oral Tablet, through Oral route, started on 2018-07-06, presumably until 2018-07-06\n- 50 ML famotidine 0.4 MG/ML Injection, through Intravenous route, started on 2018-07-05, presumably until 2018-07-05\n- olanzapine 2.5 MG Oral Tablet, through Oral route, started on 2018-07-05, presumably until 2018-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime as needed (nausea, insomnia)\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-07-05, presumably until 2018-09-10, with intended 6 refill(s). Instructions: take 1 Tab by mouth every day While on prednisone\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-07-06, presumably until 2018-07-06\n- prednisone 2.5 MG Oral Tablet, through Oral route, started on 2018-07-06, presumably until 2018-07-06\n- hydrocortisone 25 MG/ML Topical Cream, through Topical route, started on 2018-07-06, presumably until 2018-07-06\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-07-05, presumably until 2018-07-05\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2018-07-06, presumably until 2018-07-06\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2018-07-06, presumably until 2018-07-06\n- levothyroxine sodium 0.025 MG Oral Tablet, through Oral route, started on 2018-07-06, presumably until 2018-07-06, with intended 0 refill(s). Instructions: take 11 Tabs by mouth every morning before breakfast\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-07-05, presumably until 2018-07-06\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2018-07-05, presumably until 2018-07-05\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2018-07-05, presumably until 2018-07-06\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2018-07-05, presumably until 2018-07-06\n- prochlorperazine 5 MG Oral Tablet, through Oral route, started on 2018-07-06, presumably until 2018-07-06\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2018-07-05, presumably until 2018-07-05\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2018-07-05, presumably until 2018-07-06\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2018-07-06, presumably until 2018-07-06\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2018-07-05, presumably until 2018-07-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-07-10 00:00:00, ended at 2018-07-10 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nausea and vomiting\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- prochlorperazine 10 MG Oral Tablet, started on 2018-07-10, presumably until 2019-03-20, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY 8 HOURS AS NEEDED FOR NAUSEA OR VOMITING\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-07-11 00:00:00, ended at 2018-07-11 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2018-07-11, presumably until 2018-08-19, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-07-25 10:54:38, ended at 2018-07-25 11:30:54\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Non-toxic uninodular goiter\n- Benign neoplasm of adrenal gland\n- Osteoporosis\n- Nausea\n- Vitamin D deficiency\n- Cancer-related fatigue\n- Hypothyroidism\n- Insomnia\n\n### Drug\n- levothyroxine sodium 0.15 MG Oral Capsule, started on 2018-06-15, presumably until 2018-07-30, with intended 0 refill(s)\n- levothyroxine sodium 0.125 MG Oral Capsule, started on 2018-06-15, presumably until 2018-07-26, with intended 0 refill(s)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-07-26 00:00:00, ended at 2018-07-26 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypothyroidism\n- Primary diagnosis: Non-toxic uninodular goiter\n\n### Drug\n- levothyroxine sodium 0.15 MG Oral Capsule, started on 2018-07-30, presumably until 2018-08-12, with intended 3 refill(s). Instructions: Tirosint 150 mcg , take 2 capsules by mouth daily = total of 300 mcg per day\n- levothyroxine sodium 0.15 MG Oral Tablet, started on 2018-07-30, presumably until 2018-09-13, with intended 3 refill(s). Instructions: Levothyroxine 150 mcg tablet, take 2 tabs by mouth before breakfast daily = total of 300 mcg per day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-07-26 00:00:00, ended at 2018-07-26 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-07-26 07:46:00, ended at 2018-07-26 10:19:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 133 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-07-26 10:20:00, ended at 2018-07-26 12:39:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 80 (unit per liter)\n- Iron [Mass/volume] in Serum or Plasma: 178 (microgram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.06 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 5 (nanogram per milliliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.99 (million per microliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 62 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.38 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 29 (nanogram per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.3 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 151 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 148 (milligram per deciliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: 24 (nanogram per milliliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.6 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.9 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 36.6 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 6.71 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 81.4 (percent)\n- Thyrotropin [Units/volume] in Serum or Plasma: 6.78 (micro-international unit per milliliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 76 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.11 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 26.3 (percent)\n- Ferritin [Mass/volume] in Serum or Plasma: 878.5 (nanogram per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 4.6 (percent)\n- Platelets [#/volume] in Blood by Automated count: 198 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.2 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 109.0 (femtoliter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Vitamin D deficiency\n- Chronic kidney disease stage 3\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm of retroperitoneum\n- Hypothyroidism\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-07-26 11:04:52, ended at 2018-07-26 11:59:35\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2018-07-26, presumably until 2019-04-16, with intended 3 refill(s). Instructions: take 1 Cap by mouth 2 times a day\n- 72 HR scopolamine 0.0139 MG/HR Transdermal System, through Transdermal route, started on 2018-07-26, presumably until 2018-07-27, with intended 3 refill(s). Instructions: apply 1 Patch to skin every 72 hours\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-07-26 12:40:00, ended at 2018-07-27 18:30:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.92 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 216 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.24 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.2 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.33 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.5 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.9 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.2 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 132 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 26.1 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 2.7 (percent)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 109 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.6 (gram per deciliter)\n- Left ventricular Ejection fraction: 39.6 (percent)\n- MCH [Entitic mass] by Automated count: 36.6 (picogram)\n- MCV [Entitic volume] by Automated count: 109.1 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 200 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 3.4 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 93.7 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 92 (unit per liter)\n- Body height: 5' 4.961\" (inch (US))\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.61 (million per microliter)\n\n### Procedure\n- Initial observation care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination \n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; initiation of prolonged chemotherapy infusion (more than 8 hours), requiring use of a portable or implantable pump\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Chemotherapy administration; intravenous, push technique, single or initial substance/drug\n\n### Condition\n- Pain due to neoplastic disease\n- Secondary malignant neoplasm of lymph node\n- Chronic congestive heart failure\n- Chronic kidney disease stage 3\n- Generalized ischemic myocardial dysfunction\n- Anemia in neoplastic disease\n- Chronic systolic heart failure\n- Secondary malignant neoplasm of lung\n- Electrocardiogram abnormal\n- Major depression, single episode\n- Cardiomyopathy\n- Disorder of pancreas\n- Non-toxic uninodular goiter\n- Hypothyroidism\n- Nausea\n- Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm of retroperitoneum\n- Secondary malignant neoplasm of bone\n- Vitamin D deficiency\n- Post-surgical malabsorption\n\n### Drug\n- thiamine 100 MG Oral Tablet, through Oral route, started on 2018-07-26, presumably until 2018-07-27\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, through Oral route, started on 2018-07-26, presumably until 2018-08-01, with intended 0 refill(s). Instructions: take by mouth\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2018-07-27, presumably until 2018-07-27\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2018-07-26, presumably until 2018-07-26\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-07-27, presumably until 2018-07-27\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-07-26, presumably until 2019-04-14, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 6 hours as needed for Pain (headache)\n- prednisone 2.5 MG Oral Tablet, through Oral route, started on 2018-07-27, presumably until 2018-07-27\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-07-26, presumably until 2018-07-26\n- amitriptyline hydrochloride 25 MG Oral Tablet, through Oral route, started on 2018-07-26, presumably until 2018-07-27\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2018-07-27, presumably until 2018-07-27\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2018-07-27, presumably until 2018-07-27\n- levothyroxine sodium 0.025 MG Oral Tablet, through Oral route, started on 2018-07-27, presumably until 2018-07-27\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2018-07-29, presumably until 2018-07-29, with intended 0 refill(s). Instructions: inject 0.6 mL subcutaneous (under the skin) One Time With Dr. Cunningham on 7/02\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2018-07-26, presumably until 2018-07-26\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-07-26, presumably until 2018-07-27\n- prochlorperazine 10 MG Oral Tablet, through Oral route, started on 2018-07-27, presumably until 2018-07-27\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2018-07-26, presumably until 2018-07-26\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2018-07-26, presumably until 2018-08-19, with intended 0 refill(s). Instructions: Take 1 tab in the Am and 2 tabs in the PM as previously prescribed by cardiology\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2018-07-26, presumably until 2018-07-27\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2018-07-26, presumably until 2018-07-26\n- loratadine 10 MG Oral Tablet, through Oral route, started on 2018-07-28, presumably until 2018-08-07, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily For 10 days with neulasta to prevent bone pain\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2018-07-26, presumably until 2018-07-26\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2018-07-26, presumably until 2018-07-27\n- 72 HR scopolamine 0.0139 MG/HR Transdermal System, through Transdermal route, started on 2018-07-26, presumably until 2018-09-10, with intended 3 refill(s). Instructions: apply 1 Patch to skin every 72 hours\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2018-07-27, presumably until 2018-07-27\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2018-07-26, presumably until 2018-07-26\n- magnesium sulfate 40 MG/ML Injection, through Intravenous route, started on 2018-07-27, presumably until 2018-07-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-08-01 00:00:00, ended at 2018-08-01 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, started on 2018-08-01, presumably until 2019-01-22, with intended 1 refill(s). Instructions: Take 1-2 caps TID with meals\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-08-01, presumably until 2018-08-19, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-08-01 00:00:00, ended at 2018-08-01 00:00:00\nThe patient in this visit was 57 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, through Oral route, started on 2018-08-01, presumably until 2018-08-01, with intended 0 refill(s). Instructions: take by mouth\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-08-01, presumably until 2018-08-01, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-19 09:03:00, ended at 2018-08-19 14:33:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 55 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 25.2 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.38 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 36.0 (picogram)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.4 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 16.1 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 78.6 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.2 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.4 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.0 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Iron [Mass/volume] in Serum or Plasma: 170 (microgram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 65 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 85 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 133 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.51 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 150 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.04 (million per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.37 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.7 (percent)\n- MCHC [Mass/volume] by Automated count: 33.5 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 30 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.01 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- MCV [Entitic volume] by Automated count: 107.4 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Ferritin [Mass/volume] in Serum or Plasma: 1379.2 (nanogram per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 4.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 211 (thousand per microliter)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm of retroperitoneum\n- Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-08-19 10:42:51, ended at 2018-08-19 11:19:28\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Generalized ischemic myocardial dysfunction\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2018-08-19, presumably until 2018-11-24, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2018-08-19, presumably until 2018-12-13, with intended 5 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed for Nausea\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2018-08-19, presumably until 2018-11-03, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-08-19, presumably until 2018-09-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n- carvedilol 3.125 MG Oral Tablet, started on 2018-08-19, presumably until 2018-08-20, with intended 3 refill(s). Instructions: Take 1 tab in the Am and 2 tabs in the PM as previously prescribed by cardiology\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-08-19 14:34:00, ended at 2018-08-20 20:04:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 3.3 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 145 (unit per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 113 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 35.4 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.00 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.37 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 212 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.4 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 92 (unit per liter)\n- Body height: 5' 4.961\" (inch (US))\n- Lymphocytes/100 leukocytes in Blood by Automated count: 3.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.7 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.0 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.37 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 108.3 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 93.8 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 25.3 (percent)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 28 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 214 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.4 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 10.67 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 18 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.13 (million per microliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Secondary malignant neoplasm of lung\n- Hypothyroidism\n- Takotsubo cardiomyopathy\n- Chronic kidney disease stage 3\n- Secondary malignant neoplasm of bone\n- Secondary malignant neoplasm of intrapelvic lymph nodes\n- Chronic kidney disease due to hypertension\n- Non-toxic uninodular goiter\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- thiamine 100 MG Oral Tablet, through Oral route, started on 2018-08-20, presumably until 2018-08-20\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, through Oral route, started on 2018-08-19, presumably until 2018-08-20\n- 50 ML famotidine 0.4 MG/ML Injection, through Intravenous route, started on 2018-08-19, presumably until 2018-08-19\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-08-20, presumably until 2018-08-20\n- prednisone 2.5 MG Oral Tablet, through Oral route, started on 2018-08-20, presumably until 2018-08-20\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-08-19, presumably until 2018-08-19\n- amitriptyline hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-08-19, presumably until 2018-08-19\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2018-08-20, presumably until 2018-08-20\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2018-08-20, presumably until 2018-08-20, with intended 0 refill(s). Instructions: inject 0.6 mL subcutaneous (under the skin) One Time 24-72 hours after chemotherapy\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-08-19, presumably until 2018-08-20\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-08-20, presumably until 2018-08-20\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2018-08-19, presumably until 2018-08-19\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2018-08-19, presumably until 2018-08-20\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2018-08-19, presumably until 2018-08-20\n- loratadine 10 MG Oral Tablet, through Oral route, started on 2018-08-20, presumably until 2019-04-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily (over the counter) take for 10 days during neulasta for bone pain\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2018-08-19, presumably until 2018-08-19\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2018-08-20, presumably until 2018-08-20\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2018-08-19, presumably until 2018-08-19\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-08-20 00:00:00, ended at 2018-08-20 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Generalized ischemic myocardial dysfunction\n\n### Drug\n- carvedilol 3.125 MG Oral Tablet, started on 2018-08-20, presumably until 2019-02-25, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY MORNING AND 2 TABLETS BY MOUTH EVERY EVENING\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-09-09 00:00:00, ended at 2018-09-09 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2018-09-11, presumably until 2018-09-12, with intended 11 refill(s). Instructions: take 1 Cap by mouth every other day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-09-09 00:00:00, ended at 2018-09-09 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amitriptyline hydrochloride 25 MG Oral Tablet, started on 2018-09-10, presumably until 2018-09-14, with intended 0 refill(s). Instructions: Start 25mg po nightly at bedtime, in 1 week increase to 50mg for 1 week then increase to 75mg.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-09-10 00:00:00, ended at 2018-09-10 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-09-10, presumably until 2019-01-22, with intended 6 refill(s). Instructions: take 1 Tab by mouth every day While on prednisone\n- hydrocortisone 25 MG/ML Topical Cream, started on 2018-09-10, presumably until 2019-04-14, with intended 2 refill(s). Instructions: Apply to external hemorrhoid BID prn pain\n- mupirocin 0.02 MG/MG Topical Ointment, started on 2018-09-10, presumably until 2019-04-14, with intended 2 refill(s). Instructions: Apply to affected area BID prn rash\n- 72 HR scopolamine 0.0139 MG/HR Transdermal System, through Transdermal route, started on 2018-09-10, presumably until 2018-12-14, with intended 3 refill(s). Instructions: apply 1 Patch to skin every 72 hours\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-09-10 00:00:00, ended at 2018-09-10 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, started on 2018-09-12, presumably until 2018-09-19, with intended 3 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH EVERY OTHER DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-09-11 00:00:00, ended at 2018-09-11 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2018-09-11, presumably until 2018-09-12, with intended 2 refill(s). Instructions: take 1 Cap by mouth every other day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-12 07:35:00, ended at 2018-09-12 09:49:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 40.2 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Generalized ischemic myocardial dysfunction\n- Cardiomyopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-12 09:50:00, ended at 2018-09-12 12:27:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-12 09:50:00, ended at 2018-09-12 12:27:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 128 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Secondary malignant neoplasm of right lung\n- Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplasm of left lung\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-09-12 12:28:00, ended at 2018-09-12 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 173 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 18 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.03 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Ferritin [Mass/volume] in Serum or Plasma: 1367.7 (nanogram per milliliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.08 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 112.3 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 78.5 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.5 (percent)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 52 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.44 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.78 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 233 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.89 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 123 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 37.1 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 48 (unit per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 70 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 23.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.7 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 35 (milligram per deciliter)\n- Iron [Mass/volume] in Serum or Plasma: 137 (microgram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.4 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 6.0 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.7 (percent)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Hypothyroidism\n- Primary malignant neoplasm of retroperitoneum\n- Visual disturbance\n- Chronic kidney disease stage 3\n- Vitamin D deficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-09-13 14:55:30, ended at 2018-09-13 16:25:22\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Intraocular pressure of left eye: 17 (millimeter mercury column)\n- Intraocular pressure of right eye: 16 (millimeter mercury column)\n\n### Procedure\n- Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; retina\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Tear film insufficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-09-13 17:15:00, ended at 2018-09-15 11:06:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 2 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 113 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.77 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 234 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 163 (unit per liter)\n- Body height: 5' 5\" (inch (US))\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 75 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 31 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.7 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 36.7 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 232 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 24.0 (percent)\n- Leukocytes [#/volume] in Body fluid by Manual count: 1 (milli-international unit per milliliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.15 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 71 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.2 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.01 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.9 (percent)\n- MCV [Entitic volume] by Automated count: 111.4 (femtoliter)\n\n### Procedure\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach\n- Hospital discharge day management; more than 30 minutes\n\n### Condition\n- Acquired absence of organ\n- Acquired absence of spleen\n- Atherosclerosis of coronary artery without angina pectoris\n- Pain due to neoplastic disease\n- Suicidal thoughts\n- Absent kidney\n- Generalized ischemic myocardial dysfunction\n- Insomnia\n- Iron deficiency anemia\n- Chronic kidney disease due to hypertension\n- Secondary malignant neoplasm of lymph node\n- Anemia in neoplastic disease\n- Cardiomyopathy\n- Disorder of digestive system\n- Hypothyroidism\n- Post-surgical malabsorption\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplasm of lung\n- Vitamin D deficiency\n- Disorder of pancreas\n- Old myocardial infarction\n- Chronic kidney disease stage 3\n- Major depression, single episode\n- Nausea\n- Obesity\n- Secondary malignant neoplasm of bone\n\n### Drug\n- thiamine 100 MG Oral Tablet, through Oral route, started on 2018-09-14, presumably until 2018-09-15\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, through Oral route, started on 2018-09-13, presumably until 2018-09-15\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2018-09-14, presumably until 2018-09-15\n- 50 ML famotidine 0.4 MG/ML Injection, through Intravenous route, started on 2018-09-13, presumably until 2018-09-13\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2018-09-13, presumably until 2018-09-14\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-09-14, presumably until 2018-09-15\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-09-13, presumably until 2018-09-13\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2018-09-14, presumably until 2018-09-14\n- amitriptyline hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-09-13, presumably until 2019-04-14, with intended 0 refill(s). Instructions: take 75 mg by mouth every bedtime \n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2018-09-14, presumably until 2018-09-15\n- levothyroxine sodium 0.025 MG Oral Tablet, through Oral route, started on 2018-09-14, presumably until 2018-09-15\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2018-09-14, presumably until 2018-09-15\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-09-14, presumably until 2018-09-15\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2018-09-13, presumably until 2018-09-14\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2018-09-13, presumably until 2018-09-15\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2018-09-13, presumably until 2018-09-15\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2018-09-13, presumably until 2018-09-13\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2018-09-13, presumably until 2019-01-13, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals.\n- 72 HR scopolamine 0.0139 MG/HR Transdermal System, through Transdermal route, started on 2018-09-14, presumably until 2018-09-14\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2018-09-14, presumably until 2018-09-15\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2018-09-13, presumably until 2018-09-13\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2018-09-14, presumably until 2018-09-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-09-19 00:00:00, ended at 2018-09-19 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2018-09-19, presumably until 2018-10-17, with intended 3 refill(s). Instructions: take 1 Cap by mouth 3 times a week\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-09-25 13:38:34, ended at 2018-09-25 14:54:06\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Chest pain\n- Electrocardiogram abnormal\n- Ventricular premature complex\n- Old myocardial infarction\n- Primary diagnosis: Cardiomyopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-10-11 07:29:00, ended at 2018-10-11 13:38:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.62 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 3.4 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.3 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 81.8 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 41 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.01 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.9 (percent)\n- MCV [Entitic volume] by Automated count: 118.0 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 68 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 37.5 (picogram)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 111 (millimole per liter)\n- Ferritin [Mass/volume] in Serum or Plasma: 837.0 (nanogram per milliliter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.8 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.33 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 31.8 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 146 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 147 (milligram per deciliter)\n- Iron [Mass/volume] in Serum or Plasma: 118 (microgram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.30 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.04 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 225 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 21.8 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Chronic kidney disease stage 3\n- Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-10-11 13:39:00, ended at 2018-10-12 17:49:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 218 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.94 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Body height: 5' 5.354\" (inch (US))\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration; intravenous, push technique, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Pain due to neoplastic disease\n- Primary malignant neoplasm of soft tissues\n- Insomnia\n- Nausea\n- Secondary malignant neoplasm of lung\n- Secondary malignant neoplasm of bone\n- Secondary malignant neoplasm of lymph node\n- Hypothyroidism\n- Polyneuropathy\n- Primary diagnosis: Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- epoetin alfa 20000 UNT/ML Injectable Solution, started on 2018-10-11, presumably until 2018-10-11\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, through Oral route, started on 2018-10-11, presumably until 2018-10-12\n- 2 ML prochlorperazine 5 MG/ML Injection, started on 2018-10-11, presumably until 2018-10-11\n- 50 ML famotidine 0.4 MG/ML Injection, through Intravenous route, started on 2018-10-11, presumably until 2018-10-11\n- Abuse-Deterrent 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2018-10-12, presumably until 2018-10-12\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-10-11, presumably until 2018-10-12\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-10-11, presumably until 2018-10-11\n- vitamin B12 1 MG/ML Injectable Solution, started on 2018-10-11, presumably until 2018-10-12\n- amitriptyline hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-10-11, presumably until 2018-10-11\n- 0.5 ML influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 an..., through Intramuscular route, started on 2018-10-11, presumably until 2018-10-11\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-10-11, presumably until 2018-10-11\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2018-10-12, presumably until 2018-10-12\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2018-10-11, presumably until 2018-10-11\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2018-10-11, presumably until 2018-10-12\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2018-10-11, presumably until 2018-10-12\n- levothyroxine sodium 0.137 MG Oral Tablet, through Oral route, started on 2018-10-12, presumably until 2018-10-12\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2018-10-11, presumably until 2018-10-12\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2018-10-11, presumably until 2018-10-11\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2018-10-11, presumably until 2018-10-12\n- magnesium chloride 598 MG Delayed Release Oral Tablet, through Oral route, started on 2018-10-12, presumably until 2018-10-12\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2018-10-12, presumably until 2018-10-12\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2018-10-11, presumably until 2018-10-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-10-17 00:00:00, ended at 2018-10-17 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, started on 2018-10-17, presumably until 2018-10-17, with intended 3 refill(s). Instructions: Take 1 capsule ,  every other day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-10-17 00:00:00, ended at 2018-10-17 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Vitamin D deficiency\n\n### Drug\n- ergocalciferol 1.25 MG Oral Capsule, started on 2018-10-18, presumably until 2019-02-14, with intended 3 refill(s). Instructions: TAKE 1 CAPSULE BY MOUTH EVERY OTHER DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-10-30 00:00:00, ended at 2018-10-30 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-10-31, presumably until 2019-01-24, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-10-31 00:00:00, ended at 2018-10-31 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-01 00:00:00, ended at 2018-11-01 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-01 00:00:00, ended at 2018-11-01 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-01 00:00:00, ended at 2018-11-01 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-01 07:40:00, ended at 2018-11-01 08:27:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Neutrophils/100 leukocytes in Blood by Automated count: 77.1 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 49 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.1 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 112.1 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 889.4 (nanogram per milliliter)\n- Glucose [Mass/volume] in Serum or Plasma: 145 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 190 (thousand per microliter)\n- Thiamine pyrophosphate [Moles/volume] in Blood: 194 (nanomole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.95 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.9 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5.5 (percent)\n- MCH [Entitic mass] by Automated count: 36.7 (picogram)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.3 (percent)\n- Iron [Mass/volume] in Serum or Plasma: 127 (microgram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.50 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.47 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 64 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 184 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.97 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 16.1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.02 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 27.0 (percent)\n\n### Procedure\n- Collection of blood specimen from a completely implantable venous access device\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n- Polyneuropathy\n- Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-01 08:28:00, ended at 2018-11-01 16:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 154 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-01 08:28:00, ended at 2018-11-01 16:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-11-01 13:40:25, ended at 2018-11-01 15:14:33\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.961\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- magnesium oxide 400 MG Oral Capsule, through Oral route, started on 2018-11-01, presumably until 2019-04-14, with intended 3 refill(s). Instructions: take 400 mg by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-11-01 15:19:16, ended at 2018-11-01 16:28:34\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.961\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cancer-related fatigue\n- Nausea\n- Primary diagnosis: Pain due to neoplastic disease\n\n### Drug\n- Abuse-Deterrent 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2018-11-01, presumably until 2019-01-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- methylphenidate hydrochloride 5 MG Oral Tablet, through Oral route, started on 2018-11-01, presumably until 2019-01-24, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day as needed (fatigue)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-11-01 17:00:00, ended at 2018-11-03 13:09:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 26.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.4 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5 (percent)\n- MCV [Entitic volume] by Automated count: 112.1 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 96.4 (percent)\n- Body height: 5' 3.78\" (inch (US))\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Monocytes [#/volume] in Blood by Manual count: 1.17 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 91 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.83 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.22 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 60 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.017 (nanogram per milliliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.00 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 227 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 31.7 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.7 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 0.59 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 37.2 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 10 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 10.33 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 30 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 170 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 187 (thousand per microliter)\n\n### Procedure\n- Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)\n- Hospital discharge day management; more than 30 minutes\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Chronic kidney disease stage 3\n- Pain due to neoplastic disease\n- Acquired absence of organ\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Disorder of pancreas\n- Hypothyroidism\n- Insomnia\n- Obstructive sleep apnea syndrome\n- Old myocardial infarction\n- Polyneuropathy\n- Chronic congestive heart failure\n- Hypertensive heart and renal disease with (congestive) heart failure\n- Major depression, single episode\n- Atherosclerosis of coronary artery without angina pectoris\n- Chronic systolic heart failure\n- Absent kidney\n- Chronic gout without tophus\n- Disorder of digestive system\n- Electrocardiogram abnormal\n- Secondary malignant neoplasm of bone\n- Acquired absence of spleen\n- Chest pain\n- Post-surgical malabsorption\n- Primary malignant neoplasm of retroperitoneum\n- Type 2 diabetes mellitus\n- Iron deficiency anemia\n- Nausea\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplasm of lung\n- Vitamin D deficiency\n- Secondary malignant neoplasm of lymph nodes of multiple sites\n- Takotsubo cardiomyopathy\n\n### Drug\n- epoetin alfa 20000 UNT/ML Injectable Solution, started on 2018-11-01, presumably until 2018-11-01\n- thiamine 100 MG Oral Tablet, through Oral route, started on 2018-11-02, presumably until 2018-11-03\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, through Oral route, started on 2018-11-01, presumably until 2018-11-03\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2018-11-02, presumably until 2018-11-03\n- 50 ML famotidine 0.4 MG/ML Injection, through Intravenous route, started on 2018-11-01, presumably until 2018-11-01\n- Abuse-Deterrent 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2018-11-02, presumably until 2018-11-03\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2018-11-02, presumably until 2018-11-02\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-11-02, presumably until 2018-11-03\n- 0.5 ML varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML Injection, through Intramuscular route, started on 2018-11-02, presumably until 2018-11-02\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-11-02, presumably until 2018-11-02\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2018-11-02, presumably until 2018-11-03\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-11-01, presumably until 2018-11-01\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2018-11-02, presumably until 2018-11-03\n- vitamin B12 1 MG/ML Injectable Solution, started on 2018-11-01, presumably until 2018-11-03\n- amitriptyline hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-11-01, presumably until 2018-11-02\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2018-11-02, presumably until 2018-11-03\n- levothyroxine sodium 0.025 MG Oral Tablet, through Oral route, started on 2018-11-02, presumably until 2018-11-03\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2018-11-03, presumably until 2018-12-14, with intended 0 refill(s). Instructions: take 2 Tabs by mouth daily\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-11-01, presumably until 2018-11-01\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2018-11-01, presumably until 2018-11-02\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2018-11-01, presumably until 2018-11-03\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2018-11-01, presumably until 2018-11-03\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2018-11-01, presumably until 2018-11-01\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2018-11-01, presumably until 2018-11-03\n- aluminum hydroxide 40 MG/ML / magnesium hydroxide 40 MG/ML / simethicone 4 MG/ML Oral Suspension, through Oral route, started on 2018-11-03, presumably until 2018-11-03\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2018-11-02, presumably until 2018-11-03\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2018-11-01, presumably until 2018-11-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-06 00:00:00, ended at 2018-11-06 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-11-18 00:00:00, ended at 2018-11-18 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- levothyroxine sodium 0.137 MG Oral Capsule, through Oral route, started on 2018-11-21, presumably until 2018-11-21, with intended 0 refill(s). Instructions: take 2.0073 Caps by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-18 00:00:00, ended at 2018-11-18 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- levothyroxine sodium 0.137 MG Oral Capsule, through Oral route, started on 2018-11-18, presumably until 2019-02-14, with intended 3 refill(s). Instructions: take 2.0073 Caps by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-22 10:30:00, ended at 2018-11-22 14:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.42 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 184 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.5 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.13 (milligram per deciliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 940.8 (nanogram per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 9.6 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.8 (percent)\n- MCV [Entitic volume] by Automated count: 113.2 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 86.8 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 166 (unit per liter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 70 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.49 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.2 (percent)\n- Iron [Mass/volume] in Serum or Plasma: 107 (microgram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 55 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.24 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 192 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 81 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 24.9 (percent)\n- MCH [Entitic mass] by Automated count: 38.6 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.0 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.84 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Chronic kidney disease stage 3\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-11-22 10:51:32, ended at 2018-11-22 11:52:36\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.551\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Obstructive sleep apnea syndrome\n- Primary malignant neoplasm of soft tissues\n- Disorder of pancreas\n- Generalized ischemic myocardial dysfunction\n- Hypothyroidism\n- Iron deficiency anemia\n- Non-toxic uninodular goiter\n- Atherosclerosis of coronary artery without angina pectoris\n- Chronic kidney disease stage 3\n- Takotsubo cardiomyopathy\n- Post-surgical malabsorption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-11-22 14:19:33, ended at 2018-11-22 15:02:15\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.551\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-22 15:00:00, ended at 2018-11-22 16:15:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 51.3 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Poisoning by drug AND/OR medicinal substance\n- Accidental poisoning\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-22 16:16:00, ended at 2018-11-22 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.157\" (inch (US))\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2018-11-22, presumably until 2018-11-22\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-11-23 14:45:00, ended at 2018-11-24 19:10:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 78 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 165 (unit per liter)\n- Body height: 5' 5.157\" (inch (US))\n- Erythrocyte distribution width [Ratio] by Automated count: 24.4 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 38.3 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 8.84 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Glucose [Mass/volume] in Blood: 244 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 286 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.22 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.94 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 26 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.2 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 115.9 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 1.1 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 96.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.60 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 212 (thousand per microliter)\n\n### Procedure\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Hospital discharge day management; 30 minutes or less\n- Introduction of Monoclonal Antibody into Central Vein, Percutaneous Approach\n\n### Condition\n- Disorder of pancreas\n- Hypothyroidism\n- Old myocardial infarction\n- Primary diagnosis: Chronic kidney disease stage 3\n- Essential hypertension\n- Secondary malignant neoplasm of bone\n- Cardiomyopathy\n- Vitamin D deficiency\n- Pain due to neoplastic disease\n- Atherosclerosis of coronary artery without angina pectoris\n- Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplasm of lung\n- Iron deficiency anemia\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- epoetin alfa 20000 UNT/ML Injectable Solution, started on 2018-11-23, presumably until 2018-11-23\n- thiamine 100 MG Oral Tablet, through Oral route, started on 2018-11-24, presumably until 2018-11-24\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, through Oral route, started on 2018-11-23, presumably until 2018-11-24\n- Abuse-Deterrent 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2018-11-24, presumably until 2018-11-24\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2018-11-24, presumably until 2018-12-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed (for nausea or anxiety)\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-11-24, presumably until 2018-11-24\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-11-24, presumably until 2018-11-24\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2018-11-24, presumably until 2018-11-24\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-11-23, presumably until 2018-11-23\n- ergocalciferol 1.25 MG Oral Capsule, through Oral route, started on 2018-11-24, presumably until 2018-11-24\n- amitriptyline hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-11-23, presumably until 2018-11-23\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2018-11-23, presumably until 2018-11-23\n- prochlorperazine 10 MG Oral Tablet, through Oral route, started on 2018-11-24, presumably until 2018-11-24\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2018-11-23, presumably until 2018-11-23\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2018-11-23, presumably until 2018-11-24\n- 2 ML ondansetron 2 MG/ML Injection, started on 2018-11-23, presumably until 2018-11-23\n- levothyroxine sodium 0.137 MG Oral Tablet, through Oral route, started on 2018-11-24, presumably until 2018-11-24\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2018-11-23, presumably until 2018-11-24\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2018-11-23, presumably until 2018-11-23\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2018-11-23, presumably until 2018-11-24\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2018-11-24, presumably until 2018-11-24\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2018-11-23, presumably until 2018-11-23\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-25 00:00:00, ended at 2018-11-25 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Polyneuropathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-11-25 00:00:00, ended at 2018-11-25 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-11-25 11:26:43, ended at 2018-11-25 14:07:45\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.354\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Polyneuropathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-11-25 15:17:00, ended at 2018-11-25 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2018-11-25, presumably until 2018-11-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-02 00:00:00, ended at 2018-12-02 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-05 08:14:00, ended at 2018-12-05 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- MCH [Entitic mass] by Automated count: 37.5 (picogram)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.12 (million per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 1101.8 (nanogram per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 114.2 (femtoliter)\n- Iron [Mass/volume] in Serum or Plasma: 152 (microgram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.6 (percent)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 53 (percent)\n- Platelets [#/volume] in Blood by Automated count: 122 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.0 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 29.0 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Night blindness\n- Chronic kidney disease stage 3\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-12-05 08:39:37, ended at 2018-12-05 10:36:20\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.551\" (inch (US))\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 91 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.30 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 177 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 208 (unit per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Primary diagnosis: Night blindness\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-12-06 00:00:00, ended at 2018-12-06 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 20 MG/ML Injectable Solution, started on 2018-12-06, presumably until 2018-12-06\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-06 00:00:00, ended at 2018-12-06 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for closed chest procedures; (including bronchoscopy) not otherwise specified\n\n### Condition\n- Obstructive sleep apnea syndrome\n- Gastroesophageal reflux disease without esophagitis\n- Secondary malignant neoplasm of left lung\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2018-12-06, presumably until 2018-12-06\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2018-12-06, presumably until 2018-12-06\n- cefazolin 1000 MG Injection, started on 2018-12-06, presumably until 2018-12-06\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2018-12-06, presumably until 2018-12-06\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2018-12-06, presumably until 2018-12-06\n- 2 ML ondansetron 2 MG/ML Injection, started on 2018-12-06, presumably until 2018-12-06\n- midazolam 1 MG/ML Injectable Solution, started on 2018-12-06, presumably until 2018-12-06\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-06 06:13:00, ended at 2018-12-07 09:36:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n- INR in Blood by Coagulation assay: 1.1 (ratio)\n\n### Procedure\n- Radiologic examination, chest; single view\n- Ablation therapy for reduction or eradication of 1 or more pulmonary tumor(s) including pleura or chest wall when involved by tumor extension, percutaneous, including imaging guidance when performed, unilateral; cryoablation\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Autoimmune thyroiditis\n- Generalized ischemic myocardial dysfunction\n- Obstructive sleep apnea syndrome\n- Old myocardial infarction\n- Primary malignant neoplasm of pancreas\n- Absent kidney\n- Acquired absence of organ\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Chronic kidney disease stage 3\n- Secondary malignant neoplasm of left lung\n- Abnormal findings on diagnostic imaging of lung\n- Acquired absence of spleen\n- Secondary malignant neoplasm of lung\n- Atherosclerosis of coronary artery without angina pectoris\n- Chronic kidney disease due to hypertension\n- Iron deficiency anemia\n- Obesity\n- Primary malignant neoplasm of retroperitoneum\n- Type 2 diabetes mellitus\n\n### Drug\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, through Oral route, started on 2018-12-07, presumably until 2018-12-07\n- Abuse-Deterrent 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2018-12-06, presumably until 2018-12-07\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-12-06, presumably until 2018-12-06\n- levothyroxine sodium 0.125 MG Oral Tablet, through Oral route, started on 2018-12-07, presumably until 2018-12-07\n- amitriptyline hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-12-06, presumably until 2018-12-06\n- levothyroxine sodium 0.025 MG Oral Tablet, through Oral route, started on 2018-12-07, presumably until 2018-12-07\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2018-12-06, presumably until 2018-12-06\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-12-06, presumably until 2018-12-06\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2018-12-06, presumably until 2018-12-06\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2018-12-06, presumably until 2018-12-06\n- levofloxacin 500 MG Oral Tablet, through Oral route, started on 2018-12-03, presumably until 2019-01-22, with intended 0 refill(s). Instructions: take 500 mg by mouth daily Take for 1 week\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2018-12-06, presumably until 2018-12-06\n- 2 ML ondansetron 2 MG/ML Injection, started on 2018-12-06, presumably until 2018-12-06\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-12-06, presumably until 2018-12-06\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2018-12-07, presumably until 2018-12-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-12 00:00:00, ended at 2018-12-12 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-12 07:47:00, ended at 2018-12-12 14:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 163 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 89.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 52 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 110.8 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.4 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 141 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 26.8 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.9 (percent)\n- Retinol [Mass/volume] in Serum or Plasma: 5.9 (microgram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 184 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.92 (thousand per microliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.57 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.5 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.28 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.8 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.00 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 37.8 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.0 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.79 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 151 (thousand per microliter)\n\n### Procedure\n- Therapeutic radiology treatment planning; complex\n- Special treatment procedure (eg, total body irradiation, hemibody radiation, per oral or endocavitary irradiation)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplastic disease\n- Night blindness\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-12 07:47:00, ended at 2018-12-12 14:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; thoracic\n\n### Condition\n- Malignant neoplasm of connective and soft tissue of thorax\n- Primary malignant neoplasm of soft tissues\n- Primary malignant neoplasm of trunk\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-12-12, presumably until 2018-12-12\n- gadobenate, through Intravenous route, started on 2018-12-12, presumably until 2018-12-12\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2018-12-12, presumably until 2018-12-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-12 07:47:00, ended at 2018-12-12 14:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-12 07:47:00, ended at 2018-12-12 14:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 144 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-12 07:47:00, ended at 2018-12-12 14:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-12 15:00:00, ended at 2018-12-12 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Ferritin [Mass/volume] in Serum or Plasma: 788.2 (nanogram per milliliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 14 (percent)\n- Iron [Mass/volume] in Serum or Plasma: 31 (microgram per deciliter)\n- Body height: 5' 4.567\" (inch (US))\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n- Chronic kidney disease stage 3\n\n### Drug\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2018-12-12, presumably until 2018-12-12\n- 2 ML ondansetron 2 MG/ML Injection, started on 2018-12-12, presumably until 2018-12-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-13 00:00:00, ended at 2018-12-13 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2018-12-13, presumably until 2019-01-03, with intended 2 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-13 07:15:00, ended at 2018-12-13 16:23:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Unlisted procedure, medical radiation physics, dosimetry and treatment devices, and special services\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-12-13 16:24:00, ended at 2018-12-14 21:44:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Urine: 62.65 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.22 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 39.0 (picogram)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 334 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 167 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.3 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 157 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 9.62 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 114.9 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.2 (millimole per liter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.08 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Body height: 5' 5.748\" (inch (US))\n- Erythrocytes [#/volume] in Blood by Automated count: 2.44 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.0 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 96.5 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Sodium/Creatinine [Molar ratio] in Urine: 163 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: >1000 (picogram per milliliter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 66 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.7 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 26.9 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.0 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n\n### Procedure\n- Hospital discharge day management; more than 30 minutes\n- Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach\n\n### Condition\n- Acquired absence of organ\n- Chronic congestive heart failure\n- Obstructive sleep apnea syndrome\n- Atherosclerosis of coronary artery without angina pectoris\n- Cardiomyopathy\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Polyneuropathy due to drug\n- Vitamin D deficiency\n- Major depression, single episode\n- Pain due to neoplastic disease\n- Urinary tract infectious disease\n- Anemia in neoplastic disease\n- Hypothyroidism\n- Old myocardial infarction\n- Primary malignant neoplasm of soft tissues\n- Post-surgical malabsorption\n- Secondary malignant neoplasm of lung\n- Type 2 diabetes mellitus\n- Absent kidney\n- Acquired absence of spleen\n- Chronic kidney disease stage 3\n- Chronic systolic heart failure\n- Takotsubo cardiomyopathy\n- Anemia due to and following chemotherapy\n- Nausea\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- epoetin alfa 20000 UNT/ML Injectable Solution, started on 2018-12-13, presumably until 2018-12-13\n- thiamine 100 MG Oral Tablet, through Oral route, started on 2018-12-14, presumably until 2018-12-14\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, through Oral route, started on 2018-12-13, presumably until 2018-12-14\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2018-12-14, presumably until 2018-12-14\n- 2 ML prochlorperazine 5 MG/ML Injection, started on 2018-12-14, presumably until 2018-12-14\n- Abuse-Deterrent 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2018-12-14, presumably until 2018-12-14\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2018-12-14, presumably until 2019-01-03, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed (for nausea or anxiety)\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2018-12-13, presumably until 2018-12-13\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-12-14, presumably until 2018-12-14\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2018-12-14, presumably until 2019-02-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily\n- 5 ML palonosetron 0.05 MG/ML Injection, through Intravenous route, started on 2018-12-13, presumably until 2018-12-13\n- amitriptyline hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-12-13, presumably until 2018-12-13\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2018-12-14, presumably until 2018-12-14\n- levothyroxine sodium 0.025 MG Oral Tablet, through Oral route, started on 2018-12-14, presumably until 2018-12-14\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2018-12-14, presumably until 2018-12-14\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2018-12-13, presumably until 2018-12-13\n- lisinopril 5 MG Oral Tablet, through Oral route, started on 2018-12-13, presumably until 2018-12-13\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2018-12-13, presumably until 2018-12-14\n- levofloxacin 500 MG Oral Tablet, through Oral route, started on 2018-12-14, presumably until 2018-12-14\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2018-12-13, presumably until 2018-12-14\n- magnesium lactate 84 MG Extended Release Oral Tablet, through Oral route, started on 2018-12-14, presumably until 2018-12-14\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2018-12-13, presumably until 2018-12-13\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2018-12-13, presumably until 2018-12-14\n- 72 HR scopolamine 0.0139 MG/HR Transdermal System, through Transdermal route, started on 2018-12-14, presumably until 2019-01-13, with intended 3 refill(s). Instructions: apply 1 Patch to skin every 72 hours\n- aluminum hydroxide 40 MG/ML / magnesium hydroxide 40 MG/ML / simethicone 4 MG/ML Oral Suspension, through Oral route, started on 2018-12-14, presumably until 2018-12-14\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2018-12-14, presumably until 2018-12-14\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2018-12-13, presumably until 2018-12-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-15 14:36:00, ended at 2018-12-15 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- 0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2018-12-15, presumably until 2018-12-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-17 04:20:00, ended at 2018-12-17 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan\n- Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, onl\n- Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications\n\n### Condition\n- Secondary malignant neoplastic disease\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-12-21 00:00:00, ended at 2018-12-21 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- lisinopril 5 MG Oral Tablet, started on 2018-12-21, presumably until 2018-12-21, with intended 0 refill(s). Instructions: GENERIC FOR ZESTRIL--- TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-23 00:00:00, ended at 2018-12-23 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- lisinopril 5 MG Oral Tablet, started on 2018-12-23, presumably until 2019-01-24, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY (evening)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-23 14:54:00, ended at 2018-12-23 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereotactic body radiation therapy, treatment management, per treatment course, to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions\n- Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions\n- Therapeutic radiology simulation-aided field setting; simple\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Secondary malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-24 00:00:00, ended at 2018-12-24 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 68 (unit per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-24 08:35:00, ended at 2018-12-24 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions\n\n### Condition\n- Chronic kidney disease stage 3\n- Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplastic disease\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-25 08:42:00, ended at 2018-12-25 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions\n\n### Condition\n- Secondary malignant neoplastic disease\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-26 10:42:00, ended at 2018-12-26 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions\n\n### Condition\n- Secondary malignant neoplastic disease\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-27 08:45:00, ended at 2018-12-27 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions\n\n### Condition\n- Secondary malignant neoplastic disease\n- Primary malignant neoplasm of retroperitoneum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-01-03 11:49:00, ended at 2019-01-03 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 68 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.8 (percent)\n- MCH [Entitic mass] by Automated count: 38.8 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.8 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.43 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 77.3 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 4.3 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 158 (unit per liter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.8 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.11 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 22 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 1566.2 (nanogram per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.0 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 153 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.79 (million per microliter)\n- Iron [Mass/volume] in Serum or Plasma: 119 (microgram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.30 (thousand per microliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 24.5 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 152 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 117.6 (femtoliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.1 (milligram per deciliter)\n- Body height: 5' 4.055\" (inch (US))\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.22 (milligram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 47 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n- Chronic kidney disease stage 3\n\n### Drug\n- 50 ML famotidine 0.4 MG/ML Injection, through Intravenous route, started on 2019-01-03, presumably until 2019-01-03\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2019-01-03, presumably until 2019-01-03\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2019-01-03, presumably until 2019-01-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-01-03 12:40:41, ended at 2019-01-03 15:19:59\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.961\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2019-01-03, presumably until 2019-02-14, with intended 1 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed (for nausea or anxiety)\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2019-01-03, presumably until 2019-04-14, with intended 2 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-01-13 00:00:00, ended at 2019-01-13 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- Abuse-Deterrent 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2019-01-14, presumably until 2019-02-10, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-13 00:00:00, ended at 2019-01-13 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Nausea and vomiting\n\n### Drug\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2019-01-13, presumably until 2019-01-24, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals.\n- 72 HR scopolamine 0.0139 MG/HR Transdermal System, through Transdermal route, started on 2019-01-13, presumably until 2019-03-12, with intended 3 refill(s). Instructions: apply 1 Patch to skin every 72 hours\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-01-13 00:00:00, ended at 2019-01-13 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, started on 2019-01-13, presumably until 2019-01-24, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH TWICE DAILY WITH MEALS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-01-21 00:00:00, ended at 2019-01-21 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2019-01-22, presumably until 2019-01-24, with intended 0 refill(s). Instructions: GENERIC FOR PROTONIX--- TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-22 00:00:00, ended at 2019-01-22 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Dysuria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-01-22 08:52:04, ended at 2019-01-22 10:45:17\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.528\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Pain due to neoplastic disease\n- Primary diagnosis: Polyneuropathy\n\n### Drug\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2019-01-22, presumably until 2019-02-14, with intended 0 refill(s). Instructions: take 1 Cap by mouth 3 times a day Start at 300mg TID. If this improves your symptoms we may consider 600 mg at bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-01-23 08:36:00, ended at 2019-01-23 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-01-23 08:36:00, ended at 2019-01-23 08:36:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Blood: 197 (milligram per deciliter)\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-01-24 00:00:00, ended at 2019-01-24 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- methylphenidate hydrochloride 5 MG Oral Tablet, through Oral route, started on 2019-01-24, presumably until 2019-07-23, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day as needed (fatigue)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-01-24 00:00:00, ended at 2019-01-24 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2019-01-24, presumably until 2019-01-26, with intended 11 refill(s). Instructions: take 1 Tab by mouth daily\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2019-01-24, presumably until 2019-02-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n- calcium carbonate 1250 MG / cholecalciferol 200 UNT Oral Tablet, through Oral route, started on 2019-01-24, presumably until 2019-04-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day with meals\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-01-24 00:00:00, ended at 2019-01-24 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- lisinopril 5 MG Oral Tablet, started on 2019-01-24, presumably until 2019-03-01, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY (evening)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-24 00:00:00, ended at 2019-01-24 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- methylphenidate hydrochloride 5 MG Oral Tablet, through Oral route, started on 2019-01-24, presumably until 2019-02-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day as needed (fatigue)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-01-24 12:26:00, ended at 2019-01-24 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.22 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCH [Entitic mass] by Automated count: 38.1 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 239 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 100 (unit per liter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.57 (million per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 843 (nanogram per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 84.2 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.9 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 259 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.3 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.3 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.42 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 117.9 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.11 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5.8 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.9 (percent)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n- Dysuria\n- Primary malignant neoplasm of retroperitoneum\n- Chronic kidney disease stage 3\n\n### Drug\n- epoetin alfa 20000 UNT/ML Injectable Solution, started on 2019-01-24, presumably until 2019-01-24\n- 0.5 ML varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML Injection, through Intramuscular route, started on 2019-01-24, presumably until 2019-01-24\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2019-01-24, presumably until 2019-01-24\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2019-01-24, presumably until 2019-01-24\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2019-01-24, presumably until 2019-01-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-01-24 13:25:06, ended at 2019-01-24 15:06:42\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4.528\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-01-26 00:00:00, ended at 2019-01-26 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2019-01-27, presumably until 2019-04-14, with intended 11 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-02-10 00:00:00, ended at 2019-02-10 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- Abuse-Deterrent 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2019-02-12, presumably until 2019-03-11, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-11 00:00:00, ended at 2019-02-11 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, through Oral route, started on 2019-02-11, presumably until 2019-03-01, with intended 2 refill(s). Instructions: take 1-2 Caps by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-02-13 15:56:00, ended at 2019-02-13 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen; without contrast material\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-14 00:00:00, ended at 2019-02-14 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-14 00:00:00, ended at 2019-02-14 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperglycemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-14 00:00:00, ended at 2019-02-14 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-02-14 00:00:00, ended at 2019-02-14 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.2 MG Oral Capsule, through Oral route, started on 2019-02-14, presumably until 2019-03-31, with intended 3 refill(s). Instructions: take 1 Cap by mouth every day Take with 100 mcg daily\n- levothyroxine sodium 0.1 MG Oral Capsule, through Oral route, started on 2019-02-14, presumably until 2019-03-31, with intended 3 refill(s). Instructions: take 1 Cap by mouth every day Take with 200 mcg daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-02-14 09:11:00, ended at 2019-02-14 10:12:44\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.276\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cancer-related fatigue\n- Nausea\n- Primary diagnosis: Pain due to neoplastic disease\n\n### Drug\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2019-02-14, presumably until 2019-04-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 3 to 4 hours as needed (pain)\n- methylphenidate hydrochloride 5 MG Oral Tablet, through Oral route, started on 2019-02-14, presumably until 2019-08-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day as needed (fatigue)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-02-14 11:59:00, ended at 2019-02-14 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 21 (millimole per liter)\n- Ferritin [Mass/volume] in Serum or Plasma: 924 (nanogram per milliliter)\n- Sodium [Moles/volume] in Serum or Plasma: 127 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Protein/Creatinine [Mass Ratio] in Urine: 0.21 (milligram per milligram)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.1 (gram per deciliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- MCV [Entitic volume] by Automated count: 115.2 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 28 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 116 (unit per liter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 1615 (picogram per milliliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.7 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.3 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.2 (percent)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Protein [Mass/volume] in Urine collected for unspecified duration: 15.0 (milligram per deciliter)\n- Creatinine [Mass/volume] in Urine: 71.48 (milligram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n- Retinol [Mass/volume] in Serum or Plasma: 6.1 (microgram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 485 (milligram per deciliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 51 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.8 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.75 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.91 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 81.6 (percent)\n- Platelets [#/volume] in Blood by Automated count: 180 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5.0 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.40 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 94 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.97 (million per microliter)\n- Iron [Mass/volume] in Serum or Plasma: 94 (microgram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.36 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 37.4 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Declotting by thrombolytic agent of implanted vascular access device or catheter\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Chronic kidney disease stage 3\n- Disorder of kidney and/or ureter\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- epoetin alfa 20000 UNT/ML Injectable Solution, started on 2019-02-14, presumably until 2019-02-14\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2019-02-14, presumably until 2019-02-14\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2019-02-14, presumably until 2019-02-14\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2019-02-14, presumably until 2019-02-14\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2019-02-14, presumably until 2019-02-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-20 00:00:00, ended at 2019-02-20 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of nervous system due to type 2 diabetes mellitus\n- Vitamin A deficiency\n- Post-surgical malabsorption\n\n### Drug\n- ubidecarenone, through Oral route, started on 2019-02-20, presumably until 2019-04-14, with intended 3 refill(s). Instructions: take 1 Hudgins by mouth every 12 hours\n- vitamin K1, through Oral route, started on 2019-02-20, presumably until 2019-04-14, with intended 3 refill(s). Instructions: take 1 Kiser by mouth every 12 hours\n- folic acid, through Oral route, started on 2019-02-20, presumably until 2019-04-14, with intended 3 refill(s). Instructions: take 1 Vale by mouth every 12 hours\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-02-25 00:00:00, ended at 2019-02-25 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.53 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.4 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Anion gap in Serum or Plasma: 20 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 638 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 28 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 126 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 91 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 116 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 15 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-02-25 07:50:00, ended at 2019-02-25 13:40:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hemoglobin [Mass/volume] in Blood: 12.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 115.9 (femtoliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.34 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.6 (thousand per microliter)\n- Ferritin [Mass/volume] in Serum or Plasma: 943 (nanogram per milliliter)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 38.0 (picogram)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.5 (percent)\n- Iron [Mass/volume] in Serum or Plasma: 78 (microgram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.7 (percent)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 43 (percent)\n- Platelets [#/volume] in Blood by Automated count: 164 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Chronic kidney disease stage 3\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-02-25 08:07:00, ended at 2019-02-25 09:02:47\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 16 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 126 (millimole per liter)\n- Phosphate [Mass/volume] in Serum or Plasma: 2.8 (milligram per deciliter)\n- Body height: 5' 5\" (inch (US))\n- Creatinine [Mass/volume] in Serum or Plasma: 1.49 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 639 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 92 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 28 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 18 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of retroperitoneum\n- Chronic kidney disease stage 3\n- Hypo-osmolality and or hyponatremia\n- Primary diagnosis: Acute renal failure syndrome\n- Hyperglycemia\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2019-02-25 13:41:00, ended at 2019-03-01 15:30:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Corticotropin [Mass/volume] in Plasma: 14.4 (picogram per milliliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.7 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 6.73 (thousand per microliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.34 (million per microliter)\n- Glutamate decarboxylase 65 Ab [Units/volume] in Serum by Immunoassay: <5 (international unit per milliliter)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.7 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.32 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.017 (nanogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 31 (milligram per deciliter)\n- Base excess in Blood by calculation: -9 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 0.75 (nanogram per deciliter)\n- C peptide [Mass/volume] in Serum or Plasma: 1.37 (nanogram per milliliter)\n- Glucose [Mass/volume] in Blood: 466 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.3 (percent)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 10.6 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 2.9 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.1 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Glutamate decarboxylase 65 Ab [Moles/volume] in Serum: 0.01 (nanomole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 4.0 (percent)\n- MCH [Entitic mass] by Automated count: 38.1 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 164 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 20 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Body height: 5' 5\" (inch (US))\n- Creatinine [Mass/volume] in Serum or Plasma: 1.63 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 687 (milligram per deciliter)\n- Insulin Ab [Units/volume] in Serum by Radioimmunoassay (RIA): <0.4 (unit per milliliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.0 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 117.3 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.78 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 84.0 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Islet cell 512 Ab [Units/volume] in Serum: SEE BELOW (unit per milliliter)\n\n### Procedure\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; initial, 31 minutes to 1 hour\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination\n- Hospital discharge day management; more than 30 minutes\n- Collection of venous blood by venipuncture\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Radiologic examination, chest; 2 views\n- Physical therapy evaluation: low complexity, requiring these components: A history with no personal factors and/or comorbidities that impact the plan of care; An examination of body system(s) using standardized tests and measures addressing 1-2 elements f\n- Occupational therapy evaluation, moderate complexity, requiring these components: An occupational profile and medical and therapy history, which includes an expanded review of medical and/or therapy records and additional review of physical, cognitive, or\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Absent kidney\n- Acquired absence of organ\n- Acquired absence of spleen\n- Asthenia\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Electrocardiogram abnormal\n- Hypertensive heart and renal disease with (congestive) heart failure\n- Old myocardial infarction\n- Polyneuropathy due to type 2 diabetes mellitus\n- Vitamin A deficiency\n- Chronic congestive heart failure\n- Disorder of pancreas\n- Hypoinsulinemia following procedure\n- Insomnia\n- Conduction disorder of the heart\n- Diabetic ketoacidosis without coma\n- Drug-induced diabetes mellitus\n- Hypothyroidism\n- Mild protein-calorie malnutrition (weight for age 75-89 percent of standard)\n- Pain due to neoplastic disease\n- Abdominal pain\n- Hyperosmolar coma due to type 2 diabetes mellitus\n- Hyperosmolarity\n- Polyneuropathy due to drug\n- Secondary malignant neoplasm of left lung\n- Atherosclerosis of coronary artery without angina pectoris\n- Hypo-osmolality and or hyponatremia\n- Post-surgical malabsorption\n- Vitamin D deficiency\n- Chronic systolic heart failure\n- Disorder of digestive system\n- Fatigue\n- Hyperglycemia due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n- Acute renal failure syndrome\n- Anemia in neoplastic disease\n- Diabetes mellitus without complication\n- Dyspnea\n- Primary diagnosis: Hyperglycemia\n- Major depression, single episode\n- Malaise\n- Nausea\n- Primary malignant neoplasm of retroperitoneum\n- Chronic kidney disease stage 3\n- Essential hypertension\n- Obesity\n- Obstructive sleep apnea syndrome\n- Primary malignant neoplasm of soft tissues\n- Secondary malignant neoplasm of bone\n- Dehydration\n- Gout\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2019-02-26, presumably until 2019-02-26\n- amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule, through Oral route, started on 2019-02-26, presumably until 2019-02-28\n- 3 ML insulin isophane, human 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2019-02-28, presumably until 2019-03-01, with intended 0 refill(s). Instructions: inject 14 Units subcutaneous (under the skin) 2 times a day\n- Abuse-Deterrent 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2019-02-26, presumably until 2019-03-01\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2019-02-25, presumably until 2019-02-28\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2019-02-26, presumably until 2019-03-01\n- 1000 ML potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2019-02-25, presumably until 2019-02-25\n- 3 ML insulin lispro 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2019-02-28, presumably until 2019-03-03, with intended 0 refill(s). Instructions: inject 1-25 Units subcutaneous (under the skin) 3 times a day before meals Inject according to the printed scale given to you at the hospital\n- amitriptyline hydrochloride 75 MG Oral Tablet, through Oral route, started on 2019-02-25, presumably until 2019-02-28\n- amylase 180000 UNT / lipase 36000 UNT / protease 114000 UNT Delayed Release Oral Capsule, through Oral route, started on 2019-02-28, presumably until 2019-03-03, with intended 1 refill(s). Instructions: Take 1 capsule with each meal (3 times a day) and 1 capsule with each snack up to 3 times a day. Take capsules whole with a generous amount of liquid. Do not crush or chew\n- insulin isophane, human 100 UNT/ML Injectable Suspension, through Subcutaneous route, started on 2019-02-26, presumably until 2019-03-01\n- levothyroxine sodium 0.1 MG Injection, through Intravenous route, started on 2019-02-27, presumably until 2019-03-01\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2019-02-26, presumably until 2019-03-01\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2019-02-26, presumably until 2019-03-01\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2019-02-25, presumably until 2019-02-26\n- hydromorphone hydrochloride 2 MG Oral Tablet, through Oral route, started on 2019-02-25, presumably until 2019-03-01\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2019-03-01, presumably until 2019-03-01\n- lisinopril 5 MG Oral Tablet, started on 2019-03-01, presumably until 2019-04-16, with intended 3 refill(s). Instructions: STOP taking this medication until your kidney function is normal (creatinine of 1 or less on your labs) or until Dr. Tran tells you to restart it  Take 1 tablet by mouth daily (evening)\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2017-11-12, presumably until 2019-04-16, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning And 2 tablets orally in the PM\n- carvedilol 6.25 MG Oral Tablet, through Oral route, started on 2019-02-26, presumably until 2019-03-01\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2019-03-01, presumably until 2019-03-03, with intended 0 refill(s). Instructions: inject 25 Units subcutaneous (under the skin) daily in the evening\n- dabigatran etexilate 150 MG Oral Capsule, through Oral route, started on 2019-02-25, presumably until 2019-03-01\n- isopropyl alcohol 0.7 ML/ML Medicated Pad, started on 2019-02-27, presumably until 2019-03-03, with intended 0 refill(s). Instructions: 1 Each by Misc.(Non-Drug; Combo Route) route 4 times a day before meals and bedtime\n- glucagon (rDNA) 1 MG Injection, through Intramuscular route, started on 2019-02-27, presumably until 2019-04-16, with intended 0 refill(s). Instructions: inject 1 mg into a muscle as needed\n- 72 HR scopolamine 0.0139 MG/HR Transdermal System, through Transdermal route, started on 2019-02-28, presumably until 2019-02-28\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2019-02-27, presumably until 2019-03-01\n- glucose 4000 MG Chewable Tablet, through Oral route, started on 2019-03-01, presumably until 2019-03-03, with intended 0 refill(s). Instructions: take 4-8 Tabs by mouth as needed for Low blood sugar You should keep sugar with you at all times. You can use juice or dextrose (glucose) tablets. The tablets can be bought over the counter at most pharmacies. If you are using juice, substitute an equivalent amount of carbohydrates (in grams) with juice. See instructions provided by diabetes educator nurse.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-03 00:00:00, ended at 2019-03-03 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperosmolarity\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n- Chronic kidney disease stage 3\n\n### Drug\n- 3 ML insulin lispro 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2019-03-03, presumably until 2019-04-14, with intended 2 refill(s). Instructions: inject 1-25 Units subcutaneous (under the skin) 3 times a day before meals Inject according to the printed scale given to you at the hospital\n- amylase 180000 UNT / lipase 36000 UNT / protease 114000 UNT Delayed Release Oral Capsule, started on 2019-03-03, presumably until 2019-03-06, with intended 3 refill(s). Instructions: Take 1 capsule with each meal (3 times a day) and 1 capsule with each snack up to 3 times a day.   Take capsules whole with a generous amount of liquid. Do not crush or chew\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2019-03-03, presumably until 2019-04-11, with intended 0 refill(s). Instructions: inject 25 Units subcutaneous (under the skin) daily in the evening\n- isopropyl alcohol 0.7 ML/ML Medicated Pad, started on 2019-03-03, presumably until 2019-04-14, with intended 6 refill(s). Instructions: 1 Each by Misc.(Non-Drug; Combo Route) route 4 times a day before meals and bedtime\n- glucose 4000 MG Chewable Tablet, through Oral route, started on 2019-03-03, presumably until 2019-04-16, with intended 1 refill(s). Instructions: take 4-8 Tabs by mouth as needed for Low blood sugar You should keep sugar with you at all times. You can use juice or dextrose (glucose) tablets. The tablets can be bought over the counter at most pharmacies. If you are using juice, substitute an equivalent amount of carbohydrates (in grams) with juice. See instructions provided by diabetes educator nurse.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-03-03 00:00:00, ended at 2019-03-03 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, started on 2019-03-03, presumably until 2019-04-16, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY 8 HOURS AS NEEDED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-06 00:00:00, ended at 2019-03-06 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amylase 180000 UNT / lipase 36000 UNT / protease 114000 UNT Delayed Release Oral Capsule, started on 2019-03-06, presumably until 2019-04-16, with intended 3 refill(s). Instructions: Take 1 capsule with each meal (3 times a day) and 1 capsule with each snack up to 3 times a day.   Take capsules whole with a generous amount of liquid. Do not crush or chew\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-06 13:59:45, ended at 2019-03-06 14:59:24\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.039\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of soft tissues\n- Pain due to neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-07 00:00:00, ended at 2019-03-07 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 2 diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-07 12:18:00, ended at 2019-03-07 23:59:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- Ferritin [Mass/volume] in Serum or Plasma: 794 (nanogram per milliliter)\n- Iron [Mass/volume] in Serum or Plasma: 99 (microgram per deciliter)\n- MCH [Entitic mass] by Automated count: 37.0 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 59 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.7 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.89 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.0 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 19 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.29 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 6.5 (percent)\n- MCV [Entitic volume] by Automated count: 117.6 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 74.4 (percent)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 62 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.1 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 31.5 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.06 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.53 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 109 (unit per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.8 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 66 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.27 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Platelets [#/volume] in Blood by Automated count: 162 (thousand per microliter)\n\n### Procedure\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Collection of venous blood by venipuncture\n- Declotting by thrombolytic agent of implanted vascular access device or catheter\n\n### Condition\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n- Candidiasis\n- Localized infection of skin AND/OR subcutaneous tissue\n- Primary malignant neoplasm of soft tissues\n- Anemia of chronic disease\n- Non-toxic uninodular goiter\n- Primary malignant neoplasm of retroperitoneum\n- Actinic keratosis\n- Chronic kidney disease stage 3\n- Hypertrophic condition of skin\n- Pain due to neoplastic disease\n- Neoplasm of uncertain behavior of skin\n- Complication due to diabetes mellitus\n- Eruption\n- Hypothyroidism\n- Chronic ulcer of skin\n- Tear film insufficiency\n\n### Drug\n- epoetin alfa 20000 UNT/ML Injectable Solution, started on 2019-03-07, presumably until 2019-03-07\n- 2 ML famotidine 10 MG/ML Injection, through Intravenous route, started on 2019-03-07, presumably until 2019-03-07\n- levothyroxine sodium 0.3 MG Oral Tablet, through Oral route, started on 2019-03-07, presumably until 2019-03-07\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2019-03-07, presumably until 2019-03-07\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2019-03-07, presumably until 2019-03-07\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2019-03-07, presumably until 2019-03-07\n- 1 ML epoetin alfa 40000 UNT/ML Injection, started on 2019-03-07, presumably until 2019-03-07\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2019-03-07, presumably until 2019-03-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-03-10 00:00:00, ended at 2019-03-10 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of soft tissues\n\n### Drug\n- prednisone 5 MG Oral Tablet, started on 2019-03-10, presumably until 2019-04-11, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-11 00:00:00, ended at 2019-03-11 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Eruption\n- Hyperosmolarity\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Primary malignant neoplasm of soft tissues\n- Chronic kidney disease stage 3\n- Type 2 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-03-11 00:00:00, ended at 2019-03-11 00:00:00\nThe patient in this visit was 58 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- Abuse-Deterrent 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2019-03-11, presumably until 2019-03-12, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Malignant tumor of pancreas within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of pancreatic_cancer means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "6355de1049fe519e0dd4e238bc93b384668a26cddbde4b38d1ec58f4f7e61907", "prompt_hash": "31853fba1d9afe14eaaa6c0928dc3cc9b59cd5c5e0a896f877b3d068e6a588bf", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
{"doc_id": 4, "doc": {"person_id": 115970088, "visit_occurrence_id": 46889670, "death_date": "2014-11-07", "visit_concept_name": "Outpatient Visit", "visit_start_datetime": "2012-02-04 06:37:00", "visit_end_datetime": "2012-02-04 23:59:00", "visit_length_in_hours": 17.366666666666667, "integrated_visit_record": "## Visit\nThis visit record, was from Outpatient Visit, started at 2012-02-04 06:37:00, ended at 2012-02-04 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Benign carcinoid tumor\n- Imaging of abdomen abnormal\n- Malignant carcinoid tumor\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 126, "patient_first_visit_date": "2010-02-13 08:45:00", "patient_last_visit_date": "2014-11-07 18:40:00", "end_obs_date": "2013-02-03", "hypertension_type": "new", "hypertension_one_year_diagnosis": 0, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "new", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "new", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "recurrent", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "recurrent", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "recurrent", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 26, "cumulated_visit_num": 26, "cumulated_approximate_token_count": 6639, "visit_cumulated": "## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-13 08:45:00, ended at 2010-02-13 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 4.25\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of small intestine\n- Malignant carcinoid tumor of small intestine\n- Primary malignant neoplasm of ileum\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-02-14 00:00:00, ended at 2010-02-14 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-14 17:15:00, ended at 2010-02-14 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation and report on referred material requiring preparation of slides\n- Morphometric analysis, tumor\n\n### Condition\n- Primary malignant neoplasm of cecum\n- Primary malignant neoplasm of ileum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-15 12:58:00, ended at 2010-02-15 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, pelvis; with contrast material(s)\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n- Computed tomography, abdomen; with contrast material(s)\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Benign carcinoid tumor\n- Primary malignant neoplasm of ileum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-02-16 00:00:00, ended at 2010-02-16 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-02-17 00:00:00, ended at 2010-02-17 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-17 14:00:00, ended at 2010-02-17 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 4.567\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2010-03-02 05:27:00, ended at 2010-03-19 15:45:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 95 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 938 (unit per liter)\n- Body height: 5' 4\" (inch (US))\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.3 (percent)\n- Prothrombin time (PT): 20.5 (second)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.4 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.2 (picogram)\n- Anion gap in Serum or Plasma: <2 (millimole per liter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.16 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 52 (milliliter per minute per square meter)\n- INR in Platelet poor plasma by Coagulation assay: 1.8 (ratio)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.4 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 97 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.54 (million per microliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 5.9 (percent)\n- MCV [Entitic volume] by Automated count: 91.9 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 455 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 27.6 (second)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 3.6 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.5 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 5.3 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 34 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.7 (thousand per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 4.2 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 35.2 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 5.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 144 (millimole per liter)\n\n### Procedure\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Computed tomography, abdomen; with contrast material(s)\n- Simple excision of other lymphatic structure\n- Tube thoracostomy, includes connection to drainage system (eg, water seal), when performed, open (separate procedure)\n- Other repair of diaphragm\n- Excision of lesion of other soft tissue\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Level III - Surgical pathology, gross and microscopic examination Abortion, induced Abscess Aneurysm - arterial/ventricular Anus, tag Appendix, other than incidental Artery, atheromatous plaque Bartholin's gland cyst Bone fragment(s), other than pathologi\n- Excision of lesion or tissue of diaphragm\n- Computed tomography, pelvis; with contrast material(s)\n- Collection of venous blood by venipuncture\n- Insertion of pleural tube drain\n- Open and other right hemicolectomy\n- Radiologic examination, abdomen; single anteroposterior view\n- Radiologic examination, chest; single view, frontal\n- Fluoroscopy (separate procedure), up to 1 hour physician or other qualified health care professional time\n- Cholecystectomy\n- Insertion of other (naso-)gastric tube\n- Radiological guidance (ie, fluoroscopy, ultrasound, or computed tomography), for percutaneous drainage (eg, abscess, specimen collection), with placement of catheter, radiological supervision and interpretation\n- Hepatotomy; for percutaneous drainage of abscess or cyst, 1 or 2 stages\n- Total hepatectomy\n\n### Condition\n- Leukocytosis\n- Neoplasm of lymph node\n- Secondary malignant neoplasm of intra-abdominal organs\n- Ascites\n- Neoplasm of intrathoracic lymph nodes\n- Postprocedural state finding\n- Pleural effusion\n- Primary malignant neoplasm of ileum\n- Benign carcinoid tumor\n- Pneumothorax\n- Secondary malignant neoplasm of large intestine\n- Secondary malignant neoplastic disease\n- Malignant carcinoid tumor\n- Abscess of liver\n- Disorder of lung\n- Secondary malignant neoplasm of liver\n- Gastrointestinal complication of procedure\n- Intestinal obstruction\n- Lung field abnormal\n- Secondary malignant neoplasm of retroperitoneum and peritoneum\n- Atelectasis\n- Functional disorder of intestine\n\n### Drug\n- 50 ML sodium bicarbonate 84 MG/ML Injection, through Intravenous route, started on 2010-03-13, presumably until 2010-03-13\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2010-03-14, presumably until 2010-03-14\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2010-03-02, presumably until 2010-03-03\n- menthol, through Submucosal route, started on 2010-03-09, presumably until 2010-03-14\n- benzocaine, through Submucosal route, started on 2010-03-09, presumably until 2010-03-14\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2010-03-11, presumably until 2010-03-16\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2010-03-17, presumably until 2010-05-05, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2010-03-08, presumably until 2010-03-09\n- benzocaine 140 MG/ML / butamben 20 MG/ML / tetracaine 20 MG/ML Mucosal Spray, through Topical route, started on 2010-03-09, presumably until 2010-03-09\n- naloxone hydrochloride 0.4 MG/ML Injectable Solution, started on 2010-03-02, presumably until 2010-03-02\n- lidocaine 40 MG/ML Topical Cream, through Topical route, started on 2010-03-13, presumably until 2010-03-13\n- cefoxitin 1000 MG Injection, through Intravenous route, started on 2010-03-02, presumably until 2010-03-03\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2010-03-03, presumably until 2010-03-16\n- diatrizoate, through Oral route, started on 2010-03-15, presumably until 2010-03-15\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2010-03-11, presumably until 2010-03-11\n- cetylpyridinium, through Submucosal route, started on 2010-03-09, presumably until 2010-03-14\n- heparin sodium, porcine 10000 UNT/ML Injectable Solution, started on 2010-03-04, presumably until 2010-03-15\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.01 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2010-03-04, presumably until 2010-03-05\n- 10 ML furosemide 10 MG/ML Injection, started on 2010-03-06, presumably until 2010-03-09\n- diatrizoic acid, through Oral route, started on 2010-03-15, presumably until 2010-03-15\n- soybean oil 200 MG/ML Injectable Suspension, through Intravenous route, started on 2010-03-13, presumably until 2010-03-15\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2010-03-15, presumably until 2010-03-16\n- 1 ML vitamin K1 10 MG/ML Injection, through Intravenous route, started on 2010-03-02, presumably until 2010-03-02\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2010-03-09, presumably until 2010-03-17\n- 2 ML ondansetron 2 MG/ML Injection, started on 2010-03-10, presumably until 2010-03-10\n- 1000 ML glucose 50 MG/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2010-03-05, presumably until 2010-03-13\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2010-03-06, presumably until 2010-03-07\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2010-03-07, presumably until 2010-04-18, with quantity of 60.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed for Pain. \n- 2 ML metoclopramide 5 MG/ML Injection, started on 2010-03-06, presumably until 2010-03-14\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2010-03-07, presumably until 2010-03-10\n- lidocaine hydrochloride 20 MG/ML Injectable Solution, started on 2010-03-13, presumably until 2010-03-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-03-24 00:00:00, ended at 2010-03-24 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-03-24 13:41:00, ended at 2010-03-24 14:13:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 57 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 310 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.05 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 9.1 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 89.0 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 477 (thousand per microliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 27.1 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.2 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 1.9 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.8 (percent)\n- Globulin [Mass/volume] in Serum: 4.9 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.1 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 140 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.8 (picogram)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-03-24 14:14:00, ended at 2010-03-24 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-04-18 11:26:00, ended at 2010-04-18 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign carcinoid tumor\n- Primary malignant neoplasm of small intestine\n- Malignant carcinoid tumor of small intestine\n- Primary malignant neoplasm of ileum\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-04-19 14:52:00, ended at 2010-04-19 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.4 (percent)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 81.6 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.58 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- MCH [Entitic mass] by Automated count: 26.7 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 8.3 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 79.3 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 110 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.68 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.1 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.72 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 544 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 82 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 60 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.65 (million per microliter)\n- Globulin [Mass/volume] in Serum: 5.2 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 602 (unit per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-04-21 11:55:00, ended at 2010-04-21 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-05 10:38:00, ended at 2010-05-05 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Carcinoid syndrome\n- Benign carcinoid tumor\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2010-05-05, presumably until 2011-05-05, with quantity of 30.0, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-05-08 00:00:00, ended at 2010-05-08 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-06-02 08:15:00, ended at 2010-06-02 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 3.78\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-06-12 15:27:00, ended at 2010-06-12 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, pelvis; with contrast material(s)\n- Computed tomography, abdomen; with contrast material(s)\n\n### Condition\n- Abscess of peritoneum\n- Benign carcinoid tumor\n- Minor laceration of liver without open wound into abdominal cavity\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-07-18 13:30:00, ended at 2010-07-18 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of islets of Langerhans\n- Benign carcinoid tumor\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-08-04 13:49:00, ended at 2010-08-04 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-18 14:01:00, ended at 2010-12-18 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, pelvis; with contrast material(s)\n- Computed tomography, abdomen; with contrast material(s)\n\n### Condition\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-01-02 00:00:00, ended at 2011-01-02 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-01-03 00:00:00, ended at 2011-01-03 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-16 13:26:00, ended at 2011-01-16 13:55:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 58 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.45 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.3 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 21.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.6 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.14 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 90.5 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 209 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.1 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 123 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.42 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- MCH [Entitic mass] by Automated count: 30.6 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 114 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.45 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.5 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.0 (percent)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-16 13:56:00, ended at 2011-01-16 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-02-04 06:37:00, ended at 2012-02-04 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Benign carcinoid tumor\n- Imaging of abdomen abnormal\n- Malignant carcinoid tumor\n\n### Drug\n- No drugs.\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Malignant tumor of pancreas within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-13 08:45:00, ended at 2010-02-13 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 4.25\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of small intestine\n- Malignant carcinoid tumor of small intestine\n- Primary malignant neoplasm of ileum\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-02-14 00:00:00, ended at 2010-02-14 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-14 17:15:00, ended at 2010-02-14 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation and report on referred material requiring preparation of slides\n- Morphometric analysis, tumor\n\n### Condition\n- Primary malignant neoplasm of cecum\n- Primary malignant neoplasm of ileum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-15 12:58:00, ended at 2010-02-15 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, pelvis; with contrast material(s)\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n- Computed tomography, abdomen; with contrast material(s)\n\n### Condition\n- Secondary malignant neoplasm of liver\n- Benign carcinoid tumor\n- Primary malignant neoplasm of ileum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-02-16 00:00:00, ended at 2010-02-16 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-02-17 00:00:00, ended at 2010-02-17 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-17 14:00:00, ended at 2010-02-17 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 4.567\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2010-03-02 05:27:00, ended at 2010-03-19 15:45:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 95 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 938 (unit per liter)\n- Body height: 5' 4\" (inch (US))\n- Hematocrit [Volume Fraction] of Blood by Automated count: 32.3 (percent)\n- Prothrombin time (PT): 20.5 (second)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.4 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.2 (picogram)\n- Anion gap in Serum or Plasma: <2 (millimole per liter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.16 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 52 (milliliter per minute per square meter)\n- INR in Platelet poor plasma by Coagulation assay: 1.8 (ratio)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.4 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 97 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.54 (million per microliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 5.9 (percent)\n- MCV [Entitic volume] by Automated count: 91.9 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 455 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 27.6 (second)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 3.6 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.5 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 5.3 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 34 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.7 (thousand per microliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 4.2 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 35.2 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 5.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 144 (millimole per liter)\n\n### Procedure\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Computed tomography, abdomen; with contrast material(s)\n- Simple excision of other lymphatic structure\n- Tube thoracostomy, includes connection to drainage system (eg, water seal), when performed, open (separate procedure)\n- Other repair of diaphragm\n- Excision of lesion of other soft tissue\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Level III - Surgical pathology, gross and microscopic examination Abortion, induced Abscess Aneurysm - arterial/ventricular Anus, tag Appendix, other than incidental Artery, atheromatous plaque Bartholin's gland cyst Bone fragment(s), other than pathologi\n- Excision of lesion or tissue of diaphragm\n- Computed tomography, pelvis; with contrast material(s)\n- Collection of venous blood by venipuncture\n- Insertion of pleural tube drain\n- Open and other right hemicolectomy\n- Radiologic examination, abdomen; single anteroposterior view\n- Radiologic examination, chest; single view, frontal\n- Fluoroscopy (separate procedure), up to 1 hour physician or other qualified health care professional time\n- Cholecystectomy\n- Insertion of other (naso-)gastric tube\n- Radiological guidance (ie, fluoroscopy, ultrasound, or computed tomography), for percutaneous drainage (eg, abscess, specimen collection), with placement of catheter, radiological supervision and interpretation\n- Hepatotomy; for percutaneous drainage of abscess or cyst, 1 or 2 stages\n- Total hepatectomy\n\n### Condition\n- Leukocytosis\n- Neoplasm of lymph node\n- Secondary malignant neoplasm of intra-abdominal organs\n- Ascites\n- Neoplasm of intrathoracic lymph nodes\n- Postprocedural state finding\n- Pleural effusion\n- Primary malignant neoplasm of ileum\n- Benign carcinoid tumor\n- Pneumothorax\n- Secondary malignant neoplasm of large intestine\n- Secondary malignant neoplastic disease\n- Malignant carcinoid tumor\n- Abscess of liver\n- Disorder of lung\n- Secondary malignant neoplasm of liver\n- Gastrointestinal complication of procedure\n- Intestinal obstruction\n- Lung field abnormal\n- Secondary malignant neoplasm of retroperitoneum and peritoneum\n- Atelectasis\n- Functional disorder of intestine\n\n### Drug\n- 50 ML sodium bicarbonate 84 MG/ML Injection, through Intravenous route, started on 2010-03-13, presumably until 2010-03-13\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2010-03-14, presumably until 2010-03-14\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2010-03-02, presumably until 2010-03-03\n- menthol, through Submucosal route, started on 2010-03-09, presumably until 2010-03-14\n- benzocaine, through Submucosal route, started on 2010-03-09, presumably until 2010-03-14\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2010-03-11, presumably until 2010-03-16\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2010-03-17, presumably until 2010-05-05, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. \n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2010-03-08, presumably until 2010-03-09\n- benzocaine 140 MG/ML / butamben 20 MG/ML / tetracaine 20 MG/ML Mucosal Spray, through Topical route, started on 2010-03-09, presumably until 2010-03-09\n- naloxone hydrochloride 0.4 MG/ML Injectable Solution, started on 2010-03-02, presumably until 2010-03-02\n- lidocaine 40 MG/ML Topical Cream, through Topical route, started on 2010-03-13, presumably until 2010-03-13\n- cefoxitin 1000 MG Injection, through Intravenous route, started on 2010-03-02, presumably until 2010-03-03\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2010-03-03, presumably until 2010-03-16\n- diatrizoate, through Oral route, started on 2010-03-15, presumably until 2010-03-15\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2010-03-11, presumably until 2010-03-11\n- cetylpyridinium, through Submucosal route, started on 2010-03-09, presumably until 2010-03-14\n- heparin sodium, porcine 10000 UNT/ML Injectable Solution, started on 2010-03-04, presumably until 2010-03-15\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.01 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2010-03-04, presumably until 2010-03-05\n- 10 ML furosemide 10 MG/ML Injection, started on 2010-03-06, presumably until 2010-03-09\n- diatrizoic acid, through Oral route, started on 2010-03-15, presumably until 2010-03-15\n- soybean oil 200 MG/ML Injectable Suspension, through Intravenous route, started on 2010-03-13, presumably until 2010-03-15\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2010-03-15, presumably until 2010-03-16\n- 1 ML vitamin K1 10 MG/ML Injection, through Intravenous route, started on 2010-03-02, presumably until 2010-03-02\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2010-03-09, presumably until 2010-03-17\n- 2 ML ondansetron 2 MG/ML Injection, started on 2010-03-10, presumably until 2010-03-10\n- 1000 ML glucose 50 MG/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2010-03-05, presumably until 2010-03-13\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2010-03-06, presumably until 2010-03-07\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2010-03-07, presumably until 2010-04-18, with quantity of 60.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed for Pain. \n- 2 ML metoclopramide 5 MG/ML Injection, started on 2010-03-06, presumably until 2010-03-14\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2010-03-07, presumably until 2010-03-10\n- lidocaine hydrochloride 20 MG/ML Injectable Solution, started on 2010-03-13, presumably until 2010-03-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-03-24 00:00:00, ended at 2010-03-24 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-03-24 13:41:00, ended at 2010-03-24 14:13:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 57 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 310 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.05 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 9.1 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 89.0 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 477 (thousand per microliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 27.1 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.2 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 1.9 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.8 (percent)\n- Globulin [Mass/volume] in Serum: 4.9 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.1 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 140 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.8 (picogram)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-03-24 14:14:00, ended at 2010-03-24 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-04-18 11:26:00, ended at 2010-04-18 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign carcinoid tumor\n- Primary malignant neoplasm of small intestine\n- Malignant carcinoid tumor of small intestine\n- Primary malignant neoplasm of ileum\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-04-19 14:52:00, ended at 2010-04-19 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.4 (percent)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 81.6 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.58 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- MCH [Entitic mass] by Automated count: 26.7 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 8.3 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.5 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 79.3 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 110 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.68 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.1 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.72 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 544 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 82 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 60 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.65 (million per microliter)\n- Globulin [Mass/volume] in Serum: 5.2 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 602 (unit per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-04-21 11:55:00, ended at 2010-04-21 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-05 10:38:00, ended at 2010-05-05 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Carcinoid syndrome\n- Benign carcinoid tumor\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2010-05-05, presumably until 2011-05-05, with quantity of 30.0, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-05-08 00:00:00, ended at 2010-05-08 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-06-02 08:15:00, ended at 2010-06-02 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 3.78\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-06-12 15:27:00, ended at 2010-06-12 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, pelvis; with contrast material(s)\n- Computed tomography, abdomen; with contrast material(s)\n\n### Condition\n- Abscess of peritoneum\n- Benign carcinoid tumor\n- Minor laceration of liver without open wound into abdominal cavity\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-07-18 13:30:00, ended at 2010-07-18 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of islets of Langerhans\n- Benign carcinoid tumor\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-08-04 13:49:00, ended at 2010-08-04 23:59:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-18 14:01:00, ended at 2010-12-18 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, pelvis; with contrast material(s)\n- Computed tomography, abdomen; with contrast material(s)\n\n### Condition\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-01-02 00:00:00, ended at 2011-01-02 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-01-03 00:00:00, ended at 2011-01-03 00:00:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-16 13:26:00, ended at 2011-01-16 13:55:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 58 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.45 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.3 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 21.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.6 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.14 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 90.5 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 209 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.1 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 123 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.42 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- MCH [Entitic mass] by Automated count: 30.6 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 114 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.45 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.5 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.0 (percent)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-01-16 13:56:00, ended at 2011-01-16 23:59:00\nThe patient in this visit was 55 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-02-04 06:37:00, ended at 2012-02-04 23:59:00\nThe patient in this visit was 56 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Benign carcinoid tumor\n- Imaging of abdomen abnormal\n- Malignant carcinoid tumor\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Malignant tumor of pancreas within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of pancreatic_cancer means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "4e111607d796fa2c947e09be3420421e1d55bb7a5bb17c33554c75592758b10a", "prompt_hash": "e0261e1abbda28890d2ea9c313a8f8ccf0f49dbea10455c581b1c5102e30d192", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
{"doc_id": 5, "doc": {"person_id": 115972447, "visit_occurrence_id": 149609476, "death_date": null, "visit_concept_name": "Pharmacy visit", "visit_start_datetime": "2019-11-27 00:00:00", "visit_end_datetime": "2019-11-27 00:00:00", "visit_length_in_hours": 0.0, "integrated_visit_record": "## Visit\nThis visit record, was from Pharmacy visit, started at 2019-11-27 00:00:00, ended at 2019-11-27 00:00:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2019-11-27, presumably until 2019-11-27, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n", "approximate_token_count": 120, "patient_first_visit_date": "2016-09-02 08:55:59", "patient_last_visit_date": "2022-01-20 00:00:00", "end_obs_date": "2020-11-26", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 1, "obesity_type": "recurrent", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "recurrent", "hyperlipidemia_one_year_diagnosis": 1, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "new", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "recurrent", "pancreatic_cancer_one_year_diagnosis": 1, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 38, "cumulated_visit_num": 38, "cumulated_approximate_token_count": 10964, "visit_cumulated": "## Visit\nThis visit record, was from Office Visit, started at 2016-09-02 08:55:59, ended at 2016-09-02 09:47:59\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 9.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n- Hypoglycemia\n\n### Drug\n- hydrochlorothiazide 12.5 MG Oral Tablet, through Oral route, presumably until 2017-02-01, with intended 0 refill(s). Instructions: take 25 mg by mouth every day\n- aspirin 81 MG Chewable Tablet, through Oral route, presumably until 2019-06-17, with intended 0 refill(s). Instructions: take 81 mg by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-09-28 00:00:00, ended at 2016-09-28 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydrochlorothiazide 12.5 MG Oral Capsule, started on 2016-09-28, presumably until 2017-01-10, with intended 2 refill(s). Instructions: TAKE ONE CAPSULE BY MOUTH EVERY DAY, HOLD IF SBP< 95\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-01-10 00:00:00, ended at 2017-01-10 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydrochlorothiazide 12.5 MG Oral Capsule, through Oral route, started on 2017-01-10, presumably until 2017-02-11, with intended 0 refill(s). Instructions: take 12.5 mg by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-02-01 10:09:51, ended at 2017-02-01 11:11:30\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 9.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-02-11 00:00:00, ended at 2017-02-11 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydrochlorothiazide 12.5 MG Oral Capsule, started on 2017-02-13, presumably until 2017-10-02, with intended 5 refill(s). Instructions: TAKE 1 CAPSULE (12.5 MG) BY MOUTH EVERY MORNING\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-06-09 00:00:00, ended at 2017-06-09 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 143 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 229 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 40 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2375 (cells per microliter)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.29 (milli-international unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 189 (milligram per deciliter calculated)\n- Eosinophils [#/volume] in Blood by Automated count: 285 (cells per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 52 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 15.7 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.9 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 9 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 90.0 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 45.6 (percent)\n- Platelets [#/volume] in Blood by Automated count: 230 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 5.7 (calculated)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 46.1 (percent)\n- MCH [Entitic mass] by Automated count: 30.7 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 63 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 37 (cells per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.12 (million per liter)\n- Globulin [Mass/volume] in Serum: 2.7 (gram per deciliter calculated)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.2 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 676 (cells per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2827 (cells per microliter)\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 1.7 (calculated)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.19 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 38.3 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: NOT APPLICABLE (calculated)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 160 (milligram per deciliter calculated)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 10.0 (femtoliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 12.9 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-10-02 00:00:00, ended at 2017-10-02 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydrochlorothiazide 12.5 MG Oral Capsule, started on 2017-10-02, presumably until 2017-10-10, with intended 5 refill(s). Instructions: TAKE 1 CAPSULE (12.5 MG) BY MOUTH EVERY MORNING\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-10-10 10:26:39, ended at 2017-10-10 11:07:44\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 9.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, started on 2017-10-10, presumably until 2018-04-09, with intended 5 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-04-09 00:00:00, ended at 2018-04-09 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, started on 2018-04-09, presumably until 2018-06-09, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-09 00:00:00, ended at 2018-06-09 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- hydrochlorothiazide 25 MG Oral Tablet, started on 2018-06-11, presumably until 2018-11-11, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-11-11 00:00:00, ended at 2018-11-11 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- hydrochlorothiazide 25 MG Oral Tablet, started on 2018-11-12, presumably until 2019-01-15, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-28 00:00:00, ended at 2018-12-28 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 6.7 (calculated)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: NOT APPLICABLE (calculated)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 38 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 184 (milligram per deciliter calculated)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 217 (milligram per deciliter calculated)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.18 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 32 (milligram per deciliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 179 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 255 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-01-15 08:09:39, ended at 2019-01-15 10:02:51\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 47 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 46.2 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 49.7 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 64 (cells per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 10.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.25 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter calculated)\n- Monocytes [#/volume] in Blood by Automated count: 856 (cells per microliter)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 10.6 (femtoliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 241 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Testosterone [Mass/volume] in Serum or Plasma: 490 (nanogram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- MCH [Entitic mass] by Automated count: 29.8 (picogram)\n- MCV [Entitic volume] by Automated count: 88.3 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3976 (cells per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2800 (cells per microliter)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.79 (milli-international unit per liter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 166 (milligram per deciliter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 22 (calculated)\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 1.5 (calculated)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 38 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 6.3 (calculated)\n- Eosinophils [#/volume] in Blood by Automated count: 304 (cells per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 15.6 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 60 (unit per liter)\n- Body height: 5' 9.5\" (inch (US))\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 172 (milligram per deciliter calculated)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 203 (milligram per deciliter calculated)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 11 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.23 (million per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.0 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 249 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 28 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.8 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 35.0 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Testosterone Free [Mass/volume] in Serum or Plasma: 56.0 (picogram per milliliter)\n\n### Procedure\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)\n- Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diag\n\n### Condition\n- Essential hypertension\n\n### Drug\n- lisinopril 40 MG Oral Tablet, through Oral route, started on 2019-01-15, presumably until 2019-01-30, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-01-30 00:00:00, ended at 2019-01-30 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lisinopril 20 MG Oral Tablet, through Oral route, started on 2019-01-30, presumably until 2019-06-07, with intended 11 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-02-10 00:00:00, ended at 2019-02-10 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- hydrochlorothiazide 25 MG Oral Tablet, started on 2019-02-11, presumably until 2019-02-11, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-05-06 00:00:00, ended at 2019-05-06 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypoglycemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-05-06 00:00:00, ended at 2019-05-06 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Proinsulin [Moles/volume] in Serum or Plasma: 159.5 (picomole per liter)\n- C peptide [Mass/volume] in Serum or Plasma: 3.54 (nanogram per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypoglycemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-04 08:26:33, ended at 2019-06-04 09:51:36\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 9.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypoglycemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2019-06-06 17:17:00, ended at 2019-06-07 18:33:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- C peptide [Mass/volume] in Serum or Plasma: 3.05 (nanogram per milliliter)\n- Proinsulin [Moles/volume] in Serum or Plasma: 125 (picomole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- chlorproPAMIDE [Mass/volume] in Serum or Plasma: Not Detected (nanogram per milliliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Nateglinide [Mass/volume] in Serum or Plasma: Not Detected (nanogram per milliliter)\n- glyBURIDE [Mass/volume] in Serum or Plasma: Not Detected (nanogram per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.10 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 116 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Insulin-like growth factor-II [Mass/volume] in Serum or Plasma: 805 (nanogram per milliliter)\n- TOLAZamide [Mass/volume] in Serum or Plasma: Not Detected (nanogram per milliliter)\n- Glimepride [Mass/volume] in Serum or Plasma: Not Detected (nanogram per milliliter)\n- Insulin Ab [Units/volume] in Serum by Radioimmunoassay (RIA): <0.4 (unit per milliliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- TOLBUTamide [Mass/volume] in Serum or Plasma: Not Detected (nanogram per milliliter)\n- Glucose [Mass/volume] in Blood: 67 (milligram per deciliter)\n- Repaglinide [Mass/volume] in Serum or Plasma: Not Detected (nanogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- glipiZIDE [Mass/volume] in Serum or Plasma: Not Detected (nanogram per milliliter)\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n- Hospital discharge day management; more than 30 minutes\n- Collection of venous blood by venipuncture\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n\n### Condition\n- Essential hypertension\n- Primary diagnosis: Hypoglycemia\n- Neoplasm of uncertain behavior of digestive organ\n- Seizure\n- Benign tumor of endocrine pancreas\n\n### Drug\n- lisinopril 20 MG Oral Tablet, through Oral route, started on 2019-06-07, presumably until 2020-02-10, with intended 11 refill(s). Instructions: take 20 mg by mouth every morning \n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2019-06-07, presumably until 2019-06-07\n- 1000 ML glucose 50 MG/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2019-06-07, presumably until 2019-06-07\n- glucagon (rDNA) 1 MG Injection, started on 2019-06-07, presumably until 2019-06-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-10 18:36:00, ended at 2019-06-10 23:59:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen; with contrast material(s)\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n\n### Condition\n- Disorder of pancreas\n- Hypoglycemia\n- Benign tumor of endocrine pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-17 09:52:41, ended at 2019-06-17 10:20:20\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of plasma protein metabolism\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-20 00:00:00, ended at 2019-06-20 00:00:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for upper gastrointestinal endoscopic procedures, endoscope introduced proximal to duodenum; not otherwise specified\n\n### Condition\n- Benign tumor of endocrine pancreas\n- Gastro-esophageal reflux disease with esophagitis\n- Diaphragmatic hernia\n- Disorder of pancreas\n\n### Drug\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2019-06-20, presumably until 2019-06-20\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2019-06-20, presumably until 2019-06-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2019-06-20 00:00:00, ended at 2019-06-20 00:00:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s) (includes endoscopic ultrasound examination of the esophagus, stomach, and either the duodenum or a surgicall\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-06-20 00:00:00, ended at 2019-06-20 00:00:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-20 06:42:00, ended at 2019-06-20 11:15:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n- Glucose [Mass/volume] in Blood: 82 (milligram per deciliter)\n\n### Procedure\n- Morphometric analysis, tumor\n- Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s), (includes endoscopic ultrasound examination limited to the esophagus, stomach or duodenum, and adjacent stru\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Barretts esophagus with low grade dysplasia\n- Benign neuroendocrine tumor\n- Diaphragmatic hernia\n- Disorder of pancreas\n- Hypoglycemia\n- Malignant neuroendocrine tumor\n- Benign tumor of endocrine pancreas\n- Essential hypertension\n- Primary diagnosis: Gastro-esophageal reflux disease with esophagitis\n- Disorder of plasma protein metabolism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-01 00:00:00, ended at 2019-07-01 00:00:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Barretts esophagus with low grade dysplasia\n\n### Drug\n- omeprazole 20 MG Delayed Release Oral Capsule, through Oral route, started on 2019-07-01, presumably until 2020-06-30, with intended 12 refill(s). Instructions: take 20 mg by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-02 00:00:00, ended at 2019-07-02 00:00:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign tumor of endocrine pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-08-08 10:01:00, ended at 2019-08-08 23:59:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Carcinoid tumor\n- Benign tumor of endocrine pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-30 00:00:00, ended at 2019-08-30 00:00:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign tumor of endocrine pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-08-30 12:28:27, ended at 2019-08-30 14:41:41\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 9.488\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign tumor of endocrine pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-03 09:36:35, ended at 2019-10-03 10:57:23\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign tumor of endocrine pancreas\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-03 10:37:00, ended at 2019-10-03 23:59:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 15.5 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 63.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 112 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.82 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.11 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 271 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 12.9 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 46.9 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.1 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 80 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.19 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 89.5 (femtoliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 22.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.24 (million per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.6 (percent)\n- Prothrombin time (PT): 12.4 (second)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- MCH [Entitic mass] by Automated count: 29.6 (picogram)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.03 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Essential hypertension\n- Benign tumor of endocrine pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-03 11:10:19, ended at 2019-10-03 12:35:49\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign tumor of endocrine pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2019-10-28 00:00:00, ended at 2019-10-28 00:00:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Anesthesia for intraperitoneal procedures in upper abdomen including laparoscopy; pancreatectomy, partial or total (eg, Whipple procedure)\n\n### Condition\n- Gastroesophageal reflux disease without esophagitis\n- Hyperlipidemia\n- Benign tumor of endocrine pancreas\n- Essential hypertension\n\n### Drug\n- 10 ML calcium chloride 100 MG/ML Injection, through Intravenous route, started on 2019-10-28, presumably until 2019-10-28\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2019-10-28, presumably until 2019-10-28\n- 1 ML octreotide 0.05 MG/ML Injection, started on 2019-10-28, presumably until 2019-10-28\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2019-10-28, presumably until 2019-10-28\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2019-10-28, presumably until 2019-10-28\n- cefoxitin 1000 MG Injection, through Intravenous route, started on 2019-10-28, presumably until 2019-10-28\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2019-10-28, presumably until 2019-10-28\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2019-10-28, presumably until 2019-10-28\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2019-10-28, presumably until 2019-10-28\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2019-10-28, presumably until 2019-10-28\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2019-10-28, presumably until 2019-10-28\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2019-10-28, presumably until 2019-10-28\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2019-10-28, presumably until 2019-10-28\n- 2 ML ondansetron 2 MG/ML Injection, started on 2019-10-28, presumably until 2019-10-28\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2019-10-28, presumably until 2019-10-28\n- midazolam 1 MG/ML Injectable Solution, started on 2019-10-28, presumably until 2019-10-28\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2019-10-28, presumably until 2019-10-28\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2019-10-28, presumably until 2019-10-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2019-10-28 00:00:00, ended at 2019-10-28 00:00:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Injection(s), including indwelling catheter placement, continuous infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, interlaminar\n- Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, cervical or thora\n\n### Condition\n- Persistent pain following procedure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2019-10-28 09:31:00, ended at 2019-11-04 20:44:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Leukocytes [#/volume] in Specimen by Automated count: 9.0 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 42 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 43.4 (millimeter mercury column)\n- Chloride [Moles/volume] in Serum or Plasma: 96 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.21 (million per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.96 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 83.1 (percent)\n- Potassium [Moles/volume] in Blood: 4.5 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5.7 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 69 (unit per liter)\n- Bicarbonate [Moles/volume] in Specimen: 26.1 (millimole per liter)\n- Body height: 5' 10\" (inch (US))\n- Platelets [#/volume] in Blood by Automated count: 278 (thousand per microliter)\n- Sodium [Moles/volume] in Blood: 136 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 5.8 (percent)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 174 (millimeter mercury column)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Calcium.ionized [Moles/volume] in Blood: 1.15 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.13 (milligram per deciliter)\n- Glucose [Mass/volume] in Blood: 89 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 16.68 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 216 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 46.7 (percent)\n- Hemoglobin [Mass/volume] in Blood: 15.2 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 14.6 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.2 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.0 (milligram per deciliter)\n- Prothrombin time (PT): 12.8 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 12.9 (percent)\n- Hematocrit [Volume Fraction] of Blood: 43 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.15 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 90.4 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Base excess in Blood by calculation: 1 (millimole per liter)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n\n### Procedure\n- Excision of Duodenum, Open Approach\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Excision of Pancreas, Open Approach\n- Collection of venous blood by venipuncture\n- Dilation of Pancreatic Duct with Intraluminal Device, Open Approach\n- Radiologic examination, abdomen; 1 view\n- Excision of Omentum, Open Approach\n- Morphometric analysis, tumor\n- Resection of Gallbladder, Open Approach\n\n### Condition\n- Disorder of intestine\n- Disorder of upper gastrointestinal tract\n- Primary diagnosis: Benign tumor of endocrine pancreas\n- Functional disorder of intestine\n- Persistent pain following procedure\n- Essential hypertension\n- Malignant neuroendocrine tumor\n- Obesity\n- Disorder of plasma protein metabolism\n- Hyperlipidemia\n- Hypoglycemia\n- Low blood pressure\n- Primary malignant neoplasm of islets of Langerhans\n- Intestinal obstruction co-occurrent and due to decreased peristalsis\n\n### Drug\n- glycerin, started on 2019-11-04, presumably until 2019-11-04\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2019-11-03, presumably until 2019-11-04\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2019-10-31, presumably until 2019-11-01\n- mineral oil 1000 MG/ML Enema, through Rectal route, started on 2019-11-04, presumably until 2019-11-04\n- 1 ML octreotide 0.1 MG/ML Injection, started on 2019-10-29, presumably until 2019-11-01\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2019-10-28, presumably until 2019-10-29\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2019-11-04, presumably until 2019-11-04, with intended 0 refill(s). Instructions: take 1 Tab (40 mg total) by mouth daily\n- magnesium citrate 58.2 MG/ML Oral Solution, through Oral route, started on 2019-11-04, presumably until 2019-11-04\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2019-10-29, presumably until 2019-11-04\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2019-11-04, presumably until 2020-02-29, with intended 0 refill(s). Instructions: take 2 Tabs (650 mg total) by mouth every 6 hours as needed\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2019-10-28, presumably until 2019-10-28\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2019-11-03, presumably until 2020-02-29, with intended 0 refill(s). Instructions: inject 0.4 mL (40 mg total) subcutaneous (under the skin) daily\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2019-10-30, presumably until 2020-02-29, with intended 0 refill(s). Instructions: take 2 Caps (200 mg total) by mouth 2 times a day\n- calcium chloride 0.001 MEQ/ML / glucose 50 MG/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2019-10-29, presumably until 2019-11-02\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2019-10-29, presumably until 2019-11-04\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2019-10-28, presumably until 2019-10-28\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2019-10-29, presumably until 2019-10-29\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2019-10-30, presumably until 2019-11-02\n- guanfacine 1 MG Oral Tablet, through Oral route, started on 2019-10-30, presumably until 2019-11-02\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2019-10-30, presumably until 2020-02-29, with intended 0 refill(s). Instructions: take 1 Tab (4 mg total) by mouth every 6 hours as needed\n- ibuprofen 600 MG Oral Tablet, through Oral route, started on 2019-11-02, presumably until 2020-02-29, with intended 0 refill(s). Instructions: take 1 Tab (600 mg total) by mouth every 6 hours\n- 2 ML ondansetron 2 MG/ML Injection, started on 2019-10-28, presumably until 2019-11-01\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2019-10-30, presumably until 2019-10-30\n- sennosides, USP 35.2 MG/ML Oral Solution, through Oral route, started on 2019-11-01, presumably until 2019-11-04\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2019-11-03, presumably until 2020-02-29, with intended 0 refill(s). Instructions: take 1 Tab (5 mg total) by mouth every 6 hours as needed\n- simethicone 80 MG Chewable Tablet, through Oral route, started on 2019-10-31, presumably until 2019-10-31\n- water 1000 MG/ML Irrigation Solution, through Topical route, started on 2019-11-04, presumably until 2019-11-04\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2019-11-04, presumably until 2019-11-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-14 13:20:34, ended at 2019-11-14 14:08:12\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign tumor of endocrine pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-11-27 00:00:00, ended at 2019-11-27 00:00:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2019-11-27, presumably until 2019-11-27, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n"}, "target": "Yes", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Malignant tumor of pancreas within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Office Visit, started at 2016-09-02 08:55:59, ended at 2016-09-02 09:47:59\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 9.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n- Hypoglycemia\n\n### Drug\n- hydrochlorothiazide 12.5 MG Oral Tablet, through Oral route, presumably until 2017-02-01, with intended 0 refill(s). Instructions: take 25 mg by mouth every day\n- aspirin 81 MG Chewable Tablet, through Oral route, presumably until 2019-06-17, with intended 0 refill(s). Instructions: take 81 mg by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2016-09-28 00:00:00, ended at 2016-09-28 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydrochlorothiazide 12.5 MG Oral Capsule, started on 2016-09-28, presumably until 2017-01-10, with intended 2 refill(s). Instructions: TAKE ONE CAPSULE BY MOUTH EVERY DAY, HOLD IF SBP< 95\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-01-10 00:00:00, ended at 2017-01-10 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydrochlorothiazide 12.5 MG Oral Capsule, through Oral route, started on 2017-01-10, presumably until 2017-02-11, with intended 0 refill(s). Instructions: take 12.5 mg by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-02-01 10:09:51, ended at 2017-02-01 11:11:30\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 9.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-02-11 00:00:00, ended at 2017-02-11 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydrochlorothiazide 12.5 MG Oral Capsule, started on 2017-02-13, presumably until 2017-10-02, with intended 5 refill(s). Instructions: TAKE 1 CAPSULE (12.5 MG) BY MOUTH EVERY MORNING\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-06-09 00:00:00, ended at 2017-06-09 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 143 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 229 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 40 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2375 (cells per microliter)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.29 (milli-international unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 189 (milligram per deciliter calculated)\n- Eosinophils [#/volume] in Blood by Automated count: 285 (cells per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 52 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 15.7 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.9 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 9 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 90.0 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 45.6 (percent)\n- Platelets [#/volume] in Blood by Automated count: 230 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 5.7 (calculated)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 46.1 (percent)\n- MCH [Entitic mass] by Automated count: 30.7 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 63 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 37 (cells per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.12 (million per liter)\n- Globulin [Mass/volume] in Serum: 2.7 (gram per deciliter calculated)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.2 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 676 (cells per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2827 (cells per microliter)\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 1.7 (calculated)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.19 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 38.3 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 24 (milligram per deciliter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: NOT APPLICABLE (calculated)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 160 (milligram per deciliter calculated)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 10.0 (femtoliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 12.9 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2017-10-02 00:00:00, ended at 2017-10-02 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydrochlorothiazide 12.5 MG Oral Capsule, started on 2017-10-02, presumably until 2017-10-10, with intended 5 refill(s). Instructions: TAKE 1 CAPSULE (12.5 MG) BY MOUTH EVERY MORNING\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-10-10 10:26:39, ended at 2017-10-10 11:07:44\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 9.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, started on 2017-10-10, presumably until 2018-04-09, with intended 5 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-04-09 00:00:00, ended at 2018-04-09 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, started on 2018-04-09, presumably until 2018-06-09, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-06-09 00:00:00, ended at 2018-06-09 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- hydrochlorothiazide 25 MG Oral Tablet, started on 2018-06-11, presumably until 2018-11-11, with intended 3 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-11-11 00:00:00, ended at 2018-11-11 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- hydrochlorothiazide 25 MG Oral Tablet, started on 2018-11-12, presumably until 2019-01-15, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-28 00:00:00, ended at 2018-12-28 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 6.7 (calculated)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: NOT APPLICABLE (calculated)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 38 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 184 (milligram per deciliter calculated)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 217 (milligram per deciliter calculated)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.18 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 32 (milligram per deciliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 179 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 255 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-01-15 08:09:39, ended at 2019-01-15 10:02:51\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 47 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 46.2 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 49.7 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 64 (cells per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 10.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.25 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter calculated)\n- Monocytes [#/volume] in Blood by Automated count: 856 (cells per microliter)\n- Platelet mean volume [Entitic volume] in Blood by Rees-Ecker: 10.6 (femtoliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 241 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Testosterone [Mass/volume] in Serum or Plasma: 490 (nanogram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- MCH [Entitic mass] by Automated count: 29.8 (picogram)\n- MCV [Entitic volume] by Automated count: 88.3 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3976 (cells per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2800 (cells per microliter)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 1.79 (milli-international unit per liter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 166 (milligram per deciliter)\n- Urea nitrogen/Creatinine [Mass Ratio] in Serum or Plasma: 22 (calculated)\n- Albumin/Globulin [Mass Ratio] in Serum or Plasma: 1.5 (calculated)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 38 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 6.3 (calculated)\n- Eosinophils [#/volume] in Blood by Automated count: 304 (cells per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 15.6 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 60 (unit per liter)\n- Body height: 5' 9.5\" (inch (US))\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 172 (milligram per deciliter calculated)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 203 (milligram per deciliter calculated)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 11 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.23 (million per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.0 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 249 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 28 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.8 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 35.0 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Testosterone Free [Mass/volume] in Serum or Plasma: 56.0 (picogram per milliliter)\n\n### Procedure\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)\n- Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diag\n\n### Condition\n- Essential hypertension\n\n### Drug\n- lisinopril 40 MG Oral Tablet, through Oral route, started on 2019-01-15, presumably until 2019-01-30, with intended 2 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-01-30 00:00:00, ended at 2019-01-30 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lisinopril 20 MG Oral Tablet, through Oral route, started on 2019-01-30, presumably until 2019-06-07, with intended 11 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-02-10 00:00:00, ended at 2019-02-10 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- hydrochlorothiazide 25 MG Oral Tablet, started on 2019-02-11, presumably until 2019-02-11, with intended 2 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-05-06 00:00:00, ended at 2019-05-06 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypoglycemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-05-06 00:00:00, ended at 2019-05-06 00:00:00\nThe patient in this visit was 48 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Proinsulin [Moles/volume] in Serum or Plasma: 159.5 (picomole per liter)\n- C peptide [Mass/volume] in Serum or Plasma: 3.54 (nanogram per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypoglycemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-04 08:26:33, ended at 2019-06-04 09:51:36\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 9.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypoglycemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2019-06-06 17:17:00, ended at 2019-06-07 18:33:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- C peptide [Mass/volume] in Serum or Plasma: 3.05 (nanogram per milliliter)\n- Proinsulin [Moles/volume] in Serum or Plasma: 125 (picomole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- chlorproPAMIDE [Mass/volume] in Serum or Plasma: Not Detected (nanogram per milliliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Nateglinide [Mass/volume] in Serum or Plasma: Not Detected (nanogram per milliliter)\n- glyBURIDE [Mass/volume] in Serum or Plasma: Not Detected (nanogram per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.10 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 116 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Insulin-like growth factor-II [Mass/volume] in Serum or Plasma: 805 (nanogram per milliliter)\n- TOLAZamide [Mass/volume] in Serum or Plasma: Not Detected (nanogram per milliliter)\n- Glimepride [Mass/volume] in Serum or Plasma: Not Detected (nanogram per milliliter)\n- Insulin Ab [Units/volume] in Serum by Radioimmunoassay (RIA): <0.4 (unit per milliliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- TOLBUTamide [Mass/volume] in Serum or Plasma: Not Detected (nanogram per milliliter)\n- Glucose [Mass/volume] in Blood: 67 (milligram per deciliter)\n- Repaglinide [Mass/volume] in Serum or Plasma: Not Detected (nanogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- glipiZIDE [Mass/volume] in Serum or Plasma: Not Detected (nanogram per milliliter)\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n- Hospital discharge day management; more than 30 minutes\n- Collection of venous blood by venipuncture\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n\n### Condition\n- Essential hypertension\n- Primary diagnosis: Hypoglycemia\n- Neoplasm of uncertain behavior of digestive organ\n- Seizure\n- Benign tumor of endocrine pancreas\n\n### Drug\n- lisinopril 20 MG Oral Tablet, through Oral route, started on 2019-06-07, presumably until 2020-02-10, with intended 11 refill(s). Instructions: take 20 mg by mouth every morning \n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2019-06-07, presumably until 2019-06-07\n- 1000 ML glucose 50 MG/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2019-06-07, presumably until 2019-06-07\n- glucagon (rDNA) 1 MG Injection, started on 2019-06-07, presumably until 2019-06-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-10 18:36:00, ended at 2019-06-10 23:59:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen; with contrast material(s)\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n\n### Condition\n- Disorder of pancreas\n- Hypoglycemia\n- Benign tumor of endocrine pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-17 09:52:41, ended at 2019-06-17 10:20:20\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of plasma protein metabolism\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-20 00:00:00, ended at 2019-06-20 00:00:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for upper gastrointestinal endoscopic procedures, endoscope introduced proximal to duodenum; not otherwise specified\n\n### Condition\n- Benign tumor of endocrine pancreas\n- Gastro-esophageal reflux disease with esophagitis\n- Diaphragmatic hernia\n- Disorder of pancreas\n\n### Drug\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2019-06-20, presumably until 2019-06-20\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2019-06-20, presumably until 2019-06-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2019-06-20 00:00:00, ended at 2019-06-20 00:00:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s) (includes endoscopic ultrasound examination of the esophagus, stomach, and either the duodenum or a surgicall\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-06-20 00:00:00, ended at 2019-06-20 00:00:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-20 06:42:00, ended at 2019-06-20 11:15:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11\" (inch (US))\n- Glucose [Mass/volume] in Blood: 82 (milligram per deciliter)\n\n### Procedure\n- Morphometric analysis, tumor\n- Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s), (includes endoscopic ultrasound examination limited to the esophagus, stomach or duodenum, and adjacent stru\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Barretts esophagus with low grade dysplasia\n- Benign neuroendocrine tumor\n- Diaphragmatic hernia\n- Disorder of pancreas\n- Hypoglycemia\n- Malignant neuroendocrine tumor\n- Benign tumor of endocrine pancreas\n- Essential hypertension\n- Primary diagnosis: Gastro-esophageal reflux disease with esophagitis\n- Disorder of plasma protein metabolism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-01 00:00:00, ended at 2019-07-01 00:00:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Barretts esophagus with low grade dysplasia\n\n### Drug\n- omeprazole 20 MG Delayed Release Oral Capsule, through Oral route, started on 2019-07-01, presumably until 2020-06-30, with intended 12 refill(s). Instructions: take 20 mg by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-02 00:00:00, ended at 2019-07-02 00:00:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign tumor of endocrine pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-08-08 10:01:00, ended at 2019-08-08 23:59:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Carcinoid tumor\n- Benign tumor of endocrine pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-30 00:00:00, ended at 2019-08-30 00:00:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign tumor of endocrine pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-08-30 12:28:27, ended at 2019-08-30 14:41:41\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 9.488\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign tumor of endocrine pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-03 09:36:35, ended at 2019-10-03 10:57:23\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign tumor of endocrine pancreas\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-03 10:37:00, ended at 2019-10-03 23:59:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 15.5 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 63.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 112 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.82 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.11 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 271 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 12.9 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 46.9 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.1 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 22 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 80 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.19 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 89.5 (femtoliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 22.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.24 (million per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.6 (percent)\n- Prothrombin time (PT): 12.4 (second)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- MCH [Entitic mass] by Automated count: 29.6 (picogram)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.03 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Essential hypertension\n- Benign tumor of endocrine pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-03 11:10:19, ended at 2019-10-03 12:35:49\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign tumor of endocrine pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2019-10-28 00:00:00, ended at 2019-10-28 00:00:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Anesthesia for intraperitoneal procedures in upper abdomen including laparoscopy; pancreatectomy, partial or total (eg, Whipple procedure)\n\n### Condition\n- Gastroesophageal reflux disease without esophagitis\n- Hyperlipidemia\n- Benign tumor of endocrine pancreas\n- Essential hypertension\n\n### Drug\n- 10 ML calcium chloride 100 MG/ML Injection, through Intravenous route, started on 2019-10-28, presumably until 2019-10-28\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2019-10-28, presumably until 2019-10-28\n- 1 ML octreotide 0.05 MG/ML Injection, started on 2019-10-28, presumably until 2019-10-28\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2019-10-28, presumably until 2019-10-28\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2019-10-28, presumably until 2019-10-28\n- cefoxitin 1000 MG Injection, through Intravenous route, started on 2019-10-28, presumably until 2019-10-28\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2019-10-28, presumably until 2019-10-28\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2019-10-28, presumably until 2019-10-28\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2019-10-28, presumably until 2019-10-28\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2019-10-28, presumably until 2019-10-28\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2019-10-28, presumably until 2019-10-28\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2019-10-28, presumably until 2019-10-28\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2019-10-28, presumably until 2019-10-28\n- 2 ML ondansetron 2 MG/ML Injection, started on 2019-10-28, presumably until 2019-10-28\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2019-10-28, presumably until 2019-10-28\n- midazolam 1 MG/ML Injectable Solution, started on 2019-10-28, presumably until 2019-10-28\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2019-10-28, presumably until 2019-10-28\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2019-10-28, presumably until 2019-10-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2019-10-28 00:00:00, ended at 2019-10-28 00:00:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Injection(s), including indwelling catheter placement, continuous infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, interlaminar\n- Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, cervical or thora\n\n### Condition\n- Persistent pain following procedure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2019-10-28 09:31:00, ended at 2019-11-04 20:44:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Leukocytes [#/volume] in Specimen by Automated count: 9.0 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 42 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 43.4 (millimeter mercury column)\n- Chloride [Moles/volume] in Serum or Plasma: 96 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.21 (million per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.96 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 83.1 (percent)\n- Potassium [Moles/volume] in Blood: 4.5 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5.7 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 27 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 69 (unit per liter)\n- Bicarbonate [Moles/volume] in Specimen: 26.1 (millimole per liter)\n- Body height: 5' 10\" (inch (US))\n- Platelets [#/volume] in Blood by Automated count: 278 (thousand per microliter)\n- Sodium [Moles/volume] in Blood: 136 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 5.8 (percent)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 174 (millimeter mercury column)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Calcium.ionized [Moles/volume] in Blood: 1.15 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.13 (milligram per deciliter)\n- Glucose [Mass/volume] in Blood: 89 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 16.68 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 216 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 46.7 (percent)\n- Hemoglobin [Mass/volume] in Blood: 15.2 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 14.6 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.2 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.0 (milligram per deciliter)\n- Prothrombin time (PT): 12.8 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 12.9 (percent)\n- Hematocrit [Volume Fraction] of Blood: 43 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.15 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 90.4 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Base excess in Blood by calculation: 1 (millimole per liter)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n\n### Procedure\n- Excision of Duodenum, Open Approach\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Excision of Pancreas, Open Approach\n- Collection of venous blood by venipuncture\n- Dilation of Pancreatic Duct with Intraluminal Device, Open Approach\n- Radiologic examination, abdomen; 1 view\n- Excision of Omentum, Open Approach\n- Morphometric analysis, tumor\n- Resection of Gallbladder, Open Approach\n\n### Condition\n- Disorder of intestine\n- Disorder of upper gastrointestinal tract\n- Primary diagnosis: Benign tumor of endocrine pancreas\n- Functional disorder of intestine\n- Persistent pain following procedure\n- Essential hypertension\n- Malignant neuroendocrine tumor\n- Obesity\n- Disorder of plasma protein metabolism\n- Hyperlipidemia\n- Hypoglycemia\n- Low blood pressure\n- Primary malignant neoplasm of islets of Langerhans\n- Intestinal obstruction co-occurrent and due to decreased peristalsis\n\n### Drug\n- glycerin, started on 2019-11-04, presumably until 2019-11-04\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2019-11-03, presumably until 2019-11-04\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2019-10-31, presumably until 2019-11-01\n- mineral oil 1000 MG/ML Enema, through Rectal route, started on 2019-11-04, presumably until 2019-11-04\n- 1 ML octreotide 0.1 MG/ML Injection, started on 2019-10-29, presumably until 2019-11-01\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2019-10-28, presumably until 2019-10-29\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2019-11-04, presumably until 2019-11-04, with intended 0 refill(s). Instructions: take 1 Tab (40 mg total) by mouth daily\n- magnesium citrate 58.2 MG/ML Oral Solution, through Oral route, started on 2019-11-04, presumably until 2019-11-04\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2019-10-29, presumably until 2019-11-04\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2019-11-04, presumably until 2020-02-29, with intended 0 refill(s). Instructions: take 2 Tabs (650 mg total) by mouth every 6 hours as needed\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2019-10-28, presumably until 2019-10-28\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2019-11-03, presumably until 2020-02-29, with intended 0 refill(s). Instructions: inject 0.4 mL (40 mg total) subcutaneous (under the skin) daily\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2019-10-30, presumably until 2020-02-29, with intended 0 refill(s). Instructions: take 2 Caps (200 mg total) by mouth 2 times a day\n- calcium chloride 0.001 MEQ/ML / glucose 50 MG/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2019-10-29, presumably until 2019-11-02\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2019-10-29, presumably until 2019-11-04\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2019-10-28, presumably until 2019-10-28\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2019-10-29, presumably until 2019-10-29\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2019-10-30, presumably until 2019-11-02\n- guanfacine 1 MG Oral Tablet, through Oral route, started on 2019-10-30, presumably until 2019-11-02\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2019-10-30, presumably until 2020-02-29, with intended 0 refill(s). Instructions: take 1 Tab (4 mg total) by mouth every 6 hours as needed\n- ibuprofen 600 MG Oral Tablet, through Oral route, started on 2019-11-02, presumably until 2020-02-29, with intended 0 refill(s). Instructions: take 1 Tab (600 mg total) by mouth every 6 hours\n- 2 ML ondansetron 2 MG/ML Injection, started on 2019-10-28, presumably until 2019-11-01\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2019-10-30, presumably until 2019-10-30\n- sennosides, USP 35.2 MG/ML Oral Solution, through Oral route, started on 2019-11-01, presumably until 2019-11-04\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2019-11-03, presumably until 2020-02-29, with intended 0 refill(s). Instructions: take 1 Tab (5 mg total) by mouth every 6 hours as needed\n- simethicone 80 MG Chewable Tablet, through Oral route, started on 2019-10-31, presumably until 2019-10-31\n- water 1000 MG/ML Irrigation Solution, through Topical route, started on 2019-11-04, presumably until 2019-11-04\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2019-11-04, presumably until 2019-11-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-14 13:20:34, ended at 2019-11-14 14:08:12\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign tumor of endocrine pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-11-27 00:00:00, ended at 2019-11-27 00:00:00\nThe patient in this visit was 49 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2019-11-27, presumably until 2019-11-27, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Malignant tumor of pancreas within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of pancreatic_cancer means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "e95f21a2104015cc564c6132b833620fff56f65331fc6b0bc465f3d989e736b9", "prompt_hash": "15c7005053b7d0c50862f566cc126263380ca29bb0a6bde5642348d9a75a6b2c", "target_hash": "85a39ab345d672ff8ca9b9c6876f3adcacf45ee7c1e2dbd2408fd338bd55e07e", "exact_match": 0.0, "f1_gu_yn": [1, 0], "recall_gu_yn": [1, 0]}
{"doc_id": 6, "doc": {"person_id": 115967851, "visit_occurrence_id": 70127301, "death_date": null, "visit_concept_name": "Case Management Visit", "visit_start_datetime": "2015-01-13 00:00:00", "visit_end_datetime": "2015-01-13 00:00:00", "visit_length_in_hours": 0.0, "integrated_visit_record": "## Visit\nThis visit record, was from Case Management Visit, started at 2015-01-13 00:00:00, ended at 2015-01-13 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant lymphoma\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 87, "patient_first_visit_date": "2013-12-06 20:51:00", "patient_last_visit_date": "2019-11-12 15:30:00", "end_obs_date": "2016-01-13", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 1, "obesity_type": "recurrent", "obesity_one_year_diagnosis": 1, "asthma_type": "recurrent", "asthma_one_year_diagnosis": 1, "hyperlipidemia_type": "recurrent", "hyperlipidemia_one_year_diagnosis": 1, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "new", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "recurrent", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "recurrent", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 24, "cumulated_visit_num": 24, "cumulated_approximate_token_count": 8562, "visit_cumulated": "## Visit\nThis visit record, was from Inpatient Visit, started at 2013-12-06 20:51:00, ended at 2013-12-25 12:47:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 98 (unit per liter)\n- Bicarbonate [Moles/volume] in Specimen: 29.8 (millimole per liter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 128 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.9 (percent)\n- Lactate [Moles/volume] in Blood: 1.7 (millimole per liter)\n- Left ventricular Ejection fraction: 63 (percent)\n- MCH [Entitic mass] by Automated count: 32.0 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.3 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.31 (thousand per microliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: N/A (milligram per deciliter)\n- Body height: 5' 9.685\" (inch (US))\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 75 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.0 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 98.1 (percent)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 96 (millimeter mercury column)\n- Platelets [#/volume] in Blood by Automated count: 571 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Base deficit in Blood: 9.0 (millimole per liter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 111 (millimole per liter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 509 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 12.2 (gram per deciliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 4.3 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 98 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- INR in Platelet poor plasma by Coagulation assay: 1.5 (ratio)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.42 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 35.4 (gram per deciliter)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 145 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 48 (milligram per deciliter)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: 15.3 (microgram per milliliter)\n- Base excess in Blood by calculation: 6.0 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.6 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.6 (percent)\n- Prothrombin time (PT): 17.3 (second)\n- Sodium [Moles/volume] in Blood: 141 (millimole per liter)\n- Thrombin time: 17.3 (second)\n- aPTT in Platelet poor plasma by Coagulation assay: 84.4 (second)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 43.1 (millimeter mercury column)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 3.6 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.32 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.40 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.59 (million per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.89 (thousand per microliter)\n- Potassium [Moles/volume] in Blood: 3.8 (millimole per liter)\n- Urate [Mass/volume] in Serum or Plasma: 6.0 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.2 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Calcium.ionized [Moles/volume] in Blood: 1.35 (millimole per liter)\n- Cortisol [Mass/volume] in Serum or Plasma: 14.3 (microgram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.2 (percent)\n- Hematocrit [Volume Fraction] of Blood: 36 (percent)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 931 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 676 (unit per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 2.4 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- MCV [Entitic volume] by Automated count: 92.5 (femtoliter)\n\n### Procedure\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Computed tomography, head or brain; without contrast material\n- Endoscopic sphincterotomy and papillotomy\n- Arterial puncture, withdrawal of blood for diagnosis\n- Endoscopic catheterization of the biliary ductal system, radiological supervision and interpretation\n- Continuous invasive mechanical ventilation for less than 96 consecutive hours\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Endoscopic insertion of stent into bile duct\n- Radiologic examination, chest; single view, frontal\n- Occupational therapy evaluation\n- Radiologic examination, abdomen; single anteroposterior view\n- Hospital discharge day management; more than 30 minutes\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Controlled ventilation procedure and therapy, initiation and management\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Physical therapy evaluation\n- Insertion of endotracheal tube\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Collection of venous blood by venipuncture\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n- Central venous catheter placement with guidance\n- Insertion of catheter into artery\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Endoscopic dilatation of bile duct\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes\n- Infusion chemotherapy for malignant neoplasm\n- Biopsy of lymphatic structure\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Decalcification procedure (List separately in addition to code for surgical pathology examination)\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination\n- Bone marrow sampling\n\n### Condition\n- Disorder of pancreas\n- Jaundice\n- Morbid obesity\n- Shock\n- Disturbance of consciousness\n- Electrocardiogram abnormal\n- Lymphocytosis\n- Malignant lymphoma of lymph nodes of axilla AND/OR upper limb\n- Monocytosis\n- Pleural effusion\n- Systemic inflammatory response syndrome\n- Acute renal failure syndrome\n- Lung field abnormal\n- Lymphocytopenia\n- Nodular lymphoma of lymph nodes of axilla and upper limb\n- Acidosis\n- Abnormal glucose level\n- Acute respiratory failure\n- Disorder of hematopoietic structure\n- Dyspnea\n- Primary diagnosis: Malignant lymphoma\n- Obstruction of bile duct\n- Asthma\n- Atelectasis\n- Benign prostatic hyperplasia without outflow obstruction\n- Diarrhea\n- Flatulence, eructation and gas pain\n- Hyperlipidemia\n- Malignant lymphoma of intra-abdominal lymph nodes\n- Pain in limb\n- Thrombocytopenic disorder\n- Acute tubular necrosis\n- Altered mental status\n- Cardiac arrhythmia\n- Essential hypertension\n- Gout\n- Non-infectious systemic inflammatory response syndrome without acute organ failure\n- Pulmonary congestion and hypostasis\n- Abnormal breathing\n- Glaucoma\n- Wheezing\n\n### Drug\n- sodium bicarbonate 650 MG Oral Tablet, through Oral route, started on 2013-12-14, presumably until 2013-12-18\n- 0.5 ML filgrastim 0.6 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2013-12-20, presumably until 2013-12-24, with intended 0 refill(s). Instructions: inject 1 mL subcutaneous (under the skin) daily. 600mcg (2 syringes) daily for 5 days\n- candesartan cilexetil 16 MG Oral Tablet, through Oral route, presumably until 2014-02-25. Instructions: take 16 mg by mouth daily.\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2013-12-20, presumably until 2013-12-25\n- finasteride 5 MG Oral Tablet, through Oral route, started on 2013-12-07, presumably until 2014-02-25. Instructions: take 5 mg by mouth daily.\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2013-12-11, presumably until 2013-12-17\n- 14 ACTUAT fluticasone propionate 0.25 MG/ACTUAT / salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler, through Inhalation, started on 2013-12-22, presumably until 2014-10-15, with intended 2 refill(s). Instructions: 1 Puff by Inhalation route 2 times a day.\n- loperamide hydrochloride 2 MG Oral Capsule, through Oral route, started on 2013-12-08, presumably until 2013-12-25\n- losartan potassium 50 MG Oral Tablet, through Oral route, started on 2013-12-07, presumably until 2013-12-09\n- vancomycin 1000 MG Injection, through Intravenous route, started on 2013-12-13, presumably until 2013-12-19\n- levalbuterol 0.417 MG/ML Inhalation Solution, through Inhalation, started on 2013-12-12, presumably until 2013-12-22\n- chlorhexidine gluconate 1.2 MG/ML Mouthwash, through Submucosal route, started on 2013-12-14, presumably until 2013-12-15\n- allopurinol 300 MG Oral Tablet, through Oral route, started on 2013-12-09, presumably until 2014-12-24, with intended 1 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2013-12-20, presumably until 2013-12-24\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2013-12-19, presumably until 2013-12-25\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2013-12-17, presumably until 2013-12-18\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2013-12-13, presumably until 2013-12-21\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-12-12, presumably until 2013-12-20\n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2013-12-07, presumably until 2013-12-10. Instructions: take 20 mg by mouth every bedtime.\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2013-12-14, presumably until 2013-12-18\n- aspirin 325 MG Oral Tablet, through Oral route, started on 2013-12-08, presumably until 2014-02-25. Instructions: take 325 mg by mouth every morning with breakfast.\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2013-12-18, presumably until 2013-12-25\n- albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution, through Inhalation, started on 2013-12-11, presumably until 2013-12-24\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2013-12-21, presumably until 2013-12-21\n- amylase 180000 UNT / lipase 36000 UNT / protease 114000 UNT Delayed Release Oral Capsule, through Oral route, started on 2013-12-23, presumably until 2013-12-25, with intended 2 refill(s). Instructions: take 2 Caps by mouth 3 times a day with meals.\n- quetiapine 25 MG Oral Tablet, through Oral route, started on 2013-12-17, presumably until 2013-12-21\n- probenecid 500 MG Oral Tablet, through Oral route, started on 2013-12-07, presumably until 2013-12-08. Instructions: take 500 mg by mouth 2 times a day.\n- allopurinol 100 MG Oral Tablet, through Oral route, started on 2013-12-07, presumably until 2013-12-07\n- melatonin 3 MG Oral Tablet, through Oral route, started on 2013-12-17, presumably until 2013-12-17\n- insulin isophane, human 100 UNT/ML Injectable Suspension, through Subcutaneous route, started on 2013-12-15, presumably until 2013-12-23\n- 10 ML furosemide 10 MG/ML Injection, started on 2013-12-14, presumably until 2013-12-25\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2013-12-09, presumably until 2014-02-25. Instructions: take 25 mg by mouth Every Day.\n- mineral oil 0.14 MG/MG / petrolatum 0.749 MG/MG / phenylephrine hydrochloride 0.0025 MG/MG Rectal Ointment, through Rectal route, started on 2013-12-19, presumably until 2013-12-24\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2013-12-08, presumably until 2013-12-12\n- ipratropium bromide 0.2 MG/ML Inhalation Solution, through Inhalation, started on 2013-12-12, presumably until 2013-12-13\n- 0.8 ML filgrastim 0.6 MG/ML Prefilled Syringe, started on 2013-12-22, presumably until 2013-12-24\n- potassium chloride 1.33 MEQ/ML Oral Solution, through Oral route, started on 2013-12-15, presumably until 2013-12-23\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2013-12-14, presumably until 2013-12-25\n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2013-12-24, presumably until 2014-10-14, with intended 0 refill(s). Instructions: 1 Puff by Inhalation route every 4 hours as needed for Bronchospasm/Wheezing.\n- atropine sulfate 0.025 MG / diphenoxylate hydrochloride 2.5 MG Oral Tablet, through Oral route, started on 2013-12-18, presumably until 2013-12-23\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-12-13, presumably until 2013-12-13\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2013-12-13, presumably until 2013-12-19\n- 200 ACTUAT ipratropium bromide 0.017 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2013-12-13, presumably until 2013-12-14\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-12-09, presumably until 2013-12-12\n- amylase 60000 UNT / lipase 12000 UNT / protease 38000 UNT Delayed Release Oral Capsule, through Oral route, started on 2013-12-11, presumably until 2013-12-21\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-12-07, presumably until 2013-12-24\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2013-12-20, presumably until 2013-12-20\n- 5 ML doxorubicin hydrochloride 2 MG/ML Injection, through Intravenous route, started on 2013-12-21, presumably until 2013-12-21\n- 10 ML etomidate 2 MG/ML Injection, through Intravenous route, started on 2013-12-13, presumably until 2013-12-13\n- magnesium sulfate 20 MG/ML Injection, through Intravenous route, started on 2013-12-15, presumably until 2013-12-17\n- prednisone 50 MG Oral Tablet, through Oral route, started on 2013-12-14, presumably until 2013-12-18\n- omeprazole 20 MG Delayed Release Oral Capsule, through Oral route, started on 2013-12-24, presumably until 2014-12-24, with intended 0 refill(s). Instructions: take 20 mg by mouth daily.\n- latanoprost 0.05 MG/ML Ophthalmic Solution, through Intraocular route, started on 2013-12-07, presumably until 2013-12-24. Instructions: instill 1 Drop to both eyes every bedtime.\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2013-12-07, presumably until 2013-12-18\n- haloperidol 2 MG/ML Oral Solution, through Oral route, started on 2013-12-17, presumably until 2013-12-17\n- prednisone 20 MG Oral Tablet, through Oral route, started on 2013-12-14, presumably until 2013-12-18\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2013-12-16, presumably until 2013-12-16\n- magnesium sulfate 40 MG/ML Injection, through Intravenous route, started on 2013-12-15, presumably until 2013-12-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2013-12-07 00:00:00, ended at 2013-12-07 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for upper gastrointestinal endoscopic procedure\n\n### Condition\n- Obstruction of bile duct\n\n### Drug\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2013-12-07, presumably until 2013-12-07\n- 10 ML esmolol hydrochloride 10 MG/ML Injection, through Intravenous route, started on 2013-12-07, presumably until 2013-12-07\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-12-07, presumably until 2013-12-07\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-12-07, presumably until 2013-12-07\n- succinylcholine chloride 20 MG/ML Injectable Solution, started on 2013-12-07, presumably until 2013-12-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2013-12-12 00:00:00, ended at 2013-12-12 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 10 ML bupivacaine hydrochloride 5 MG/ML Injection, started on 2013-12-12, presumably until 2013-12-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2013-12-12 00:00:00, ended at 2013-12-12 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for all procedures on nerves, muscles, tendons, fascia, and bursae of shoulder and axilla\n\n### Condition\n- Lymphadenopathy\n\n### Drug\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2013-12-12, presumably until 2013-12-12\n- cefazolin 1000 MG Injection, started on 2013-12-12, presumably until 2013-12-12\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-12-12, presumably until 2013-12-12\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-12-12, presumably until 2013-12-12\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-12-12, presumably until 2013-12-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-12-31 00:00:00, ended at 2013-12-31 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-25 00:00:00, ended at 2014-02-25 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for upper gastrointestinal endoscopic procedure\n\n### Condition\n- Obstruction of bile duct\n\n### Drug\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2014-02-25, presumably until 2014-02-25\n- 2 ML ondansetron 2 MG/ML Injection, started on 2014-02-25, presumably until 2014-02-25\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-02-25, presumably until 2014-02-25\n- succinylcholine chloride 20 MG/ML Injectable Solution, started on 2014-02-25, presumably until 2014-02-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-25 10:45:00, ended at 2014-02-25 15:31:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 9\" (inch (US))\n\n### Procedure\n- Combined endoscopic catheterization of the biliary and pancreatic ductal systems, radiological supervision and interpretation\n- Endoscopic retrograde cholangiopancreatography\n- Endoscopic retrograde cholangiopancreatography (ERCP); with removal and exchange of stent(s), biliary or pancreatic duct, including pre- and post-dilation and guide wire passage, when performed, including sphincterotomy, when performed, each stent exchang\n- Replacement of stent (tube) in biliary or pancreatic duct\n\n### Condition\n- Chronic obstructive lung disease\n- Anemia\n- Essential hypertension\n- Hyperlipidemia\n- Malignant lymphoma\n- Asthma\n- Blood coagulation disorder\n- Glaucoma\n- Morbid obesity\n- Obstruction of bile duct\n- Benign prostatic hyperplasia without outflow obstruction\n\n### Drug\n- finasteride 5 MG Oral Tablet, through Oral route. Instructions: take 5 mg by mouth daily.\n- potassium chloride 20 MEQ Powder for Oral Solution, through Oral route, presumably until 2014-08-14. Instructions: take 20 mEq by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-05-30 00:00:00, ended at 2014-05-30 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-06-05 00:00:00, ended at 2014-06-05 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for upper gastrointestinal endoscopic procedure\n\n### Condition\n- Obstruction of bile duct\n\n### Drug\n- 2 ML alfentanil 0.5 MG/ML Injection, started on 2014-06-05, presumably until 2014-06-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-06-05 12:15:00, ended at 2014-06-05 17:14:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- Combined endoscopic catheterization of the biliary and pancreatic ductal systems, radiological supervision and interpretation\n- Endoscopic retrograde cholangiopancreatography\n- Endoscopic retrograde cholangiopancreatography (ERCP); with removal and exchange of stent(s), biliary or pancreatic duct, including pre- and post-dilation and guide wire passage, when performed, including sphincterotomy, when performed, each stent exchang\n- Replacement of stent (tube) in biliary or pancreatic duct\n\n### Condition\n- Glaucoma\n- Hyperlipidemia\n- Obstruction of bile duct\n- Gout\n- Essential hypertension\n- Asthma\n- Benign prostatic hyperplasia without outflow obstruction\n- Malignant lymphoma of intra-abdominal lymph nodes\n\n### Drug\n- ferrous sulfate 325 MG Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 325 mg by mouth daily.\n- loperamide hydrochloride 2 MG Oral Capsule, through Oral route, with intended 0 refill(s). Instructions: take 2 mg by mouth as needed.\n- omeprazole 40 MG Delayed Release Oral Capsule, through Oral route, with intended 0 refill(s). Instructions: take 40 mg by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-06-18 00:00:00, ended at 2014-06-18 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-14 00:00:00, ended at 2014-08-14 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for upper gastrointestinal endoscopic procedure\n\n### Condition\n- Obstruction of bile duct\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-08-14, presumably until 2014-08-14\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2014-08-14, presumably until 2014-08-14\n- 2 ML alfentanil 0.5 MG/ML Injection, started on 2014-08-14, presumably until 2014-08-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-08-14 00:00:00, ended at 2014-08-14 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2014-08-14, presumably until 2014-10-15, with intended 0 refill(s). Instructions: take 1 tablet by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-14 10:10:00, ended at 2014-08-14 15:53:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- Replacement of stent (tube) in biliary or pancreatic duct\n- Combined endoscopic catheterization of the biliary and pancreatic ductal systems, radiological supervision and interpretation\n- Endoscopic dilatation of bile duct\n- Endoscopic retrograde cholangiopancreatography (ERCP); with removal and exchange of stent(s), biliary or pancreatic duct, including pre- and post-dilation and guide wire passage, when performed, including sphincterotomy, when performed, each stent exchang\n\n### Condition\n- Morbid obesity\n- Asthma\n- Obstruction of bile duct\n- Benign prostatic hyperplasia without outflow obstruction\n- Essential hypertension\n- Glaucoma\n- Gout\n- Malignant lymphoma\n\n### Drug\n- finasteride 5 MG Oral Tablet, through Oral route, presumably until 2014-10-14, with intended 0 refill(s). Instructions: take 5 mg by mouth daily.\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-08-14, presumably until 2014-08-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-08-15 00:00:00, ended at 2014-08-15 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-15 00:00:00, ended at 2014-10-15 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for upper gastrointestinal endoscopic procedure\n\n### Condition\n- Obstruction of bile duct\n\n### Drug\n- 10 ML esmolol hydrochloride 10 MG/ML Injection, through Intravenous route, started on 2014-10-15, presumably until 2014-10-15\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-10-15, presumably until 2014-10-15\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2014-10-15, presumably until 2014-10-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-10-15 00:00:00, ended at 2014-10-15 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant lymphoma\n- Obstruction of bile duct\n\n### Drug\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2014-10-15, presumably until 2014-10-15, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-10-15 00:00:00, ended at 2014-10-15 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-15 09:26:00, ended at 2014-10-15 16:17:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- Endoscopic retrograde cholangiopancreatography\n- Combined endoscopic catheterization of the biliary and pancreatic ductal systems, radiological supervision and interpretation\n- Endoscopic retrograde cholangiopancreatography (ERCP); with removal and exchange of stent(s), biliary or pancreatic duct, including pre- and post-dilation and guide wire passage, when performed, including sphincterotomy, when performed, each stent exchang\n- Replacement of stent (tube) in biliary or pancreatic duct\n\n### Condition\n- Essential hypertension\n- Gout\n- Morbid obesity\n- Obstruction of bile duct\n- Glaucoma\n- Asthma\n- Anemia\n- Benign prostatic hyperplasia without outflow obstruction\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-01-07 00:00:00, ended at 2015-01-07 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for upper gastrointestinal endoscopic procedure\n\n### Condition\n- Obstruction of bile duct\n- Essential hypertension\n- Morbid obesity\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2015-01-07, presumably until 2015-01-07\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2015-01-07, presumably until 2015-01-07\n- ketamine 100 MG/ML Injectable Solution, started on 2015-01-07, presumably until 2015-01-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-01-07 00:00:00, ended at 2015-01-07 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2015-01-07, presumably until 2015-12-09, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-01-07 00:00:00, ended at 2015-01-07 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant lymphoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-01-07 10:08:00, ended at 2015-01-07 16:08:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- Endoscopic retrograde cholangiopancreatography\n- Replacement of stent (tube) in biliary or pancreatic duct\n- Combined endoscopic catheterization of the biliary and pancreatic ductal systems, radiological supervision and interpretation\n- Endoscopic retrograde cholangiopancreatography (ERCP); with removal and exchange of stent(s), biliary or pancreatic duct, including pre- and post-dilation and guide wire passage, when performed, including sphincterotomy, when performed, each stent exchang\n\n### Condition\n- Benign prostatic hyperplasia without outflow obstruction\n- Glaucoma\n- Gout\n- Asthma\n- Essential hypertension\n- Obstruction of bile duct\n- Hyperlipidemia\n- Malignant lymphoma of intra-abdominal lymph nodes\n- Neoplasm of digestive tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-01-13 00:00:00, ended at 2015-01-13 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant lymphoma\n\n### Drug\n- No drugs.\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Malignant tumor of pancreas within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2013-12-06 20:51:00, ended at 2013-12-25 12:47:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 98 (unit per liter)\n- Bicarbonate [Moles/volume] in Specimen: 29.8 (millimole per liter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 128 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.9 (percent)\n- Lactate [Moles/volume] in Blood: 1.7 (millimole per liter)\n- Left ventricular Ejection fraction: 63 (percent)\n- MCH [Entitic mass] by Automated count: 32.0 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.3 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.31 (thousand per microliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: N/A (milligram per deciliter)\n- Body height: 5' 9.685\" (inch (US))\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 75 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.0 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 98.1 (percent)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 96 (millimeter mercury column)\n- Platelets [#/volume] in Blood by Automated count: 571 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Base deficit in Blood: 9.0 (millimole per liter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 111 (millimole per liter)\n- Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay: 509 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 12.2 (gram per deciliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 4.3 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 98 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- INR in Platelet poor plasma by Coagulation assay: 1.5 (ratio)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.42 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 35.4 (gram per deciliter)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 145 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 48 (milligram per deciliter)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: 15.3 (microgram per milliliter)\n- Base excess in Blood by calculation: 6.0 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.8 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.6 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.6 (percent)\n- Prothrombin time (PT): 17.3 (second)\n- Sodium [Moles/volume] in Blood: 141 (millimole per liter)\n- Thrombin time: 17.3 (second)\n- aPTT in Platelet poor plasma by Coagulation assay: 84.4 (second)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 43.1 (millimeter mercury column)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 3.6 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.32 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.40 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.59 (million per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.89 (thousand per microliter)\n- Potassium [Moles/volume] in Blood: 3.8 (millimole per liter)\n- Urate [Mass/volume] in Serum or Plasma: 6.0 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.2 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Calcium.ionized [Moles/volume] in Blood: 1.35 (millimole per liter)\n- Cortisol [Mass/volume] in Serum or Plasma: 14.3 (microgram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 19.2 (percent)\n- Hematocrit [Volume Fraction] of Blood: 36 (percent)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 931 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 676 (unit per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 2.4 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- MCV [Entitic volume] by Automated count: 92.5 (femtoliter)\n\n### Procedure\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n- Computed tomography, head or brain; without contrast material\n- Endoscopic sphincterotomy and papillotomy\n- Arterial puncture, withdrawal of blood for diagnosis\n- Endoscopic catheterization of the biliary ductal system, radiological supervision and interpretation\n- Continuous invasive mechanical ventilation for less than 96 consecutive hours\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Endoscopic insertion of stent into bile duct\n- Radiologic examination, chest; single view, frontal\n- Occupational therapy evaluation\n- Radiologic examination, abdomen; single anteroposterior view\n- Hospital discharge day management; more than 30 minutes\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Controlled ventilation procedure and therapy, initiation and management\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Physical therapy evaluation\n- Insertion of endotracheal tube\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Collection of venous blood by venipuncture\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n- Central venous catheter placement with guidance\n- Insertion of catheter into artery\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moder\n- Endoscopic dilatation of bile duct\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes\n- Infusion chemotherapy for malignant neoplasm\n- Biopsy of lymphatic structure\n- Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coor\n- Decalcification procedure (List separately in addition to code for surgical pathology examination)\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination\n- Bone marrow sampling\n\n### Condition\n- Disorder of pancreas\n- Jaundice\n- Morbid obesity\n- Shock\n- Disturbance of consciousness\n- Electrocardiogram abnormal\n- Lymphocytosis\n- Malignant lymphoma of lymph nodes of axilla AND/OR upper limb\n- Monocytosis\n- Pleural effusion\n- Systemic inflammatory response syndrome\n- Acute renal failure syndrome\n- Lung field abnormal\n- Lymphocytopenia\n- Nodular lymphoma of lymph nodes of axilla and upper limb\n- Acidosis\n- Abnormal glucose level\n- Acute respiratory failure\n- Disorder of hematopoietic structure\n- Dyspnea\n- Primary diagnosis: Malignant lymphoma\n- Obstruction of bile duct\n- Asthma\n- Atelectasis\n- Benign prostatic hyperplasia without outflow obstruction\n- Diarrhea\n- Flatulence, eructation and gas pain\n- Hyperlipidemia\n- Malignant lymphoma of intra-abdominal lymph nodes\n- Pain in limb\n- Thrombocytopenic disorder\n- Acute tubular necrosis\n- Altered mental status\n- Cardiac arrhythmia\n- Essential hypertension\n- Gout\n- Non-infectious systemic inflammatory response syndrome without acute organ failure\n- Pulmonary congestion and hypostasis\n- Abnormal breathing\n- Glaucoma\n- Wheezing\n\n### Drug\n- sodium bicarbonate 650 MG Oral Tablet, through Oral route, started on 2013-12-14, presumably until 2013-12-18\n- 0.5 ML filgrastim 0.6 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2013-12-20, presumably until 2013-12-24, with intended 0 refill(s). Instructions: inject 1 mL subcutaneous (under the skin) daily. 600mcg (2 syringes) daily for 5 days\n- candesartan cilexetil 16 MG Oral Tablet, through Oral route, presumably until 2014-02-25. Instructions: take 16 mg by mouth daily.\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2013-12-20, presumably until 2013-12-25\n- finasteride 5 MG Oral Tablet, through Oral route, started on 2013-12-07, presumably until 2014-02-25. Instructions: take 5 mg by mouth daily.\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2013-12-11, presumably until 2013-12-17\n- 14 ACTUAT fluticasone propionate 0.25 MG/ACTUAT / salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler, through Inhalation, started on 2013-12-22, presumably until 2014-10-15, with intended 2 refill(s). Instructions: 1 Puff by Inhalation route 2 times a day.\n- loperamide hydrochloride 2 MG Oral Capsule, through Oral route, started on 2013-12-08, presumably until 2013-12-25\n- losartan potassium 50 MG Oral Tablet, through Oral route, started on 2013-12-07, presumably until 2013-12-09\n- vancomycin 1000 MG Injection, through Intravenous route, started on 2013-12-13, presumably until 2013-12-19\n- levalbuterol 0.417 MG/ML Inhalation Solution, through Inhalation, started on 2013-12-12, presumably until 2013-12-22\n- chlorhexidine gluconate 1.2 MG/ML Mouthwash, through Submucosal route, started on 2013-12-14, presumably until 2013-12-15\n- allopurinol 300 MG Oral Tablet, through Oral route, started on 2013-12-09, presumably until 2014-12-24, with intended 1 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2013-12-20, presumably until 2013-12-24\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2013-12-19, presumably until 2013-12-25\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2013-12-17, presumably until 2013-12-18\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2013-12-13, presumably until 2013-12-21\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-12-12, presumably until 2013-12-20\n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2013-12-07, presumably until 2013-12-10. Instructions: take 20 mg by mouth every bedtime.\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2013-12-14, presumably until 2013-12-18\n- aspirin 325 MG Oral Tablet, through Oral route, started on 2013-12-08, presumably until 2014-02-25. Instructions: take 325 mg by mouth every morning with breakfast.\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2013-12-18, presumably until 2013-12-25\n- albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution, through Inhalation, started on 2013-12-11, presumably until 2013-12-24\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2013-12-21, presumably until 2013-12-21\n- amylase 180000 UNT / lipase 36000 UNT / protease 114000 UNT Delayed Release Oral Capsule, through Oral route, started on 2013-12-23, presumably until 2013-12-25, with intended 2 refill(s). Instructions: take 2 Caps by mouth 3 times a day with meals.\n- quetiapine 25 MG Oral Tablet, through Oral route, started on 2013-12-17, presumably until 2013-12-21\n- probenecid 500 MG Oral Tablet, through Oral route, started on 2013-12-07, presumably until 2013-12-08. Instructions: take 500 mg by mouth 2 times a day.\n- allopurinol 100 MG Oral Tablet, through Oral route, started on 2013-12-07, presumably until 2013-12-07\n- melatonin 3 MG Oral Tablet, through Oral route, started on 2013-12-17, presumably until 2013-12-17\n- insulin isophane, human 100 UNT/ML Injectable Suspension, through Subcutaneous route, started on 2013-12-15, presumably until 2013-12-23\n- 10 ML furosemide 10 MG/ML Injection, started on 2013-12-14, presumably until 2013-12-25\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2013-12-09, presumably until 2014-02-25. Instructions: take 25 mg by mouth Every Day.\n- mineral oil 0.14 MG/MG / petrolatum 0.749 MG/MG / phenylephrine hydrochloride 0.0025 MG/MG Rectal Ointment, through Rectal route, started on 2013-12-19, presumably until 2013-12-24\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2013-12-08, presumably until 2013-12-12\n- ipratropium bromide 0.2 MG/ML Inhalation Solution, through Inhalation, started on 2013-12-12, presumably until 2013-12-13\n- 0.8 ML filgrastim 0.6 MG/ML Prefilled Syringe, started on 2013-12-22, presumably until 2013-12-24\n- potassium chloride 1.33 MEQ/ML Oral Solution, through Oral route, started on 2013-12-15, presumably until 2013-12-23\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2013-12-14, presumably until 2013-12-25\n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2013-12-24, presumably until 2014-10-14, with intended 0 refill(s). Instructions: 1 Puff by Inhalation route every 4 hours as needed for Bronchospasm/Wheezing.\n- atropine sulfate 0.025 MG / diphenoxylate hydrochloride 2.5 MG Oral Tablet, through Oral route, started on 2013-12-18, presumably until 2013-12-23\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-12-13, presumably until 2013-12-13\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2013-12-13, presumably until 2013-12-19\n- 200 ACTUAT ipratropium bromide 0.017 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2013-12-13, presumably until 2013-12-14\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-12-09, presumably until 2013-12-12\n- amylase 60000 UNT / lipase 12000 UNT / protease 38000 UNT Delayed Release Oral Capsule, through Oral route, started on 2013-12-11, presumably until 2013-12-21\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-12-07, presumably until 2013-12-24\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, started on 2013-12-20, presumably until 2013-12-20\n- 5 ML doxorubicin hydrochloride 2 MG/ML Injection, through Intravenous route, started on 2013-12-21, presumably until 2013-12-21\n- 10 ML etomidate 2 MG/ML Injection, through Intravenous route, started on 2013-12-13, presumably until 2013-12-13\n- magnesium sulfate 20 MG/ML Injection, through Intravenous route, started on 2013-12-15, presumably until 2013-12-17\n- prednisone 50 MG Oral Tablet, through Oral route, started on 2013-12-14, presumably until 2013-12-18\n- omeprazole 20 MG Delayed Release Oral Capsule, through Oral route, started on 2013-12-24, presumably until 2014-12-24, with intended 0 refill(s). Instructions: take 20 mg by mouth daily.\n- latanoprost 0.05 MG/ML Ophthalmic Solution, through Intraocular route, started on 2013-12-07, presumably until 2013-12-24. Instructions: instill 1 Drop to both eyes every bedtime.\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2013-12-07, presumably until 2013-12-18\n- haloperidol 2 MG/ML Oral Solution, through Oral route, started on 2013-12-17, presumably until 2013-12-17\n- prednisone 20 MG Oral Tablet, through Oral route, started on 2013-12-14, presumably until 2013-12-18\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2013-12-16, presumably until 2013-12-16\n- magnesium sulfate 40 MG/ML Injection, through Intravenous route, started on 2013-12-15, presumably until 2013-12-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2013-12-07 00:00:00, ended at 2013-12-07 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for upper gastrointestinal endoscopic procedure\n\n### Condition\n- Obstruction of bile duct\n\n### Drug\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2013-12-07, presumably until 2013-12-07\n- 10 ML esmolol hydrochloride 10 MG/ML Injection, through Intravenous route, started on 2013-12-07, presumably until 2013-12-07\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-12-07, presumably until 2013-12-07\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-12-07, presumably until 2013-12-07\n- succinylcholine chloride 20 MG/ML Injectable Solution, started on 2013-12-07, presumably until 2013-12-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2013-12-12 00:00:00, ended at 2013-12-12 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 10 ML bupivacaine hydrochloride 5 MG/ML Injection, started on 2013-12-12, presumably until 2013-12-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2013-12-12 00:00:00, ended at 2013-12-12 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for all procedures on nerves, muscles, tendons, fascia, and bursae of shoulder and axilla\n\n### Condition\n- Lymphadenopathy\n\n### Drug\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2013-12-12, presumably until 2013-12-12\n- cefazolin 1000 MG Injection, started on 2013-12-12, presumably until 2013-12-12\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-12-12, presumably until 2013-12-12\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-12-12, presumably until 2013-12-12\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-12-12, presumably until 2013-12-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-12-31 00:00:00, ended at 2013-12-31 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-25 00:00:00, ended at 2014-02-25 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for upper gastrointestinal endoscopic procedure\n\n### Condition\n- Obstruction of bile duct\n\n### Drug\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2014-02-25, presumably until 2014-02-25\n- 2 ML ondansetron 2 MG/ML Injection, started on 2014-02-25, presumably until 2014-02-25\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-02-25, presumably until 2014-02-25\n- succinylcholine chloride 20 MG/ML Injectable Solution, started on 2014-02-25, presumably until 2014-02-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-02-25 10:45:00, ended at 2014-02-25 15:31:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 9\" (inch (US))\n\n### Procedure\n- Combined endoscopic catheterization of the biliary and pancreatic ductal systems, radiological supervision and interpretation\n- Endoscopic retrograde cholangiopancreatography\n- Endoscopic retrograde cholangiopancreatography (ERCP); with removal and exchange of stent(s), biliary or pancreatic duct, including pre- and post-dilation and guide wire passage, when performed, including sphincterotomy, when performed, each stent exchang\n- Replacement of stent (tube) in biliary or pancreatic duct\n\n### Condition\n- Chronic obstructive lung disease\n- Anemia\n- Essential hypertension\n- Hyperlipidemia\n- Malignant lymphoma\n- Asthma\n- Blood coagulation disorder\n- Glaucoma\n- Morbid obesity\n- Obstruction of bile duct\n- Benign prostatic hyperplasia without outflow obstruction\n\n### Drug\n- finasteride 5 MG Oral Tablet, through Oral route. Instructions: take 5 mg by mouth daily.\n- potassium chloride 20 MEQ Powder for Oral Solution, through Oral route, presumably until 2014-08-14. Instructions: take 20 mEq by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-05-30 00:00:00, ended at 2014-05-30 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-06-05 00:00:00, ended at 2014-06-05 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for upper gastrointestinal endoscopic procedure\n\n### Condition\n- Obstruction of bile duct\n\n### Drug\n- 2 ML alfentanil 0.5 MG/ML Injection, started on 2014-06-05, presumably until 2014-06-05\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-06-05 12:15:00, ended at 2014-06-05 17:14:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- Combined endoscopic catheterization of the biliary and pancreatic ductal systems, radiological supervision and interpretation\n- Endoscopic retrograde cholangiopancreatography\n- Endoscopic retrograde cholangiopancreatography (ERCP); with removal and exchange of stent(s), biliary or pancreatic duct, including pre- and post-dilation and guide wire passage, when performed, including sphincterotomy, when performed, each stent exchang\n- Replacement of stent (tube) in biliary or pancreatic duct\n\n### Condition\n- Glaucoma\n- Hyperlipidemia\n- Obstruction of bile duct\n- Gout\n- Essential hypertension\n- Asthma\n- Benign prostatic hyperplasia without outflow obstruction\n- Malignant lymphoma of intra-abdominal lymph nodes\n\n### Drug\n- ferrous sulfate 325 MG Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 325 mg by mouth daily.\n- loperamide hydrochloride 2 MG Oral Capsule, through Oral route, with intended 0 refill(s). Instructions: take 2 mg by mouth as needed.\n- omeprazole 40 MG Delayed Release Oral Capsule, through Oral route, with intended 0 refill(s). Instructions: take 40 mg by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-06-18 00:00:00, ended at 2014-06-18 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-14 00:00:00, ended at 2014-08-14 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for upper gastrointestinal endoscopic procedure\n\n### Condition\n- Obstruction of bile duct\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-08-14, presumably until 2014-08-14\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2014-08-14, presumably until 2014-08-14\n- 2 ML alfentanil 0.5 MG/ML Injection, started on 2014-08-14, presumably until 2014-08-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-08-14 00:00:00, ended at 2014-08-14 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2014-08-14, presumably until 2014-10-15, with intended 0 refill(s). Instructions: take 1 tablet by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-14 10:10:00, ended at 2014-08-14 15:53:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- Replacement of stent (tube) in biliary or pancreatic duct\n- Combined endoscopic catheterization of the biliary and pancreatic ductal systems, radiological supervision and interpretation\n- Endoscopic dilatation of bile duct\n- Endoscopic retrograde cholangiopancreatography (ERCP); with removal and exchange of stent(s), biliary or pancreatic duct, including pre- and post-dilation and guide wire passage, when performed, including sphincterotomy, when performed, each stent exchang\n\n### Condition\n- Morbid obesity\n- Asthma\n- Obstruction of bile duct\n- Benign prostatic hyperplasia without outflow obstruction\n- Essential hypertension\n- Glaucoma\n- Gout\n- Malignant lymphoma\n\n### Drug\n- finasteride 5 MG Oral Tablet, through Oral route, presumably until 2014-10-14, with intended 0 refill(s). Instructions: take 5 mg by mouth daily.\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2014-08-14, presumably until 2014-08-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-08-15 00:00:00, ended at 2014-08-15 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-15 00:00:00, ended at 2014-10-15 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for upper gastrointestinal endoscopic procedure\n\n### Condition\n- Obstruction of bile duct\n\n### Drug\n- 10 ML esmolol hydrochloride 10 MG/ML Injection, through Intravenous route, started on 2014-10-15, presumably until 2014-10-15\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-10-15, presumably until 2014-10-15\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2014-10-15, presumably until 2014-10-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-10-15 00:00:00, ended at 2014-10-15 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant lymphoma\n- Obstruction of bile duct\n\n### Drug\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2014-10-15, presumably until 2014-10-15, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-10-15 00:00:00, ended at 2014-10-15 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-15 09:26:00, ended at 2014-10-15 16:17:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- Endoscopic retrograde cholangiopancreatography\n- Combined endoscopic catheterization of the biliary and pancreatic ductal systems, radiological supervision and interpretation\n- Endoscopic retrograde cholangiopancreatography (ERCP); with removal and exchange of stent(s), biliary or pancreatic duct, including pre- and post-dilation and guide wire passage, when performed, including sphincterotomy, when performed, each stent exchang\n- Replacement of stent (tube) in biliary or pancreatic duct\n\n### Condition\n- Essential hypertension\n- Gout\n- Morbid obesity\n- Obstruction of bile duct\n- Glaucoma\n- Asthma\n- Anemia\n- Benign prostatic hyperplasia without outflow obstruction\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-01-07 00:00:00, ended at 2015-01-07 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for upper gastrointestinal endoscopic procedure\n\n### Condition\n- Obstruction of bile duct\n- Essential hypertension\n- Morbid obesity\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2015-01-07, presumably until 2015-01-07\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2015-01-07, presumably until 2015-01-07\n- ketamine 100 MG/ML Injectable Solution, started on 2015-01-07, presumably until 2015-01-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-01-07 00:00:00, ended at 2015-01-07 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2015-01-07, presumably until 2015-12-09, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-01-07 00:00:00, ended at 2015-01-07 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant lymphoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-01-07 10:08:00, ended at 2015-01-07 16:08:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- Endoscopic retrograde cholangiopancreatography\n- Replacement of stent (tube) in biliary or pancreatic duct\n- Combined endoscopic catheterization of the biliary and pancreatic ductal systems, radiological supervision and interpretation\n- Endoscopic retrograde cholangiopancreatography (ERCP); with removal and exchange of stent(s), biliary or pancreatic duct, including pre- and post-dilation and guide wire passage, when performed, including sphincterotomy, when performed, each stent exchang\n\n### Condition\n- Benign prostatic hyperplasia without outflow obstruction\n- Glaucoma\n- Gout\n- Asthma\n- Essential hypertension\n- Obstruction of bile duct\n- Hyperlipidemia\n- Malignant lymphoma of intra-abdominal lymph nodes\n- Neoplasm of digestive tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-01-13 00:00:00, ended at 2015-01-13 00:00:00\nThe patient in this visit was 77 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant lymphoma\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Malignant tumor of pancreas within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of pancreatic_cancer means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "47eb80c36818df39d9f059ac25fcfa70657a55c25b0c64ff6d1d5f73f3dd291d", "prompt_hash": "23aede4d393ba179b60461acf3560236857db6b4093e4ae124a1612870a9a2c4", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
{"doc_id": 7, "doc": {"person_id": 115969234, "visit_occurrence_id": 50395737, "death_date": null, "visit_concept_name": "Outpatient Visit", "visit_start_datetime": "2012-09-20 11:03:00", "visit_end_datetime": "2012-09-20 16:30:00", "visit_length_in_hours": 5.45, "integrated_visit_record": "## Visit\nThis visit record, was from Outpatient Visit, started at 2012-09-20 11:03:00, ended at 2012-09-20 16:30:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences\n\n### Condition\n- Headache\n- Abnormal findings on diagnostic imaging of skull and head\n- Benign neoplasm of cerebral meninges\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 138, "patient_first_visit_date": "2011-07-01 01:00:00", "patient_last_visit_date": "2020-07-23 11:32:00", "end_obs_date": "2013-09-20", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 0, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "new", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "new", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "recurrent", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "recurrent", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 17, "cumulated_visit_num": 17, "cumulated_approximate_token_count": 3788, "visit_cumulated": "## Visit\nThis visit record, was from Outpatient Visit, started at 2011-07-01 01:00:00, ended at 2011-07-01 12:08:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance imaging guidance for needle placement (eg, for biopsy, needle aspiration, injection, or placement of localization device) radiological supervision and interpretation\n\n### Condition\n- Benign neoplasm of brain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-07-01 08:07:58, ended at 2011-07-01 17:41:14\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of brain\n\n### Drug\n- atenolol 25 MG Oral Tablet, through Oral route, presumably until 2015-11-12. Instructions: take 25 mg by mouth daily.\n- metformin hydrochloride 500 MG Oral Tablet, through Oral route, presumably until 2012-03-25. Instructions: take 1,000 mg by mouth daily.\n- acetaminophen 300 MG / codeine phosphate 30 MG Oral Tablet, through Oral route, presumably until 2011-07-05. Instructions: take  by mouth as needed.\n- vitamin B12 0.5 MG Oral Tablet, through Oral route. Instructions: take 500 mcg by mouth daily.\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, through Subcutaneous route. Instructions: inject 10 Units subcutaneous (under the skin) Every Day \n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route. Instructions: take 81 mg by mouth daily.\n- levothyroxine sodium 0.15 MG Oral Tablet, through Oral route. Instructions: take 100 mcg by mouth daily \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-07-01 12:09:00, ended at 2011-07-01 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Benign neoplasm of brain\n- Neoplasm of brain\n- Thoracic spondylosis without myelopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-07-02 10:19:00, ended at 2011-07-05 12:52:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.16 (millimole per liter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 7.8 (percent)\n- Prothrombin time (PT): 14.4 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 31 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 329 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 6.8 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Body height: 5' 4\" (inch (US))\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 91.0 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- MCH [Entitic mass] by Automated count: 32.5 (picogram)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.17 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.1 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 96.4 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 172 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.1 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 3.1 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.52 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 6.7 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.8 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.33 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.45 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 26.8 (second)\n\n### Procedure\n- Induction of hypothermia\n- Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper limbs\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Computer assisted surgery with MR/MRA\n- Central motor evoked potential study (transcranial motor stimulation); lower limbs\n- Collection of venous blood by venipuncture\n- Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in lower limbs\n- Central motor evoked potential study (transcranial motor stimulation); upper limbs\n- Excision of lesion or tissue of cerebral meninges\n- Occupational therapy evaluation\n- Computed tomography, head or brain; without contrast material\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Intraoperative neurophysiology testing, per hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Disorder of brain\n- Benign neoplasm of cerebral meninges\n- Acquired absence of cervix and uterus\n- Nausea\n- Essential hypertension\n- Type 2 diabetes mellitus without complication\n- Acquired hypothyroidism\n\n### Drug\n- atenolol 25 MG Oral Tablet, through Oral route, started on 2011-07-03, presumably until 2011-07-05. Instructions: take 25 mg by mouth daily.\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2011-07-05, presumably until 2011-09-22, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2011-07-03, presumably until 2011-07-03. Instructions: take 150 mcg by mouth daily.\n- dexamethasone 1.5 MG Oral Tablet, through Oral route, started on 2011-07-05, presumably until 2011-07-05\n- docusate sodium 10 MG/ML Oral Solution, through Oral route, started on 2011-07-03, presumably until 2012-07-03, with intended 0 refill(s). Instructions: take 25 mL by mouth 2 times a day.\n- acetaminophen 300 MG / codeine phosphate 30 MG Oral Tablet, through Oral route, started on 2011-07-03, presumably until 2012-01-01, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed.\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2011-07-03, presumably until 2011-07-03\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2011-07-04, presumably until 2011-07-05\n- 1 ML hydralazine hydrochloride 20 MG/ML Injection, started on 2011-07-03, presumably until 2011-07-03\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2011-07-04, presumably until 2011-09-22, with intended 1 refill(s). Instructions: take 1 Cap by mouth 2 times a day.\n- dexamethasone 1 MG Oral Tablet, through Oral route, started on 2011-07-05, presumably until 2011-07-09, with intended 0 refill(s). Instructions: take 1 Tab by mouth. Please taper over next 5 days:  Take 3 tabs tid x one day then; 2 tabs x tid x one day then; 2 tabs bid x one day then;  1 tab bid x one day then; 1 tab in the am x one day then dc.\n- insulin isophane, human 100 UNT/ML Injectable Suspension, through Subcutaneous route, started on 2011-07-04, presumably until 2011-07-05\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2011-07-03, presumably until 2011-07-03. Instructions: take 150 mcg by mouth daily.\n- vitamin B12 0.5 MG Oral Tablet, through Oral route, started on 2011-07-03, presumably until 2011-07-05. Instructions: take 500 mcg by mouth daily.\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2011-07-03, presumably until 2011-07-05\n- 250 ML esmolol hydrochloride 10 MG/ML Injection, through Intravenous route, started on 2011-07-02, presumably until 2011-07-03\n- 1000 ML potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-07-02, presumably until 2011-07-03\n- levothyroxine sodium 0.075 MG Oral Tablet, through Oral route, started on 2011-07-04, presumably until 2011-07-05. Instructions: take 150 mcg by mouth daily.\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2011-07-02, presumably until 2011-07-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-07-09 10:41:51, ended at 2011-07-09 14:32:28\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neoplasm of cerebral meninges\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-09-22 13:31:06, ended at 2011-09-22 17:47:10\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neoplasm of cerebral meninges\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-09-22 14:56:00, ended at 2011-09-22 19:14:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Benign neoplasm of cerebral meninges\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-09-22 19:15:00, ended at 2011-09-22 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences\n\n### Condition\n- Benign neoplasm of cerebral meninges\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-03-25 00:00:00, ended at 2012-03-25 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abdominal pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-03-25 07:50:05, ended at 2012-03-25 11:36:27\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abdominal pain\n\n### Drug\n- metformin hydrochloride 1000 MG Oral Tablet, through Oral route, presumably until 2015-11-12. Instructions: take 1,000 mg by mouth 2 times a day.  \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-03-25 10:23:00, ended at 2012-03-25 11:31:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Abdominal pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-03-25 11:32:00, ended at 2012-03-25 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Abdominal pain\n- Primary malignant neoplasm of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-03-27 00:00:00, ended at 2012-03-27 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abdominal pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-05-07 06:53:00, ended at 2012-05-07 12:53:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- Other endoscopy of small intestine\n- Small intestinal endoscopy, enteroscopy beyond second portion of duodenum, not including ileum; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)\n\n### Condition\n- Abdominal pain\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2012-05-07, presumably until 2012-05-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-06-01 00:00:00, ended at 2012-06-01 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neoplasm of cerebral meninges\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-09-08 00:00:00, ended at 2012-09-08 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neoplasm of cerebral meninges\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-09-20 11:03:00, ended at 2012-09-20 16:30:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences\n\n### Condition\n- Headache\n- Abnormal findings on diagnostic imaging of skull and head\n- Benign neoplasm of cerebral meninges\n\n### Drug\n- No drugs.\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Malignant tumor of pancreas within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-07-01 01:00:00, ended at 2011-07-01 12:08:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance imaging guidance for needle placement (eg, for biopsy, needle aspiration, injection, or placement of localization device) radiological supervision and interpretation\n\n### Condition\n- Benign neoplasm of brain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-07-01 08:07:58, ended at 2011-07-01 17:41:14\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of brain\n\n### Drug\n- atenolol 25 MG Oral Tablet, through Oral route, presumably until 2015-11-12. Instructions: take 25 mg by mouth daily.\n- metformin hydrochloride 500 MG Oral Tablet, through Oral route, presumably until 2012-03-25. Instructions: take 1,000 mg by mouth daily.\n- acetaminophen 300 MG / codeine phosphate 30 MG Oral Tablet, through Oral route, presumably until 2011-07-05. Instructions: take  by mouth as needed.\n- vitamin B12 0.5 MG Oral Tablet, through Oral route. Instructions: take 500 mcg by mouth daily.\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, through Subcutaneous route. Instructions: inject 10 Units subcutaneous (under the skin) Every Day \n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route. Instructions: take 81 mg by mouth daily.\n- levothyroxine sodium 0.15 MG Oral Tablet, through Oral route. Instructions: take 100 mcg by mouth daily \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-07-01 12:09:00, ended at 2011-07-01 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Benign neoplasm of brain\n- Neoplasm of brain\n- Thoracic spondylosis without myelopathy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-07-02 10:19:00, ended at 2011-07-05 12:52:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.16 (millimole per liter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 7.8 (percent)\n- Prothrombin time (PT): 14.4 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 31 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 110 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 329 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 6.8 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Body height: 5' 4\" (inch (US))\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 91.0 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- MCH [Entitic mass] by Automated count: 32.5 (picogram)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.17 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.1 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 96.4 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 172 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.1 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 3.1 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.52 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 6.7 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.8 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 6.33 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.45 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 26.8 (second)\n\n### Procedure\n- Induction of hypothermia\n- Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper limbs\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Computer assisted surgery with MR/MRA\n- Central motor evoked potential study (transcranial motor stimulation); lower limbs\n- Collection of venous blood by venipuncture\n- Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in lower limbs\n- Central motor evoked potential study (transcranial motor stimulation); upper limbs\n- Excision of lesion or tissue of cerebral meninges\n- Occupational therapy evaluation\n- Computed tomography, head or brain; without contrast material\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Intraoperative neurophysiology testing, per hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Disorder of brain\n- Benign neoplasm of cerebral meninges\n- Acquired absence of cervix and uterus\n- Nausea\n- Essential hypertension\n- Type 2 diabetes mellitus without complication\n- Acquired hypothyroidism\n\n### Drug\n- atenolol 25 MG Oral Tablet, through Oral route, started on 2011-07-03, presumably until 2011-07-05. Instructions: take 25 mg by mouth daily.\n- famotidine 20 MG Oral Tablet, through Oral route, started on 2011-07-05, presumably until 2011-09-22, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2011-07-03, presumably until 2011-07-03. Instructions: take 150 mcg by mouth daily.\n- dexamethasone 1.5 MG Oral Tablet, through Oral route, started on 2011-07-05, presumably until 2011-07-05\n- docusate sodium 10 MG/ML Oral Solution, through Oral route, started on 2011-07-03, presumably until 2012-07-03, with intended 0 refill(s). Instructions: take 25 mL by mouth 2 times a day.\n- acetaminophen 300 MG / codeine phosphate 30 MG Oral Tablet, through Oral route, started on 2011-07-03, presumably until 2012-01-01, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed.\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2011-07-03, presumably until 2011-07-03\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2011-07-04, presumably until 2011-07-05\n- 1 ML hydralazine hydrochloride 20 MG/ML Injection, started on 2011-07-03, presumably until 2011-07-03\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2011-07-04, presumably until 2011-09-22, with intended 1 refill(s). Instructions: take 1 Cap by mouth 2 times a day.\n- dexamethasone 1 MG Oral Tablet, through Oral route, started on 2011-07-05, presumably until 2011-07-09, with intended 0 refill(s). Instructions: take 1 Tab by mouth. Please taper over next 5 days:  Take 3 tabs tid x one day then; 2 tabs x tid x one day then; 2 tabs bid x one day then;  1 tab bid x one day then; 1 tab in the am x one day then dc.\n- insulin isophane, human 100 UNT/ML Injectable Suspension, through Subcutaneous route, started on 2011-07-04, presumably until 2011-07-05\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, started on 2011-07-03, presumably until 2011-07-03. Instructions: take 150 mcg by mouth daily.\n- vitamin B12 0.5 MG Oral Tablet, through Oral route, started on 2011-07-03, presumably until 2011-07-05. Instructions: take 500 mcg by mouth daily.\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2011-07-03, presumably until 2011-07-05\n- 250 ML esmolol hydrochloride 10 MG/ML Injection, through Intravenous route, started on 2011-07-02, presumably until 2011-07-03\n- 1000 ML potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-07-02, presumably until 2011-07-03\n- levothyroxine sodium 0.075 MG Oral Tablet, through Oral route, started on 2011-07-04, presumably until 2011-07-05. Instructions: take 150 mcg by mouth daily.\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2011-07-02, presumably until 2011-07-04\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-07-09 10:41:51, ended at 2011-07-09 14:32:28\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neoplasm of cerebral meninges\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-09-22 13:31:06, ended at 2011-09-22 17:47:10\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neoplasm of cerebral meninges\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-09-22 14:56:00, ended at 2011-09-22 19:14:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Benign neoplasm of cerebral meninges\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-09-22 19:15:00, ended at 2011-09-22 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences\n\n### Condition\n- Benign neoplasm of cerebral meninges\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-03-25 00:00:00, ended at 2012-03-25 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abdominal pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-03-25 07:50:05, ended at 2012-03-25 11:36:27\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abdominal pain\n\n### Drug\n- metformin hydrochloride 1000 MG Oral Tablet, through Oral route, presumably until 2015-11-12. Instructions: take 1,000 mg by mouth 2 times a day.  \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-03-25 10:23:00, ended at 2012-03-25 11:31:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Abdominal pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-03-25 11:32:00, ended at 2012-03-25 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Abdominal pain\n- Primary malignant neoplasm of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-03-27 00:00:00, ended at 2012-03-27 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abdominal pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-05-07 06:53:00, ended at 2012-05-07 12:53:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 4\" (inch (US))\n\n### Procedure\n- Other endoscopy of small intestine\n- Small intestinal endoscopy, enteroscopy beyond second portion of duodenum, not including ileum; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)\n\n### Condition\n- Abdominal pain\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2012-05-07, presumably until 2012-05-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-06-01 00:00:00, ended at 2012-06-01 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neoplasm of cerebral meninges\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-09-08 00:00:00, ended at 2012-09-08 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neoplasm of cerebral meninges\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-09-20 11:03:00, ended at 2012-09-20 16:30:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences\n\n### Condition\n- Headache\n- Abnormal findings on diagnostic imaging of skull and head\n- Benign neoplasm of cerebral meninges\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Malignant tumor of pancreas within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of pancreatic_cancer means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "9d6e19feae59736afd0fb742a4860b6a462ea3f778f4642c9313e0d7f86ea158", "prompt_hash": "a4b960aed518704e14caccb8001452c25520a0b7cf07ded707532b3d4e47449b", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
{"doc_id": 8, "doc": {"person_id": 115970629, "visit_occurrence_id": 54969640, "death_date": "2014-06-16", "visit_concept_name": "Outpatient Visit", "visit_start_datetime": "2013-06-30 13:06:00", "visit_end_datetime": "2013-06-30 23:59:00", "visit_length_in_hours": 10.883333333333333, "integrated_visit_record": "## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-30 13:06:00, ended at 2013-06-30 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences\n\n### Condition\n- Primary malignant neoplasm of intrahepatic bile duct\n- Secondary malignant neoplasm of brain and spinal cord\n- Malaise\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 141, "patient_first_visit_date": "2009-01-24 00:00:00", "patient_last_visit_date": "2014-03-30 13:29:42", "end_obs_date": "2014-06-16", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 1, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "new", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "new", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "recurrent", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "recurrent", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "recurrent", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "recurrent", "liver_cancer_one_year_diagnosis": 1, "visit_sequence_number": 92, "cumulated_visit_num": 92, "cumulated_approximate_token_count": 34172, "visit_cumulated": "## Visit\nThis visit record, was from Telehealth, started at 2009-01-24 00:00:00, ended at 2009-01-24 00:00:00\nThe patient in this visit was 65 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2009-03-17 00:00:00, ended at 2009-03-17 00:00:00\nThe patient in this visit was 65 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, started on 2009-03-18, presumably until 2009-09-21, with quantity of 90.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily. \n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2009-03-18, presumably until 2009-09-21, with quantity of 180.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth 2 times a day. Please note that this replaces Toprol XL 50 mg. \n- irbesartan 150 MG Oral Tablet, through Oral route, started on 2009-03-18, presumably until 2009-09-21, with quantity of 90.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth every bedtime. PLEASE DISPENSE GENERIC FORMULATION.  PATIENT WAS TOLD BY PHARMACY THAT THERE IS A GENERIC BRAND FOR AVAPRO. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2009-09-21 00:00:00, ended at 2009-09-21 00:00:00\nThe patient in this visit was 66 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, started on 2009-09-21, presumably until 2009-12-22, with quantity of 90.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. FAX: 999-999-9999 \n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2009-09-21, presumably until 2009-12-22, with quantity of 180.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day. Please note that this replaces Toprol XL 50 mg. FAX: 999-999-9999 \n- irbesartan 150 MG Oral Tablet, through Oral route, started on 2009-09-21, presumably until 2009-12-22, with quantity of 90.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime. PLEASE DISPENSE GENERIC FORMULATION.  PATIENT WAS TOLD BY PHARMACY THAT THERE IS A GENERIC BRAND FOR AVAPRO. FAX: 999-999-9999 \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2009-09-29 14:11:01, ended at 2009-09-29 14:32:30\nThe patient in this visit was 66 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute bronchitis\n\n### Drug\n- 200 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2009-09-29, presumably until 2009-12-22, with intended 0 refill(s). Instructions: 1-2 Puffs by Inhalation route every 6 hours as needed \n- codeine phosphate 2 MG/ML / promethazine hydrochloride 1.25 MG/ML Oral Solution, through Oral route, started on 2009-09-29, presumably until 2009-12-22, with intended 0 refill(s). Instructions: take 5 mL by mouth every bedtime as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2009-12-22 10:54:12, ended at 2009-12-22 11:54:43\nThe patient in this visit was 66 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 8.75\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, started on 2009-12-22, presumably until 2010-12-23, with quantity of 90.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. FAX: 999-999-9999 \n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2009-12-22, presumably until 2010-12-23, with quantity of 180.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day. Please note that this replaces Toprol XL 50 mg. FAX: 999-999-9999 \n- valsartan 80 MG Oral Tablet, through Oral route, started on 2009-12-22, presumably until 2010-12-23, with quantity of 90.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-12-22 12:03:00, ended at 2009-12-22 23:59:00\nThe patient in this visit was 66 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 4.6 (gram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 135 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.4 (gram per deciliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 246 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 64 (unit per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Cholesterol non HDL/Cholesterol.total [Mass Ratio] in Serum or Plasma: 1.3 (ratio)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 33.1 (picogram)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.1 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 199 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.51 (micro-international unit per milliliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 101 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 2.4 (ratio)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.95 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.7 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 49 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 93 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 51 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 10.0 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 101 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.9 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 97.9 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 132 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-12-30 10:49:00, ended at 2009-12-30 14:55:00\nThe patient in this visit was 66 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine)\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-12-30 14:56:00, ended at 2009-12-30 23:59:00\nThe patient in this visit was 66 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Heart murmur\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-12 09:54:00, ended at 2010-05-12 23:59:00\nThe patient in this visit was 66 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Mammography; bilateral\n- Computer-aided detection (computer algorithm analysis of digital image data for lesion detection) with further review for interpretation, with or without digitization of film radiographic images; diagnostic mammography (List separately in addition to code\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-12-23 12:50:06, ended at 2010-12-23 13:45:27\nThe patient in this visit was 67 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 9\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n- Primary malignant neoplasm of female breast\n- Insomnia\n\n### Drug\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, started on 2010-12-23, presumably until 2011-12-29, with quantity of 90.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. FAX: 999-999-9999 \n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2010-12-23, presumably until 2011-12-29, with quantity of 180.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day. Please note that this replaces Toprol XL 50 mg. FAX: 999-999-9999 \n- valsartan 80 MG Oral Tablet, through Oral route, started on 2010-12-23, presumably until 2011-12-29, with quantity of 90.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. \n- zolpidem tartrate 10 MG Oral Tablet, through Oral route, started on 2010-12-23, presumably until 2011-06-21, with quantity of 20.0, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth every bedtime as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-23 13:49:00, ended at 2010-12-23 23:59:00\nThe patient in this visit was 67 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 46 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 66 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.3 (thousand per microliter)\n- Lipoprotein a [Mass/volume] in Serum or Plasma: 6.98 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 49 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.6 (percent)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 46 (nanogram per milliliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Cholesterol non HDL/Cholesterol.total [Mass Ratio] in Serum or Plasma: 1.1 (ratio)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.3 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 251 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 108 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 115 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 2.2 (ratio)\n- Platelets [#/volume] in Blood by Automated count: 194 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 10.1 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 96 (millimole per liter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 32 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.92 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.1 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 98.5 (femtoliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 130 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 33.4 (picogram)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Essential hypertension\n- Insomnia\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-02-03 11:33:00, ended at 2011-02-03 14:23:00\nThe patient in this visit was 67 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 9\" (inch (US))\n\n### Procedure\n- Endoscopic polypectomy of large intestine\n- Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- [Endoscopic] polypectomy of rectum\n- Colonoscopy, flexible; with biopsy, single or multiple\n\n### Condition\n- Diverticular disease of colon\n- Internal hemorrhoids\n- Benign neoplasm of rectum and anal canal\n- Benign neoplasm of colon\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2011-02-03, presumably until 2011-02-03\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-02-03, presumably until 2011-02-03\n- midazolam 1 MG/ML Injectable Solution, started on 2011-02-03, presumably until 2011-02-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-03-02 13:22:00, ended at 2011-03-02 23:59:00\nThe patient in this visit was 67 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 10.8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-18 10:30:00, ended at 2011-05-18 23:59:00\nThe patient in this visit was 67 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computer-aided detection (computer algorithm analysis of digital image data for lesion detection) with further review for interpretation, with or without digitization of film radiographic images; diagnostic mammography (List separately in addition to code\n- Mammography; bilateral\n\n### Condition\n- Fibrocystic disease of breast\n- Abnormal findings on diagnostic imaging of breast\n- Postmenopausal state\n- Postprocedural state finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-11-10 11:41:22, ended at 2011-11-10 12:15:18\nThe patient in this visit was 68 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-11-10 12:25:00, ended at 2011-11-10 23:59:00\nThe patient in this visit was 68 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 134 (milligram per deciliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 240 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 2.6 (ratio)\n- Lipoprotein a [Mass/volume] in Serum or Plasma: 6.9 (milligram per deciliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 63 (milligram per deciliter)\n- Cholesterol non HDL/Cholesterol.total [Mass Ratio] in Serum or Plasma: 1.4 (ratio)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-11-14 13:58:38, ended at 2011-11-14 14:22:16\nThe patient in this visit was 68 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 8.346\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Urinary tract infectious disease\n- Essential hypertension\n\n### Drug\n- sulfamethoxazole 800 MG / trimethoprim 160 MG Oral Tablet, through Oral route, started on 2011-11-14, presumably until 2012-05-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2011-11-16 00:00:00, ended at 2011-11-16 00:00:00\nThe patient in this visit was 68 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Viral hepatitis C\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-11-23 11:52:00, ended at 2011-11-23 23:59:00\nThe patient in this visit was 68 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 189 (unit per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Viral hepatitis C\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-12-29 09:58:24, ended at 2011-12-29 10:46:14\nThe patient in this visit was 68 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Postprocedural state finding\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, started on 2011-12-29, presumably until 2012-06-18, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. FAX: 999-999-9999\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2011-12-29, presumably until 2013-01-02, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day. Please note that this replaces Toprol XL 50 mg. FAX: 999-999-9999\n- valsartan 80 MG Oral Tablet, through Oral route, started on 2011-12-29, presumably until 2012-06-18, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-12-29 10:58:00, ended at 2011-12-29 23:59:00\nThe patient in this visit was 68 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 39 (nanogram per milliliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 260 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.9 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 129 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 2.6 (ratio)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.73 (milli-international unit per liter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 39 (nanogram per milliliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 12.8 (percent)\n- MCH [Entitic mass] by Automated count: 34.0 (picogram)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 70 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 92 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 106 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 99.5 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 130 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.8 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.80 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 188 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.2 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 48 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 101 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.3 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 45 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Postprocedural state finding\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-03-20 08:59:00, ended at 2012-03-20 23:59:00\nThe patient in this visit was 68 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 8.484\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-05-08 07:52:00, ended at 2012-05-08 23:59:00\nThe patient in this visit was 68 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 8.965\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2012-05-08, presumably until 2012-05-08\n- ascorbic acid 226 MG / cuprous oxide 0.8 MG / dl-alpha tocopheryl acetate 200 UNT / lutein 5 MG / zinc oxide 34.8 MG Oral Capsule, through Oral route, presumably until 2012-06-18. Instructions: take  by mouth.  \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-05-17 07:38:00, ended at 2012-05-17 23:59:00\nThe patient in this visit was 68 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 48 (unit per liter)\n- Body height: 5' 8.583\" (inch (US))\n- Cholesterol [Mass/volume] in Serum or Plasma: 234 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 91 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 127 (milligram per deciliter)\n- Cholesterol non HDL/Cholesterol.total [Mass Ratio] in Serum or Plasma: 1.4 (ratio)\n- Triglyceride [Moles/volume] in Serum or Plasma: 81 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 2.6 (ratio)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 1000 ML potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2012-05-17, presumably until 2012-05-17\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2012-05-17, presumably until 2012-05-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-06-06 10:30:00, ended at 2012-06-06 23:59:00\nThe patient in this visit was 68 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Screening mammography, bilateral (2-view study of each breast)\n- Computer-aided detection (computer algorithm analysis of digital image data for lesion detection) with further review for interpretation, with or without digitization of film radiographic images; screening mammography (List separately in addition to code \n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2012-06-17 07:11:00, ended at 2012-06-18 16:32:00\nThe patient in this visit was 68 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.67 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Body height: 5' 9.5\" (inch (US))\n- Erythrocyte distribution width [Ratio] by Automated count: 12.7 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 110 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.5 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 131 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 95 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.5 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 90.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 202 (thousand per microliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.64 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.61 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.7 (percent)\n- MCHC [Mass/volume] by Automated count: 35.2 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 97.8 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 3.9 (percent)\n- MCH [Entitic mass] by Automated count: 34.5 (picogram)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug provided in a facility (List separately in addition to code for primary procedure)\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Diagnostic interview and evaluation, not otherwise specified\n- Rhythm ECG, 1-3 leads; interpretation and report only\n- Radiologic examination, pelvis; 1 or 2 views\n- Radiologic examination, spine, lumbosacral; 2 or 3 views\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Physical therapy evaluation\n\n### Condition\n- Lumbosacral spondylosis without myelopathy\n- Low back pain\n- Abrasion and/or friction burn of skin\n- Contusion of head and/or neck\n- Leukocytosis\n- Pathological fracture of vertebra\n- Closed fracture lumbar vertebra\n- Essential hypertension\n- Age related macular degeneration\n- Constipation\n- Hypo-osmolality and or hyponatremia\n- Injury of head\n- Superficial injury of lower limb, excluding foot\n\n### Drug\n- acetaminophen 300 MG / codeine phosphate 30 MG Oral Tablet, through Oral route, started on 2012-06-17, presumably until 2012-12-15, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 4 hours as needed.\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2012-06-17, presumably until 2012-06-18\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2012-06-17, presumably until 2012-06-17\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2012-06-17, presumably until 2012-06-17\n- valsartan 80 MG Oral Tablet, through Oral route, started on 2012-06-17, presumably until 2012-06-24, with intended 3 refill(s). Instructions: take 1.5 Tabs by mouth daily.\n- ascorbic acid 226 MG / cuprous oxide 0.8 MG / dl-alpha tocopheryl acetate 200 UNT / lutein 5 MG / zinc oxide 34.8 MG Oral Capsule, through Oral route, started on 2012-06-17, presumably until 2012-06-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2012-06-24 00:00:00, ended at 2012-06-24 00:00:00\nThe patient in this visit was 68 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- valsartan 80 MG Oral Tablet, through Oral route, started on 2012-06-24, presumably until 2012-07-10, with intended 3 refill(s). Instructions: take 1.5 Tabs by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2012-07-10 00:00:00, ended at 2012-07-10 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- valsartan 80 MG Oral Tablet, through Oral route, started on 2012-07-10, presumably until 2012-07-12, with intended 1 refill(s). Instructions: take 1.5 Tabs by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-07-12 00:00:00, ended at 2012-07-12 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- valsartan 40 MG Oral Tablet, through Oral route, started on 2012-07-12, presumably until 2013-01-02, with intended 1 refill(s). Instructions: take 3 Tabs by mouth daily. NOTE NEW DOSE, PATIENT HAVING DIFFICULT TIME CUTTING 80 MG TABLETS IN HALF, NEEDS 120 MG DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-07-24 15:01:36, ended at 2012-07-24 15:31:47\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Closed fracture lumbar vertebra\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-07-24 15:42:00, ended at 2012-07-24 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, spine, lumbosacral; 2 or 3 views\n\n### Condition\n- Closed fracture lumbar vertebra\n- Lumbosacral spondylosis without myelopathy\n- Postural kyphosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-07-25 00:00:00, ended at 2012-07-25 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Closed fracture lumbar vertebra\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2012-07-25 00:00:00, ended at 2012-07-25 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Closed fracture lumbar vertebra\n- Phobic disorder\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2012-07-25, presumably until 2013-01-21, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed (CLAUSTROPHOBIA).\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-07-25 00:00:00, ended at 2012-07-25 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Closed fracture lumbar vertebra\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2012-08-21 00:00:00, ended at 2012-08-21 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Closed fracture lumbar vertebra\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-09-24 14:57:00, ended at 2012-09-24 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, spine, lumbosacral; 2 or 3 views\n\n### Condition\n- Arthropathy\n- Scoliosis deformity of spine\n- Disorder of back\n- Acquired deformity of spine\n- Lumbosacral spondylosis without myelopathy\n- Spondylosis without myelopathy\n- Low back pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-11-12 12:16:00, ended at 2012-11-12 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, spine, lumbosacral; 2 or 3 views\n\n### Condition\n- Low back pain\n- Lumbosacral spondylosis without myelopathy\n- Disorder of back\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-01-02 13:26:11, ended at 2013-01-02 14:29:01\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Postmenopausal state\n- Hypo-osmolality and or hyponatremia\n- Primary diagnosis: Essential hypertension\n- Primary malignant neoplasm of female breast\n- Postprocedural state finding\n\n### Drug\n- valsartan 40 MG Oral Tablet, through Oral route, started on 2013-01-02, presumably until 2013-03-01, with intended 1 refill(s). Instructions: take 3 Tabs by mouth daily. NOTE NEW DOSE, PATIENT HAVING DIFFICULT TIME CUTTING 80 MG TABLETS IN HALF, NEEDS 120 MG DAILY\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2013-01-02, presumably until 2013-03-01, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day. Please note that this replaces Toprol XL 50 mg. FAX: 999-999-9999\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-01-02 14:40:00, ended at 2013-01-02 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Cholesterol [Mass/volume] in Serum or Plasma: 256 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.6 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 38 (nanogram per milliliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Platelets [#/volume] in Blood by Automated count: 237 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.5 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.90 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 130 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 86 (unit per liter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 2.9 (ratio)\n- MCV [Entitic volume] by Automated count: 97.1 (femtoliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 38 (nanogram per milliliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.76 (milli-international unit per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 142 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.1 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 38 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 95 (millimole per liter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 88 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 72 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.1 (picogram)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Essential hypertension\n- Hypo-osmolality and or hyponatremia\n- Postmenopausal state\n- Postprocedural state finding\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-01-23 13:47:00, ended at 2013-01-23 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine)\n\n### Condition\n- Disorder of endocrine system\n- Postmenopausal state\n- Toxic diffuse goiter with no crisis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2013-02-13 00:00:00, ended at 2013-02-13 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Nausea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-02-13 15:24:39, ended at 2013-02-13 15:53:50\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Nausea\n\n### Drug\n- promethazine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2013-02-13, presumably until 2013-03-04, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed for Nausea.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-13 15:57:00, ended at 2013-02-13 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 370 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.1 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 87 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.8 (percent)\n- MCV [Entitic volume] by Automated count: 96.6 (femtoliter)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 206 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.0 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.3 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 10.4 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.5 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 639 (unit per liter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Amylase [Enzymatic activity/volume] in Serum or Plasma: 66 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 229 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.02 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Nausea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2013-02-14 00:00:00, ended at 2013-02-14 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Blood chemistry abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-14 13:40:00, ended at 2013-02-14 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 10.4 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 367 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 581 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 208 (unit per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Blood chemistry abnormal\n- Nausea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2013-02-18 00:00:00, ended at 2013-02-18 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of biliary tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-18 12:23:00, ended at 2013-02-18 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; limited study\n- Ultrasound, abdominal, real time with image documentation; complete\n\n### Condition\n- Cholelithiasis without obstruction\n- Nausea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-02-19 00:00:00, ended at 2013-02-19 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Blood chemistry abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-20 10:35:00, ended at 2013-02-20 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 131 (millimole per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 15.0 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.35 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 97.0 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 238 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 96 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.87 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.2 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 61.3 (percent)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 134 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 115 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 343 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Hemoglobin [Mass/volume] in Blood: 12.9 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 361 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 10.1 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 33.3 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.78 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 21.9 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.6 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.79 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.1 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.6 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Blood chemistry abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-02-20 11:03:51, ended at 2013-02-20 12:44:39\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 9\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Jaundice\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-21 00:00:00, ended at 2013-02-21 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for upper gastrointestinal endoscopic procedure\n\n### Condition\n- Obstruction of bile duct\n- Abdominal pain\n\n### Drug\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2013-02-21, presumably until 2013-02-21\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-02-21, presumably until 2013-02-21\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-02-21, presumably until 2013-02-21\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-02-21, presumably until 2013-02-21\n- succinylcholine chloride 20 MG/ML Injectable Solution, started on 2013-02-21, presumably until 2013-02-21\n- midazolam 1 MG/ML Injectable Solution, started on 2013-02-21, presumably until 2013-02-21\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2013-02-21 11:11:00, ended at 2013-03-01 15:34:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.9 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 314 (unit per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 12.8 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.5 (percent)\n- Eosinophils/100 leukocytes in Blood by Manual count: 3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.54 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.9 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 33.7 (picogram)\n- Monocytes [#/volume] in Blood by Manual count: 0.2 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 86 (unit per liter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 3 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.0 (percent)\n- Neutrophils/100 leukocytes in Blood by Manual count: 80 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 35 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 246 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Body height: 5' 10.8\" (inch (US))\n- Erythrocyte distribution width [Ratio] by Automated count: 15.6 (percent)\n- Monocytes/100 leukocytes in Blood by Manual count: 2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.3 (thousand per microliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.3 (ratio)\n- Neutrophils [#/volume] in Blood by Automated count: 8.98 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 5.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.9 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.18 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Manual count: 10.0 (thousand per microliter)\n- Prothrombin time (PT): 15.8 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 1.0 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 35.2 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.27 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 286 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 9 (percent)\n- MCV [Entitic volume] by Automated count: 99.0 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 87.7 (percent)\n\n### Procedure\n- Percutaneous needle biopsy lung\n- Combined endoscopic catheterization of the biliary and pancreatic ductal systems, radiological supervision and interpretation\n- Percutaneous placement of drainage catheter for combined internal and external biliary drainage or of a drainage stent for internal biliary drainage in patients with an inoperable mechanical biliary obstruction, radiological supervision and interpretation\n- Computed tomography, abdomen; without contrast material, followed by contrast material(s) and further sections\n- Other percutaneous procedures on biliary tract\n- Cholangiography and/or pancreatography; through existing catheter, radiological supervision and interpretation\n- Unlisted procedure, biliary tract\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Computed tomography, pelvis; with contrast material(s)\n- Change of percutaneous biliary drainage catheter\n- Computed tomography, abdomen; with contrast material(s)\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Endoscopic sphincterotomy and papillotomy\n- Computed tomography, thorax, diagnostic; without contrast material\n- Introduction of percutaneous transhepatic stent for internal and external biliary drainage\n- Injection procedure for cholangiography through an existing catheter (eg, percutaneous transhepatic or T-tube)\n- Biliary endoscopy, percutaneous via T-tube or other tract; diagnostic, with collection of specimen(s) by brushing and/or washing, when performed (separate procedure)\n- Change of percutaneous tube or drainage catheter with contrast monitoring (eg, genitourinary system, abscess), radiological supervision and interpretation\n- Other cholangiogram\n- Collection of venous blood by venipuncture\n- Replacement of stent (tube) in biliary or pancreatic duct\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n- Radiologic examination, abdomen; single anteroposterior view\n- Physical therapy evaluation\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Prophylactic administration of vaccine against other diseases\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Disorder of biliary tract\n- Jaundice\n- Neoplasm of uncertain behavior of liver and/or biliary passages\n- Eruption\n- Obstruction of bile duct\n- Disease of liver\n- Abdominal pain\n- Primary diagnosis: Essential hypertension\n- Localized swelling, mass and lump, trunk\n- Anemia of chronic disease\n- Atelectasis\n- Gastrointestinal hemorrhage\n- Hypo-osmolality and or hyponatremia\n- Pleurisy\n- Orthostatic hypotension\n\n### Drug\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2013-02-25, presumably until 2013-02-25\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2013-02-22, presumably until 2013-02-22\n- sodium phosphate, dibasic 59.3 MG/ML / sodium phosphate, monobasic 161 MG/ML Enema, through Rectal route, started on 2013-02-25, presumably until 2013-02-25\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2013-02-24, presumably until 2013-03-01\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2013-02-21, presumably until 2013-02-28\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2013-02-22, presumably until 2013-02-24\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2013-02-23, presumably until 2013-03-01\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2013-02-23, presumably until 2013-03-25, with intended 3 refill(s). Instructions: take 2 Tabs by mouth every bedtime.\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2013-02-24, presumably until 2013-02-24\n- metronidazole 500 MG Oral Tablet, through Oral route, started on 2013-02-21, presumably until 2013-02-28\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-02-22, presumably until 2013-03-01\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-02-28, presumably until 2013-02-28\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2013-02-27, presumably until 2013-08-27, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed for Pain.\n- 0.5 ML Streptococcus pneumoniae type 1 capsular polysaccharide antigen 0.05 MG/ML / Streptococcus pneumoniae type 10A capsular polysaccharide antigen 0.05 MG/ML / Streptococcus pneumoniae type 11A capsular polysaccharide antigen 0.05 MG/ML / Streptococ..., started on 2013-02-22, presumably until 2013-02-22\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2013-02-22, presumably until 2013-02-28\n- 1 ML promethazine hydrochloride 25 MG/ML Injection, started on 2013-02-25, presumably until 2013-02-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2013-03-04 00:00:00, ended at 2013-03-04 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-03-04 08:07:18, ended at 2013-03-04 09:07:35\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Jaundice\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-04 09:11:00, ended at 2013-03-04 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 226 (unit per liter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 175 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 7.0 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.5 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 92 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.59 (million per microliter)\n- MCH [Entitic mass] by Automated count: 32.1 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 542 (unit per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- MCV [Entitic volume] by Automated count: 94.5 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 127 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.5 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 13.6 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 5.0 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 444 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 131 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Jaundice\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-11 11:36:00, ended at 2013-03-11 13:07:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 6.339\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of intrahepatic bile duct\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-11 13:08:00, ended at 2013-03-11 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.6 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 60 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 94 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 5.1 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.3 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 319 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.88 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 425 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.20 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.7 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 11.4 (percent)\n- MCH [Entitic mass] by Automated count: 32.2 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 5.92 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 77.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.3 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 100 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 116 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 3.1 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.3 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.63 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.3 (percent)\n- MCV [Entitic volume] by Automated count: 94.8 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 130 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-13 00:00:00, ended at 2013-03-13 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for upper gastrointestinal endoscopic procedure\n\n### Condition\n- Obstruction of bile duct\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-03-13, presumably until 2013-03-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-13 13:30:00, ended at 2013-03-13 18:10:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 9.016\" (inch (US))\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Endoscopy and biopsy of upper gastrointestinal tract\n- Ultrasonography of digestive system\n- Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s) (includes endoscopic ultrasound examination of the esophagus, stomach, and either the duodenum or a surgicall\n\n### Condition\n- Secondary malignant neoplasm of lung\n- Primary malignant neoplasm of female breast\n- Anemia of chronic disease\n- Imaging of abdomen abnormal\n- Obstruction of bile duct\n- Essential hypertension\n- Primary malignant neoplasm\n\n### Drug\n- benzocaine 140 MG/ML / butamben 20 MG/ML / tetracaine 20 MG/ML Mucosal Spray, through Topical route, started on 2013-03-13, presumably until 2013-03-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2013-03-18 00:00:00, ended at 2013-03-18 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-25 08:08:00, ended at 2013-03-25 08:52:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 6.08 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 5.0 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.2 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 91.7 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.3 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 27.9 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.2 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 131 (millimole per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 56 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.04 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 134 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.8 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.73 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 77.9 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 2.5 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.2 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 330 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 301 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.83 (thousand per microliter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Essential hypertension\n- Pain due to neoplastic disease\n- Primary malignant neoplasm of intrahepatic bile duct\n- Hypokalemia\n- Acquired absence of breast\n- Benign neoplasm of colon\n- Obstruction of bile duct\n- Estrogen receptor positive tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-25 08:53:00, ended at 2013-03-25 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 5.748\" (inch (US))\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Obstruction of bile duct\n- Jaundice\n- Hypokalemia\n- Primary diagnosis: Benign neoplasm of colon\n- Primary malignant neoplasm of intrahepatic bile duct\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2013-03-25, presumably until 2013-09-03, with intended 1 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed. For nausea and vomiting.\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2013-03-25, presumably until 2013-05-03, with intended 2 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2013-03-25, presumably until 2013-07-24, with intended 2 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed. For nausea and vomiting.\n- sodium chloride 9 MG/ML Injection, started on 2013-03-25, presumably until 2013-03-25\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2013-03-25, presumably until 2013-09-17, with intended 3 refill(s). Instructions: take 1-2 Tabs by mouth every bedtime.\n- prochlorperazine 10 MG Oral Tablet, through Oral route, started on 2013-03-25, presumably until 2013-07-29, with intended 2 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed. For nausea and vomiting.\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-03-25, presumably until 2013-03-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-27 00:00:00, ended at 2013-03-27 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on upper anterior abdominal wall; not otherwise specified\n\n### Condition\n- Obstruction of bile duct\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, started on 2013-03-27, presumably until 2013-03-27\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2013-03-27, presumably until 2013-03-27\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2013-03-27, presumably until 2013-03-27\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2013-03-27, presumably until 2013-03-27\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-03-27, presumably until 2013-03-27\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-03-27, presumably until 2013-03-27\n- succinylcholine chloride 20 MG/ML Injectable Solution, started on 2013-03-27, presumably until 2013-03-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-27 11:02:00, ended at 2013-03-28 13:50:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 9\" (inch (US))\n\n### Procedure\n- Change of percutaneous tube or drainage catheter with contrast monitoring (eg, genitourinary system, abscess), radiological supervision and interpretation\n- Cholangiography and/or pancreatography; through existing catheter, radiological supervision and interpretation\n- Injection procedure for cholangiography through an existing catheter (eg, percutaneous transhepatic or T-tube)\n- Change of percutaneous biliary drainage catheter\n- Replacement of stent (tube) in biliary or pancreatic duct\n\n### Condition\n- Gastrointestinal complication of procedure\n- Primary diagnosis: Obstruction of bile duct\n- Primary malignant neoplasm of extrahepatic bile duct\n- Essential hypertension\n- Primary malignant neoplasm of intrahepatic bile duct\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-03-27, presumably until 2013-03-27\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2013-03-27, presumably until 2013-03-27\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-03-27, presumably until 2013-03-27\n- 1 ML morphine sulfate 2 MG/ML Prefilled Syringe, through Intravenous route, started on 2013-03-27, presumably until 2013-03-28\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2013-03-27, presumably until 2013-03-27\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2013-03-27, presumably until 2013-03-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2013-03-28 22:56:00, ended at 2013-04-03 15:30:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Body height: 5' 9\" (inch (US))\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.10 (million per microliter)\n- Globulin [Mass/volume] in Serum: 5.0 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.2 (picogram)\n- Prothrombin time (PT): 16.3 (second)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 5.0 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.4 (ratio)\n- MCV [Entitic volume] by Automated count: 91.3 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 45 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.0 (percent)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.3 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.9 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.3 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 95.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 291 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.77 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.2 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.6 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 3.4 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 347 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.1 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.95 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n\n### Procedure\n- Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, without imaging guidance; age 5 years or older\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Radiological guidance (ie, fluoroscopy, ultrasound, or computed tomography), for percutaneous drainage (eg, abscess, specimen collection), with placement of catheter, radiological supervision and interpretation\n- Percutaneous aspiration of liver\n- Injection procedure for cholangiography through an existing catheter (eg, percutaneous transhepatic or T-tube)\n- Hepatotomy; for percutaneous drainage of abscess or cyst, 1 or 2 stages\n- Change of percutaneous biliary drainage catheter\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Radiologic examination, abdomen; complete, including decubitus and/or erect views\n- Central venous catheter placement with guidance\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Cholangiography and/or pancreatography; through existing catheter, radiological supervision and interpretation\n- Change of percutaneous tube or drainage catheter with contrast monitoring (eg, genitourinary system, abscess), radiological supervision and interpretation\n\n### Condition\n- Acute cholecystitis\n- Anemia of chronic disease\n- Postprocedural state finding\n- Streptococcal infectious disease\n- Disorder of biliary tract\n- Bacterial infection due to Klebsiella pneumoniae\n- Obstruction of bile duct\n- Primary malignant neoplasm of extrahepatic bile duct\n- Valvular endocarditis\n- Essential hypertension\n- Primary diagnosis: Fever\n- Hypokalemia\n- Intra-abdominal and pelvic swelling, mass and lump\n- Primary malignant neoplasm of intrahepatic bile duct\n- Abscess of liver\n- Perforation of gallbladder\n- Bacteremia\n- Venous thrombosis\n- Vomiting\n- Age related macular degeneration\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2013-03-29, presumably until 2013-03-29\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2013-03-29, presumably until 2013-04-01\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2013-03-31, presumably until 2013-04-01\n- lidocaine 40 MG/ML Topical Cream, through Topical route, started on 2013-04-02, presumably until 2013-04-02\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-03-28, presumably until 2013-03-30\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2013-04-02, presumably until 2013-04-03\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2013-04-01, presumably until 2013-04-01\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2013-03-31, presumably until 2013-03-31\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2013-03-29, presumably until 2013-04-03\n- piperacillin 4000 MG / tazobactam 500 MG Injection, through Intravenous route, started on 2013-03-30, presumably until 2013-03-31\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2013-03-30, presumably until 2013-04-02\n- 0.8 ML filgrastim 0.6 MG/ML Prefilled Syringe, started on 2013-03-30, presumably until 2013-03-30\n- 0.8 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2013-03-31, presumably until 2013-04-01\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2013-04-02, presumably until 2013-11-27, with intended 0 refill(s). Instructions: 3 mL by Intravenous route Every Day.\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2013-03-31, presumably until 2013-04-21, with intended 0 refill(s). Instructions: 50 mL by Intravenous route every 6 hours. Give through Saturday 05/09/2024.\n- metronidazole 500 MG Oral Tablet, through Oral route, started on 2013-03-31, presumably until 2013-04-01\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-04-01, presumably until 2013-04-01\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-03-29, presumably until 2013-03-31\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2013-03-29, presumably until 2013-03-30\n- 100 ML metronidazole 5 MG/ML Injection, through Intravenous route, started on 2013-03-29, presumably until 2013-03-30\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2013-03-29, presumably until 2013-04-03\n- lidocaine hydrochloride 20 MG/ML Injectable Solution, started on 2013-04-02, presumably until 2013-04-02\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-04-07 00:00:00, ended at 2013-04-07 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-08 17:57:00, ended at 2013-04-08 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Fever\n- Acute cholecystitis\n- Postprocedural state finding\n- Lymphadenopathy\n- Disorder of biliary tract\n- Obstruction of bile duct\n- Primary malignant neoplasm of extrahepatic bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-11 09:51:00, ended at 2013-04-11 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- ertapenem 1000 MG Injection, through Intravenous route, started on 2013-04-11, presumably until 2013-04-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-04-15 00:00:00, ended at 2013-04-15 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-04-15 00:00:00, ended at 2013-04-15 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Postprocedural state finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-15 07:44:00, ended at 2013-04-15 08:23:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 112 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 69 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 59 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.12 (thousand per microliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.7 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.8 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 63.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 386 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.7 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.3 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 5.2 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.25 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.5 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.18 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 372 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.6 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.0 (percent)\n- MCH [Entitic mass] by Automated count: 29.8 (picogram)\n- MCV [Entitic volume] by Automated count: 91.2 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.95 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Jaundice\n- Benign neoplasm of colon\n- Hypokalemia\n- Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-15 08:24:00, ended at 2013-04-15 09:29:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 6.535\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n- Benign neoplasm of colon\n- Jaundice\n- Primary malignant neoplasm of intrahepatic bile duct\n- Hypokalemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-21 12:38:00, ended at 2013-04-21 17:37:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 9\" (inch (US))\n\n### Procedure\n- Injection procedure for cholangiography through an existing catheter (eg, percutaneous transhepatic or T-tube)\n- Change of percutaneous biliary drainage catheter\n- Cholangiography and/or pancreatography; through existing catheter, radiological supervision and interpretation\n- Replacement of stent (tube) in biliary or pancreatic duct\n- Percutaneous placement of drainage catheter for combined internal and external biliary drainage or of a drainage stent for internal biliary drainage in patients with an inoperable mechanical biliary obstruction, radiological supervision and interpretation\n\n### Condition\n- Obstruction of bile duct\n- Primary malignant neoplasm of intrahepatic bile duct\n- Cellulitis and abscess of trunk\n- Gastrointestinal complication of procedure\n- Perforation of gallbladder\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-04-21, presumably until 2013-04-21\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2013-04-21, presumably until 2013-04-21\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-24 13:55:00, ended at 2013-04-24 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Obstruction of bile duct\n- Primary malignant neoplasm of intrahepatic bile duct\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-29 10:30:00, ended at 2013-04-29 12:57:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 8.898\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malaise\n- Sepsis\n- Solitary nodule of lung\n- Tachycardia\n- Obstruction of bile duct\n- Disorder of spleen\n- Leukocytosis\n- Primary malignant neoplasm of intrahepatic bile duct\n- Primary diagnosis: Anemia\n- Valvular endocarditis\n- Malnutrition (calorie)\n- Acute posthemorrhagic anemia\n- Inflammatory disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-29 12:58:00, ended at 2013-04-29 14:42:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 8.898\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n- Primary malignant neoplasm of intrahepatic bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-29 14:43:00, ended at 2013-04-29 17:08:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 115 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 128 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.01 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 520 (unit per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 3.0 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 5.7 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 9.40 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 130 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.4 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 310 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.0 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 17.6 (percent)\n- MCH [Entitic mass] by Automated count: 30.0 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 92.2 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.2 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.2 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.97 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 3.8 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 1.90 (million per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Fever\n- Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2013-04-29 17:09:00, ended at 2013-05-03 16:55:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 79 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 261 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.5 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.9 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Base deficit in Blood: 4.0 (millimole per liter)\n- Body height: 5' 9\" (inch (US))\n- Erythrocyte distribution width [Ratio] by Automated count: 18.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- Lactate [Moles/volume] in Blood: 1.0 (millimole per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.5 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 4.8 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 1.8 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 6.7 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.4 (percent)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Prothrombin time (PT): 18.0 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 86 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.11 (million per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 33.5 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 414 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- INR in Platelet poor plasma by Coagulation assay: 1.6 (ratio)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.50 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 83.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 243 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.0 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.71 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 5.6 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 91.8 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.2 (percent)\n\n### Procedure\n- Injection procedure for cholangiography through an existing catheter (eg, percutaneous transhepatic or T-tube)\n- Selective catheter placement, arterial system; additional second order, third order, and beyond, abdominal, pelvic, or lower extremity artery branch, within a vascular family (List in addition to code for initial second or third order vessel as appropriat\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Angiography through existing catheter for follow-up study for transcatheter therapy, embolization or infusion, other than for thrombolysis\n- Physical therapy evaluation\n- Selective catheter placement, arterial system; initial third order or more selective abdominal, pelvic, or lower extremity artery branch, within a vascular family\n- Other cholangiogram\n- Arteriography of femoral and other lower extremity arteries\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Replacement of stent (tube) in biliary or pancreatic duct\n- Collection of venous blood by venipuncture\n- Occupational therapy evaluation\n- Cholangiography and/or pancreatography; through existing catheter, radiological supervision and interpretation\n- Change of percutaneous tube or drainage catheter with contrast monitoring (eg, genitourinary system, abscess), radiological supervision and interpretation\n- Other endovascular procedures on other vessels\n- Change of percutaneous biliary drainage catheter\n- Angiography, visceral, selective or supraselective (with or without flush aortogram), radiological supervision and interpretation\n- Transfusion, blood or blood components\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Transcatheter occlusion or embolization (eg, for tumor destruction, to achieve hemostasis, to occlude a vascular malformation), percutaneous, any method, non-central nervous system, non-head or neck\n- Arteriography of other intra-abdominal arteries\n- Packed blood cell transfusion\n- Transcatheter therapy, embolization, any method, radiological supervision and interpretation\n- Angiography, selective, each additional vessel studied after basic examination, radiological supervision and interpretation (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Anemia\n- Anemia of chronic disease\n- Sepsis\n- Hypo-osmolality and or hyponatremia\n- Malaise\n- Primary malignant neoplasm of intrahepatic bile duct\n- Perforation of gallbladder\n- Aneurysm of visceral artery\n- Mechanical complication of vascular device\n- Generalized abdominal pain\n- Valvular endocarditis\n\n### Drug\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2013-05-02, presumably until 2013-05-02\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-04-30, presumably until 2013-05-01\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2013-05-02, presumably until 2013-05-02\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2013-04-29, presumably until 2013-05-02\n- ertapenem 1000 MG Injection, through Intravenous route, started on 2013-04-29, presumably until 2013-06-24, with intended 0 refill(s). Instructions: 1 g by Intravenous route Every Day.\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2013-04-29, presumably until 2013-05-02\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2013-04-30, presumably until 2013-05-03\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2013-04-29, presumably until 2013-04-29\n- 200 ML fluconazole 2 MG/ML Injection, through Intravenous route, started on 2013-04-29, presumably until 2013-05-02\n- 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2013-04-29, presumably until 2013-05-03\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2013-04-30, presumably until 2013-05-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-05 12:50:00, ended at 2013-05-05 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 9.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n- Primary malignant neoplasm of intrahepatic bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-06 16:44:00, ended at 2013-05-06 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Declotting by thrombolytic agent of implanted vascular access device or catheter\n\n### Condition\n- No conditions.\n\n### Drug\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2013-05-06, presumably until 2013-05-06\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-13 09:00:00, ended at 2013-05-13 09:41:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 8.898\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Fever\n- Benign neoplasm of colon\n- Jaundice\n- Hypokalemia\n- Valvular endocarditis\n- Primary diagnosis: Anemia\n- Hypo-osmolality and or hyponatremia\n- Abscess of peritoneum\n- Obstruction of bile duct\n\n### Drug\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, presumably until 2013-09-03. Instructions: take 10 mEq by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-13 09:42:00, ended at 2013-05-13 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Magnesium [Mass/volume] in Serum or Plasma: 1.8 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.44 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.8 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.4 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.1 (percent)\n- Body height: 5' 8.898\" (inch (US))\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.22 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 16.9 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 82 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.4 (percent)\n- Platelets [#/volume] in Blood by Automated count: 199 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.2 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 362 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.35 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.0 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.8 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 104 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.6 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.8 (percent)\n- MCV [Entitic volume] by Automated count: 92.6 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 63.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 132 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 71 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.8 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.92 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n- Primary malignant neoplasm of intrahepatic bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-14 07:30:00, ended at 2013-05-14 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Benign neoplasm of colon\n- Jaundice\n- Primary diagnosis: Obstruction of bile duct\n- Hypokalemia\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2013-05-14, presumably until 2013-05-14\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2013-05-14, presumably until 2013-05-14\n- sodium chloride 9 MG/ML Injection, started on 2013-05-14, presumably until 2013-05-14\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-05-14, presumably until 2013-05-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-20 08:20:00, ended at 2013-05-20 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 27.0 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.60 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.4 (percent)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 21.4 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.1 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 150 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 66 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 2.8 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.9 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.26 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 91 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 239 (unit per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.4 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.98 (million per microliter)\n- MCV [Entitic volume] by Automated count: 90.8 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.82 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 112 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 8.9 (gram per deciliter)\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2013-05-20, presumably until 2013-05-20\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2013-05-20, presumably until 2013-05-20\n- sodium chloride 9 MG/ML Injection, started on 2013-05-20, presumably until 2013-05-20\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-05-20, presumably until 2013-05-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-27 08:00:00, ended at 2013-05-27 14:44:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 9\" (inch (US))\n\n### Procedure\n- Cholangiography and/or pancreatography; through existing catheter, radiological supervision and interpretation\n- Collection of blood specimen from a completely implantable venous access device\n- Injection procedure for cholangiography through an existing catheter (eg, percutaneous transhepatic or T-tube)\n- Replacement of stent (tube) in biliary or pancreatic duct\n- Change of percutaneous biliary drainage catheter\n- Change of percutaneous tube or drainage catheter with contrast monitoring (eg, genitourinary system, abscess), radiological supervision and interpretation\n\n### Condition\n- Disorder of biliary tract\n- Primary malignant neoplasm of intrahepatic bile duct\n- Obstruction of bile duct\n- Abscess of liver\n- Disorder of gallbladder\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-05-27, presumably until 2013-05-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-03 08:43:00, ended at 2013-06-03 09:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 2.7 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 26.9 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 58.5 (percent)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 108 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 48 (unit per liter)\n- Body height: 5' 8.898\" (inch (US))\n- Hemoglobin [Mass/volume] in Blood: 8.9 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.9 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.03 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.8 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 442 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.3 (percent)\n- MCH [Entitic mass] by Automated count: 29.4 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.99 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.8 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 23.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 44 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 216 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.6 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.50 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.3 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 131 (millimole per liter)\n\n### Procedure\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary diagnosis: Anemia\n- Obstruction of bile duct\n- Valvular endocarditis\n- Primary malignant neoplasm of intrahepatic bile duct\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2013-06-03, presumably until 2013-06-03\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2013-06-03, presumably until 2013-06-03\n- sodium chloride 9 MG/ML Injection, started on 2013-06-03, presumably until 2013-06-03\n- ertapenem 1000 MG Injection, through Intravenous route, started on 2013-06-03, presumably until 2013-06-24, with intended 0 refill(s). Instructions: 1 g by Intravenous route Every Day.\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-06-03, presumably until 2013-06-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-03 10:00:00, ended at 2013-06-03 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n\n### Condition\n- Bleeding\n- Fever\n- Sepsis\n- Acute and subacute bacterial endocarditis\n- Fistula of gallbladder\n- Hypokalemia\n- Jaundice\n- Abscess of peritoneum\n- Primary diagnosis: Obstruction of bile duct\n- Benign neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-06 12:50:00, ended at 2013-06-06 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Antineoplastic poisoning\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-10 08:15:00, ended at 2013-06-10 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 8.8 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.3 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 29.7 (picogram)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.9 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.2 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 75.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.1 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.53 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 87 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 95 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 110 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.64 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 129 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 85 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 26.2 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 278 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.11 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.97 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.8 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 512 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Anemia\n- Obstruction of bile duct\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2013-06-10, presumably until 2013-06-10\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2013-06-10, presumably until 2013-06-10\n- sodium chloride 9 MG/ML Injection, started on 2013-06-10, presumably until 2013-06-10\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-06-10, presumably until 2013-06-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-13 11:09:00, ended at 2013-06-13 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of intrahepatic bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-24 08:20:00, ended at 2013-06-24 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Glucose [Mass/volume] in Serum or Plasma: 106 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.2 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 418 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 24.5 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 128 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 938 (unit per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 86.8 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 17.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.34 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 71.4 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.8 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.30 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 130 (unit per liter)\n- Body height: 5' 8.898\" (inch (US))\n- Chloride [Moles/volume] in Serum or Plasma: 94 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.82 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.66 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.5 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 114 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 8.2 (gram per deciliter)\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Transfusion, blood or blood components\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of intrahepatic bile duct\n- Hypokalemia\n- Benign neoplasm of colon\n- Obstruction of bile duct\n- Anemia\n- Jaundice\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2013-06-24, presumably until 2013-06-24\n- heparin sodium, porcine 100 UNT/ML Injectable Solution, through Intravenous route, started on 2013-06-20, presumably until 2013-10-23, with intended 3 refill(s). Instructions: 3 mL by Intravenous route One Time.\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2013-06-24, presumably until 2013-06-24\n- sodium chloride 9 MG/ML Injection, started on 2013-06-24, presumably until 2013-06-24\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-06-24, presumably until 2013-06-24\n- 125 ML sodium chloride 9 MG/ML Prefilled Syringe, started on 2013-06-20, presumably until 2013-10-23, with intended 3 refill(s). Instructions: 10 mL by Injection route Every Day.\n- magnesium oxide 400 MG Oral Tablet, through Oral route, started on 2013-06-24, presumably until 2013-07-24, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day. Take 1 tab twice a day x 5 days, #10\n- megestrol acetate 40 MG/ML Oral Suspension, through Oral route, started on 2013-06-24, presumably until 2013-07-12, with intended 3 refill(s). Instructions: take 20 mL by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-30 13:06:00, ended at 2013-06-30 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences\n\n### Condition\n- Primary malignant neoplasm of intrahepatic bile duct\n- Secondary malignant neoplasm of brain and spinal cord\n- Malaise\n\n### Drug\n- No drugs.\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Malignant tumor of pancreas within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Telehealth, started at 2009-01-24 00:00:00, ended at 2009-01-24 00:00:00\nThe patient in this visit was 65 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2009-03-17 00:00:00, ended at 2009-03-17 00:00:00\nThe patient in this visit was 65 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, started on 2009-03-18, presumably until 2009-09-21, with quantity of 90.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily. \n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2009-03-18, presumably until 2009-09-21, with quantity of 180.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth 2 times a day. Please note that this replaces Toprol XL 50 mg. \n- irbesartan 150 MG Oral Tablet, through Oral route, started on 2009-03-18, presumably until 2009-09-21, with quantity of 90.0, with intended 1 refill(s). Instructions: take 1 Tab by mouth every bedtime. PLEASE DISPENSE GENERIC FORMULATION.  PATIENT WAS TOLD BY PHARMACY THAT THERE IS A GENERIC BRAND FOR AVAPRO. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2009-09-21 00:00:00, ended at 2009-09-21 00:00:00\nThe patient in this visit was 66 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, started on 2009-09-21, presumably until 2009-12-22, with quantity of 90.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily. FAX: 999-999-9999 \n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2009-09-21, presumably until 2009-12-22, with quantity of 180.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day. Please note that this replaces Toprol XL 50 mg. FAX: 999-999-9999 \n- irbesartan 150 MG Oral Tablet, through Oral route, started on 2009-09-21, presumably until 2009-12-22, with quantity of 90.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime. PLEASE DISPENSE GENERIC FORMULATION.  PATIENT WAS TOLD BY PHARMACY THAT THERE IS A GENERIC BRAND FOR AVAPRO. FAX: 999-999-9999 \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2009-09-29 14:11:01, ended at 2009-09-29 14:32:30\nThe patient in this visit was 66 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Acute bronchitis\n\n### Drug\n- 200 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2009-09-29, presumably until 2009-12-22, with intended 0 refill(s). Instructions: 1-2 Puffs by Inhalation route every 6 hours as needed \n- codeine phosphate 2 MG/ML / promethazine hydrochloride 1.25 MG/ML Oral Solution, through Oral route, started on 2009-09-29, presumably until 2009-12-22, with intended 0 refill(s). Instructions: take 5 mL by mouth every bedtime as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2009-12-22 10:54:12, ended at 2009-12-22 11:54:43\nThe patient in this visit was 66 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 8.75\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, started on 2009-12-22, presumably until 2010-12-23, with quantity of 90.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. FAX: 999-999-9999 \n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2009-12-22, presumably until 2010-12-23, with quantity of 180.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day. Please note that this replaces Toprol XL 50 mg. FAX: 999-999-9999 \n- valsartan 80 MG Oral Tablet, through Oral route, started on 2009-12-22, presumably until 2010-12-23, with quantity of 90.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-12-22 12:03:00, ended at 2009-12-22 23:59:00\nThe patient in this visit was 66 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 4.6 (gram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 135 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.4 (gram per deciliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 246 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 64 (unit per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Cholesterol non HDL/Cholesterol.total [Mass Ratio] in Serum or Plasma: 1.3 (ratio)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 33.1 (picogram)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.1 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 199 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.51 (micro-international unit per milliliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 101 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 2.4 (ratio)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.95 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.7 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 49 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 93 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 51 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 10.0 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 101 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.9 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 97.9 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 132 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-12-30 10:49:00, ended at 2009-12-30 14:55:00\nThe patient in this visit was 66 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine)\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-12-30 14:56:00, ended at 2009-12-30 23:59:00\nThe patient in this visit was 66 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Heart murmur\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-12 09:54:00, ended at 2010-05-12 23:59:00\nThe patient in this visit was 66 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Mammography; bilateral\n- Computer-aided detection (computer algorithm analysis of digital image data for lesion detection) with further review for interpretation, with or without digitization of film radiographic images; diagnostic mammography (List separately in addition to code\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2010-12-23 12:50:06, ended at 2010-12-23 13:45:27\nThe patient in this visit was 67 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 9\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n- Primary malignant neoplasm of female breast\n- Insomnia\n\n### Drug\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, started on 2010-12-23, presumably until 2011-12-29, with quantity of 90.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. FAX: 999-999-9999 \n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2010-12-23, presumably until 2011-12-29, with quantity of 180.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day. Please note that this replaces Toprol XL 50 mg. FAX: 999-999-9999 \n- valsartan 80 MG Oral Tablet, through Oral route, started on 2010-12-23, presumably until 2011-12-29, with quantity of 90.0, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. \n- zolpidem tartrate 10 MG Oral Tablet, through Oral route, started on 2010-12-23, presumably until 2011-06-21, with quantity of 20.0, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth every bedtime as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-12-23 13:49:00, ended at 2010-12-23 23:59:00\nThe patient in this visit was 67 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 46 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 66 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.3 (thousand per microliter)\n- Lipoprotein a [Mass/volume] in Serum or Plasma: 6.98 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 49 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.6 (percent)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 46 (nanogram per milliliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Cholesterol non HDL/Cholesterol.total [Mass Ratio] in Serum or Plasma: 1.1 (ratio)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.3 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 251 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 108 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 115 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 2.2 (ratio)\n- Platelets [#/volume] in Blood by Automated count: 194 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 10.1 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 96 (millimole per liter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 32 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.92 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.1 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 98.5 (femtoliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 130 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 33.4 (picogram)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Essential hypertension\n- Insomnia\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-02-03 11:33:00, ended at 2011-02-03 14:23:00\nThe patient in this visit was 67 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 9\" (inch (US))\n\n### Procedure\n- Endoscopic polypectomy of large intestine\n- Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- [Endoscopic] polypectomy of rectum\n- Colonoscopy, flexible; with biopsy, single or multiple\n\n### Condition\n- Diverticular disease of colon\n- Internal hemorrhoids\n- Benign neoplasm of rectum and anal canal\n- Benign neoplasm of colon\n\n### Drug\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2011-02-03, presumably until 2011-02-03\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-02-03, presumably until 2011-02-03\n- midazolam 1 MG/ML Injectable Solution, started on 2011-02-03, presumably until 2011-02-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-03-02 13:22:00, ended at 2011-03-02 23:59:00\nThe patient in this visit was 67 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 10.8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-18 10:30:00, ended at 2011-05-18 23:59:00\nThe patient in this visit was 67 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computer-aided detection (computer algorithm analysis of digital image data for lesion detection) with further review for interpretation, with or without digitization of film radiographic images; diagnostic mammography (List separately in addition to code\n- Mammography; bilateral\n\n### Condition\n- Fibrocystic disease of breast\n- Abnormal findings on diagnostic imaging of breast\n- Postmenopausal state\n- Postprocedural state finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-11-10 11:41:22, ended at 2011-11-10 12:15:18\nThe patient in this visit was 68 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-11-10 12:25:00, ended at 2011-11-10 23:59:00\nThe patient in this visit was 68 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 134 (milligram per deciliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 240 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 2.6 (ratio)\n- Lipoprotein a [Mass/volume] in Serum or Plasma: 6.9 (milligram per deciliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 63 (milligram per deciliter)\n- Cholesterol non HDL/Cholesterol.total [Mass Ratio] in Serum or Plasma: 1.4 (ratio)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-11-14 13:58:38, ended at 2011-11-14 14:22:16\nThe patient in this visit was 68 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 8.346\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Urinary tract infectious disease\n- Essential hypertension\n\n### Drug\n- sulfamethoxazole 800 MG / trimethoprim 160 MG Oral Tablet, through Oral route, started on 2011-11-14, presumably until 2012-05-08, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2011-11-16 00:00:00, ended at 2011-11-16 00:00:00\nThe patient in this visit was 68 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Viral hepatitis C\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-11-23 11:52:00, ended at 2011-11-23 23:59:00\nThe patient in this visit was 68 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 189 (unit per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Viral hepatitis C\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-12-29 09:58:24, ended at 2011-12-29 10:46:14\nThe patient in this visit was 68 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Postprocedural state finding\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, started on 2011-12-29, presumably until 2012-06-18, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily. FAX: 999-999-9999\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2011-12-29, presumably until 2013-01-02, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day. Please note that this replaces Toprol XL 50 mg. FAX: 999-999-9999\n- valsartan 80 MG Oral Tablet, through Oral route, started on 2011-12-29, presumably until 2012-06-18, with intended 3 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-12-29 10:58:00, ended at 2011-12-29 23:59:00\nThe patient in this visit was 68 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 39 (nanogram per milliliter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 260 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 12.9 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 129 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 2.6 (ratio)\n- Globulin [Mass/volume] in Serum: 4.1 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.73 (milli-international unit per liter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 39 (nanogram per milliliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 12.8 (percent)\n- MCH [Entitic mass] by Automated count: 34.0 (picogram)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 70 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 92 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 106 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 99.5 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 130 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.8 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.80 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 188 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.2 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 48 (unit per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 101 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.3 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 45 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Postprocedural state finding\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-03-20 08:59:00, ended at 2012-03-20 23:59:00\nThe patient in this visit was 68 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 8.484\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-05-08 07:52:00, ended at 2012-05-08 23:59:00\nThe patient in this visit was 68 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 8.965\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2012-05-08, presumably until 2012-05-08\n- ascorbic acid 226 MG / cuprous oxide 0.8 MG / dl-alpha tocopheryl acetate 200 UNT / lutein 5 MG / zinc oxide 34.8 MG Oral Capsule, through Oral route, presumably until 2012-06-18. Instructions: take  by mouth.  \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-05-17 07:38:00, ended at 2012-05-17 23:59:00\nThe patient in this visit was 68 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 48 (unit per liter)\n- Body height: 5' 8.583\" (inch (US))\n- Cholesterol [Mass/volume] in Serum or Plasma: 234 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 91 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 127 (milligram per deciliter)\n- Cholesterol non HDL/Cholesterol.total [Mass Ratio] in Serum or Plasma: 1.4 (ratio)\n- Triglyceride [Moles/volume] in Serum or Plasma: 81 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 2.6 (ratio)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 1000 ML potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2012-05-17, presumably until 2012-05-17\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2012-05-17, presumably until 2012-05-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-06-06 10:30:00, ended at 2012-06-06 23:59:00\nThe patient in this visit was 68 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Screening mammography, bilateral (2-view study of each breast)\n- Computer-aided detection (computer algorithm analysis of digital image data for lesion detection) with further review for interpretation, with or without digitization of film radiographic images; screening mammography (List separately in addition to code \n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2012-06-17 07:11:00, ended at 2012-06-18 16:32:00\nThe patient in this visit was 68 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.67 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Body height: 5' 9.5\" (inch (US))\n- Erythrocyte distribution width [Ratio] by Automated count: 12.7 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 110 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.5 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 131 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 95 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.5 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 90.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 202 (thousand per microliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.64 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.61 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.7 (percent)\n- MCHC [Mass/volume] by Automated count: 35.2 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 97.8 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 3.9 (percent)\n- MCH [Entitic mass] by Automated count: 34.5 (picogram)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug provided in a facility (List separately in addition to code for primary procedure)\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Diagnostic interview and evaluation, not otherwise specified\n- Rhythm ECG, 1-3 leads; interpretation and report only\n- Radiologic examination, pelvis; 1 or 2 views\n- Radiologic examination, spine, lumbosacral; 2 or 3 views\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Physical therapy evaluation\n\n### Condition\n- Lumbosacral spondylosis without myelopathy\n- Low back pain\n- Abrasion and/or friction burn of skin\n- Contusion of head and/or neck\n- Leukocytosis\n- Pathological fracture of vertebra\n- Closed fracture lumbar vertebra\n- Essential hypertension\n- Age related macular degeneration\n- Constipation\n- Hypo-osmolality and or hyponatremia\n- Injury of head\n- Superficial injury of lower limb, excluding foot\n\n### Drug\n- acetaminophen 300 MG / codeine phosphate 30 MG Oral Tablet, through Oral route, started on 2012-06-17, presumably until 2012-12-15, with intended 0 refill(s). Instructions: take 2 Tabs by mouth every 4 hours as needed.\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2012-06-17, presumably until 2012-06-18\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2012-06-17, presumably until 2012-06-17\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2012-06-17, presumably until 2012-06-17\n- valsartan 80 MG Oral Tablet, through Oral route, started on 2012-06-17, presumably until 2012-06-24, with intended 3 refill(s). Instructions: take 1.5 Tabs by mouth daily.\n- ascorbic acid 226 MG / cuprous oxide 0.8 MG / dl-alpha tocopheryl acetate 200 UNT / lutein 5 MG / zinc oxide 34.8 MG Oral Capsule, through Oral route, started on 2012-06-17, presumably until 2012-06-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2012-06-24 00:00:00, ended at 2012-06-24 00:00:00\nThe patient in this visit was 68 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- valsartan 80 MG Oral Tablet, through Oral route, started on 2012-06-24, presumably until 2012-07-10, with intended 3 refill(s). Instructions: take 1.5 Tabs by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2012-07-10 00:00:00, ended at 2012-07-10 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- valsartan 80 MG Oral Tablet, through Oral route, started on 2012-07-10, presumably until 2012-07-12, with intended 1 refill(s). Instructions: take 1.5 Tabs by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-07-12 00:00:00, ended at 2012-07-12 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- valsartan 40 MG Oral Tablet, through Oral route, started on 2012-07-12, presumably until 2013-01-02, with intended 1 refill(s). Instructions: take 3 Tabs by mouth daily. NOTE NEW DOSE, PATIENT HAVING DIFFICULT TIME CUTTING 80 MG TABLETS IN HALF, NEEDS 120 MG DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-07-24 15:01:36, ended at 2012-07-24 15:31:47\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Closed fracture lumbar vertebra\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-07-24 15:42:00, ended at 2012-07-24 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, spine, lumbosacral; 2 or 3 views\n\n### Condition\n- Closed fracture lumbar vertebra\n- Lumbosacral spondylosis without myelopathy\n- Postural kyphosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-07-25 00:00:00, ended at 2012-07-25 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Closed fracture lumbar vertebra\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2012-07-25 00:00:00, ended at 2012-07-25 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of female breast\n- Closed fracture lumbar vertebra\n- Phobic disorder\n\n### Drug\n- lorazepam 0.5 MG Oral Tablet, through Oral route, started on 2012-07-25, presumably until 2013-01-21, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed (CLAUSTROPHOBIA).\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-07-25 00:00:00, ended at 2012-07-25 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Closed fracture lumbar vertebra\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2012-08-21 00:00:00, ended at 2012-08-21 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Closed fracture lumbar vertebra\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-09-24 14:57:00, ended at 2012-09-24 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, spine, lumbosacral; 2 or 3 views\n\n### Condition\n- Arthropathy\n- Scoliosis deformity of spine\n- Disorder of back\n- Acquired deformity of spine\n- Lumbosacral spondylosis without myelopathy\n- Spondylosis without myelopathy\n- Low back pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-11-12 12:16:00, ended at 2012-11-12 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, spine, lumbosacral; 2 or 3 views\n\n### Condition\n- Low back pain\n- Lumbosacral spondylosis without myelopathy\n- Disorder of back\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-01-02 13:26:11, ended at 2013-01-02 14:29:01\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Postmenopausal state\n- Hypo-osmolality and or hyponatremia\n- Primary diagnosis: Essential hypertension\n- Primary malignant neoplasm of female breast\n- Postprocedural state finding\n\n### Drug\n- valsartan 40 MG Oral Tablet, through Oral route, started on 2013-01-02, presumably until 2013-03-01, with intended 1 refill(s). Instructions: take 3 Tabs by mouth daily. NOTE NEW DOSE, PATIENT HAVING DIFFICULT TIME CUTTING 80 MG TABLETS IN HALF, NEEDS 120 MG DAILY\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2013-01-02, presumably until 2013-03-01, with intended 3 refill(s). Instructions: take 1 Tab by mouth 2 times a day. Please note that this replaces Toprol XL 50 mg. FAX: 999-999-9999\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-01-02 14:40:00, ended at 2013-01-02 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Cholesterol [Mass/volume] in Serum or Plasma: 256 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.6 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 38 (nanogram per milliliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Platelets [#/volume] in Blood by Automated count: 237 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.5 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.90 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 130 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 86 (unit per liter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 2.9 (ratio)\n- MCV [Entitic volume] by Automated count: 97.1 (femtoliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 38 (nanogram per milliliter)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.76 (milli-international unit per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 142 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.1 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 38 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 95 (millimole per liter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 88 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 72 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 96 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.1 (picogram)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Essential hypertension\n- Hypo-osmolality and or hyponatremia\n- Postmenopausal state\n- Postprocedural state finding\n- Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-01-23 13:47:00, ended at 2013-01-23 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine)\n\n### Condition\n- Disorder of endocrine system\n- Postmenopausal state\n- Toxic diffuse goiter with no crisis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2013-02-13 00:00:00, ended at 2013-02-13 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Nausea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-02-13 15:24:39, ended at 2013-02-13 15:53:50\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Nausea\n\n### Drug\n- promethazine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2013-02-13, presumably until 2013-03-04, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed for Nausea.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-13 15:57:00, ended at 2013-02-13 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 370 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.1 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.9 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 87 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.8 (percent)\n- MCV [Entitic volume] by Automated count: 96.6 (femtoliter)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 206 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.0 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.3 (picogram)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 10.4 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.5 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 639 (unit per liter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Amylase [Enzymatic activity/volume] in Serum or Plasma: 66 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 229 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.02 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Nausea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2013-02-14 00:00:00, ended at 2013-02-14 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Blood chemistry abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-14 13:40:00, ended at 2013-02-14 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 10.4 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 367 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 581 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 208 (unit per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Blood chemistry abnormal\n- Nausea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2013-02-18 00:00:00, ended at 2013-02-18 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of biliary tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-18 12:23:00, ended at 2013-02-18 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; limited study\n- Ultrasound, abdominal, real time with image documentation; complete\n\n### Condition\n- Cholelithiasis without obstruction\n- Nausea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-02-19 00:00:00, ended at 2013-02-19 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Blood chemistry abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-20 10:35:00, ended at 2013-02-20 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.4 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 131 (millimole per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 15.0 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.35 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 97.0 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 238 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 96 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.87 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.2 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 61.3 (percent)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 134 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 115 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 343 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Hemoglobin [Mass/volume] in Blood: 12.9 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 361 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 10.1 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 33.3 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.78 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 21.9 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.6 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 3.79 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.1 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.6 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Blood chemistry abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-02-20 11:03:51, ended at 2013-02-20 12:44:39\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 9\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Jaundice\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-21 00:00:00, ended at 2013-02-21 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for upper gastrointestinal endoscopic procedure\n\n### Condition\n- Obstruction of bile duct\n- Abdominal pain\n\n### Drug\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2013-02-21, presumably until 2013-02-21\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-02-21, presumably until 2013-02-21\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-02-21, presumably until 2013-02-21\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-02-21, presumably until 2013-02-21\n- succinylcholine chloride 20 MG/ML Injectable Solution, started on 2013-02-21, presumably until 2013-02-21\n- midazolam 1 MG/ML Injectable Solution, started on 2013-02-21, presumably until 2013-02-21\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2013-02-21 11:11:00, ended at 2013-03-01 15:34:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.9 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 314 (unit per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 12.8 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.5 (percent)\n- Eosinophils/100 leukocytes in Blood by Manual count: 3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.54 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.9 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 33.7 (picogram)\n- Monocytes [#/volume] in Blood by Manual count: 0.2 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 86 (unit per liter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 3 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.0 (percent)\n- Neutrophils/100 leukocytes in Blood by Manual count: 80 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 35 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 246 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Body height: 5' 10.8\" (inch (US))\n- Erythrocyte distribution width [Ratio] by Automated count: 15.6 (percent)\n- Monocytes/100 leukocytes in Blood by Manual count: 2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.3 (thousand per microliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.3 (ratio)\n- Neutrophils [#/volume] in Blood by Automated count: 8.98 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 5.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 34.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.9 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.18 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Manual count: 10.0 (thousand per microliter)\n- Prothrombin time (PT): 15.8 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Manual count: 1.0 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 35.2 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.27 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 286 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 9 (percent)\n- MCV [Entitic volume] by Automated count: 99.0 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 87.7 (percent)\n\n### Procedure\n- Percutaneous needle biopsy lung\n- Combined endoscopic catheterization of the biliary and pancreatic ductal systems, radiological supervision and interpretation\n- Percutaneous placement of drainage catheter for combined internal and external biliary drainage or of a drainage stent for internal biliary drainage in patients with an inoperable mechanical biliary obstruction, radiological supervision and interpretation\n- Computed tomography, abdomen; without contrast material, followed by contrast material(s) and further sections\n- Other percutaneous procedures on biliary tract\n- Cholangiography and/or pancreatography; through existing catheter, radiological supervision and interpretation\n- Unlisted procedure, biliary tract\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Computed tomography, pelvis; with contrast material(s)\n- Change of percutaneous biliary drainage catheter\n- Computed tomography, abdomen; with contrast material(s)\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Endoscopic sphincterotomy and papillotomy\n- Computed tomography, thorax, diagnostic; without contrast material\n- Introduction of percutaneous transhepatic stent for internal and external biliary drainage\n- Injection procedure for cholangiography through an existing catheter (eg, percutaneous transhepatic or T-tube)\n- Biliary endoscopy, percutaneous via T-tube or other tract; diagnostic, with collection of specimen(s) by brushing and/or washing, when performed (separate procedure)\n- Change of percutaneous tube or drainage catheter with contrast monitoring (eg, genitourinary system, abscess), radiological supervision and interpretation\n- Other cholangiogram\n- Collection of venous blood by venipuncture\n- Replacement of stent (tube) in biliary or pancreatic duct\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n- Radiologic examination, abdomen; single anteroposterior view\n- Physical therapy evaluation\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Prophylactic administration of vaccine against other diseases\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Disorder of biliary tract\n- Jaundice\n- Neoplasm of uncertain behavior of liver and/or biliary passages\n- Eruption\n- Obstruction of bile duct\n- Disease of liver\n- Abdominal pain\n- Primary diagnosis: Essential hypertension\n- Localized swelling, mass and lump, trunk\n- Anemia of chronic disease\n- Atelectasis\n- Gastrointestinal hemorrhage\n- Hypo-osmolality and or hyponatremia\n- Pleurisy\n- Orthostatic hypotension\n\n### Drug\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2013-02-25, presumably until 2013-02-25\n- diphenhydramine hydrochloride 50 MG/ML Injectable Solution, started on 2013-02-22, presumably until 2013-02-22\n- sodium phosphate, dibasic 59.3 MG/ML / sodium phosphate, monobasic 161 MG/ML Enema, through Rectal route, started on 2013-02-25, presumably until 2013-02-25\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2013-02-24, presumably until 2013-03-01\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2013-02-21, presumably until 2013-02-28\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2013-02-22, presumably until 2013-02-24\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2013-02-23, presumably until 2013-03-01\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2013-02-23, presumably until 2013-03-25, with intended 3 refill(s). Instructions: take 2 Tabs by mouth every bedtime.\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2013-02-24, presumably until 2013-02-24\n- metronidazole 500 MG Oral Tablet, through Oral route, started on 2013-02-21, presumably until 2013-02-28\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-02-22, presumably until 2013-03-01\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-02-28, presumably until 2013-02-28\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2013-02-27, presumably until 2013-08-27, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed for Pain.\n- 0.5 ML Streptococcus pneumoniae type 1 capsular polysaccharide antigen 0.05 MG/ML / Streptococcus pneumoniae type 10A capsular polysaccharide antigen 0.05 MG/ML / Streptococcus pneumoniae type 11A capsular polysaccharide antigen 0.05 MG/ML / Streptococ..., started on 2013-02-22, presumably until 2013-02-22\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2013-02-22, presumably until 2013-02-28\n- 1 ML promethazine hydrochloride 25 MG/ML Injection, started on 2013-02-25, presumably until 2013-02-26\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2013-03-04 00:00:00, ended at 2013-03-04 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-03-04 08:07:18, ended at 2013-03-04 09:07:35\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Jaundice\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-04 09:11:00, ended at 2013-03-04 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 226 (unit per liter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 175 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 7.0 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.5 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 92 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.59 (million per microliter)\n- MCH [Entitic mass] by Automated count: 32.1 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 542 (unit per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- MCV [Entitic volume] by Automated count: 94.5 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 127 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.5 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 13.6 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 5.0 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 444 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 131 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Jaundice\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-11 11:36:00, ended at 2013-03-11 13:07:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 6.339\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of intrahepatic bile duct\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-11 13:08:00, ended at 2013-03-11 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.6 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 60 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 94 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 5.1 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 10.3 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 319 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.12 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.88 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 425 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.20 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.7 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 11.4 (percent)\n- MCH [Entitic mass] by Automated count: 32.2 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 5.92 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 77.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.4 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.3 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 100 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 116 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 3.1 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.3 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.63 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.3 (percent)\n- MCV [Entitic volume] by Automated count: 94.8 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 130 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-13 00:00:00, ended at 2013-03-13 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for upper gastrointestinal endoscopic procedure\n\n### Condition\n- Obstruction of bile duct\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-03-13, presumably until 2013-03-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-13 13:30:00, ended at 2013-03-13 18:10:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 9.016\" (inch (US))\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Endoscopy and biopsy of upper gastrointestinal tract\n- Ultrasonography of digestive system\n- Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s) (includes endoscopic ultrasound examination of the esophagus, stomach, and either the duodenum or a surgicall\n\n### Condition\n- Secondary malignant neoplasm of lung\n- Primary malignant neoplasm of female breast\n- Anemia of chronic disease\n- Imaging of abdomen abnormal\n- Obstruction of bile duct\n- Essential hypertension\n- Primary malignant neoplasm\n\n### Drug\n- benzocaine 140 MG/ML / butamben 20 MG/ML / tetracaine 20 MG/ML Mucosal Spray, through Topical route, started on 2013-03-13, presumably until 2013-03-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2013-03-18 00:00:00, ended at 2013-03-18 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-25 08:08:00, ended at 2013-03-25 08:52:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 6.08 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 5.0 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.2 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 91.7 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.3 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 27.9 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.2 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 131 (millimole per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 56 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.04 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 134 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.8 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.73 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 77.9 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 2.5 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.2 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 330 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 301 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.83 (thousand per microliter)\n\n### Procedure\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Essential hypertension\n- Pain due to neoplastic disease\n- Primary malignant neoplasm of intrahepatic bile duct\n- Hypokalemia\n- Acquired absence of breast\n- Benign neoplasm of colon\n- Obstruction of bile duct\n- Estrogen receptor positive tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-25 08:53:00, ended at 2013-03-25 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 5.748\" (inch (US))\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Obstruction of bile duct\n- Jaundice\n- Hypokalemia\n- Primary diagnosis: Benign neoplasm of colon\n- Primary malignant neoplasm of intrahepatic bile duct\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2013-03-25, presumably until 2013-09-03, with intended 1 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed. For nausea and vomiting.\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2013-03-25, presumably until 2013-05-03, with intended 2 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2013-03-25, presumably until 2013-07-24, with intended 2 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed. For nausea and vomiting.\n- sodium chloride 9 MG/ML Injection, started on 2013-03-25, presumably until 2013-03-25\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2013-03-25, presumably until 2013-09-17, with intended 3 refill(s). Instructions: take 1-2 Tabs by mouth every bedtime.\n- prochlorperazine 10 MG Oral Tablet, through Oral route, started on 2013-03-25, presumably until 2013-07-29, with intended 2 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed. For nausea and vomiting.\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-03-25, presumably until 2013-03-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-27 00:00:00, ended at 2013-03-27 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on upper anterior abdominal wall; not otherwise specified\n\n### Condition\n- Obstruction of bile duct\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, started on 2013-03-27, presumably until 2013-03-27\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2013-03-27, presumably until 2013-03-27\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2013-03-27, presumably until 2013-03-27\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2013-03-27, presumably until 2013-03-27\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2013-03-27, presumably until 2013-03-27\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-03-27, presumably until 2013-03-27\n- succinylcholine chloride 20 MG/ML Injectable Solution, started on 2013-03-27, presumably until 2013-03-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-27 11:02:00, ended at 2013-03-28 13:50:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 9\" (inch (US))\n\n### Procedure\n- Change of percutaneous tube or drainage catheter with contrast monitoring (eg, genitourinary system, abscess), radiological supervision and interpretation\n- Cholangiography and/or pancreatography; through existing catheter, radiological supervision and interpretation\n- Injection procedure for cholangiography through an existing catheter (eg, percutaneous transhepatic or T-tube)\n- Change of percutaneous biliary drainage catheter\n- Replacement of stent (tube) in biliary or pancreatic duct\n\n### Condition\n- Gastrointestinal complication of procedure\n- Primary diagnosis: Obstruction of bile duct\n- Primary malignant neoplasm of extrahepatic bile duct\n- Essential hypertension\n- Primary malignant neoplasm of intrahepatic bile duct\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-03-27, presumably until 2013-03-27\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2013-03-27, presumably until 2013-03-27\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-03-27, presumably until 2013-03-27\n- 1 ML morphine sulfate 2 MG/ML Prefilled Syringe, through Intravenous route, started on 2013-03-27, presumably until 2013-03-28\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2013-03-27, presumably until 2013-03-27\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2013-03-27, presumably until 2013-03-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2013-03-28 22:56:00, ended at 2013-04-03 15:30:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Body height: 5' 9\" (inch (US))\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.10 (million per microliter)\n- Globulin [Mass/volume] in Serum: 5.0 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.2 (picogram)\n- Prothrombin time (PT): 16.3 (second)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 5.0 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 95 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.4 (ratio)\n- MCV [Entitic volume] by Automated count: 91.3 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.72 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 45 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.0 (percent)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.3 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.9 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 9.3 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 95.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 291 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.77 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.2 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.6 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 3.4 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 347 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.1 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.95 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n\n### Procedure\n- Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, without imaging guidance; age 5 years or older\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Radiological guidance (ie, fluoroscopy, ultrasound, or computed tomography), for percutaneous drainage (eg, abscess, specimen collection), with placement of catheter, radiological supervision and interpretation\n- Percutaneous aspiration of liver\n- Injection procedure for cholangiography through an existing catheter (eg, percutaneous transhepatic or T-tube)\n- Hepatotomy; for percutaneous drainage of abscess or cyst, 1 or 2 stages\n- Change of percutaneous biliary drainage catheter\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n- Radiologic examination, abdomen; complete, including decubitus and/or erect views\n- Central venous catheter placement with guidance\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Cholangiography and/or pancreatography; through existing catheter, radiological supervision and interpretation\n- Change of percutaneous tube or drainage catheter with contrast monitoring (eg, genitourinary system, abscess), radiological supervision and interpretation\n\n### Condition\n- Acute cholecystitis\n- Anemia of chronic disease\n- Postprocedural state finding\n- Streptococcal infectious disease\n- Disorder of biliary tract\n- Bacterial infection due to Klebsiella pneumoniae\n- Obstruction of bile duct\n- Primary malignant neoplasm of extrahepatic bile duct\n- Valvular endocarditis\n- Essential hypertension\n- Primary diagnosis: Fever\n- Hypokalemia\n- Intra-abdominal and pelvic swelling, mass and lump\n- Primary malignant neoplasm of intrahepatic bile duct\n- Abscess of liver\n- Perforation of gallbladder\n- Bacteremia\n- Venous thrombosis\n- Vomiting\n- Age related macular degeneration\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2013-03-29, presumably until 2013-03-29\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2013-03-29, presumably until 2013-04-01\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2013-03-31, presumably until 2013-04-01\n- lidocaine 40 MG/ML Topical Cream, through Topical route, started on 2013-04-02, presumably until 2013-04-02\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-03-28, presumably until 2013-03-30\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2013-04-02, presumably until 2013-04-03\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2013-04-01, presumably until 2013-04-01\n- ciprofloxacin 500 MG Oral Tablet, through Oral route, started on 2013-03-31, presumably until 2013-03-31\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2013-03-29, presumably until 2013-04-03\n- piperacillin 4000 MG / tazobactam 500 MG Injection, through Intravenous route, started on 2013-03-30, presumably until 2013-03-31\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2013-03-30, presumably until 2013-04-02\n- 0.8 ML filgrastim 0.6 MG/ML Prefilled Syringe, started on 2013-03-30, presumably until 2013-03-30\n- 0.8 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2013-03-31, presumably until 2013-04-01\n- heparin sodium, porcine 100 UNT/ML Prefilled Syringe, through Intravenous route, started on 2013-04-02, presumably until 2013-11-27, with intended 0 refill(s). Instructions: 3 mL by Intravenous route Every Day.\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2013-03-31, presumably until 2013-04-21, with intended 0 refill(s). Instructions: 50 mL by Intravenous route every 6 hours. Give through Saturday 05/09/2024.\n- metronidazole 500 MG Oral Tablet, through Oral route, started on 2013-03-31, presumably until 2013-04-01\n- 2 ML ondansetron 2 MG/ML Injection, started on 2013-04-01, presumably until 2013-04-01\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-03-29, presumably until 2013-03-31\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2013-03-29, presumably until 2013-03-30\n- 100 ML metronidazole 5 MG/ML Injection, through Intravenous route, started on 2013-03-29, presumably until 2013-03-30\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2013-03-29, presumably until 2013-04-03\n- lidocaine hydrochloride 20 MG/ML Injectable Solution, started on 2013-04-02, presumably until 2013-04-02\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-04-07 00:00:00, ended at 2013-04-07 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of female breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-08 17:57:00, ended at 2013-04-08 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Fever\n- Acute cholecystitis\n- Postprocedural state finding\n- Lymphadenopathy\n- Disorder of biliary tract\n- Obstruction of bile duct\n- Primary malignant neoplasm of extrahepatic bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-11 09:51:00, ended at 2013-04-11 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- ertapenem 1000 MG Injection, through Intravenous route, started on 2013-04-11, presumably until 2013-04-11\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-04-15 00:00:00, ended at 2013-04-15 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-04-15 00:00:00, ended at 2013-04-15 00:00:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Postprocedural state finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-15 07:44:00, ended at 2013-04-15 08:23:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 112 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 69 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 59 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.12 (thousand per microliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.7 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.8 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 63.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 386 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.7 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.3 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 5.2 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.25 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.5 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.18 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 372 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.6 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.0 (percent)\n- MCH [Entitic mass] by Automated count: 29.8 (picogram)\n- MCV [Entitic volume] by Automated count: 91.2 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.95 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Jaundice\n- Benign neoplasm of colon\n- Hypokalemia\n- Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-15 08:24:00, ended at 2013-04-15 09:29:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 6.535\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n- Benign neoplasm of colon\n- Jaundice\n- Primary malignant neoplasm of intrahepatic bile duct\n- Hypokalemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-21 12:38:00, ended at 2013-04-21 17:37:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 9\" (inch (US))\n\n### Procedure\n- Injection procedure for cholangiography through an existing catheter (eg, percutaneous transhepatic or T-tube)\n- Change of percutaneous biliary drainage catheter\n- Cholangiography and/or pancreatography; through existing catheter, radiological supervision and interpretation\n- Replacement of stent (tube) in biliary or pancreatic duct\n- Percutaneous placement of drainage catheter for combined internal and external biliary drainage or of a drainage stent for internal biliary drainage in patients with an inoperable mechanical biliary obstruction, radiological supervision and interpretation\n\n### Condition\n- Obstruction of bile duct\n- Primary malignant neoplasm of intrahepatic bile duct\n- Cellulitis and abscess of trunk\n- Gastrointestinal complication of procedure\n- Perforation of gallbladder\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-04-21, presumably until 2013-04-21\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2013-04-21, presumably until 2013-04-21\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-24 13:55:00, ended at 2013-04-24 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Obstruction of bile duct\n- Primary malignant neoplasm of intrahepatic bile duct\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-29 10:30:00, ended at 2013-04-29 12:57:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 8.898\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malaise\n- Sepsis\n- Solitary nodule of lung\n- Tachycardia\n- Obstruction of bile duct\n- Disorder of spleen\n- Leukocytosis\n- Primary malignant neoplasm of intrahepatic bile duct\n- Primary diagnosis: Anemia\n- Valvular endocarditis\n- Malnutrition (calorie)\n- Acute posthemorrhagic anemia\n- Inflammatory disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-29 12:58:00, ended at 2013-04-29 14:42:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 8.898\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n- Primary malignant neoplasm of intrahepatic bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-29 14:43:00, ended at 2013-04-29 17:08:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 115 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 128 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.01 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 520 (unit per liter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 3.0 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.5 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 5.7 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 9.40 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 130 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 11.4 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 310 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 20.0 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 17.6 (percent)\n- MCH [Entitic mass] by Automated count: 30.0 (picogram)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 92.2 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.2 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.5 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.2 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.97 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 3.8 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 1.90 (million per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Fever\n- Obstruction of bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2013-04-29 17:09:00, ended at 2013-05-03 16:55:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 79 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction: 261 (unit per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.5 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.9 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Base deficit in Blood: 4.0 (millimole per liter)\n- Body height: 5' 9\" (inch (US))\n- Erythrocyte distribution width [Ratio] by Automated count: 18.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 9.5 (gram per deciliter)\n- Lactate [Moles/volume] in Blood: 1.0 (millimole per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.5 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 4.8 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 1.8 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 6.7 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.4 (percent)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Prothrombin time (PT): 18.0 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 86 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.57 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.11 (million per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 33.5 (second)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 414 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): N/A (milliliter per minute per square meter)\n- INR in Platelet poor plasma by Coagulation assay: 1.6 (ratio)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.50 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 83.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 243 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.0 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.71 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 5.6 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 91.8 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.2 (percent)\n\n### Procedure\n- Injection procedure for cholangiography through an existing catheter (eg, percutaneous transhepatic or T-tube)\n- Selective catheter placement, arterial system; additional second order, third order, and beyond, abdominal, pelvic, or lower extremity artery branch, within a vascular family (List in addition to code for initial second or third order vessel as appropriat\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Angiography through existing catheter for follow-up study for transcatheter therapy, embolization or infusion, other than for thrombolysis\n- Physical therapy evaluation\n- Selective catheter placement, arterial system; initial third order or more selective abdominal, pelvic, or lower extremity artery branch, within a vascular family\n- Other cholangiogram\n- Arteriography of femoral and other lower extremity arteries\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug\n- Replacement of stent (tube) in biliary or pancreatic duct\n- Collection of venous blood by venipuncture\n- Occupational therapy evaluation\n- Cholangiography and/or pancreatography; through existing catheter, radiological supervision and interpretation\n- Change of percutaneous tube or drainage catheter with contrast monitoring (eg, genitourinary system, abscess), radiological supervision and interpretation\n- Other endovascular procedures on other vessels\n- Change of percutaneous biliary drainage catheter\n- Angiography, visceral, selective or supraselective (with or without flush aortogram), radiological supervision and interpretation\n- Transfusion, blood or blood components\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Transcatheter occlusion or embolization (eg, for tumor destruction, to achieve hemostasis, to occlude a vascular malformation), percutaneous, any method, non-central nervous system, non-head or neck\n- Arteriography of other intra-abdominal arteries\n- Packed blood cell transfusion\n- Transcatheter therapy, embolization, any method, radiological supervision and interpretation\n- Angiography, selective, each additional vessel studied after basic examination, radiological supervision and interpretation (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Anemia\n- Anemia of chronic disease\n- Sepsis\n- Hypo-osmolality and or hyponatremia\n- Malaise\n- Primary malignant neoplasm of intrahepatic bile duct\n- Perforation of gallbladder\n- Aneurysm of visceral artery\n- Mechanical complication of vascular device\n- Generalized abdominal pain\n- Valvular endocarditis\n\n### Drug\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2013-05-02, presumably until 2013-05-02\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2013-04-30, presumably until 2013-05-01\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2013-05-02, presumably until 2013-05-02\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2013-04-29, presumably until 2013-05-02\n- ertapenem 1000 MG Injection, through Intravenous route, started on 2013-04-29, presumably until 2013-06-24, with intended 0 refill(s). Instructions: 1 g by Intravenous route Every Day.\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2013-04-29, presumably until 2013-05-02\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2013-04-30, presumably until 2013-05-03\n- 1 ML hydromorphone hydrochloride 1 MG/ML Prefilled Syringe, started on 2013-04-29, presumably until 2013-04-29\n- 200 ML fluconazole 2 MG/ML Injection, through Intravenous route, started on 2013-04-29, presumably until 2013-05-02\n- 12 HR oxycodone hydrochloride 10 MG Extended Release Oral Tablet, through Oral route, started on 2013-04-29, presumably until 2013-05-03\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2013-04-30, presumably until 2013-05-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-05 12:50:00, ended at 2013-05-05 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 9.016\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n- Primary malignant neoplasm of intrahepatic bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-06 16:44:00, ended at 2013-05-06 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Declotting by thrombolytic agent of implanted vascular access device or catheter\n\n### Condition\n- No conditions.\n\n### Drug\n- alteplase 1 MG/ML Injectable Solution, through Intraluminal route, started on 2013-05-06, presumably until 2013-05-06\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-13 09:00:00, ended at 2013-05-13 09:41:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 8.898\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Fever\n- Benign neoplasm of colon\n- Jaundice\n- Hypokalemia\n- Valvular endocarditis\n- Primary diagnosis: Anemia\n- Hypo-osmolality and or hyponatremia\n- Abscess of peritoneum\n- Obstruction of bile duct\n\n### Drug\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, presumably until 2013-09-03. Instructions: take 10 mEq by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-13 09:42:00, ended at 2013-05-13 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Magnesium [Mass/volume] in Serum or Plasma: 1.8 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.44 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.8 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.4 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.1 (percent)\n- Body height: 5' 8.898\" (inch (US))\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.22 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 16.9 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 82 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.4 (percent)\n- Platelets [#/volume] in Blood by Automated count: 199 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.2 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 362 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.35 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.0 (picogram)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.8 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 104 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.6 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.0 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 29.8 (percent)\n- MCV [Entitic volume] by Automated count: 92.6 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 63.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 132 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 71 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.8 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.92 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n- Primary malignant neoplasm of intrahepatic bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-14 07:30:00, ended at 2013-05-14 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Benign neoplasm of colon\n- Jaundice\n- Primary diagnosis: Obstruction of bile duct\n- Hypokalemia\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2013-05-14, presumably until 2013-05-14\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2013-05-14, presumably until 2013-05-14\n- sodium chloride 9 MG/ML Injection, started on 2013-05-14, presumably until 2013-05-14\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-05-14, presumably until 2013-05-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-20 08:20:00, ended at 2013-05-20 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 27.0 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.60 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.4 (percent)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 21.4 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.1 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 150 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 66 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 2.8 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.9 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.26 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 91 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 239 (unit per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.4 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.98 (million per microliter)\n- MCV [Entitic volume] by Automated count: 90.8 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.82 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 112 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 8.9 (gram per deciliter)\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary diagnosis: Obstruction of bile duct\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2013-05-20, presumably until 2013-05-20\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2013-05-20, presumably until 2013-05-20\n- sodium chloride 9 MG/ML Injection, started on 2013-05-20, presumably until 2013-05-20\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-05-20, presumably until 2013-05-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-27 08:00:00, ended at 2013-05-27 14:44:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Body height: 5' 9\" (inch (US))\n\n### Procedure\n- Cholangiography and/or pancreatography; through existing catheter, radiological supervision and interpretation\n- Collection of blood specimen from a completely implantable venous access device\n- Injection procedure for cholangiography through an existing catheter (eg, percutaneous transhepatic or T-tube)\n- Replacement of stent (tube) in biliary or pancreatic duct\n- Change of percutaneous biliary drainage catheter\n- Change of percutaneous tube or drainage catheter with contrast monitoring (eg, genitourinary system, abscess), radiological supervision and interpretation\n\n### Condition\n- Disorder of biliary tract\n- Primary malignant neoplasm of intrahepatic bile duct\n- Obstruction of bile duct\n- Abscess of liver\n- Disorder of gallbladder\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-05-27, presumably until 2013-05-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-03 08:43:00, ended at 2013-06-03 09:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 2.7 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.10 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 26.9 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 58.5 (percent)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 108 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 48 (unit per liter)\n- Body height: 5' 8.898\" (inch (US))\n- Hemoglobin [Mass/volume] in Blood: 8.9 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.9 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.03 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.67 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.8 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 442 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.3 (percent)\n- MCH [Entitic mass] by Automated count: 29.4 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.99 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.8 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 23.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 44 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 216 (unit per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.6 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.50 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.3 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 131 (millimole per liter)\n\n### Procedure\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary diagnosis: Anemia\n- Obstruction of bile duct\n- Valvular endocarditis\n- Primary malignant neoplasm of intrahepatic bile duct\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2013-06-03, presumably until 2013-06-03\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2013-06-03, presumably until 2013-06-03\n- sodium chloride 9 MG/ML Injection, started on 2013-06-03, presumably until 2013-06-03\n- ertapenem 1000 MG Injection, through Intravenous route, started on 2013-06-03, presumably until 2013-06-24, with intended 0 refill(s). Instructions: 1 g by Intravenous route Every Day.\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-06-03, presumably until 2013-06-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-03 10:00:00, ended at 2013-06-03 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n\n### Condition\n- Bleeding\n- Fever\n- Sepsis\n- Acute and subacute bacterial endocarditis\n- Fistula of gallbladder\n- Hypokalemia\n- Jaundice\n- Abscess of peritoneum\n- Primary diagnosis: Obstruction of bile duct\n- Benign neoplasm of colon\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-06 12:50:00, ended at 2013-06-06 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Antineoplastic poisoning\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-10 08:15:00, ended at 2013-06-10 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 8.8 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.3 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 29.7 (picogram)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.9 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.2 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 75.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.1 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.53 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 87 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 95 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 110 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.64 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 129 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 85 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 26.2 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.7 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 278 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.11 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.97 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.8 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 512 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Anemia\n- Obstruction of bile duct\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2013-06-10, presumably until 2013-06-10\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2013-06-10, presumably until 2013-06-10\n- sodium chloride 9 MG/ML Injection, started on 2013-06-10, presumably until 2013-06-10\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-06-10, presumably until 2013-06-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-13 11:09:00, ended at 2013-06-13 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of intrahepatic bile duct\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-24 08:20:00, ended at 2013-06-24 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Glucose [Mass/volume] in Serum or Plasma: 106 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.2 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 418 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 24.5 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 128 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 938 (unit per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 86.8 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 23 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 17.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.34 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 71.4 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.0 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.8 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.30 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 130 (unit per liter)\n- Body height: 5' 8.898\" (inch (US))\n- Chloride [Moles/volume] in Serum or Plasma: 94 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 2.82 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.66 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 7 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.8 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.5 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 114 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 8.2 (gram per deciliter)\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Transfusion, blood or blood components\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of intrahepatic bile duct\n- Hypokalemia\n- Benign neoplasm of colon\n- Obstruction of bile duct\n- Anemia\n- Jaundice\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2013-06-24, presumably until 2013-06-24\n- heparin sodium, porcine 100 UNT/ML Injectable Solution, through Intravenous route, started on 2013-06-20, presumably until 2013-10-23, with intended 3 refill(s). Instructions: 3 mL by Intravenous route One Time.\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2013-06-24, presumably until 2013-06-24\n- sodium chloride 9 MG/ML Injection, started on 2013-06-24, presumably until 2013-06-24\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-06-24, presumably until 2013-06-24\n- 125 ML sodium chloride 9 MG/ML Prefilled Syringe, started on 2013-06-20, presumably until 2013-10-23, with intended 3 refill(s). Instructions: 10 mL by Injection route Every Day.\n- magnesium oxide 400 MG Oral Tablet, through Oral route, started on 2013-06-24, presumably until 2013-07-24, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day. Take 1 tab twice a day x 5 days, #10\n- megestrol acetate 40 MG/ML Oral Suspension, through Oral route, started on 2013-06-24, presumably until 2013-07-12, with intended 3 refill(s). Instructions: take 20 mL by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-30 13:06:00, ended at 2013-06-30 23:59:00\nThe patient in this visit was 69 years old, unknown race, unknown ethnicity, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences\n\n### Condition\n- Primary malignant neoplasm of intrahepatic bile duct\n- Secondary malignant neoplasm of brain and spinal cord\n- Malaise\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Malignant tumor of pancreas within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of pancreatic_cancer means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "448aef9199c5203be86aea1fbcf36982a1b51645a202560dbfdd1ff67bb6b22e", "prompt_hash": "49dddcdcb3bc3fb612d24c929cbd49606a3cd23273b150339b9cd5b20a0a7f83", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
{"doc_id": 9, "doc": {"person_id": 115968238, "visit_occurrence_id": 64730862, "death_date": null, "visit_concept_name": "Inpatient Visit", "visit_start_datetime": "2014-09-11 00:00:00", "visit_end_datetime": "2014-09-11 00:00:00", "visit_length_in_hours": 0.0, "integrated_visit_record": "## Visit\nThis visit record, was from Inpatient Visit, started at 2014-09-11 00:00:00, ended at 2014-09-11 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for hernia repairs in upper abdomen; lumbar and ventral (incisional) hernias and/or wound dehiscence\n\n### Condition\n- Incisional hernia\n\n### Drug\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2014-09-11, presumably until 2014-09-11\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2014-09-11, presumably until 2014-09-11\n- cefazolin 1000 MG Injection, started on 2014-09-11, presumably until 2014-09-11\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2014-09-11, presumably until 2014-09-11\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2014-09-11, presumably until 2014-09-11\n- 2 ML ondansetron 2 MG/ML Injection, started on 2014-09-11, presumably until 2014-09-11\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-09-11, presumably until 2014-09-11\n- succinylcholine chloride 20 MG/ML Injectable Solution, started on 2014-09-11, presumably until 2014-09-11\n- midazolam 1 MG/ML Injectable Solution, started on 2014-09-11, presumably until 2014-09-11\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2014-09-11, presumably until 2014-09-11\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2014-09-11, presumably until 2014-09-11\n\n", "approximate_token_count": 416, "patient_first_visit_date": "2008-09-26 00:00:00", "patient_last_visit_date": "2020-07-04 00:00:00", "end_obs_date": "2015-09-11", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 1, "obesity_type": "recurrent", "obesity_one_year_diagnosis": 0, "asthma_type": "recurrent", "asthma_one_year_diagnosis": 1, "hyperlipidemia_type": "new", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "new", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "recurrent", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 1, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "recurrent", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 87, "cumulated_visit_num": 87, "cumulated_approximate_token_count": 20122, "visit_cumulated": "## Visit\nThis visit record, was from Case Management Visit, started at 2008-09-26 00:00:00, ended at 2008-09-26 00:00:00\nThe patient in this visit was 68 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.0 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 59 (milliliter per minute per square meter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.6 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 120 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.3 (picogram)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.71 (million per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 279 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.3 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 70 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 88.8 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-10-27 00:00:00, ended at 2008-10-27 00:00:00\nThe patient in this visit was 68 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.1 (percent)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- INR in Platelet poor plasma by Coagulation assay: 2.8 (ratio)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.8 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.42 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.5 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.8 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 90.1 (femtoliter)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 267 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 39.6 (second)\n- Glucose [Mass/volume] in Serum or Plasma: 131 (milligram per deciliter)\n- Prothrombin time (PT): 28.5 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2008-10-31 07:09:00, ended at 2008-11-09 13:00:00\nThe patient in this visit was 68 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 43.7 (millimeter mercury column)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 33 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5.9 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.9 (percent)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n- Prothrombin time (PT): 24.7 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 2.30 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 1.11 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.8 (percent)\n- Lymphocytes [#/volume] in Blood by Manual count: 1.7 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.5 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Manual count: 4.9 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 85.7 (percent)\n- Neutrophils/100 leukocytes in Blood by Manual count: 62 (percent)\n- Base deficit in Blood: 6.0 (millimole per liter)\n- Bicarbonate [Moles/volume] in Specimen: 25.6 (millimole per liter)\n- Body height: 5' 8\" (inch (US))\n- Chloride [Moles/volume] in Serum or Plasma: 111 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Manual count: 7 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 5.6 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Amylase [Enzymatic activity/volume] in Serum or Plasma: 9 (unit per liter)\n- Base excess in Blood by calculation: 1.0 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.24 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 90.4 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.3 (milligram per deciliter)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 89 (millimeter mercury column)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.2 (percent)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Manual count: 7 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.4 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: N/A (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 40.0 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 49 (unit per liter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.5 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 184 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.9 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.6 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: <5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.0 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.94 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 98 (unit per liter)\n- INR in Platelet poor plasma by Coagulation assay: 2.3 (ratio)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.00 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 22 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 6.73 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of pancreas\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2008-11-01, presumably until 2008-11-05\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2008-10-31, presumably until 2008-10-31\n- 2 ML fentanyl 0.05 MG/ML Injection, through Intravenous route, started on 2008-10-31, presumably until 2008-11-01\n- 1 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2008-11-05, presumably until 2008-11-08\n- warfarin sodium 5 MG Oral Tablet, through Oral route, started on 2008-11-05, presumably until 2008-11-08\n- haloperidol 5 MG/ML Injectable Solution, started on 2008-11-04, presumably until 2008-11-04\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, started on 2008-11-06, presumably until 2008-11-09\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2008-11-07, presumably until 2008-11-09\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, through Oral route, started on 2008-11-07, presumably until 2009-05-08, with quantity of 60.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed for Pain. \n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2008-11-07, presumably until 2008-11-08\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2008-10-31, presumably until 2008-11-06\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2008-11-09, presumably until 2008-11-09\n- alprazolam 0.25 MG Oral Tablet, through Oral route, started on 2008-11-03, presumably until 2008-11-08\n- 5 ML metoprolol tartrate 1 MG/ML Injection, through Intravenous route, started on 2008-10-31, presumably until 2008-11-05\n- 120 ACTUAT fluticasone propionate 0.11 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2008-11-02, presumably until 2008-11-09\n- 1 ML hydralazine hydrochloride 20 MG/ML Injection, started on 2008-11-02, presumably until 2008-11-03\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2008-11-05, presumably until 2008-11-07\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2008-11-07, presumably until 2009-06-22, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily. \n- heparin sodium, porcine 10000 UNT/ML Injectable Solution, started on 2008-11-01, presumably until 2008-11-05\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2008-11-06, presumably until 2008-11-09\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2008-10-31, presumably until 2008-11-06\n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2008-11-09, presumably until 2008-11-09\n- 200 ACTUAT ipratropium bromide 0.017 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2008-11-01, presumably until 2008-11-01\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2008-11-03, presumably until 2008-11-09\n- 2 ML ondansetron 2 MG/ML Injection, started on 2008-11-02, presumably until 2008-11-02\n- 12 HR propafenone hydrochloride 225 MG Extended Release Oral Capsule, through Oral route, started on 2008-11-06, presumably until 2008-11-09\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2008-11-03, presumably until 2008-11-07\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2008-11-03, presumably until 2008-11-03\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2008-10-31, presumably until 2008-10-31\n- metoclopramide 10 MG Oral Tablet, through Oral route, started on 2008-11-09, presumably until 2009-06-22, with quantity of 90.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth 3 times a day before meals. \n- 100 ML metronidazole 5 MG/ML Injection, through Intravenous route, started on 2008-10-31, presumably until 2008-11-01\n- 100 ML propofol 10 MG/ML Injection, through Intravenous route, started on 2008-10-31, presumably until 2008-11-01\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2008-11-05, presumably until 2008-11-08\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2008-11-02, presumably until 2008-11-02\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2008-11-07, presumably until 2008-11-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-03-29 00:00:00, ended at 2009-03-29 00:00:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocyte distribution width [Ratio] by Automated count: 15.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.74 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 108 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.4 (percent)\n- MCV [Entitic volume] by Automated count: 85.2 (femtoliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 6.6 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 75 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.9 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 28.4 (picogram)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Platelets [#/volume] in Blood by Automated count: 275 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.4 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-06-27 00:00:00, ended at 2009-06-27 00:00:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.1 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Prothrombin time (PT): 16.0 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 223 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 31.9 (second)\n- INR in Platelet poor plasma by Coagulation assay: 1.3 (ratio)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.46 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 29.3 (picogram)\n- Glucose [Mass/volume] in Serum or Plasma: 110 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.5 (percent)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 86.2 (femtoliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2009-07-02 14:28:00, ended at 2009-07-04 12:25:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n- Erythrocyte distribution width [Ratio] by Automated count: 15.9 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.4 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.2 (picogram)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.6 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 88.2 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 226 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.23 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 91 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.3 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Incisional hernia\n\n### Drug\n- 200 ACTUAT albuterol 0.09 MG/ACTUAT / ipratropium bromide 0.018 MG/ACTUAT Inhalation Spray, through Inhalation, started on 2009-07-03, presumably until 2009-07-04\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2009-07-02, presumably until 2009-07-02\n- amylase 33200 UNT / lipase 10000 UNT / protease 37500 UNT Delayed Release Oral Capsule, through Oral route, started on 2009-07-02, presumably until 2009-07-04\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2009-07-02, presumably until 2009-07-04\n- cefotetan 1000 MG Injection, started on 2009-07-02, presumably until 2009-07-02\n- cyclobenzaprine hydrochloride 5 MG Oral Tablet, through Oral route, started on 2009-07-02, presumably until 2009-07-04\n- albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution, through Inhalation, started on 2009-07-02, presumably until 2009-07-03\n- montelukast 10 MG Oral Tablet, through Oral route, started on 2009-07-03, presumably until 2009-07-03\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2009-07-04, presumably until 2010-07-04, with quantity of 20.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day. \n- 12 HR propafenone hydrochloride 225 MG Extended Release Oral Capsule, through Oral route, started on 2009-07-02, presumably until 2009-07-04\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2009-07-02, presumably until 2009-12-31, with quantity of 20.0, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-09-10 00:00:00, ended at 2009-09-10 00:00:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-09-17 00:00:00, ended at 2009-09-17 00:00:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Neoplasm of digestive tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-09-18 12:28:00, ended at 2009-09-18 23:59:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Leukocytes [#/volume] in Specimen by Automated count: 6.8 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.70 (million per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 78 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- MCV [Entitic volume] by Automated count: 86.4 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.6 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 101 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.3 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.4 (picogram)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 290 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neoplasm of digestive tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-10-05 09:00:00, ended at 2009-10-05 23:59:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.535\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-11-13 00:00:00, ended at 2009-11-13 00:00:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Achilles bursitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-01-21 00:00:00, ended at 2010-01-21 00:00:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-01-29 09:52:00, ended at 2010-01-29 10:44:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-01-29 10:45:00, ended at 2010-01-29 23:59:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen; with contrast material(s)\n- Computed tomography, pelvis; with contrast material(s)\n\n### Condition\n- Acquired renal cystic disease\n- Diaphragmatic hernia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-01 11:06:00, ended at 2010-02-01 23:59:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, gastrointestinal tract, upper; with or without delayed images, with KUB\n\n### Condition\n- Malignant neoplastic disease\n- Gastroesophageal reflux disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-08 13:59:00, ended at 2010-02-08 23:59:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-21 14:17:00, ended at 2010-02-21 23:59:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Primary malignant neoplasm of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-25 11:42:00, ended at 2010-02-25 23:59:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of function of stomach\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2010-03-26 00:00:00, ended at 2010-03-31 11:32:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Amylase [Enzymatic activity/volume] in Serum or Plasma: 9 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.52 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.60 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 11.9 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.09 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: <5 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 30.1 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.8 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 34 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 25.7 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.0 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.9 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 222 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Body height: 5' 8.5\" (inch (US))\n- Eosinophils/100 leukocytes in Blood by Automated count: 9.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.02 (million per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.80 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 76 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 151 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.7 (percent)\n\n### Procedure\n- Gastric anastomosis revision\n- Collection of venous blood by venipuncture\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n\n### Condition\n- Acquired hypertrophic pyloric stenosis\n- Gastrointestinal complication of procedure\n- Disorder of function of stomach\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2010-03-26, presumably until 2010-03-29\n- menthol, through Submucosal route, started on 2010-03-26, presumably until 2010-03-28\n- benzocaine, through Submucosal route, started on 2010-03-26, presumably until 2010-03-28\n- hydrocortisone 5 MG/ML Topical Cream, through Topical route, started on 2010-03-30, presumably until 2010-03-31\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, started on 2010-03-30, presumably until 2010-03-31. Instructions: take 25 mg by mouth daily. \n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2010-03-30, presumably until 2011-03-31, with quantity of 60.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- pantoprazole 40 MG Injection, through Intravenous route, started on 2010-03-26, presumably until 2010-03-30\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2010-03-27, presumably until 2010-03-30\n- cetylpyridinium, through Submucosal route, started on 2010-03-26, presumably until 2010-03-28\n- 5 ML metoprolol tartrate 1 MG/ML Injection, through Intravenous route, started on 2010-03-30, presumably until 2010-03-30\n- 120 ACTUAT fluticasone propionate 0.11 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2010-03-28, presumably until 2010-03-31. Instructions: by Inhalation route 2 times a day. 1 puf bid\n- heparin sodium, porcine 10000 UNT/ML Injectable Solution, started on 2010-03-27, presumably until 2010-03-31\n- olmesartan medoxomil 5 MG Oral Tablet, through Oral route, started on 2010-03-30, presumably until 2010-03-30. Instructions: take by mouth. 1 TAB QD HS\n- 2 ML ondansetron 2 MG/ML Injection, started on 2010-03-26, presumably until 2010-03-28\n- 12 HR propafenone hydrochloride 225 MG Extended Release Oral Capsule, through Oral route, started on 2010-03-30, presumably until 2010-03-31. Instructions: take by mouth 2 times a day.\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2010-03-27, presumably until 2010-03-30\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2010-03-26, presumably until 2010-03-26\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2010-03-30, presumably until 2010-09-27, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-10 09:38:00, ended at 2010-05-10 23:59:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-05 10:15:00, ended at 2010-11-05 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, pelvis; with contrast material(s)\n- Computed tomography, abdomen; with contrast material(s)\n\n### Condition\n- Disease of liver\n- Disorder of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-11-14 00:00:00, ended at 2010-11-14 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-15 09:04:00, ended at 2010-11-15 09:40:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-15 09:41:00, ended at 2010-11-15 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-04-28 00:00:00, ended at 2011-04-28 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-02 12:32:00, ended at 2011-05-02 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-16 10:23:00, ended at 2011-05-16 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-07-01 00:00:00, ended at 2011-07-01 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-07-09 09:28:59, ended at 2011-07-09 15:22:27\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- Nasal endoscopy, diagnostic, unilateral or bilateral (separate procedure)\n\n### Condition\n- Primary diagnosis: Allergic rhinitis\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, presumably until 2011-08-01. Instructions: take  by mouth.\n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, presumably until 2011-11-21. Instructions: take 5 mg by mouth every bedtime as needed.\n- ketoconazole 20 MG/ML Medicated Shampoo, through Topical route, presumably until 2011-11-21. Instructions: by Topical route 2 times a day.\n- azelastine hydrochloride 0.137 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2011-07-09, presumably until 2011-11-21, with intended 6 refill(s). Instructions: 2 Sprays by Nasal route 2 times a day. 2 sprays into each nostril twice a day\n- budesonide 0.25 MG/ML Inhalation Suspension, through Inhalation, started on 2011-07-09, presumably until 2011-11-21, with intended 6 refill(s). Instructions: 2 mL by Inhalation route 2 times a day. Use as directed twice a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2011-08-01 00:00:00, ended at 2011-08-01 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2011-08-01, presumably until 2013-10-07, with intended 3 refill(s). Instructions: TAKE ONE TABLET BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-11-06 00:00:00, ended at 2011-11-06 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-11-17 11:10:52, ended at 2011-11-17 12:45:58\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Nasal endoscopy, diagnostic, unilateral or bilateral (separate procedure)\n\n### Condition\n- Chronic rhinitis\n- Primary diagnosis: Hearing loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-11-19 10:44:00, ended at 2011-11-19 11:52:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-11-19 11:53:00, ended at 2011-11-19 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen; without contrast material, followed by contrast material(s) and further sections\n\n### Condition\n- Benign carcinoid tumor\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-11-21 09:30:00, ended at 2011-11-21 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-04-20 10:25:29, ended at 2012-04-20 11:52:43\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Osteoarthritis of knee\n\n### Drug\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, through Oral route, presumably until 2013-06-15. Instructions: take 1 Tab by mouth every 6 hours as needed.  \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-04-20 10:27:00, ended at 2012-04-20 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Bone length studies (orthoroentgenogram, scanogram)\n- Radiologic examination, knee; 3 views\n\n### Condition\n- Osteoarthritis of knee\n- Joint pain\n- Arthropathy of knee joint\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-04-30 10:27:00, ended at 2012-04-30 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.339\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant poorly differentiated neuroendocrine carcinoma\n- Impaired fasting glycemia\n- Disorder of function of stomach\n\n### Drug\n- metoclopramide 10 MG Oral Tablet, through Oral route, started on 2012-04-30, presumably until 2013-04-30, with intended 1 refill(s). Instructions: take 1 Tab by mouth 4 times a day. Before meals and at bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-05-28 10:41:29, ended at 2012-05-28 12:21:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Joint pain\n- Primary malignant neoplasm of pancreas\n- Localized, primary osteoarthritis\n- Osteoarthritis of knee\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-05-28 10:46:00, ended at 2012-05-28 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of pancreas\n- Joint pain\n- Localized, primary osteoarthritis\n- Osteoarthritis of knee\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-06-02 11:00:00, ended at 2012-06-02 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, gastrointestinal tract, upper; with or without delayed images, with KUB\n\n### Condition\n- Disorder of function of stomach\n- Flatulence, eructation and gas pain\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-08-09 00:00:00, ended at 2012-08-09 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-08-13 10:58:02, ended at 2012-08-13 13:11:16\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Pre-surgery evaluation\n\n### Condition\n- Atrial fibrillation\n- Asthma\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-08-16 10:19:42, ended at 2012-08-16 11:44:33\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- Pre-surgery evaluation\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of function of stomach\n- Disorder of pancreas\n- Malignant poorly differentiated neuroendocrine carcinoma\n- Incisional hernia\n- Urinary tract infectious disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2012-08-27 08:27:00, ended at 2012-08-30 13:57:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.3 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.6 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 154 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Injection of anesthetic agent into peripheral nerve for analgesia\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Occupational therapy evaluation\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Total knee replacement\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Physical therapy evaluation\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Pre-surgery evaluation\n\n### Condition\n- Arthropathy of knee joint\n- Disorder of pancreas\n- Urinary tract infectious disease\n- Chronic obstructive lung disease\n- Incisional hernia\n- Localized osteoarthrosis uncertain if primary OR secondary\n- Obstructive sleep apnea syndrome\n- Osteoarthritis of knee\n- Degeneration of intervertebral disc\n- Low blood pressure\n- Obesity\n- Asthma\n- Essential hypertension\n- Malignant poorly differentiated neuroendocrine carcinoma\n- Disorder of function of stomach\n- Gastroesophageal reflux disease\n- Prinzmetal angina\n\n### Drug\n- polysaccharide iron complex, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ferrous gluconate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ferrous fumarate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ferrous ascorbate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ferrous sulfate 325 MG Oral Tablet, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- iron,peptonized, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ferrous succinate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2012-08-27, presumably until 2012-08-28\n- ferrous bisglycinate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ferrous cysteine glycinate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ferrous aspartate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ammonium ferrous sulfate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, started on 2012-08-30, presumably until 2012-08-30\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2012-08-27, presumably until 2012-08-30\n- soy protein-iron complex, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- fluticasone propionate 0.05 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2012-08-27, presumably until 2012-08-28\n- ferrous carbonate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ferrous glycine sulfate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- folic acid, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2012-08-28, presumably until 2012-10-14, with intended 0 refill(s). Instructions: inject 0.4 mL subcutaneous (under the skin) Every Day.\n- cefazolin 1000 MG Injection, through Intravenous route, started on 2012-08-27, presumably until 2012-08-28\n- iron succinyl milk protein complex, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- iron-dextran complex, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- montelukast 10 MG Oral Tablet, through Oral route, started on 2012-08-27, presumably until 2012-08-29\n- teferrol, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- 120 ACTUAT fluticasone propionate 0.11 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2012-08-27, presumably until 2012-08-30\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2012-08-27, presumably until 2013-06-01, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day.\n- ferrous asparto glycinate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ferrous cacodylate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2012-08-27, presumably until 2012-08-29\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2012-08-27, presumably until 2012-08-27\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2012-08-27, presumably until 2012-08-30\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- iron, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- celecoxib 200 MG Oral Capsule, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ferrous oxalate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- 12 HR propafenone hydrochloride 225 MG Extended Release Oral Capsule, through Oral route, started on 2012-08-27, presumably until 2012-08-30\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2012-08-27, presumably until 2012-08-27\n- magnesium sulfate 20 MG/ML Injection, through Intravenous route, started on 2012-08-29, presumably until 2012-08-30\n- metoclopramide 10 MG Oral Tablet, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- iron sucrose, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ferrous sulfate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- iron carbonyl, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ferrous lactate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ferrous chloride, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- olmesartan medoxomil 20 MG Oral Tablet, through Oral route, started on 2012-08-30, presumably until 2012-08-30\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2012-08-27, presumably until 2012-10-14, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain.\n- simethicone 80 MG Chewable Tablet, through Oral route, started on 2012-08-27, presumably until 2012-08-30\n- iron sorbitex, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ferrous phosphate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ascorbic acid 500 MG Oral Tablet, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2012-08-27, presumably until 2012-08-27\n- magnesium sulfate 40 MG/ML Injection, through Intravenous route, started on 2012-08-28, presumably until 2012-08-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-10-06 00:00:00, ended at 2012-10-06 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-10-14 10:19:17, ended at 2012-10-14 12:12:21\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Osteoarthritis of knee\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-10-14 10:24:00, ended at 2012-10-14 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, knee; 3 views\n- Bone length studies (orthoroentgenogram, scanogram)\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2012-10-27 00:00:00, ended at 2012-10-27 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign carcinoid tumor\n\n### Drug\n- amylase 66400 UNT / lipase 20000 UNT / protease 75000 UNT Delayed Release Oral Capsule, through Oral route, started on 2012-10-27, presumably until 2013-11-15, with intended 6 refill(s). Instructions: take 4 Caps by mouth 4 times a day before meals and bedtime.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-11-02 12:37:00, ended at 2012-11-02 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n- Computed tomography, abdomen; without contrast material, followed by contrast material(s) and further sections\n\n### Condition\n- Benign carcinoid tumor\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-11-19 13:36:00, ended at 2012-11-19 13:43:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of pancreas\n\n### Drug\n- gabapentin 300 MG Oral Capsule, through Oral route, presumably until 2013-06-15. Instructions: take 300 mg by mouth 3 times a day.  \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-11-19 13:44:00, ended at 2012-11-19 15:27:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-11-19 15:28:00, ended at 2012-11-19 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 58 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.8 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.50 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 35.2 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 83 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.3 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 92 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 14.0 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 129 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.9 (percent)\n- MCH [Entitic mass] by Automated count: 31.1 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.5 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 122 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 261 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-03-16 00:00:00, ended at 2013-03-16 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic sinusitis\n\n### Drug\n- budesonide 0.25 MG/ML Inhalation Suspension, started on 2013-03-16, presumably until 2013-06-15, with intended 5 refill(s). Instructions: Use as directed BID.  (#60)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-24 17:36:00, ended at 2013-03-24 17:36:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Low back pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-24 17:37:00, ended at 2013-03-24 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; thoracic\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; cervical\n\n### Condition\n- Spinal stenosis in cervical region\n- Low back pain\n- Degeneration of cervical intervertebral disc\n- Backache\n- Disorder of vertebral column\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-08 07:08:00, ended at 2013-04-08 07:08:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neck pain\n- Lumbosacral spondylosis without myelopathy\n- Displacement of lumbar intervertebral disc without myelopathy\n- Cervical spondylosis without myelopathy\n- Primary malignant neoplasm of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-08 07:08:00, ended at 2013-04-08 07:08:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; lumbar\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; thoracic\n- Computed tomography, cervical spine; without contrast material\n\n### Condition\n- Neck pain\n- Thoracic spondylosis without myelopathy\n- Lumbosacral spondylosis without myelopathy\n- Non-toxic multinodular goiter\n- Sciatica\n- Cervical spondylosis without myelopathy\n- Degeneration of cervical intervertebral disc\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-08 07:09:00, ended at 2013-04-08 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neck pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2013-05-11 00:00:00, ended at 2013-05-11 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amoxicillin 500 MG Oral Capsule, started on 2013-05-11, presumably until 2013-06-15, with intended 3 refill(s). Instructions: Take 4 capsules one hour prior to dental procedure\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-05-18 11:42:22, ended at 2013-05-18 13:06:27\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Strain of rotator cuff of shoulder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-18 11:45:00, ended at 2013-05-18 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, shoulder; complete, minimum of 2 views\n\n### Condition\n- Disorder of bursa of shoulder region\n- Shoulder joint pain\n- Degenerative joint disease of shoulder region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-26 13:46:00, ended at 2013-05-26 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, any joint of upper extremity; without contrast material(s)\n\n### Condition\n- Degenerative joint disease of shoulder region\n- Strain of supraspinatus muscle AND/OR tendon\n- Disorder of musculoskeletal system\n- Effusion of joint of shoulder region\n- Strain of rotator cuff of shoulder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-06-01 12:30:22, ended at 2013-06-01 13:13:51\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Rupture of tendon of biceps, long head\n- Full thickness rotator cuff tear\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-06-15 13:41:43, ended at 2013-06-15 15:23:56\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Brachial radiculitis\n- Spinal stenosis in cervical region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2013-07-08 00:00:00, ended at 2013-07-08 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- methylprednisolone acetate 80 MG/ML Injectable Suspension, started on 2013-07-08, presumably until 2013-07-08\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2013-07-08, presumably until 2013-07-08\n- sodium chloride 9 MG/ML Injection, started on 2013-07-08, presumably until 2013-07-08\n- iohexol, through Intravenous route, started on 2013-07-08, presumably until 2013-07-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-08 09:44:00, ended at 2013-07-08 12:34:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- Injection of spinal anesthetic agent for analgesia\n- Injection of other agent into spinal canal\n- Radiologic examination, spine, single view, specify level\n- Injection of steroid\n- Injection(s), of diagnostic or therapeutic substance(s) (including anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, includes contrast for localization when performed,\n- Fluoroscopic guidance and localization of needle or catheter tip for spine or paraspinous diagnostic or therapeutic injection procedures (epidural or subarachnoid) (List separately in addition to code for primary procedure)\n\n### Condition\n- Abnormal glucose level\n- Backache\n- Essential hypertension\n- Spinal stenosis\n- Chronic obstructive lung disease\n- Pain in limb\n- Spinal stenosis in cervical region\n- Degeneration of intervertebral disc\n- Asthma\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2013-07-08, presumably until 2013-07-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-10-06 11:16:21, ended at 2013-10-06 13:28:50\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Osteoarthritis of knee\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-06 11:25:00, ended at 2013-10-06 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n- Radiologic examination, knee; 3 views\n- Bone length studies (orthoroentgenogram, scanogram)\n\n### Condition\n- Acquired hallux valgus\n- Joint pain\n- Osteoarthritis of knee\n- Talipes planus\n- Acquired equinus deformity of foot\n- Bunion\n- Congenital valgus deformity of foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-10-06 12:43:09, ended at 2013-10-06 13:38:17\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acquired equinus deformity of foot\n- Congenital valgus deformity of foot\n- Tibialis tendinitis\n- Talipes planus\n- Primary diagnosis: Bunion\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-10-07 00:00:00, ended at 2013-10-07 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Neoplasm of digestive tract\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2013-10-07, presumably until 2015-01-03, with intended 6 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-10-11 00:00:00, ended at 2013-10-11 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-13 14:20:00, ended at 2013-10-13 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n- Computed tomography, abdomen; without contrast material, followed by contrast material(s) and further sections\n\n### Condition\n- Disorder of pancreas\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-21 13:36:00, ended at 2013-10-21 13:57:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.4 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 77 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.8 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 58 (milliliter per minute per square meter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-21 13:58:00, ended at 2013-10-21 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.945\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-11-15 00:00:00, ended at 2013-11-15 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign carcinoid tumor\n\n### Drug\n- amylase 66400 UNT / lipase 20000 UNT / protease 75000 UNT Delayed Release Oral Capsule, through Oral route, started on 2013-11-15, presumably until 2016-01-08, with intended 6 refill(s). Instructions: take 4 Caps by mouth 4 times a day before meals and bedtime.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-12-13 13:43:17, ended at 2013-12-13 14:41:36\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Strain of rotator cuff of shoulder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-05-17 00:00:00, ended at 2014-05-17 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Eruption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-25 10:30:00, ended at 2014-07-25 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, knee; complete, 4 or more views\n\n### Condition\n- Muscle, ligament and fascia disorders\n- Joint pain\n- Late effect of accidental fall\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-07-25 10:52:05, ended at 2014-07-25 12:26:45\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Joint pain\n- Primary diagnosis: Muscle, ligament and fascia disorders\n- Late effect of accidental fall\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-25 15:03:00, ended at 2014-08-25 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.945\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Incisional hernia\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-08-31 00:00:00, ended at 2014-08-31 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n- Atrial fibrillation\n- Chronic obstructive lung disease\n- Incisional hernia\n- Electrocardiogram abnormal\n- Conduction disorder of the heart\n- Abnormal results of cardiovascular function studies\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-08-31 00:00:00, ended at 2014-08-31 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Incisional hernia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-31 16:59:00, ended at 2014-08-31 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 63 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Prothrombin time (PT): 13.1 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.1 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 266 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.8 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.3 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.2 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- MCV [Entitic volume] by Automated count: 86.7 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.19 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.5 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant poorly differentiated neuroendocrine carcinoma\n- Incisional hernia\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-01 07:04:00, ended at 2014-09-01 10:42:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Incisional hernia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-01 10:43:00, ended at 2014-09-01 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Incisional hernia\n- Chronic obstructive lung disease\n- Hernia of anterior abdominal wall\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2014-09-11 00:00:00, ended at 2014-09-11 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for hernia repairs in upper abdomen; lumbar and ventral (incisional) hernias and/or wound dehiscence\n\n### Condition\n- Incisional hernia\n\n### Drug\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2014-09-11, presumably until 2014-09-11\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2014-09-11, presumably until 2014-09-11\n- cefazolin 1000 MG Injection, started on 2014-09-11, presumably until 2014-09-11\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2014-09-11, presumably until 2014-09-11\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2014-09-11, presumably until 2014-09-11\n- 2 ML ondansetron 2 MG/ML Injection, started on 2014-09-11, presumably until 2014-09-11\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-09-11, presumably until 2014-09-11\n- succinylcholine chloride 20 MG/ML Injectable Solution, started on 2014-09-11, presumably until 2014-09-11\n- midazolam 1 MG/ML Injectable Solution, started on 2014-09-11, presumably until 2014-09-11\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2014-09-11, presumably until 2014-09-11\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2014-09-11, presumably until 2014-09-11\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Malignant tumor of pancreas within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-09-26 00:00:00, ended at 2008-09-26 00:00:00\nThe patient in this visit was 68 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.0 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 59 (milliliter per minute per square meter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.8 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.6 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 120 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.3 (picogram)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.71 (million per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 279 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.3 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 70 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 88.8 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2008-10-27 00:00:00, ended at 2008-10-27 00:00:00\nThe patient in this visit was 68 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.1 (percent)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- INR in Platelet poor plasma by Coagulation assay: 2.8 (ratio)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.8 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.42 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 13.5 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.8 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 90.1 (femtoliter)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 267 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 39.6 (second)\n- Glucose [Mass/volume] in Serum or Plasma: 131 (milligram per deciliter)\n- Prothrombin time (PT): 28.5 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2008-10-31 07:09:00, ended at 2008-11-09 13:00:00\nThe patient in this visit was 68 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 43.7 (millimeter mercury column)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 33 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 5.9 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.9 (percent)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n- Prothrombin time (PT): 24.7 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 2.9 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 2.30 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 1.11 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 28.8 (percent)\n- Lymphocytes [#/volume] in Blood by Manual count: 1.7 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Manual count: 0.5 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Manual count: 4.9 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 85.7 (percent)\n- Neutrophils/100 leukocytes in Blood by Manual count: 62 (percent)\n- Base deficit in Blood: 6.0 (millimole per liter)\n- Bicarbonate [Moles/volume] in Specimen: 25.6 (millimole per liter)\n- Body height: 5' 8\" (inch (US))\n- Chloride [Moles/volume] in Serum or Plasma: 111 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Manual count: 7 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 5.6 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Amylase [Enzymatic activity/volume] in Serum or Plasma: 9 (unit per liter)\n- Base excess in Blood by calculation: 1.0 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.24 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 90.4 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.3 (milligram per deciliter)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 89 (millimeter mercury column)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.2 (percent)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Manual count: 7 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.4 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: N/A (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 40.0 (second)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 49 (unit per liter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.5 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 184 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.9 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.6 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: <5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.0 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.94 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 98 (unit per liter)\n- INR in Platelet poor plasma by Coagulation assay: 2.3 (ratio)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.00 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 22 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 6.73 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of pancreas\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2008-11-01, presumably until 2008-11-05\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2008-10-31, presumably until 2008-10-31\n- 2 ML fentanyl 0.05 MG/ML Injection, through Intravenous route, started on 2008-10-31, presumably until 2008-11-01\n- 1 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2008-11-05, presumably until 2008-11-08\n- warfarin sodium 5 MG Oral Tablet, through Oral route, started on 2008-11-05, presumably until 2008-11-08\n- haloperidol 5 MG/ML Injectable Solution, started on 2008-11-04, presumably until 2008-11-04\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, started on 2008-11-06, presumably until 2008-11-09\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2008-11-07, presumably until 2008-11-09\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, through Oral route, started on 2008-11-07, presumably until 2009-05-08, with quantity of 60.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed for Pain. \n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2008-11-07, presumably until 2008-11-08\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2008-10-31, presumably until 2008-11-06\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2008-11-09, presumably until 2008-11-09\n- alprazolam 0.25 MG Oral Tablet, through Oral route, started on 2008-11-03, presumably until 2008-11-08\n- 5 ML metoprolol tartrate 1 MG/ML Injection, through Intravenous route, started on 2008-10-31, presumably until 2008-11-05\n- 120 ACTUAT fluticasone propionate 0.11 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2008-11-02, presumably until 2008-11-09\n- 1 ML hydralazine hydrochloride 20 MG/ML Injection, started on 2008-11-02, presumably until 2008-11-03\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2008-11-05, presumably until 2008-11-07\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2008-11-07, presumably until 2009-06-22, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth daily. \n- heparin sodium, porcine 10000 UNT/ML Injectable Solution, started on 2008-11-01, presumably until 2008-11-05\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2008-11-06, presumably until 2008-11-09\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2008-10-31, presumably until 2008-11-06\n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2008-11-09, presumably until 2008-11-09\n- 200 ACTUAT ipratropium bromide 0.017 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2008-11-01, presumably until 2008-11-01\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2008-11-03, presumably until 2008-11-09\n- 2 ML ondansetron 2 MG/ML Injection, started on 2008-11-02, presumably until 2008-11-02\n- 12 HR propafenone hydrochloride 225 MG Extended Release Oral Capsule, through Oral route, started on 2008-11-06, presumably until 2008-11-09\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2008-11-03, presumably until 2008-11-07\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2008-11-03, presumably until 2008-11-03\n- 200 ML ciprofloxacin 2 MG/ML Injection, through Intravenous route, started on 2008-10-31, presumably until 2008-10-31\n- metoclopramide 10 MG Oral Tablet, through Oral route, started on 2008-11-09, presumably until 2009-06-22, with quantity of 90.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth 3 times a day before meals. \n- 100 ML metronidazole 5 MG/ML Injection, through Intravenous route, started on 2008-10-31, presumably until 2008-11-01\n- 100 ML propofol 10 MG/ML Injection, through Intravenous route, started on 2008-10-31, presumably until 2008-11-01\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2008-11-05, presumably until 2008-11-08\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2008-11-02, presumably until 2008-11-02\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2008-11-07, presumably until 2008-11-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-03-29 00:00:00, ended at 2009-03-29 00:00:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocyte distribution width [Ratio] by Automated count: 15.3 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.74 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 108 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.4 (percent)\n- MCV [Entitic volume] by Automated count: 85.2 (femtoliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 6.6 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 75 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.9 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 28.4 (picogram)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Platelets [#/volume] in Blood by Automated count: 275 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.4 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 97 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-06-27 00:00:00, ended at 2009-06-27 00:00:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.1 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Prothrombin time (PT): 16.0 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 223 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 31.9 (second)\n- INR in Platelet poor plasma by Coagulation assay: 1.3 (ratio)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.46 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 29.3 (picogram)\n- Glucose [Mass/volume] in Serum or Plasma: 110 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.5 (percent)\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 86.2 (femtoliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2009-07-02 14:28:00, ended at 2009-07-04 12:25:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n- Erythrocyte distribution width [Ratio] by Automated count: 15.9 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 12.4 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.6 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.2 (picogram)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.6 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 88.2 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 226 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.23 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 91 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.3 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Incisional hernia\n\n### Drug\n- 200 ACTUAT albuterol 0.09 MG/ACTUAT / ipratropium bromide 0.018 MG/ACTUAT Inhalation Spray, through Inhalation, started on 2009-07-03, presumably until 2009-07-04\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2009-07-02, presumably until 2009-07-02\n- amylase 33200 UNT / lipase 10000 UNT / protease 37500 UNT Delayed Release Oral Capsule, through Oral route, started on 2009-07-02, presumably until 2009-07-04\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2009-07-02, presumably until 2009-07-04\n- cefotetan 1000 MG Injection, started on 2009-07-02, presumably until 2009-07-02\n- cyclobenzaprine hydrochloride 5 MG Oral Tablet, through Oral route, started on 2009-07-02, presumably until 2009-07-04\n- albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution, through Inhalation, started on 2009-07-02, presumably until 2009-07-03\n- montelukast 10 MG Oral Tablet, through Oral route, started on 2009-07-03, presumably until 2009-07-03\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2009-07-04, presumably until 2010-07-04, with quantity of 20.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day. \n- 12 HR propafenone hydrochloride 225 MG Extended Release Oral Capsule, through Oral route, started on 2009-07-02, presumably until 2009-07-04\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2009-07-02, presumably until 2009-12-31, with quantity of 20.0, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-09-10 00:00:00, ended at 2009-09-10 00:00:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-09-17 00:00:00, ended at 2009-09-17 00:00:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Neoplasm of digestive tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-09-18 12:28:00, ended at 2009-09-18 23:59:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Leukocytes [#/volume] in Specimen by Automated count: 6.8 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.70 (million per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 78 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- MCV [Entitic volume] by Automated count: 86.4 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.6 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 133 (millimole per liter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.0 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 101 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.3 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.4 (picogram)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 290 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neoplasm of digestive tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-10-05 09:00:00, ended at 2009-10-05 23:59:00\nThe patient in this visit was 69 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.535\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-11-13 00:00:00, ended at 2009-11-13 00:00:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Achilles bursitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-01-21 00:00:00, ended at 2010-01-21 00:00:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-01-29 09:52:00, ended at 2010-01-29 10:44:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-01-29 10:45:00, ended at 2010-01-29 23:59:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen; with contrast material(s)\n- Computed tomography, pelvis; with contrast material(s)\n\n### Condition\n- Acquired renal cystic disease\n- Diaphragmatic hernia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-01 11:06:00, ended at 2010-02-01 23:59:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, gastrointestinal tract, upper; with or without delayed images, with KUB\n\n### Condition\n- Malignant neoplastic disease\n- Gastroesophageal reflux disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-08 13:59:00, ended at 2010-02-08 23:59:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-21 14:17:00, ended at 2010-02-21 23:59:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Primary malignant neoplasm of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-25 11:42:00, ended at 2010-02-25 23:59:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of function of stomach\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2010-03-26 00:00:00, ended at 2010-03-31 11:32:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Amylase [Enzymatic activity/volume] in Serum or Plasma: 9 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.52 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.60 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 11.9 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 7.09 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: <5 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 30.1 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.8 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 34 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 25.7 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.0 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.9 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 222 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Body height: 5' 8.5\" (inch (US))\n- Eosinophils/100 leukocytes in Blood by Automated count: 9.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.02 (million per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.80 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 76 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 151 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.7 (percent)\n\n### Procedure\n- Gastric anastomosis revision\n- Collection of venous blood by venipuncture\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n\n### Condition\n- Acquired hypertrophic pyloric stenosis\n- Gastrointestinal complication of procedure\n- Disorder of function of stomach\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2010-03-26, presumably until 2010-03-29\n- menthol, through Submucosal route, started on 2010-03-26, presumably until 2010-03-28\n- benzocaine, through Submucosal route, started on 2010-03-26, presumably until 2010-03-28\n- hydrocortisone 5 MG/ML Topical Cream, through Topical route, started on 2010-03-30, presumably until 2010-03-31\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, started on 2010-03-30, presumably until 2010-03-31. Instructions: take 25 mg by mouth daily. \n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2010-03-30, presumably until 2011-03-31, with quantity of 60.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- pantoprazole 40 MG Injection, through Intravenous route, started on 2010-03-26, presumably until 2010-03-30\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2010-03-27, presumably until 2010-03-30\n- cetylpyridinium, through Submucosal route, started on 2010-03-26, presumably until 2010-03-28\n- 5 ML metoprolol tartrate 1 MG/ML Injection, through Intravenous route, started on 2010-03-30, presumably until 2010-03-30\n- 120 ACTUAT fluticasone propionate 0.11 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2010-03-28, presumably until 2010-03-31. Instructions: by Inhalation route 2 times a day. 1 puf bid\n- heparin sodium, porcine 10000 UNT/ML Injectable Solution, started on 2010-03-27, presumably until 2010-03-31\n- olmesartan medoxomil 5 MG Oral Tablet, through Oral route, started on 2010-03-30, presumably until 2010-03-30. Instructions: take by mouth. 1 TAB QD HS\n- 2 ML ondansetron 2 MG/ML Injection, started on 2010-03-26, presumably until 2010-03-28\n- 12 HR propafenone hydrochloride 225 MG Extended Release Oral Capsule, through Oral route, started on 2010-03-30, presumably until 2010-03-31. Instructions: take by mouth 2 times a day.\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2010-03-27, presumably until 2010-03-30\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2010-03-26, presumably until 2010-03-26\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2010-03-30, presumably until 2010-09-27, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-05-10 09:38:00, ended at 2010-05-10 23:59:00\nThe patient in this visit was 70 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-05 10:15:00, ended at 2010-11-05 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, pelvis; with contrast material(s)\n- Computed tomography, abdomen; with contrast material(s)\n\n### Condition\n- Disease of liver\n- Disorder of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-11-14 00:00:00, ended at 2010-11-14 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-15 09:04:00, ended at 2010-11-15 09:40:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-11-15 09:41:00, ended at 2010-11-15 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-04-28 00:00:00, ended at 2011-04-28 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-02 12:32:00, ended at 2011-05-02 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-16 10:23:00, ended at 2011-05-16 23:59:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant neoplastic disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-07-01 00:00:00, ended at 2011-07-01 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic sinusitis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-07-09 09:28:59, ended at 2011-07-09 15:22:27\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- Nasal endoscopy, diagnostic, unilateral or bilateral (separate procedure)\n\n### Condition\n- Primary diagnosis: Allergic rhinitis\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, presumably until 2011-08-01. Instructions: take  by mouth.\n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, presumably until 2011-11-21. Instructions: take 5 mg by mouth every bedtime as needed.\n- ketoconazole 20 MG/ML Medicated Shampoo, through Topical route, presumably until 2011-11-21. Instructions: by Topical route 2 times a day.\n- azelastine hydrochloride 0.137 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2011-07-09, presumably until 2011-11-21, with intended 6 refill(s). Instructions: 2 Sprays by Nasal route 2 times a day. 2 sprays into each nostril twice a day\n- budesonide 0.25 MG/ML Inhalation Suspension, through Inhalation, started on 2011-07-09, presumably until 2011-11-21, with intended 6 refill(s). Instructions: 2 mL by Inhalation route 2 times a day. Use as directed twice a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2011-08-01 00:00:00, ended at 2011-08-01 00:00:00\nThe patient in this visit was 71 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2011-08-01, presumably until 2013-10-07, with intended 3 refill(s). Instructions: TAKE ONE TABLET BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-11-06 00:00:00, ended at 2011-11-06 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-11-17 11:10:52, ended at 2011-11-17 12:45:58\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Nasal endoscopy, diagnostic, unilateral or bilateral (separate procedure)\n\n### Condition\n- Chronic rhinitis\n- Primary diagnosis: Hearing loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-11-19 10:44:00, ended at 2011-11-19 11:52:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-11-19 11:53:00, ended at 2011-11-19 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen; without contrast material, followed by contrast material(s) and further sections\n\n### Condition\n- Benign carcinoid tumor\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-11-21 09:30:00, ended at 2011-11-21 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-04-20 10:25:29, ended at 2012-04-20 11:52:43\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Osteoarthritis of knee\n\n### Drug\n- acetaminophen 325 MG / hydrocodone bitartrate 10 MG Oral Tablet, through Oral route, presumably until 2013-06-15. Instructions: take 1 Tab by mouth every 6 hours as needed.  \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-04-20 10:27:00, ended at 2012-04-20 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Bone length studies (orthoroentgenogram, scanogram)\n- Radiologic examination, knee; 3 views\n\n### Condition\n- Osteoarthritis of knee\n- Joint pain\n- Arthropathy of knee joint\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-04-30 10:27:00, ended at 2012-04-30 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6.339\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Malignant poorly differentiated neuroendocrine carcinoma\n- Impaired fasting glycemia\n- Disorder of function of stomach\n\n### Drug\n- metoclopramide 10 MG Oral Tablet, through Oral route, started on 2012-04-30, presumably until 2013-04-30, with intended 1 refill(s). Instructions: take 1 Tab by mouth 4 times a day. Before meals and at bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-05-28 10:41:29, ended at 2012-05-28 12:21:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Joint pain\n- Primary malignant neoplasm of pancreas\n- Localized, primary osteoarthritis\n- Osteoarthritis of knee\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-05-28 10:46:00, ended at 2012-05-28 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of pancreas\n- Joint pain\n- Localized, primary osteoarthritis\n- Osteoarthritis of knee\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-06-02 11:00:00, ended at 2012-06-02 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, gastrointestinal tract, upper; with or without delayed images, with KUB\n\n### Condition\n- Disorder of function of stomach\n- Flatulence, eructation and gas pain\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-08-09 00:00:00, ended at 2012-08-09 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Joint pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-08-13 10:58:02, ended at 2012-08-13 13:11:16\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Pre-surgery evaluation\n\n### Condition\n- Atrial fibrillation\n- Asthma\n- Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-08-16 10:19:42, ended at 2012-08-16 11:44:33\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- Pre-surgery evaluation\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of function of stomach\n- Disorder of pancreas\n- Malignant poorly differentiated neuroendocrine carcinoma\n- Incisional hernia\n- Urinary tract infectious disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2012-08-27 08:27:00, ended at 2012-08-30 13:57:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.3 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 30.6 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 154 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Injection of anesthetic agent into peripheral nerve for analgesia\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Occupational therapy evaluation\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Total knee replacement\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Physical therapy evaluation\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Pre-surgery evaluation\n\n### Condition\n- Arthropathy of knee joint\n- Disorder of pancreas\n- Urinary tract infectious disease\n- Chronic obstructive lung disease\n- Incisional hernia\n- Localized osteoarthrosis uncertain if primary OR secondary\n- Obstructive sleep apnea syndrome\n- Osteoarthritis of knee\n- Degeneration of intervertebral disc\n- Low blood pressure\n- Obesity\n- Asthma\n- Essential hypertension\n- Malignant poorly differentiated neuroendocrine carcinoma\n- Disorder of function of stomach\n- Gastroesophageal reflux disease\n- Prinzmetal angina\n\n### Drug\n- polysaccharide iron complex, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ferrous gluconate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ferrous fumarate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ferrous ascorbate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ferrous sulfate 325 MG Oral Tablet, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- iron,peptonized, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ferrous succinate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2012-08-27, presumably until 2012-08-28\n- ferrous bisglycinate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ferrous cysteine glycinate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ferrous aspartate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ammonium ferrous sulfate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, started on 2012-08-30, presumably until 2012-08-30\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2012-08-27, presumably until 2012-08-30\n- soy protein-iron complex, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- fluticasone propionate 0.05 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2012-08-27, presumably until 2012-08-28\n- ferrous carbonate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ferrous glycine sulfate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- folic acid, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2012-08-28, presumably until 2012-10-14, with intended 0 refill(s). Instructions: inject 0.4 mL subcutaneous (under the skin) Every Day.\n- cefazolin 1000 MG Injection, through Intravenous route, started on 2012-08-27, presumably until 2012-08-28\n- iron succinyl milk protein complex, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- iron-dextran complex, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- montelukast 10 MG Oral Tablet, through Oral route, started on 2012-08-27, presumably until 2012-08-29\n- teferrol, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- 120 ACTUAT fluticasone propionate 0.11 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2012-08-27, presumably until 2012-08-30\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2012-08-27, presumably until 2013-06-01, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day.\n- ferrous asparto glycinate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ferrous cacodylate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- sennosides, USP 8.6 MG Oral Tablet, through Oral route, started on 2012-08-27, presumably until 2012-08-29\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2012-08-27, presumably until 2012-08-27\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2012-08-27, presumably until 2012-08-30\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- iron, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- celecoxib 200 MG Oral Capsule, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ferrous oxalate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- 12 HR propafenone hydrochloride 225 MG Extended Release Oral Capsule, through Oral route, started on 2012-08-27, presumably until 2012-08-30\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2012-08-27, presumably until 2012-08-27\n- magnesium sulfate 20 MG/ML Injection, through Intravenous route, started on 2012-08-29, presumably until 2012-08-30\n- metoclopramide 10 MG Oral Tablet, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- iron sucrose, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ferrous sulfate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- iron carbonyl, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ferrous lactate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ferrous chloride, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- olmesartan medoxomil 20 MG Oral Tablet, through Oral route, started on 2012-08-30, presumably until 2012-08-30\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2012-08-27, presumably until 2012-10-14, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain.\n- simethicone 80 MG Chewable Tablet, through Oral route, started on 2012-08-27, presumably until 2012-08-30\n- iron sorbitex, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ferrous phosphate, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- ascorbic acid 500 MG Oral Tablet, through Oral route, started on 2012-08-28, presumably until 2012-08-30\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2012-08-27, presumably until 2012-08-27\n- magnesium sulfate 40 MG/ML Injection, through Intravenous route, started on 2012-08-28, presumably until 2012-08-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-10-06 00:00:00, ended at 2012-10-06 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-10-14 10:19:17, ended at 2012-10-14 12:12:21\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Osteoarthritis of knee\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-10-14 10:24:00, ended at 2012-10-14 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, knee; 3 views\n- Bone length studies (orthoroentgenogram, scanogram)\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2012-10-27 00:00:00, ended at 2012-10-27 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Benign carcinoid tumor\n\n### Drug\n- amylase 66400 UNT / lipase 20000 UNT / protease 75000 UNT Delayed Release Oral Capsule, through Oral route, started on 2012-10-27, presumably until 2013-11-15, with intended 6 refill(s). Instructions: take 4 Caps by mouth 4 times a day before meals and bedtime.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-11-02 12:37:00, ended at 2012-11-02 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n- Computed tomography, abdomen; without contrast material, followed by contrast material(s) and further sections\n\n### Condition\n- Benign carcinoid tumor\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-11-19 13:36:00, ended at 2012-11-19 13:43:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of pancreas\n\n### Drug\n- gabapentin 300 MG Oral Capsule, through Oral route, presumably until 2013-06-15. Instructions: take 300 mg by mouth 3 times a day.  \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-11-19 13:44:00, ended at 2012-11-19 15:27:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-11-19 15:28:00, ended at 2012-11-19 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 58 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.8 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.50 (million per microliter)\n- MCHC [Mass/volume] by Automated count: 35.2 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 83 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.3 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 92 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 14.0 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 129 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.9 (percent)\n- MCH [Entitic mass] by Automated count: 31.1 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.5 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 122 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 261 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-03-16 00:00:00, ended at 2013-03-16 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic sinusitis\n\n### Drug\n- budesonide 0.25 MG/ML Inhalation Suspension, started on 2013-03-16, presumably until 2013-06-15, with intended 5 refill(s). Instructions: Use as directed BID.  (#60)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-24 17:36:00, ended at 2013-03-24 17:36:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Low back pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-24 17:37:00, ended at 2013-03-24 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; thoracic\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; cervical\n\n### Condition\n- Spinal stenosis in cervical region\n- Low back pain\n- Degeneration of cervical intervertebral disc\n- Backache\n- Disorder of vertebral column\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-08 07:08:00, ended at 2013-04-08 07:08:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neck pain\n- Lumbosacral spondylosis without myelopathy\n- Displacement of lumbar intervertebral disc without myelopathy\n- Cervical spondylosis without myelopathy\n- Primary malignant neoplasm of pancreas\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-08 07:08:00, ended at 2013-04-08 07:08:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; lumbar\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; thoracic\n- Computed tomography, cervical spine; without contrast material\n\n### Condition\n- Neck pain\n- Thoracic spondylosis without myelopathy\n- Lumbosacral spondylosis without myelopathy\n- Non-toxic multinodular goiter\n- Sciatica\n- Cervical spondylosis without myelopathy\n- Degeneration of cervical intervertebral disc\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-08 07:09:00, ended at 2013-04-08 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neck pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2013-05-11 00:00:00, ended at 2013-05-11 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amoxicillin 500 MG Oral Capsule, started on 2013-05-11, presumably until 2013-06-15, with intended 3 refill(s). Instructions: Take 4 capsules one hour prior to dental procedure\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-05-18 11:42:22, ended at 2013-05-18 13:06:27\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Strain of rotator cuff of shoulder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-18 11:45:00, ended at 2013-05-18 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, shoulder; complete, minimum of 2 views\n\n### Condition\n- Disorder of bursa of shoulder region\n- Shoulder joint pain\n- Degenerative joint disease of shoulder region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-26 13:46:00, ended at 2013-05-26 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, any joint of upper extremity; without contrast material(s)\n\n### Condition\n- Degenerative joint disease of shoulder region\n- Strain of supraspinatus muscle AND/OR tendon\n- Disorder of musculoskeletal system\n- Effusion of joint of shoulder region\n- Strain of rotator cuff of shoulder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-06-01 12:30:22, ended at 2013-06-01 13:13:51\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Rupture of tendon of biceps, long head\n- Full thickness rotator cuff tear\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-06-15 13:41:43, ended at 2013-06-15 15:23:56\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 6\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Brachial radiculitis\n- Spinal stenosis in cervical region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2013-07-08 00:00:00, ended at 2013-07-08 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- methylprednisolone acetate 80 MG/ML Injectable Suspension, started on 2013-07-08, presumably until 2013-07-08\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2013-07-08, presumably until 2013-07-08\n- sodium chloride 9 MG/ML Injection, started on 2013-07-08, presumably until 2013-07-08\n- iohexol, through Intravenous route, started on 2013-07-08, presumably until 2013-07-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-08 09:44:00, ended at 2013-07-08 12:34:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- Injection of spinal anesthetic agent for analgesia\n- Injection of other agent into spinal canal\n- Radiologic examination, spine, single view, specify level\n- Injection of steroid\n- Injection(s), of diagnostic or therapeutic substance(s) (including anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, includes contrast for localization when performed,\n- Fluoroscopic guidance and localization of needle or catheter tip for spine or paraspinous diagnostic or therapeutic injection procedures (epidural or subarachnoid) (List separately in addition to code for primary procedure)\n\n### Condition\n- Abnormal glucose level\n- Backache\n- Essential hypertension\n- Spinal stenosis\n- Chronic obstructive lung disease\n- Pain in limb\n- Spinal stenosis in cervical region\n- Degeneration of intervertebral disc\n- Asthma\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2013-07-08, presumably until 2013-07-08\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-10-06 11:16:21, ended at 2013-10-06 13:28:50\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Osteoarthritis of knee\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-06 11:25:00, ended at 2013-10-06 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n- Radiologic examination, knee; 3 views\n- Bone length studies (orthoroentgenogram, scanogram)\n\n### Condition\n- Acquired hallux valgus\n- Joint pain\n- Osteoarthritis of knee\n- Talipes planus\n- Acquired equinus deformity of foot\n- Bunion\n- Congenital valgus deformity of foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-10-06 12:43:09, ended at 2013-10-06 13:38:17\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Acquired equinus deformity of foot\n- Congenital valgus deformity of foot\n- Tibialis tendinitis\n- Talipes planus\n- Primary diagnosis: Bunion\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-10-07 00:00:00, ended at 2013-10-07 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Neoplasm of digestive tract\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2013-10-07, presumably until 2015-01-03, with intended 6 refill(s). Instructions: take 1 Tab by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-10-11 00:00:00, ended at 2013-10-11 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-13 14:20:00, ended at 2013-10-13 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstati\n- Computed tomography, abdomen; without contrast material, followed by contrast material(s) and further sections\n\n### Condition\n- Disorder of pancreas\n- Benign carcinoid tumor\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-21 13:36:00, ended at 2013-10-21 13:57:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Glucose [Mass/volume] in Serum or Plasma: 99 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 6.4 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 77 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.8 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): 58 (milliliter per minute per square meter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-21 13:58:00, ended at 2013-10-21 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.945\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2013-11-15 00:00:00, ended at 2013-11-15 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign carcinoid tumor\n\n### Drug\n- amylase 66400 UNT / lipase 20000 UNT / protease 75000 UNT Delayed Release Oral Capsule, through Oral route, started on 2013-11-15, presumably until 2016-01-08, with intended 6 refill(s). Instructions: take 4 Caps by mouth 4 times a day before meals and bedtime.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2013-12-13 13:43:17, ended at 2013-12-13 14:41:36\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Strain of rotator cuff of shoulder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-05-17 00:00:00, ended at 2014-05-17 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Eruption\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-07-25 10:30:00, ended at 2014-07-25 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, knee; complete, 4 or more views\n\n### Condition\n- Muscle, ligament and fascia disorders\n- Joint pain\n- Late effect of accidental fall\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2014-07-25 10:52:05, ended at 2014-07-25 12:26:45\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Joint pain\n- Primary diagnosis: Muscle, ligament and fascia disorders\n- Late effect of accidental fall\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-25 15:03:00, ended at 2014-08-25 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 5.945\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Incisional hernia\n- Malignant poorly differentiated neuroendocrine carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-08-31 00:00:00, ended at 2014-08-31 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Primary diagnosis: Malignant poorly differentiated neuroendocrine carcinoma\n- Atrial fibrillation\n- Chronic obstructive lung disease\n- Incisional hernia\n- Electrocardiogram abnormal\n- Conduction disorder of the heart\n- Abnormal results of cardiovascular function studies\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-08-31 00:00:00, ended at 2014-08-31 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Incisional hernia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-08-31 16:59:00, ended at 2014-08-31 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 63 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- MCHC [Mass/volume] by Automated count: 32.5 (gram per deciliter)\n- Prothrombin time (PT): 13.1 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.1 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 266 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.8 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.3 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.2 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- MCV [Entitic volume] by Automated count: 86.7 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.19 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.5 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Malignant poorly differentiated neuroendocrine carcinoma\n- Incisional hernia\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-01 07:04:00, ended at 2014-09-01 10:42:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Incisional hernia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-09-01 10:43:00, ended at 2014-09-01 23:59:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Incisional hernia\n- Chronic obstructive lung disease\n- Hernia of anterior abdominal wall\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2014-09-11 00:00:00, ended at 2014-09-11 00:00:00\nThe patient in this visit was 74 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for hernia repairs in upper abdomen; lumbar and ventral (incisional) hernias and/or wound dehiscence\n\n### Condition\n- Incisional hernia\n\n### Drug\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2014-09-11, presumably until 2014-09-11\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2014-09-11, presumably until 2014-09-11\n- cefazolin 1000 MG Injection, started on 2014-09-11, presumably until 2014-09-11\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2014-09-11, presumably until 2014-09-11\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2014-09-11, presumably until 2014-09-11\n- 2 ML ondansetron 2 MG/ML Injection, started on 2014-09-11, presumably until 2014-09-11\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2014-09-11, presumably until 2014-09-11\n- succinylcholine chloride 20 MG/ML Injectable Solution, started on 2014-09-11, presumably until 2014-09-11\n- midazolam 1 MG/ML Injectable Solution, started on 2014-09-11, presumably until 2014-09-11\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2014-09-11, presumably until 2014-09-11\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2014-09-11, presumably until 2014-09-11\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Malignant tumor of pancreas within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of pancreatic_cancer means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "dab12d4ad095e7e577dd51241eee129f9f2b6b74e146409b21f167f1792ee336", "prompt_hash": "e52a0f246ca745f1cfeb6dd639c6a2aa24ad1bba75c8eda5dd934008079caed8", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
